Abstract
Compositions and methods comprising pneumococcal polypeptide antigens and/or
nucleic acids encoding such antigens, for the treatment and prevention of
pneumococcal infection and/or pneumococcal-mediated diseases.

   PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL
                                 COLONIZATION AND/OR DISEASE
                       CROSS-REFERENCE TO RELATED APPLICATIONS
[0001]       This application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application
No. 61/762,062 filed February 7. 2013, and is a divisional of au 2014214844, which is the national
phase of PCT/US12014/015254 (WO 2014/124228), the contents of all of which are incorporated
herein by reference in their entirety.
                                         SEQUENCE LISTING
[0002]       The instant application contains a Sequence Listing which has been submitted
electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII
copy, created on February 6, 2014, is named 701039-074841-PCT_SL.txt and is 640,188 bytes in
size.
                                     FIELD OF THE INVENTION
[0003]    The present application is generally directed to methods for identifying immunogens from
organisms and pathogens, and in particular for identifying immunogens which when administered as
vaccines elicit a cellular and/or humoral immune response. The present application is also directed to
pneumococcal T-cell immunogens, and methods and compositions thereof.
                                BACKGROUND OF THE INVENTION
[0004]    Almost one million children in the developing world die of pneumococcal infections each
year. Despite the effectiveness of the conjugate pneumococcal vaccines, problems with this approach
remain including the expense of production and delivery, and resulting serotype replacement as
demonstrated in several clinical trials and epidemiologic studies. One positive effect of the current
capsular-based vaccines has been evident in the patient population that is not being vaccinated: herd
immunity plays an impressive role in the current vaccine strategy. For each case of pneumococcal
disease prevented in children, about three cases of pneumococcal disease are prevented in adults by
herd immunity. In this context at least, prevention of pneumococcal colonization is a main goal of
protein-based vaccine approaches, because blocking colonization will block disease.
[0005]    Alternative pneumococcal vaccines that elicit serotype-independent immunity., and that
maybe more readily available to economically emerging countries are needed urgently. New antigens
that can address this need would be very attractive. Additionally, current methods to identify
immunogens focus on techniques that do not fully optimize the extraction or identification of the full
antigen repertoire. This is true in the case of pneumococcus as well as other pathogens. A method
that can identify a new set of antigens has potential to be impactful for the development of vaccines
for a wide set of pathogens, including pneumococcus.
                                                     1

    WO 2014/124228                                                                 PCT/US2014/015254
                                  SUMMARY OF THE INVENTION
[0006]    An aspect of the present invention encompasses the discovery of novel antigens for
pneumococcus that elicit antigen specific immune responses in mammals. Such novel antigens,
and/or nucleic acids encoding the antigens, can be incorporated into immunogenic compositions and
administered to elicit immune responses, e.g., to provide protection against pneumococcal
colonization, invasive diseases, such as but not limited to, sepsis, and diseases and disorders caused
by pneumococcus. Such novel antigens and/or responses to novel antigens can be detected to identify
and/or characterize immune responses to pneumococcus.
[0007]    In one aspect of the present invention provides immunogenic compositions (e.g., vaccines)
comprising at least one isolated pneumococcal antigen selected from the pneumococcal proteins
SP0010, SP0043, SP0079, SP0084, SP0092, SP0098, SP0106, SP0107, SP0127, SP0149, SP0191,
SP0198, SP0249, SP0321, SP0346, SP0402, SP0453, SP0564, SP0582, SP0589, SP0601, SP0604,
SP0617, SP0620, SP0629, SP0648, SP0659, SP0662, SP0664, SP0678, SP0724, SP0742, SP0757,
SP0785,SP0787,SP0872,SP0878,SP0899,SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,
SP1376,SP1386,SP1404,SP1405,SP1419,SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,
SP1683,SP1826,SP1872,SP1891,SP1897,SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,
SP2083, SP2084, SP2088, SP2145, SP2151, SP2187, SP2192, SP2197, SP2207 and SP2218, or
fragments thereof.
[0008]    One aspect of the present invention relates to an immunogenic composition comprising at
least one isolated pneumococcal antigen or fragment thereof with the amino acid sequence selected
from SEQ ID NO: 1-76 or SEQ ID NO: 153-234, and wherein the composition elicits an immune
response against Streptococcuspneumoniae when administered to a mammal. In some embodiments,
a pneumococcal antigen or fragment thereof exists as a fusion conjugate, for example, where the
fusion conjugate is a polysaccharide conjugate. In some embodiments, a fusion conjugate comprises
the pneumococcal antigen or fragment thereof fused to a pneumococcal pneumolysoid PdT, wherein
the pneumococcal pneumolysoid PdT is conjugated to the polysaccharide. In some embodiments, the
fusion conjugate comprises a polysaccharide which is dextran, Vi polysaccharide of Salmonella typhi,
or pneumococcal cell wall polysaccharide (CWPS), or another polysaccharide of prokaryotic or
eukaryotic origin.
[0009]    In some embodiments of all aspects of the invention, an immunogenic composition induces a
IL-17A (Thl7-cell) response in a subject. In some embodiments, an immunogenic composition
induces an immune response which comprises a humoral immune response and/or cellular immune
response.
[0010]    In some embodiments, an immunogenic composition is further prepared as a vaccine that
reduces or protects a mammal against pneumococcal colonization. In some embodiments, an
                                                  2

    WO 2014/124228                                                                PCT/US2014/015254
immunogenic composition further comprises an adjuvant. In some embodiments, an immunogenic
composition as disclosed herein is administered mucosally.
[0011]    In some embodiments of all aspects of the invention, an immunogenic composition
comprises at least 3, or at least 5, or between 5-20 pneumococcal antigens or fragments or more than
20 with the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
[0012]    In some embodiments of all aspects of the invention, an immunogenic composition
comprises at least one of the pneumococcal proteins SP0785, SP1500 and SP2145.
[0013]    Another aspect of the present invention relates to a method of inducing an IL-17A response
in a subject, comprising administering to the subject at least one immunogenic composition as
disclosed herein, e.g., a pneumococcus antigen of Table 1, or a functional fragment thereof effective
to induce an immune response against Streptococcuspneumoniae in the subject.
[0014]    Another aspect of the present invention relates to a method to protect against pneumococcus
colonization, comprising administering to the subject at least one immunogenic composition as
disclosed herein, e.g., a pneumococcal antigen of Table 1, or a functional fragment thereof
[0015]    Another aspect of the present invention relates to a method to elicit an immune response
against Streptococcuspneumoniae in a mammal, the method comprising administering to the mammal
at least one immunogenic composition comprising one or more isolated pneumococcal antigen or
fragment thereof as disclosed herein in Table 1, with the amino acid sequence selected from SEQ ID
NO: 1-76 or SEQ ID NO: 153-234 in an effective to induce an immune response against
Streptococcuspneumoniae in the subject.
[0016]    Another aspect of the present invention relates to a method to protect against Salmonella
typhi colonization in a mammal, comprising administering to the mammal at least one immunogenic
composition as disclosed herein, e.g., a pneumococcus antigen of Table 1, or a functional fragment
thereof effective to induce an immune response against Streptococcuspneumoniae in the subject.
[0017]    In all embodiments of the aspects described herein, an immunogenic composition can
comprise at least one isolated pneumococcus antigen or fragment thereof selected from SP0785 or
SP1500, and/or has an amino acid sequence substantially identical to SEQ ID NO: 34 ( SP0785) or
SEQ ID NO: 51(SP1500) or a functional fragment thereof.
[0018]    Another aspect of the present invention relates to a method to protect against an invasive
disease of Streptococcuspneumoniae in a subject, comprising administering to the subject an
immunogenic composition as disclosed herein, e.g., a pneumococcus antigen of Table 1, or a
functional fragment thereof in effective to induce an immune response against Streptococcus
pneumoniae in the subject. In some embodiments, such an invasive disease is, for example, sepsis. In
such an embodiment, the method comprises an immunogenic composition comprising at least one
isolated pneumococcus antigen or fragment thereof is SP1386, SP1500, SP0084 and SP1479 and
SP0346, and/or at least one pneumococcal antigen that has an amino acid sequence substantially
                                                   3

    WO 2014/124228                                                                   PCT/US2014/015254
identical to SEQ ID NO: 46 (SP1386), SEQ ID NO: 51(SP1500), SEQ ID NO: 4 (SP0084), SEQ ID
NO: 50 (SP1479) and SEQ ID NO: 15 (SP0346) or a functional fragment thereof
[0019]    In all embodiments of the aspects described herein, an immunogenic composition can be
administered by mucosal administration, or any other applicable route, for example but not limited to,
intravenous, subcutaneous or intraperitoneal (IP) administration.
[0020]    In some embodiments, an immunogenic composition comprises at least one isolated
pneumococcus antigen selected from any one or a combination of the pneumococcus antigens with
the amino acid sequences 1-76 or SEQ ID NO: 153-234. In some embodiments, the pneumococcus
antigens are the full length pneumococcus proteins of SPOO 10, SP0043, SP0079, SP0084, SP0092,
SP0098, SP0106, SP0107, SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346, SP0402,
SP0453,SP0564,SP0582,SP0589,SP0601,SP0604,SP0617,SP0620,SP0629,SP0648,SP0659,
SP0662, SP0664, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, SP0872, SP0878, SP0899,
SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,SP1419,
SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,SP1897,
SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,SP2151,
SP2187, SP2192, SP2197, SP2207 and SP2218. In some embodiments, a pneumococcus antigen
comprises a pneumococcus protein that lacks a signal sequence and/or transmembrane domain. In
some embodiments, a pneumococcus antigen comprises a mixture of a full length pneumococcus
proteins and fragments resulting from processing, or partial processing of a signal sequence by an
expression host, e.g., E. coli or an insect cell line (e.g., the baculovirus expression system), or a
mammalian (e.g., human or Chinese hamster Ovary (CHO)) cell line. As used herein, the terms
"portion" and "fragment" or grammatical equivalents are used interchangeably.
[0021]    In some embodiments, the pneumococcal antigens are fragments of the full length
pneumococcal proteins of SP0010, SP0043, SP0079, SP0084, SP0092, SP0098, SP0106, SP0107,
SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346, SP0402, SP0453, SP0564, SP0582,
SP0589, SP0601, SP0604, SP0617, SP0620, SP0629, SP0648, SP0659, SP0662, SP0664, SP0678,
SP0724,SP0742,SP0757,SP0785,SP0787,SP0872,SP0878,SP0899,SP1002,SP1026,SP1032,
SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,SP1419,SP1479,SP1500,SP1545,
SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,SP1897,SP1942,SP1966,SP1967,
SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,SP2151,SP2187,SP2192,SP2197,
SP2207 and SP2218, for example, at least 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350 or 400 consecutive amino acids
of such proteins.
[0022]    In some embodiments, a pneumococcal antigen comprises an amino acid sequence which is
at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at
least 90%, at least 95%, at least 98% or at least 99%) identical to at 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350 or
                                                     4

    WO 2014/124228                                                              PCT/US2014/015254
400 consecutive amino acids of the pneumococcal proteins of SPOO10, SP0043, SP0079, SP0084,
SP0092, SP0098, SPO106, SP0107, SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346,
SP0402,SP0453,SP0564,SP0582,SP0589,SP0601,SP0604,SP0617,SP0620,SP0629,SP0648,
SP0659, SP0662, SP0664, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, SP0872, SP0878,
SP0899,SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,
SP1419,SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,
SP1897,SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,
SP2151, SP2187, SP2192, SP2197, SP2207 and SP2218.
[0023]    Accordingly, the inventors herein have identified pneumococcal T-cell immunogens that
both induce an IL-17A (e.g. a Th7-cell) response and protect mice from colonization. These proteins,
including SP0785, SP1500, SP2145, or fragments thereof, show promise as vaccine candidates
against colonization and sepsis. In some embodiments, a novel pneumococcal immunogens as
disclosed herein e.g., as disclosed in Table 1, are administered by mucosal immunization, and can be
optionally administered with an adjuvant, to reduce subsequent pneumococcal nasal colonization.
[0024]    In some embodiments, an immunogenic composition comprises a SP1386, SP1500, SP0084,
SP1479 and SP0346, or fragments thereof in a method to prevent or treat sepsis in a subject, such as a
mammalian subject, including a human subject.
[0025]    In some embodiments, an immunogenic composition comprising at least one isolated
pneumococcal antigen is prepared as a vaccine that reduces or protects a mammal against
pneumococcal colonization. In some embodiments, such an immunogenic composition can further
comprise at least one adjuvant, e.g., selected from the group comprising, but not limited to cholera
toxin, CFA, IFA, alum and others commonly known in the art and disclosed herein.
[0026]    Another aspect of the present invention relates to pharmaceutical composition for eliciting an
immune response in a mammal comprising the T-cell stimulating immunogens prepared according to
the methods as disclosed herein. In such embodiments, a pharmaceutical composition can further
comprise an adjuvant and/or a vaccine scaffold. In some embodiments, a pharmaceutical composition
can further comprise an adjuvant.
[0027]    In some embodiments, the immunogenic composition as disclosed herein can be
administered to a subject mucosally. In all aspects of all embodiments as described herein, a subject is
a mammalian subject, e.g., a human, however other subjects are contemplated such as domestic and
agricultural animals and the like.
[0028]    The invention also provides compositions including nucleic acids encoding a pneumococcal
antigen as described herein. In some embodiments, a composition includes an isolated nucleic acid
comprising a nucleotide sequence encoding a pneumococcal antigen selected from Table 1, or
combinations thereof, and further comprises a pharmaceutically acceptable excipient. In some
embodiments, a composition further comprises an adjuvant.
                                                   5

    WO 2014/124228                                                                    PCT/US2014/015254
[0029]     In another aspect, the invention provides methods for eliciting an immune response against
pneumococcus in a mammal based on nucleic acids described herein in Table 1. In some
embodiments, the invention provides methods for eliciting an immune response against
pneumococcus in a mammal by administering to the mammal a composition comprising a nucleic
acid, wherein the nucleic acid comprises a nucleotide sequence encoding a pneumococcal antigen as
disclosed in Table 1 or combinations thereof
[0030]     In another aspect, the invention provides methods for characterizing and/or detecting an
immune response to a pneumococcal antigen in a subject (e.g., a pneumococcal polypeptide antigen
selected from Table l or combinations thereof). In some embodiments, an immune response in a naive
subject is characterized. In some embodiments, an immune response in a subject infected, or
suspected of having been infected, with pneumococcus is characterized. In some embodiments, an
immune response in a subject administered an immunogenic composition comprising a pneumococcal
antigen (e.g., an immunogenic composition described herein) is characterized. In some embodiments,
an antibody response is characterized. In some embodiments, a B cell response is characterized. In
some embodiments, a T cell response is characterized. In some embodiments, IFN-y secretion by
antigen-specific T cells is characterized. In some embodiments, a Th1 T cell response is characterized.
In some embodiments, a Thl7 T cell response is characterized, and in some emodiments, IL-17A
secretion is characterized. In some embodiments, a cytotoxic T cell response is characterized. In some
embodiments, both a T cell and a B cell response are characterized. In some embodiments, an innate
immune response is characterized.
[0031]      The invention further provides methods of preparing compositions including
pneumococcual antigens, and antibodies that specifically bind to pneumococcal antigens as disclosed
in Table 1.
[0032]     Compositions and methods described herein can be used for the prophylaxis and/or treatment
of any pneumococcus disease, disorder, and/or condition due to a pneumococcual infection. In some
embodiments, an immunogenic composition described herein reduces risk of infection by, and/or
treats, alleviates, ameliorates, relieves, delays onset of, inhibits progression of, reduces severity of,
and/or reduces incidence of one or more symptoms or features of a pneumococcal disease, disorder,
and/or condition. In some embodiments, the prophylaxis and/or treatment of pneumococcal infection
comprises administering a therapeutically effective amount of an immunogenic composition
comprising a novel pneumococcal antigen described herein to a subject in need thereof, in such
amounts and for such time as is necessary to achieve the desired result. In certain embodiments of the
present invention a "therapeutically effective amount" of an inventive immunogenic composition is
that amount effective for treating, alleviating, ameliorating, relieving, delaying onset of, inhibiting
progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features
of pneumococcal infection.
                                                    6

    WO 2014/124228                                                                  PCT/US2014/015254
[0033]     In some embodiments, inventive prophylactic, prognostic and/or therapeutic protocols
involve administering a therapeutically effective amount of one or more immunogenic compositions
comprising a novel pneumococcal antigen to a subject such that an immune response is stimulated in
one or both of T cells and B cells. The present invention also provides novel immunogenic
compositions comprising a therapeutically effective amount of one or more pneumococcal antigens
(e.g., one or more of a polypeptide antigen selected from Table 1 or combinations thereof) and one or
more pharmaceutically acceptable excipients. In some embodiments, the present invention provides
for pharmaceutical compositions comprising an immunogenic composition as described herein. In
accordance with some embodiments, a method of administering a pharmaceutical composition
comprising inventive compositions to a subject (e.g. human, e.g., a child, adolescent, or young adult)
in need thereof is provided.
[0034]     In some embodiments, a therapeutically effective amount of an immunogenic composition is
delivered to a patient and/or animal prior to, simultaneously with, and/or after diagnosis with a
pneumococcal disease, disorder, and/or condition. In some embodiments, a therapeutic amount of an
inventive immunogenic composition is delivered to a patient and/or animal prior to, simultaneously
with, and/or after onset of symptoms of a pneumococcal disease, disorder, and/or condition.
[0035]     In some embodiments, immunogenic compositions of the present invention are administered
by any of a variety of routes, including oral, intramuscular, subcutaneous, transdermal, intradermal,
rectal, intravaginal, mucosal, nasal, buccal, enteral, sublingual; by intratracheal instillation, bronchial
instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. In some
embodiments, immunogenic compositions of the present invention are administered by a variety of
routes, including intravenous, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal,
intraperitoneal, topical (as by powders, ointments, creams, and/or drops), transdermal, or by
intratracheal instillation.
[0036]     In certain embodiments, an immunogenic composition may be administered in combination
with one or more additional therapeutic agents which treat the symptoms of pneumococcal infection
(e.g., with an antibiotic such as a beta-lactam antibiotic, an erythromycin, or a tetracycline).
[0037]     Another aspect of the present invention relates to the use of the immunogenic composition as
disclosed herein to be administered to a subject to elicit an immune response in the subject. In some
embodiments, the immune response is an antibody/B cell response, a CD4+ T cell response (including
Thl, Th2 and Thl7 cells) and/or a CD8+ T-cell response. In some embodiments, at least one adjuvant
is administered in conjunction with the immunogenic composition.
[0038]     Another aspect of the present invention relates to a method for inducing an immune response
in a subject to at least one antigen, comprising administering to the subject the immunogenic
composition as disclosed herein.
                                                    7

    WO 2014/124228                                                                PCT/US2014/015254
[0039]    Another aspect of the present invention relates to a method of vaccinating an animal, e.g., a
bird, a mammal or a human, against at least one antigen comprising administering a vaccine
composition comprising the immunogenic composition as disclosed herein.
[0040]    In all aspects as disclosed herein, an animal or a subject can be a human. In some
embodiments, the subject can be an agricultural or non-domestic animal, or a domestic animal. In
some embodiments, a vaccine composition comprising the immunogenic composition as disclosed
herein can be administered via subcutaneous, intranasal, oral, sublingual, vaginal, rectal, intradermal,
intraperitoneal, intra muscular injection, or via skin-patch for transcutaneous immunization.
[0041]    In all aspects as disclosed herein, an immune response is an antibody/B cell response, a
CD4+ T cell response (including Thl, Th2 and Thl7 responses) or a CD8+ T-cell response against
protein/peptide antigen(s). In some embodiments, an immune response is an antibody/B cell response
against the polymer, e.g., a pneumococcal polysaccharide. In some embodiments, at least one
adjuvant is administered in conjunction with the immunogenic composition.
[0042]    Another aspect of the present invention relates to the use of the immunogenic composition as
disclosed herein for use in a diagnostic for exposure to a pathogen or immunogenic agent.
[0043]    Another aspect of the present invention relates to kits for preparing an immunogenic
composition as disclosed herein. For example, such kits can comprise any one or more of the
following materials: a container comprising a polymer, e.g., a polysaccharide, cross-linked with a
plurality of first affinity molecules; and a container comprising a complementary affinity molecule
which associates with the first affinity molecule, wherein the complementary affinity molecule
associates with an antigen.
[0044]    The invention provides a variety of kits comprising one or more of the immunogenic
compositions of the invention. For example, the invention provides a kit comprising an immunogenic
composition comprising a pneumococcual antigen, or a nucleic acid encoding the antigen, wherein the
antigen is selected from Table 1 or functional fragments or combinations thereof; and instructions for
use. A kit may comprise multiple different pneumococcal antigens. A kit may comprise any of a
number of additional components or reagents in any combination. According to certain embodiments
of the invention, a kit may include, for example, (i) a pneumococcal polypeptide antigen selected
from Table 1 or combinations thereof; (ii) an adjuvant; and (iii) instructions for administering a
composition including the pneumococcal antigen and the adjuvant to a subject in need thereof.
[0045]    In some embodiments, the kit can comprise a container comprising an expression vector for
expressing a pneumococcal polypeptide antigen selected from Table 1, for example. In some
embodiments, the vector can optionally comprise a sequence for a linker peptide, wherein the
expression vector can expresses a pneumococcal polypeptide antigen selected from Table 1.
[0046]    Provided herein also is a method of vaccinating a subject, e.g., a mammal, e.g., a human with
the immunogenic compositions as disclosed herein, the method comprising administering a vaccine
composition as disclosed herein to the subject.
                                                    8

    WO 2014/124228                                                               PCT/US2014/015254
                           BRIEF DESCRIPTION OF THE DRAWINGS
[0047]    Figures 1A-1B show that pneumococcus antigens provide protection against colonization.
Figure 1A shows decreased colony forming units (CFU) in a nasal wash of mice challenged with
serotype 6B pneumococcal strain after twice weekly immunization with SP0785 in the presence of the
adjuvant cholera toxin (CT) as compared to CT alone. Figure 1B shows decreased colony forming
units (CFU) in a nasal wash of mice challenged with serotype 6B pneumococcal strain after twice
weekly immunization with SP1500 in the presence of the adjuvant cholera toxin (CT) as compared to
CT alone.
[0048]     Figure 2 shows pneumococcus antigens fused to Pdt (pneumococcal pneumolysoid PdT)
protects against sepsis challenge and prevents against invasive infection and nasopharyngeal
colonization of pneumococcus.     Figure 2 is a survival curve of mice with sepsis showing that
immunization with a fusion protein consisting of SP0785-PdT protected 80% mice against sepsis, and
fusion protein SP2145-PdT protected 90% of mice against sepsis as compared to mice immunized
with control mice (Alum only) or PdT alone (which protected only 30% of mice).
[0049]    Figures 3A-3B show pneumococcal antigens fused to PdT (pneumococcal pneumolysoid
PdT) and covalently conjugated to the Vi polysaccharide generates IL-17A and anti-Vi antibody;
protecting against sepsis challenge and preventing invasive infection and nasopharyngeal colonization
of pneumococcus. Figure 3A shows high levels of IL-17A when stimulated with whole cell vaccine
(WCV) after the mice were immunized with SP0785-PdT-Vi congugate or SP2145-PdT-Vi conjugate
as compared to the control Alum alone. Figure 3B shows high levels of anti-Vi IgG in mice were
immunized with SP0785-PdT-Vi conjugate or SP2145-PdT-Vi conjugate, as compared to Alum alone.
[0050]    Figure 4 shows pneumococcal antigens fused to Pdt (pneumococcal pneumolysoid PdT) and
covalently conjugated to the Vi polysaccharide protects against sepsis challenge and prevents against
invasive infection and nasopharyngeal colonization of pneumococcus. Figure 4 is a survival curve of
mice with sepsis showing that immunization with a fusion protein consisting of SP2145-PdT-Vi or
SP0785-PdT-Vi protected 80% mice against sepsis as compared to mice immunized with control
mice (Alum only) (which protected only 20% of mice).
[0051]    Figure 5 shows sera from immunized mice bind encapsulated pneumococcal strain Tigr4.
Figure 5 shows results from a flow cytometric assay showing that antibodies present in the serum
from mice immunized with SP0785 (black) can label the encapsulated pneumococcal strain Tigr4 as
compared to serum obtained from mice immunized with alum alone (grey). Thus, Figure 5
demonstrates that anti-SP0785 antibody is able to bind to encapsulated pneumococcal strain.
[0052]    Figures 6A-6B demonstrate protection against pneumococcal colonization by a Multiple
Antigen Presenting System (MAPS) construct. MAPS complexes were made using biotinylated type
1 pneumococcal polysaccharide attached to a fusion protein consisting of rhizavidin and SP0785,
SP1500, SP0435 or PdT. C57/BL6 mice were immunized with a mixture of 3 MAPS complexes
                                                  9

    WO 2014/124228                                                                  PCT/US2014/015254
containing SP0785, SP1500 and PdT, or a mixture of all 4 MAPS complexes described above, on
aluminum hydroxide, at a dosage of 6.7 gg of each antigen. Control mice received either aluminum
hydroxide alone (alum, negative control) or a whole cell vaccine in alum (as a positive control).
Immunization was given subcutaneously three times, two weeks apart. Blood was drawn after the
third immunization and stimulated with 10 gg/ml of S. pneumoniae whole cell antigen or 5 gg/ml of
purified SP0785, SP1500 or PdT protein. Antigen-specific or whole cell (WCB) IL-17A production
was measured 7 days post stimulation by ELISA (Figure 6A). One week after bleeding, mice were
challenged with pneumococcal 603B strain and bacterial colonization rate in the nose was determined
10 days post challenge (Figure 6B). Mice that received immunizations with either 3 or 4 MAPS
complexes were protected against pneumococcal colonization.
[0053]    Figure 7 demonstrates protection against pneumococcal colonization by a fusion protein of
SP0785, SP1500 and PdT conjugated to Vi polysaccharide of Salmonella typhi. C57BL/6 mice were
immunized with vaccines containing 5 gg of protein antigen adsorbed onto alum, subcutaneously
three times, two weeks apart. Control mice received alum alone. Two weeks after last immunization,
mice were intranasally challenged with pneumococcal 603B strain and bacterial colonization rate in
the nose was determined by nasal wash. The mice that were immunized with the fusion conjugate
were significantly protected against pneumococcal colonization compared to the mice in the control
group.
[0054]    Figure 8 demonstrates that passive transfer of rabbit serum protects mice against
pneumococcal challenge. New Zealand white rabbits were immunized with purified SP0785, SP1500
or PdT. An equal mixture of each serum from rabbits pre-immunization vs. post immunization (in this
case, 67   l each) was given to groups of 10 mice via the intraperitoneal route. Mice were then
intraperitoneally infected with a serotype 3 strain 24 hours later and mice survival was monitored for
8 days. Group received post immunization serum had 60% survival comparing to 0% survival in the
pre-serum group, a difference that was highly statistically significant, attesting to the protective
capacity of antibodies to these proteins for pneumococcal invasive disease.
                        DETAILED DESCRIPTION OF THE INVENTION
[00551        Streptococcus pneumoniae (S. pneumoniae) is a common cause of bacterial pneumonia,
meningitis, otitis media, and bacteremia in children, the elderly, and immunodeficient individuals. S.
pneumoniae can be subdivided into approximately 90 serotypes, based on the capsular polysaccharide
of the organism. However, disease is generally caused by approximately 30 types of S. pneumoniae
isolates. The World Health Organization estimates that there are one million deaths among children
due to pneumococcal meningitis and sepsis each year, with 98% of these deaths occurring in
developing countries. The emergence of pneumococcal strains with antimicrobial resistance
underscores the need for treating and preventing pneumococcal infection by methods in addition to
antimicrobials.
                                                  10

    WO 2014/124228                                                                   PCT/US2014/015254
[00561         One aspect of the present invention encompasses the discovery of novel antigens for
pneumococcus that elicit antigen specific immune responses in mammals. Such novel antigens,
and/or nucleic acids encoding the antigens, can be incorporated into immunogenic compositions and
administered to elicit immune responses, e.g., to provide protection against pneumococcal
colonization, invasive diseases, such as but not limited to, sepsis, and diseases and disorders caused
by pneumococcus organisms. Such novel antigens and/or responses to novel antigens can be detected
to identify and/or characterize immune responses to pneumococcal organisms.
[00571         Another aspect of the present invention provides immunogenic compositions (e.g.,
vaccines) comprising at least one isolated pneumococcus antigen selected from the pneumococcus
proteins listed in Table 1, e.g., SP0010, SP0043, SP0079, SP0084, SP0092, SP0098, SP0106,
SP0107, SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346, SP0402, SP0453, SP0564,
SP0582,SP0589,SP0601,SP0604,SP0617,SP0620,SP0629,SP0648,SP0659,SP0662,SP0664,
SP0678,SP0724,SP0742,SP0757,SP0785,SP0787,SP0872,SP0878,SP0899,SP1002,SP1026,
SP1032,SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,SP1419,SP1479,SP1500,
SP1545,SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,SP1897,SP1942,SP1966,
SP1967,SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,SP2151,SP2187,SP2192,
SP2197, SP2207 and SP2218, or functional fragments thereof, such as those shown in SEQ ID NO:
153-234. In some embodiments, an immunogenic composition comprising at least one isolated
pneumococcus antigen selected from the pneumococcus proteins of SP0785, SP1500,
SP0346,SP1386, SP0084, SP1479 and SP2145 which protect against pneumococcus and
pneumococcal infection, such as sepsis.
[0058]     It should be understood that this invention is not limited to the particular methodology,
protocols, and reagents, etc., described herein and as such may vary. The terminology used herein is
for the purpose of describing particular embodiments only, and is not intended to limit the scope of
the present invention, which is defined solely by the claims.
Definitions
[0059]     The term "antigen" as used herein refers to a molecule (e.g., a polypeptide) that elicits a
specific immune response. Antigen specific immunological responses, also known as adaptive
immune responses, are mediated by lymphocytes (e.g., T cells, B cells) that express antigen receptors
(e.g., T cell receptors, B cell receptors). In certain embodiments, an antigen is a T cell antigen, and
elicits a cellular immune response. In certain embodiments, an antigen is a B cell antigen, and elicits a
humoral (i.e., antibody) response. In certain embodiments, an antigen is both a T cell antigen and a B
cell antigen. As used herein, the term "antigen" encompasses both a full-length polypeptide as well as
a portion of the polypeptide, that represent immunogenic fragments (i.e., fragments that elicit an
antigen specific T cell response, B cell response, or both) of such complete polypeptides. In some
embodiments, antigen is a peptide epitope found within a polypeptide sequence (e.g., a peptide
epitope bound by a Major Histocompatibility Complex (MHC) molecule (e.g., MHC class I, or MHC
                                                     11

    WO 2014/124228                                                                  PCT/US2014/015254
class II). Accordingly, peptides 5-15 amino acids in length, and longer polypeptides, e.g., having 60,
70, 75, 80, 85, 90, 100, 150, 200 250, or more amino acids, can be "antigens". In an exemplary
example, the present invention provides a SP0785 polypeptide antigen. In some embodiments, a
SP0785 polypeptide antigen includes a full-length SP0785 polypeptide amino acid sequence (e.g., a
full-length SP0785 polypeptide of SEQ ID NO:34). In some embodiments, a SP0785 polypeptide
antigen includes a portion of a SP0785 polypeptide (e.g., a portion of the SP0785 polypeptide of SEQ
ID NO:34, which portion includes at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 contiguous amino
acids of SEQ ID NO:34). In some embodiments, a portion of a SP0785 polypeptide corresponds to a
protein having the amino acid sequence of SEQ ID NO: 190. In some embodiments, a SP0785
polypeptide antigen contains one or more amino acid alterations (e.g., deletion, substitution, and/or
insertion) from a naturally-occurring wild-type SP0785 polypeptide sequence. For example, a SP0785
polypeptide antigen may contain an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to SEQ ID NO:34 or a portion thereof (e.g., at least 7,
8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100,
150, 200, 250, 300, 350, or 400 consecutive amino acids of the sequence shown in SEQ ID NO:34).
Alternatively, a SP0785 polypeptide antigen may contain a portion (e.g., at least 7, 8, 9, 10, 11, 12,
13,14,15,16,17,18,19,20,25,30,35,45,50,60,65,70,75,80,85,90,95,100,150,200,250,
300, 350, or 400 consecutive amino acids) of a sequence that is at least 60% (e.g., at least 65%,     70
                                                                                                         %,
75%, 80%, 85%, 90%, 95%, or 98%) identical to SEQ ID NO:34 or SEQ ID NO: 190. SP0785
polypeptide antigen is used as an example. This concept is applicable to other polypeptide antigen
described herein including, but not limited to, SP1500, SP0346, SP1386, SP0084, SP1479, and
SP2145 polypeptide antigens, and any of those polypeptide antigens listed in Table 1.
[0060]        The term "pneumococcal antigen" refers to an antigen that elicits an antigen specific
immune response against any organism of the pneumococcal genus, such as a Streptococcus
pneumonia organism, etc. In some embodiments, a pneumococcal antigen elicits an antigen specific
immune response against S. pneumonia organisms of multiple species. Pneumococcal antigens
include full-length polypeptides encoded by pneumococcal genes shown in Table 1 (SEQ ID NO: 1
76), as well as immunogenic portions of the polypeptides shown in Table 2 (SEQ ID NOs: 153-234).
[0061]     The term "immunogenic composition" as used herein refers to a composition that is capable
of eliciting an immune response, such as an antibody or cellular immune response, when administered
to a subject. In some embodiments, an immunogenic composition includes a polypeptide or peptide
antigen. The immunogenic compositions of the present invention may or may not be
immunoprotective or therapeutic. When the immunogenic compositions of the present invention
prevent, ameliorate, palliate or eliminate disease from the subject, then the immunogenic composition
may optionally be referred to as a vaccine. As used herein, however, the term immunogenic
composition is not intended to be limited to vaccines. In some embodiments, an immunogenic
                                                   12

    WO 2014/124228                                                                 PCT/US2014/015254
composition includes a nucleic acid encoding a polypeptide or peptide antigen. An immunogenic
composition can include molecules that induce an immune response against multiple antigens.
[0062]    The term "antibody" as used herein refers to any immunoglobulin, whether natural or wholly
or partially synthetically produced. All derivatives thereof that maintain specific binding ability are
also included in the term. The term also covers any protein having a binding domain which is
homologous or largely homologous to an immunoglobulin-binding domain. Such proteins may be
derived from natural sources, or partly or wholly synthetically produced. An antibody may be
monoclonal or polyclonal. An antibody may be a member of any immunoglobulin class, including any
of the human classes: IgG, IgM, IgA, IgD, and IgE. As used herein, the terms "antibody fragment" or
"characteristic portion of an antibody" are used interchangeably and refer to any derivative of an
antibody which is less than full-length. In general, an antibody fragment retains at least a significant
portion of the full-length antibody's specific binding ability. Examples of antibody fragments include,
but are not limited to, Fab, Fab', F(ab')2, scFv, Fv, dsFv diabody, and Fd fragments. An antibody
fragment may be produced by any means. For example, an antibody fragment may be enzymatically
or chemically produced by fragmentation of an intact antibody and/or it may be recombinantly
produced from a gene encoding the partial antibody sequence. Alternatively or additionally, an
antibody fragment may be wholly or partially synthetically produced. An antibody fragment may
optionally comprise a single chain antibody fragment. Alternatively or additionally, an antibody
fragment may comprise multiple chains which are linked together, for example, by disulfide linkages.
An antibody fragment may optionally comprise a multimolecular complex. A functional antibody
fragment will typically comprise at least about 50 amino acids and more typically will comprise at
least about 200 amino acids.
[0063]    The terms "Cytotoxic T Lymphocyte" or "CTL" refers to lymphocytes which induce death
via apoptosis or other mechanisms in targeted cells. CTLs form antigen-specific conjugates with
target cells via interaction of TCRs with processed antigen (Ag) on target cell surfaces, resulting in
apoptosis of the targeted cell. Apoptotic bodies are eliminated by macrophages. The term "CTL
response" is used to refer to the primary immune response mediated by CTL cells.
[0064]    The term "cell mediated immunity" or "CMI" as used herein refers to an immune response
that does not involve antibodies or complement but rather involves the activation of, for example,
macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes (T-cells), T-helper
cells, neutrophils, and the release of various cytokines in response to a target antigen. Stated another
way, CMI refers to immune cells (such as T cells and other lymphocytes) which bind to the surface of
other cells that display a target antigen (such as antigen presenting cells (APC)) and trigger a
response. The response may involve either other lymphocytes and/or any of the other white blood
cells (leukocytes) and the release of cytokines. Cellular immunity protects the body by: (i) activating
antigen-specific cytotoxic T-lymphocytes (CTLs) that are able to destroy body cells displaying
epitopes of foreign antigen on their surface, such as virus-infected cells and cells with intracellular
                                                   13

    WO 2014/124228                                                                     PCT/US2014/015254
bacteria; (2) activating macrophages and NK cells, enabling them to destroy intracellular pathogens;
and (3) stimulating cells to secrete a variety of cytokines or chemokines that influence the function of
other cells such as T cells, macrophages or neutrophils involved in adaptive immune responses and
innate immune responses.
[0065]     The term "immune cell" as used herein refers to any cell which can release a cytokine,
chemokine or antibody in response to a direct or indirect antigenic stimulation. Included in the term
"immune cells" herein are lymphocytes, including natural killer (NK) cells, T-cells (CD4+ and/or
CD8+ cells), B-cells, macrophages; leukocytes; dendritic cells; mast cells; monocytes; and any other
cell which is capable of producing a cytokine or chemokine molecule in response to direct or indirect
antigen stimulation. Typically, an immune cell is a lymphocyte, for example a T-cell lymphocyte.
[0066]     The term "cytokine" as used herein refers to a molecule released from an immune cell in
response to stimulation with an antigen. Examples of such cytokines include, but are not limited to:
GM-CSF; IL-la; IL-1 ; IL-2; IL-3; IL-4; IL-5; IL-6; IL-7; IL-8; IL-10; IL-12; IL-17A, IL-17F or
other members of the IL-17 family, IL-22, IL-23, IFN-y; IFN-; IFN-a; MIP-la; MIP-1; TGF-a;
TNFa       or TNF. The term "cytokine" does not include antibodies
[0067]     The term "in vitro" as used herein refers to events that occur in an artificial environment,
e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within an organism (e.g., animal,
plant, and/or microbe).
[0068]     As used herein, the term "in vivo" refers to events that occur within an organism (e.g.,
animal, plant, and/or microbe).
[0069]     The term "isolated" as used herein, means that the isolated entity has been separated from at
least one component with which it was previously associated. When most other components have
been removed, the isolated entity is "purified." Isolation and/or purification and/or concentration may
be performed using any techniques known in the art including, for example, chromatography,
fractionation, precipitation, or other separation.
[0070]     The term "adjuvant" as used herein refers to any agent or entity which increases the
antigenic response (e.g., immune response) by a cell or a subject to a target antigen. In some
embodiments, an adjuvant is used to enhance an immune response to a peptide antigen administered
to a subject. In some embodiments, an adjuvant is used to enhance an immune response to an antigen
encoded by a nucleic acid administered to a subject.
[0071]     As used herein, the term "pathogen" refers to an organism or molecule that causes a disease
or disorder in a subject. For example, pathogens include but are not limited to viruses, fungi, bacteria,
parasites and other infectious organisms or molecules therefrom, as well as taxonomically related
macroscopic organisms within the categories algae, fungi, yeast and protozoa or the like.
[0072]     As used herein, the term "prokaryotic pathogen" refers to a bacterial pathogen.
                                                      14

    WO 2014/124228                                                                  PCT/US2014/015254
[0073]    As used herein, the term "viral pathogen" refers to a virus that causes illness or disease, such
as HIV.
[0074]    As used herein, the term "parasitic pathogen" refers to a microorganism that is parasitic,
residing for an extended period inside a host cell or host organism that gains benefits from the host
and at the same time causes illness or disease. A parasitic pathogen can be bacteria, viruses, fungi, and
parasites, and protists.
[0075]    The term "functional fragment" or "portion" as used in the context of a functional fragment
of an immunogen of protein "x" (e.g., an pneumococcal antigen or immunogen listed Table 1) refers
to a fragment of such a protein or peptide that mediates, effects or elicits a cellular and/or humoral
immune response as similar to the protein or peptide from which it was derived (e.g. a fragment
thereof). Accordingly, the term "functional" when used in conjunction with "derivative" or "variant"
or "fragment" refers to a polypeptide which possess a biological activity that is substantially similar to
a biological activity of the entity or molecule of which it is a derivative or variant or fragment thereof.
By "substantially similar" in this context is meant that at least 25%, at least 35%, at least 50% of the
relevant or desired biological activity of a corresponding wild-type peptide is retained. In the instance
of a fragment of a pneumococcal antigen, such as for example, SP0785 (e.g., SEQ ID NO: 34), a
functional fragment of SEQ ID NO: 34 or SEQ ID NO: 190 would be a protein or peptide comprising
a portion of SEQ ID NO: 34 or SEQ ID NO: 190 which retained an activity for eliciting an IL-17A
response in splenocytes or human PMBC, and protect against colonization by pneumococcal
organism; preferably the fragment of SEQ ID NO: 34 or SEQ ID NO: 190 retains at least 25%, at
least 35%, at least 50% at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least
100% or even higher (i.e., the variant or derivative has greater activity than the wild-type), e.g., at
least 110%, at least 120%, or more activity as compared to the full length SEQ ID NO: 34 or SEQ ID
NO: 190 to elicit an IL-17A response in splenocytes or human PMBC and protect against colonization
by pneumococcus. Such functional fragments of the immunogens (e.g. antigens) listed in Table 1 can
be assessed by the assays as disclosed in the Examples, e.g., to assess if a functional fragment elicits
an IL-17A response in mouse splenocytes or human PBMCs in vitro as disclosed in Example 2, or
protects colonization in vivo in a mouse colonization model, where mice are challenged with a
serotype of pneumococcal strain (e.g., serotypes 6B, 14F or 19F) after biweekly immunization with a
pneumococcal antigen (or functional fragment), and assessing for presence of pneumococcal
colonization in the nasopharynx, as disclosed in Example 3.
[0076]       A "fragment" of an antigen or immunogen of Table 1 as that term is used herein will be at
least 15 amino acids in length, and can be, for example, at least 16, at least 17, at least 18, at least 19,
at least 20 or at least 25 amino acids or greater inclusive.
[00771       The term "Cytotoxic T Lymphocyte" or "CTL" refers to lymphocytes which induce
apoptosis in targeted cells. CTLs form antigen-specific conjugates with target cells via interaction of
TCRs with processed antigen (Ag) on target cell surfaces, resulting in apoptosis of the targeted cell.
                                                   15

    WO 2014/124228                                                                 PCT/US2014/015254
Apoptotic bodies are eliminated by macrophages. The term "CTL response" is used to refer to the
primary immune response mediated by CTL cells.
[0078]    The term "cell mediated immunity" or "CMI" as used herein refers to an immune response
that does not involve antibodies or complement but rather involves the activation of macrophages,
natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes (T-cells), and the release of
various cytokines in response to a target antigen. Stated another way, CMI refers to immune cells
(such as T cells and lymphocytes) which bind to the surface of other cells that display the antigen
(such as antigen presenting cells (APS)) and trigger a response. The response can involve either other
lymphocytes and/or any of the other white blood cells (leukocytes) and the release of cytokines.
Accordingly, cell-mediated immunity (CMI) is an immune response that does not involve antibodies
but rather involves the activation of macrophages and NK-cells, the production of antigen-specific
cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. Cellular
immunity protects the body by: (i) activating antigen-specific cytotoxic T-lymphocytes (CTLs) that
are able to destroy body cells displaying epitopes of foreign antigen on their surface, such as virus
infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens; (2)
activating macrophages and NK cells, enabling them to destroy intracellular pathogens; and (3)
stimulating cells to secrete a variety of cytokines that influence the function of other cells involved in
adaptive immune responses and innate immune responses. Without wishing to be bound by theory and
by way of background, the immune system was separated into two branches: humoral immunity, for
which the protective function of immunization could be found in the humor (cell-free bodily fluid or
serum) and cellular immunity, for which the protective function of immunization was associated with
cells.
[0079]    The term "immune cell" as used herein refers to any cell which can release a cytokine in
response to a direct or indirect antigenic stimulation. Included in the term "immune cells" herein are
lymphocytes, including natural killer (NK) cells, T-cells (CD4+ and/or CD8+ cells), B-cells,
macrophages and monocytes, Th cells; Th1 cells; Th2 cells; Tc cells; stromal cells; endothelial cells;
leukocytes; dendritic cells; macrophages; mast cells and monocytes and any other cell which is
capable of producing a cytokine molecule in response to direct or indirect antigen stimulation.
Typically, an immune cell is a lymphocyte, for example a T-cell lymphocyte.
[0080]    The term "nucleic acid" as used herein, in its broadest sense, refers to any compound and/or
substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a
nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide
chain via a phosphodiester linkage. As used herein, the terms "oligonucleotide" and "polynucleotide"
can be used interchangeably. In some embodiments, "nucleic acid" encompasses RNA as well as
single and/or double-stranded DNA and/or cDNA. Furthermore, the terms "nucleic acid," "DNA,"
"RNA," and/or similar terms include nucleic acid analogs, i.e. analogs having other than a
phosphodiester backbone. The term "nucleotide sequence encoding an amino acid sequence" includes
                                                    16

    WO 2014/124228                                                                 PCT/US2014/015254
all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid
sequence. Nucleic acids can be purified from natural sources, produced using recombinant expression
systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of
chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs
having chemically modified bases or sugars, backbone modifications, etc. A nucleic acid sequence is
presented in the 5' to 3' direction unless otherwise indicated.
[0081]    The term "polypeptide", as used herein, generally has its art-recognized meaning of a
polymer of at least three amino acids. However, the term is also used to refer to specific classes of
antigen polypeptides, such as, for example, SP0785 polypeptides, SP1500 polypeptides, SP0346
polypeptides, SP1386 polypeptides, SP0084 polypeptides, SP1479 polypeptides and SP2145
polypeptides. For each such class, the present specification provides several examples of known
sequences of such polypeptides. Those of ordinary skill in the art will appreciate, however, that the
term "polypeptide", as used herein to refer to "polypeptide antigen", is intended to be sufficiently
general as to encompass not only polypeptides having a sequence recited herein, but also to
encompass polypeptides having a variation of the sequence that elicits an antigen-specific response to
the polypeptide. For example, a "SP0785 polypeptide" includes the SP0785 polypeptide shown in
SEQ ID NO:34, as well as polypeptides that have variations of a SEQ ID NO:34 sequence, such as for
example, a fragment of SP0785 as shown in SEQ ID NO: 190, and that maintain the ability to elicit
an antigen-specific response to a polypeptide of SEQ ID NO:34. Those of ordinary skill in the art
understand that protein sequences generally tolerate some substitution without destroying
immunogenicity and antigen specificity. Thus, any polypeptide that retains immunogenicity and
shares at least about 30-40% overall sequence identity, often greater than about 50%, 60%, 70%, or
80%, and further usually including at least one region of much higher identity, often greater than 90%
or even 95%, 96%, 97%, 98%, or 99% in one or more highly conserved regions, usually
encompassing at least 3-4 and often up to 20 or more amino acids, with another polypeptide of the
same class, is encompassed within the relevant term "polypeptide" as used herein. Other regions of
similarity and/or identity can be determined by those of ordinary skill in the art by analysis of the
sequences of various polypeptides presented herein. See the definition of Antigen. It will be
appreciated that proteins or polypeptides often contain amino acids other than the 20 amino acids
commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including
the terminal amino acids, can be modified in a given polypeptide, either by natural processes such as
glycosylation and other post-translational modifications, or by chemical modification techniques
which are well known in the art. Known modifications which can be present in polypeptides of the
present invention include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation,
covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a
polynucleotide or polynucleotide derivative, covalent attachment of a lipid or lipid derivative,
covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation,
                                                   17

    WO 2014/124228                                                                PCT/US2014/015254
demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate,
formulation, gamma-carboxylation, glycation, glycosylation, GPI anchor formation, hydroxylation,
iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation,
prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to
proteins such as arginylation, and ubiquitination.
[0082]    One example of an algorithm that is suitable for determining percent sequence identity and
sequence similarity is the BLAST algorithm, which is described in Altschul et al., Nuc. Acids Res.
25:3389-3402, 1977. BLAST is used, with the parameters described herein, to determine percent
sequence identity for the nucleic acids and proteins of the present disclosure. Software for performing
BLAST analysis is publicly available through the National Center for Biotechnology Information
(available at the following internet address: ncbi.nlm.nih.gov). This algorithm involves first
identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query
sequence, which either match or satisfy some positive-valued threshold score T when aligned with a
word of the same length in a database sequence. T is referred to as the neighborhood word score
threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating
searches to find longer HSPs containing them. The word hits are extended in both directions along
each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are
calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching
residues; always>0) and N (penalty score for mismatching residues; always<0). For amino acid
sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in
each direction are halted when: the cumulative alignment score falls off by the quantity X from its
maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one
or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST
algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The
BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation
(E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP
program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring
matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA, 89:10915 (1989)) alignments (B) of 50,
expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
[0083]    The BLAST algorithm also performs a statistical analysis of the similarity between two
sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA, 90:5873-5787, 1993). One
measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which
provides an indication of the probability by which a match between two nucleotide or amino acid
sequences would occur by chance. For example, a nucleic acid is considered similar to a reference
sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference
nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than
about 0.001.
                                                   18

    WO 2014/124228                                                                     PCT/US2014/015254
[0084]    The term "subject" is used interchangeably herein with "patient" or "individual" refers to any
organism to which a composition of this invention may be administered, e.g., for experimental,
diagnostic, and/or therapeutic purposes. Typical subjects include mammals such as mice, rats, rabbits,
non-human primates, domestic animals and humans. In some embodiments, the term "subject" refers
to any animal in which it is useful to elicit an immune response. The subject can be a wild, domestic,
commercial or companion animal such as a bird or mammal. The subject can be a human. Although in
one embodiment of the invention it is contemplated that the immunogenic compositions as disclosed
herein can also be suitable for the therapeutic or preventative treatment in humans, it is also applicable
to warm-blooded vertebrates, e.g., mammals, such as non-human primates, (particularly higher
primates), sheep, dog, rodent (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbits, cows, and non
mammals such as chickens, ducks, or turkeys. In another embodiment, the subject is a wild animal,
for example a bird such as for the diagnosis of avian flu. In some embodiments, the subject is an
experimental animal or animal substitute as a disease model. The subject may be a subject in need of
veterinary treatment, where eliciting an immune response to an antigen is useful to prevent a disease
and/or to control the spread of a disease, for example SIV, STL1, SFV, or in the case of live-stock,
hoof and mouth disease, or in the case of birds Marek's disease or avian influenza, and other such
diseases.
[00851        The term "recombinant" when used to describe a nucleic acid molecule, means a
polynucleotide of genomic, cDNA, viral, semisynthetic, and/or synthetic origin, which, by virtue of its
origin or manipulation, is not associated with all or a portion of the polynucleotide sequences with
which it is associated in nature. The term recombinant as used with respect to a peptide, polypeptide,
protein, or recombinant fusion protein, means a polypeptide produced by expression from a
recombinant polynucleotide. The term recombinant as used with respect to a host cell means a host
cell into which a recombinant polynucleotide has been introduced. Recombinant is also used herein to
refer to, with reference to material (e.g., a cell, a nucleic acid, a protein, or a vector) that the material
has been modified by the introduction of a heterologous material (e.g., a cell, a nucleic acid, a protein,
or a vector).
[00861        The term "vectors" refers to a nucleic acid molecule capable of transporting or mediating
expression of a heterologous nucleic acid to which it has been linked to a host cell; a plasmid is a
species of the genus encompassed by the term "vector." The term "vector" typically refers to a nucleic
acid sequence containing an origin of replication and other entities necessary for replication and/or
maintenance in a host cell. Vectors capable of directing the expression of genes and/or nucleic acid
sequence to which they are operatively linked are referred to herein as "expression vectors". In
general, expression vectors of utility are often in the form of "plasmids" which refer to circular double
stranded DNA molecules which, in their vector form are not bound to the chromosome, and typically
comprise entities for stable or transient expression or the encoded DNA. Other expression vectors that
can be used in the methods as disclosed herein include, but are not limited to plasmids, episomes,
                                                     19

    WO 2014/124228                                                                  PCT/US2014/015254
bacterial artificial chromosomes, yeast artificial chromosomes, bacteriophages or viral vectors, and
such vectors can integrate into the host's genome or replicate autonomously in the particular cell. A
vector can be a DNA or RNA vector. Other forms of expression vectors known by those skilled in the
art which serve the equivalent functions can also be used, for example self replicating
extrachromosomal vectors or vectors which integrates into a host genome. Preferred vectors are those
capable of autonomous replication and/or expression of nucleic acids to which they are linked.
[00871        An individual who is "suffering from" a disease, disorder, and/or condition has been
diagnosed with or displays one or more symptoms of the disease, disorder, and/or condition.
[0088]    An individual who is "susceptible to" a disease, disorder, and/or condition has not been
diagnosed with and/or may not exhibit symptoms of the disease, disorder, and/or condition. In some
embodiments, a disease, disorder, and/or condition is associated with a pneumococcal infection.
Without wishing to be bound to theory, S. pneumoniae is responsible for 15-50% of all episodes of
community-acquired pneumonia, 30-50% of all cases of acute otitis media and a significant
proportion of bacteremia and bacterial meningitis. In some embodiments, an individual who is
susceptible to a pneumococcal infection may be exposed to a pneumococcus (e.g., by ingestion,
inhalation, physical contact, etc.). In some embodiments, an individual who is susceptible to a
pneumococcal infection may be exposed to an individual who is infected with the microbe. In some
embodiments, an individual who is susceptible to a pneumococcal infection is one who is in a location
where the microbe is prevalent (e.g., one who is traveling to a location where the microbe is
prevalent). In some embodiments, an individual who is susceptible to a pneumococcal infection is
susceptible due to young age (e.g., a child, adolescent, or young adult). In some embodiments, a
subject who is susceptible is to pneumococcal infection is a subject with Job's syndrome (subject
lacking Th-17 cell-mediated response) or a aggamaglobunemic subject (a subject lacking antibody
mediated response). In some embodiments, a subject who is susceptible is a subject whose immune
system is compromised, such as those living with HIV, or has an auto-immune disease, or has
influenza. In some embodiments, a subject who is susceptible to a pneumococcal infection is a
subject who has other risk factors, such as, but not limited to smoking, injection drug use, Hepatitis C,
and COPD. In some embodiments, an individual who is susceptible to a disease, disorder, and/or
condition will develop the disease, disorder, and/or condition. In some embodiments, an individual
who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder,
and/or condition.
[0089]    The term "therapeutically effective amount" as used herein means an amount of a
therapeutic, prophylactic, and/or diagnostic agent (e.g., inventive immunogenic composition) that is
sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or
condition, to treat, alleviate, ameliorate, relieve, alleviate symptoms of, prevent, delay onset of, inhibit
progression of, reduce severity of, and/or reduce incidence of the disease, disorder, and/or condition.
                                                    20

    WO 2014/124228                                                                     PCT/US2014/015254
[0090]     The term "therapeutic agent" as used herein refers to any agent that, when administered to a
subject, has a therapeutic, prophylactic, and/or diagnostic effect and/or elicits a desired biological
and/or pharmacological effect.
[0091]     The term "treating" as used herein refers to the term "treating" refers to partially or
completely alleviating, ameliorating, relieving, delaying onset of, inhibiting progression of, reducing
severity of, and/or reducing incidence of one or more symptoms or features of a particular disease,
disorder, and/or condition. For example, "treating" a microbial infection may refer to inhibiting
survival, growth, and/or spread of the microbe. Treatment may be administered to a subject who does
not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early
signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing
pathology associated with the disease, disorder, and/or condition. In some embodiments, treatment
comprises delivery of an immunogenic composition (e.g., a vaccine) to a subject.
[0092]     The term "vaccine" as used herein refers to an entity comprising at least one immunogenic
component (e.g., an immunogenic component which includes a peptide or protein, and/or an
immunogenic component which includes a nucleic acid). In certain embodiments, a vaccine includes
at least two immunogenic components. In some embodiments, a vaccine is capable of stimulating an
immune response of both T cells and B cells. In some embodiments, any assay available in the art
may be used to determine whether T cells and/or B cells have been stimulated. In some embodiments,
T cell stimulation may be assayed by monitoring antigen-induced production of cytokines, antigen
induced proliferation of T cells, and/or antigen-induced changes in protein expression. In some
embodiments, B cell stimulation may be assayed by monitoring antibody titers, antibody affinities,
antibody performance in neutralization assays, class-switch recombination, affinity maturation of
antigen-specific antibodies, development of memory B cells, development of long-lived plasma cells
that can produce large amounts of high-affinity antibodies for extended periods of time, germinal
center reactions, and/or antibody performance in neutralization assays. In some embodiments, a
vaccine further includes at least one adjuvant that can help stimulate an immune response in T cells
and/or B cells.
[0093]       The term "pharmaceutically acceptable" refers to compounds and compositions which
may be administered to mammals without undue toxicity. The term "pharmaceutically acceptable
carriers" excludes tissue culture medium. Exemplary pharmaceutically acceptable salts include but are
not limited to mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the
like, and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
Pharmaceutically acceptable carriers are well known in the art.
[0094]       The term "wild-type" as used herein refers to the typical or the most common form
existing in nature or as it normally exists in vivo.
[00951       The term "mutant" refers to an organism or cell with any change in its genetic material, in
particular a change (i.e., deletion, substitution, addition, or alteration) relative to a wild-type
                                                    21

    WO 2014/124228                                                                       PCT/US2014/015254
polynucleotide sequence or any change relative to a wild-type protein sequence. The term "variant"
may be used interchangeably with "mutant". Although it is often assumed that a change in the genetic
material results in a change of the function of the protein, the terms "mutant" and "variant" refer to a
change in the sequence of a wild-type protein regardless of whether that change alters the function of
the protein (e.g., increases, decreases, imparts a new function), or whether that change has no effect
on the function of the protein (e.g., the mutation or variation is silent).
[0096]     The term "reduced" or "reduce" or "decrease" as used herein generally means a decrease by
a statistically significant amount relative to a reference. For avoidance of doubt, "reduced" means
statistically significant decrease of at least 10% as compared to a reference level, for example a
decrease by at least 20%, at least 30%, at least 40%, at least t 50%, or least 60%, or least 70%, or least
80%, at least 90% or more, up to and including a 100% decrease (i.e., absent level as compared to a
reference sample), or any decrease between 10-l100% as compared to a reference level, as that term is
defined herein.
[0097]     The term "low" as used herein generally means lower by a statically significant amount; for
the avoidance of doubt, "low" means a statistically significant value at least 10% lower than a
reference level, for example a value at least 20% lower than a reference level, at least 30% lower than
a reference level, at least 40% lower than a reference level, at least 50% lower than a reference level,
at least 60% lower than a reference level, at least 70% lower than a reference level, at least 80% lower
than a reference level, at least 90% lower than a reference level, up to and including 100% lower than
a reference level (i.e., absent level as compared to a reference sample).
[0098]     The terms "increased" or "increase" as used herein generally mean an increase by a statically
significant amount; such as a statistically significant increase of at least 10% as compared to a
reference level, including an increase of at least 20%, at least 30%, at least 40%, at least 50%, at least
60%, at least 70%, at least 80%, at least 90%, at least 100% or more, inclusive, including, for example
at least 2 fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold increase or greater as
compared to a reference level, as that term is defined herein.
[0099]     The term "high" as used herein generally means a higher by a statically significant amount
relative to a reference; such as a statistically significant value at least 10% higher than a reference
level, for example at least 20% higher, at least 30% higher, at least 40% higher, at least 50% higher, at
least 60% higher, at least 70% higher, at least 80% higher, at least 90% higher, at least 100% higher,
inclusive, such as at least 2-fold higher, at least 3-fold higher, at least 4-fold higher, at least 5-fold
higher, at least 10-fold higher or more, as compared to a reference level.
[00100] As used herein and in the claims, the singular forms include the plural reference and vice
versa unless the context clearly indicates otherwise. Other than in the operating examples, or where
otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used
herein should be understood as modified in all instances by the term "about."
                                                       22

    WO 2014/124228                                                                  PCT/US2014/015254
[00101] As used herein, the terms "approximately" or "about" in reference to a number are generally
taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater
than or less than) of the number unless otherwise stated or otherwise evident from the context (except
where such number would be less than 0% or exceed 100% of a possible value).
[00102] As used herein, the term "comprising" means that other elements can also be present in
addition to the defined elements presented. The use of "comprising" indicates inclusion rather than
limitation.
[00103] The term "consisting of' refers to compositions, methods, and respective components thereof
as described herein, which are exclusive of any element not recited in that description of the
embodiment.
[00104] As used herein the term "consisting essentially of' refers to those elements required for a
given embodiment. The term permits the presence of elements that do not materially affect the basic
and novel or functional characteristic(s) of that embodiment of the invention.
[00105] All patents and other publications identified are expressly incorporated herein by reference
for the purpose of describing and disclosing, for example, the methodologies described in such
publications that might be used in connection with the present invention. These publications are
provided solely for their disclosure prior to the filing date of the present application. Nothing in this
regard should be construed as an admission that the inventors are not entitled to antedate such
disclosure by virtue of prior invention or for any other reason. All statements as to the date or
representation as to the contents of these documents is based on the information available to the
applicants and does not constitute any admission as to the correctness of the dates or contents of these
documents.
[00106] Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as those commonly understood to one of ordinary skill in the art to which this invention
pertains. Although any known methods, devices, and materials may be used in the practice or testing
of the invention, the methods, devices, and materials in this regard are described herein.
Pneumococcal Antigens
[00107] The inventors have previously demonstrated that one mechanism of protection against
pneumococcal colonization was using a WCV (whole cell vaccine) that confers protection against
both colonization and invasive disease in mice. (Malley et al., 69 Infect. Immun. 4870-73 (2001);
Malley et al., 74 Infect. Immun. 4290-92 (2004).). It was previously demonstrated that protection
against colonization following immunization with WCV (whole cell vaccine) is antibody-independent
and dependent on CD4+ T cells (Malley et al., 102 P.N.A.S. USA 102,4848-53 (2005); Trzcinski et
al., 73 Infect. Immun. 7043-46 (2005)). The effector T cell is the CD4+ TH17 cell, with neutralization
of IL-17A response with an anti IL-17A antibody diminished the protection by the WCV, and IL-17A
receptor knockout mice are not protected by the WCV. In contrast, IFN-gamma or IL-4 deficient mice
(which are skewed away from THI or TH2 responses, respectively) are fully protected (Lu et al., 4
                                                   23

        WO 2014/124228                                                                  PCT/US2014/015254
PLoS Pathogens. e1000159 (2008)). Rats and mice immunized with the WCV are reported to be
significantly protected against pneumococcal sepsis in two pneumonia models (Malley et al., 2001).
[00108] Using bioinformatics analysis as disclosed herein, the inventors have identified specific
pneumococcal antigens which are listed in Table I which protect against pneumococcal colonization
and infection, such as against pneumococcal sepsis infection. These pneumococcal antigens listed in
Table 1 can be administered as vaccines, in the presence or absence of an adjuvant, to elicit a systemic
IL-17A response and reduce or protect against intranasal pneumococcal colonization. In some
embodiments, a pneumococcal antigen of any listed in Table I can be administered as mucosal
vaccines to protect against intranasal pneumococcal colonization as well as pneumococcal infection,
such as sepsis.
[00109] Table 1. Table 1 lists the amino acid sequence identification numbers of the pneumococcal
immunogens. The amino acid sequences and nucleotide sequences of the pneumococcal antigens are
available on world-wide web site: "xbase.ac.uk/genome/streptococcus-pneumoniae
tigr4/NC_003028/features?page=1", which is incorporated herein in its entirety by reference.
                                            Prot    DNA     Gene ID NO.        GenBank          Immunogenic
                                             ein    SEQ                      Accession No       fragments of the
Pneumococcal
                   Predicted functions      SEQ      ID                                         pneumococcal
antigen name
                                             ID     NO:                                         antigen
                                            NO:
                   hypothetical protein       1      77       15899959       NP_344563.1        SP0010 (23-end)
SP0010
                                                                                                (SEQ ID NO:153)
                   competence factor          2      78       15899988       NP344592.1
                                                                                                SP0043 (42-end)
SP0043             transport protein                                                            (SEQ ID NO: 154)
                   ComB
                   potassium uptake           3      79       15900024       NP_344628.1        SP0079 (24-end)
SP0079
                   protein, Trk family                                                          (SEQ ID NO: 155)
                   histidine kinase (EC       4      80       15900028       NP344632.1         SP0084 (110-end)
SPOO84
                   2.7.13.3) (IMGterm)                                                          (SEQ ID NO: 156)
                   carbohydrate ABC           5      81       15900035       NP_344639.1
                   transporter substrate-                                                        P0092 (30-end)
SP0092             binding protein,
                                                                                                (SEQ ID NO: 157)
                   CUTI family (TC
                   3.A.1.1.-) (IMGterm)
                                              6      82       15900041       NP_344645.1        SP0098 (30-end)
SP0098             hypothetical protein
                                                                                                (SEQ ID NO: 158)
SP0106             L-serine ammonia-          7      83       15900049       NP_344653.1        SP0106 (29-end)
                                                 24

        WO 2014/124228                                                 PCT/US2014/015254
                                     Prot    DNA Gene ID NO.  GenBank      Immunogenic
                                      ein    SEQ             Accession No  fragments of the
Pneumococcal
               Predicted functions   SEQ      ID                           pneumococcal
antigen name
                                      ID     NO:                           antigen
                                     NO:
               lyase (EC 4.3.1.17)                                         (SEQ ID NO: 159)
               (IMGterm)
                                        8     84  15900069   NP_344673.1   SPO107 (30-end)
SP0107         LysM domain protein
                                                                           (SEQ ID NO: 160)
                                        9     85  15900069   NP344673.1    SP0127 (26-end)
SP0127         hypothetical protein
                                                                           (SEQ ID NO: 161)
                                       10     86  15900087   NP344691.1    SP0149 (25-end)
SP0149         lipoprotein
                                                                           (SEQ ID NO: 162)
                                       11     87  15900128   NP344732.1    SP0191 (26-end)
SP0191         hypothetical protein
                                                                           (SEQ ID NO: 163)
                                       12     88  15900134   NP_344738.1   SP0198 (45-end)
SP0198         hypothetical protein
                                                                           (SEQ ID NO: 164)
                                       13     89  15900184   NP_344788.1   SP0249 (26-end)
SP0249         PTS system, IIB
               component                                                   (SEQ ID NO: 165)
               PTS system, IIA         14     90  15900253   NP_344857.1   SP0321 (1-end)
SP0321
               component                                                   (SEQ ID NO: 14)
               capsular                15     91  15900275   NP_344879.1
               polysaccharide                                              SP0346 (98-end)
SP0346
               biosynthesis protein                                        (SEQ ID NO: 166)
               Cps4A
               signal peptidase.       16     92  15900321   NP_344925.1
               Serine peptidase.                                           SP0402 (29-end)
SPO402
               MEROPS family                                               (SEQ ID NO: 167)
               S26A (IMGterm)
               amino acid ABC          17     93  15900370   NP_344974.1
               transporter substrate
               binding protein,
                                                                           SP0453 (25-298)
SP0453         PAAT family (TC
                                                                           (SEQ ID NO: 168)
               3.A.1.3.-) / amino
               acid ABC transporter
               membrane protein,
                                          25

       WO 2014/124228                                                   PCT/US2014/015254
                                     Prot    DNA  Gene ID NO.  GenBank       Immunogenic
                                      ein    SEQ              Accession No   fragments of the
Pneumococcal
               Predicted functions   SEQ      ID                             pneumococcal
antigen name
                                      ID     NO:                             antigen
                                     NO:
               PAAT family (TC
               3.A.1.3.-) (IMGterm)
                                      18      94   15900476   NP_345080.1    SP0564 (21-end)
SP0564         hypothetical protein
                                                                             (SEQ ID NO: 169)
                                      19      95   15900492   NP_345096.1    SP0582 (92-end)
SP0582         hypothetical protein
                                                                             (SEQ ID NO: 170)
               serine O-              20      96   15900498   NP_345102.1
                                                                             SP0589 (36-end)
SP0589         acetyltransferase (EC
                                                                             (SEQ ID NO: 171)
               2.3.1.30) (IMGterm)
               transmembrane          21      97   15900509   NP345113.1     SP0601 (36-297)
SP0601
               protein Vexp3                                                 (SEQ ID NO: 172)
               sensor histidine       22      98   15900512   NP_345116.1    SP0604 (223-end)
SP0604
               kinase VncS                                                   (SEQ ID NO: 173)
                                      23      99   15900525   NP_345129.1    SP0617 (44-end)
SP0617         hypothetical protein
                                                                             (SEQ ID NO: 174)
               amino acid ABC         24      100  15900528   NP_345132.1
               transporter substrate
                                                                             SP0620 (27-end)
SP0620         binding protein,
                                                                             (SEQ ID NO: 175)
               PAAT family (TC
               3.A.1.3.-) (IMGterm)
               D-Ala-D-Ala            25      101  15900536   NP_345140.1
               carboxypeptidase.
                                                                             SP0629 (21-end)
SP0629         Metallopeptidase.
               MEROPS family                                                 (SEQ ID NO: 176)
               M15B (IMGterm)
                                      26      102  15900551   NP_345155.1    SP0648 (40-776)
                                                                             (SEQ ID NO:
               beta-galactosidase
                                                                             177), SP0648
SP0648         (EC:3.2.1.23)
                                                                             (777-1676)
               (IMGterm)
                                                                             (SEQ ID NO:
                                                                             178), SP0648
                                          26

     WO 2014/124228                                                   PCT/US2014/015254
                                     Prot    DNA  Gene ID NO.  GenBank       Immunogenic
                                      ein    SEQ              Accession No   fragments of the
Pneumococcal
               Predicted functions   SEQ      ID                             pneumococcal
antigen name
                                      ID     NO:                             antigen
                                     NO:
                                                                             (1677-end)
                                                                             (SEQ ID NO: 179)
                                      27      103  15900560   NP_345164.1    SP0659 (28-end)
SP0659         thioredoxin family
               protein                                                       (SEQ ID NO: 180)
                                      28      104  15900563   NP_345167.1    SP0662 (29-276)
                                                                             (SEQ ID NO:
               sensor histidine
SP0662                                                                       181), SP0662
               kinase, putative(30ed
                                                                             (300-end)
                                                                             (SEQ ID NO: 182)
                                      29      105  15900565   NP_345169.1    SP0664 (103-629)
                                                                             (SEQ ID NO:
                                                                             183), SP0664
               zinc metalloprotease                                          (630-1200)
SP0664
               ZmpB                                                          (SEQ ID NO:
                                                                             184), SP0664
                                                                             (1201-end)
                                                                             (SEQ ID NO: 185)
                                      30      106  15900579   NP345183.1     SP0678 (23-end)
SP0678         hypothetical protein                                          (E
                                                                             (SEQ IDDN:16
                                                                                      NO: 186)
               hydroxyethylthiazole   31      107  15900621   NP_345225.1    SP0724 (35-end)
SP0724
               kinase, putative                                              (SEQ ID NO: 187)
                                      32      108  15900637   NP345241.1     SP0742 (43-end)
SP0742         hypothetical protein
                                                                             (SEQ ID NO: 188)
                                      33      109  15900651   NP_345255.1    SP0757 (44-451)
SP0757         cell division protein
               FtsX (IMGterm)                                                (SEQ ID NO: 189)
                                      34      110  15900678   NP_345282.1    SP0785 (33-end)
SP0785         hypothetical protein
                                                                             (SEQ ID NO: 190)
                                      35      111  15900680   NP_345284.1    SP0787 (43-290)
SP0787         hypothetical protein
                                                                             (SEQ ID NO: 191)
               D,D-                   36      112  15900755   NP_345359.1    SP0872 (30-end)
SP0872
               carboxypeptidase                                              (SEQ ID NO: 192)
                                          27

        WO 2014/124228                                                  PCT/US2014/015254
                                     Prot    DNA  Gene ID NO.  GenBank      Immunogenic
                                      ein    SEQ              Accession No  fragments of the
Pneumococcal
                Predicted functions  SEQ      ID                            pneumococcal
antigen name
                                      ID     NO:                            antigen
                                     NO:
                PBP3. Serine
                peptidase. MEROPS
                family S 11
                (IMGterm)
                                      37      113  15900761   NP345365.1    SP0878 (245-end)
SP0878          SpoE family protein
                                                                            (SEQ ID NO: 193)
                                      38      114  15900781   NP_345385.1   SP0899 (31-end)
SP0899          hypothetical protein
                                                                            (SEQ ID NO: 194)
                                      39      115  15900875   NP_345479.1   SP1002 (22-end)
SP1002          adhesion lipoprotein
                                                                            (SEQ ID NO: 195)
                                      40      116  15900897   NP_345501.1   SP1026 (24-end)
SP1026          hypothetical protein
                                                                            (SEQ ID NO: 196)
                iron-compound ABC     41      117  15900903   NP_345507.1
                transporter, iron                                            SP1032 (22-end)
SP 1032
                compound-binding                                            (SEQ ID NO: 197)
                protein
                                      42      118  15900938   NP345542.1    SP1069 (34-end)
SP1069          hypothetical protein                                        (E     DN:18
                                                                            (SEQ ID NO: 198)
                                      43      119  15901019   NP_345623.1    SP1154 (155-694)
                                                                            (SEQ ID NO:
                IgA1-specific                                                199) ID1NO:
                metallopeptidase.                                           (695-14
SP1154          Metallo peptidase.
                                                                            (SEQ ID NO:
                MEROPS family
                                                                            200), SP1154
                M26 (IMGterm)                                               (1375-end)
                                                                            (1375-end)
                                                                            (SEQ ID NO: 201)
                                      44      120  15901127   NP_345731.1    SP1267 (25-end)
SP1267          licC protein
                                                                            (SEQ ID NO: 202)
                shikimate             45      121  15901230   NP_345834.1
                                                                             SP1376 (32-end)
SP1376          dehydrogenase (EC
                                                                            (SEQ ID NO: 203)
                1.1.1.25) (IMGterm)
                                          28

      WO 2014/124228                                                   PCT/US2014/015254
                                      Prot    DNA  Gene ID NO.  GenBank      Immunogenic
                                       ein    SEQ              Accession No  fragments of the
Pneumococcal
                Predicted functions   SEQ      ID                            pneumococcal
antigen name
                                       ID     NO:                            antigen
                                      NO:
                spermidine/putrescine  46      122  15901240   NP_345844.1
                ABC transporter,                                             SP1386 (33-end)
SP1386
                spermidine/putrescine                                        (SEQ ID NO: 204)
                -binding protein
                                       47      123  15901258   NP_345862.1   SP1404 (31-end)
SP1404          hypothetical protein
                                                                             (SEQ ID NO: 205)
                transcriptional        48      124  15901259   NP_345863.1   SP1405 (19-end)
SP1405
                regulator Spx                                                (SEQ ID NO: 206)
                acetyltransferase,     49      125  15901272   NP_345876.1   SP1419 (27-end)
SP1419
                GNAT family                                                  (SEQ ID NO: 207)
                peptidoglycan N-       50      126  15901329   NP345933.1
                                                                             SP1479 (40-end)
SP1479          acetylglucosamine
                                                                             (SEQ ID NO: 208)
                deacetylase A
                amino acid ABC         51      127  15901347   NP_345951.1
                transporter substrate
SP1500          binding protein,
                                                                             (SEQ ID NO: 209)
                PAAT family (TC
                3.A.1.3.-) (IMGterm)
                                       52      128  15901388   NP345992.1    SP1545 (29-end)
SP1545          hypothetical protein                                         (E     DN:20
                                                                             (SEQ ID NO: 210)
                                       53      129  15901403   NP346007.1    SP1560 (28-end)
SP1560          hypothetical protein                                         (E     DN:21
                                                                             (SEQ ID NO: 211)
                1-acyl-sn-glycerol-3-  54      130  15901460   NP_346064.1
                phosphate                                                    SP1624 (1-217)
SP 1624
                acyltransferase (EC                                          (SEQ ID NO: 212)
                2.3.1.51) (IMGterm)
                                       55      131  15901487   NP_346091.1   SP1652 (62-397)
SP1652          hypothetical protein
                                                                             (SEQ ID NO: 213)
                carbohydrate ABC       56      132  15901518   NP346122.1
                                                                             SP1683 (65-end)
SP1683          transporter substrate
                                                                             (SEQ ID NO: 214)
                binding protein,
                                           29

     WO 2014/124228                                                     PCT/US2014/015254
                                       Prot    DNA  Gene ID NO.  GenBank      Immunogenic
                                        ein    SEQ              Accession No  fragments of the
Pneumococcal
               Predicted functions     SEQ      ID                            pneumococcal
antigen name
                                        ID     NO:                            antigen
                                       NO:
               CUTI family (TC
               3.A.1.1.-) (IMGterm)
               ABC transporter,         57      133  15901655   NP_346259.1
                                                                              SP1826 (36-end)
SP1826         substrate-binding
               protein
                                   protein(SEQ                                      ID NO: 215)
               iron-compound ABC        58      134  15901700   NP_346304.1
               transporter, iron-                                             SP1872 (40-end)
SP1872
               compound-binding                                               (SEQ ID NO: 216)
               protein
               oligopeptide ABC         59      135  15901718   NP_346322.1
               transporter,                                                   SP1891 (40-end)
SP1891
               oligopeptide-binding                                           (SEQ ID NO: 217)
               protein AmiA
               multiple sugar-          60      136  15901724   NP_346328.1
                                                                              SP1897 (30-end)
SP1897         binding protein
                                                                              (SEQ ID NO: 218)
               (IMGterm)
               transcriptional          61      137  15901766   NP_346370.1   SP1942 (37-end)
SP1942
               regulator, putative                                            (SEQ ID NO: 219)
               UDP-N-                   62      138  15901789   NP_346393.1
               acetylglucosamine 1
                                                                              SP1966 (25-end)
SP1966         carboxyvinyltransfera
                                                                              (SEQ ID NO: 220)
               se (EC 2.5.1.7)
               (IMGterm)
                                        63      139  15901790   NP_346394.1   SP1967 (30-end);
SP1967         hypothetical protein
                                                                              (SEQ ID NO: 221)
                                        64      140  15901821   NP_346425.1   SP1998 (51-end)
SP1998         L-asparaginase (EC
               3.5.1.1) (IMGterm)                                             (SEQ ID NO: 222)
                                        65      141  15901868   NP_346472.1   SP2048 (40-end)
SP2048         hypothetical protein
                                                                              (SEQ ID NO: 223)
               competence protein       66      142  15901870   NP_346474.1   SP2050 (35-end)
SP2050
               CglD                                                           (SEQ ID NO: 224)
                                            30

       WO 2014/124228                                                                   PCT/US2014/015254
                                           Prot    DNA    Gene ID NO.          GenBank        Immunogenic
                                            ein    SEQ                      Accession No      fragments of the
Pneumococcal
                  Predicted functions      SEQ      ID                                        pneumococcal
antigen name
                                            ID     NO:                                        antigen
                                           NO:
                  sensor histidine          67      143     15901899        NP_346503.1       SP2083 (192-end)
SP2083
                  kinase PnpS                                                                 (SEQ ID NO: 225)
                  phosphate ABC             68      144     15901900        NP_346504.1
                  transporter substrate
SP2084            binding protein, PhoT
                                                                                              (SEQ ID NO: 226)
                  family (TC 3.A.1.7.1)
                  (IMGterm)
                  phosphate uptake          69      145     15901904         NP_346508.1
                                                                                              SP2088 (30-end);
SP2088            regulator, PhoU
                                                                                              (SEQ ID NO: 227)
                  (IMGterm)
                                            70      146     15901958        NP_346562.1       SP2145 (1-end)
SP2145            antigen, cell wall
                  surface anchor family                                                       (SEQ ID NO: 70)
                  carbamate kinase (EC      71      147     15901963        NP_346567.1       SP2151 (25-end)
SP2151
                  2.7.2.2) (IMGterm)                                                          (SEQ ID NO: 228)
                                            72      148     15901994        NP_346598.1       SP2187 (32-end);
SP2187            hypothetical protein
                                                                                              (SEQ ID NO: 229)
                  sensor histidine          73      149     15901999        NP_346603.1       SP2192 (224-end)
SP2192
                  kinase                                                                      (SEQ ID NO: 230)
                  ABC transporter,          74      150     15902004        NP346608.1
                                                                                              SP2197 (30-end)
SP2197            substrate-binding
                                                                                              (SEQ ID NO: 231)
                  protein, putative
                                            75      151     15902014        NP_346618.1       SP2207 (30-end)
SP2207            competence protein
                  ComF, putative                                                              (SEQ ID NO: 232)
                  rod shape-                76      152     15902022         NP_346626.1
                                                                                              SP2218 (106-end)
SP2218            determining protein
                                                                                                    ID NO: 234)
                  MreC (IMGterm) MreC(IM~erm)(SEQ
[00110] In some cases, the other appropriate S. pneumoniae antigen is at least at least 70%, 80%,
85%, 90%, 95%, 97%, 98%, or 99% identity to the corresponding wild-type S. pneumoniae protein
disclosed in Table 1. Sequences of the above-mentioned polypeptides, and nucleic acids that encode
                                                31

     WO 2014/124228                                                                PCT/US2014/015254
them, are known; see, for example, the S. pneumoniae ATCC 700669 complete genome sequence
under GenBank accession number FM211187.1 and linked polypeptide sequences therein.
[00111] In addition to those nucleic acids and polypeptides described in Table 1 above, this
application also provides immunogenic compositions that include one or more of the polypeptides or
genes listed in Table 2, or variants or fragments thereof as described herein. The DNA and protein
sequence of each gene and protein may be found by searching for the Locus Tag in the publicly
available database, Entrez Gene, as described above.
[00112] In one aspect of the present invention provides immunogenic compositions (e.g., vaccines)
comprising at least one isolated pneumococcus antigen selected from the pneumococcal proteins
SP0010, SP0043, SP0079, SP0084, SP0092, SP0098, SP0106, SP0107, SP0127, SP0149, SP0191,
SP0198, SP0249, SP0321, SP0346, SP0402, SP0453, SP0564, SP0582, SP0589, SP0601, SP0604,
SP0617, SP0620, SP0629, SP0648, SP0659, SP0662, SP0664, SP0678, SP0724, SP0742, SP0757,
SP0785,SP0787,SP0872,SP0878,SP0899,SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,
SP1376,SP1386,SP1404,SP1405,SP1419,SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,
SP1683,SP1826,SP1872,SP1891,SP1897,SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,
SP2083, SP2084, SP2088, SP2145, SP2151, SP2187, SP2192, SP2197, SP2207 and SP2218, or
fragments thereof. In some embodiments, the pneumococcal antigen has an amino acid sequence
selected from any or a combination from SEQ ID NO: 1-76, or functional fragments thereof. In some
embodiments, the pneumococcus antigen corresponding to SEQ ID NO: 1-76 are encoded by nucleic
acids of SEQ ID NO: 77-152. In some embodiments, fragments of the pneumococcal antigen are
encompassed for use in the methods and composistions as disclosed herein, for example,
pneumococcus antigens corresponding to SEQ ID NO: 153-234 as disclosed in Table 1. Other
functional fragments of the pneumococcus antigens are encompassed for use in the methods and
compositions as disclosed herein, and can be assessed by one of ordinary skill in the art to determine
if they provide protection against pneumococcus colonization, according to the methods as disclosed
in Example 3 herein. A functional fragment of a pneumococcal antigen of SEQ ID NO: 1-76 or SEQ
ID NO: 153-234 can also be assessed by one of ordinary skill in the art for protection against an
invasive disease, such as sepsis according to the methods as disclosed in Example 4 and 5, in
particular when used alone or as part of a fusion protein with PdT. In some embodiments, a functional
fragment of a pneumococcal antigen of SEQ ID NO: 1-76 or SEQ ID NO: 153-234 can also be
assessed by one of ordinary skill in the art for protection against an S.typhi according to the methods
as disclosed in Example 5, in particular when used alone or as part of a fusion protein with PdT and/or
fused to Vi.
[00113] In some embodiments, an immunogenic compositon comprises at least one isolated
pneumococcal antigen selected from any one or a combination of the pneumococcal antigens with the
amino acid sequences SEQ ID NO: 1-76 or SEQ ID NO: 153-234. In some embodiments, the
pneumococcal antigens are the full length pneumococcal proteins of SPOO 10, SP0043, SP0079,
                                                   32

    WO 2014/124228                                                                   PCT/US2014/015254
SP0084, SP0092, SP0098, SP0106, SP0107, SP0127, SP0149, SP0191, SP0198, SP0249, SP0321,
SP0346, SP0402, SP0453, SP0564, SP0582, SP0589, SP0601, SP0604, SP0617, SP0620, SP0629,
SP0648, SP0659, SP0662, SP0664, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, SP0872,
SP0878,SP0899,SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,
SP1405,SP1419,SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,
SP1891,SP1897,SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,
SP2145, SP2151, SP2187, SP2192, SP2197, SP2207 and SP2218. In some embodiments, a
pneumococcal antigen comprises a pneumococcal protein that lacks a signal sequence and/or
transmembrane domain. In some embodiments, a pneumococcal antigen comprises a mixture of a full
length pneumococcal proteins and fragments resulting from processing, or partial processing of a
signal sequence by an expression host, e.g., E. coli or an insect cell line (e.g., the baculovirus
expression system), or a mammalian (e.g., human or Chinese hamster Ovary (CHO)) cell line. As
used herein, the terms "portion" and "fragment" or grammatical equivalents are used interchangeably.
[00114] In some embodiments, the pneumococcal antigens are a fragment of the full length
pneumococcal proteins of SP0010, SP0043, SP0079, SP0084, SP0092, SP0098, SP0106, SP0107,
SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346, SP0402, SP0453, SP0564, SP0582,
SP0589, SP0601, SP0604, SP0617, SP0620, SP0629, SP0648, SP0659, SP0662, SP0664, SP0678,
SP0724,SP0742,SP0757,SP0785,SP0787,SP0872,SP0878,SP0899,SP1002,SP1026,SP1032,
SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,SP1419,SP1479,SP1500,SP1545,
SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,SP1897,SP1942,SP1966,SP1967,
SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,SP2151,SP2187,SP2192,SP2197,
SP2207 and SP2218, for example, at least 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350 or 400 consecutive amino acids
of such proteins. In some embodiments, fragment of the full-length pneumococcal protein correspond
to SEQ ID NO: 153-234. In some embodiments, a fragment of a pneumococcal protein is a functional
fragment of any of SEQ ID NO: 153-234, for example, at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350 or 400
consecutive amino acids of pneumococcal antigens corresponding to SEQ ID NO: 153-234.
[00115] In some embodiments, a pneumococcal antigen comprises an amino acid sequence which is
at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at
least 90%, at least 95%, at least 98% or at least 99%) identical to at 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350 or
400 consecutive amino acids of the pneumococcal proteins of SPOO10, SP0043, SP0079, SP0084,
SP0092, SP0098, SP0106, SP0107, SP0127, SP0149, SP0191, SP0198, SP0249, SP0321, SP0346,
SP0402,SP0453,SP0564,SP0582,SP0589,SP0601,SP0604,SP0617,SP0620,SP0629,SP0648,
SP0659, SP0662, SP0664, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, SP0872, SP0878,
SP0899,SP1002,SP1026,SP1032,SP1069,SP1154,SP1267,SP1376,SP1386,SP1404,SP1405,
                                                   33

    WO 2014/124228                                                                   PCT/US2014/015254
SP1419,SP1479,SP1500,SP1545,SP1560,SP1624,SP1652,SP1683,SP1826,SP1872,SP1891,
SP1897,SP1942,SP1966,SP1967,SP1998,SP2048,SP2050,SP2083,SP2084,SP2088,SP2145,
SP2151, SP2187, SP2192, SP2197, SP2207 and SP2218, or fragments thereof, e.g., fragments of
pneumococcal antigens corresponding to SEQ ID NO: 153-234.
[00116]    The inventors demonstrate herein that the pneumococcal antigen SP0785 showed IL-17
response to protein stimulation and protection against pneumococcal colonization, and that SP0785
PdT protected 80% of mice from sepsis infection and SP0785-PdT-Vi protected against Salmonella
typhi infection. The inventors also demonstrated that the pneumococcal antigen SP1500 elicited an
IL-17 response to protein stimulation and protected against pneumococcal colonization, and also
resulted in protection of 50% of mice from from pneumococcal infection, and that the pneumococcal
antigen SP0346 protected 60% of mice from from pneumococcal infection and sepsis, that the
pneumococcal antigens SP1386, SP0084 and SP1479 protected 50% of mice from from
pneumococcal infection. The inventors also demonstrated that SP2145, when conjugated to PdT
(SP2145-PdT) protected 80% of mice from sepsis infection and that SP2145-PdT-Vi protected against
S.typhi infection. Accordingly, these antigens provide novel compositions for eleciting immune
responses with the aim of eleciting beneficial immune responses, e.g., to protect against
pneumococcal infections and associated pathogens. These antigens provide novel targets for
characterizing pneumococcal infections and immune responses to pneumococcal infections.
[00117] Accordingly, in one aspect of the invention provides an immunogenic composition (e.g.,
vaccine) comprising an isolated pneumococcal antigen selected from a SP0785 polypeptide antigen, a
SP1500 polypeptide antigen, a SP0346 polypeptide antigen, a SP1386 polypeptide antigen, a SP0084
polypeptide antigen, a SP1479 polypeptide antigen, a SP2145 polypeptide antigen, and combinations
thereof.
[00118] In some embodiments, an immunogenic composition comprises a SP0785 pneumococcal
polypeptide antigen. In some embodiments, a SP0785 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP0785 polypeptide sequence. In some
embodiments, a SP0785 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:34. In some embodiments, a SP0785
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:35. In some embodiments, a SP0785
pneumococcal polypeptide antigen is encoded by SEQ ID NO: 110 or a fragment thereof. In some
embodiments, functional fragment of a SP0785 pneumococcal polypeptide antigen comprises amino
acids of SEQ ID NO: 190 or comprises an amino acid sequence that is at least 60% (e.g., at least 65%,
                                                   34

    WO 2014/124228                                                                   PCT/US2014/015254
70%, 75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:190.
[00119] In some embodiments, an immunogenic composition comprises a SP1500 pneumococcal
polypeptide antigen. In some embodiments, a SP1500 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP1500 polypeptide sequence. In some
embodiments, a SP1500 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:51. In some embodiments, a SP1500
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:51. In some embodiments, a SP1500
pneumococcal polypeptide antigen is encoded by SEQ ID NO: 127 or a fragment thereof. In some
embodiments, functional fragment of a SP1500 pneumococcal polypeptide antigen comprises amino
acids of SEQ ID NO: 209 or comprises an amino acid sequence that is at least 60% (e.g., at least 65%,
70%, 75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:209.
[00120] In some embodiments, an immunogenic composition comprises a SP0346 pneumococcual
polypeptide antigen. In some embodiments, a SP0346 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP0346 polypeptide sequence. In some
embodiments, a SP0346 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:15. In some embodiments, a SP0346
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:15. In some embodiments, a SP0346
pneumococcal polypeptide antigen is encoded by SEQ ID NO: 91 or a fragment thereof. In some
embodiments, functional fragment of a SP0346 pneumococcal polypeptide antigen comprises amino
acids of SEQ ID NO: 166 or comprises an amino acid sequence that is at least 6 0% (e.g., at least 6 5%,
70%, 75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:166.
                                                   35

    WO 2014/124228                                                                    PCT/US2014/015254
[00121] In some embodiments, an immunogenic composition comprises a SP1386 pneumococcal
polypeptide antigen. In some embodiments, a SP1386 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP1386 polypeptide sequence. In some
embodiments, a SP1386 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:46. In some embodiments, a SP1386
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:46. In some embodiments, a SP1386
pneumococcal polypeptide antigen is encoded by SEQ ID NO: 122 or a fragment thereof. In some
embodiments, functional fragment of a SP1386 pneumococcal polypeptide antigen comprises amino
acids of SEQ ID NO: 204 or comprises an amino acid sequence that is at least 60% (e.g., at least 65%,
70%, 75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO: 204.
[00122] In some embodiments, an immunogenic composition comprises a SP0084 pneumococcal
polypeptide antigen. In some embodiments, a SP0084 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP0084 polypeptide sequence. In some
embodiments, a SP0084 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:4. In some embodiments, a SP0084
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:4. In some embodiments, a SP0084 pneumococcal
polypeptide antigen is encoded by the sequence shown in SEQ ID NO: 80 or a fragment thereof. In
some embodiments, functional fragment of a SP0084 pneumococcal polypeptide antigen comprises
amino acids of SEQ ID NO: 156 or comprises an amino acid sequence that is at least 60% (e.g., at
least 65%, 7 0%, 7 5%, 80%, 85%, 90%, 95%, or       98
                                                       %) identical to at least 7, 8, 9, 10, 11, 12, 13, 14,
15,16,17,18,19,20,25,30,35,45,50,60,65,70,75,80,85,90,95,100,150,200,250,300,350,
or 400 consecutive amino acids of the sequence shown in SEQ ID NO:156.
[00123] In some embodiments, an immunogenic composition comprises a SP1479 pneumococcal
polypeptide antigen. In some embodiments, a SP1479 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
                                                   36

    WO 2014/124228                                                                   PCT/US2014/015254
200, 250, 300, 350, or 400 consecutive amino acids of a SP1479 polypeptide sequence. In some
embodiments, a SP1479 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:50. In some embodiments, a SP1479
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:50. In some embodiments, a SP1479
pneumococcal polypeptide antigen is encoded by the sequence shown in SEQ ID NO: 126 or a
fragment thereof. In some embodiments, functional fragment of a SP1479 pneumococcal
polypeptide antigen comprises amino acids of SEQ ID NO: 208 or comprises an amino acid sequence
that is at least 60% (e.g., at least 65%, 7 0%, 7 5%, 80%, 85%, 90%, 95%, or 98%) identical to at least
7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100,
150, 200, 250, 300, 350, or 400 consecutive amino acids of the sequence shown in SEQ ID NO: 208.
[00124] In some embodiments, an immunogenic composition comprises a SP2145 pneumococcal
polypeptide antigen. In some embodiments, a SP2145 polypeptide antigen comprises at least 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150,
200, 250, 300, 350, or 400 consecutive amino acids of a SP2145 polypeptide sequence. In some
embodiments, a SP2145 polypeptide antigen comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400
consecutive amino acids of the sequence shown in SEQ ID NO:70. In some embodiments, a SP2145
polypeptide antigen comprises an amino acid sequence that is at least 60% (e.g., at least 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 98%) identical to at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, or 400 consecutive
amino acids of the sequence shown in SEQ ID NO:70. In some embodiments, a SP2145
pneumococcal polypeptide antigen is encoded by the sequence shown in SEQ ID NO: 146 or a
fragment thereof. In some embodiments, functional fragment of a SP2145 pneumococcal
polypeptide antigen comprises amino acids of SEQ ID NO: 70 or comprises an amino acid sequence
that is at least 60% (e.g., at least 65%, 7 0%, 7 5%, 80%, 85%, 90%, 95%, or 98%) identical to at least
7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 100,
150, 200, 250, 300, 350, or 400 consecutive amino acids of the sequence shown in SEQ ID NO: 70.
[00125] In some embodiments, an immunogenic composition comprises two or more isolated
pneumococcal antigens. In some embodiments, the two or more isolated antigens comprise two or
more of a polypeptide antigens selected from Table 1. In some embodiments, the two or more isolated
pneumococcal antigens comprise three or more of a polypeptide antigen selected from Table 1. In
some embodiments, the two or more isolated pneumococcal antigens comprise four or more of a
polypeptide antigen selected from Table 1. In some embodiments, the two or more isolated
                                                    37

     WO 2014/124228                                                               PCT/US2014/015254
pneumococcal antigens comprise five, six, seven or more of a polypeptide antigen selected from
Table 1. In some embodiments, the two or more isolated pneumococcal antigens comprise eight
polypeptide antigens selected from Table 1.
[00126] The inventive pneumococcal antigens as described herein may be used in conjunction with
other pneumococcal antigens such as those known in the art, such as those disclosed in US patent
WO/2000/037105, 7,217,791 and 7,585,669, US2006/0121058, US2012/0251577, US2011/0159040,
US2012/0189649, and US20110020386 which are incorporated herein in their entirety by reference.
Other appropriate S. pneumoniae antigens for combination vaccines include Pneumococcal surface
protein A (PspA); derivatives of PspA, Choline-binding protein A (CbpA) and derivatives thereof;
Pneumococcal surface adhesin A (PsaA); caseinolytic protease; sortase A (SrtA); pilus 1 RrgA
adhesin; PpmA; PrtA; PavA; LytA; Stk-PR; PcsB; RrgB and derivatives thereof. For further details,
see, e.g., A.D Ogunniyi et al., "Protection against Streptococcus pneumoniae elicited by immunization
with pneumolysin and CbpA," Infect Immun. 2001 October; 69 (10):5997-6003; which is
incorporated by reference herein in its entirety.
[00127] Derivatives of PspA include proline-rich segments with the non-proline block (PR+NPB,
further described below as well as in Daniels, C. C. et al. (2010) Infection and Immunity 78:2163-72)
and related constructs comprising all or a fragment of the proline-rich region of PspA (e.g., regions
containing one or more of the sequences PAPAP (SEQ ID NO: 262), PKP, PKEPEQ (SEQ ID NO:
402) and PEKP (SEQ ID NO: 403) and optionally including a non-proline block). An example of the
non-proline-block has the exemplary sequence EKSADQQAEEDYARRSEEEYNRLTQQQ (SEQ ID
NO: 239), which generally has no proline residues in an otherwise proline-rich area of the non-coiled
region of PspA. PspA and its derivatives can include genes expressing similar proline-rich structures
(i.e. PKP, PKEPEQ (SEQ ID NO: 402) and PEKP (SEQ ID NO: 403)), with or without the NPB. The
amino acids at either end of the NPB mark the boundaries of the proline-rich region. In one example,
the amino-terminal boundary to the PR-region is DLKKAVNE (SEQ ID NO: 240), and the carboxy
terminal boundary is (K/G)TGW(K/G)QENGMW (SEQ ID NO: 241). Peptides containing the NPB
are particularly immunogenic, suggesting that the NPB may be an important epitope. Exemplary
immunogenic PspA polypeptides and derivatives thereof (e.g. with and without the coiled-coil
structure are described, e.g., in International Patent Publication W02013109995; which is
incorporated by reference herein in its entirety. Immunogenic PspA polypeptides include both PR and
NPB sequences (PR+NPB). Immunogenic PspA polypeptides can include only a PR sequence (PR
only) and lack the NPB.
[00128]    In some embodiments, an immunogenic composition comprises an isolated pneumococcal
polypeptide antigen selected from Table 1. In some embodiments, an immunogenic composition
comprises two, three, four, five or more isolated pneumococcal polypeptide antigens selected from
Table 1. In some embodiments, a pneumococcal antigen is fused to a heterologous polypeptide (e.g.,
                                                   38

    WO 2014/124228                                                                PCT/US2014/015254
an epitope tag). In some embodiments, an immunogenic composition comprising a pneumococcal
antigen includes a pharmaceutically acceptable excipient.
[00129] While pneumococcal antigens are disclosed in WO/2000/037105, unlike in the present
invention, in WO/2000/037105 their ability to induce a Thl7 cell response was not assessed or
known. Additionally, pneumococcal antigens are also disclosed in US application 2012/0189649 and
US2012/0251577. However unlike the present invention, in the '649 and '577 applications, a whole
genome library was used instead of purified proteins to screen for antigens which elicited a Thl7
response, thus high expression levels of the antigens are likely to be required for an immunogenic
effect or to elicit a Thl 7 response. In the present invention, purified pneumococcal antigen proteins
are used, and thus has an advantage of very low background and requires lower expression levels of
each pneumococcal antigen to induce an immunogenic effect and elicit a Thl 7 response, as
demonstrated in the Examples.
[00130] The pneumococcal antigens as described herein can be prepared using recombinant DNA
technology, purified from natural sources, or synthesized chemically. In some embodiments, where a
pneumococcal antigen as described herein is fused or conjugated to PdT, the PdT can differ in amino
acid sequence from a naturally occurring S. pneumoniae pneumolysin protein.
[00131] Nucleic acids encoding truncated and/or mutated forms of a pneumococcal antigen as
described herein can be prepared, for example, by polymerase chain reaction (PCR). Nucleic acids
encoding such proteins can be chosen for having codons, which are preferred or non-preferred, for a
particular expression system. For example, the nucleic acid can be one in which at least one codon,
preferably at least 10%, or 20% of the codons have been altered such that the sequence is optimized
for expression in E. coli, yeast, human, insect, or CHO cells.
[00132] Nucleic acids encoding truncated and/or mutated forms of a pneumococcal antigen as
described herein can be fused to nucleotide sequences encoding (1) other pneumococcal proteins, such
as autolysin, surface protein A, neuraminidase, hyaluronate lysate, choline binding protein A, or (2)
non-pneumococcal proteins from organisms such as hemophilus influenza b, meningococcus group A,
B, or C, or streptococcus group B. The nucleic acids encoding such fused protein are expressed in the
expression systems.
[00133] Pneumolysin truncates can be useful carriers of polysaccharides, as hosts may lacking pre
existing antibodies to such a carrier polypeptide. Pneumolysin is a virulence factor in pneumococcal
infections and there is little antigenic variation of the pneumolysin among pneumococci with different
subtypes.
[00134] A pneumococcal antigen as described herein, when administered to a mammal such as a
human, when fused to a polysaccharide induces immune response that exceeds in magnitude, type,
and/or duration the immune response induced by administration to a mammal of only the
polysaccharide component. Accordingly, the pneumococcal antigen component must be of a length
sufficient to induce such an enhanced immune response. For fragments of a naturally occurring
                                                    39

    WO 2014/124228                                                                    PCT/US2014/015254
pneumococcal antigen as described herein, the fragments are at least 8, 10, 25, 50, 75, 100, 125, 150,
175, 200, 250, 300, 350, 400, 425, 450, 460, 465, 460, 465, or more amino acids in length. For
pneumococcal antigens, varying in sequence from a naturally occurring S. pneumoniae antigens as
described herein, the polypeptide can be at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98% or more identical to a naturally occurring S. pneumococcal antigens as described
herein in Table 1.
[00135] The polysaccharide component which can be conjugated to one or more of a pneumococcal
antigen as described herein can be any S. pneumoniae capsular polysaccharide, including but not
limited to, any of subtypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A,
19F, 19A, 20, 22F, 23A, 23F, 24F, 27, 33F, or 34. In some embodiments, the capsular polysaccharide
is selected from subtypes 4, 6B, 9V, 14, 18C, 19F, or 23F. In some embodiments, the polysaccharide
is serotype 14. In other embodiments, the polysaccharide is serotype 18C. One or more of different
capsular polysaccharides can be conjugated to a single polypeptide or a plurality of polypeptides. For
example, a multivalent conjugate can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 different capsular
polysaccharides. Polysaccharides can be conjugated to polypeptides, for example, via a monomeric
linkage (only one end of the polysaccharide is attached to the polypeptide), a looped linkage (a single
polypeptide is attached to looped polysaccharides), or cross-linked (multiple polysaccharides attached
to multiple polypeptides).
[00136] Methods for the purification of polypeptides, e.g., a pneumococcal antigen as described
herein, can be performed by one of ordinary skill in the art, and polypeptide or polysaccharide
purification and conjugation processes are described in, e.g., U.S. Pat. Nos. 4,242,501; 4,686,102;
5,623,057; and 5,565,204, which are incorporated herein in its entirety by reference.
[00137] The immunogenic compositions described herein can be administered to a mammal to elicit
an immune response (a prophylactic and/or therapeutic immune response) against S. pneumoniae in
the mammal. A pharmaceutical composition containing a pneumococcal antigen, alone or as a
conjugate can be delivered in a pharmaceutically acceptable carrier, buffer, or preservative which is
suitable for a vaccine including, but not limited to, physiological saline or other injectable liquids.
Additives customary in vaccines may also be present, for example stabilizers such as lactose or
sorbitol, and adjuvants to enhance the immunogenic response such as aluminum phosphate,
hydroxide, or sulphate and stearyl tyrosine. The vaccine produced may also be used as components of
multivalent vaccines which elicit an immune response against a plurality of infectious agents.
[00138] The compositions can be administered in any manner known in the art, e.g., orally
intramuscularly, intravenously, intraarterially, intrathecally, intradermally, intraperitoneally,
intranasally, intrapulmonarily, intraocularly, intravaginally, intrarectally or subcutaneously. They can
be introduced into the gastrointestinal tract or the respiratory tract, e.g., by inhalation of a solution or
powder containing the conjugates. In some embodiments, the compositions can be administered via a
skin patch.
                                                   40

    WO 2014/124228                                                               PCT/US2014/015254
[00139] A pharmaceutical composition (e.g., a vaccine) is administered in an amount sufficient to
elicit production of antibodies as part of an immunogenic response. Dosage for any given patient
depends upon many factors, including the patient's size, general health, sex, body surface area, age,
the particular compound to be administered, time and route of administration, and other drugs being
administered concurrently. Determination of optimal dosage is well within the abilities of a
pharmacologist of ordinary skill.
[00140] The ability of a composition to elicit an immune response in a host mammal can be assayed
by using methods for measuring immune responses that are well known in the art. For example, the
generation of cytotoxic T cells can be demonstrated in a standard "Cr release assay, by measuring
intracellular cytokine expression or secretion, or by using major histocompatibility complex (MHC)
tetramers. Standard assays, such as enzyme-linked immunosorbent assay (ELISA) or enzyme-linked
immunospot (ELISPOT), can be used to measure cytokine profiles attributable to T cell activation. T
cell proliferation can be measured using assays such as 3H-thymidine uptake and other assays known
in the art. B cell responses can be measured using art recognized assays such as ELISA. Other
methodologies can also be used to evaluate the effects of the conjugates on pathogen-associated
lesions or on other pathogen levels generally (e.g., pneumococci clearance in challenged mice treated
with the conjugate).
[00141] The composition described herein can be used in the manufacture of a medicament for the
prevention or treatment of an infection with S. pneumoniae or conditions associated with such
infection.
Adjuvants
[00142] In some embodiments, an immunogenic composition comprising a pneumococcal antigen
includes an adjuvant. In some embodiments, an immunogenic composition includes a mineral
containing adjuvant. In some embodiments, the mineral-containing adjuvant includes aluminum
hydroxide. In some embodiments, an immunogenic composition includes an adjuvant comprising an
immunomodulatory oligonucleotide. In some embodiments, an immunogenic composition includes
IC3 1TM adjuvant (Intercell AG). In some embodiments, an immunogenic composition includes an
adjuvant comprising a toxin. In some embodiments, an immunogenic composition includes an
adjuvant comprising an endotoxin. In some embodiments, an immunogenic composition includes an
adjuvant comprising a muramyl dipeptide. In some embodiments, an immunogenic composition
includes an adjuvant comprising an oil emulsion. In some embodiments, an immunogenic
composition includes an adjuvant comprising a saponin. In some embodiments, an immunogenic
composition includes an adjuvant comprising an immune stimulating complex (ISCOM). In some
embodiments, an immunogenic composition includes an adjuvant comprising a nonionic block
copolymer. In some embodiments, an immunogenic composition includes virus-like particles (VLPs),
for example, a cholera toxin. In some embodiments, an immunogenic composition includes replicons.
In some embodiments, an immunogenic composition includes an adjuvant comprising liposomes. In
                                                  41

    WO 2014/124228                                                                PCT/US2014/015254
some embodiments, an immunogenic composition includes an adjuvant comprising microparticles. In
some embodiments, an immunogenic composition includes an adjuvant comprising biodegradable
microspheres. In some embodiments, an immunogenic composition includes an adjuvant comprising a
cytokine. In some embodiments, an immunogenic composition includes an adjuvant comprising a
lipopeptide.
[00143] Immunogenic compositions may contain adjuvants. In some embodiments, cholera toxin
(CT) can be used as an adjuvant for intranasal administration, resulting in protection from
pneumococcal colonization. Alum is an affective adjuvant for subcutaneous injection. Adjuvants are
typically a heterogeneous group of substances that enhance the immunological response against an
antigen that is administered simultaneously. In some instances, adjuvants are added to a vaccine to
improve the immune response so that less vaccine is needed. Adjuvants serve to bring the antigen
the substance that stimulates the specific protective immune response-into contact with the immune
system and influence the type of immunity produced, as well as the quality of the immune response
(magnitude or duration). Adjuvants can also decrease the toxicity of certain antigens and provide
solubility to some vaccine components. Almost all adjuvants used today for enhancement of the
immune response against antigens are particles or form particles together with the antigen. In the book
"Vaccine Design-the subunit and adjuvant approach" (Ed: Powell & Newman, Plenum Press, 1995)
almost all known adjuvants are described both regarding their immunological activity and regarding
their chemical characteristics. The type of adjuvants that do not form particles are a group of
substances that act as immunological signal substances and that under normal conditions consist of
the substances that are formed by the immune system as a consequence of the immunological
activation after administration of particulate adjuvant systems.
[00144] Adjuvants for vaccines are well known in the art. Suitable additional adjuvants include, but
are not limited to: complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA), saponin,
mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic
polyols, polyaninons, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins,
dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and
Corynebacterium parvum. Selection of an adjuvant depends on the animal subject to be vaccinated.
Additional examples include, but are not limited to, monoglycerides and fatty acids( e. g. a mixture of
mono-olein, oleic acid, and soybean oil); mineral salts, e.g., aluminium hydroxide and aluminium or
calcium phosphate gels; oil emulsions and surfactant based formulations, e.g., MF59 (microfluidised
detergent stabilized oil-in-water emulsion), QS21 (purified saponin), AS02 [SBAS2] (oil-in-water
emulsion + MPL + QS-21), Montanide ISA-51 and ISA-720 (stabilized water-in-oil emulsion);
particulate adjuvants, e.g., virosomes (unilamellar liposomal vehicles incorporating influenza
haemagglutinin), AS04 ([SBAS4] Al salt with MPL), ISCOMS (structured complex of saponins and
lipids), polylactide co-glycolide (PLG); microbial derivatives (natural and synthetic), e.g.,
monophosphoryl lipid A (MPL), Detox (MPL + M. Phlei cell wall skeleton), AGP [RC-529]
                                                  42

    WO 2014/124228                                                               PCT/US2014/015254
(synthetic acylated monosaccharide), DCChol (lipoidal immunostimulators able to self organize into
liposomes), OM-174 (lipid A derivative), CpG motifs (synthetic oligonucleotides containing
immunostimulatory CpG motifs), modified LT and CT (genetically modified bacterial toxins to
provide non-toxic adjuvant effects); endogenous human immunomodulators, e.g., hGM-CSF or hIL
12 (cytokines that can be administered either as protein or plasmid encoded), Immudaptin (C3d
tandem array) and inert vehicles, such as gold particles. Newer adjuvants are described in United
States Patent No. 6,890,540, United States Patent Application No. 2005/0244420, and
PCT/SE97/01003, and US2012/0135025, the contents of which are incorporated herein in their
entirety by reference. The adjuvant can also be selected from the group consisting of QS- 21, Detox
PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL-1005, GERBU, TERamide, PSC97B, Adjumer, PG
026, GSK-I, GcMAF, B-alethine, MPC-026, Adjuvax, CpG ODN, Betafectin, Alum, and MF59.
[00145] In some embodiments, alternative adjuvants can be used, such as a pharmaceutically
acceptable adjuvant. For example, oils or hydrocarbon emulsion adjuvants should not be used for
human vaccination. One example of an adjuvant suitable for use with humans is alum (alumina gel).
Details of common adjuvants which are contemplated to be added to the vaccine comprising an
antigen as disclosed in Table 1 include those discussed below:
[00146] Complete Freund's Adjuvant (CFA): A mineral oil adjuvant; uses a water-in-oil emulsion
which is primarily oil. For many years the adjuvant of choice was complete Freund's adjuvant. This
adjuvant, while potent immunogenically, also has had a significant history of frequently producing
abscesses, granulomas and tissue sloughs. It contains paraffin oil, killed mycobacteria and mannide
monoosleate. The paraffin oil is not metabolized; it is either expressed through the skin (via a
granuloma or abscess) or phagocytized by macrophages. Multiple exposures to CFA will cause severe
hypersensitivity reactions. Accidental exposure of personnel to CFA can result in sensitization to
tuberculin.
[00147] Incomplete Freund's Adjuvant (IFA): Also a mineral oil adjuvant. Composition similar to
CFA but does not contain the killed mycobacteria so does not produce as severe reactions. Used for
the booster immunizations following the initial injection with antigen-CFA. IFA can be used for
initial injection if the antigen is strongly immunogenic.
[00148] Montanide ISA (Incomplete Seppic Adjuvant): A mineral oil adjuvant. Uses mannide oleate
as the major surfactant component. The antibody response is generally similar to that with IFA.
Montanide ISA may have a lessened inflammatory response.
[00149] Ribi Adjuvant System (RAS): An oil-in-water emulsion that contains detoxified endotoxin
and mycobacterial cell wall components in 2% squalene. Multiple formulations are commercially
available, dependent on use. Is an alternative to CFA. Lower viscosity than CFA. Results (titers) often
comparable to those with CFA. The squalene oil is metabolizable. RAS has a lower incidence of toxic
reactions.
                                                  43

    WO 2014/124228                                                               PCT/US2014/015254
[00150] TiterMax: Another water-in-oil emulsion, this preparation combines a synthetic adjuvant and
microparticulate silica with the metabolizable oil squalene. The copolymer is the immunomodulator
component. Antigen is bound to the copolymer and presented to the immune cells in a highly
concentrated form. Less toxicity than CFA. TiterMax usually produces the same results as CFA.
[00151] Syntex Adjuvant Formulation (SAF): A preformed oil-in-water emulsion. Uses a block
copolymer for a surfactant. A muramyl dipeptide derivative is the immunostimulatory component. All
in squalene, a metabolizable oil. SAF can bias the humoral response to IgG2a in the mouse, but is less
toxic than CFA.
[00152] Aluminum Salt Adjuvants: Most frequently used as adjuvants for vaccine antigen delivery.
Generally weaker adjuvants than emulsion adjuvants. Aluminum Salt Adjuvants are best used with
strongly immunogenic antigens, but result generally in mild inflammatory reactions.
[00153] Nitrocellulose-adsorbed antigen: The nitrocellulose is basically inert, leading to almost no
inflammatory response. Slow degradation of nitrocellulose paper allows prolonged release of antigen.
Does not produce as dramatic an antibody response as CFA. Nitrocellulose-adsorbed antigen is good
for use if only a small amount of antigen can be recovered from a gel band, e.g., for animal
immunization.
[00154] Encapsulated or entrapped antigens: Permits prolonged release of antigen over time; can also
have immunostimulators in preparation for prolonged release. Preparation of encapsulated or
entrapped antigens is complex.
[00155] Immune-stimulating complexes (ISCOMs): Antigen modified saponin/cholesterol micelles.
Stable structures are formed which rapidly migrate to draining lymph nodes. Both cell-mediated and
humoral immune responses are achieved. Low toxicity; ISCOMs can elicit significant antibody
response. Quil A is one example, QS-21 is another.
[00156] GerbuR adjuvant: An aqueous phase adjuvant which uses immunostimulators in combination
with zinc proline. GerbuR does not have a depot effect and has minimal inflammatory effect. GerbuR
requires frequent boosting to maintain high titers.
[00157] Another group of adjuvants include immune stimulators such as cytokines IL-12, IL-4 and
costimulatory molecules such as B7. A wide range of molecules having immune stimulating effects
are known including accessory molecules such as ICAM and LFA. In some embodiments, GM-CSF
is administered to the patient before the initial immune administration. GM-CSF can be administered
using a viral vector or an isolated protein in a pharmaceutical formulation. Combinations of adjuvants
can be used such as CM-CSF, ICAM and LFA. While a strong immune response is typically
generated to infectious disease antigens, tumor associated antigens typically generate a weaker
immune response. Thus, immune stimulators such as described above are preferably used with them.
[00158] In some embodiments, a pneumococcal vaccine can contain several pneumococcal antigens
and/or be formulated with different or novel adjuvants, or incorporated in vaccine scaffolds, such as a
fusion-conjugate (e.g., a fusion with a pneumolysoid and conjugation to a polysaccharide as proposed
                                                   44

     WO 2014/124228                                                                     PCT/US2014/015254
in Lu et al, Infection and Immunity, 2009), or using a scaffold, as disclosed in PCT/US12/37412 and
WO 2012/155007 (which are incorporated herein in their entirety by reference) to improve
immunogenicity and facilitate different routes of administration. Accordingly, a composition
comprising at least 2, or at least about 3, or at least about 4, or at least about 5, or at least about 6, or
at least about 7, or at least about 8, or at least about 9, or at least about 10, or at least about 12, or at
least about 14, or at least about 16, or at least about 18, or at least about 20, or at least about 25, or any
integer between about 2 and about 26 different antigens or more that 25 different antigens can be
used, alone or in combination with an adjuvant and/or vaccine scaffold, such as a polysaccharide can
be used.
[00159] In another aspect, the invention provides methods for eliciting an immune response against
pneumococcus in a mammal. The methods include, for example, administering to the mammal an
immunogenic composition comprising an isolated pneumococcal polypeptide antigen selected from
Table 1 or fragments and combinations thereof, e.g., an immunogenic composition described herein.
[00160]     In some embodiments, a method elicits an immune response against pneumococcus. In some
embodiments, a method elicits a T cell response to a pneumococcal antigen (e.g., a CD4+ T cell
mediated immune response and/or a CD8+ T cell mediated immune response). In some embodiments,
a method elicits a Th1 T cell response. In some embodiments, a method elicits a Thl7 T cell response.
In some embodiments, a method elicits IFN-y secretion by antigen-specific T cells. In some
embodiments, a method elicits an antibody response (e.g., an IgG response, and/or an IgA response).
In some embodiments, a method elicits a cytotoxic T cell (CTL) response. In some embodiments, a
method elicits a B cell-mediated immune response. In some embodiments, a method elicits both a T
cell- and a B cell-mediated response. In some embodiments, a method elicits an innate immune
response.
[00161]     In some embodiments, a method reduces the incidence of pneumococcal infection in
subjects administered the composition. In some embodiments, a method reduces the likelihood of
lower tract infection by a pneumococcus. In some embodiments, a method reduces the likelihood of
upper tract infection by a pneumococcal organism. In some embodiments, a method reduces the
likelihood of chronic infection by a pneumococcal organism. In some embodiments, a method reduces
the likelihood of suffering from pelvic inflammatory disease due to a pneumococcal infection. In
some embodiments, a method reduces the likelihood of infertility subsequent to a pneumococcal
infection.
[00162]     In some embodiments of a method, an immunogenic composition is administered to the
mammal at least two times (e.g., two, three, four, or five times).
[00163] In some embodiments, an immunogenic composition administered after a first administration
(i.e., as a boost) differs from the composition administered initially, e.g., the composition includes a
different pneumococcal antigen or a different subset of pneumococcal antigens, or a different
pneumococcal antigen substance (polypeptide or nucleic acid encoding same), or a different dose of
                                                     45

    WO 2014/124228                                                                PCT/US2014/015254
antigen, or a different adjuvant, or a different dose of adjuvant. In some embodiments, a boost is
administered by a different route than a previous administration.
[00164] In some embodiments, the mammal is at risk for infection with pneumococcus. In some
embodiments, the mammal is infected with a pneumococcal infection. In some embodiments, the
mammal is a human.
[00165]    In some embodiments, an immunogenic composition administered in a method comprises an
adjuvant. In some embodiments, an adjuvant is a mineral-containing adjuvant. In some embodiments,
an immunogenic composition administered in a method comprises a pharmaceutically acceptable
excipient.
[00166]    In some embodiments, a pneumococcal antigen composition includes an adjuvant. In some
embodiments, the adjuvant includes mineral-containing adjuvant. Mineral-containing adjuvants can
be formulated as gels, in crystalline form, in amorphous form, as particles, etc. Mineral-containing
adjuvants include, for example, aluminum salts and/or calcium salts (e.g., aluminum hydroxide,
aluminum phosphate, aluminum sulfate, calcium phosphate, etc.). In some embodiments, a
pneumococcal antigen composition includes aluminum hydroxide. Alhydrogel.TM. is an example of
an aluminum hydroxide gel adjuvant.
[00167] In some embodiments, an adjuvant includes an immunomodulatory oligonucleotide. In some
embodiments, an immunomodulatory oligonucleotide sequence includes CpG (unmethylated
cytosine-guanosine) motifs. Oligonucleotides having CpG motifs can include nucleotide analogs
and/or non-naturally occurring internucleoside linkages (e.g., phosphorothioate linkages). For
examples of various oligonucleotides include CpG motifs, see Kandimalla, et al., Nuc. Acids Res.
31(9): 2393-2400, 2003; WO02/26757; W099/62923; Krieg, Nat. Med. 9(7): 831-835, 2003;
McCluskie, et al., FEMS Immunol. Med. Microbiol. 32:179-185, 2002; W098/40100; U.S. Pat. No.
6,207,646; U.S. Pat. No. 6,239,116 and U.S. Pat. No. 6,429,199. Other immunomodulatory nucleotide
sequences double stranded RNA sequences, palindromic sequences, and poly(dG) sequences.
[00168] In some embodiments, an adjuvant comprises IC.sub.31.TM. (Intercell AG). IC31.TM. is a
synthetic adjuvant that includes an antimicrobial peptide, KLK, and an immunostimulatory
oligonucleotide, ODNia, and acts as a Toll-like Receptor 9 (TLR9) agonist. In some embodiments,
an adjuvant includes a toxin. In some embodiments, a toxin is a bacterial ADP-ribosylating toxin, e.g.,
cholera toxin (CT), E. coli heat labile toxin, or pertussis toxin. In some embodiments, the bacterial
toxin is a detoxified form of an ADP-ribosylating toxin (see, e.g., Beignon, et al., Inf. Immun.
70(6):3012-3019, 2002; Pizza, et al., Vaccine 19:2534-2541, 2001; Pizza, et al., Int. J. Med.
Microbiol. 290(4-5):455-461, 2000; Scharton-Kersten et al., Inf. Immun.68(9):5306-5313, 2000;
Ryan et al., Inf. Immun 67(12):6270-6280, 1999; Partidos et al., Immunol. Lett. 67(3):209-216, 1999;
Peppoloni et al., Vaccines 2(2):285-293, 2003; and Pine et al., J. Control Release 85(1-3):263-270,
2002). In some embodiments, an adjuvant includes an endotoxin such as monophosphoryl lipid A or
3-De-O-acylated monophosphoryl lipid A (see U.S. Pat. No. 4,987,237 and GB 2122204B).
                                                   46

    WO 2014/124228                                                               PCT/US2014/015254
[00169] In some embodiments, an adjuvant includes a muramyl dipeptide (e.g., N-acetyl-muramyl-L
threonyl-D-isoglutamine(thr-MDP), N-acetyl-normuramyl-1-alanyl-d-isoglutamine(nor-MDP), and
N-acetylmuramyl-1-alanyl-d-isoglutaminyl-1-alanine-2-(l'-2'-dipalmitoyl-s-    -n-glycero-3
hydroxyphosphoryloxy)-ethylamine MTP-PE). In some, an adjuvant includes an oil emulsion and/or
emulsifier-based adjuvant. In some embodiments, an oil emulsion adjuvant includes a Freund's
Adjuvant (e.g., Complete Freund's adjuvant (CFA), or incomplete Freund's adjuvant (IFA)). In some
embodiments, an oil-emulsion adjuvant includes a squalene water emulsion, such as MF59 (Novartis;
see, e.g., W09014837), or a Synex adjuvant formulation (SAF)). In some embodiments, an oil
emulsion includes a dispersing agent, e.g., a mono- or di-C.sub.12-C.sub.24-fatty acid ester of
sorbitan or mannide, e.g., sorbitan mono-stearate, sorbitan mon-oleate, or mannide mono-oleate.
Examples of oil emulsions that include squalene and dispersing agents includes ArlacelTM,
MontanideTM ISA-720, and MontanideTM ISA-703. Other oil emulsions are described, e.g., in WO
95/17210 and EP 0399842.
[00170] In some embodiments, an adjuvant includes a saponin. Saponins are steroid and/or
triterpenoid glycosides derived from plants such as Quillaja saponaria, Saponaria officianalis, Smilax
ornata, and Gypsophilla paniculata. Fractions of saponin-containing extracts that have been described
and that can be used as adjuvants for pneumococcal antigens include Quil.TM.A, QS21, QS7, QS17,
QS18, QH-A, QH-B, QH-C, and QuilA (see, e.g., U.S. Pat. No. 5,057,540). In some embodiments,
QS21 is used as an adjuvant.
[00171]    In some embodiments, an adjuvant includes an immune stimulating complex (ISCOM).
ISCOMs are particles that typically include a glycoside (e.g., a saponin) and a lipid. In some
embodiments, an ISCOM includes a saponin and a cholesterol. In some embodiments, an ISCOM
includes a saponin, a cholesterol, and a phospholipid (e.g., phosphatidylcholine and/or
phosphatidylethanolamine). In some embodiments, an ISCOM includes a nonionic block copolymer.
ISCOMs can include additional adjuvants, e.g., additional adjuvant substances described herein (see,
e.g., WO 05/002620). In some embodiments, an ISCOM includes a substance that targets it to a
mucosal membrane (see, e.g., WO97/030728). Other ISCOM compositions and preparation of the
compositions suitable for combination with pneumococcal antigens provided herein are described,
e.g., in U.S. Pat. Pub. No. 20060121065, WO 00/07621, WO 04/004762, WO 02/26255, and WO
06/078213. In some embodiments, an adjuvant comprises an AbISCO@ adjuvant (e.g., Matrix-MTM,
Isconova). In some embodiments, an adjuvant comprises AbISCO@-100. In some embodiments, an
adjuvant comprises AbISCO@-300.
[00172] In some embodiments, an adjuvant includes a nonionic block copolymer. Nonionic block
copolymers typicaly include two chains of hydrophobic polyoxyethylenes of various lengths
combined with a block of hydrophobic polyoxypropylene. In some embodiments, a nonionic block
copolymer is formulated in an oil-in-water emulsion (e.g., with oil and squalene).
                                                47

    WO 2014/124228                                                                   PCT/US2014/015254
[00173] In some embodiments, an adjuvant includes virus like particles (VLPs). VLPs are non
replicating, non infectious particles that typically include one or more viral proteins, optionally
formulated with an additional component such as a phospholipid. In some embodiments, a VLP
includes proteins from one or more of the following: an influenza virus (e.g., a hemaglutinin (HA) or
neuraminidase (NA) polyptide), Hepatitis B virus (e.g., a core or capsid polypeptide), Hepatitis E
virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk
virus, human papilloma virus, HIV, RNA-phages,         Q13-phage  (e.g., a coat protein), GA-phage, fr
phage, AP205 phage, a Ty (e.g., retrotransposon Ty protein p l). See, e.g., W003/024480,
W003/024481, W008/061,243, and W007/098,186. In some embodiments, an adjuvant includes
replicons. Replicons resemble VLPs in that they are noninfectious particles including viral proteins,
and further include a nucleic acid encoding a polypeptide (e.g., an antigen). In some embodiments, a
replicon includes proteins from an alphavirus. Alphaviruses include, e.g., Eastern Equine Encephalitis
Virus (EEE), Venezuelan Equine Encephalitis Virus (VEE), Everglades Virus, Mucambo Virus,
Pixuna Virus, Western Equine Encephalitis Virus (WEE), Sindbis Virus, Semliki Forest Virus,
Middleburg Virus, Chikungunya Virus, O'nyong-nyong Virus, Ross River Virus, Barmah Forest
Virus, Getah Virus, Sagiyama Virus, Bebaru Virus, Mayaro Virus, Una Virus, Aura Virus, Whataroa
Virus, Babanki Virus, Kyzylagach Virus, Highlands J Virus, Fort Morgan Virus, Ndumu Virus, and
Buggy Creek Virus. In some embodiments, an adjuvant includes a replicon that includes a nucleic
acid encoding one or more pneumococcal antigens described herein. In some embodiments, an
adjuvant includes a replicon that encodes a cytokine (e.g., interleukin-12 (IL-12), IL-23, or
granulocyte-macrophage colony-stimulating factor (GM-CSF)). Production and uses of replicons are
described, e.g., in W008/058,035, W008/085,557, and W008/033,966). In some embodiments, a
VLP or replicon adjuvant includes one or more pneumococcal antigens (i.e., VLP or replicon particles
include a pneumococcal antigen as part of the particles). In some embodiments, a VLP or replicon
adjuvant is co-administered with a pneumococcal antigen polypeptide.
[00174] In some embodiments, an adjuvant includes liposomes, which are are artificially-constructed
spherical lipid vesicles (see, e.g., U.S. Pat. Nos. 4,053,585; 6,090,406; and 5,916,588). In certain
embodiments, a lipid to be used in liposomes can be, but is not limited to, one or a plurality of the
following: phosphatidylcholine, lipid A, cholesterol, dolichol, sphingosine, sphingomyelin, ceramide,
glycosylceramide, cerebroside, sulfatide, phytosphingosine, phosphatidyl-ethanolamine,
phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, cardiolipin, phosphatidic acid, and
lyso-phosphatides. In some embodiments, an adjuvant includes a liposome and a ligand for a Toll-like
Receptor (TLR; see, e.g., WO/2005/013891, WO/2005/07951 1, WO/2005/079506, and
WO/2005/013891). In some embodiments, an adjuvant includes JVRS-100. JVRS-100 comprises
cationic liposomes combined with non-coding oligonucleotides or plasmids.
[00175] In some embodiments, an adjuvant includes microparticles comprised of a polymer, e.g., a
polymer of acrylic or methacrylic acid, polyphosphazenes, polycarbonates, polylactic acid,
                                                    48

    WO 2014/124228                                                                  PCT/US2014/015254
polyglycolic acid, copolymers of lactic acid or glycolic acid, polyhydroxybutyric acid,
polyorthoesters, polyanhydrides, polysiloxanes, polycaprolactone, or a copolymer prepared from the
monomers of these polymers. In some embodiments, an adjuvant includes microparticles comprised
of a polymer selected from the group consisting of polyvinylpyrrolidone, polyvinylalcohol,
polyhydroxyethylmethacrylate, polyacrylamide, polymethacrylamide, and polyethyleneglycol (see,
e.g., U.S. Pat. No. 5,500,161).
[00176] In some embodiments, an adjuvant includes biodegradable microspheres (e.g., microspheres
comprised of poly(D,L-lactic acid), poly(D,L-glycolic acid), poly(. epsilon. -caprolactone), polye
(.alpha. -hydroxy actid), polyhydroxybutyric acid, a polyorthoester, a polyanhydride, etc.).
[00177] In some embodiments, an adjuvant includes a cytokine. In some embodiments, an adjuvant
includes IL-12. In some embodiments, an adjuvant includes IL-23. In some embodiments, an adjuvant
includes GM-CSF. In some embodiments, an adjuvant includes a lipopeptide. In some embodiments,
an adjuvant includes a Pam-3-Cys lipopeptide. In some embodiments, an adjuvant including a
lipopeptide activates Toll-like receptors (TLRs).
Additional components of Vaccines or Immunogenic compositions
[00178] In addition to the antigens and the adjuvants described above, a vaccine formulation or
immunogenic composition may include one or more additional components.
[00179] In certain embodiments, the vaccine formulation or immunogenic composition may include
one or more stabilizers such as sugars (such as sucrose, glucose, or fructose), phosphate (such as
sodium phosphate dibasic, potassium phosphate monobasic, dibasic potassium phosphate, or
monosodium phosphate), glutamate (such as monosodium L-glutamate), gelatin (such as processed
gelatin, hydrolyzed gelatin, or porcine gelatin), amino acids (such as arginine, asparagine, histidine,
L-histidine, alanine, valine, leucine, isoleucine, serine, threonine, lysine, phenylalanine, tyrosine, and
the alkyl esters thereof), inosine, or sodium borate.
[00180] In certain embodiments, the vaccine formulation or immunogenic composition includes one
or more buffers such as a mixture of sodium bicarbonate and ascorbic acid. In some embodiments, the
vaccine formulation may be administered in saline, such as phosphate buffered saline (PBS), or
distilled water.
[00181] In certain embodiments, the vaccine formulation or immunogenic composition includes one
or more surfactants such as polysorbate 80 (Tween 80), Triton X-100, Polyethylene glycol tert
octylphenyl ether t-Octylphenoxypolyethoxyethanol 4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene
glycol (TRITON X-100); Polyoxyethylenesorbitan monolaurate Polyethylene glycol sorbitan
monolaurate (TWEEN 20); and 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and
oxirane (TYLOXAPOL). A surfactant can be ionic or nonionic.
[00182] In certain embodiments, the vaccine formulation or immunogenic composition includes one
or more salts such as sodium chloride, ammonium chloride, calcium chloride, or potassium chloride.
                                                   49

    WO 2014/124228                                                                 PCT/US2014/015254
[00183] In certain embodiments, a preservative is included in the vaccine or immunogenic
composition. In other embodiments, no preservative is used. A preservative is most often used in
multi-dose vaccine vials, and is less often needed in single-dose vaccine vials. In certain
embodiments, the preservative is 2-phenoxyethanol, methyl and propyl parabens, benzyl alcohol,
and/or sorbic acid.
[00184] In certain embodiments, the vaccine formulation or immunogenic composition is a
controlled release formulation.
Modifications
[00185]       In some embodiments, the vaccine can comprise at least one immunogen of the sequences
listed in Table 1, or an immunogen which is a functional fragment or has substantial identity to an
immunogen listed in Table 1. Further S. pneumoniae antigens as disclosed herein for combination
vaccines include conjugated S. pneumoniaepolysaccharides. The conjugated polysaccharides may be,
for example, as described in U.S. Pat. No. 5,623,057, U.S. Pat. No. 5,371,197, or
PCT/US2011/023526, which are incorporated herein in their entirety.
[00186] In some embodiments, the pneumococcal antigens described herein may be used with or
without modification. In some embodiments, a pneumococcal antigen may be modified to elicit the
desired immune response. In some embodiments, a pneumococcal antigen is conjugated to an
appropriate immunogenic carrier such as tetanus toxin, pneumolysin, keyhole limpet hemocyanin, or
the like.
[00187] In some embodiments, one or more pneumococcal antigen is present in a scaffold, such as a
fusion-conjugate (e.g., a fusion with a pneumolysoid and conjugation to a polysaccharide as proposed
in Lu et al, Infection and Immunity, 2009), or using a scaffold, as disclosed in PCT/US12/37412, WO
2012/155007 and US2011/0206716, which are incorporated herein in its entirety by reference.
[00188] In some embodiments, a pneumococcal polypeptide antigen is fused to PdT. In some
embodiments, PdT represents a nonhemolytic variant of pneumolysin, or a nonhemolytic variant of
pneumolysin (PdT) (W433F, D385N, and C428G).
[00189] In some embodiments, a pneumococcal polypeptide antigen can exist as a conjugate to
provide for a synergistic immunogenic reaction to an antigenic sugar moiety. For example, the Vi
polysaccharide of Salmonella typhi could be used. Vi capsular polysaccharide has been developed
against bacterial enteric infections, such as typhoid fever (Robbins et al., 150(3) J. Infect. Dis. 436-49
(1984); Levine et al., 7 Baillieres Clin. Gastroenterol. 501-17 (1993)). Vi is a polymer of a-1-4
galacturonic acid with an N acetyl at position C-2 and variable 0-acetylation at C-3. The virulence of
S. typhi correlates with the expression of this molecule (Sharma et al., 101 P.N.A.S. USA 17492-97
(2004)). The Vi polysaccharide vaccine ofS. typhi has several advantages: Side effects are infrequent
and mild, a single dose yields consistent immunogenicity and efficacy. Vi polysaccharide may be
reliably standardized by physicochemical methods verified for other polysaccharide vaccines, Vi is
                                                  50

    WO 2014/124228                                                               PCT/US2014/015254
stable at room temperature and it may be administered simultaneously with other vaccines without
affecting immunogenicity and tolerability (Azze et al., 21 Vaccine 2758-60 (2003)).
[00190] Thus, the Vi polysaccharide of Salmonella typhi may be conjugated to a fusion protein of a
pneumococcal polypeptide antigen, where the pneumococcal polypeptide antigen is fused to PdT or
another protein, such that the resulting vaccine confers immunity against one pathogen, or two
different pathogens: where the pneumococcal polypeptide antigen confers protection against
pneumococcus, a Vi-pneumococcal antigen:PdT construct raises an immunogenic response against S.
typhi andpneumococcus. Other examples include combining sugars from encapsulated bacteria (such
as meningococcus, S. aureus, pneumococcus, etc.) and tuberculous protein, to provide a vaccine that
protects against two different pathogens.
[00191] Other polysaccharide (PS) moities that may be used in the present invention in alternative to
dextran, pneumococcal cell wall polysaccharide (CWPS) etc., include carbohydrate antigens of
cancers. For example, the Tn antigen, an oligosaccharide expressed exclusively by cancer cells
(Buskus et al., 44 Angew Chem. Int'l Ed. 5985-88 (2005)). In some embodiment, the present
invention provides for an immunogenic composition comprising a fusion protein of a truncated
pneumococcal antigen and a nonhemolytic pneumolysin PdT protein, conjugated with CWPS.
[00192] In one aspect of the invention, the polysaccharide has a molecular mass of <500 kDa. In
another aspect of the invention, the PS has a molecular mass of <70 kDa.
[00193]       In some embodiments, a pneumococcal antigen as disclosed herein is present in an
immunogenic multiple antigen presenting system (MAPS) as disclosed in WO 2012/155007, which is
incorporated herein in its entirety by reference, where the pneumococcal antigen as disclosed herein in
present in an immunogenic complex comprising at least one type of polymer, e.g., a polysaccharide,
that can, optionally, be antigenic; at least one pneumococcal antigen as disclosed herein; and at least
one complementary affinity-molecule pair comprising (i) a first affinity molecule that associates with
the polymer, and (ii) a complementary affinity molecule that associates with the protein or peptide;
such that the first and complementary affinity molecules serve as an indirect link between the polymer
with the antigenic protein or peptide. Accordingly, the polymer can attach at least 1, or at least 2, or a
plurality of the same or different protein or peptide antigens. In some embodiments, the polymer is
antigenic, e.g., the polymer is a pneumococcal capsular polysaccharide. In some embodiments, the
pneumococcal antigens are recombinant pneumococcal antigens. Accordingly, one aspect of the
present invention relates to an immunogenic composition comprising a polymer, at least one
pneumococcal antigen, and at least one complementary affinity-molecule pair, where the
complementary affinity-molecule pair comprises a first affinity molecule that associates with the
polymer and a complementary affinity molecule that associates with the pneumococcal antigen, so
that when the first affinity molecule associates with the complementary affinity molecule, it indirectly
links the antigen to the polymer.
                                                   51

    WO 2014/124228                                                                  PCT/US2014/015254
[00194]      In some embodiments, a first affinity molecule in a immunogenic complex is cross-linked
to the polymer with a cross-linking reagent, for example, a cross-linking reagent selected from
CDAP(1-cyano-4-dimethylaminopyridinium tetrafluoroborate), EDC (1-Ethyl-3-[3
dimethylaminopropyl] carbodiimide hydrochloride), sodium cyanoborohydride; cyanogen bromide; or
ammonium bicarbonate/iodoacetic acid. In some embodiments, the first affinity molecule is cross
linked to carboxyl, hydroxyl, amino, phenoxyl, hemiacetal, and mecapto functional groups of the
polymer. In some embodiments, the first affinity molecule is covalently bonded to the polymer. In
some embodiments, the first affinity molecule is biotin or a derivative thereof, or a molecule with
similar structure or physical property as biotin, for example, an amine-PEG3 -biotin ((+)-biotinylation
3-6,9-trixaundecanediamine) or derivative thereof.
[00195]      In some embodiments, a pneumococcal antigen of the immunogenic complex is a fusion
protein comprising a pneumococcal antigenic protein or peptide fused to the complementary affinity
binding molecule. The fusion can be a genetic construct, i.e., a recombinant fusion peptide or protein.
In some embodiments, a pneumococcal antigen can be covalently attached as a fusion protein to the
complementary affinity molecule. In alternative embodiments, the antigen is non-covalently attached
to the complementary affinity molecule.
[00196]      In some embodiments, a complementary affinity molecule in an immunogenic complex is
a biotin-binding protein or a derivative or a functional portion thereof. In some embodiments, a
complementary affinity molecule is an avidin-like protein or a derivative or a functional portion
thereof, for example but not limited to, rhizavidin or a derivative thereof. In some embodiments, a
complementary affinity molecule is avidin or streptavidin or a derivative or a functional portion
thereof.
[00197]    In some embodiments, a polymer of the immunogenic complex is branched chain polymer,
e.g., a branched polysaccharide, or alternatively, can be a straight chain polymer, e.g., a single chain
polymer, e.g., polysaccharide. In some embodiments, the polymer is a polysaccharide, for example,
dextran or a derivative thereof. In some embodiments, a polymer, e.g., dextran polysaccharide can be
of average molecular weight of 425kD 500kDa, inclusive, or in some embodiments, greater than
500kDa. In some embodiments, a polymer, e.g., dextran polysaccharide can be of average molecular
weight of 60kD-9OkDa, inclusive, or in some embodiments, smaller than 70 kDa. The dextran
polymer can be derived from a bacterium, such as Leuconostoc mesenteroides.
[00198]      In some embodiments, an immunogenic composition as disclosed herein comprises at
least 2 antigens, or at 3 least antigens, or at least 5 antigens, or between 2-10 antigens, or between 10
15 antigens, or between 15-20 antigens, or between 20-50 antigens, or between 50 100 antigens, or
more than 100 antigens, inclusive. In some embodiments, where an immunogenic composition as
disclosed herein comprises at least 2 antigens, the antigens can be the same antigen or at least 2
different antigens. In some embodiments, the antigens can be from the same or different pathogens, or
can be different epitopes or parts of the same antigenic protein, or can be the same antigen which is
                                                     52

    WO 2014/124228                                                                PCT/US2014/015254
specific to different serotypes or seasonal variations of the same pathogen (e.g., influenza virus A, B,
and C).
[00199]       A pneumococcal antigen as disclosed herein when present alone, or in an immunogenic
complex can elicit both humoral and cellular responses to one or multiple antigens at the same time.
The immunogenic compositions provide for a long-lasting memory response, potentially protecting a
subject from future infection. This allows for a single immunogenic composition that raises a high
titer of functional anti-polysaccharide antibody, and is similar or compares favorably with the
antibody level induced by conventional conjugate vaccine
[00200] In another embodiment of the present invention, an immunogenic composition can comprise
a fusion protein polysaccharide conjugate, consisting of a pneumococcal antigen selected from Table
1, fused to PdT, where the pneumococcal antigen:PdT fusion protein is conjugated to a
polysaccharide, such that immunity to pneumococcal antigen is enhanced. The polysaccharide may
be dextran, a Vi polysaccharide of Salmonella typhi, or pneumococcal cell wall polysaccharide
(CWPS), or another polysaccharide of prokaryotic or eukaryotic origin.
[00201] Nucleic acids encoding truncated and/or mutated forms of a S. pneumoniaeprotein antigens
can be fused to nucleotide sequences encoding (1) other pneumococcal proteins, such as autolysin,
surface protein A, neuraminidase, hyaluronate lysate, choline binding protein A, or (2) non
pneumococcal proteins from organisms such as hemophilus influenza b, meningococcus group A, B,
or C, or streptococcus group B. The nucleic acids encoding such fused protein are expressed in the
expression systems.
[00202] Pneumolysin truncates can be useful carriers of polysaccharides, as hosts may lacking pre
existing antibodies to such a carrier polypeptide. Pneumolysin is a virulence factor in pneumococcal
infections and there is little antigenic variation of the pneumolysin among pneumococci with different
subtypes.
[00203] The polysaccharide-protein conjugate, when administered to a mammal such as a human,
induces immune response that exceeds in magnitude, type, and/or duration the immune response
induced by administration to a mammal of only the polysaccharide component. Accordingly, the
polypeptide component must be of a length sufficient to induce such an enhanced immune response.
For fragments of a naturally occurring pneumococcal antigen, the fragments are at least 8, 10, 25, 50,
75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 425, 450, 460, 465, 460, 465, or more amino acids in
length. For polypeptides, varying in sequence from a naturally occurring pneumococcal antigens, the
polypeptide can be at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or
more identical to a naturally occurring pneumococcal antigens listed in Table 1.
[00204]       The polysaccharide component of the conjugate can be any S. pneumoniae capsular
polysaccharide, including but not limited to, any of subtypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A,
11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 19A, 20, 22F, 23A, 23F, 24F, 27, 33F, or 34. In some
embodiments, the capsular polysaccharide is selected from subtypes 4, 6B, 9V, 14, 18C, 19F, or 23F.
                                                    53

    WO 2014/124228                                                                  PCT/US2014/015254
In some embodiments, the polysaccharide is serotype 14. In other embodiments, the polysaccharide is
serotype 18C. One or more of different capsular polysaccharides can be conjugated to a single
polypeptide or a plurality of polypeptides. For example, a multivalent conjugate can include at least 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10 different capsular polysaccharides. Polysaccharides can be conjugated to
polypeptides, for example, via a monomeric linkage (only one end of the polysaccharide is attached to
the polypeptide), a looped linkage (a single polypeptide is attached to looped polysaccharides), or
cross-linked (multiple polysaccharides attached to multiple polypeptides).
[00205]        Methods for the purification of polypeptides, e.g., pneumococcal antigen polypeptides
described in the examples and in Table 1, and the conjugation of polysaccharides to polypeptides are
described in in, e.g., U.S. Pat. Nos. 4,242,501; 4,686,102; 5,623,057; and 5,565,204, which are
incorporated herein in their entirety by reference.
[00206]        The conjugates or polypeptides described herein can be administered to a mammal to
elicit an immune response (a prophylactic and/or therapeutic immune response) against S.
pneumoniae in the mammal. A pharmaceutical composition containing a conjugate or polypeptide can
be delivered in a pharmaceutically acceptable carrier, buffer, or preservative which is suitable for a
vaccine including, but not limited to physiological saline or other injectable liquids. Additives
customary in vaccines may also be present, for example stabilizers such as lactose or sorbitol, and
adjuvants to enhance the immunogenic response such as aluminum phosphate, hydroxide, or sulphate
and stearyl tyrosine. The vaccine produced may also be used as components of multivalent vaccines
which elicit an immune response against a plurality of infectious agents.
[00207] In some embodiments, a pneumococcal polypeptide antigen is post-translationally modified,
e.g. by phosphorylation, myristoylation, acylation, glycosylation, glycation, and the like. In some
embodiments, a pneumococcal polypeptide antigen is lipidated. Conjugation to the lipid moiety may
be direct or indirect (e.g., via a linker). The lipid moiety may be synthetic or naturally produced. In
some embodiments, a pneumococcal polypeptide antigen is chemically conjugated to a lipid moiety.
In some embodiments, a DNA construct encoding a pneumococcal polypeptide antigen comprises a
lipidation sequence. A lipidation sequence may be N-terminal or C-terminal to the polypeptide, and
may be embedded in a signal or other sequence. An exemplary lipidation sequence is the signal
sequence of the E. coli gene RlpB.
[00208] In some embodiments, a pneumococcal polypeptide antigen is covalently bound to another
molecule. This may, for example, increase the half-life, solubility, bioavailability, or immunogenicity
of the antigen. Molecules that may be covalently bound to the antigen include a carbohydrate, biotin,
poly(ethylene glycol) (PEG), polysialic acid, N-propionylated polysialic acid, nucleic acids,
polysaccharides, and PLGA. In some embodiments, the naturally produced form of a polypeptide is
covalently bound to a moiety that stimulates the immune system. An example of such a moiety is a
lipid moiety. In some instances, lipid moieties are recognized by a Toll-like receptor (TLR) such as
TLR2 or TLR4 and activate the innate immune system.
                                                     54

    WO 2014/124228                                                                    PCT/US2014/015254
DNA vaccines; Nucleic acid Compositions and antigen expression
[00209] In certain aspects, the vaccine comprises one or more of the nucleic acids disclosed herein or
corresponding to the polypeptides described herein. When a nucleic acid vaccine is administered to a
patient, the corresponding gene product (such as a desired antigen) is produced in the patient's body.
In some embodiments, nucleic acid vaccine vectors that include optimized recombinant
polynucleotides can be delivered to a mammal (including humans) to induce a therapeutic or
prophylactic immune response. The nucleic acid may be, for example, DNA, RNA, or a synthetic
nucleic acid. The nucleic acid may be single stranded or double stranded.
[00210] Various types of vectors are suitable for expression of pneumococcal antigens in an
expression system (e.g., in a host cell). In some embodiments, a composition includes a vector
suitable for expression in vitro (whether in a cell or in a cell-free system), e.g., for producing a
polypeptide composition. The term "vector" refers to a nucleic acid molecule capable of transporting
another nucleic acid to which it has been linked and can include, for example, a plasmid, cosmid or
viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA.
Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno-associated
viruses. Other types of viral vectors are known in the art.
[00211] Nucleic acid vaccine vectors (e.g., adenoviruses, liposomes, papillomaviruses, retroviruses,
etc.) can be administered directly to the mammal for transduction of cells in vivo. The nucleic acid
vaccines can be formulated as pharmaceutical compositions for administration in any suitable manner,
including parenteral administration. Plasmid vectors are typically more efficient for gene transfer to
muscle tissue. The potential to deliver DNA vectors to mucosal surfaces by oral administration has
also been reported (PLGA encapsulated Rotavirus and Hepatitis B) and DNA plasmids have been
utilized for direct introduction of genes into other tissues. DNA vaccines have been introduced into
animals primarily by intramuscular injection, by gene gun delivery, or by electroporation. After being
introduced, the plasmids are generally maintained episomally without replication. Expression of the
encoded proteins has been shown to persist for extended time periods, providing stimulation of B and
T cells.
[00212] In determining the effective amount of the vector to be administered in the treatment or
prophylaxis of an infection or other condition, the physician evaluates vector toxicities, progression of
the disease, and the production of anti-vector antibodies, if any. Often, the dose equivalent of a naked
nucleic acid from a vector is from about 1 gg to 1 mg for a typical 70 kilogram patient, and doses of
vectors used to deliver the nucleic acid are calculated to yield an equivalent amount of therapeutic
nucleic acid. Administration can be accomplished via single or divided doses. The toxicity and
therapeutic efficacy of the nucleic acid vaccine vectors can be determined using standard
pharmaceutical procedures in cell cultures or experimental animals.
[00213] A nucleic acid vaccine can contain DNA, RNA, a modified nucleic acid, or a combination
thereof. In some embodiments, the vaccine comprises one or more cloning or expression vectors; for
                                                   55

    WO 2014/124228                                                                PCT/US2014/015254
instance, the vaccine may comprise a plurality of expression vectors each capable of autonomous
expression of a nucleotide coding region in a mammalian cell to produce at least one immunogenic
polypeptide. An expression vector often includes a eukaryotic promoter sequence, such as the
nucleotide sequence of a strong eukaryotic promoter, operably linked to one or more coding regions.
The compositions and methods herein may involve the use of any particular eukaryotic promoter, and
a wide variety are known; such as a CMV or RSV promoter. The promoter can be heterologous with
respect to the host cell. The promoter used may be a constitutive promoter.
[00214] A vector useful in the present compositions and methods can be circular or linear, single
stranded or double stranded and can be a plasmid, cosmid, or episome. In a suitable embodiment, each
nucleotide coding region is on a separate vector; however, it is to be understood that one or more
coding regions can be present on a single vector, and these coding regions can be under the control of
a single or multiple promoters.
[00215] Numerous plasmids may be used for the production of nucleic acid vaccines. Suitable
embodiments of the nucleic acid vaccine employ constructs using the plasmids VR1O12 (Vical Inc.,
San Diego Calif.), pCMVI.UBF3/2 (S. Johnston, University of Texas) or pcDNA3.1 (InVitrogen
Corporation, Carlsbad, Calif.) as the vector. In addition, the vector construct can contain
immunostimulatory sequences (ISS), such as unmethylated dCpG motifs, that stimulate the animal's
immune system. The nucleic acid vaccine can also encode a fusion product containing the
immunogenic polypeptide. Plasmid DNA can also be delivered using attenuated bacteria as delivery
system, a method that is suitable for DNA vaccines that are administered orally. Bacteria are
transformed with an independently replicating plasmid, which becomes released into the host cell
cytoplasm following the death of the attenuated bacterium in the host cell.
[00216] DNA vaccines, including the DNA encoding the desired antigen, can be introduced into a
host cell in any suitable form including, the fragment alone, a linearized plasmid, a circular plasmid, a
plasmid capable of replication, an episome, RNA, etc. Preferably, the gene is contained in a plasmid.
In certain embodiments, the plasmid is an expression vector. Individual expression vectors capable of
expressing the genetic material can be produced using standard recombinant techniques. See e.g.,
Maniatis et al., 1985 Molecular Cloning: A Laboratory Manual or DNA Cloning, Vol. I and II (D. N.
Glover, ed., 1985) for general cloning methods.
[00217] Routes of administration include, but are not limited to, intramuscular, intranasal,
intraperitoneal, intradermal, subcutaneous, intravenous, intraarterially, intraoccularly and oral as well
as topically, transdermally, by inhalation or suppository or to mucosal tissue such as by lavage to
vaginal, rectal, urethral, buccal and sublingual tissue. Typical routes of administration include
intramuscular, intraperitoneal, intradermal and subcutaneous injection. Genetic constructs may be
administered by means including, but not limited to, traditional syringes, needleless injection devices,
"microprojectile bombardment gene guns", or other physical methods such as electroporation ("EP"),
                                                   56

    WO 2014/124228                                                                  PCT/US2014/015254
"hydrodynamic method", or ultrasound. DNA vaccines can be delivered by any method that can be
used to deliver DNA as long as the DNA is expressed and the desired antigen is made in the cell.
[00218] In some embodiments, a DNA vaccine is delivered via known transfection reagents such as
cationic liposomes, fluorocarbon emulsion, cochleate, tubules, gold particles, biodegradable
microspheres, or cationic polymers. Cochleae delivery vehicles are stable phospholipid calcium
precipitants consisting of phosphatidyl serine, cholesterol, and calcium; this nontoxic and
noninflammatory transfection reagent can be present in a digestive system. Biodegradable
microspheres comprise polymers such as poly(lactide-co-glycolide), a polyester that can be used in
producing microcapsules of DNA for transfection. Lipid-based microtubes often consist of a lipid of
spirally wound two layers packed with their edges joined to each other. When a tubule is used, the
nucleic acid can be arranged in the central hollow part thereof for delivery and controlled release into
the body of an animal.
[00219] In some embodiments, DNA vaccine is delivered to mucosal surfaces via microspheres.
Bioadhesive microspheres can be prepared using different techniques and can be tailored to adhere to
any mucosal tissue including those found in eye, nasal cavity, urinary tract, colon and gastrointestinal
tract, offering the possibilities of localized as well as systemic controlled release of vaccines.
Application of bioadhesive microspheres to specific mucosal tissues can also be used for localized
vaccine action. In some embodiments, an alternative approach for mucosal vaccine delivery is the
direct administration to mucosal surfaces of a plasmid DNA expression vector which encodes the
gene for a specific protein antigen.
[00220] The DNA plasmid vaccines according to the present invention are formulated according to
the mode of administration to be used. In some embodiments where DNA plasmid vaccines are
injectable compositions, they are sterile, and/or pyrogen free and/or particulate free. In some
embodiments, an isotonic formulation is preferably used. Generally, additives for isotonicity can
include sodium chloride, dextrose, mannitol, sorbitol and lactose. In some embodiments, isotonic
solutions such as phosphate buffered saline are preferred. In some embodiments, stabilizers include
gelatin and albumin. In some embodiments, a vasoconstriction agent is added to the formulation. In
some embodiments, a stabilizing agent that allows the formulation to be stable at room or ambient
temperature for extended periods of time, such as LGS or other polycations or polyanions is added to
the formulation.
[00221] In some embodiments, the DNA vaccine may further comprises a pharmacologically
acceptable carrier or diluent. Suitable carriers for the vaccine are well known to those skilled in the art
and include but are not limited to proteins, sugars, etc. Such carriers may be aqueous or non-aqueous
solutions, suspensions, and emulsions. Examples of non-aqueous carriers are propylene glycol,
polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including
saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose and
                                                    57

    WO 2014/124228                                                                  PCT/US2014/015254
sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient
replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.
Preservatives and antimicrobials include antioxidants, chelating agents, inert gases and the like.
Preferred preservatives include formalin, thimerosal, neomycin, polymyxin B and amphotericin B.
[00222] An alternative approach to delivering the nucleic acid to an animal involves the use of a viral
or bacterial vector. Examples of suitable viral vectors include adenovirus, polio virus, pox viruses
such as vaccinia, canary pox, and fowl pox, herpes viruses, including catfish herpes virus, adenovirus
associated vector, and retroviruses. Exemplary bacterial vectors include attenuated forms of
Salmonella, Shigella, Edwardsiella ictaluri, Yersinia ruckerii, and Listeria monocytogenes. In some
embodiments, the nucleic acid is a vector, such as a plasmid, that is capable of autologous expression
of the nucleotide sequence encoding the immunogenic polypeptide.
[00223] A vector can include a nucleic acid encoding a pneumococcal antigen in a form suitable for
expression of the nucleic acid in a host cell. A recombinant expression vector typically includes one
or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed.
Regulatory sequences include promoters, enhancers and other expression control elements (e.g.,
polyadenylation signals). Regulatory sequences include those which direct constitutive expression of
a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. A sequence
encoding a pneumococcal antigen can include a sequence encoding a signal peptide (e.g., a
heterologous signal peptide) such that the antigen is secreted from a host cell. The design of the
expression vector can depend on such factors as the choice of the host cell to be transformed, the level
of expression of protein desired, and the like.
[00224] Recombinant expression vectors can be designed for expression and production of
pneumococcal antigens in prokaryotic or eukaryotic cells. For example, antigens can be expressed in
E. coli, insect cells (e.g., using baculovirus expression vectors), yeast cells or mammalian cells.
Suitable host cells are discussed further in Goeddel, Gene Expression Technology Methods in
Enzymology 185, Academic Press, San Diego, Calif., 1990. Alternatively, a recombinant expression
vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences
and T7 polymerase.
[00225] Expression of polypeptides in prokaryotes is often carried out in E. coli with vectors
containing constitutive or inducible promoters directing the expression of either fusion or non-fusion
proteins. Fusion vectors add a number of amino acids to a protein encoded therein, e.g., to the amino
terminus or carboxy terminus of the recombinant protein, e.g., to increase expression of recombinant
protein; to increase the solubility of the recombinant protein; and/or to aid in the purification of the
recombinant antigen by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is
introduced at the junction of the fusion moiety and the recombinant antigen to enable separation of the
recombinant antigen from the fusion moiety subsequent to purification of the fusion protein. Such
enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
                                                   58

    WO 2014/124228                                                                 PCT/US2014/015254
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D. B. and Johnson,
K. S. Gene 67:31-40, 1988), pMAL (New England Biolabs, Beverly, Mass.) and pRITS (Pharmacia,
Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein
A, respectively, to the target recombinant protein. Pneumococcal antigen expression vectors provided
herein include yeast expression vectors, vectors for expression in insect cells (e.g., a baculovirus
expression vector) and vectors suitable for expression in mammalian cells.
[00226] An expression vector for use in mammalian cells can include viral regulatory elements. For
example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and
Simian Virus 40. A vector can include an inducible promoter, e.g., a promoter regulated by a steroid
hormone, by a polypeptide hormone (e.g., by means of a signal transduction pathway), or by a
heterologous polypeptide (e.g., the tetracycline-inducible systems, "Tet-On" and "Tet-Off'; see, e.g.,
Clontech Inc., CA, Gossen and Bujard, Proc. Natl. Acad. Sci. USA 89:5547, 1992, and Paillard,
Human Gene Therapy 9:983, 1989).
[00227] A host cell can be any prokaryotic or eukaryotic cell. For example, a pneumococcal antigen
can be expressed in bacterial cells (such as E. coli), insect cells, yeast or mammalian cells (such as
Chinese hamster ovary cells (CHO) or COS cells (African green monkey kidney cells CV-1 origin
SV40 cells; Gluzman, Cell 23:175-182, 1981). Other suitable host cells are known to those skilled in
the art.
[00228] Vector DNA can be introduced into host cells via conventional transformation or
transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to
refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a
host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated
transfection, lipofection, gene gun, or electroporation.
[00229] A host cell can be used to produce (i.e., express) a pneumococcal antigen. Accordingly, the
invention further provides methods for producing a pneumococcal antigen using host cells. In one
embodiment, the method includes culturing a host cell (into which a recombinant expression vector
encoding a pneumococcal antigen has been introduced) in a suitable medium such that a
pneumococcal antigen is produced. In another embodiment, the method further includes isolating a
pneumococcal antigen from the medium or the host cell. Purified pneumococcal antigens can be used
for administration to mammals to induce an immune response, and/or to generate antibodies specific
for the antigens.
[00230] The present invention also provides nucleic acid compositions that encode pneumococcal
antigens for administration to a subject in vivo, e.g., to elicit an immune response to the antigen. In
some embodiments, a nucleic acid composition for administration in vivo includes a naked DNA
plasmid encoding a pneumococcal antigen. Bacterial vectors, replicon vectors, live attenuated
bacteria, and viral vectors for expression of heterologous genes also can be used. Live attenuated viral
vectors (e.g., recombinant vaccinia (e.g., modified vaccinia Ankara (MVA), IDT Germany),
                                                  59

    WO 2014/124228                                                                  PCT/US2014/015254
recombinant adenovirus, avian poxvirus (e.g., canarypox (e.g., ALVACTM, Aventis Pasteur) or
fowlpox), poliovirus, and alphavirus virion vectors) have been successful in inducing cell-mediated
immune response to antigens. Avian poxviruses are defective in mammalian hosts, but can express
inserted heterologous genes under early promoters. Recombinant adenovirus and poliovirus vectors
can thrive in the gut and so can stimulate efficient mucosal immune responses. Finally, attenuated
bacteria can also be used as a vehicle for DNA vaccine delivery. Examples of suitable bacteria include
S. enterica, S. tymphimurium, Listeria, and BCG. The use of mutant bacteria with weak cell walls can
aid the exit of DNA plasmids from the bacterium.
[00231] Nucleic acid compositions used for immunization can include an adjuvant (e.g., an adjuvant
such as a polymer, a saponin, muramyl dipeptide, liposomes, immunomodulatory oligonucleotide, or
another adjuvant described herein) to promote nucleic acid uptake. Regardless of route, adjuvants can
be administered before, during, or after administration of the nucleic acid. In some embodiments, an
adjuvant increases the uptake of nucleic acid into host cells and/or increases expression of the antigen
from the nucleic acid within the cell, induce antigen-presenting cells to infiltrate the region of tissue
where the antigen is being expressed, or increase the antigen-specific response provided by
lymphocytes.
[00232] The terms "homology", "identity" and "similarity" refer to the degree of sequence similarity
between two peptides or between two optimally aligned nucleic acid molecules. Homology and
identity can each be determined by comparing a position in each sequence which can be aligned for
purposes of comparison. For example, it is based upon using a standard homology software in the
default position, such as BLAST, version 2.2.14. When an equivalent position in the compared
sequences is occupied by the same base or amino acid, then the molecules are identical at that
position; when the equivalent site occupied by similar amino acid residues (e.g., similar in steric
and/or electronic nature such as, for example conservative amino acid substitutions), then the
molecules can be referred to as homologous (similar) at that position. Expression as a percentage of
homology/similarity or identity refers to a function of the number of similar or identical amino acids
at positions shared by the compared sequences, respectively. A sequence which is "unrelated" or
"non-homologous" shares less than 40% identity, though preferably less than 25% identity with the
sequences as disclosed herein.
[00233] In some embodiments, a pneumococcal antigen is a variant of a penumococcal antigen of
Table 1 which is substantial identical to a sequence of SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
The term "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino
acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85%
sequence identity, preferably at least 90% to 95% sequence identity, more usually at least 99%
sequence identity as compared to a reference sequence over a comparison window of at least 18
nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16
amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the
                                                  60

    WO 2014/124228                                                                 PCT/US2014/015254
reference sequence to the sequence which can include deletions or additions which total 20 percent or
less of the reference sequence over the comparison window. The reference sequence can be a subset
of a larger sequence. The term "similarity", when used to describe a polypeptide, is determined by
comparing the amino acid sequence and the conserved amino acid substitutes of one polypeptide to
the sequence of a second polypeptide.
[00234] In some embodiments, a pneumococcal antigen is homologous to a sequence of SEQ ID NO:
1-76 or SEQ ID NO: 153-234. As used herein, the terms "homologous" or "homologues" are used
interchangeably, and when used to describe a polynucleotide or polypeptide, indicates that two
polynucleotides or polypeptides, or designated sequences thereof, when optimally aligned and
compared, for example using BLAST, version 2.2.14 with default parameters for an alignment (see
herein) are identical, with appropriate nucleotide insertions or deletions or amino-acid insertions or
deletions, in at least 60% of the nucleotides, usually from about 75% to 99%, and more preferably at
least about 98 to 99% of the nucleotides. The term "homolog" or "homologous" as used herein also
refers to homology with respect to structure and/or function. With respect to sequence homology,
sequences are homologs if they are at least 60 at least 70%, at least 80%, at least 90%, at least 95%
identical, at least 97% identical, or at least 99% identical. Determination of homologs of the genes or
peptides of the present invention can be easily ascertained by the skilled artisan.
[00235] In some cases, it there may be advantages to designing vaccines based on antigens that are
"surface-expressed" rather than cytoplasmic. Annotated genomes often describes protein location
based on homology with other identified proteins, but this may be an imperfect or often incorrect
approach, as homologous proteins form two different organisms may not necessarily be located at the
same site (nor have the same function) in both. Thus, an additional tool for determination of the
location of the protein (surface versus other) may be very helpful and may also be used in the
chloroform method described herein.
[00236] An embodiment of the present method comprises identifying a protein, "X" of interest, then
removing the gene encoding for X from the organism, then replacing that gene with a gene encoding
for a tagged version of the X protein (e.g., tagged with His, HA, OVA peptide, among others), which
can be detected readily with monoclonal or polyclonal antibodies. After confirmation of the genetic
construct, the organism is then grown, stained with an antibody that recognizes the tag (and is also
fused to a fluorophore). Flow cytometry is then used to evaluate whether the antibodies are attached to
the surface of the organism, in which case, the antigen can be deduced to be surface-expressed.
Similar strategies using antibodies attached to magnetic beads can be used as well. For
pneumococcus, for example, the organism can be evaluated in its encapsulated or unencapsulated
form. An antigen can be surface expressed, but hidden under the capsule, for selection of antigen
purposes, it may be advantageous to select an antigen that is both surface expressed and accessible
despite capsulation.
                                                   61

    WO 2014/124228                                                                 PCT/US2014/015254
[00237] The identified immunogenic proteins or mixtures thereof may be used in a multivalent or
individual vaccine, which can be administered in many forms (intramuscularly, subcutaneously,
mucosally, transdermally). For example, combinations or permutations of the twelve pneumococcal
immunogens may be more efficacious against colonization versus disease. A combination of several
immunogens with both characteristics may provide a superior vaccine.
Antibodies
[00238] Antibodies directed against a pneumococcal antigen or functional fragment thereof as
disclosed in Table 1 may be used in a prophylactic or therapeutic application to confer immunity from
a first individual to a second individual (e.g., to augment the second individual's immune response
against S. pneumoniae or to provide a response if the second individual is an immunocompromised
patient). Antibodies directed against a a pneumococcal antigen as disclosed herein can be generated in
an immunocompetent host (e.g., by administering to the immunocompetent host a conjugate described
herein), harvested from the host and transfused into a recipient in need of treatment or prophylaxis,
thereby conferring resistance to the recipient against not only the pneumolysin toxin, but also against
S. pneumoniae and any possibly other bacteria which bind antibodies elicited by the pneumococcal
antigen.
[00239] Antibodies elicited by a composition described herein can be formulated as a pharmaceutical
composition and be used to confer a prophylactic or therapeutic immune response to an individual.
Suitable components and methods of administration for pharmaceutical compositions are described
herein. For eliciting passive immunity, the pharmaceutical composition may contain polyclonal
antibodies or monoclonal antibodies or their derivatives of fragments. A pharmaceutical composition
contains a prophylactically or therapeutically effective amount of an antibody, fragment, or derivative,
as determined by standard clinical techniques.
[00240] Accordingly, this invention provides, inter alia, antibodies, or antigen-binding fragments
thereof, to a novel pneumococcal antigen described herein, e.g., those listed in Table 1, or a SP0785
polypeptide antigen, a SP1500 polypeptide antigen, a SP0346 polypeptide antigen, a SP1386
polypeptide antigen, a SP0084 polypeptide antigen, a SP1479polypeptide antigen, a CT067
polypeptide antigen, a CT476 polypeptide antigen, a p6 polypeptide antigen, a SP2145 polypeptide
antigen, or any pneumococcal antigen listed in Table 1, e.g., SEQ ID NO: 1-76 or SEQ ID NO: 153
234), or functional fragments or variants thereof. The antibodies can be of the various isotypes,
including: IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgAl, IgA2, IgD, or IgE. In some embodiments,
an antibody is an IgG isotype, e.g., IgG1. An antibody against a pneumococcal antigen can be full
length (e.g., an IgG1 or IgG4 antibody) or can include only an antigen-binding fragment (e.g., a Fab,
F(ab) 2, Fv or a single chain Fv fragment). These include monoclonal antibodies, recombinant
antibodies, chimeric antibodies, human antibodies, and humanized antibodies, as well as antigen
binding fragments of the foregoing.
                                                    62

    WO 2014/124228                                                                PCT/US2014/015254
[00241] Monoclonal antibodies can be produced by a variety of techniques, including conventional
monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler
and Milstein, Nature 256: 495, 1975. Polyclonal antibodies can be produced by immunization of
animal or human subjects. See generally, Harlow, E. and Lane, D. Antibodies: A Laboratory Manual,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988. Antibodies against
pneumococcal antigens described herein can be used, e.g., for diagnostic assays, or for therapeutic
applications.
[00242] In some embodiments of the present invention, a subject's response to an immunogenic
composition described herein is evaluated, e.g., to determine efficacy of the composition, and/or to
compare responses elicited by the composition to responses elicited by a different composition.
Nucleic Acids Encoding Pneumococcal Polypeptide antigens
[00243] Nucleic acids encoding a pneumococcal polypeptide antigen or a fragment or variant of
pneumococcal polypeptide can be administered to a mammal (e.g., a human) to generate a
prophylactic and/or therapeutic immune response in the mammal. The immune response can be an
anti-pneumococcal humoral and/or a cellular immune response.
[00244] Polypeptides that can be encoded by the nucleic acid constructs include one or more
pneumococcal polypeptide antigens, alone or fused to a fusion polypeptide, e.g. PdT and/or a
polysaccharide and/or another antigen, e.g., Vi. In addition, a nucleic acid can encode a combination
of two or more such polypeptides, fragments, or variants.
[00245] Nucleic acid expression constructs can be prepared by using standard recombinant DNA
methods. Regulatory elements can be included in a construct to facilitate expression of the nucleic
acid encoding the polypeptide. These elements include sequences for enhancing expression in human
or other mammalian cells, e.g., promoters, RNA stabilization sequences 5' and/or 3' to the coding
sequence, introns (which can be placed at any location within or adjacent to the encoded sequence),
and poly(A) addition sites, as well as an origin of replication and one or more genes encoding
selectable markers enabling the constructs to replicate and be selected in prokaryotic and/or
eukaryotic hosts. A T7 polymerase promoter or other type of promoter (e.g., a tissue-specific
promoter or a cell-specific promoter such as a muscle-specific promoter) is optionally present at the 5'
end of the coding sequence, and a sequence encoding a FLAG or other mAb determinant is optionally
present at the 3' end of the coding sequence. The construct may also contain other transcriptional and
translational signals, such as a Kozak sequence.
[00246] The construct may in addition include a sequence encoding a targeting signal that directs the
encoded polypeptide to a desired intracellular compartment, the targeting signal being linked to the
polypeptide. Targeting signals can direct the encoded polypeptide to endoplasmic reticulum (ER), the
golgi, the nucleus, a lysosome, a class II peptide loading compartment, or an endosome, and include
signal peptides, ER retention peptides, and lysosome-targeting peptides.
                                                  63

    WO 2014/124228                                                                    PCT/US2014/015254
[00247] The nucleic acids can be used in any vector that allows for expression in cells of a mammal.
The vector can be, e.g., a non-viral vector such as a plasmid or bacterial vector, an integrating viral
vector, or a non-integrating viral vector. An example of a suitable vector is the family of pcDNA
mammalian expression vectors (Invitrogen), which permit direct and rapid cloning of PCR products.
[00248] Various delivery systems can be used to deliver nucleic acids encoding polypeptides into
appropriate cells. The nucleic acids encoding the polypeptides can be delivered in a pharmaceutically
acceptable carrier such as saline, or as colloidal suspensions, or as powders, with or without diluents.
The nucleic acids can be "naked" or associated with delivery vehicles and delivered using delivery
systems known in the art, such as lipids, liposomes, microspheres, microparticles or microcapsules,
gold particles, ISCOMS, nanoparticles, polymers, condensing agents, polysaccharides, polyamino
acids, dendrimers, saponins, QS21, adsorption enhancing materials, adjuvants, or fatty acids. Nucleic
acids can also be delivered to a cell, e.g., a skeletal muscle cell, either in vitro or in vivo, using
electroporation.
[00249] The nucleic acids can be administered using standard methods, e.g., those described in
Donnelly et al., J. Immunol. Methods 176:145, 1994, and Vitiello et al., J. Clin. Invest. 95:341, 1995,
and can be delivered into subjects in any manner known in the art, e.g., orally intramuscularly,
intravenously, intraarterially, intrathecally, intradermally, intraperitoneally, intranasally,
intrapulmonarily, intraocularly, intravaginally, intrarectally or subcutaneously. They can be
introduced into the gastrointestinal tract or the respiratory tract, e.g., by inhalation of a solution or
powder containing the nucleic acids. Administration can be local or systemic.
[00250] It is expected that a dosage of approximately 100-2000 jig of nucleic acid would be
administered to an individual. Where the patient is an adult human, vaccination regimens can include,
e.g., intramuscular, intradermal, inhalation, or subcutaneous administrations of 10-1000 jig of a
plasmid DNA when delivered in a microparticle, or of about 10-2500 jig, e.g., 100 to 2000, or 500 to
1000 jig, of naked plasmid DNA delivered intramuscularly or intradermally, repeated 3-6 times. As is
well known in the medical arts, dosage for any given patient depends upon many factors, including
the patient's size, general health, sex, body surface area, age, the particular compound to be
administered, time and route of administration, and other drugs being administered concurrently.
Determination of optimal dosage is well within the abilities of a pharmacologist of ordinary skill.
[00251] Other standard delivery methods, e.g., biolistic transfer or ex vivo treatment, can also be
used. In ex vivo treatment, antigen presenting cells (APCs) such as dendritic cells, peripheral blood
mononuclear cells, or bone marrow cells can be obtained from a patient or an appropriate donor and
activated ex vivo with the nucleic acid, and then implanted or reinfused into the patient.
[00252] The nucleic acids can be administered alone or in combination with other therapies known in
the art, e.g., antimicrobial agents. In addition, the nucleic acids can be administered in combination
with other treatments designed to enhance immune responses, e.g., by co-administration with
                                                    64

    WO 2014/124228                                                                 PCT/US2014/015254
adjuvants, cytokines (or nucleic acids encoding cytokines), or CpG oligonucleotides, as is well known
in the art.
[00253] The ability of a nucleic acid to elicit an immune response in a host mammal can be assayed
by using methods for measuring immune responses that are well known in the art. For example, the
generation of cytotoxic T cells can be demonstrated in a standard .sup.5 1Cr release assay, by
measuring intracellular cytokine expression or secretion, or by using MHC tetramers. Standard assays,
such as ELISA or ELISPOT, can be used to measure cytokine profiles attributable to T cell activation.
T cell proliferation can be measured using assays such as .sup.3H-thymidine uptake and other assays
known in the art. B cell responses can be measured using art recognized assays such as ELISA. Other
methodologies can also be used to evaluate the effects of the nucleic acids on pathogen-associated
lesions or on other pathogen levels generally (e.g., pneumococci clearance in challenged mice treated
with the conjugate).
[00254] The nucleic acids described herein can be used in the manufacture of a medicament for the
prevention or treatment of an infection with S. pneumoniae or conditions associated with such
infection.
Assays for T Cell Activation
[00255]     In some embodiments, various assays can be utilized in order to characterize an antigen or
composition and/or to determine whether an immune response has been stimulated in a T cell or
group of T cells. In some embodiments, assays are used to characterize a T cell response in a subject
that has been administered an immunogenic composition to elicit an anti-pneumococcal response
(e.g., to evaluate whether a detectable T cell response has been elicited and/or to evaluate the potency
of the response). The novel pneumococcal antigens described herein also provide diagnostic agents to
evaluate exposure to pneumococcal infections (e.g., in non-vaccinated subjects). In some
embodiments, assays are used to characterize a T cell response in a subject to determine whether the
subject has been infected with a pneumococcal organism. The subject can be a subject suspected of
exposure to a pneumococcal organism recently (i.e., an assay to detect a response can be performed
with a sample taken from the subject about 3, 4, 5, 6, 7, 8, 9, 10, 14, 30, or more days after suspected
exposure to apneumococcalorganism). The subject can be a subject suspected of exposure to a
pneumococcal organism weeks, months, or years prior to the assay. The novel pneumococcal antigens
described herein also provide prognostic agents to evaluate outcomes of exposure to a pneumococcal
organism (e.g., in subjects known to be, or to have been, infected with a pneumococcal organism). In
some embodiments, assays are used to characterize a T cell response in a subject to assess the
likelihood of sequelae (e.g., sepsis) to infection with a pneumococcal organism.
[00256] In some embodiments, stimulation of an immune response in T cells is determined by
measuring antigen-induced production of cytokines by T cells. In some embodiments, stimulation of
an immune response in T cells can be determined by measuring antigen-induced production of IFN-y,
                                                   65

    WO 2014/124228                                                                 PCT/US2014/015254
IL-4, IL-2, IL-6, IL-10, IL-17 and/or TNF-a by T cells. In some embodiments, antigen-induced
production of cytokines by T cells can be measured by intracellular cytokine staining followed by
flow cytometry. Other suitable methods include surface capture staining followed by flow cytometry,
or methods that determine cytokine concentration in supernatants of activated T cell cultures, such as
ELISA or ELISPOT assays.
[00257] In some embodiments, antigen-produced production of cytokines by T cells is measured by
ELISPOT assay. ELISPOT assays typically employ a technique very similar to the sandwich enzyme
linked immunosorbent assay (ELISA) technique. An antibody (e.g. monoclonal antibody, polyclonal
antibody, etc.) is coated aseptically onto a PVDF (polyvinylidene fluoride)-backed microplate.
Antibodies are chosen for their specificity for the cytokine of interest. The plate is blocked (e.g., with
a serum protein that is non-reactive with any of the antibodies in the assay). Cells to be tested for
cytokine production are plated out at varying densities, along with antigen or mitogen, and then
placed in a humidified 370 C CO 2 incubator for a specified period of time. Cytokine secreted by
activated cells is captured locally by the coated antibody on the high surface area PVDF membrane.
After washing the wells to remove cells, debris, and media components, a secondary antibody (e.g. a
biotinylated polyclonal antibody) specific for the cytokine is added to the wells. This antibody is
reactive with a distinct epitope of the target cytokine and thus is employed to detect the captured
cytokine. Following a wash to remove any unbound biotinylated antibody, the detected cytokine is
then visualized using an avidin-HRP, and a precipitating substrate (e.g., AEC, BCIP/NBT). The
colored end product (a spot, usually red or blue) typically represents an individual cytokine-producing
cell. Spots can be counted manually (e.g., with a dissecting microscope) or using an automated reader
to capture the microwell images and to analyze spot number and size. In some embodiments, each
spot correlates to a single cytokine-producing cell.
[00258] In some embodiments, an immune response in T cells is said to be stimulated if between
about 1% and about 100% of antigen-specific T cells produce cytokines. In some embodiments, an
immune response in T cells is said to be stimulated if at least about 1%, at least about 5%, at least
about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 90%, at least
about 95%, at least about 99%, or about 100% of antigen-specific T cells produce cytokines.
[00259] In some embodiments, an immune response in T cells is said to be stimulated if immunized
subjects comprise at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about
500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10.000-fold, at least about
50.000-fold, at least about 100.000-fold, or greater than at least about 100.000-fold more cytokine
producing cells than do naive controls.
[00260] In some embodiments, stimulation of an immune response in T cells can be determined by
measuring antigen-induced proliferation of T cells. In some embodiments, antigen-induced
proliferation may be measured as uptake of H 3-thymidine in dividing T cells (sometimes referred to as
"lymphocyte transformation test, or "LTT"). In some embodiments, antigen-induced proliferation is
                                                   66

    WO 2014/124228                                                                    PCT/US2014/015254
said to have occurred if .sup.3H-thymidine uptake (given as number of counts from a .gamma.
counter) is at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at
least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least
about 10.000-fold, or greater than at least about 10.000-fold higher than a naive control.
[00261] In some embodiments, antigen-induced proliferation may be measured by flow cytometry. In
some embodiments, antigen-induced proliferation may be measured by a carboxyfluorescein
succinimidyl ester (CFSE) dilution assay. CFSE is a non-toxic, fluorescent, membrane-permeating
dye that binds the amino groups of cytoplasmic proteins with its succinimidyl-reactive group (e.g., T
cell proteins). When cells divide, CFSE-labeled proteins are equally distributed between the daughter
cells, thus halving cell fluorescence with each division. Consequently, antigen-specific T cells lose
their fluorescence after culture in the presence of the respective antigen (CFSE.sup.low) and are
distinguishable from other cells in culture (CFSE.sup.high). In some embodiments, antigen-induced
proliferation is said to have occurred if CFSE dilution (given as the percentage of CFSE          cells out of
all CFSE* cells) is at least about 5%, at least about 10%, at least about 25%, at least about 50%, at
least about 7 5%, at least about 90%, at least about 95%, or at least about 100%.
[00262] In some embodiments, an immune response in T-cells is said to be stimulated if cellular
markers of T cell activation are expressed at different levels (e.g., higher or lower levels) relative to
unstimulated cells. In some embodiments, CD1 1a, CD27, CD25, CD40L, CD44, CD45RO, and/or
CD69 are more highly expressed in activated T cells than in unstimulated T cells. In some
embodiments, L-selectin (CD62L), CD45RA, and/or CCR7 are less highly expressed in activated T
cells than in unstimulated T cells.
[00263] In some embodiments, an immune response in T cells is measured by assaying cytotoxicity
by effector CD8+ T cells against antigen-pulsed target cells. For example, a 5 'chromium ( 51Cr) release
assay can be performed. In this assay, effector CD8+ T cells bind infected cells presenting virus
peptide on class I MHC and signal the infected cells to undergo apoptosis. If the cells are labeled with
51
  Cr before the effector CD8+ T cells are added, the amount of 5 Cr released into the supernatant is
proportional to the number of targets killed. In some embodiments, an immune response in T cells is
measured by an in vivo cytotoxicity assay in which target cells are antigen pulsed and labeled with a
fluorescent dye, then transferred into immunized animals. Specific cytolytic T cells cause the
disappearance of fluorescently labeled cells that are pulsed with a relevant antigen, but no decrease in
cells pulsed with a control antigen. See, e.g., Coligan et al., Current Protocols in Immunology,
3.11.14-16, John Wiley & Sons, Inc., 2007. In some embodiments, an immune response in T cells is
measured by detecting expression of one or more of Perforin, Granzyme B, or CD107a (e.g., by
ELISPOT or flow cytometry). See, e.g., Betts et al., J. Immunol. Meth. 281(1-2):65-78, 2003.
In Vivo Assays
[00264] In some embodiments, an immunogenic composition may be characterized (e.g., to assess
efficacy in inducing a beneficial response in animal models) by infecting groups of immunized and
                                                    67

    WO 2014/124228                                                                    PCT/US2014/015254
non-immunized mice (e.g., 3 or more weeks after vaccination) with a dose of a chlamydia organism
that typically produces a particular pathology (e.g., upper urogenital tract infection) or bacterial
burden. The magnitude and duration of pathology or bacterial burden due to infection of both groups
is monitored and compared. In one example, B cell responses are characterized by transferring serum
from immune mice as a "passive vaccine" to assess protection of non-immune mice from pathological
effects or burden of infection. In some embodiments, infiltrating leukocyte populations are
characterized (e.g., to assess the number and type cells in a region of infection, e.g., whether
CD4.sup.+ T cells, CD8.sup.+ T cells, or other cell types are present). Animal models for chlamydial
urogenital infection have been described. In some embodiments, a chlamydia organism is applied as
an intravaginal inoculum, and infection and pathology of one or more of lower and upper genital
tracts of the infected animal is characterized. See, e.g., Barron et al. (J. Infect. Dis. 143(1):63-6,
1981), which describes an intravaginal infection model in mice. In some embodiments, clearance of
primary infection is a measure of protective immunity in this model. In some embodiments, detection
of CD4+ T cell responses of a Th1 subtype correlate with protection (Morrison et al., Infect. Immun
70:2741-2751, 2002).
[00265] In some embodiments, an immunogenic composition is assessed in an animal model of
pneumococcal infection. In some embodiments, lower urogenital tract infection by pneumococcus is
assessed in the model (e.g., lower tract bacterial burden and/or inflammation due to infection is
assessed). In some embodiments, upper tract infection by chlamydia is assessed in the model (e.g.,
one or more of upper tract bacterial burden, inflammation, infertility, collagen deposition, scarring
due to infection, are assessed). In some embodiments, an ability to prevent ascension of a chlamydia
infection from the lower tract to the upper genital tract is assessed. In some embodiments, rate of
bacterial clearance from the lower tract is assessed. In some embodiments, rate of bacterial clearance
from the upper tract is assessed. In some embodiment, the rate of bacterial clearance from the nose is
assessed. In some embodiments, an immunogenic composition is assessed in an animal model in
multiple strains of the animal of interest (e.g., multiple mouse strains). In some embodiments,
presence and size of hydrosalpinx (fluid blockage of fallopian tubes) is assessed.
[00266] In some embodiments, desirable immunogenic compositions are characterized as having one
or more of the above effects in vivo (e.g., in an animal model). For example, in some embodiments, an
immunogenic composition reduces lower urogenital tract infection by chlamydia bacteria. In some
embodiments, an immunogenic composition reduces lower tract bacterial burden. In some
embodiments, an immunogenic composition reduces lower tract inflammation due to infection. In
some embodiments, an immunogenic composition reduces upper tract infection by pneumococcus. In
some embodiments, an immunogenic composition reduces ascension of a pneumococcal infection
from the lower tract to the upper genital tract. In some embodiments, an immunogenic composition
increases the rate of bacterial clearance from the lower tract and/or the upper tract. In some
                                                   68

    WO 2014/124228                                                                 PCT/US2014/015254
embodiments, an immunogenic composition has one or more of the above effects in multiple animal
strains (e.g., multiple mouse strains).
[00267] In some embodiments, pneumococcal antigens of Table 1 or functional fragments thereof for
use in the immunogenic compositions as disclosed herein elicits an IL-17A response in mouse
splenocytes or human PBMCs in vitro as disclosed in Example 2, and/or protects colonization in vivo
in a mouse colonization model, where mice are challenged with a serotype of pneumococcal strain
(e.g., serotypes 6B, 14F or 19F) after biweekly immunization with a pneumococcal antigen (or
functional fragment), and assessing for presence of pneumococcal colonization in the nose, as
disclosed in Example 3.
[00268] One of ordinary skill in the art will recognize that the assays described above are only
exemplary methods which could be utilized in order to determine whether T cell activation and/or B
cell activation has occurred. Any assay known to one of skill in the art which can be used to
determine whether T and/or B cell activation has occurred falls within the scope of this invention. The
assays described herein as well as additional assays that could be used to determine whether T and/or
B cell activation has occurred are described in Current Protocols in Immunology (John Wiley & Sons,
Hoboken, N.Y., 2007; incorporated herein by reference).
[00269] Ongoing studies assess immunogenicity in outbred animal strains, and characterize the
efficacy of these proteins in protecting against invasive disease in aspiration/sepsis models. In some
embodiments, one can test the ability of a pneumococcal antigen, e.g., an antigen listed in Table 1, or
a homologue or functional fragment or variant of an antigen listed in Table 1 to elicit an immune
response in vivo, by measuring a CMI response to the target antigen. CMI assays are known in the art
and described, for example, in United States Patent Application 2005/0014205, WO/1987/005400,
United States Patent 5,674,698 and commercially available kits such as IMMUNKNOW@ CYLEX
Immune cell function assay Product No. 4400, which are incorporated in their entirety by reference
herein for use in the present invention.
Applications and use of the immunogenic compositions
[00270]       The S. pneumoniae vaccines described herein may be used for prophylactic and/or
therapeutic treatment of S. pneumoniae. Accordingly, this application provides a method for treating a
subject suffering from or susceptible to S. pneumoniae infection, comprising administering an
effective amount of any of the vaccine formulations described herein. In some aspects, the method
inhibits S. pneumoniae colonization in an individual. In some aspects, the method inhibits S.
pneumoniae symptoms or sequelae, such as sepsis. The subject receiving the vaccination may be a
male or a female, and may be a child or adult. In some embodiments, the subject being treated is a
human. In other embodiments, the subject is a non-human animal.
[00271]       Accordingly, the immunogenic compositions and methods described herein can be used
for the prophylaxis and/or treatment of any pneumococcal infection, pneumococcal disease, disorder,
and/or condition, or a pneumococcal infection, such as sepsis. As used herein, "prophylaxis" refers to
                                                   69

    WO 2014/124228                                                                 PCT/US2014/015254
uses before onset of symptoms due to a pneumococcal infection, pneumococcal disease, disorder,
and/or condition and/or before known exposure to a Streptococcuspneumoniae organism. Subjects
include, but are not limited to, humans and/or other primates; and other animals susceptible to
infection by S. pneumoniae organisms, including commercially relevant mammals such as cattle, pigs,
horses, sheep, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens,
ducks, geese, and/or turkeys.
1. Prophylactic Use
[00272]      In prophylactic embodiments, a vaccine or immunogenic composition as disclosed herein
is administered to a subject to induce an immune response that can help protect against the
establishment of S. pneumoniae, for example by protecting against colonization, the first and
necessary step in disease. Thus, in some aspects, the method inhibits infection by S. pneumoniae in a
non-colonized or uninfected subject. In another aspect, the method may reduce the duration of
colonization in an individual who is already colonized.
[00273]      In some embodiments, a vaccine or immunogenic composition as disclosed herein confer
protective immunity, allowing a vaccinated individual to exhibit delayed onset of symptoms or
sequelae, or reduced severity of symptoms or sequelae, as the result of his or her exposure to the
vaccine. In certain embodiments, the reduction in severity of symptoms or sequelae is at least 25%,
40%, 50%, 60%, 70%, 80% or even 90%. In particular embodiments, vaccinated individuals may
display no symptoms or sequelae upon contact with S. pneumoniae, do not become colonized by S.
pneumoniae, or both. Protective immunity is typically achieved by one or more of the following
mechanisms: mucosal, humoral, or cellular immunity. Mucosal immunity is primarily the result of
secretory IgA (sIGA) antibodies on mucosal surfaces of the respiratory, gastrointestinal, and
genitourinary tracts. The sIGA antibodies are generated after a series of events mediated by antigen
processing cells, B and T lymphocytes, that result in sIGA production by B lymphocytes on mucosa
lined tissues of the body. Humoral immunity is typically the result of IgG antibodies and IgM
antibodies in serum. Cellular immunity can be achieved through cytotoxic T lymphocytes or through
delayed-type hypersensitivity that involves macrophages and T lymphocytes, as well as other
mechanisms involving T cells without a requirement for antibodies. In particular, cellular immunity
may be mediated by THI or TH17 cells.
[00274]       Essentially any individual has a certain risk of becoming infected with S. pneumoniae.
However, certain sub-populations have an increased risk of infection. In some embodiments, a
vaccine formulation as described herein (e.g., a composition comprising one or more polypeptides
from Table 1 or 2, or nucleic acids encoding the polypeptides, or antibodies reactive with the
polypeptides) is administered to patients that are immunocompromised.
[00275]      An immunocompromising condition arising from a medical treatment is likely to expose
the individual in question to a higher risk of infection with S. pneumoniae. It is possible to treat an
infection prophylactically in an individual having the immunocompromised condition before or
                                                   70

    WO 2014/124228                                                                  PCT/US2014/015254
during treatments known to compromise immune function. By prophylactically treating with an
antigenic composition (e.g., two or more antigens from Table 1 or 2, or nucleic acids encoding the
antigens), or with antibodies reactive to two or more antigens from Table 1 or 2, before or during a
treatment known to compromise immune function, it is possible to prevent a subsequent S.
pneumoniae infection or to reduce the risk of the individual contracting an infection due to the
immunocompromised condition. Should the individual contract an S. pneumoniae infection e.g.,
following a treatment leading to an immunocompromised condition it is also possible to treat the
infection by administering to the individual an antigen composition.
[00276]       The following groups are at increased risk of pneumococcal disease or its complications,
and therefore it is advantageous for subjects falling into one or more of these groups to receive a
vaccine formulation described herein: children, especially those from 1 month to 5 years old or 2
months to 2 years old; children who are at least 2 years of age with asplenia, splenic dysfunction or
sickle-cell disease; children who are at least 2 years of age with nephrotic syndrome, chronic
cerebrospinal fluid leak, HIV infection or other conditions associated with immunosuppression.
[00277]       In another embodiment, at least one dose of the pneumococcal antigen composition is
given to adults in the following groups at increased risk of pneumococcal disease or its complications:
all persons 65 years of age; adults with asplenia, subjects with Job's syndrome (subject lacking Th-17
cell-mediated response), subjects with aggamaglobunemia (a subject lacking antibody-mediated
response), splenic dysfunction or sickle-cell disease; adults with the following conditions: chronic
cardiorespiratory disease, cirrhosis, alcoholism, chronic renal disease, nephrotic syndrome, diabetes
mellitus, chronic cerebrospinal fluid leak, HIV infection, AIDS and other conditions associated with
immunosuppression (Hodgkin's disease, lymphoma, multiple myeloma, immunosuppression for organ
transplantation), individuals with cochlear implants; individuals with long-term health problems such
as heart disease and lung disease, as well as individuals who are taking any drug or treatment that
lowers the body's resistance to infection, such as long-term steroids, certain cancer drugs, radiation
therapy; Alaskan natives and certain Native American populations.
2. Therapeutic Use
[00278]       In therapeutic applications, a vaccine or immunogenic composition as disclosed herein
may be administered to a patient suffering from S. pneumoniae infection, in an amount sufficient to
treat the patient. Treating the patient, in this case, refers to reducing S. pneumoniae symptoms and/or
bacterial load and/or sequelae bin an infected individual. In some embodiments, treating the patient
refers to reducing the duration of symptoms or sequelae, or reducing the intensity of symptoms or
sequelae. In some embodiments, the vaccine reduces transmissibility of S. pneumoniae from the
vaccinated patient. In certain embodiments, the reductions described above are at least 25%, 30%,
40%, 50%, 60%, 70%, 80% or even 90%.
                                                     71

    WO 2014/124228                                                                   PCT/US2014/015254
[00279]       In therapeutic embodiments, the vaccine is administered to an individual post-infection.
The vaccine may be administered shortly after infection, e.g. before symptoms or sequelae manifest,
or may be administered during or after manifestation of symptoms or sequelae.
[00280]       A therapeutic S. pneumoniae vaccine can reduce the intensity and/or duration of the
various symptoms or sequelae of S. pneumoniae infection. Symptoms or sequelae of S. pneumoniae
infection can take many forms. Invasive pneumococcal diseases include acute sinusitis, otitis media,
meningitis, bacteremia, sepsis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis,
cellulitis, and brain abscess. Accordingly, in some cases, an infected patient develops pneumonia,
acute sinusitis, otitis media (ear infection), meningitis, bacteremia, sepsis, osteomyelitis, septic
arthritis, endocarditis, peritonitis, pericarditis, cellulitis, or brain abscess.
[00281]       Sepsis is a rare but life-threatening complication of S. pneumoniae infection, where the
bacterium invades the bloodstream and systemic inflammation results. Typically, fever is observed
and white blood cell count increases. A further description of sepsis is found in Goldstein, B. et al.
"International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in
pediatrics." Pediatr Crit. Care Med. January 2005; 6 (1):2-8.
[00282]       In some embodiments, immunogenic compositions in accordance with the present
invention may be used to treat, alleviate, ameliorate, relieve, delay onset of, inhibit progression of,
reduce risk of infection by, and reduce severity of, and/or reduce incidence of one or more symptoms
or features of a pneumococcal disease, disorder, and/or condition. In some embodiments, inventive an
immunogenic composition may be used to treat, alleviate, ameliorate, relieve, delay onset of, inhibit
progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of
pneumococcal infection (e.g., but not limited to sepsis, pneumonia,acute otitis media, bacteremia and
bacterial meningitis).
[00283]       In one aspect of the invention, a method for the prophylaxis and/or treatment of
pneumococcal infection is provided. In some embodiments, the prophylaxis and/or treatment of
pneumococcal infection comprises administering a therapeutically effective amount of an
immunogenic composition described herein to a subject in need thereof, in such amounts and for such
time as is necessary to achieve the desired result. In certain embodiments of the present invention a
"therapeutically effective amount" of an inventive immunogenic composition is that amount effective
for reducing risk of infection by, or treating, alleviating, ameliorating, relieving, delaying onset of,
inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or
features of pneumococcal infection. A therapeutically effective amount may be determined on a
population basis, and is not required to be an amount that naturally induces a protective response in a
particular subject.
[00284]       In some embodiments, inventive prophylactic and/or therapeutic protocols involve
administering a therapeutically effective amount of one or more inventive immunogenic compositions
to a healthy subject (i.e., a subject who does not display any symptoms of chlamydia infection and/or
                                                      72

    WO 2014/124228                                                                  PCT/US2014/015254
who has not been diagnosed with pneumococcal infection). For example, healthy individuals may be
vaccinated using inventive immunogenic compositions prior to development of pneumococcal
infection and/or onset of symptoms of pneumococcal infection; at risk individuals (e.g., patients
exposed to individuals suffering from pneumococcal infection, patients with HIV or a compromised
immune system, or a subject who is susceptible is to pneumococcal infection such as a subject with
Job's syndrome (subject lacking Th-17 cell-mediated response) or a subject with aggamaglobunemic
(a subject lacking antibody-mediated response)) can be treated substantially contemporaneously with
(e.g., within 48 hours, within 24 hours, or within 12 hours of) the onset of symptoms of and/or
exposure to pneumococcal infection. Of course individuals known to have pneumococcal infection or
sepsis may receive treatment at any time.
[00285]       In some embodiments, inventive prophylactic and/or therapeutic protocols involve
administering a therapeutically effective amount of one or more inventive immunogenic compositions
to a subject such that an immune response is stimulated in both T cells and B cells.
[00286]       In some embodiments, by combining one or more pneumococcal antigens and adjuvants,
immune responses (e.g. T cell and/or B cell responses) can be tailored to preferentially elicit the most
desirable type of immune response for a given indication, e.g., humoral response, Th1 T cell response,
Thl7 T cell response, IFN-y secretion by antigen-specific T cells, cytotoxic T cell response, antibody
response, B cell response, innate immune response, or a combination of these responses.
Assaying Vaccination Efficacy
[00287]       The efficacy of vaccination with the a vaccine or immunogenic composition as disclosed
herein may be determined in a number of ways, in addition to the clinical outcomes described above.
First, one may assay IL-17 levels (particularly IL-17A) by stimulating T cells derived from the subject
after vaccination. The IL-17 levels may be compared to IL-17 levels in the same subject before
vaccination. Increased IL-17 (e.g., IL-17A) levels, such as a 1.5 fold, 2-fold, 5-fold, 10-fold, 20-fold,
50-fold or 100-fold or more increase, would indicate an increased response to the vaccine.
Alternatively (or in combination), one may assay neutrophils in the presence of T cells or antibodies
from the patient for pneumococcal killing. Increased pneumococcal killing, such as a 1.5 fold, 2-fold,
5-fold, 10-fold, 20-fold, 50-fold or 100-fold or more increase, would indicate an increased response to
the vaccine. In addition, one may measure T.sub.H17 cell activation, where increased T.sub.H17 cell
activation, such as a 1.5 fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold or 100-fold or more increase,
correlates with an increased response to the vaccine. One may also measure levels of an antibody
specific to the vaccine, where increased levels of the specific antibody, such as a 1.5 fold, 2-fold, 5
fold, 10-fold, 20-fold, 50-fold or 100-fold or more increase, are correlated with increased vaccine
efficacy. In certain embodiments, two or more of these assays are used. For example, one may
measure IL-17 levels and the levels of vaccine-specific antibody. Alternatively, one may follow
                                                   73

    WO 2014/124228                                                                  PCT/US2014/015254
epidemiological markers such as incidence of, severity of, or duration of pneumococcal infection in
vaccinated individuals compared to unvaccinated individuals.
[00288]      Vaccine efficacy may also be assayed in various model systems such as the mouse model.
For instance, BALB/c or C57BL/6 strains of mice may be used. After administering the test vaccine
to a subject (as a single dose or multiple doses), the experimenter administers a challenge dose of S.
pneumoniae. In some cases, a challenge dose administered intranasally is sufficient to cause S.
pneumoniae colonization (especially nasal colonization) in an unvaccinated animal, and in some cases
a challenge dose administered via aspiration is sufficient to cause sepsis and a high rate of lethality in
unvaccinated animals. One can then measure the reduction in colonization or the reduction in lethality
in vaccinated animals. As demonstrated in Examples 1-3, the efficacy of polypeptides of Table 1 in
inhibiting S. pneumoniae nasal colonization following intranasal challenge in the mouse model can be
assessed. Examples 3 and 4 show the efficacy of polypeptides of Table 1 in protecting against sepsis
and death following infection with S. pneumoniaevia aspiration in the mouse model.
Immunogenic Compositions and Formulations
[00289] In one embodiment, an immunogenic composition as disclosed herein, e.g., a vaccine or
immunogenic composition described herein, can comprise a pharmaceutically acceptable carrier. In
another embodiment, the vaccine composition described herein is formulated for administering to a
mammal. Suitable formulations can be found in Remington's Pharmaceutical Sciences, 16th and 18th
Eds., Mack Publishing, Easton, Pa. (1980 and 1990), and Introduction to Pharmaceutical Dosage
Forms, 4th Edition, Lea & Febiger, Philadelphia (1985), each of which is incorporated herein by
reference.
[00290] In one embodiment, a vaccine compositions as described herein comprise pharmaceutically
acceptable carriers that are inherently nontoxic and nontherapeutic. Examples of such carriers include
ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin,
buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride
mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate,
disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal
silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and polyethylene
glycol. For all administrations, conventional depot forms are suitably used. Such forms include, for
example, microcapsules, nano-capsules, liposomes, plasters, inhalation forms, nose sprays, sublingual
tablets, and sustained release preparations. For examples of sustained release compositions, see U.S.
Patent Nos. 3,773,919, 3,887,699, EP 58,481A, EP 158,277A, Canadian Patent No. 1176565; U.
Sidman et al., Biopolymers 22:547 (1983) and R. Langer et al., Chem. Tech. 12:98 (1982). The
proteins will usually be formulated at a concentration of about 0.1 mg/ml to 100 mg/ml per
application per patient.
[00291] In one embodiment, other ingredients can be added to vaccine formulations, including
antioxidants, e.g., ascorbic acid; low molecular weight (less than about ten residues) polypeptides,
                                                   74

    WO 2014/124228                                                                   PCT/US2014/015254
e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins;
hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid,
aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including
cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; and sugar
alcohols such as mannitol or sorbitol.
[00292] In one embodiment, a vaccine composition as described herein for administration must be
sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2
micron membranes).
[00293] In some embodiments, a vaccine composition as described herein further comprises
pharmaceutical excipients including, but not limited to biocompatible oils, physiological saline
solutions, preservatives, carbohydrate, protein, amino acids, osmotic pressure controlling agents,
carrier gases, pH-controlling agents, organic solvents, hydrophobic agents, enzyme inhibitors, water
absorbing polymers, surfactants, absorption promoters and anti-oxidative agents. Representative
examples of carbohydrates include soluble sugars such as hydropropyl cellulose, carboxymethyl
cellulose, sodium carboxyl cellulose, hyaluronic acid, chitosan, alginate, glucose, xylose, galactose,
fructose, maltose, saccharose, dextran, chondroitin sulfate, etc. Representative examples of proteins
include albumin, gelatin, etc. Representative examples of amino acids include glycine, alanine,
glutamic acid, arginine, lysine, and their salts.
[00294] In some embodiments, the immunogens as described herein can be solubilized in water, a
solvent such as methanol, or a buffer. Suitable buffers include, but are not limited to, phosphate
                       2
buffered saline Ca      +/Mg2 + free (PBS), normal saline (150 mM NaCl in water), and Tris buffer.
Antigen not soluble in neutral buffer can be solubilized in 10 mM acetic acid and then diluted to the
desired volume with a neutral buffer such as PBS. In the case of antigen soluble only at acid pH,
acetate-PBS at acid pH may be used as a diluent after solubilization in dilute acetic acid. Glycerol can
be a suitable non-aqueous buffer for use in the present invention.
[00295] If the immunogen as disclosed herein is not soluble per se, the immunogen can be present in
the formulation in a suspension or even as an aggregate. In some embodiments, hydrophobic antigen
can be solubilized in a detergent, for example a polypeptide containing a membrane-spanning domain.
Furthermore, for formulations containing liposomes, an antigen in a detergent solution (e.g., a cell
membrane extract) may be mixed with lipids, and liposomes then may be formed by removal of the
detergent by dilution, dialysis, or column chromatography.
[00296] In some embodiments, a vaccine composition is administered in combination with other
therapeutic ingredients including, e.g., y-interferon, cytokines, chemotherapeutic agents, or anti
inflammatory or anti-viral agents.
[00297] In some embodiments, a vaccine composition is administered in a pure or substantially pure
form, but it is preferable to present it as a pharmaceutical composition, formulation or preparation.
Such formulation comprises polypeptides described herein together with one or more
                                                    75

    WO 2014/124228                                                                   PCT/US2014/015254
pharmaceutically acceptable carriers and optionally other therapeutic ingredients. Other therapeutic
ingredients include compounds that enhance antigen presentation, e.g., gamma interferon, cytokines,
chemotherapeutic agents, or anti-inflammatory agents. The formulations can conveniently be
presented in unit dosage form and may be prepared by methods well known in the pharmaceutical art.
For example, Plotkin and Mortimer (In 'Vaccines', 1994, W.B. Saunders Company; 2nd edition)
describes vaccination of animals or humans to induce an immune response specific for particular
pathogens, as well as methods of preparing antigen, determining a suitable dose of antigen, and
assaying for induction of an immune response.
{40298} In some embodiments, a vaccine composition as described herein further comprises an
adjuvant, as described herein.
[00299]     Formulations of vaccine compositions suitable for intravenous, intramuscular, intranasal,
oral, subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous solutions
of the active ingredient with solutions which are preferably isotonic with the blood of the recipient.
Such formulations may be conveniently prepared by dissolving solid active ingredient in water
containing physiologically compatible substances such as sodium chloride (e.g., 0.1-2.0 M), glycine,
and the like, and having a buffered pH compatible with physiological conditions to produce an
aqueous solution, and rendering the solution sterile. These may be present in unit or multi-dose
containers, for example, sealed ampoules or vials.
[00300] Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can
be prepared according to methods known to those skilled in the art, for example, as described in U. S.
Patent No. 4,522,811.
[00301] Formulations for an intranasal delivery are described in US Patent Nos. 5,427,782, 5,843,451
and 6,398,774, which are incorporated herein in their entirety by reference. Other means of mucosal
administration are also encompassed herein.
[00302] The formulations of a vaccine composition as disclosed herein can also incorporate a
stabilizer. Illustrative stabilizers are polyethylene glycol, proteins, saccharide, amino acids, inorganic
acids, and organic acids which may be used either on their own or as admixtures. Two or more
stabilizers may be used in aqueous solutions at the appropriate concentration and/or pH. The specific
osmotic pressure in such aqueous solution is generally in the range of 0.1-3.0 osmoses, preferably in
the range of 0.80-1.2. The pH of the aqueous solution is adjusted to be within the range of 5.0-9.0,
preferably within the range of 6-8.
[00303] When oral preparations are desired, a vaccine composition can be combined with typical
carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl
cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
[00304] The present invention provides immunogenic compositions (e.g., vaccines) comprising a
novel pneumococcal antigen, e.g., one or more of a polypeptide antigen selected from Table 1 or
functional fragments thereof and any combinations thereof, and one or more pharmaceutically
                                                    76

    WO 2014/124228                                                                  PCT/US2014/015254
acceptable excipients. In accordance with some embodiments, a method of administering an inventive
immunogenic composition to a subject in need thereof is provided. In some embodiments, inventive
compositions are administered to humans. For the purposes of the present invention, the phrase
"active ingredient" generally refers to an inventive immunogenic composition comprising at least one
chlamydia antigen and optionally comprising one or more additional agents, such as an adjuvant.
[00305] Although the descriptions of immunogenic compositions provided herein are principally
directed to compositions which are suitable for administration to humans, it will be understood by the
skilled artisan that such compositions are generally suitable for administration to animals of all sorts.
Modification of immunogenic compositions suitable for administration to humans in order to render
the compositions suitable for administration to various animals is well understood, and the ordinarily
skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary,
if any, experimentation. Subjects to which administration of the immunogenic compositions of the
invention is contemplated include, but are not limited to, humans and/or other primates; mammals,
including commercially relevant mammals such as domestic animals, cattle, pigs, horses, sheep, cats,
and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese,
and/or turkeys.
[00306] The formulations of the immunogenic compositions described herein may be prepared by
any method known or hereafter developed in the art of vaccines. In some embodiments, such
preparatory methods include the step of bringing the antigen(s) (or nucleic acids encoding the
antigens, for nucleic acid based applications) into association with one or more excipients and/or one
or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging
the product into a desired single- or multi-dose unit.
[00307] An immunogenic composition of the invention may be prepared, packaged, and/or sold in
bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a "unit dose" is
discrete amount of the immunogenic composition comprising a predetermined amount of the
antigen(s).
[00308] The relative amounts of the antigen(s), the pharmaceutically acceptable excipient(s), and/or
any additional ingredients (e.g., adjuvant) in a composition of the invention will vary, depending upon
the identity, size, and/or condition of the subject treated and further depending upon the route by
which the composition is to be administered.
[00309] Immunogenic formulations of the present invention may additionally comprise a
pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion
media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic
agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited
to the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21.sup.st
Edition, A. R. Gennaro, (Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporated herein
by reference) discloses various excipients used in formulating pharmaceutical compositions and
                                                   77

    WO 2014/124228                                                                     PCT/US2014/015254
known techniques for the preparation thereof. Except insofar as any conventional excipient is
incompatible with a substance or its derivatives, such as by producing any undesirable biological
effect or otherwise interacting in a deleterious manner with any other component(s) of the
immunogenic composition, its use is contemplated to be within the scope of this invention.
[00310] In some embodiments, the pharmaceutically acceptable excipient is at least 95%, 96%, 97%,
98%, 99%, or 100% pure. In some embodiments, the excipient is approved for use in humans and for
veterinary use. In some embodiments, the excipient is approved by United States Food and Drug
Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments,
the excipient meets the standards of the United States Pharmacopoeia (USP), the European
Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.
[00311] Pharmaceutically acceptable excipients used in the manufacture of immunogenic
compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents,
surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering
agents, lubricating agents, and/or oils. Such excipients may optionally be included in the inventive
formulations.
[00312] Injectable formulations, for example, sterile injectable aqueous or oleaginous suspensions
may be formulated according to the known art using suitable dispersing or wetting agents and
suspending agents. A sterile injectable preparation may be a sterile injectable solution, suspension or
emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3
butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's
solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can
be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are
used in the preparation of injectables.
[00313] Injectable formulations can be sterilized, for example, by filtration through a bacterial
retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which
can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00314] In order to prolong release of an immunogenic composition and stimulate maximal uptake by
antigen presenting cells in the vicinity of an injection site, it is often desirable to slow the absorption
from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid
suspension of crystalline or amorphous material with poor water solubility. Alternatively, delayed
absorption of a parenterally administered drug form may be accomplished by dissolving or
suspending the drug in an oil vehicle.
[00315] In some embodiments, an immunogenic composition is administered to a mucosal surface.
Compositions for rectal or vaginal administration can include suppositories which can be prepared by
mixing immunogenic compositions of this invention with suitable excipients such as cocoa butter,
                                                    78

    WO 2014/124228                                                                 PCT/US2014/015254
polyethylene glycol or a suppository wax, which are solid at ambient temperature but liquid at body
temperature and therefore melt in the rectum or vaginal cavity and release antigen.
[00316] In some embodiments, an immunogenic composition is administered orally. Solid dosage
forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid
dosage forms, the antigen can be mixed with at least one inert, pharmaceutically acceptable excipient
such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose,
sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose,
alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d)
disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption
accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants
such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,
and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise
buffering agents.
[00317] Suitable devices for use in delivering immunogenic compositions by an intradermal route
described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499;
5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Jet injection
devices which deliver liquid immunogenic compositions to the dermis via a liquid jet injector and/or
via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are
suitable. Jet injection devices are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302;
5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163;
5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT
publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use
compressed gas to accelerate an immunogenic composition in powder form through the outer layers
of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used
in the classical mantoux method of intradermal administration.
[00318] General considerations in the formulation and/or manufacture of pharmaceutical agents may
be found, for example, in Remington: The Science and Practice of Pharmacy 21.sup.st ed., Lippincott
Williams & Wilkins, 2005.
[00319] The vaccine formulation or immunogenic composition may be suitable for administration to
a human patient, and vaccine or immunogenic composition preparation may conform to USFDA
guidelines. In some embodiments, the vaccine formulation or immunogenic composition is suitable
for administration to a non-human animal. In some embodiments, the vaccine or immunogenic
composition is substantially free of either endotoxins or exotoxins. Endotoxins may include pyrogens,
such as lipopolysaccharide (LPS) molecules. The vaccine or immunogenic composition may also be
substantially free of inactive protein fragments which may cause a fever or other side effects. In some
                                                   79

    WO 2014/124228                                                                  PCT/US2014/015254
embodiments, the composition contains less than 1%, less than 0.1%, less than 0.01%, less than
0.001%, or less than 0.0001% of endotoxins, exotoxins, and/or inactive protein fragments. In some
embodiments, the vaccine or immunogenic composition has lower levels of pyrogens than industrial
water, tap water, or distilled water. Other vaccine or immunogenic composition components may be
purified using methods known in the art, such as ion-exchange chromatography, ultrafiltration, or
distillation. In other embodiments, the pyrogens may be inactivated or destroyed prior to
administration to a patient. Raw materials for vaccines, such as water, buffers, salts and other
chemicals may also be screened and depyrogenated. All materials in the vaccine may be sterile, and
each lot of the vaccine may be tested for sterility. Thus, in certain embodiments the endotoxin levels
in the vaccine fall below the levels set by the USFDA, for example 0.2 endotoxin (EU)/kg of product
for an intrathecal injectable composition; 5 EU/kg of product for a non-intrathecal injectable
composition, and 0.25-0.5 EU/mL for sterile water.
[00320] In certain embodiments, the preparation comprises less than 50%, 20%, 10%, or 5% (by dry
weight) contaminating protein. In certain embodiments, the desired molecule is present in the
substantial absence of other biological macromolecules, such as other proteins (particularly other
proteins which may substantially mask, diminish, confuse or alter the characteristics of the component
proteins either as purified preparations or in their function in the subject reconstituted mixture). In
certain embodiments, at least 8 0%, 9 0%, 95%, 99%, or     99 8
                                                              . % (by dry weight) of biological
macromolecules of the same type present (but water, buffers, and other small molecules, especially
molecules having a molecular weight of less than 5000, can be present). In some embodiments, the
vaccine or immunogenic composition comprising purified subunit proteins contains less than 5%, 2%,
1%, 0. 5%, 0. 2 %, 0. 1% of protein from host cells in which the subunit proteins were expressed,
relative to the amount of purified subunit. In some embodiments, the desired polypeptides are
substantially free of nucleic acids and/or carbohydrates. For instance, in some embodiments, the
vaccine or immunogenic composition contains less than 5%, less than 2%, less than 1%, less than
0.5%, less than 0. 2 %, or less than 0. 1% host cell DNA and/or RNA. In certain embodiments, at least
8 %
  0   , 9 0%, 9 5%, 99
                       %, or 99 8
                               . % (by dry weight) of biological macromolecules of the same type are
present in the preparation (but water, buffers, and other small molecules, especially molecules having
a molecular weight of less than 5000, can be present).
[00321] It is preferred that the vaccine or immunogenic composition has low or no toxicity, within a
reasonable risk-benefit ratio. In certain embodiments, the vaccine or immunogenic composition
comprises ingredients at concentrations that are less than LD.50 measurements for the animal being
vaccinated. LD50 measurements may be obtained in mice or other experimental model systems, and
extrapolated to humans and other animals. Methods for estimating the LD50 of compounds in humans
and other animals are well-known in the art. A vaccine formulation or immunogenic composition, and
any component within it, might have an LD50 value in rats of greater than 100 g/kg, greater than 50
g/kg, greater than 20 g/kg, greater than 10 g/kg, greater than 5 g/kg, greater than 2 g/kg, greater than 1
                                                    80

    WO 2014/124228                                                                  PCT/US2014/015254
g/kg, greater than 500 mg/kg, greater than 200 mg/kg, greater than 100 mg/kg, greater than 50 mg/kg,
greater than 20 mg/kg, or greater than 10 mg/kg. A vaccine formulation or immunogenic composition
that comprises a toxin such as botulinum toxin (which can be used as an adjuvant) should contain
significantly less than the LD50 of botulinum toxin.
[00322] The formulations suitable for introduction of the vaccine formulations or pharmaceutical
composition vary according to route of administration. Formulations suitable for parenteral
administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular,
intradermal, intraperitoneal, intranasal, and subcutaneous routes, include aqueous and non-aqueous,
isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes
that render the formulation isotonic with the blood of the intended recipient, and aqueous and non
aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents,
stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed
containers, such as ampoules and vials.
[00323] Injection solutions and suspensions can be prepared from sterile powders, granules, and
tablets of the kind previously described. In the case of adoptive transfer of therapeutic T cells, the
cells can be administered intravenously or parenterally.
[00324] Formulations suitable for oral administration can consist of (a) liquid solutions, such as an
effective amount of the polypeptides or packaged nucleic acids suspended in diluents, such as water,
saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the
active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and
(d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol,
calcium phosphates, corn starch, potato starch, tragacanth, microcrystalline cellulose, acacia, gelatin,
colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other
excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives,
flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge
forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well
as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose
and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known
in the art. The pharmaceutical compositions can be encapsulated, e.g., in liposomes, or in a
formulation that provides for slow release of the active ingredient.
[00325] The antigens, alone or in combination with other suitable components, can be made into
aerosol formulations (e.g., they can be "nebulized") to be administered via inhalation. Aerosol
formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane,
propane, nitrogen, and the like. Aerosol formulations can be delivered orally or nasally.
[00326] Suitable formulations for vaginal or rectal administration include, for example, suppositories,
which consist of the polypeptides or packaged nucleic acids with a suppository base. Suitable
suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is
                                                    81

    WO 2014/124228                                                                PCT/US2014/015254
also possible to use gelatin rectal capsules which consist of a combination of the polypeptides or
packaged nucleic acids with a base, including, for example, liquid triglycerides, polyethylene glycols,
and paraffin hydrocarbons.
Doses and Routes of Administration
1. Dosage Forms, Amounts, and Timing
[00327] The amount of antigen in each vaccine or immunogenic composition dose is selected as an
effective amount, which induces a prophylactic or therapeutic response, as described above, in either a
single dose or over multiple doses. Preferably, the dose is without significant adverse side effects in
typical vaccinees. Such amount will vary depending upon which specific antigen is employed.
Generally, it is expected that a dose will comprise 1-1000 jig of each protein, in some instances 2-100
jig, for instance 4-40 jig. In some aspects, the vaccine formulation comprises 1-1000 jig of the
polypeptide and 1-250 jig of the adjuvant. In some embodiments, the appropriate amount of antigen to
be delivered will depend on the age, weight, and health (e.g. immunocompromised status) of a
subject. When present, typically an adjuvant will be present in amounts from 1 gg-250 jig per dose,
for example 50-150 jig, 75-125 jig or 100 jig.
[00328] In some embodiments, only one dose of the vaccine is administered to achieve the results
described above. In other embodiments, following an initial vaccination, subjects receive one or more
boost vaccinations, for a total of two, three, four or five vaccinations. Advantageously, the number is
three or fewer. A boost vaccination may be administered, for example, about 1 month, 2 months, 4
months, 6 months, or 12 months after the initial vaccination, such that one vaccination regimen
involves administration at 0, 0.5-2 and 4-8 months. It may be advantageous to administer split doses
of vaccines which may be administered by the same or different routes.
[00329] The vaccines and immunogenic compositions described herein may take on a variety of
dosage forms. In certain embodiments, the composition is provided in solid or powdered (e.g.,
lyophilized) form; it also may be provided in solution form. In certain embodiments, a dosage form is
provided as a dose of lyophilized composition and at least one separate sterile container of diluent.
[00330] In some embodiments, the composition will be administered in a dose escalation manner,
such that successive administrations of the composition contain a higher concentration of composition
than previous administrations. In some embodiments, the composition will be administered in a
manner such that successive administrations of the composition contain a lower concentration of
composition than previous administrations.
[00331] The precise dose to be employed in the formulation will also depend on the route of
administration and should be decided according to the judgment of the practitioner and each patient's
circumstances. For example, a range of 25 pig -900 pig total immunogen protein can be administered
intradermally, monthly for 3 months. Ultimately, the attending physician will decide the amount of
protein or vaccine composition to administer to particular individuals.
                                                   82

    WO 2014/124228                                                                    PCT/US2014/015254
[00332] In some embodiments, a therapeutically effective amount of an inventive immunogenic
composition is delivered to a patient and/or animal prior to, simultaneously with, and/or after
exposure to a chlamydia organism or diagnosis with a chlamydial disease, disorder, and/or condition.
In some embodiments, a therapeutic amount of an inventive composition is delivered to a patient
and/or animal prior to, simultaneously with, and/or after onset of symptoms of a chlamydial disease,
disorder, and/or condition. In some embodiments, the amount of an immunogenic composition is
sufficient to reduce risk of infection by, or treat, alleviate, ameliorate, relieve, delay onset of, inhibit
progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of
the chlamydial disease, disorder, and/or condition.
[00333] Immunogenic compositions, according to the method of the present invention, may be
administered using any amount and any route of administration effective for treatment. The exact
amount required will vary from subject to subject, depending on the species, age, and general
condition of the subject, the severity of the infection, the particular composition, its mode of
administration, its mode of activity, and the like. The specific effective dose level for any particular
subject or organism will depend upon a variety of factors including the immunogenicity of the antigen
composition employed; the specific composition employed; the nature of adjuvant used; the age, body
weight, general health, sex and diet of the subject; the time of administration, route of administration,
and like factors well known in the medical arts.
[00334] In therapeutic applications, compositions are administered to a patient suffering from a
disease in an amount sufficient to treat the patient. Therapeutic applications of a composition
described herein include reducing transmissibility, slowing disease progression, reducing bacterial
viability or replication, or inhibiting the expression of proteins required for toxicity, such as by 90%,
80%, 70%, 60%, 50%, 40%, 30%, 20% or 10% of the levels at which they would occur in individuals
who are not treated with the composition.
[00335] In prophylactic embodiments, compositions are administered to a human or other mammal to
induce an immune response that can inhibit the establishment of an infectious disease or other
condition. In some embodiments, a composition may partially block the bacterium from establishing
an infection.
[00336] In some embodiments, the compositions are administered in combination with antibiotics.
This co-administration is particularly appropriate when the pharmaceutical composition is
administered to a patient who has recently been exposed (or is suspected of having been recently
exposed) to S. pneumoniae. Many antibiotics are used to treat pneumococcal infections, including
penicillin, amoxicillin, amoxicillin/clavulanate, cefuroxime, cefotaxime, ceftriaxone, and vancomycin.
The appropriate antibiotic may be selected based on the type and severity of the infection, as well as
any known antibiotic resistance of the infection (Jacobs M R "Drug-resistant Streptococcus
pneumoniae: rational antibiotic choices" Am J. Med. 1999 May 3; 106 (5A):19S-25S).
2. Administration
                                                    83

    WO 2014/124228                                                                   PCT/US2014/015254
[00337] A method of immunization or vaccinating a mammal against pneumococcal infections
comprises administering a vaccine composition described herein.
[00338] In some embodiments, the immunogenic compositions or vaccine compositions as described
herein can be administered intravenously, intranasally, intramuscularly, subcutaneously,
infraperitoneally or orally. A preferred route of administration is intranasal or by other mucosal route.
[00339] Vaccination can be conducted by conventional methods. For example, an immunogen as
polypeptide as disclosed in Table 1 can be used in a suitable diluent such as saline or water, and
optionally with complete or incomplete adjuvants. The vaccine can be administered by any route
appropriate for eliciting an immune response. The vaccine can be administered once or at periodic
intervals until an immune response is elicited. Immune responses can be detected by a variety of
methods known to those skilled in the art, including but not limited to, antibody production,
cytotoxicity assay, proliferation assay and cytokine release assays. For example, samples of blood can
be drawn from the immunized mammal, and analyzed for the presence of antibodies against the
immunogen protein used in the vaccination by ELISA and the titer of these antibodies can be
determined by methods known in the art.
[00340] Immunogenic compositions of the present invention may be administered by any route that
elicits an immune response. In some embodiments, an immunogenic composition is administered
subcutaneously. In some embodiments, an immunogenic composition is administered intramuscularly.
In some embodiments, the immunogenic compositions of the present invention are administered by a
variety of routes, including oral, intravenous, intra-arterial, intramedullary, intrathecal,
intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders,
ointments, creams, and/or drops), transdermal, mucosal, nasal, buccal, enteral, sublingual; by
intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray,
and/or aerosol.
[00341] The vaccine formulations and pharmaceutical compositions herein can be delivered by
administration to an individual, typically by systemic administration (e.g., intravenous,
intraperitoneal, intramuscular, intradermal, subcutaneous, subdermal, transdermal, intracranial,
intranasal, mucosal, anal, vaginal, oral, buccal route or they can be inhaled) or they can be
administered by topical application. In some embodiments, the route of administration is
intramuscular. In other embodiments, the route of administration is subcutaneous. In yet other
embodiments, the route of administration is mucosal. In certain embodiments, the route of
administration is transdermal or intradermal
[00342] Certain routes of administration are particularly appropriate for vaccine formulations and
immunogenic compositions comprising specified adjuvants. In particular, transdermal administration
is one suitable route of administration for S. pneumoniae vaccines comprising toxins (e.g. cholera
toxin or labile toxin); in other embodiments, the administration is intranasal. Vaccines formulated
with Alphavirus replicons may be administered, for example, by the intramuscular or the
                                                     84

    WO 2014/124228                                                                 PCT/US2014/015254
subcutaneous route. Vaccines comprising Monophosphory Lipid A (MPL), Trehalose
Dicoynomycolate (TDM), and dioctadecyldimethylammonium bromide (DDA) are suitable (inter
alia) for intramuscular and subcutaneous administration. A vaccine comprising resiquimod may be
administered topically or subcutaneously, for example.
[00343] In certain embodiments, an immunogenic composition of the invention may be administered
in amounts that include a protein antigen in ranges of 1 g-500gg. In some embodiments, a dose of
about 10tg, 20, 30 jig, 50 jig, or 100 jig is administered to a human.
[00344] In some embodiments, an immunogenic composition is administered more than once (e.g.,
twice, three times, four times, five times). In some embodiments, a boost is given about one week,
two weeks, three weeks, one month, three months, six months, one year, or longer after an initial
immunization.
Preparation and Storage of Vaccine Formulations and Immunogenic Compositions
[00345] The S. pneumoniae vaccines and immunogenic compositions described herein may be
produced using a variety of techniques. For example, a polypeptide may be produced using
recombinant DNA technology in a suitable host cell. A suitable host cell may be bacterial, yeast,
mammalian, or other type of cell. The host cell may be modified to express an exogenous copy of one
of the relevant polypeptide genes. Typically, the gene is operably linked to appropriate regulatory
sequences such as a strong promoter and a polyadenylation sequence. In some embodiments, the
promoter is inducible or repressible. Other regulatory sequences may provide for secretion or
excretion of the polypeptide of interest or retention of the polypeptide of interest in the cytoplasm or
in the membrane, depending on how one wishes to purify the polypeptide. The gene may be present
on an extrachromosomal plasmid, or may be integrated into the host genome. One of skill in the art
will recognize that it is not necessary to use a nucleic acid 100% identical to the naturally-occurring
sequence. Rather, some alterations to these sequences are tolerated and may be desirable. For
instance, the nucleic acid may be altered to take advantage of the degeneracy of the genetic code such
that the encoded polypeptide remains the same. In some embodiments, the gene is codon-optimized to
improve expression in a particular host. The nucleic acid may be produced, for example, by PCR or
by chemical synthesis.
[00346] Once a recombinant cell line has been produced, a polypeptide may be isolated from it. The
isolation may be accomplished, for example, by affinity purification techniques or by physical
separation techniques (e.g., a size column).
[00347] In a further aspect of the present disclosure, there is provided a method of manufacture
comprising mixing one or more polypeptides or an immunogenic fragment or variant thereof with a
carrier and/or an adjuvant.
[00348] In some embodiments, antigens for inclusion the vaccine formulations and immunogenic
compositions may be produced in cell culture. One method comprises providing one or more
expression vectors and cloning nucleotides encoding one or more polypeptides selected from
                                                   85

    WO 2014/124228                                                                PCT/US2014/015254
polypeptides having an amino acid sequence of Table 1, such as SEQ ID NO: 1-76 or 153-234, then
expressing and isolating the polypeptides.
[00349] The immunogenic polypeptides described herein, and nucleic acid compositions that express
the polypeptides, can be packaged in packs, dispenser devices, and kits for administering nucleic acid
compositions to a mammal. For example, packs or dispenser devices that contain one or more unit
dosage forms are provided. Typically, instructions for administration of the compounds will be
provided with the packaging, along with a suitable indication on the label that the compound is
suitable for treatment of an indicated condition, such as those disclosed herein.
Use of Immunogenic Compositions
1. Defense Against S. pneumoniae Infection
[00350] The immunogenic compositions of the present disclosure are designed to elicit an immune
response against S. pneumoniae. Compositions described herein (e.g., ones comprising one or more
polypeptides of Table 1 or 2, or nucleic acids encoding the polypeptides) may stimulate an antibody
response or a cell-mediated immune response, or both, in the mammal to which it is administered. In
some embodiments, the composition stimulates a THI-biased CD4+ T cell response, a TH17-biased
CD4+ T cell response and/or a CD8+ T cell response. In some embodiments, the composition
stimulates an antibody response. In some embodiments, the composition stimulates a THI-biased
CD4+ T cell response, TH17-biased CD4+ T cell response and/or a CD8+ T cell response, and an
antibody response.
[00351] In certain embodiments, the composition (e.g., one comprising one or more polypeptides of
Table 1 or 2, or nucleic acids encoding the polypeptides, or antibodies reactive with the peptides)
includes a cytokine or nucleotide coding region encoding a cytokine such as IL-17, to provide
additional stimulation to the immune system of the mammal. In certain embodiments, the composition
comprises a cytokine such as IL-17.
[00352] While not wishing to be bound by theory, in some embodiments a T.sub.H17 cell response is
desirable in mounting an immune response to the compositions disclosed herein, e.g., ones comprising
one or more polypeptides of Table 1 or 2. In certain embodiments, an active T.sub.H17 response is
beneficial in clearing a pneumococcal infection. For instance, mice lacking the IL-17A receptor show
decreased whole cell vaccine-based protection from a pneumococcal challenge (Lu et al.,
"Interleukin-17A mediates acquired immunity to pneumococcal colonization." PLoS Pathog. 2008
Sep. 19; 4 (9)).
[00353] Thus, herein is provided a method of increasing IL-17 production by administering the
compositions described herein (e.g., ones comprising one or more polypeptides of Table 1 or 2) to a
subject. Furthermore, this application provides a method of activating T.sub.H17 cells by
administering said compositions to a subject. In certain embodiments, increased IL-17A levels result
in increased pneumococcal killing by neutrophils or neutrophil-like cells, for instance by inducing
recruitment and activation of neutrophils of neutrophil-like cells. In certain embodiments, this
                                                  86

    WO 2014/124228                                                                 PCT/US2014/015254
pneumococcal killing is independent of antibodies and complement. However, specific antibody
production and complement activation may be useful additional mechanisms that contribute to
clearing of a pneumococcal infection.
[00354] Immunogenic compositions containing immunogenic polypeptides or polynucleotides
encoding immunogenic polypeptides together with a pharmaceutical carrier are also provided.
[00355] In some instances, the immunogenic composition comprises one or more nucleic acids
encoding one or more polypeptides of SEQ ID NOS: 1-76, such as one or more nucleic acids selected
from SEQ ID Nos. 77-152. In some embodiments these nucleic acids are expressed in the immunized
individual, producing the encoded S. pneumoniae antigens, and the S. pneumoniae antigens so
produced can produce an immunostimulatory effect in the immunized individual.
[00356] Such a nucleic acid-containing immunostimulatory composition may comprise, for example,
an origin of replication, and a promoter that drives expression of one or more nucleic acids encoding
one or more polypeptides of SEQ ID NOS: 1-76. Such a composition may also comprise a bacterial
plasmid vector into which is inserted a promoter (sometimes a strong viral promoter), one or more
nucleic acids encoding one or more polypeptides of SEQ ID NOS: 1-76, and a
polyadenylation/transcriptional termination sequence. In some instances, the nucleic acid is DNA.
Diagnostic Uses
[00357] This application provides, inter alia, a rapid, inexpensive, sensitive, and specific method for
detection of S. pneumoniae in patients. In this respect it should be useful to all hospitals and
physicians examining and treating patients with or at risk for S. pneumoniae infection. Detection kits
can be simple enough to be set up in any local hospital laboratory, and the antibodies and antigen
binding portions thereof can readily be made available to all hospitals treating patients with or at risk
for S. pneumoniae infection. As used herein, "patient" refers to an individual (such as a human) that
either has an S. pneumoniae infection or has the potential to contract an S. pneumoniae infection. A
patient may be an individual (such as a human) that has an S. pneumoniae infection, has the potential
to contract an S. pneumoniae infection, who has recovered from S. pneumoniae infection, and/or an
individual whose infection status is unknown.
[00358] In some embodiments, one may perform a diagnostic assay using two or more antibodies,
each of which binds one of the antigens of Table 1 detect S. pneumoniae in an individual. As
disclosed in Example 5, sera from a mouse immunized with SP0785 detected the presence to type 4
TIGR4 S.pneumoniae strain. Accordingly, in some embodiment, one of the antigens for use in a
diagnostic is any pneumococcal antigen selected from SEQ ID NO: 1-76. The instant disclosure also
provides a method of phenotyping biological samples from patients suspected of having a S.
pneumoniae infection: (a) obtaining a biological sample from a patient; (b) contacting the sample with
two or more S. pneumoniae-specific antibodies or antigen-binding portions thereof under conditions
that allow for binding of the antibody or antigen-binding portion to an epitope of S. pneumoniae;
where binding indicates the presence of S. pneumoniae in the sample. In some embodiments, the
                                                  87

    WO 2014/124228                                                                 PCT/US2014/015254
binding to the biological sample is compared to binding of the same antibody to a negative control
tissue, wherein if the biological sample shows the presence of S. pneumoniae as compared to the
negative control tissue, the patient is identified as likely having a S. pneumoniae infection. In some
cases, binding of one antibody indicates the presence of S. pneumoniae; in other cases, the binding of
two or more antibodies indicates the presence of S. pneumoniae. The aforementioned test may be
appropriately adjusted to detect other bacterial infections, for instance by using an antibody
immunoreactive a homolog (from another bacterial species) of one of the proteins described in Table
1. In some embodiments, the antibodies raised against a S. pneumoniae protein in Table 1 will also
bind the homolog in another Streptococcus species, especially if the homologs have a high percentage
sequence identity.
[00359] Alternatively, one may use an antigen of Table 1 (such as SEQ ID NO: 1-76) to detect anti
S. pneumoniae antibodies in an individual. The instant disclosure also provides a method of
phenotyping biological samples from patients suspected of having a S. pneumoniae infection: (a)
obtaining a biological sample from a patient; (b) contacting the sample with two or more S.
pneumoniae-specific antigens selected from Table 1 or portions or functional fragments thereof under
conditions that allow for binding of the antigen (or portion thereof) to any host antibodies present in
the sample; where binding indicates the presence of anti-S. pneumoniae antibodies in the sample. In
some embodiments, the binding to the biological sample is compared to binding of the same antigen
to a negative control tissue, wherein if the biological sample shows the presence of anti-S.
pneumoniae antibodies as compared to the negative control tissue, the patient is identified as likely
either (1) having a S. pneumoniae infection, or (2) having had a S. pneumoniae infection in the past.
In some cases, detecting one antibody indicates a current or past infection with S. pneumoniae; in
other cases, detecting two or more antibodies indicates a current or past infection with S. pneumoniae.
The aforementioned test may be appropriately adjusted to detect other bacterial infections, for
instance by using a homolog (from another bacterial species (e.g., a Streptococcal species) of the
proteins described in Table 1.
[00360] In some embodiments, the immune cell response of a mammalian cell may be quantified ex
vivo. A method for such quantification comprises administering the compositions herein disclosed to a
mammalian T cell ex vivo, and quantifying the change in cytokine production of the mammalian T
cell in response to the composition. In these methods, the cytokine may be, for example, IL-17.
[00361] The binding of an S. pneumoniae antibody to an antigen (e.g., a polypeptide of Table 1, such
as SEQ ID NO: 1-76) may be measured using any appropriate method. Such methods include ELISA
(enzyme-linked immunosorbent assay), Western blotting, competition assay, and spot-blot. The
detection step may be, for instance, chemiluminescent, fluorescent, or colorimetric. One suitable
method for measuring antibody-protein binding is the Luminex xMAP system, where peptides are
bound to a dye-containing microsphere. Certain systems, including the xMAP system, are amenable
to measuring several different markers in multiplex, and could be used to measure levels of antibodies
                                                    88

     WO 2014/124228                                                                  PCT/US2014/015254
at once. In some embodiments, other systems are used to assay a plurality of markers in multiplex.
For example, profiling may be performed using any of the following systems: antigen microarrays,
bead microarrays, nanobarcodes particle technology, arrayed proteins from cDNA expression
libraries, protein in situ array, protein arrays of living transformants, universal protein array, lab-on-a
chip microfluidics, and peptides on pins. Another type of clinical assay is a chemiluminescent assay to
detect antibody binding. In some such assays, including the VITROS Eci anti-HCV assay, antibodies
are bound to a solid-phase support made up of microparticles in liquid suspension, and a surface
fluorometer is used to quantify the enzymatic generation of a fluorescent product.
[00362] In some embodiments, if the biological sample shows the presence of S. pneumoniae (e.g.,
by detecting one or more polypeptide of Table 1, such as SEQ ID NO: 1-76, or an antibody that binds
one of said polypeptides), one may administer a therapeutically effective amount of the compositions
and therapies described herein to the patient. The biological sample may comprise, for example,
blood, semen, urine, vaginal fluid, mucus, saliva, feces, urine, cerebrospinal fluid, or a tissue sample.
In some embodiments, the biological sample is an organ intended for transplantation. In certain
embodiments, before the detection step, the biological sample is subject to culture conditions that
promote the growth of S. pneumoniae.
[00363] The diagnostic tests herein (e.g., those that detect a polypeptide of Table 1, such as SEQ ID
NO: 1-76, or an antibody that binds one of said polypeptides) may be used to detect S. pneumoniae in
a variety of samples, including samples taken from patients and samples obtained from other sources.
For example, the diagnostic tests may be used to detect S. pneumoniae in food, drink, or ingredients
for food and drink; on objects such as medical instruments, medical devices such as cochlear implants
and pacemakers, shoes, clothing, furniture including hospital furniture, and drapes including hospital
drapes; or in samples taken from the environment such as plant samples. In some embodiments, the
tests herein may be performed on samples taken from animals such as agricultural animals (cows,
pigs, chickens, goats, horses and the like), companion animals (dogs, cats, birds, and the like), or wild
animals. In certain embodiments, the tests herein may be performed on samples taken from cell
cultures such as cultures of human cells that produce a therapeutic protein, cultures of bacteria
intended to produce a useful biological molecule, or cultures of cells grown for research purposes.
[00364] This disclosure also provides a method of determining the location of a S. pneumoniae
infection in a patient comprising: (a) administering a pharmaceutical composition comprising a
labeled S. pneumoniae antibody or antigen-binding portion thereof to the patient, and (b) detecting the
label, wherein binding indicates a S. pneumoniae infection in a particular location in the patient. Such
a diagnostic may also comprise comparing the levels of binding in the patient to a control. In certain
embodiments, the method further comprises, if the patient has a S. pneumoniae infection, treating the
infection by administering a therapeutically effective amount of a S. pneumoniae-binding antibody or
antigen-binding portion thereof to the patient. In certain embodiments, the method further comprises,
if the patient has a S. pneumoniae infection, treating the infection by administering a therapeutically
                                                     89

    WO 2014/124228                                                                  PCT/US2014/015254
effective amount of a S. pneumoniae protein of Table 1 or 2, or immunogenic portion thereof, to the
patient. The method may further comprise determining the location and/or volume of the S.
pneumoniae in the patient. This method may be used to evaluate the spread of S. pneumoniae in the
patient and determine whether a localized therapy is appropriate.
[00365] In some embodiments, the anti-S. pneumoniae antibodies or T cells described herein may be
used to make a prognosis of the course of infection. In some embodiments, the anti-S. pneumoniae
antibodies or T cells herein may be detected in a sample taken from a patient. If antibodies or T cells
are present at normal levels, it would indicate that the patient has raised an immune response against
anti-S. pneumoniae. If antibodies or T cells are absent, or present at reduced levels, it would indicate
that the patient is failing to raise a sufficient response against anti-S. pneumoniae, and a more
aggressive treatment would be recommended. In some embodiments, antibodies or T cells present at
reduced levels refers to antibodies that are present at less than 50%, 20%, 10%, 5%, 2%, or 1% the
level of antibodies or T cells typical in a patient with a normal immune system. Antibodies may be
detected by affinity for any of the antigens described herein (e.g., those in Table 1 and/or 2), for
example using ELISA. T cells may be detected by ex vivo responses for any of the antigens described
herein (e.g., those in Table 1 and/or 2), for example using ELISA or ELISPOT assays.
[00366] In some embodiments, detection of specific S. pneumoniae antigens (e.g., those in Table 1
and/or 2, such as SEQ ID NO: 1-76 and/or SEQ ID NO: 153-234) may be used to predict the progress
and symptoms of S. pneumoniae infection in a patient. It will be understood by one of skill in the art
that the methods herein are not limited to detection of S. pneumoniae. Other embodiments include the
detection of related bacteria including bacteria with proteins homologous to the proteins described in
Table 1 or 2. Such related bacteria include, for example, other strains of Streptococcus.
Accordingly, in some embodiments, such pneumococcal antigen proteins of Table 1 or immunogen
mixtures may be useful in diagnostics.
Kits
[00367] Another aspect of the present invention provides a variety of kits comprising one or more of
the pneumococcal antigens as described herein. For example, the invention provides a kit including a
novel pneumococcal antigen and instructions for use. A kit may include multiple different
pneumococcal antigens. A kit may include any of a number of additional components or reagents in
any combination. All of the various combinations are not set forth explicitly but each combination is
included in the scope of the invention.
[00368] According to certain embodiments of the invention, a kit may include, for example, (i) an
immunogenic composition including at least one of the following chlamydia antigens:
SP0785,SP1500, SP0346,SP1386, SP0084, SP1479 and SP2145 polypeptide antigens; and (ii)
instructions for administering the composition to a subject in need thereof. In some embodiments, the
kit further includes an adjuvant.
                                                     90

    WO 2014/124228                                                                  PCT/US2014/015254
[00369]     Kits that include nucleic acids encoding chlamydia antigens are also provided. In certain
embodiments, a kit may include, for example, (i) a composition including a nucleic acid encoding a
pneumococcal antigen; (ii) instructions for use of the nucleic acid compositing (e.g., instructions for
expressing the nucleic acid for producing the antigen, or instructions for administering the
composition to a subject in need thereof to elicit a response against pneumococcus).
[00370] Instructions included with kits may, for example, include protocols and/or describe
conditions for production of immunogenic compositions and/or administration of immunogenic
compositions, to a subject in need thereof, etc. Kits generally include one or more vessels or
containers so that some or all of the individual components and reagents may be separately housed.
Kits may also include a means for enclosing individual containers in relatively close confinement for
commercial sale, e.g., a plastic box, in which instructions, packaging materials such as styrofoam,
etc., may be enclosed. An identifier, e.g., a bar code, radio frequency identification (ID) tag, etc., may
be present in or on the kit or in or one or more of the vessels or containers included in the kit. An
identifier can be used, e.g., to uniquely identify the kit for purposes of quality control, inventory
control, tracking, movement between workstations, etc.
[00371]       Some embodiments of the technology described herein can be defined according to any of
the following numbered paragraphs:
   1.An immunogenic composition comprising at least one isolated pneumococcal antigen or fragment
        thereof with the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234,
        and wherein the composition elicits an immune response against Streptococcus pneumoniae
        when administered to a mammal.
  2. The immunogenic composition of paragraph 1, wherein the pneumococcal antigen or fragment
        thereof exists as a fusion conjugate.
   3.The immunogenic composition of paragraph 2, wherein the fusion conjugate is a polysaccharide
        conjugate.
  4. The immunogenic composition of paragraph 3, wherein the fusion conjugate comprises the
        pneumococcal antigen or fragment thereof fused to a pneumococcal pneumolysoid PdT,
        wherein the pneumococcal pneumolysoid PdT is conjugated to the polysaccharide.
   5.The immunogenic composition of any of paragraphs 2 to 4, wherein the polysaccharide is dextran,
        Vi polysaccharide of Salmonella typhi, or pneumococcal cell wall polysaccharide (CWPS), or
        another polysaccharide of prokaryotic or eukaryotic origin.
   6. The immunogenic composition of any of paragraphs I to 5, wherein the immunogenic
        composition induces a IL-17A (Thl7-cell) response in a subject.
   7. The immunogenic composition of any of paragraphs 1 to 6, wherein the immunogenic
        composition is further prepared as a vaccine that reduces or protects a mammal against
        pneumococcal colonization.
                                                   91

 WO 2014/124228                                                              PCT/US2014/015254
8.The immunogenic composition of any of paragraphs I to 7, wherein the immunogenic
     composition further comprises an adjuvant.
9. The immunogenic composition of any of paragraphs I to 8, wherein said immunogenic
     composition is administered mucosally.
10. The immunogenic composition of any of paragraphs 1 to 9, wherein the immunogenic
     composition comprises at least 2 pneumococcal antigens or fragments with the amino acid
     sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
11. The immunogenic composition of any of paragraphs 1 to 10, wherein the immunogenic
     composition comprises at least 3 pneumococcal antigens or fragments with the amino acid
     sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
12. The immunogenic composition of any of paragraphs I to 11, wherein the immunogenic
     composition comprises at least 5 pneumococcal antigens or fragments with the amino acid
     sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
13. The immunogenic composition of any of paragraphs 1 to 12, wherein the immunogenic
     composition comprises between 5 and 20 pneumococcal antigens or fragments thereof with the
     amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
14. The immunogenic composition of any of paragraphs I to 13, wherein the immunogenic
     composition comprises more than 20 pneumococcal antigens or fragments thereof with the
     amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
15. The method of any of paragraphs 1 to 14, wherein a pneumococcal protein or protein fragment
     is at least one of the pneumococcal proteins SP0785, SP1500 and SP2145.
16. The method of any of paragraphs I to 15, wherein the immune response comprises a humoral
     immune response.
17. The method of any of paragraphs I to 15, wherein the immune response comprises a cellular
     immune response.
18. A method of inducing an IL-17A response in a subject, comprising administering to the subject
     at least one immunogenic composition of any of paragraphs 1 - 17 effective to induce an
     immune response against Streptococcuspneumoniae in the subject.
19. A method to protect against pneumococcal colonization, comprising administering to the
     subject at least one immunogenic composition of any of paragraphs 1 - 17.
20. A method to elicit an immune response against Streptococcuspneumoniae in a mammal, the
     method comprising administering to the mammal at least one immunogenic composition
     comprising one or more isolated pneumococcal antigen or fragment thereof with the amino acid
     sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234 in an effective to induce an
     immune response against Streptococcuspneumoniae in the subject.
21. A method to protect against Streptococcuspenumoniae or Salmonaell typhii colonization in a
     mammal, comprising administering to the mammal at least one immunogenic composition of
                                               92

   WO 2014/124228                                                             PCT/US2014/015254
      any of paragraphs 1 - 17 in effective to induce an immune response against Streptococcus
      pneumoniae in the subject.
  22. The method of any of paragraphs 18-21, wherein the immunogenic composition comprises at
      least one isolated pneumococcal antigen or fragment thereof is SP0785 or SP1500.
  23. The method of paragraph 22, wherein the pneumococcal antigen or fragment thereof has an
      amino acid sequence selected from SEQ ID NO: 34 ( SP0785) or SEQ ID NO: 51(SP1500).
  24. A method to protect against an invasive disease of Streptococcuspneumoniae in a subject,
      comprising administering to the subject an immunogenic composition of any of paragraphs 1
      17 in effective to induce an immune response against Streptococcuspneumoniae in the subject.
  25. The method of paragraph 24, wherein the invasive disease is sepsis.
  26. The method of paragraph 24, wherein the immunogenic composition comprises at least one
      isolated pneumococcal antigen or fragment thereof is SP1386, SP1500, SP0084 and SP1479
      and SP0346.
  27. The method of paragraph 26, wherein the pneumococcal antigen or fragment thereof has an
      amino acid sequence selected from SEQ ID NO: 46 (SP1386), SEQ ID NO: 51(SP1500), SEQ
      ID NO: 4 (SP0084), SEQ ID NO: 50 (SP1479) and SEQ ID NO: 15 (SP0346).
  28. The method of any of paragraphs 18-27, wherein the pneumococcal antigen or fragment thereof
      is conjugated to the pneumococcal pneumolysoid PdT.
  29. The method of any of paragraphs 18-27, wherein the pneumococcal antigen or fragment thereof
      is conjugated to the Vi polysaccharide of Salmonella typhi.
  30. The method of any of paragraphs 18-29, wherein the pneumococcal antigen or fragment thereof
      is conjugated to the pneumococcal pneumolysoid PdT and the Vi polysaccharide of Salmonella
      typhi.
  31. The method of any of paragraphs 18-30, wherein the administration is mucosal administration.
  32. The method of any of paragraphs 18-31, wherein the administration is intravenous,
      subcutaneous or intraperitoneal (IP) administration.
  33. The method of any of paragraphs 18-32, wherein the immune response comprises a humoral
      immune response.
  34. The method of any of paragraphs 18-32, wherein the immune response comprises a cellular
      immune response.
                                             EXAMPLES
Materials and Methods:
[00372] Materials: Aluminum hydroxide (alum) was from Brenntag North America (2%
Alhydrogel). Ni-NTA resin was purchased from Qiagen. CloneEZ PCR cloning kit was obtained from
Genscript Inc. All other reagents were obtained from Sigma or Thermo Fisher Scientific.
[00373] Construction of expression library.
                                                 93

    WO 2014/124228                                                                PCT/US2014/015254
[00374] The extracellular domains of selected proteins were amplified using TIGR4 genomic DNA
as template by PCR and then integrated into pET21b expression vectors using the CloneEZ PCR
cloning kit. Signal and transmembrane sequences were excluded from cloning. Detailed cloning
region and primer sequences are listed in table I. For proteins that are unusually large (SP0648,
SP0664 and SP 1154, larger than 250 kDa) and proved difficult to purify as full-length, we divided
their sequence into 3 parts and purified each separately. We chose to divide the proteins based on the
prediction of their secondary structure by BCL::Jufo
(http://meilerlab.org/index.php/servers/show?sid=5), making truncations in areas that are not
conserved by amino acid sequence. Thus the final protein library consists of 80 proteins/peptides.
Plasmid sequences were verified by Genewiz Inc.
[00375] Protein Purification. E. coli transformants containing the relevant cloned proteins were
grown to OD600=0.6, and protein expression was induced with 0.2 mM IPTG at 16'C overnight.
Cells were spun down and pellets were resuspended in lysis buffer (20 mM Tris-HCl, 500 mM NaCl,
pH8.0) and then lysed by sonication. The proteins of interest were purified from supernatant over a
Ni-NTA column; proteins were eluted in imidazole buffer. Protein-containing elutions were
combined, purified over a gel-filtration column and eluted in PBS buffer.
[00376] Generation of the Vi conjugates. Vi was resuspended to 5 mg/ml in buffer A (0.2 M MES,
150 mM NaCl, pH 5.9), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and NHS-Sulfo
was added into solution as powder for 30 minutes at 40C . Reaction buffer was raised to pH7.5 by
addtion of 1M Na2HPO 4. Proteins were then added to the reaction as 2mg/mg, protein/sugar. The
reaction was carried out at 40C for 48 hours with rotation. Conjugates were separated by elution
through a Sephacryl S500 gel filtration column and collection of the void volume fractions.
[00377] Stimulation of mice splenocytes and human peripheral blood mononuclear cells
(PBMC). Spleens were harvested from either whole cell vaccine (WCV) immunized C57BL/6 mice
or mice have been repeatedly colonized with S. pneumoniae were processed into a cellular suspension
and stimulated with different concentration of recombinant proteins. Splenocytes were incubated for 3
days; plates were then spun to pellet cells, after which the supernatants were collected and assayed for
IL-17A using a mouse IL-17A ELISA kit (R&D Systems, Inc).
[00378] Human PBMC were separated from healthy adult volunteers and cultured in 96 well plates.
Cells were stimulated with different concentration of recombinant proteins for 4 days and then
analyzed for IL-17A in the supernatant using a human IL-17A ELISA kit (ebioscience).
[00379] Antigen preparations.
[00380] For intranasal (i.n.) immunization: Vaccines were prepared the same day of immunization by
mixing purified proteins (5 ptg) with 1 ptg Cholera toxin (CT) per mouse in a final 20 pl of saline. For
subcutaneous (s.c.) immunzation: One day prior to immunization, vaccines were prepared as follows.
Frozen aliquots were thawed or lyophilized vials were reconstituted with sterile water, diluted to the
                                                   94

    WO 2014/124228                                                               PCT/US2014/015254
appropriate concentration, and mixed with aluminum hydroxide (alum) at the indicated concentration
in a 15 ml conical tube, which was then tumbled overnight at 40C to allow for adsorption.
[00381] Immunization and challenge of mice. C57BL/6J mice were used in all the experiments.
The age at time of first immunization was between 4-6 weeks. I.n. immunization was done by
instilling 20 l of saline, adjuvant only, or adjuvant mixed with antigen as specified atraumatically
into unanesthetized mice, a procedure that puts no immunogen into the lungs; secondary
immunizations were given after one week. S.c. immunization was performed 3 times every two
weeks. Gently restrained, nonanesthetized mice received injections of 200 l containing adjuvant with
or without antigen in the lower part of the back at 2-week intervals. Blood was drawn 2 weeks after
the last immunization, and assayed for antibody and for IL-1 7A production in vitro upon stimulation
with WCA. Nasopharyngeal colonization with the clinical pneumococcal isolate 0603 (serotype 6B)
was carried out as previously described [4]. Intraperitoneal (IP) challenge was given 1000 cfu of
strain WU2-ply (an engineered strain that replaced ply with His-tagged ply) in 200 p1l PBS, and
sickness or death of mice was monitored twice daily for 14 days. All animal studies were approved by
our local animal ethics committees.
[00382] Enzyme-linked immunosorbent assay (ELISA) and IL-17A production in whole blood
samples. Assays for murine antibodies for individual protein and IL-17A production in whole blood
were carried out as previously described [2].
[00383] Binding of antibody to encapsulated Tigr4 strains. S. pneumoniae Tigr4 strain was grown
to OD600=0.8 and collected by centrifugation. Bacteria were killed at 58'C for 1 hour and washed
with PBS twice. Bacteria were blocked with 1 ml PBS/1% BSA rotating overnight at 4'C. Cells were
spun down and resuspended in 250 pl of PBS-Tween/1% BSA with 1:50 dilution of heat inactivated
mouse serum. Samples were rotated at room temerature (RT) for 1 hour, and washed with PBS
Tween/1%BSA twice. 250 pl of PBS-Tween/1% BSA with 1:50 dilution of anti-mouse alexa Fluro
488 was added into cells and samples were rotated at RT for 1 hour. Samples were washed with PBS
Tween/IBSA twice and then resupended in 500 pl PBS. Flow cytometry was performed in
Children's Hospital Boston.
[00384] Statistical analysis. Antibody and IL-17A concentrations and NP colonization densities
were compared by the Mann-Whitney U test using PRISM (version 4.0a, GraphPad Software, Inc).
Differences in survival were analyzed with the Kaplan-Meier test, using PRISM as well.
                                              EXAMPLE 1
[00385] Selection of protein candidates by bioinformatic analysis
[00386] At present, there are at least 42 S. pneumoniae sequences available from the integrated
microbial genomes website (world wide web: "//img.jgi.doe.gov/cgi-bin/w/main.cgi"). Beginning
with the sequenced TIGR4 strain, the inventors analyzed the genome for predicted secretion signal
                                                  95

     WO 2014/124228                                                               PCT/US2014/015254
 peptides and cell wall anchor motifs. The inventors identified 335 proteins with a secretion signal
 peptide in TIGR4 and 15 proteins with possible cell wall anchor motifs.
  [00387] The protein library was further narrowed down to 76 proteins based on the following
 parameters which were chosen a priori:
  [00388] (a) Conservation across all the sequenced pneumococci (>90% identity at the amino acid
 level).
  [00389] (b) Exclusion of any protein that had >40% homology with proteins in the human genome
  [00390] (c) Exclusion of proteins that contain an extracellular domain smaller than 100 amino acids.
  [00391] The breakdown of the 76 proteins is as follows: 23 hypothetical proteins, 17 proteins that
 play a role in substrate binding and transportation, 17 proteins with enzymatic activities and 19 others
 of unknown or hypothetical function. A full list of the proteins and their sequence is shown in Table
 2.
  [00392] TABLE 2: A list of the pneumococcal proteins SEQ ID NO: 1-83 and the primer sequences
 for isolation and amplification. * Amino acid residues used for cloning; end refers to C-terminus.
                           Predicted             Primer
Proteins*                  functions             names          Sequences
                                                                CGGGATCCGAATTCGAGCTCCGAAA
                                                 SpOO10-1      AAGAAGTCGTCTATAC (SEQ ID NO:
SP0010 (23-end) (SEQ       hpotei                               233)
ID NO: 153)                                                     CTCGAGTGCGGCCGCAAGCTTTTTT
                                                 SpOO10-2      AGAACCTCATAAACATC (SEQ ID
                                                               NO: 235)
                                                                CGGGATCCGAATTCGAGCTCCGAGA
                                                 Sp0043-1      AGGAGATGAGTTTGTC (SEQ ID NO:
                           competence factor
SP0043 (42-end)                                                 236)
                           transport protein
(SEQ ID NO: 154)                                                CTCGAGTGCGGCCGCAAGCTTCTCT
                           ComB
                                                 Sp0043-2       TTGTTCAAAAATTGATC (SEQ ID NO:
                                                                237)
                                                                CGGGATCCGAATTCGAGCTCCAAGC
                                                 Sp0079-1      AGGATATGAATATTATC (SEQ ID NO:
SP0079 (24-end)            potaium tk                           238)
                           protein, Trk
(SEQ ID NO: 155)                                                CTCGAGTGCGGCCGCAAGCTTCGAA
                           family
                                                 Sp0079-2       TTCAATGCTACTAGG (SEQ ID NO:
                                                                404)
SP0084 (110-end)           histidine kinase                     CGGGATCCGAATTCGAGCTCCTTTG
(SEQ ID NO: 156)           (EC 2.7.13.3)                       ATTCCTTGGAAGAAAG (SEQ ID NO:
                                                   96

    WO 2014/124228                                              PCT/US2014/015254
                   (IMGterm)                        405)
                                                    CTCGAGTGCGGCCGCAAGCTTGGCT
                                     Sp 0 0 8 4 - 2 TTATTTTCACTACCAG (SEQ ID NO:
                                                    242)
                   carbohydrate ABC                 CGGGATCCGAATTCGAGCTCCAACA
                   transporter       Sp0092-1       GCAAAAAAGCTGCTG (SEQ ID NO:
                   substrate-binding                243)
SP0092 (30-end)
                   protein, CUT1
(SEQ ID NO: 157)   pCTCGAGTGCGGCCGCAAGCTTTTTTT
     (SEQID
         O: 57)    family (T C
                     family-(TC      Sp0092-2       TGTTTTTCAAGAATTCATC (SEQ ID
                   3.A. 1.1. -)
                                                    N
                                                    NO::24
                                                         244)
                   (IMGterm)
                                                    CGGGATCCGAATTCGAGCTCCGACG
                                     Sp0098-1       GGATTAAGAGCCTAC (SEQ ID NO:
SP0098 (30-end)    hypothetical                     245)
(SEQ ID NO: 158)   protein                          CTCGAGTGCGGCCGCAAGCTTACGT
                                     Sp0098-2       CTGCTTGGTGTGGAT (SEQ ID NO:
                                                    246)
                                                    CGGGATCCGAATTCGAGCTCCGTTC
                   L-serine          SpO106-1       GTATTGGGAAGATTG (SEQ ID NO:
SP0106 (29-end)    ammonia-lyase                    247)
(SEQ ID NO: 159)   (EC 4.3.1.17)                    CTCGAGTGCGGCCGCAAGCTTTTTA
                   (IMGterm)         Sp06-2         AAGAAATTGACATTGTG (SEQ ID NO:
                                                    248)
                                                    CGGGATCCGAATTCGAGCTCCCAAG
                                     SpO107-1       AATCATCAACTTACAC (SEQ ID NO:
SP0107 (30-end)    LysM domain                      249)
(SEQ ID NO: 160)   protein                          CTCGAGTGCGGCCGCAAGCTTATAC
                                     Sp07-2         CAGCCATTGTTAAGCC (SEQ ID NO:
                                                    250)
                                                    CGGGATCCGAATTCGAGCTCCGAGA
                                     Sp0127-1       CGACGATTAATATTAAG (SEQ ID NO:
SP0127 (26-end)    hypothetical                     251)
(SEQ ID NO: 161)   protein                          CTCGAGTGCGGCCGCAAGCTTTAGG
                                     Sp0127-2       CGTTTAATGTAAGACTC (SEQ ID NO:
                                                    252)
SP0149 (25-end)    lipoprotein       Sp0149-1       CGGGATCCGAATTCGAGCTCCAACT
                                       97

    WO 2014/124228                                        PCT/US2014/015254
(SEQ ID NO: 162)                              CAGAAAAGAAAGCAGAC (SEQ ID
                                              NO: 253)
                                              CTCGAGTGCGGCCGCAAGCTTCCAA
                                     Sp0149-2 ACTGGTTGATCCAAAC (SEQ ID NO:
                                              254)
                                              CGGGATCCGAATTCGAGCTCCCCAG
                                     Sp0191-1 CTACAAAAACAGAAAAAG     (SEQ ID
SP0191 (26-end)    hypothetical               NO: 255)
(SEQ ID NO: 163)   protein                    CTCGAGTGCGGCCGCAAGCTTTTGT
                                     Sp0191-2 TCTGTCGCGCCATTTGC (SEQ ID NO:
                                              256)
                                              CGGGATCCGAATTCGAGCTCCAATA
                                     Sp0198-1 CCAATACTGCAAATGC (SEQ ID NO:
SP0198 (45-end)    hypothetical               257)
(SEQ ID NO: 164)   protein                    CTCGAGTGCGGCCGCAAGCTTTTTA
                                     Sp0198-2 GTTAAAACGATTTGGTC (SEQ ID NO:
                                              258)
                                              CGGGATCCGAATTCGAGCTCCCAAT
                                     Sp0249-1 CTAGTGGAGTTGAGG (SEQ ID NO:
SP0249 (26-end)    PTS system, JIB            259)
(SEQ ID NO: 165)   component                  CTCGAGTGCGGCCGCAAGCTTCCCA
                                     Sp0249-2 CTAATCAAAGATAGG (SEQ ID NO:
                                              260)
                                              CGGGATCCGAATTCGAGCTCCATGA
                                     Sp0321-1 AAATTGTACTTGTAG (SEQ ID NO:
SP0321 (1-end)     PTS system, IIA            261)
(SEQ ID NO: 14)    component                  CTCGAGTGCGGCCGCAAGCTTAATA
                                     Sp0321-2 CCCGATTCGAAATCTTC (SEQ ID NO:
                                              263)
                                              CGGGATCCGAATTCGAGCTCCGGAC
                   capsular          Sp0346-1 TGACCAATCGTTTAAATG (SEQ ID
SP0346 (98-end)    polysaccharide             NO: 264)
(SEQ ID NO: 166)   biosynthesis               CTCGAGTGCGGCCGCAAGCTTTCTA
                   protein Cps4A     Sp0346-2 CCCTCCATCACATCC (SEQ ID NO:
                                              265)
SP0402 (29-end)    signal peptidase. Sp04O2-1 CGGGATCCGAATTCGAGCTCCTGGA
                                       98

    WO 2014/124228                                         PCT/US2014/015254
(SEQ ID NO: 167)   Serine peptidase.           GCAATGTTCGCGTAG (SEQ ID NO:
                   MEROPS family               266)
                   S26A (IMGterm)              CTCGAGTGCGGCCGCAAGCTTAAAT
                                      Sp04O2-2 GTTCCGATACGGGTG (SEQ ID NO:
                                               267)
                   amino acid ABC              CGGGATCCGAATTCGAGCTCCGATG
                   transporter        Sp0453-1 AATATTTACGCATCG (SEQ ID NO:
                   substrate-binding           268)
                   protein, PAAT
                   family (TC
SP0453 (25-298)    3.A.1.3.-) / amino
(SEQ ID NO: 168)   acid ABC                    CTCGAGTGCGGCCGCAAGCTTACCA
                   transporter        Sp0453-2 GCACCACGCAAGAG (SEQ ID NO:
                   membrane protein,           269)
                   PAAT family (TC
                   3.A.1.3.-)
                   (IMGterm)
                                               CGGGATCCGAATTCGAGCTCCTTTT
                                      Sp0564-1 CAAGTACGGTGACTAAG (SEQ ID
SP0564 (21-end)    hypothetical                NO: 270)
(SEQ ID NO: 169)   protein                     CTCGAGTGCGGCCGCAAGCTTCTTG
                                      Sp0564-2 AACTTGATGCCATTTTC (SEQ ID NO:
                                               271)
                                               CGGGATCCGAATTCGAGCTCCGATA
                                      Sp0582-1 AAACCCTTTCTTCTGC (SEQ ID NO:
SP0582 (92-end)    hypothetical                272)
(SEQ ID NO: 170)   protein                     CTCGAGTGCGGCCGCAAGCTTAAAT
                                      Sp0582-2 GTGATTTCTGTAAAAATAC (SEQ ID
                                               NO: 273)
                                               CGGGATCCGAATTCGAGCTCCGCCC
                   serine 0-          Sp0589-1
                                               ACCGTCTCTCGCAT (SEQ ID NO: 274)
SP0589 (36-end)    acetyltransferase
                                               CTCGAGTGCGGCCGCAAGCTTCAAA
(SEQ ID NO: 171)   (EC 2.3.1.30)
                   DO )
                   (ME.)              Sp0589-2 CCAGACGATCTGTGAC (SEQ ID NO:
                   (IMGterm)
                                               25
                                               275)
SP0601 (36-297)    transmembrane               CGGGATCCGAATTCGAGCTCCATCA
(SEQ ID NO: 172)   protein Vexp3               AGGGAGCTACTGCCAAG (SEQ ID
                                       99

    WO 2014/124228                                              PCT/US2014/015254
                                                    NO: 276)
                                                    CTCGAGTGCGGCCGCAAGCTTCATA
                                      Sp 0 6 0 1- 2 CCAGAGATAGATTGCTC (SEQ ID
                                                    NO: 277)
                                                    CGGGATCCGAATTCGAGCTCCGAAG
SP0604 (223-end)   sensor histidine   SpO6O4-1      CCATTCTCCAGCTGG (SEQ ID NO:
(SEQ ID NO: 173)   kinase VncS                      278)
                                                    CTCGAGTGCGGCCGCAAGCTTGTCT
                                      SpO6O4-2      TGGACGACTTTTGG (SEQ ID
                                                                            NO: 279)
                                                    CGGGATCCGAATTCGAGCTCCAACG
                                      Sp0617-1      GAGATTTTCAAGGAGC (SEQ ID NO:
SP0617 (44-end)    hypothetical                     280)
(SEQ ID NO: 174)   protein                          CTCGAGTGCGGCCGCAAGCTTCTCA
                                      Sp0617-2      CTAGTCTCATATATTTTTC (SEQ ID
                                                    NO: 281)
                   amino acid ABC                   CGGGATCCGAATTCGAGCTCCAGCG
                   transporter        Sp0620-1      CTCAAAAGACAATCG (SEQ ID NO:
                   substrate-binding                282)
SP0620 (27-end)
                   protein, PAAT
(SEQ ID NO: 175)                                    CTCGAGTGCGGCCGCAAGCTTTTGT
                   family (T C
                     family-(TC       Sp0620-2      AACTGAGATTGATCTG (SEQ ID NO:
                                                    283)
                   (IMGterm)
                                                    CGGGATCCGAATTCGAGCTCCCAAG
                   D-Ala-D-Ala
                                      Sp0629-1      AAAAAACAAAAAATGAAG      (SEQ ID
SP0629 (21-end)    caopeptidase.                    NO: 284)
                   Metallo peptidase.
(SEQ ID NO: 176)                                    CTCGAGTGCGGCCGCAAGCTTATCG
                   MEROPS family
                   M15B (IMGterm)     Sp0629-2      ACGTAGTCTCCGCC (SEQ ID NO:
                                                    285)
                                                    CGGGATCCGAATTCGAGCTCCGAAT
                                      Sp0648-1      CTGTAGTTTATGCGG (SEQ ID NO:
SP0648 (40-776)         g                           286)
                   (EC :3 .2. 1.23)
(SEQ ID NO: 177)                                    CTCGAGTGCGGCCGCAAGCTTTGCT
                   (IMGterm)
                                      Sp0648-2      AATTCTTTGTTTTCC (SEQ ID NO:
                                                    287)
SP0648 (777-1676)                                   CGGGATCCGAATTCGAGCTCCTCCA
(SEQ ID NO: 178)                                    AAGTAGCTGACTCAG (SEQ ID NO:
                                        100

    WO 2014/124228                                               PCT/US2014/015254
                                                     288)
                                                     CTCGAGTGCGGCCGCAAGCTTAGAC
                                      Sp 0 6 4 8 - 4 TCAAGGTAGTAGTCTG (SEQ ID NO:
                                                     289)
                                                     CGGGATCCGAATTCGAGCTCCGTAG
                                      Sp0648-5       ATGGAAAAGTTCCG (SEQ ID NO:
SP0648 (1677-end)                                    290)
(SEQ ID NO: 179)                                     CTCGAGTGCGGCCGCAAGCTTGTCT
                                      Sp0648-6       TCTTTTTTACCTTTAG (SEQ ID NO:
                                                     291)
                                                     CGGGATCCGAATTCGAGCTCCGAAC
                                      Sp0659-1       ACCAAACGAAAGATG (SEQ ID NO:
SP0659 (28-end)    thioredoxin family                292)
(SEQ ID NO: 180)   protein                           CTCGAGTGCGGCCGCAAGCTTGGCT
                                      Sp0659-2       AATTCCTTCAAAGTTTG (SEQ ID NO:
                                                     293)
                                                     CGGGATCCGAATTCGAGCTCCTACT
                                      Sp0662-1       ATCAATCAAGTTCTTC (SEQ ID NO:
SP0662 (29-276)    sensor histidine                  294)
(SEQ ID NO: 181)   kinase, putative                  CTCGAGTGCGGCCGCAAGCTTGAGC
                                      Sp0662-2       TGACTCCGAACCTGGTC (SEQ ID NO:
                                                     295)
                                                     CGGGATCCGAATTCGAGCTCCAAAC
                                         2Sp662-3    GCTGGATTGCTCCT (SEQ ID NO: 296)
SP0662 (300-end)
                                                     CTCGAGTGCGGCCGCAAGCTTGCTA
(SEQ ID NO: 182)
                                      Sp0662-4       GTTTCTATTCTATTTAT (SEQ ID NO:
                                                     297)
                                                     CGGGATCCGAATTCGAGCTCCACCC
                                      Sp0664-1       TAGCGCTGGCTAGTCG (SEQ ID NO:
SP0664 (103-629)   metalloprotease                   298)
(SEQ ID NO: 183)                                     CTCGAGTGCGGCCGCAAGCTTCTCA
                   ZmpB
                                      Sp0664-2       ACTTTTTTAAGATCTA (SEQ ID NO:
                                                     299)
                                                     CGGGATCCGAATTCGAGCTCCCTTA
SP0664 (630-1200)                     Sp0664-3       AAAATATTAAACGTAC (SEQ ID NO:
(SEQ ID NO: 184)                                     300)
                                        101

    WO 2014/124228                                         PCT/US2014/015254
                                               CTCGAGTGCGGCCGCAAGCTTGATT
                                 Sp 0 6 6 4 -4 GCATTAACTCTATAGTC (SEQ ID NO:
                                               301)
                                               CGGGATCCGAATTCGAGCTCCAAAG
                                 Sp0664-5      ATTTATATTTAGAAG (SEQ ID NO:
SP0664 (1201-end)                              302)
(SEQ ID NO: 185)                               CTCGAGTGCGGCCGCAAGCTTTTTA
                                 Sp0664-6      AAGATTGAAGTTTTAAAGC (SEQ ID
                                               NO: 303)
                                               CGGGATCCGAATTCGAGCTCCCGTA
                                 Sp0678-1      TTCGCCGTGCGGCTA (SEQ ID NO:
SP0678 (23-end)    hypothetical                34
(SEQ ID NO: 186)   protein
                                               CTCGAGTGCGGCCGCAAGCTTGCTA
                                 SpO678-2      GTCTTCACTTTCC (SEQ ID NO:
                                                                          305)
                                               CGGGATCCGAATTCGAGCTCCGATG
                                 Sp0724-1      ATTCCCGTGAAGTTC (SEQ ID NO:
SP0724 (35-end)    Ole                         306)
                   ole kinase,
(SEQ ID NO: 187)                               CTCGAGTGCGGCCGCAAGCTTTTCA
                   putative
                                 Sp0724-2      TAAACCTCTCCTTTG (SEQ ID NO:
                                               307)
                                               CGGGATCCGAATTCGAGCTCCGCTG
                                 Sp0742-1      ATCAGGTCTTTGTTG (SEQ ID NO:
SP0742 (43-end)    hypothetical                308)
(SEQ ID NO: 188)   protein                     CTCGAGTGCGGCCGCAAGCTTATCA
                                 Sp0742-2      ATTTCATAGCCCATCAG (SEQ ID NO:
                                               309)
                                               CGGGATCCGAATTCGAGCTCCATTT
                   cell division Sp0757-1      TCAATACAGCGAAAC (SEQ ID NO:
SP0757 (44-451)                                310)
                   protein FtsX
(SEQ ID NO: 189)   (IMGterm)                   CTCGAGTGCGGCCGCAAGCTTAAAT
                                 Sp0757-2      GAAGCTAACTTGAAGAG (SEQ ID
                                               NO: 311)
                                               CGGGATCCGAATTCGAGCTCCTTTA
SP0785 (33-end)    hypothetical  Sp0785-1      GACAACCTTCTCAGAC (SEQ ID NO:
(SEQ ID NO: 190)   protein                     312)
                                 SpO785-2      CTCGAGTGCGGCCGCAAGCTTATTA
                                   102

    WO 2014/124228                                       PCT/US2014/015254
                                             GTTGCTTCATCAGCC (SEQ ID NO:
                                             313)
                                             CGGGATCCGAATTCGAGCTCCTCTC
                                    Sp0787-1 GTCAAGTCAATAAAG (SEQ ID NO:
SP0787 (43-290)    hypothetical              314)
(SEQ ID NO: 191)   protein                   CTCGAGTGCGGCCGCAAGCTTCGTC
                                    Sp0787-2 GTCATAAAACTAAACG (SEQ ID NO:
                                             315)
                   D,D-                      CGGGATCCGAATTCGAGCTCCAAAC
                   carboxypeptidase Sp0872-1 ATGCGATTGCTGTTG (SEQ ID NO:
SP0872 (30-end)    PBP3. Serine              316)
(SEQ ID NO: 192)   peptidase.                CTCGAGTGCGGCCGCAAGCTTTAAT
                   MEROPS family    Sp0872-2 TTCTCGTTAACAAAGCG (SEQ ID NO:
                   S1I (IMGterm)             317)
                                             CGGGATCCGAATTCGAGCTCCACAG
                                    Sp0878-1 AGGAAGCTGTTCAAAATC (SEQ ID
SP0878 (245-end)   SpoE family               NO: 318)
(SEQ ID NO: 193)   protein                   CTCGAGTGCGGCCGCAAGCTTTTGT
                                    Sp0878-2 TGTAACACTTTTCGAGG (SEQ ID NO:
                                             319)
                                             CGGGATCCGAATTCGAGCTCCGAGG
                                    Sp0899-1 GGACGAATCAAAGGC (SEQ ID NO:
SP0899 (31-end)    hypothetical              320)
(SEQ ID NO: 194)   protein                   CTCGAGTGCGGCCGCAAGCTTAAGT
                                    Sp0899-2 TTAACCCACTTATCATTATC (SEQ ID
                                             NO: 321)
                                             CGGGATCCGAATTCGAGCTCCGGTC
                                    Sp1O02-1 AAAAGGAAAGTCAGAC (SEQ ID NO:
SP1002 (22-end)    adhesion                  322)
(SEQ ID NO: 195)   lipoprotein               CTCGAGTGCGGCCGCAAGCTTCTTT
                                    Sp1O02-2 AATTCTTCTGCTAGAATAC (SEQ ID
                                             NO: 323)
                                             CGGGATCCGAATTCGAGCTCCGTTC
SP1026 (24-end)    hypothetical     Sp1026-1 ATCAAGATGTCAAAC (SEQ ID NO:
(SEQ ID NO: 196)   protein                   324)
                                    Sp1026-2 CTCGAGTGCGGCCGCAAGCTTGCCA
                                     103

    WO 2014/124228                                          PCT/US2014/015254
                                                GATGTTGAAAAGAGAG (SEQ ID NO:
                                                325)
                                                CGGGATCCGAATTCGAGCTCCTCTA
                   iron-compound      Sp1032-1  ATTCTGTTAAAAATGAAG (SEQ ID
SP1032 (22-end)    ABC transporter,             NO: 326)
(SEQ ID NO: 197)   iron compound-               CTCGAGTGCGGCCGCAAGCTTTTTC
                   binding protein    Sp1032-2  GCATTTTTGCATGCATTTC (SEQ ID
                                                NO: 327)
                                                CGGGATCCGAATTCGAGCTCCTCTT
                                      Sp1069-1  CAATGAATAAATCAG   (SEQ ID NO:
SP1069 (34-end)    hypothetical                 328)
(SEQ ID NO: 198)   protein                      CTCGAGTGCGGCCGCAAGCTTTTCG
                                      Sp1069-2  ATGACTTGTCCTGCTTC (SEQ ID NO:
                                                329)
                                                CGGGATCCGAATTCGAGCTCCGAAA
                   IgAl-specific      Sp1154-1  ATCATCTTTTGCTAAATTAC (SEQ ID
SPI 154 (155-694)  metallopeptidase.            NO: 330)
                   Metallo peptidase.
(SEQ ID NO: 199)                                CTCGAGTGCGGCCGCAAGCTTTGTG
                   MEROPS family
                   M26OS fatmily      Sp 1154-2 TTTGATTCGGTTGAAAC (SEQ ID NO:
                   M26 (IMGterm)
                                                31
                                                331)
                                                CGGGATCCGAATTCGAGCTCCTCCA
                                      Sp 1154-3 ATTCAAATGGAAACG (SEQ ID NO:
SP1154 (695-1374)                               332)
(SEQ ID NO: 200)                                CTCGAGTGCGGCCGCAAGCTTACCA
                                      Sp 1154-4 AAGAAGTCCAAATGG (SEQ ID NO:
                                                333)
                                                CGGGATCCGAATTCGAGCTCCAAGG
                                      Sp 1154-5 GGAATGCTTCACCATTAG (SEQ ID
SP1154 (1375-end)                               NO: 334)
(SEQ ID NO: 201)                                CTCGAGTGCGGCCGCAAGCTTTTTTT
                                      Sp 1154-6 TATTCTCAAAAATTG (SEQ ID NO:
                                                335)
                                                CGGGATCCGAATTCGAGCTCCTTGG
SP1267 (25-end)                       Sp1267-1  TTCAGGTTAATCAAAAAC (SEQ ID
                   licC protein
(SEQ ID NO: 202)                                NO: 336)
                                      Sp1267-2  CTCGAGTGCGGCCGCAAGCTTATTT
                                       104

    WO 2014/124228                                             PCT/US2014/015254
                                                   TCGTTTTTAAGAATTTC (SEQ ID NO:
                                                   337)
                                                   CGGGATCCGAATTCGAGCTCCGCGA
                   shikimate          Sp1376-1     CAGCTACCAACGGTG (SEQ ID NO:
SP1376 (32-end)    dehydrogenase                   338)
(SEQ ID NO: 203)   (EC 1.1.1.25)                   CTCGAGTGCGGCCGCAAGCTTTTGG
                   (IMGterm)          Sp1376-2     TATTTTTCTGTTAAAG (SEQ ID NO:
                                                   339)
                   spermidine/putresc              CGGGATCCGAATTCGAGCTCCGATA
                   ine ABC            Sp1386-1     GTCAAAAATTGGTTATC (SEQ ID NO:
SP1386 (33-end)    transporter,                    340)
(SEQ ID NO: 204)   spermidine/putresc              CTCGAGTGCGGCCGCAAGCTTCTTC
                   ine-binding        Sp1386-2     CGATACATTTTAAACTG (SEQ ID NO:
                   protein                         341)
                                                   CGGGATCCGAATTCGAGCTCCGCCT
                                      Sp1404-1     ATGAAGGCAAAGTAG (SEQ ID NO:
SP1404 (31-end)    hypothetical                    342)
(SEQ ID NO: 205)   protein                         CTCGAGTGCGGCCGCAAGCTTCTTT
                                      Sp1404-2     CCAAGAGAAATCTTTC (SEQ ID NO:
                                                   343)
                                                   CGGGATCCGAATTCGAGCTCCTGGT
                                      Sp1405-1     TAGAAAAACATAAGG (SEQ ID NO:
SP1405 (19-end)    transcriptional                 344)
(SEQ ID NO: 206)   regulator Spx                   CTCGAGTGCGGCCGCAAGCTTCTAA
                                      Sp1405-2     TACCAGCTCTCATTC (SEQ ID NO:
                                                   345)
                                                   CGGGATCCGAATTCGAGCTCCATGT
                                      Sp1419-1     TTCAAAATTGGGCTTC (SEQ ID NO:
SP1419 (27-end)    acetyltransferase,              346)
(SEQ ID NO: 207)   GNAT family                     CTCGAGTGCGGCCGCAAGCTTACAT
                                      Sp1419-2     TCTTCCCTACTTATACC (SEQ ID NO:
                                                   347)
                                                   CGGGATCCGAATTCGAGCTCCAAGA
                   peptidoglycan N
SP1479 (40-end)    aetylglcan         Sp1 4 7 9 -1 TCTACCAGCAAAAAAG (SEQ ID NO:
(SEQ ID NO: 208)                                   348)
                   deacetylase A
                                      Sp1479-2     CTCGAGTGCGGCCGCAAGCTTTTCA
                                       105

    WO 2014/124228                                        PCT/US2014/015254
                                              TCACGACTATAGTACAGC (SEQ ID
                                              NO: 349)
                   amino acid ABC             CGGGATCCGAATTCGAGCTCCACTA
                   transporter       Sp1500-1 GTGGAGATAATTGGTC (SEQ ID NO:
                   substrate-binding          350)
SP1500 (27-end)
                   protein, PAAT
(SEQ ID NO: 209)                              CTCGAGTGCGGCCGCAAGCTTCTGT
                   family (T C
                    family (TC       Sp1500-2 CCTTCTTTTACTTCTTTG (SEQ ID NO:
                                              351)
                   (IMGterm)
                                              CGGGATCCGAATTCGAGCTCCGAAG
                                     Sp1545-1 GAGAAAAATTAGCTC (SEQ ID NO:
SP1545 (29-end)    hypothetical               352)
(SEQ ID NO: 210)   protein                    CTCGAGTGCGGCCGCAAGCTTTAGG
                                     Sp1545-2 CCCTCCTTGTTGACC (SEQ ID NO:
                                              353)
                                              CGGGATCCGAATTCGAGCTCCCAAA
                                     Sp1560-1 ACAGTACCAGTGCTAG (SEQ ID NO:
SP1560 (28-end)    hypothetical               354)
(SEQ ID NO: 211)   protein                    CTCGAGTGCGGCCGCAAGCTTATTC
                                     Sp1560-2 GTTTTTGAACTAGTTGC (SEQ ID NO:
                                              355)
                   1-acyl-sn-                 CGGGATCCGAATTCGAGCTCCATGT
                   glycerol-3-       Sp1624-1 TTTATACTTATTTGCGTG (SEQ ID
SP1624 (1-217)     phosphate                  NO: 356)
(SEQ ID NO: 212)   acyltransferase            CTCGAGTGCGGCCGCAAGCTTGGCA
                   (EC 2.3.1.51)     Sp1624-2 GGGATGCGGATAAACC (SEQ ID NO:
                   (IMGterm)                  357)
                                              CGGGATCCGAATTCGAGCTCCAAAG
                                     Sp1652-1 TAACCAGTCCCAACATGG (SEQ ID
SP1652 (62-397)    hypothetical               NO: 358)
(SEQ ID NO: 213)   protein                    CTCGAGTGCGGCCGCAAGCTTACTG
                                     Sp1652-2 GATGAAGCATTGCTATAC (SEQ ID
                                              NO: 359)
                   carbohydrate ABC           CGGGATCCGAATTCGAGCTCCAAAT
SP1683 (65-end)    croyrt          B
                   transporter       Sp1683-1 CAATCATCGAAGCGTTTG (SEQ ID
                   substrate-binding          NO: 360)
                                      106

    WO 2014/124228                                                  PCT/US2014/015254
                   protein, CUTI
                                                        CTCGAGTGCGGCCGCAAGCTTTTGT
                   family (TC
                   3.A.1. 1.-)           Sp 1 6 8 3 - 2 TTCATAGCTTTTTTGATTG (SEQ ID
                                                        NO: 361)
                   (IMGterm)
                                                        CGGGATCCGAATTCGAGCTCCATGC
                                         Sp1826-1       CTAATTATAAATTTGTTG (SEQ ID
                   ABC transporter,                     N:32
SP1826 (36-end)                                         NO: 362)
                   substrate-binding
(SEQ ID NO: 215)                                        CTCGAGTGCGGCCGCAAGCTTTTTT
                   protein
                                         Sp1826-2       CTACCCTCCTTTTCC (SEQ ID NO:
                                                        363)
                                                        CGGGATCCGAATTCGAGCTCCGAAG
                   iron-compound         Sp1872-1       AAAAAGCTGATAAAAGTC (SEQ ID
SP1872 (40-end)    ABC transporter,                     NO: 364)
(SEQ ID NO: 216)   iron-compound-                       CTCGAGTGCGGCCGCAAGCTTGCTG
                   binding protein       Sp1872-2       AATTAGAATACGTACAA (SEQ ID
                                                        NO: 365)
                                                        CGGGATCCGAATTCGAGCTCCACAG
                   oligopeptide ABC
                                         Sp1891-1       AGGTAACCATTAAAAG (SEQ ID NO:
                   transporter,
SP1891 (40-end)    origopepte-                          366)
(SEQ ID NO: 217)                                        CTCGAGTGCGGCCGCAAGCTTTTTC
                   binding protein
                   AiAi        pSp1891-2                AAAGCTTTTTGTATGTC (SEQ ID NO:
                   AmiA
                                                        367)
                                                        CGGGATCCGAATTCGAGCTCCGCGG
                                         Sp1897-1       ATGGCACAGTGACC (SEQ ID NO:
SP1897 (30-end)    multipe                              368)
                   binding protein
(SEQ ID NO: 218)                                        CTCGAGTGCGGCCGCAAGCTTATCC
                   (IMGterm)
                                         Sp1897-2       ACATCCGCTTTCATC (SEQ ID NO:
                                                        369)
                                                        CGGGATCCGAATTCGAGCTCCAAAA
                                         Sp1942-1       CCTATAAAAAAATCGGTG (SEQ ID
SP1942 (37-end)    transcriptional                      NO: 370)
(SEQ ID NO: 219)   regulator, putative                  CTCGAGTGCGGCCGCAAGCTTATTA
                                         Spl1942-2      TCTTCATCACCAACAGG (SEQ ID NO:
                                                        371)
SP1966 (25-end)    UDP-N-                               CGGGATCCGAATTCGAGCTCCGCAG
(SEQ ID NO: 220)   acetylglucosamine                    TCTTACCCTTGTTGGC (SEQ ID NO:
                                           107

    WO 2014/124228                                              PCT/US2014/015254
                   1-                               372)
                   carboxyvinyltransf               CTCGAGTGCGGCCGCAAGCTTTTCA
                   erase (EC 2.5.1.7) Sp1 9 6 6 - 2 TCTTCATCACTTGCC (SEQ ID NO:
                   (IMGterm)                        373)
                                                    CGGGATCCGAATTCGAGCTCCATAG
                                      Sp1967-1      AGGTTCCAGGTGGTTCG (SEQ ID
SP1967 (30-end);   hypothetical                     NO: 374)
(SEQ ID NO: 221)   protein                          CTCGAGTGCGGCCGCAAGCTTGGGA
                                      Sp1967-2      TTGTTTTTCAAGTAATC (SEQ ID NO:
                                                    375)
                                                    CGGGATCCGAATTCGAGCTCCGGGA
                                      Sp1998-1      TTGTTTTTCAAGTAATC (SEQ ID NO:
SP1998 (51-end)    asparaginase (EC                 376)
                   3.5.1.1)
(SEQ ID NO: 222)                                    CTCGAGTGCGGCCGCAAGCTTGCCT
                   (IMGterm)
                                      Sp1998-2      TCCATATAGTCTTTC (SEQ ID NO:
                                                    377)
                                                    CGGGATCCGAATTCGAGCTCCAGTC
                                      Sp2048-1      AGCTCCTCATTTCAG (SEQ ID NO:
SP2048 (40-end)    hypothetical                     378)
(SEQ ID NO: 223)   protein                          CTCGAGTGCGGCCGCAAGCTTACTT
                                      Sp2048-2      TTTTCTTTTTCCACAC (SEQ ID NO:
                                                    379)
                                                    CGGGATCCGAATTCGAGCTCCGTAG
                                      Sp2050-1      AGGAACAGATTTTCT (SEQ ID NO:
SP2050 (35-end)    competence                       380)
(SEQ ID NO: 224)   protein CglD                     CTCGAGTGCGGCCGCAAGCTTATTT
                                      Sp205O-2      TTTGTTTCCTTAATGCG (SEQ ID NO:
                                                    381)
                                                    CGGGATCCGAATTCGAGCTCCTTTA
                                      Sp2083-1      GCCCCACCCAATCTGTG (SEQ ID NO:
SP2083 (192-end)   sensor histidine                 382)
(SEQ ID NO: 225)   kinase PnpS                      CTCGAGTGCGGCCGCAAGCTTGTCC
                                      Sp2083-2      TGTGCGAAAGATTGG (SEQ ID NO:
                                                    383)
SP2084 (30-end)    phosphate ABC                    CGGGATCCGAATTCGAGCTCCAAAC
                                      Sp2084-1
(SEQ ID NO: 226)   transporter                      AGTCAGCTTCAGGAAC (SEQ ID NO:
                                       108

    WO 2014/124228                                              PCT/US2014/015254
                   substrate-binding                384)
                   protein, PhoT
                                                    CTCGAGTGCGGCCGCAAGCTTTTTA
                   family (TC
                   3.A.1.7.1)         Sp2 0 8 4 - 2 ATCTTGTCCCAGGTGG (SEQ ID NO:
                   (IMGterm)                        385)
                                                    CGGGATCCGAATTCGAGCTCCGCCT
                                      Sp2088-1      TACTGGCCTTAGCCTCC (SEQ ID NO:
SP2088 (30-end);   phospate u                       386)
                   regulator, PhoU
(SEQ ID NO: 227)   (IMGterm)                        CTCGAGTGCGGCCGCAAGCTTATTC
                                      Sp2088-2      AAATCCACTAGTTCTC (SEQ ID NO:
                                                    387)
                                                    CGGGATCCGAATTCGAGCTCCATGA
                                      Sp2145-1      AACCACTACTTGAAACC (SEQ ID
                   antigen, cell wall
SP2145 (1-end)                                      NO: 388)
                   surface anchor
(SEQ ID NO: 70)                                     CTCGAGTGCGGCCGCAAGCTTGTGA
                   family
                                      Sp2145-2      CTTGGTAACCAGCTG (SEQ ID NO:
                                                    389)
                                                    CGGGATCCGAATTCGAGCTCCCAAC
                   carbamate kinase   Sp2151-1      AAGAAGCTTTAGTTG (SEQ ID NO:
SP2151 (25-end)                                     390)
                   (EC 2.7.2.2)
(SEQ ID NO: 228)                                    CTCGAGTGCGGCCGCAAGCTTTCCT
                   (IMGterm)
                                      Sp2151-2      TTTTCAATAATTGTTCC (SEQ ID NO:
                                                    391)
                                                    CGGGATCCGAATTCGAGCTCCGTAA
                                      Sp2187-1      TGGAAGAAACAGGAT (SEQ ID NO:
SP2187 (32-end);   hypothetical                     392)
(SEQ ID NO: 229)   protein                          CTCGAGTGCGGCCGCAAGCTTAGTG
                                      Sp2187-2      AATAATAACTGGCGAATC (SEQ ID
                                                    NO: 393)
                                                    CGGGATCCGAATTCGAGCTCCGAGC
                                      Sp2192-1      AAATTGTAAAATTGC (SEQ ID NO:
SP2192 (224-end)   sensor histidine                 394)
(SEQ ID NO: 230)   kinase                           CTCGAGTGCGGCCGCAAGCTTCAAG
                                      Sp2192-2      CTAATCTTAAATTCC (SEQ ID NO:
                                                    395)
SP2197 (30-end)    ABC transporter,   Sp2197-1      CGGGATCCGAATTCGAGCTCCAAAG
                                       109

     WO 2014/124228                                                                PCT/US2014/015254
(SEQ ID NO: 231)           substrate-binding                    ACAACAAAGAGGCAGAAC                (SEQ ID
                           protein, putative                    NO: 396)
                                                                CTCGAGTGCGGCCGCAAGCTTTTTC
                                                 Sp2197-2       ACAAATTCGTTGGTGAAG (SEQ ID
                                                                NO: 397)
                                                                CGGGATCCGAATTCGAGCTCCTGTT
                                                 Sp2207-1       CAGACTGTGATTCTAC (SEQ ID NO:
SP2207 (30-end)            competence                           398)
       SP2207protein               ComF,
(SEQ ID NO: 232)           putive                               CTCGAGTGCGGCCGCAAGCTTTCTT
                           putative
                                                 Sp2207-2       ACAAGGGAAAATGTT (SEQ ID NO:
                                                                399)
                                                                CGGGATCCGAATTCGAGCTCCTCTA
                           rod shape-            Sp2218-1       AATTGCAAGCCACAAAG (SEQ ID
SP2218 (106-end)           determining                          NO: 400)
(SEQ ID NO: 234)           protein MreC                         CTCGAGTGCGGCCGCAAGCTTTGAA
                           (IMGterm)             Sp2218-2       TTCCCCACTAATTCTATC (SEQ ID
                                                                NO: 401)
                                               EXAMPLE 2
  [00393] Screening antigens from mouse splenocytes and human peripheral blood mononuclear
 cells (PBMC).
  [00394] 60 proteins out of 80 genetic constructs were successfully cloned and expressed in, then
 purified from, E. coli. These proteins were then used in stimulation experiments with either mouse
 splenocytes or human PBMC to evaluate the ability of these proteins to recall a potent IL-17A
 response (elicitation of IL-1 7A responses is a predictor of immunogenicity and protection against
 colonization by a pneumococcal antigen - (see Moffitt KL, Gierahn TM, Lu YJ, et al. T(H)17-Based
 Vaccine Design for Prevention of Streptococcus pneumoniae Colonization. Cell Host Microbe 2011;
 9:158-65).
  [00395] The mouse splenocytes were obtained from three sources: 1. Mice previously immunized
 with a whole cell vaccine (WCV); 2. Mice previously colonized with a single strain of S. pneumoniae
 for 10 days and 3. Mice were sequentially colonized with S. pneumoniae serotype 6B, 14F and 19F
 strains. These three different models were used to identify putative protective surface antigens, as the
 inventors assessed if these antigens are sufficiently expressed during colonization to elicit a response
 by immune cells following colonization. Furthermore, the inventors assessed if some of the surface
 proteins would also confer protection against colonization and/or invasive disease in mice. Any given
 protein may provide protection against colonization, invasive disease, or both; since both colonization
                                                   110

   WO 2014/124228                                                                PCT/US2014/015254
and invasive disease prevention are important goals of vaccination, the evaluation of the ability to
confer protection in either model was included. The inventors also assessed if humans - who are all
naturally exposed to pneumococci during their lifetime - were also capable of responding to the
proteins, as more evidence that this protein may be expressed during human colonization. The
responses to each protein in the different screens are summarized in Table 3 (which also includes
whether the protein is protective against colonization, to be discussed below).
[00396] Table 3: Summary of IL-1 7A response to protein stimulation and protection against
colonization. *, IL-17A production in response to protein stimulation: -, <25 pg/ml, +, >25 pg/ml, ++,
>100 pg/ml, +++, >250 pg/ml, ** ND, not determined
           Proteins         Mouse IL-1 7A               Human IL-1 7A           Protection
                            (responses to 0.2/1/5 pg     (responses to 1/10 pg  in mice
                            of protein)*                 of protein)*
            SP0346          +/++/++                                             No
            SP0648          +/++/+                                              No
            SP0785          +/-/++                      +/+                     Yes
            SP0787          +++/-/-                     +/-                     No
            SPi 154             /++                      -/-                    No
            SP1376          -/-/++                      -/+                     No
            SP1500          +/-/-                       +++/-                   Yes
            SP1545          -/-/-                       ++/-                    No
            SP1872          -/-/-                       +++/-                   No
            SP1897          +/-/-                       ++/+                    No
            SP1942          +/-/++                      +/-                     No
            SP2145          -/-/+                       +/-                     No
            SP2151          ++/++/+++                    -/-                    No
            SP2207          +/++/+                      +/-                     No
            SP0043          +/-/-                       -/-                     ND**
            SP0079          +/+++/-                     -/-                     ND**
            SP0084          +/++/-                       -/+                    ND**
            SP0092          +/+/-                        -/+                    ND**
            SP0098          +/+++/++                     -/-                    ND**
            SP0149          -/-/-                       +/+                     ND**
            SPO191          +/-/-                       -/+                     ND**
            SP0198          -/+/-                       +/-                     ND**
            SP0249          -/++/+++                    -/+                     ND**
                                                  111

   WO 2014/124228                                                               PCT/US2014/015254
           SP0321                                                              ND**
           SP0402                                                              ND**
           SP0453            /+++/-.ND**                                       ND**
           SP0564         +/-/-                         ++/-                   ND**
           SP0582           ++                          -/-                    ND**
           SP0601                                                              ND**
           SP0604                                                              ND**
           SP0617                                       +/+                    ND**
           SP0620                                       +/-                    ND**
           SP0629                                       +/+                    ND**
           SP0659                                                              ND**
           SP0662                                                              ND**
           SP0678                                                              ND**
           SP0757                                                              ND**
           SP0878                                                              ND**
           SP0899                                                              ND**
           SP1002                                                              ND**
           SP1032                                                              ND**
           SP1069                                                              ND**
           SP1386                                                              ND**
           SP1404                                                              ND**
           SP1479                                                              ND**
           SP1560                                                              ND**
           SP1652                                                              ND**
           SP1683         +/+/+                                                ND**
           Sp1826                                       ND**                   ND**
           SP2084         +/+/+                                                ND**
           SP2192                                                              ND**
           SP2197                                                              ND**
           SP2218                                                              ND**
                                            EXAMPLE 3
[00397] SP0785 and SP1500 provide protection against colonization
[00398] The inventors then tested the 14 antigens to see if they could provide protection in a mouse
colonization model. For each protein tested, 5 ptg of each antigen were mixed with adjuvant CT and
used to immunize mice twice weekly. Mice were challenged with a serotype 6B pneumococcal strain
                                                112

   WO 2014/124228                                                                PCT/US2014/015254
and the protection was accessed 7 days later for pneumococcal colonization in the nose. Two proteins,
SP0785 and SP1500 showed significant protection compared to the adjuvant alone group (p=0.0023
and p=0.0009 for SP0785 and SP1500, respectively) (Figure 1). The other 12 antigens tested were not
protective in this colonization model.
                                             EXAMPLE 4
[00399] Protection against sepsis challenge
[00400] At the same time, the inventors evaluated whether these proteins could confer protection,
when used as immunogens, against invasive disease. Groups (n=10 mice per group) of C57/BL6 mice
were immunized with one of the 15 proteins subcutaneously with aluminum hydroxide as adjuvant
and then challenged in an intraperitoneal (IP) infection model with an engineered WU2 strain (wild
type ply replaced with a tagged ply). This infection leads to 80% death of control mice starting at 3-4
days post infection. As summarized in Table 4, protein SP0346 protected 60% of the immunized mice
compared to 20% of the alum group (p=0.0254). Four proteins protected 50% of mice, such as
SP1386, SP1500, SP0084 and SP1479. The protection from the remaining 10 proteins was lower than
50%.
[00401] Table 4: Protection against sepsis following immunization by the subcutaneous route, using
aluminum hydroxide as adjuvant.
                                 Proteins                    Survival rate
                                                            (survival/total)
                                  None                           2/10
                                 SP0785                          3/10
                                 SP2145                          1/10
                                 SP1826                          3/10
                                 SPO191                          3/10
                                 SP0198                          4/10
                                 SP0564                          4/10
                                 Sp1069                          2/10
                                 SP1942                          3/10
                                 SP2151                          3/10
                                 SP2197                          0/10
                                 SP1386                          5/10
                                 SP1500                          5/10
                                 SP0084                          5/10
                                 SP1479                          5/10
                                 SP0346                          6/10
                                                 113

    WO 2014/124228                                                                  PCT/US2014/015254
                                               EXAMPLE 5
[00402] Protection against sepsis by proteins fusing to PdT
[00403] The inventors have previously shown that immunization with a fusion conjugate, in which a
pneumococcal protein is genetically fused to the pneumococcal pneumolysoid PdT and then
covalently coupled to a polysaccharide, can enhance immune responses and protection ( Lu YJ et al.,
Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a
fusion protein with the cell wall polysaccharide. Infect Immun 2009; 77:2076-83.; Lu et al., A
bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. Vaccine 2012;
30:3405-12). The inventors next tested some antigens in fusion proteins with PdT and also fusion
protein conjugated to the Salmonella typhi polysaccharide, Vi (our nomenclature for a fusion protein
of protein X and PdT, then conjugated to Vi is X-PdT-Vi). As shown in Figure 2, immunization with
a fusion protein consisting of SP0785-PdT protected 80% mice against sepsis and fusion protein
SP2145-PdT protected 90%. The protection is not due to PdT alone, which only protects 30% of the
infected mice, not statistically different from the mortality rate of control mice. Fusion proteins
SP0785-PdT, SP2145-PdT and SP1500-PdT were conjugated to Vi polysaccharide as described
before. These mice made high level of IL-17A when stimulated with whole cell vaccine (WCV)
(Figure 3A), which raises the strong possibility that these two constructs may protect against both
pneumococcal colonization and disease. Figure 3B shows that these fusion conjugates also elicit
robust antibodies to the Vi polysaccharide, predicting protection against S. typhi as well.
[00404] Similarly to fusion proteins, SP2145-PdT-Vi and SP0785-PdT-Vi significantly protected
mice when compared to immunization with alum alone (80% survival in either group compared to
20% survival in alum group, P<0.006 for either comparison; Fig. 4).
                                               EXAMPLE 6
[00405] Sera from mice immunized with SP0785 binds to an encapsulated Tigr4 strain.
[00406] A flow cytometric assay was performed to test whether antibodies against these antigens
(SP0785, SP1500, SP2145) can bind to the surface of encapsulated pneumococcal strain. The type 4
clinical isolate TIGR4 strain was cultured to late-log phase and heat fixed. Binding of mouse anti-sera
was detected by FITC labeled anti-mouse IgG. As shown in Figure 5, serum from mice immunized
with SP0785 (black) can label the bacteria when compared to serum obtained from mice immunized
with alum alone (grey), which indicates that anti-SP0785 antibody is able to bind to encapsulated
pneumococcal strain.
[00407] In summary, the inventors have identified two proteins SP0785 and SP1500 that protect
against pneumococcal colonization, and SP0346 that protects against sepsis. Fusion proteins SP0785
PdT and SP2145-PdT or the conjugation of these two proteins to Vi protected mice against sepsis
challenge.
                                                   114

    WO 2014/124228                                                                   PCT/US2014/015254
                                               EXAMPLE 7
[00408] MAPS complexes were made using biotinylated type-I pneumococcal polysaccharide
attached to a fusion protein consisting of rhizavidin and SP0785, SP1500, SP0435 or PdT. C57/BL6
mice were immunized with a mixture of 3 MAPS complexes containing SP0785, SP1500 and PdT, or
a mixture of all 4 MAPS complexes described above, on aluminum hydroxide, at a dosage of 6.7 jag
of each antigen. Control mice received either aluminum hydroxide alone (alum, negative control) or a
whole cell vaccine in alum (as a positive control). Immunization was given subcutaneously three
times, two weeks apart. Blood was drawn after the third immunization and stimulated with 10 gg/ml
of S. pneumoniae whole cell antigen or 5 gg/ml of purified SP0785, SP1500 or PdT protein. Antigen
specific or whole cell (WCB) IL-17A production was measured 7 days post stimulation by ELISA
(Figure 6A). One week after bleeding, mice were challenged with pneumococcal 603B strain and
bacterial colonization rate in the nose was determined 10 days post challenge (Figure 6B). Mice that
received immunizations with either 3 or 4 MAPS complexes were protected against pneumococcal
colonization.
[00409] C57BL/6 mice were immunized with vaccines containing 5 jag of protein antigen (a fusion
protein of SP0785, SP 1500 and PdT conjugated to Vi polysaccharide of Salmonella typhi) adsorbed
onto alum, subcutaneously three times, two weeks apart. Control mice received alum alone. Two
weeks after last immunization, mice were intranasally challenged with pneumococcal 603B strain and
bacterial colonization rate in the nose was determined by nasal wash. The mice that were immunized
with the fusion conjugate were significantly protected against pneumococcal colonization compared
to the mice in the control group (Figure 7).
[00410] New Zealand white rabbits were immunized with purified SP0785, SP1500 or PdT. An equal
mixture of each serum from rabbits pre-immunization vs. post immunization (in this case, 67 gl each)
was given to groups of 10 mice via the intraperitoneal route. Mice were then intraperitoneally infected
with a serotype 3 strain 24 hours later and mice survival was monitored for 8 days. Group received
post immunization serum had 60% survival comparing to 0% survival in the pre-serum group, a
difference that was highly statistically significant, attesting to the protective capacity of antibodies to
these proteins for pneumococcal invasive disease (Figure 8).
                                             REFERENCES
[00411] All references described herein are incorporated herein in their entirity by reference.
1. Moffitt KL, Gierahn TM, Lu YJ, et al. T(H) 17-Based Vaccine Design for Prevention of
Streptococcus pneumoniae Colonization. Cell Host Microbe 2011; 9:158-65.
2. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R. Protection against Pneumococcal
colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall
polysaccharide. Infect Immun 2009; 77:2076-83.
                                                   115

    WO 2014/124228                                                               PCT/US2014/015254
3. Lu YJ, Zhang F, Sayeed S, et al. A bivalent vaccine to protect against Streptococcus pneumoniae
and Salmonella typhi. Vaccine 2012; 30:3405-12.
                                                116

   WO 2014/124228                               PCT/US2014/015254
[00412] SEQUENCES:
Pneumococcal      Protein SEQ ID   DNA SEQ ID
 antigen name           NO:           NO:
    SP0010         SEQ ID NO: 1   SEQ ID NO: 77
    SP0043         SEQ ID NO: 2   SEQ ID NO: 78
    SP0079         SEQ ID NO: 3   SEQ ID NO: 79
    SP0084         SEQ ID NO: 4   SEQ ID NO: 80
    SP0092         SEQ ID NO: 5   SEQ ID NO: 81
    SP0098         SEQ ID NO: 6   SEQ ID NO: 82
    SP0106         SEQ ID NO: 7   SEQ ID NO: 83
    SP0107         SEQ ID NO: 8   SEQ ID NO: 84
    SP0127         SEQ ID NO: 9   SEQ ID NO: 85
    SP0149        SEQ ID NO: 10   SEQ ID NO: 86
    SP0191        SEQ ID NO: 11   SEQ ID NO: 87
    SP0198        SEQ ID NO: 12   SEQ ID NO: 88
    SP0249        SEQ ID NO: 13   SEQ ID NO: 89
    SP0321        SEQ ID NO: 14   SEQ ID NO: 90
    SP0346        SEQ ID NO: 15   SEQ ID NO: 91
    SP0402        SEQ ID NO: 16   SEQ ID NO: 92
    SP0453        SEQ ID NO: 17   SEQ ID NO: 93
    SP0564        SEQ ID NO: 18   SEQ ID NO: 94
    SP0582        SEQ ID NO: 19   SEQ ID NO: 95
    SP0589        SEQ ID NO: 20   SEQ ID NO: 96
    SP0601        SEQ ID NO: 21   SEQ ID NO: 97
    SP0604        SEQ ID NO: 22   SEQ ID NO: 98
    SP0617        SEQ ID NO: 23   SEQ ID NO: 99
    SP0620        SEQ ID NO: 24  SEQ ID NO: 100
    SP0629        SEQ ID NO: 25  SEQ ID NO: 101
    SP0648        SEQ ID NO: 26  SEQ ID NO: 102
    SP0659        SEQ ID NO: 27  SEQ ID NO: 103
    SP0662        SEQ ID NO: 28  SEQ ID NO: 104
    SP0664        SEQ ID NO: 29  SEQ ID NO: 105
    SP0678        SEQ ID NO: 30  SEQ ID NO: 106
    SP0724        SEQ ID NO: 31  SEQ ID NO: 107
                                       117

  WO 2014/124228                               PCT/US2014/015254
Pneumococcal     Protein SEQ ID  DNA SEQ ID
antigen name           NO:           NO:
   SP0742        SEQ ID NO: 32  SEQ ID NO: 108
   SP0757        SEQ ID NO: 33  SEQ ID NO: 109
   SP0785        SEQ ID NO: 34  SEQ ID NO: 110
   SP0787        SEQ ID NO: 35  SEQ IDNO: 111
   SP0872        SEQ ID NO: 36  SEQ ID NO: 112
   SP0878        SEQ ID NO: 37  SEQ ID NO: 113
   SP0899        SEQ ID NO: 38  SEQ ID NO: 114
   SP1002        SEQ ID NO: 39  SEQ ID NO: 115
   SP1026        SEQ ID NO: 40  SEQ ID NO: 116
   SP1032        SEQ ID NO: 41  SEQ ID NO: 117
   SP1069        SEQ ID NO: 42  SEQ ID NO: 118
   SP1154        SEQ ID NO: 43  SEQ ID NO: 119
   SP1267        SEQ ID NO: 44  SEQ ID NO: 120
   SP1376        SEQ ID NO: 45  SEQ ID NO: 121
   SP1386        SEQ ID NO: 46  SEQ ID NO: 122
   SP1404        SEQ ID NO: 47  SEQ ID NO: 123
   SP1405        SEQ ID NO: 48  SEQ ID NO: 124
   SP1419        SEQ ID NO: 49  SEQ ID NO: 125
   SP1479        SEQ ID NO: 50  SEQ ID NO: 126
   SP1500        SEQ ID NO: 51  SEQ ID NO: 127
   SP1545        SEQ ID NO: 52  SEQ ID NO: 128
   SP1560        SEQ ID NO: 53  SEQ ID NO: 129
   SP1624        SEQ ID NO: 54  SEQ ID NO: 130
   SP1652        SEQ ID NO: 55  SEQ ID NO: 131
   SP1683        SEQ ID NO: 56  SEQ ID NO: 132
   SP1826        SEQ ID NO: 57  SEQ ID NO: 133
   SP1872        SEQ ID NO: 58  SEQ ID NO: 134
   SP1891        SEQ ID NO: 59  SEQ ID NO: 135
   SP1897        SEQ ID NO: 60  SEQ ID NO: 136
   SP1942        SEQ ID NO: 61  SEQ ID NO: 137
   SP1966        SEQ ID NO: 62  SEQ ID NO: 138
   SP1967        SEQ ID NO: 63  SEQ ID NO: 139
   SP1998        SEQ ID NO: 64  SEQ ID NO: 140
                                     118

   WO 2014/124228                                PCT/US2014/015254
Pneumococcal      Protein SEQ ID   DNA SEQ ID
 antigen name           NO:            NO:
    SP2048        SEQ ID NO: 65   SEQ ID NO: 141
    SP2050        SEQ ID NO: 66   SEQ ID NO: 142
    SP2083        SEQ ID NO: 67   SEQ ID NO: 143
    SP2084        SEQ ID NO: 68   SEQ ID NO: 144
    SP2088        SEQ ID NO: 69   SEQ ID NO: 145
    SP2145        SEQ ID NO: 70   SEQ ID NO: 146
    SP2151        SEQ ID NO: 71   SEQ ID NO: 147
    SP2187        SEQ ID NO: 72   SEQ ID NO: 148
    SP2192        SEQ ID NO: 73   SEQ ID NO: 149
    SP2197        SEQ ID NO: 74   SEQ ID NO: 150
    SP2207        SEQ ID NO: 75   SEQ ID NO: 151
    SP2218        SEQ ID NO: 76   SEQ ID NO: 152
SEQ ID NO: 153 / SP0010 (23-end)
SEQ ID NO: 154 / SP0043 (42-end)
SEQ ID NO: 155 / SP0079 (24-end)
SEQ ID NO: 156 / SP0084 (110-end)
SEQ ID NO: 157 / SP0092 (30-end)
SEQ ID NO: 158 / SP0098 (30-end)
SEQ ID NO: 159 / SPO 106 (29-end)
SEQ ID NO: 160 / SPO107 (30-end)
SEQ ID NO: 161 / SP0127 (26-end)
SEQ ID NO: 162 / SP0149 (25-end)
SEQ ID NO: 163 / SPO191 (26-end)
SEQ ID NO: 164 / SP0198 (45-end)
SEQ ID NO: 165 / SP0249 (26-end)
SEQ ID NO: 14 / SP0321 (1-end)
SEQ ID NO: 166 / SP0346 (98-end)
SEQ ID NO: 167 / SP0402 (29-end)
SEQ ID NO: 168 / SP0453 (25-298)
SEQ ID NO: 169 / SP0564 (21-end)
SEQ ID NO: 170 / SP0582 (92-end)
SEQ ID NO: 171 / SP0589 (36-end)
SEQ ID NO: 172 / SP0601 (36-297)
SEQ ID NO: 173 / SP0604 (223-end)
                                       119

  WO 2014/124228                       PCT/US2014/015254
SEQ ID NO: 174 / SP0617 (44-end)
SEQ ID NO: 175 / SP0620 (27-end)
SEQ ID NO: 176 / SP0629 (21-end)
SEQ ID NO: 177 / SP0648 (40-776)
SEQ ID NO: 178 / SP0648 (777-1676)
SEQ ID NO: 179 / SP0648 (1677-end)
SEQ ID NO: 180 / SP0659 (28-end)
SEQ ID NO: 181 / SP0662 (29-276)
SEQ ID NO: 182 / SP0662 (300-end)
SEQ ID NO: 183 / SP0664 (103-629)
SEQ ID NO: 184 / SP0664 (630-1200)
SEQ ID NO: 185 / SP0664 (1201-end)
SEQ ID NO: 186 / SP0678 (23-end)
SEQ ID NO: 187 / SP0724 (35-end)
SEQ ID NO: 188 / SP0742 (43-end)
SEQ ID NO: 189 / SP0757 (44-45 1)
SEQ ID NO: 190 / SP0785 (33-end)
SEQ ID NO: 191 / SP0787 (43-290)
SEQ ID NO: 192 / SP0872 (30-end)
SEQ ID NO: 193 / SP0878 (245-end)
SEQ ID NO: 194 / SP0899 (31-end)
SEQ ID NO: 195 / SP1002 (22-end)
SEQ ID NO: 196 / SP1026 (24-end)
SEQ ID NO: 197 / SP1032 (22-end)
SEQ ID NO: 198 / SP1069 (34-end)
SEQ ID NO: 199 / SP1154 (155-694)
SEQ ID NO: 200 / SP1154 (695-1374)
SEQ ID NO: 201 / SP1154 (1375-end)
SEQ ID NO: 202 / SP1267 (25-end)
SEQ ID NO: 203 / SP1376 (32-end)
SEQ ID NO: 204 / SP1386 (33-end)
SEQ ID NO: 205 / SP1404 (31-end)
SEQ ID NO: 206 / SP1405 (19-end)
SEQ ID NO: 207 / SP1419 (27-end)
SEQ ID NO: 208 / SP1479 (40-end)
SEQ ID NO: 209 / SP1500 (27-end)
SEQ ID NO: 210 / SP1545 (29-end)
                                   120

  WO 2014/124228                      PCT/US2014/015254
SEQ ID NO: 211 / SP1560 (28-end)
SEQ ID NO: 212 / SP1624 (1-217)
SEQ ID NO: 213 / SP1652 (62-397)
SEQ ID NO: 214 / SP1683 (65-end)
SEQ ID NO: 215 / SP1826 (36-end)
SEQ ID NO: 216 / SP1872 (40-end)
SEQ ID NO: 217 / SP1891 (40-end)
SEQ ID NO: 218 / SP1897 (30-end)
SEQ ID NO: 219 / SP1942 (37-end)
SEQ ID NO: 220 / SP1966 (25-end)
SEQ ID NO: 221 / SP1967 (30-end)
SEQ ID NO: 222 / SP1998 (51-end)
SEQ ID NO: 223 / SP2048 (40-end)
SEQ ID NO: 224 / SP2050 (35-end)
SEQ ID NO: 225 / SP2083 (192-end)
SEQ ID NO: 226 / SP2084 (30-end)
SEQ ID NO: 227 / SP2088 (30-end)
SEQ ID NO: 70 / SP2145 (1-end)
SEQ ID NO: 228 / SP2151 (25-end)
SEQ ID NO: 229 / SP2187 (32-end)
SEQ ID NO: 230 / SP2192 (224-end)
SEQ ID NO: 231 / SP2197 (30-end)
SEQ ID NO: 232 / SP2207 (30-end)
SEQ ID NO: 234 / SP2218 (106-end)
                                  121

  WO 2014/124228                                                              PCT/US2014/015254
CLAIMS:
     1. An immunogenic composition comprising at least one isolated pneumococcal antigen or
         fragment thereof with the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ
         ID NO: 153-234, and wherein the composition elicits an immune response against
         Streptococcuspneumoniae when administered to a mammal.
     2.  The immunogenic composition of claim 1, wherein the pneumococcal antigen or
         fragment thereof exists as a fusion conjugate.
     3.  The immunogenic composition of claim 2, wherein the fusion conjugate is a
         polysaccharide conjugate.
     4.  The immunogenic composition of claim 3, wherein the fusion conjugate comprises the
         pneumococcal antigen or fragment thereof fused to a pneumococcal pneumolysoid PdT,
         wherein the pneumococcal pneumolysoid PdT is conjugated to the polysaccharide.
     5.  The immunogenic composition of any of claims 2 to 4, wherein the polysaccharide is
         dextran, Vi polysaccharide of Salmonella typhi, or pneumococcal cell wall polysaccharide
         (CWPS), or another polysaccharide of prokaryotic or eukaryotic origin.
     6.  The immunogenic composition of any of claims 1 to 5, wherein the immunogenic
         composition induces a IL-17A (Thl7-cell) response in a subject.
     7.  The immunogenic composition of any of claims 1 to 6, wherein the immunogenic
         composition is further prepared as a vaccine that reduces or protects a mammal against
         pneumococcal colonization.
     8.  The immunogenic composition of any of claims I to 7, wherein the immunogenic
         composition further comprises an adjuvant.
     9.  The immunogenic composition of any of claims 1 to 8, wherein said immunogenic
         composition is administered mucosally.
     10. The immunogenic composition of any of claims 1 to 9, wherein the immunogenic
         composition comprises at least 3 pneumococcal antigens or fragments with the amino
         acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
     11. The immunogenic composition of any of claims 1 to 10, wherein the immunogenic
         composition comprises at least 5 pneumococcal antigens or fragments with the amino
         acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
     12. The immunogenic composition of any of claims I to 11, wherein the immunogenic
         composition comprises between 5 and 20 pneumococcal antigens or fragments thereof
         with the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
                                             122

WO 2014/124228                                                            PCT/US2014/015254
   13. The immunogenic composition of any of claims 1 to 12, wherein the immunogenic
       composition comprises more than 20 pneumococcal antigens or fragments thereof with
       the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234.
   14. The method of any of claims I to 13, wherein a pneumococcal protein or protein fragment
       is at least one of the pneumococcal proteins SP0785, SP1500 and SP2145.
   15. The method of any of claims I to 14, wherein the immune response comprises a humoral
       immune response.
   16. The method of any of claims I to 14, wherein the immune response comprises a cellular
       immune response.
   17. A method of inducing an IL-17A response in a subject, comprising administering to the
       subject at least one immunogenic composition of any of claims 1 - 16 effective to induce
       an immune response against Streptococcuspneumoniae in the subject.
   18. A method to protect against pneumococcal colonization, comprising administering to the
       subject at least one immunogenic composition of any of claims 1 - 16.
   19. A method to elicit an immune response against Streptococcuspneumoniae in a mammal,
       the method comprising administering to the mammal at least one immunogenic
       composition comprising one or more isolated pneumococcal antigen or fragment thereof
       with the amino acid sequence selected from SEQ ID NO: 1-76 or SEQ ID NO: 153-234 in
       an effective to induce an immune response against Streptococcuspneumoniae in the
       subj ect.
   20. A method to protect against Salmonella typhi colonization in a mammal, comprising
       administering to the mammal at least one immunogenic composition of any of claims 1
       16 in effective to induce an immune response against Streptococcuspneumoniae in the
       subj ect.
   21. The method of any of claims 17-20, wherein the immunogenic composition comprises at
       least one isolated pneumococcal antigen or fragment thereof is SP0785 or SP1500.
   22. The method of claim 21, wherein the pneumococcal antigen or fragment thereof has an
       amino acid sequence selected from SEQ ID NO: 34 ( SP0785) or SEQ ID NO:
       51(SPi500).
   23. A method to protect against an invasive disease of Streptococcuspneumoniae in a
       subject, comprising administering to the subject an immunogenic composition of any of
       claims 1 - 16 in effective to induce an immune response against Streptococcus
       pneumoniae in the subject.
   24. The method of claim 23, wherein the invasive disease is sepsis.
   25. The method of claim 23, wherein the immunogenic composition comprises at least one
       isolated pneumococcal antigen or fragment thereof is SP1386, SP1500, SP0084 and
       SP1479 and SP0346.
                                           123

WO 2014/124228                                                             PCT/US2014/015254
   26. The method of claim 25, wherein the pneumococcal antigen or fragment thereof has an
       amino acid sequence selected from SEQ ID NO: 46 (SP1386), SEQ ID NO: 51(SP1500),
       SEQ ID NO: 4 (SP0084), SEQ ID NO: 50 (SP1479) and SEQ ID NO: 15 (SP0346).
   27. The method of any of claims 17-26, wherein the pneumococcal antigen or fragment
       thereof is conjugated to the pneumococcal pneumolysoid PdT.
   28. The method of any of claims 17-26, wherein the pneumococcal antigen or fragment
       thereof is conjugated to the Vi polysaccharide of Salmonella typhi.
   29. The method of any of claims 17-28, wherein the pneumococcal antigen or fragment
       thereof is conjugated to the pneumococcal pneumolysoid Pdt and the Vi polysaccharide
       of Salmonella typhi.
   30. The method of any of claims 17-29, wherein the administration is mucosal administration.
   31. The method of any of claims 17-30, wherein the administration is intravenous,
       subcutaneous or intraperitoneal (IP) administration.
   32. The method of any of claims 17 to 31, wherein the immune response comprises a humoral
       immune response.
   33. The method of any of claims 17 to 31, wherein the immune response comprises a cellular
       immune response.
                                           124

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
                                                 SEQUENCE LISTING
<removed-date>
              <110> CHILDREN'S MEDICAL CENTER CORPORATION
              <120> PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL
                    COLONIZATION AND/OR DISEASE
              <130> 701039<U+2701>074841<U+2701>PCT
              <140>
              <141>
<removed-apn>
              <150> 61/762,062
              <151> 2013<U+2701>02<U+2701>07
              <160> 405
              <170> PatentIn version 3.5
              <210>   1
              <211>   422
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 1
              Met Arg Lys Phe Leu Ile Ile Leu Leu Leu Pro Ser Phe Leu Thr Ile
              1               5                   10                  15
              Ser Lys Val Val Ser Thr Glu Lys Glu Val Val Tyr Thr Ser Lys Glu
                          20                  25                  30
              Ile Tyr Tyr Leu Ser Gln Ser Asp Phe Gly Ile Tyr Phe Arg Glu Lys
                      35                  40                  45
              Leu Ser Ser Pro Met Val Tyr Gly Glu Val Pro Val Tyr Ala Asn Glu
                  50                  55                  60
              Asp Leu Val Val Glu Ser Gly Lys Leu Thr Pro Lys Thr Ser Phe Gln
              65                  70                  75                  80
              Ile Thr Glu Trp Arg Leu Asn Lys Gln Gly Ile Pro Val Phe Lys Leu
                              85                  90                  95
              Ser Asn His Gln Phe Ile Ala Ala Asp Lys Arg Phe Leu Tyr Asp Gln
                          100                 105                 110
                                                      Page 1

              Ser Glu Val Thr Pro Thr Ile Lys Lys Val Trp Leu Glu Ser Asp Phe
<removed-date>
                      115                 120                 125
              Lys Leu Tyr Asn Ser Pro Tyr Asp Leu Lys Glu Val Lys Ser Ser Leu
                  130                 135                 140
              Ser Ala Tyr Ser Gln Val Ser Ile Asp Lys Thr Met Phe Val Glu Gly
              145                 150                 155                 160
<removed-apn>
              Arg Glu Phe Leu His Ile Asp Gln Ala Gly Trp Val Ala Lys Glu Ser
                              165                 170                 175
              Thr Ser Glu Glu Asp Asn Arg Met Ser Lys Val Gln Glu Met Leu Ser
                          180                 185                 190
              Glu Lys Tyr Gln Lys Asp Ser Phe Ser Ile Tyr Val Lys Gln Leu Thr
                      195                 200                 205
              Thr Gly Lys Glu Ala Gly Ile Asn Gln Asp Glu Lys Met Tyr Ala Ala
                  210                 215                 220
              Ser Val Leu Lys Leu Ser Tyr Leu Tyr Tyr Thr Gln Glu Lys Ile Asn
              225                 230                 235                 240
              Glu Gly Leu Tyr Gln Leu Asp Thr Thr Val Lys Tyr Val Ser Ala Val
                              245                 250                 255
              Asn Asp Phe Pro Gly Ser Tyr Lys Pro Glu Gly Ser Gly Ser Leu Pro
                          260                 265                 270
              Lys Lys Glu Asp Asn Lys Glu Tyr Ser Leu Lys Asp Leu Ile Thr Lys
                      275                 280                 285
              Val Ser Lys Glu Ser Asp Asn Val Ala His Asn Leu Leu Gly Tyr Tyr
                  290                 295                 300
              Ile Ser Asn Gln Ser Asp Ala Thr Phe Lys Ser Lys Met Ser Ala Ile
              305                 310                 315                 320
              Met Gly Asp Asp Trp Asp Pro Lys Glu Lys Leu Ile Ser Ser Lys Met
                                                  Page 2

                                325               330                 335
<removed-date>
              Ala Gly Lys Phe Met Glu Ala Ile Tyr Asn Gln Asn Gly Phe Val Leu
                          340                 345                 350
              Glu Ser Leu Thr Lys Thr Asp Phe Asp Ser Gln Arg Ile Ala Lys Gly
                      355                 360                 365
<removed-apn>
              Val Ser Val Lys Val Ala His Lys Ile Gly Asp Ala Asp Glu Phe Lys
                  370                 375                 380
              His Asp Thr Gly Val Val Tyr Ala Asp Ser Pro Phe Ile Leu Ser Ile
              385                 390                 395                 400
              Phe Thr Lys Asn Ser Asp Tyr Asp Thr Ile Ser Lys Ile Ala Lys Asp
                              405                 410                 415
              Val Tyr Glu Val Leu Lys
                          420
              <210>   2
              <211>   449
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 2
              Met Lys Pro Glu Phe Leu Glu Ser Ala Glu Phe Tyr Asn Arg Arg Tyr
              1               5                   10                  15
              His Asn Phe Ser Ser Ser Val Ile Val Pro Met Ala Leu Leu Leu Val
                          20                  25                  30
              Phe Leu Leu Gly Phe Ala Thr Val Ala Glu Lys Glu Met Ser Leu Ser
                      35                  40                  45
              Thr Arg Ala Thr Val Glu Pro Ser Arg Ile Leu Ala Asn Ile Gln Ser
                  50                  55                  60
              Thr Ser Asn Asn Arg Ile Leu Val Asn His Leu Glu Glu Asn Lys Leu
              65                  70                  75                  80
                                                  Page 3

              Val Lys Lys Gly Asp Leu Leu Val Gln Tyr Gln Glu Gly Ala Glu Gly
<removed-date>
                              85                  90                  95
              Val Gln Ala Glu Ser Tyr Ala Ser Gln Leu Asp Met Leu Lys Asp Gln
                          100                 105                 110
              Lys Lys Gln Leu Glu Tyr Leu Gln Lys Ser Leu Gln Glu Gly Glu Asn
                      115                 120                 125
<removed-apn>
              His Phe Pro Glu Glu Asp Lys Phe Gly Tyr Gln Ala Thr Phe Arg Asp
                  130                 135                 140
              Tyr Ile Ser Gln Ala Gly Ser Leu Arg Ala Ser Thr Ser Gln Gln Asn
              145                 150                 155                 160
              Glu Thr Ile Ala Ser Gln Asn Ala Ala Ala Ser Gln Thr Gln Ala Glu
                              165                 170                 175
              Ile Gly Asn Leu Ile Ser Gln Thr Glu Ala Lys Ile Arg Asp Tyr Gln
                          180                 185                 190
              Thr Ala Lys Ser Ala Ile Glu Thr Gly Ala Ser Leu Ala Gly Gln Asn
                      195                 200                 205
              Leu Ala Tyr Ser Leu Tyr Gln Ser Tyr Lys Ser Gln Gly Glu Glu Asn
                  210                 215                 220
              Pro Gln Thr Lys Val Gln Ala Val Ala Gln Val Glu Ala Gln Ile Ser
              225                 230                 235                 240
              Gln Leu Glu Ser Ser Leu Ala Thr Tyr Arg Val Gln Tyr Ala Gly Ser
                              245                 250                 255
              Gly Thr Gln Gln Ala Tyr Ala Ser Gly Leu Ser Ser Gln Leu Glu Ser
                          260                 265                 270
              Leu Lys Ser Gln His Leu Ala Lys Val Gly Gln Glu Leu Thr Leu Leu
                      275                 280                 285
              Ala Gln Lys Ile Leu Glu Ala Glu Ser Gly Lys Lys Val Gln Gly Asn
                                                  Page 4

                    290                 295                300
<removed-date>
              Leu Leu Asp Lys Gly Lys Val Thr Ala Ser Glu Asp Gly Val Leu His
              305                 310                 315                 320
              Leu Asn Pro Glu Thr Ser Asp Ser Ser Met Val Ala Glu Gly Ala Leu
                              325                 330                 335
<removed-apn>
              Leu Ala Gln Leu Tyr Pro Ser Leu Glu Arg Glu Gly Lys Ala Lys Leu
                          340                 345                 350
              Thr Ala Tyr Leu Ser Ser Lys Tyr Val Ala Arg Ile Lys Val Gly Asp
                      355                 360                 365
              Ser Val Arg Tyr Thr Thr Thr His Asp Ala Gly Asn Gln Leu Phe Leu
                  370                 375                 380
              Asp Ser Thr Ile Thr Ser Ile Asp Ala Thr Ala Thr Lys Thr Glu Lys
              385                 390                 395                 400
              Gly Asn Phe Phe Lys Ile Glu Ala Glu Thr Asn Leu Thr Ser Glu Gln
                              405                 410                 415
              Ala Glu Lys Leu Arg Tyr Gly Val Glu Gly Arg Leu Gln Met Ile Thr
                          420                 425                 430
              Gly Lys Lys Ser Tyr Leu Arg Tyr Tyr Leu Asp Gln Phe Leu Asn Lys
                      435                 440                 445
              Glu
              <210>   3
              <211>   221
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 3
              Met Ser Asp Arg Thr Ile Gly Ile Leu Gly Leu Gly Ile Phe Gly Ser
              1               5                   10                  15
                                                  Page 5

              Ser Val Leu Ala Ala Leu Ala Lys Gln Asp Met Asn Ile Ile Ala Ile
<removed-date>
                          20                  25                  30
              Asp Asp His Ala Glu Arg Ile Asn Gln Phe Glu Pro Val Leu Ala Arg
                      35                  40                  45
              Gly Val Ile Gly Asp Ile Thr Asp Glu Glu Leu Leu Arg Ser Ala Gly
                  50                  55                  60
<removed-apn>
              Ile Asp Thr Cys Asp Thr Val Val Val Ala Thr Gly Glu Asn Leu Glu
              65                  70                  75                  80
              Ser Ser Val Leu Ala Val Met His Cys Lys Ser Leu Gly Val Pro Thr
                              85                  90                  95
              Val Ile Ala Lys Val Lys Ser Gln Thr Ala Lys Lys Val Leu Glu Lys
                          100                 105                 110
              Ile Gly Ala Asp Ser Val Ile Ser Pro Glu Tyr Glu Met Gly Gln Ser
                      115                 120                 125
              Leu Ala Gln Thr Ile Leu Phe His Asn Ser Val Asp Val Phe Gln Leu
                  130                 135                 140
              Asp Lys Asn Val Ser Ile Val Glu Met Lys Ile Pro Gln Ser Trp Ala
              145                 150                 155                 160
              Gly Gln Ser Leu Ser Lys Leu Asp Leu Arg Gly Lys Tyr Asn Leu Asn
                              165                 170                 175
              Ile Leu Gly Phe Arg Glu Gln Glu Asn Ser Pro Leu Asp Val Glu Phe
                          180                 185                 190
              Gly Pro Asp Asp Leu Leu Lys Ala Asp Thr Tyr Ile Leu Ala Val Ile
                      195                 200                 205
              Asn Asn Gln Tyr Leu Asp Thr Leu Val Ala Leu Asn Ser
                  210                 215                 220
              <210> 4
                                                  Page 6

              <211> 350
<removed-date>
              <212> PRT
              <213> Streptococcus pneumoniae
              <400> 4
              Met Lys Leu Lys Ser Tyr Ile Leu Val Gly Tyr Ile Ile Ser Thr Leu
              1               5                   10                  15
              Leu Thr Ile Leu Val Val Phe Trp Ala Val Gln Lys Met Leu Ile Ala
                          20                  25                  30
<removed-apn>
              Lys Gly Glu Ile Tyr Phe Leu Leu Gly Met Thr Ile Val Ala Ser Leu
                      35                  40                  45
              Val Gly Ala Gly Ile Ser Leu Phe Leu Leu Leu Pro Val Phe Thr Ser
                  50                  55                  60
              Leu Gly Lys Leu Lys Glu His Ala Lys Arg Val Ala Ala Lys Asp Phe
              65                  70                  75                  80
              Pro Ser Asn Leu Glu Val Gln Gly Pro Val Glu Phe Gln Gln Leu Gly
                              85                  90                  95
              Gln Thr Phe Asn Glu Met Ser His Asp Leu Gln Val Ser Phe Asp Ser
                          100                 105                 110
              Leu Glu Glu Ser Glu Arg Glu Lys Gly Leu Met Ile Ala Gln Leu Ser
                      115                 120                 125
              His Asp Ile Lys Thr Pro Ile Thr Ser Ile Gln Ala Thr Val Glu Gly
                  130                 135                 140
              Ile Leu Asp Gly Ile Ile Lys Glu Ser Glu Gln Ala His Tyr Leu Ala
              145                 150                 155                 160
              Thr Ile Gly Arg Gln Thr Glu Arg Leu Asn Lys Leu Val Glu Glu Leu
                              165                 170                 175
              Asn Phe Leu Thr Leu Asn Thr Ala Arg Asn Gln Val Glu Thr Thr Ser
                          180                 185                 190
                                                  Page 7

              Lys Asp Ser Ile Phe Leu Asp Lys Leu Leu Ile Glu Cys Met Ser Glu
<removed-date>
                      195                 200                 205
              Phe Gln Phe Leu Ile Glu Gln Glu Arg Arg Asp Val His Leu Gln Val
                  210                 215                 220
              Ile Pro Glu Ser Ala Arg Ile Glu Gly Asp Tyr Ala Lys Leu Ser Arg
              225                 230                 235                 240
<removed-apn>
              Ile Leu Val Asn Leu Val Asp Asn Ala Phe Lys Tyr Ser Ala Pro Gly
                              245                 250                 255
              Thr Lys Leu Glu Val Val Ala Lys Leu Glu Lys Asp Gln Leu Ser Ile
                          260                 265                 270
              Ser Val Thr Asp Glu Gly Gln Gly Ile Ala Pro Glu Asp Leu Glu Asn
                      275                 280                 285
              Ile Phe Lys Arg Leu Tyr Arg Val Glu Thr Ser Arg Asn Met Lys Thr
                  290                 295                 300
              Gly Gly His Gly Leu Gly Leu Ala Ile Ala Arg Glu Leu Ala His Gln
              305                 310                 315                 320
              Leu Gly Gly Glu Ile Thr Val Ser Ser Gln Tyr Gly Leu Gly Ser Thr
                              325                 330                 335
              Phe Thr Leu Val Leu Asn Leu Ser Gly Ser Glu Asn Lys Ala
                          340                 345                 350
              <210>   5
              <211>   491
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 5
              Met Lys Asn Trp Lys Lys Tyr Ala Phe Ala Ser Ala Ser Val Val Ala
              1               5                   10                  15
              Leu Ala Ala Gly Leu Ala Ala Cys Gly Asn Leu Thr Gly Asn Ser Lys
                          20                  25                  30
                                                  Page 8

<removed-date>
              Lys Ala Ala Asp Ser Gly Asp Lys Pro Val Ile Lys Met Tyr Gln Ile
                      35                  40                  45
              Gly Asp Lys Pro Asp Asn Leu Asp Glu Leu Leu Ala Asn Ala Asn Lys
                  50                  55                  60
              Ile Ile Glu Glu Lys Val Gly Ala Lys Leu Asp Ile Gln Tyr Leu Gly
              65                  70                  75                  80
<removed-apn>
              Trp Gly Asp Tyr Gly Lys Lys Met Ser Val Ile Thr Ser Ser Gly Glu
                              85                  90                  95
              Asn Tyr Asp Ile Ala Phe Ala Asp Asn Tyr Ile Val Asn Ala Gln Lys
                          100                 105                 110
              Gly Ala Tyr Ala Asp Leu Thr Glu Leu Tyr Lys Lys Glu Gly Lys Asp
                      115                 120                 125
              Leu Tyr Lys Ala Leu Asp Pro Ala Tyr Ile Lys Gly Asn Thr Val Asn
                  130                 135                 140
              Gly Lys Ile Tyr Ala Val Pro Val Ala Ala Asn Val Ala Ser Ser Gln
              145                 150                 155                 160
              Asn Phe Ala Phe Asn Gly Thr Leu Leu Ala Lys Tyr Gly Ile Asp Ile
                              165                 170                 175
              Ser Gly Val Thr Ser Tyr Glu Thr Leu Glu Pro Val Leu Lys Gln Ile
                          180                 185                 190
              Lys Glu Lys Ala Pro Asp Val Val Pro Phe Ala Ile Gly Lys Val Phe
                      195                 200                 205
              Ile Pro Ser Asp Asn Phe Asp Tyr Pro Val Ala Asn Gly Leu Pro Phe
                  210                 215                 220
              Val Ile Asp Leu Glu Gly Asp Thr Thr Lys Val Val Asn Arg Tyr Glu
              225                 230                 235                 240
                                                  Page 9

              Val Pro Arg Phe Lys Glu His Leu Lys Thr Leu His Lys Phe Tyr Glu
<removed-date>
                              245                 250                 255
              Ala Gly Tyr Ile Pro Lys Asp Val Ala Thr Ser Asp Thr Ser Phe Asp
                          260                 265                 270
              Leu Gln Gln Asp Thr Trp Phe Val Arg Glu Glu Thr Val Gly Pro Ala
                      275                 280                 285
<removed-apn>
              Asp Tyr Gly Asn Ser Leu Leu Ser Arg Val Ala Asn Lys Asp Ile Gln
                  290                 295                 300
              Ile Lys Pro Ile Thr Asn Phe Ile Lys Lys Asn Gln Thr Thr Gln Val
              305                 310                 315                 320
              Ala Asn Phe Val Ile Ser Asn Asn Ser Lys Asn Lys Glu Lys Ser Met
                              325                 330                 335
              Glu Ile Leu Asn Leu Leu Asn Thr Asn Pro Glu Leu Leu Asn Gly Leu
                          340                 345                 350
              Val Tyr Gly Pro Glu Gly Lys Asn Trp Glu Lys Ile Glu Gly Lys Glu
                      355                 360                 365
              Asn Arg Val Arg Val Leu Asp Gly Tyr Lys Gly Asn Thr His Met Gly
                  370                 375                 380
              Gly Trp Asn Thr Gly Asn Asn Trp Ile Leu Tyr Ile Asn Glu Asn Val
              385                 390                 395                 400
              Thr Asp Gln Gln Ile Glu Asn Ser Lys Lys Glu Leu Ala Glu Ala Lys
                              405                 410                 415
              Glu Ser Pro Ala Leu Gly Phe Ile Phe Asn Thr Asp Asn Val Lys Ser
                          420                 425                 430
              Glu Ile Ser Ala Ile Ala Asn Thr Met Gln Gln Phe Asp Thr Ala Ile
                      435                 440                 445
              Asn Thr Gly Thr Val Asp Pro Asp Lys Ala Ile Pro Glu Leu Met Glu
                                                  Page 10

                  450                   455                 460
<removed-date>
              Lys Leu Lys Ser Glu Gly Ala Tyr Glu Lys Val Leu Asn Glu Met Gln
              465                 470                 475                 480
              Lys Gln Tyr Asp Glu Phe Leu Lys Asn Lys Lys
                              485                 490
<removed-apn>
              <210>   6
              <211>   303
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 6
              Met Arg Lys Trp Thr Lys Gly Phe Leu Ile Phe Gly Val Val Thr Thr
              1               5                   10                  15
              Val Ile Gly Phe Ile Leu Leu Phe Val Gly Ile Gln Ser Asp Gly Ile
                          20                  25                  30
              Lys Ser Leu Leu Ser Met Ser Lys Glu Pro Val Tyr Asp Ser Arg Thr
                      35                  40                  45
              Glu Lys Leu Thr Phe Gly Lys Glu Val Glu Asn Leu Glu Ile Thr Leu
                  50                  55                  60
              His Gln His Thr Leu Thr Ile Thr Asp Ser Phe Asp Asp Gln Ile His
              65                  70                  75                  80
              Ile Ser Tyr His Pro Ser Leu Ser Ala His His Asp Leu Ile Thr Asn
                              85                  90                  95
              Gln Asn Asp Arg Thr Leu Ser Leu Thr Asp Lys Lys Leu Ser Glu Thr
                          100                 105                 110
              Pro Phe Leu Ser Ser Gly Ile Gly Gly Ile Leu His Ile Ala Ser Ser
                      115                 120                 125
              Tyr Ser Ser Arg Phe Glu Glu Val Ile Leu Arg Leu Pro Lys Gly Arg
                  130                 135                 140
                                                  Page 11

              Thr Leu Lys Gly Ile Asn Ile Ser Ala Asn Arg Gly Gln Thr Thr Ile
<removed-date>
              145                 150                 155                 160
              Ile Asn Ala Ser Leu Glu Asn Ala Thr Leu Asn Thr Asn Ser Tyr Ile
                              165                 170                 175
              Leu Arg Ile Glu Gly Ser Arg Ile Lys Asn Ser Lys Leu Thr Thr Pro
                          180                 185                 190
<removed-apn>
              Asn Ile Val Asn Ile Phe Asp Thr Val Leu Thr Asp Ser Gln Leu Glu
                      195                 200                 205
              Ser Thr Glu Asn His Phe His Ala Glu Asn Ile Gln Val His Gly Lys
                  210                 215                 220
              Val Glu Leu Thr Ala Lys Asp Tyr Leu Arg Ile Ile Leu Asp Gln Lys
              225                 230                 235                 240
              Glu Ser Gln Arg Ile Asn Trp Asp Ile Ser Ser Asn Tyr Gly Ser Ile
                              245                 250                 255
              Phe Gln Phe Thr Arg Glu Lys Pro Glu Ser Arg Gly Thr Glu Leu Ser
                          260                 265                 270
              Asn Pro Tyr Lys Thr Glu Lys Thr Asp Val Lys Asp Gln Leu Ile Ala
                      275                 280                 285
              Arg Ser Asp Asp Asn Ile Asp Leu Ile Ser Thr Pro Ser Arg Arg
                  290                 295                 300
              <210>   7
              <211>   354
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 7
              Met Thr Gln Asn Val Glu Ser Leu Leu Val Ser Ile Val Ile Ser Ala
              1               5                   10                  15
              Tyr Asn Glu Glu Lys Tyr Leu Pro Gly Leu Ile Glu Asp Leu Lys Asn
                          20                  25                  30
                                                  Page 12

<removed-date>
              Gln Thr Tyr Pro Lys Glu Asp Ile Glu Ile Leu Phe Ile Asn Ala Met
                      35                  40                  45
              Ser Thr Asp Gly Thr Thr Ala Ile Ile Gln Gln Phe Ile Lys Glu Asp
                  50                  55                  60
              Thr Glu Phe Asn Ser Ile Arg Leu Tyr Asn Asn Pro Lys Lys Asn Gln
              65                  70                  75                  80
<removed-apn>
              Ala Ser Gly Phe Asn Leu Gly Val Lys His Ser Val Gly Asp Leu Ile
                              85                  90                  95
              Leu Lys Ile Asp Ala His Ser Lys Val Thr Glu Thr Phe Val Met Asn
                          100                 105                 110
              Asn Val Ala Ile Ile Gln Gln Gly Glu Phe Val Cys Gly Gly Pro Arg
                      115                 120                 125
              Pro Thr Ile Val Glu Gly Lys Gly Lys Trp Ala Glu Thr Leu His Leu
                  130                 135                 140
              Val Glu Glu Asn Met Phe Gly Ser Ser Ile Ala Asn Tyr Arg Asn Ser
              145                 150                 155                 160
              Ser Glu Asp Arg Tyr Val Ser Ser Ile Phe His Gly Met Tyr Lys Arg
                              165                 170                 175
              Glu Val Phe Gln Lys Val Gly Leu Val Asn Glu Gln Leu Gly Arg Thr
                          180                 185                 190
              Glu Asp Asn Asp Ile His Tyr Arg Ile Arg Glu Tyr Gly Tyr Lys Ile
                      195                 200                 205
              Arg Tyr Ser Pro Ser Ile Leu Ser Tyr Gln Tyr Ile Arg Pro Thr Phe
                  210                 215                 220
              Lys Lys Met Leu His Gln Lys Tyr Ser Asn Gly Leu Trp Ile Gly Leu
              225                 230                 235                 240
                                                  Page 13

              Thr Ser His Val Gln Phe Lys Cys Leu Ser Leu Phe His Tyr Val Pro
<removed-date>
                              245                 250                 255
              Cys Leu Phe Val Leu Ser Leu Val Phe Ser Leu Ala Leu Leu Pro Ile
                          260                 265                 270
              Thr Phe Val Phe Ile Thr Leu Leu Leu Gly Ala Tyr Phe Leu Leu Leu
                      275                 280                 285
<removed-apn>
              Ser Leu Leu Thr Leu Leu Thr Leu Leu Lys His Lys Asn Gly Phe Leu
                  290                 295                 300
              Ile Val Met Pro Phe Ile Leu Phe Ser Ile His Phe Ala Tyr Gly Leu
              305                 310                 315                 320
              Gly Thr Ile Val Gly Leu Ile Arg Gly Phe Lys Trp Lys Lys Glu Tyr
                              325                 330                 335
              Lys Arg Thr Ile Ile Tyr Leu Asp Lys Ile Ser Gln Ile Asn Gln Asn
                          340                 345                 350
              Met Leu
              <210>   8
              <211>   195
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 8
              Met Lys Ser Ile Thr Lys Lys Ile Lys Ala Thr Leu Ala Gly Val Ala
              1               5                   10                  15
              Ala Leu Phe Ala Val Phe Ala Pro Ser Phe Val Ser Ala Gln Glu Ser
                          20                  25                  30
              Ser Thr Tyr Thr Val Lys Glu Gly Asp Thr Leu Ser Glu Ile Ala Glu
                      35                  40                  45
              Thr His Asn Thr Thr Val Glu Lys Leu Ala Glu Asn Asn His Ile Asp
                  50                  55                  60
                                                  Page 14

<removed-date>
              Asn Ile His Leu Ile Tyr Val Asp Gln Glu Leu Val Ile Asp Gly Pro
              65                  70                  75                  80
              Val Ala Pro Val Ala Thr Pro Ala Pro Ala Thr Tyr Ala Ala Pro Ala
                              85                  90                  95
              Ala Gln Asp Glu Thr Val Ser Ala Pro Val Ala Glu Thr Pro Val Val
                          100                 105                 110
<removed-apn>
              Ser Glu Thr Val Val Ser Thr Val Ser Gly Ser Glu Ala Glu Ala Lys
                      115                 120                 125
              Glu Trp Ile Ala Gln Lys Glu Ser Gly Gly Ser Tyr Thr Ala Thr Asn
                  130                 135                 140
              Gly Arg Tyr Ile Gly Arg Tyr Gln Leu Thr Asp Ser Tyr Leu Asn Gly
              145                 150                 155                 160
              Asp Tyr Ser Ala Glu Asn Gln Glu Arg Val Ala Asp Ala Tyr Val Ala
                              165                 170                 175
              Gly Arg Tyr Gly Ser Trp Thr Ala Ala Lys Asn Phe Trp Leu Asn Asn
                          180                 185                 190
              Gly Trp Tyr
                      195
              <210>   9
              <211>   227
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 9
              Met Lys Val Leu Ala Phe Asp Thr Ser Ser Lys Ala Leu Ser Leu Ala
              1               5                   10                  15
              Ile Leu Glu Asp Lys Gln Val Leu Ala Glu Thr Thr Ile Asn Ile Lys
                          20                  25                  30
              Lys Asn His Ser Ile Thr Leu Met Pro Ala Ile Asp Phe Leu Met Ala
                      35                  40                  45
                                                  Page 15

<removed-date>
              Ser Leu Asp Trp Thr Pro Lys Asp Leu Asp Arg Ile Val Val Ala Glu
                  50                  55                  60
              Gly Pro Gly Ser Tyr Thr Gly Leu Arg Ile Ala Val Ala Thr Ala Lys
              65                  70                  75                  80
              Thr Leu Ala His Thr Leu Asn Ile Glu Leu Val Gly Met Ser Ser Leu
<removed-apn>
                              85                  90                  95
              Leu Ala Leu Val Pro His Gln Gln Glu Gly Leu Phe Val Pro Leu Met
                          100                 105                 110
              Asp Ala Arg Arg Asn Asn Val Tyr Ala Gly Phe Tyr Glu Asn Ala Lys
                      115                 120                 125
              Pro Val Met Ala Glu Ala His Leu Ser Phe Glu Glu Val Leu Glu Lys
                  130                 135                 140
              Val Lys Gly Thr Ser Gln Val Thr Phe Val Gly Glu Val Gly Pro Phe
              145                 150                 155                 160
              Val Glu Gln Ile Gln Lys His Leu Pro Arg Thr Asp Tyr Lys Glu Thr
                              165                 170                 175
              Leu Pro Asn Ala Ala Asn Leu Ala Leu Leu Ala Trp Asp Lys Glu Ala
                          180                 185                 190
              Asp Ser Leu His Asp Phe Val Pro Asn Tyr Leu Lys Arg Val Glu Ala
                      195                 200                 205
              Glu Glu Asn Trp Leu Lys Asn His Thr Glu Ser Gly Glu Ser Tyr Ile
                  210                 215                 220
              Lys Arg Leu
              225
              <210> 10
              <211> 284
              <212> PRT
                                                  Page 16

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 10
              Met Lys Ile Lys Lys Trp Leu Gly Leu Ala Ala Leu Ala Thr Val Ala
              1               5                   10                  15
              Gly Leu Ala Leu Ala Ala Cys Gly Asn Ser Glu Lys Lys Ala Asp Asn
                          20                  25                  30
<removed-apn>
              Ala Thr Thr Ile Lys Ile Ala Thr Val Asn Arg Ser Gly Ser Glu Glu
                      35                  40                  45
              Lys Arg Trp Asp Lys Ile Gln Glu Leu Val Lys Lys Asp Gly Ile Thr
                  50                  55                  60
              Leu Glu Phe Thr Glu Phe Thr Asp Tyr Ser Gln Pro Asn Lys Ala Thr
              65                  70                  75                  80
              Ala Asp Gly Glu Val Asp Leu Asn Ala Phe Gln His Tyr Asn Phe Leu
                              85                  90                  95
              Asn Asn Trp Asn Lys Glu Asn Gly Lys Asp Leu Val Ala Ile Ala Asp
                          100                 105                 110
              Thr Tyr Ile Ser Pro Ile Arg Leu Tyr Ser Gly Leu Asn Gly Ser Ala
                      115                 120                 125
              Asn Lys Tyr Thr Lys Val Glu Asp Ile Pro Ala Asn Gly Glu Ile Ala
                  130                 135                 140
              Val Pro Asn Asp Ala Thr Asn Glu Ser Arg Ala Leu Tyr Leu Leu Gln
              145                 150                 155                 160
              Ser Ala Gly Leu Ile Lys Leu Asp Val Ser Gly Thr Ala Leu Ala Thr
                              165                 170                 175
              Val Ala Asn Ile Lys Glu Asn Pro Lys Asn Leu Lys Ile Thr Glu Leu
                          180                 185                 190
              Asp Ala Ser Gln Thr Ala Arg Ser Leu Ser Ser Val Asp Ala Ala Val
                      195                 200                 205
                                                  Page 17

<removed-date>
              Val Asn Asn Thr Phe Val Thr Glu Ala Lys Leu Asp Tyr Lys Lys Ser
                  210                 215                 220
              Leu Phe Lys Glu Gln Ala Asp Glu Asn Ser Lys Gln Trp Tyr Asn Ile
              225                 230                 235                 240
              Ile Val Ala Lys Lys Asp Trp Glu Thr Ser Pro Lys Ala Asp Ala Ile
<removed-apn>
                              245                 250                 255
              Lys Lys Val Ile Ala Ala Tyr His Thr Asp Asp Val Lys Lys Val Ile
                          260                 265                 270
              Glu Glu Ser Ser Asp Gly Leu Asp Gln Pro Val Trp
                      275                 280
              <210>   11
              <211>   189
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 11
              Met Lys Lys Ile Val Leu Val Ser Leu Ala Phe Leu Phe Val Leu Val
              1               5                   10                  15
              Gly Cys Gly Gln Lys Lys Glu Thr Gly Pro Ala Thr Lys Thr Glu Lys
                          20                  25                  30
              Asp Thr Leu Gln Ser Ala Leu Pro Val Ile Glu Asn Ala Glu Lys Asn
                      35                  40                  45
              Thr Val Val Thr Lys Thr Leu Val Leu Pro Lys Ser Asp Asp Gly Ser
                  50                  55                  60
              Gln Gln Thr Gln Thr Ile Thr Tyr Lys Asp Lys Thr Phe Leu Ser Leu
              65                  70                  75                  80
              Ala Ile Gln Gln Lys Arg Pro Val Ser Asp Glu Leu Lys Thr Tyr Ile
                              85                  90                  95
              Asp Gln His Gly Val Glu Glu Thr Gln Lys Ala Leu Leu Glu Ala Glu
                                                  Page 18

                            100                  105                110
<removed-date>
              Glu Lys Asp Lys Ser Ile Ile Glu Ala Arg Lys Leu Ala Gly Phe Lys
                      115                 120                 125
              Leu Glu Thr Lys Leu Leu Ser Ala Thr Glu Leu Gln Thr Thr Thr Ser
                  130                 135                 140
<removed-apn>
              Phe Asp Phe Gln Val Leu Asp Val Lys Lys Ala Ser Gln Leu Glu His
              145                 150                 155                 160
              Leu Lys Asn Ile Gly Leu Glu Asn Leu Leu Lys Asn Glu Pro Ser Lys
                              165                 170                 175
              Tyr Ile Ser Asp Arg Leu Ala Asn Gly Ala Thr Glu Gln
                          180                 185
              <210>   12
              <211>   152
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 12
              Met Lys Leu Lys Arg Phe Thr Leu Ser Leu Ala Ser Leu Ala Ser Phe
              1               5                   10                  15
              Ser Leu Leu Val Ala Cys Ser Gln Arg Ala Gln Gln Val Gln Gln Pro
                          20                  25                  30
              Val Ala Gln Gln Gln Val Gln Gln Pro Ala Gln Gln Asn Thr Asn Thr
                      35                  40                  45
              Ala Asn Ala Gly Gly Asn Gln Asn Gln Ala Ala Pro Val Gln Asn Gln
                  50                  55                  60
              Pro Val Ala Gln Pro Thr Asp Ile Asp Gly Thr Tyr Thr Gly Gln Asp
              65                  70                  75                  80
              Asp Gly Asp Arg Ile Thr Leu Val Val Thr Gly Thr Thr Gly Thr Trp
                              85                  90                  95
                                                       Page 19

              Thr Glu Leu Glu Ser Asp Gly Asp Gln Lys Val Lys Gln Val Thr Leu
<removed-date>
                          100                 105                 110
              Asp Ser Ala Asn Gln Arg Met Ile Ile Gly Asp Asp Val Lys Ile Tyr
                      115                 120                 125
              Thr Val Asn Gly Asn Gln Ile Val Val Asp Asp Met Asp Arg Asp Pro
                  130                 135                 140
<removed-apn>
              Ser Asp Gln Ile Val Leu Thr Lys
              145                 150
              <210>   13
              <211>   102
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 13
              Met Val Lys Ile Gly Leu Phe Cys Ala Ala Gly Phe Ser Thr Gly Met
              1               5                   10                  15
              Leu Val Asn Asn Met Lys Ile Ala Ala Gln Ser Ser Gly Val Glu Ala
                          20                  25                  30
              Glu Ile Glu Ala Phe Ser Gln Ser Lys Leu Ala Asp Tyr Ala Pro Asn
                      35                  40                  45
              Ile Asp Val Ala Leu Leu Gly Pro Gln Val Ala Tyr Thr Leu Asp Lys
                  50                  55                  60
              Ser Lys Glu Ile Cys Asp Lys Cys Asp Val Pro Ile Ala Val Ile Pro
              65                  70                  75                  80
              Met Met Asp Tyr Gly Met Leu Asp Gly Lys Lys Val Leu Asp Leu Ala
                              85                  90                  95
              Leu Ser Leu Ile Ser Gly
                          100
              <210> 14
              <211> 144
              <212> PRT
                                                  Page 20

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 14
              Met Lys Ile Val Leu Val Gly His Gly His Phe Ala Thr Gly Ile Tyr
              1               5                   10                  15
              Ser Ser Leu Gln Leu Ile Ala Gly Asn Gln Glu Asn Val Glu Ala Ile
                          20                  25                  30
<removed-apn>
              Asp Phe Val Glu Gly Met Ser Ala Asp Glu Leu Lys Gln Lys Ile Leu
                      35                  40                  45
              Leu Ala Ile Ser Asn Glu Glu Glu Val Leu Ile Leu Ser Asp Leu Leu
                  50                  55                  60
              Gly Gly Ser Pro Phe Lys Val Ser Ser Thr Ile Met Gly Glu Asn Pro
              65                  70                  75                  80
              Ala Lys Thr Met Asn Val Leu Ser Gly Leu Asn Leu Ala Met Leu Met
                              85                  90                  95
              Glu Ala Val Phe Ala Arg Met Ala His Ser Phe Asp Glu Val Val Asn
                          100                 105                 110
              Lys Ser Val Val Ala Ala Gln Gly Gly Val Val Asn Gly Lys Glu Leu
                      115                 120                 125
              Phe Ser Thr Asp Ala Glu Glu Glu Glu Glu Asp Phe Glu Ser Gly Ile
                  130                 135                 140
              <210>   15
              <211>   481
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 15
              Met Ser Arg Arg Phe Lys Lys Ser Arg Ser Gln Lys Val Lys Arg Ser
              1               5                   10                  15
              Val Asn Ile Val Leu Leu Thr Ile Tyr Leu Leu Leu Val Cys Phe Leu
                          20                  25                  30
                                                  Page 21

              Leu Phe Leu Ile Phe Lys Tyr Asn Ile Leu Ala Phe Arg Tyr Leu Asn
<removed-date>
                      35                  40                  45
              Leu Val Val Thr Ala Leu Val Leu Leu Val Ala Leu Val Gly Leu Leu
                  50                  55                  60
              Leu Ile Ile Tyr Lys Lys Ala Glu Lys Phe Thr Ile Phe Leu Leu Val
              65                  70                  75                  80
<removed-apn>
              Phe Ser Ile Leu Val Ser Ser Val Ser Leu Phe Ala Val Gln Gln Phe
                              85                  90                  95
              Val Gly Leu Thr Asn Arg Leu Asn Ala Thr Ser Asn Tyr Ser Glu Tyr
                          100                 105                 110
              Ser Ile Ser Val Ala Val Leu Ala Asp Ser Glu Ile Glu Asn Val Thr
                      115                 120                 125
              Gln Leu Thr Ser Val Thr Ala Pro Thr Gly Thr Asn Asn Glu Asn Ile
                  130                 135                 140
              Gln Lys Leu Leu Ala Asp Ile Lys Ser Ser Gln Asn Thr Asp Leu Thr
              145                 150                 155                 160
              Val Asn Gln Ser Ser Ser Tyr Leu Ala Ala Tyr Lys Ser Leu Ile Ala
                              165                 170                 175
              Gly Glu Thr Lys Ala Ile Val Leu Asn Ser Val Phe Glu Asn Ile Ile
                          180                 185                 190
              Glu Ser Glu Tyr Pro Asp Tyr Ala Ser Lys Ile Lys Lys Ile Tyr Thr
                      195                 200                 205
              Lys Gly Phe Thr Lys Lys Val Glu Ala Pro Lys Thr Ser Lys Ser Gln
                  210                 215                 220
              Ser Phe Asn Ile Tyr Val Ser Gly Ile Asp Thr Tyr Gly Pro Ile Ser
              225                 230                 235                 240
              Ser Val Ser Arg Ser Asp Val Asn Ile Leu Met Thr Val Asn Arg Asp
                                                  Page 22

                              245                 250                 255
<removed-date>
              Thr Lys Lys Ile Leu Leu Thr Thr Thr Pro Arg Asp Ala Tyr Val Pro
                          260                 265                 270
              Ile Ala Asp Gly Gly Asn Asn Gln Lys Asp Lys Leu Thr His Ala Gly
                      275                 280                 285
<removed-apn>
              Ile Tyr Gly Val Asp Ser Ser Ile His Thr Leu Glu Asn Leu Tyr Gly
                  290                 295                 300
              Val Asp Ile Asn Tyr Tyr Val Arg Leu Asn Phe Thr Ser Phe Leu Lys
              305                 310                 315                 320
              Leu Ile Asp Leu Leu Gly Gly Ile Asp Val Tyr Asn Asp Gln Glu Phe
                              325                 330                 335
              Thr Ala His Thr Asn Gly Lys Tyr Tyr Pro Ala Gly Asn Val His Leu
                          340                 345                 350
              Asp Ser Glu Gln Ala Leu Gly Phe Val Arg Glu Arg Tyr Ser Leu Ala
                      355                 360                 365
              Asp Gly Asp Arg Asp Arg Gly Arg His Gln Gln Lys Val Ile Val Ala
                  370                 375                 380
              Ile Leu Gln Lys Leu Thr Ser Thr Glu Val Leu Lys Asn Tyr Ser Thr
              385                 390                 395                 400
              Ile Ile Asn Ser Leu Gln Asp Ser Ile Gln Thr Asn Met Pro Leu Glu
                              405                 410                 415
              Thr Met Ile Asn Leu Val Asn Ala Gln Leu Glu Ser Gly Gly Asn Tyr
                          420                 425                 430
              Lys Val Asn Ser Gln Asp Leu Lys Gly Thr Gly Arg Met Asp Leu Pro
                      435                 440                 445
              Ser Tyr Ala Met Pro Asp Ser Asn Leu Tyr Val Met Glu Ile Asp Asp
                  450                 455                 460
                                                  Page 23

<removed-date>
              Ser Ser Leu Ala Val Val Lys Ala Ala Ile Gln Asp Val Met Glu Gly
              465                 470                 475                 480
              Arg
              <210>   16
<removed-apn>
              <211>   204
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 16
              Met Asn Ser Phe Lys Asn Phe Leu Lys Glu Trp Gly Leu Phe Leu Leu
              1               5                   10                  15
              Ile Leu Ser Leu Leu Ala Leu Ser Arg Ile Phe Phe Trp Ser Asn Val
                          20                  25                  30
              Arg Val Glu Gly His Ser Met Asp Pro Thr Leu Ala Asp Gly Glu Ile
                      35                  40                  45
              Leu Phe Val Val Lys His Leu Pro Ile Asp Arg Phe Asp Ile Val Val
                  50                  55                  60
              Ala His Glu Glu Asp Gly Asn Lys Asp Ile Val Lys Arg Val Ile Gly
              65                  70                  75                  80
              Met Pro Gly Asp Thr Ile Arg Tyr Glu Asn Asp Lys Leu Tyr Ile Asn
                              85                  90                  95
              Asp Lys Glu Thr Asp Glu Pro Tyr Leu Ala Asp Tyr Ile Lys Arg Phe
                          100                 105                 110
              Lys Asp Asp Lys Leu Gln Ser Thr Tyr Ser Gly Lys Gly Phe Glu Gly
                      115                 120                 125
              Asn Lys Gly Thr Phe Phe Arg Ser Ile Ala Gln Lys Ala Gln Ala Phe
                  130                 135                 140
              Thr Val Asp Val Asn Tyr Asn Thr Asn Phe Ser Phe Thr Val Pro Glu
                                                  Page 24

              145                   150               155                 160
<removed-date>
              Gly Glu Tyr Leu Leu Leu Gly Asp Asp Arg Leu Val Ser Ser Asp Ser
                              165                 170                 175
              Arg His Val Gly Thr Phe Lys Ala Lys Asp Ile Thr Gly Glu Ala Lys
                          180                 185                 190
<removed-apn>
              Phe Arg Leu Trp Pro Ile Thr Arg Ile Gly Thr Phe
                      195                 200
              <210>   17
              <211>   521
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 17
              Met Arg Lys Ile Tyr Leu Ser Ile Phe Thr Ser Leu Leu Leu Met Leu
              1               5                   10                  15
              Gly Leu Val Asn Val Ala Gln Ala Asp Glu Tyr Leu Arg Ile Gly Met
                          20                  25                  30
              Glu Ala Ala Tyr Ala Pro Phe Asn Trp Thr Gln Asp Asp Asp Ser Asn
                      35                  40                  45
              Gly Ala Val Lys Ile Asp Gly Thr Asn Gln Tyr Ala Asn Gly Tyr Asp
                  50                  55                  60
              Val Gln Ile Ala Lys Lys Ile Ala Lys Asp Leu Gly Lys Glu Pro Leu
              65                  70                  75                  80
              Val Val Lys Thr Lys Trp Glu Gly Leu Val Pro Ala Leu Thr Ser Gly
                              85                  90                  95
              Lys Ile Asp Met Ile Ile Ala Gly Met Ser Pro Thr Ala Glu Arg Lys
                          100                 105                 110
              Gln Glu Ile Ala Phe Ser Ser Ser Tyr Tyr Thr Ser Glu Pro Val Leu
                      115                 120                 125
                                                  Page 25

              Leu Val Lys Lys Asp Ser Ala Tyr Ala Ser Ala Lys Ser Leu Asp Asp
<removed-date>
                  130                 135                 140
              Phe Asn Gly Ala Lys Ile Thr Ser Gln Gln Gly Val Tyr Leu Tyr Asn
              145                 150                 155                 160
              Leu Ile Ala Gln Ile Pro Gly Ala Lys Lys Glu Thr Ala Met Gly Asp
                              165                 170                 175
<removed-apn>
              Phe Ala Gln Met Arg Gln Ala Leu Glu Ala Gly Val Ile Asp Ala Tyr
                          180                 185                 190
              Val Ser Glu Arg Pro Glu Ala Leu Thr Ala Glu Ala Ala Asn Ser Lys
                      195                 200                 205
              Phe Lys Met Ile Gln Val Glu Pro Gly Phe Lys Thr Gly Glu Glu Asp
                  210                 215                 220
              Thr Ala Ile Ala Ile Gly Leu Arg Lys Asn Asp Asn Arg Ile Ser Gln
              225                 230                 235                 240
              Ile Asn Ala Ser Ile Glu Thr Ile Ser Lys Asp Asp Gln Val Ala Leu
                              245                 250                 255
              Met Asp Arg Met Ile Lys Glu Gln Pro Ala Glu Ala Thr Thr Thr Glu
                          260                 265                 270
              Glu Thr Ser Ser Ser Phe Phe Ser Gln Val Ala Lys Ile Leu Ser Glu
                      275                 280                 285
              Asn Trp Gln Gln Leu Leu Arg Gly Ala Gly Ile Thr Leu Leu Ile Ser
                  290                 295                 300
              Ile Val Gly Thr Ile Ile Gly Leu Ile Ile Gly Leu Ala Ile Gly Val
              305                 310                 315                 320
              Phe Arg Thr Ala Pro Leu Ser Glu Asn Lys Val Ile Tyr Gly Leu Gln
                              325                 330                 335
              Lys Leu Val Gly Trp Val Leu Asn Val Tyr Ile Glu Ile Phe Arg Gly
                                                  Page 26

                            340                  345              350
<removed-date>
              Thr Pro Met Ile Val Gln Ser Met Val Ile Tyr Tyr Gly Thr Ala Gln
                      355                 360                 365
              Ala Phe Gly Ile Asn Leu Asp Arg Thr Leu Ala Ala Ile Phe Ile Val
                  370                 375                 380
<removed-apn>
              Ser Ile Asn Thr Gly Ala Tyr Met Thr Glu Ile Val Arg Gly Gly Ile
              385                 390                 395                 400
              Leu Ala Val Asp Lys Gly Gln Phe Glu Ala Ala Thr Ala Leu Gly Met
                              405                 410                 415
              Thr His Asn Gln Thr Met Arg Lys Ile Val Leu Pro Gln Val Val Arg
                          420                 425                 430
              Asn Ile Leu Pro Ala Thr Gly Asn Glu Phe Val Ile Asn Ile Lys Asp
                      435                 440                 445
              Thr Ser Val Leu Asn Val Ile Ser Val Val Glu Leu Tyr Phe Ser Gly
                  450                 455                 460
              Asn Thr Val Ala Thr Gln Thr Tyr Gln Tyr Phe Gln Thr Phe Thr Ile
              465                 470                 475                 480
              Ile Ala Val Ile Tyr Phe Val Leu Thr Phe Thr Val Thr Arg Ile Leu
                              485                 490                 495
              Arg Phe Ile Glu Arg Arg Met Asp Met Asp Thr Tyr Thr Thr Gly Ala
                          500                 505                 510
              Asn Gln Met Gln Thr Glu Asp Leu Lys
                      515                 520
              <210>   18
              <211>   131
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 18
                                                       Page 27

              Met Ser Lys Lys Leu Asn Arg Lys Lys Gln Leu Arg Asn Gly Leu Arg
<removed-date>
              1               5                   10                  15
              Arg Ala Gly Ala Phe Ser Ser Thr Val Thr Lys Val Val Asp Glu Thr
                          20                  25                  30
              Lys Lys Val Val Lys Arg Ala Glu Gln Ser Ala Ser Ala Ala Gly Lys
                      35                  40                  45
<removed-apn>
              Ala Val Ser Lys Lys Val Glu Gln Ala Val Glu Ala Thr Lys Glu Gln
                  50                  55                  60
              Ala Gln Lys Val Ala Asn Ser Val Glu Asp Phe Ala Ala Asn Leu Gly
              65                  70                  75                  80
              Gly Leu Pro Leu Asp Arg Ala Lys Thr Phe Tyr Asp Glu Gly Ile Lys
                              85                  90                  95
              Ser Ala Ser Asp Phe Lys Asn Trp Thr Glu Lys Glu Leu Leu Ala Leu
                          100                 105                 110
              Lys Gly Ile Gly Pro Ala Thr Ile Lys Lys Leu Lys Glu Asn Gly Ile
                      115                 120                 125
              Lys Phe Lys
                  130
              <210>   19
              <211>   333
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 19
              Met Ile Lys Thr Phe Leu Ser Ala Leu Ser Val Ile Leu Phe Ser Ile
              1               5                   10                  15
              Pro Ile Ile Thr Tyr Ser Phe Phe Pro Ser Ser Asn Leu Asn Ile Trp
                          20                  25                  30
              Leu Ser Thr Gln Pro Ile Leu Ala Gln Ile Tyr Ala Phe Pro Leu Ala
                      35                  40                  45
                                                  Page 28

<removed-date>
              Thr Ala Thr Met Ala Ala Ile Leu Ser Phe Leu Phe Phe Phe Leu Ser
                  50                  55                  60
              Phe Tyr Lys Lys Asn Lys Gln Ile Arg Phe Tyr Ser Gly Ile Leu Leu
              65                  70                  75                  80
              Leu Leu Ser Leu Ile Leu Leu Leu Phe Gly Thr Asp Lys Thr Leu Ser
                              85                  90                  95
<removed-apn>
              Ser Ala Ser Asn Lys Thr Lys Thr Leu Lys Leu Val Thr Trp Asn Val
                          100                 105                 110
              Ala Asn Gln Ile Glu Ala Gln His Ile Glu Arg Ile Phe Ser His Phe
                      115                 120                 125
              Asp Ala Asp Met Ala Ile Phe Pro Glu Leu Ala Thr Asn Ile Arg Gly
                  130                 135                 140
              Glu Gln Glu Asn Gln Arg Ile Lys Leu Leu Phe His Gln Val Gly Leu
              145                 150                 155                 160
              Ser Met Ala Asn Tyr Asp Ile Phe Thr Ser Pro Pro Thr Asn Ser Gly
                              165                 170                 175
              Ile Ala Pro Val Thr Val Ile Val Lys Lys Ser Tyr Gly Phe Tyr Thr
                          180                 185                 190
              Glu Ala Lys Thr Phe His Thr Thr Arg Phe Gly Thr Ile Val Leu His
                      195                 200                 205
              Ser Arg Lys Gln Asn Ile Pro Asp Ile Ile Ala Leu His Thr Ala Pro
                  210                 215                 220
              Pro Leu Pro Gly Leu Met Glu Ile Trp Lys Gln Asp Leu Asn Ile Ile
              225                 230                 235                 240
              His Asn Gln Leu Ala Ser Lys Tyr Pro Lys Ala Ile Ile Ala Gly Asp
                              245                 250                 255
                                                  Page 29

              Phe Asn Ala Thr Met Arg His Gly Ala Leu Ala Lys Ile Ser Ser His
<removed-date>
                          260                 265                 270
              Arg Asp Ala Leu Asn Ala Leu Pro Pro Phe Glu Arg Gly Thr Trp Asn
                      275                 280                 285
              Ser Gln Ser Pro Lys Leu Phe Asn Ala Thr Ile Asp His Ile Leu Leu
                  290                 295                 300
<removed-apn>
              Pro Lys Asn His Tyr Tyr Val Lys Asp Leu Asp Ile Val Ser Phe Gln
              305                 310                 315                 320
              Asn Ser Asp His Arg Cys Ile Phe Thr Glu Ile Thr Phe
                              325                 330
              <210>   20
              <211>   205
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 20
              Met Gly Trp Trp Arg Glu Thr Ile Asp Ile Val Lys Glu Asn Asp Pro
              1               5                   10                  15
              Ala Ala Arg Thr Thr Leu Glu Val Leu Leu Thr Tyr Pro Gly Val Lys
                          20                  25                  30
              Ala Leu Ala Ala His Arg Leu Ser His Phe Leu Trp Lys His Gly Phe
                      35                  40                  45
              Lys Leu Leu Ala Arg Met Tyr Ser Gln Phe Trp Arg Phe Trp Thr Gln
                  50                  55                  60
              Ile Glu Ile His Pro Gly Ala Gln Ile Asp Ser Gly Val Phe Ile Asp
              65                  70                  75                  80
              His Gly Ser Gly Leu Val Ile Gly Glu Thr Ala Ile Val Glu Lys Gly
                              85                  90                  95
              Val Leu Leu Tyr His Gly Val Thr Leu Gly Gly Thr Gly Lys Asp Cys
                          100                 105                 110
                                                  Page 30

<removed-date>
              Gly Lys Arg His Pro Thr Val Arg Lys Gly Ala Leu Ile Ser Ala His
                      115                 120                 125
              Ala Gln Val Ile Gly Pro Val Glu Ile Gly Glu Asn Ala Lys Val Gly
                  130                 135                 140
              Ala Ala Ala Val Val Val Ala Asp Val Pro Ser Asp Val Thr Val Val
              145                 150                 155                 160
<removed-apn>
              Gly Ile Pro Ala Lys Ile Val Arg Leu His Gly Lys Lys Asp Glu Pro
                              165                 170                 175
              Val Ile His Glu Val Glu Glu Lys Arg Glu Tyr Tyr Val Asn Lys Leu
                          180                 185                 190
              Glu Gln Ala Lys Asp Ala Ser His Arg Ser Ser Gly Leu
                      195                 200                 205
              <210>   21
              <211>   459
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 21
              Met Leu His Asn Ala Phe Ala Tyr Val Thr Arg Lys Phe Phe Lys Ser
              1               5                   10                  15
              Ile Val Ile Phe Leu Ile Ile Leu Leu Met Ala Ser Leu Ser Leu Val
                          20                  25                  30
              Gly Leu Ser Ile Lys Gly Ala Thr Ala Lys Ala Ser Gln Glu Thr Phe
                      35                  40                  45
              Lys Asn Ile Thr Asn Ser Phe Ser Met Gln Ile Asn Arg Arg Val Asn
                  50                  55                  60
              Gln Gly Thr Pro Arg Gly Ala Gly Asn Ile Lys Gly Glu Asp Ile Lys
              65                  70                  75                  80
              Lys Ile Thr Glu Asn Lys Ala Ile Glu Ser Tyr Val Lys Arg Ile Asn
                              85                  90                  95
                                                  Page 31

<removed-date>
              Ala Ile Gly Asp Leu Thr Gly Tyr Asp Leu Ile Glu Thr Pro Glu Thr
                          100                 105                 110
              Lys Lys Asn Leu Thr Ala Asp Arg Ala Lys Arg Phe Gly Ser Ser Leu
                      115                 120                 125
              Met Ile Thr Gly Val Asn Asp Ser Ser Lys Glu Asp Lys Phe Val Ser
<removed-apn>
                  130                 135                 140
              Gly Ser Tyr Lys Leu Val Glu Gly Glu His Leu Thr Asn Asp Asp Lys
              145                 150                 155                 160
              Asp Lys Ile Leu Leu His Lys Asp Leu Ala Ala Lys His Gly Trp Lys
                              165                 170                 175
              Val Gly Asp Lys Val Lys Leu Asp Ser Asn Ile Tyr Asp Ala Asp Asn
                          180                 185                 190
              Glu Lys Gly Ala Lys Glu Thr Val Glu Val Thr Ile Lys Gly Leu Phe
                      195                 200                 205
              Asp Gly His Asn Lys Ser Ala Val Thr Tyr Ser Gln Glu Leu Tyr Glu
                  210                 215                 220
              Asn Thr Ala Ile Thr Asp Ile His Thr Ala Ala Lys Leu Tyr Gly Tyr
              225                 230                 235                 240
              Thr Glu Asp Thr Ala Ile Tyr Gly Asp Ala Thr Phe Phe Val Thr Ala
                              245                 250                 255
              Asp Lys Asn Leu Asp Asp Val Met Lys Glu Leu Asn Gly Ile Ser Gly
                          260                 265                 270
              Ile Asn Trp Lys Ser Tyr Thr Leu Val Lys Ser Ser Ser Asn Tyr Pro
                      275                 280                 285
              Ala Leu Glu Gln Ser Ile Ser Gly Met Tyr Lys Met Ala Asn Leu Leu
                  290                 295                 300
                                                  Page 32

<removed-date>
              Phe Trp Gly Ser Leu Ser Phe Ser Val Leu Leu Leu Ala Leu Leu Leu
              305                 310                 315                 320
              Ser Leu Trp Ile Asn Ala Arg Arg Lys Glu Val Gly Ile Leu Leu Ser
                              325                 330                 335
              Ile Gly Leu Lys Gln Ala Ser Ile Leu Gly Gln Phe Ile Thr Glu Ser
                          340                 345                 350
<removed-apn>
              Ile Leu Ile Ala Ile Pro Ala Leu Val Ser Ala Tyr Phe Leu Ala Asn
                      355                 360                 365
              Tyr Thr Ala Arg Ala Ile Gly Asn Thr Val Leu Ala Asn Val Thr Ser
                  370                 375                 380
              Gly Val Ala Lys Gln Ala Ser Lys Ala Ala Gln Ala Ser Asn Leu Gly
              385                 390                 395                 400
              Gly Gly Ala Glu Val Asp Gly Phe Ser Lys Thr Leu Ser Ser Leu Asp
                              405                 410                 415
              Ile Ser Ile Gln Thr Ser Asp Phe Ile Ile Ile Phe Val Leu Ala Leu
                          420                 425                 430
              Val Leu Val Val Leu Val Met Ala Leu Ala Ser Ser Asn Leu Leu Arg
                      435                 440                 445
              Lys Gln Pro Lys Glu Leu Leu Leu Asp Gly Glu
                  450                 455
              <210>   22
              <211>   442
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 22
              Met Lys Arg Thr Gly Leu Phe Ala Lys Ile Phe Ile Tyr Thr Phe Ser
              1               5                   10                  15
              Ile Phe Ser Val Leu Val Ile Cys Leu His Leu Ala Ile Tyr Phe Leu
                          20                  25                  30
                                                  Page 33

<removed-date>
              Phe Pro Ser Thr Tyr Leu Ser His Arg Gln Glu Thr Ile Gly Gln Lys
                      35                  40                  45
              Ala Thr Ala Ile Ala Gln Ser Leu Glu Gly Lys Asp Arg Gln Ser Ile
                  50                  55                  60
              Glu Gln Val Leu Asp Leu Tyr Ser Gln Thr Ser Asp Ile Lys Gly Thr
<removed-apn>
              65                  70                  75                  80
              Val Lys Gly Glu Met Thr Glu Asp Lys Leu Glu Val Lys Asp Ser Leu
                              85                  90                  95
              Pro Leu Asp Thr Asp Arg Gln Thr Thr Ser Leu Phe Ile Glu Glu Arg
                          100                 105                 110
              Glu Val Lys Thr Gln Asp Gly Gly Thr Met Ile Leu Gln Phe Leu Ala
                      115                 120                 125
              Ser Met Asp Leu Gln Lys Glu Ala Glu Gln Ile Ser Leu Gln Phe Leu
                  130                 135                 140
              Pro Tyr Thr Leu Leu Ala Ser Phe Leu Ile Ser Leu Leu Val Ala Tyr
              145                 150                 155                 160
              Ile Tyr Ala Arg Thr Ile Val Ala Pro Ile Leu Glu Ile Lys Arg Val
                              165                 170                 175
              Thr Arg Arg Met Met Asp Leu Asp Ser Gln Val Arg Leu Arg Val Asp
                          180                 185                 190
              Ser Lys Asp Glu Ile Gly Asn Leu Lys Glu Gln Ile Asn Ser Leu Tyr
                      195                 200                 205
              Gln His Leu Leu Thr Val Ile Ala Asp Leu His Glu Lys Asn Glu Ala
                  210                 215                 220
              Ile Leu Gln Leu Glu Lys Met Lys Val Glu Phe Leu Arg Gly Ala Ser
              225                 230                 235                 240
                                                  Page 34

<removed-date>
              His Glu Leu Lys Thr Pro Leu Ala Ser Leu Lys Ile Leu Ile Glu Asn
                              245                 250                 255
              Met Arg Glu Asn Ile Gly Arg Tyr Lys Asp Arg Asp Gln Tyr Leu Gly
                          260                 265                 270
              Val Ala Leu Gly Ile Val Asp Glu Leu Asn His His Val Leu Gln Ile
                      275                 280                 285
<removed-apn>
              Leu Ser Leu Ser Ser Val Gln Glu Leu Arg Asp Asp Arg Glu Thr Ile
                  290                 295                 300
              Asp Leu Leu Gln Met Thr Gln Asn Leu Val Lys Asp Tyr Ala Leu Leu
              305                 310                 315                 320
              Ala Lys Glu Arg Glu Leu Gln Ile Asp Asn Ser Leu Thr His Gln Gln
                              325                 330                 335
              Ala Tyr Leu Asn Pro Ser Val Met Lys Leu Ile Leu Ser Asn Leu Ile
                          340                 345                 350
              Ser Asn Ala Ile Lys His Ser Val Pro Gly Gly Leu Val Arg Ile Gly
                      355                 360                 365
              Glu Arg Glu Gly Glu Leu Phe Ile Glu Asn Ser Cys Ser Ser Glu Glu
                  370                 375                 380
              Gln Glu Lys Leu Ala Gln Ser Phe Ser Asp Asn Ala Ser Arg Lys Val
              385                 390                 395                 400
              Lys Gly Ser Gly Met Gly Leu Phe Val Val Lys Ser Leu Leu Glu His
                              405                 410                 415
              Glu Lys Leu Ala Tyr Arg Phe Glu Met Glu Glu Asn Ser Leu Thr Phe
                          420                 425                 430
              Phe Ile Asp Phe Pro Lys Val Val Gln Asp
                      435                 440
                                                  Page 35

              <210>   23
<removed-date>
              <211>   240
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 23
              Met Leu Glu Arg Trp Arg Asp Met Arg Trp Leu Phe Arg Leu Ile Gly
              1               5                   10                  15
              Ala Phe Phe Ser Phe Val Trp Arg Leu Phe Trp Arg Leu Val Trp Ile
<removed-apn>
                          20                  25                  30
              Val Val Leu Leu Cys Val Leu Ala Phe Gly Leu Leu Trp Tyr Leu Asn
                      35                  40                  45
              Gly Asp Phe Gln Gly Ala Leu Lys Gln Ala Glu Arg Ser Val Lys Ile
                  50                  55                  60
              Gly Gln Gln Ser Ile Asp Gln Trp Glu Lys Thr Gly Gln Leu Pro Lys
              65                  70                  75                  80
              Leu Ser Gln Thr Asp Ser His Gln His Ser Glu Gly Arg Trp Ala Gln
                              85                  90                  95
              Ala Ser Ala Arg Ile Tyr Leu Asp Pro Gln Met Asp Ser Arg Phe Gln
                          100                 105                 110
              Glu Ala Tyr Leu Glu Ala Ile Gln Asn Trp Asn Gln Thr Gly Ala Phe
                      115                 120                 125
              Asn Phe Glu Leu Val Thr Glu Ser Ser Lys Ala Asp Ile Thr Ala Thr
                  130                 135                 140
              Glu Met Asn Asp Gly Gly Thr Pro Val Ala Gly Glu Ala Glu Ser Gln
              145                 150                 155                 160
              Thr Asn Leu Leu Thr Gly Gln Phe Leu Ser Val Thr Val Arg Leu Asn
                              165                 170                 175
              His Tyr Tyr Leu Ser Asn Pro Tyr Tyr Gly Tyr Ser Tyr Glu Arg Leu
                          180                 185                 190
                                                  Page 36

<removed-date>
              Val His Thr Ala Glu His Glu Leu Gly His Ala Ile Gly Leu Asp His
                      195                 200                 205
              Thr Asp Glu Lys Ser Val Met Gln Pro Ala Gly Ser Phe Tyr Gly Ile
                  210                 215                 220
              Gln Glu Glu Asp Val Ala Asn Leu Arg Lys Ile Tyr Glu Thr Ser Glu
              225                 230                 235                 240
<removed-apn>
              <210>   24
              <211>   266
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 24
              Met Lys Lys Phe Ser Leu Leu Leu Ala Ile Leu Pro Phe Leu Val Ala
              1               5                   10                  15
              Cys Glu Asn Gln Ala Thr Pro Lys Glu Thr Ser Ala Gln Lys Thr Ile
                          20                  25                  30
              Val Leu Ala Thr Ala Gly Asp Val Pro Pro Phe Asp Tyr Glu Asp Lys
                      35                  40                  45
              Gly Asn Leu Thr Gly Phe Asp Ile Glu Val Leu Lys Ala Val Asp Glu
                  50                  55                  60
              Lys Leu Ser Asp Tyr Glu Ile Gln Phe Gln Arg Thr Ala Trp Glu Ser
              65                  70                  75                  80
              Ile Phe Pro Gly Leu Asp Ser Gly His Tyr Gln Ala Ala Ala Asn Asn
                              85                  90                  95
              Leu Ser Tyr Thr Lys Glu Arg Ala Glu Lys Tyr Leu Tyr Ser Leu Pro
                          100                 105                 110
              Ile Ser Asn Asn Pro Leu Val Leu Val Ser Asn Lys Lys Asn Pro Leu
                      115                 120                 125
              Thr Ser Leu Asp Gln Ile Ala Gly Lys Thr Thr Gln Glu Asp Thr Gly
                  130                 135                 140
                                                  Page 37

<removed-date>
              Thr Ser Asn Ala Gln Phe Ile Asn Asn Trp Asn Gln Lys His Thr Asp
              145                 150                 155                 160
              Asn Pro Ala Thr Ile Asn Phe Ser Gly Glu Asp Ile Gly Lys Arg Ile
                              165                 170                 175
              Leu Asp Leu Ala Asn Gly Glu Phe Asp Phe Leu Val Phe Asp Lys Val
<removed-apn>
                          180                 185                 190
              Ser Val Gln Lys Ile Ile Lys Asp Arg Gly Leu Asp Leu Ser Val Val
                      195                 200                 205
              Asp Leu Pro Ser Ala Asp Ser Pro Ser Asn Tyr Ile Ile Phe Ser Ser
                  210                 215                 220
              Asp Gln Lys Glu Phe Lys Glu Gln Phe Asp Lys Ala Leu Lys Glu Leu
              225                 230                 235                 240
              Tyr Gln Asp Gly Thr Leu Glu Lys Leu Ser Asn Thr Tyr Leu Gly Gly
                              245                 250                 255
              Ser Tyr Leu Pro Asp Gln Ser Gln Leu Gln
                          260                 265
              <210>   25
              <211>   238
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 25
              Met Lys Lys Arg Tyr Leu Val Leu Thr Ala Leu Leu Ala Leu Ser Leu
              1               5                   10                  15
              Ala Ala Cys Ser Gln Glu Lys Thr Lys Asn Glu Asp Gly Glu Thr Lys
                          20                  25                  30
              Thr Glu Gln Thr Ala Lys Ala Asp Gly Thr Val Gly Ser Lys Ser Gln
                      35                  40                  45
              Gly Ala Ala Gln Lys Lys Ala Glu Val Val Asn Lys Gly Asp Tyr Tyr
                                                  Page 38

                  50                     55                 60
<removed-date>
              Ser Ile Gln Gly Lys Tyr Asp Glu Ile Ile Val Ala Asn Lys His Tyr
              65                  70                  75                  80
              Pro Leu Ser Lys Asp Tyr Asn Pro Gly Glu Asn Pro Thr Ala Lys Ala
                              85                  90                  95
<removed-apn>
              Glu Leu Val Lys Leu Ile Lys Ala Met Gln Glu Ala Gly Phe Pro Ile
                          100                 105                 110
              Ser Asp His Tyr Ser Gly Phe Arg Ser Tyr Glu Thr Gln Thr Lys Leu
                      115                 120                 125
              Tyr Gln Asp Tyr Val Asn Gln Asp Gly Lys Ala Ala Ala Asp Arg Tyr
                  130                 135                 140
              Ser Ala Arg Pro Gly Tyr Ser Glu His Gln Thr Gly Leu Ala Phe Asp
              145                 150                 155                 160
              Val Ile Gly Thr Asp Gly Asp Leu Val Thr Glu Glu Lys Ala Ala Gln
                              165                 170                 175
              Trp Leu Leu Asp His Ala Ala Asp Tyr Gly Phe Val Val Arg Tyr Leu
                          180                 185                 190
              Lys Gly Lys Glu Lys Glu Thr Gly Tyr Met Ala Glu Glu Trp His Leu
                      195                 200                 205
              Arg Tyr Val Gly Lys Glu Ala Lys Glu Ile Ala Ala Ser Gly Leu Ser
                  210                 215                 220
              Leu Glu Glu Tyr Tyr Gly Phe Glu Gly Gly Asp Tyr Val Asp
              225                 230                 235
              <210>    26
              <211>    2233
              <212>    PRT
              <213>    Streptococcus pneumoniae
              <400> 26
                                                  Page 39

              Met Gly Lys Gly His Trp Asn Arg Lys Arg Val Tyr Ser Ile Arg Lys
<removed-date>
              1               5                   10                  15
              Phe Ala Val Gly Ala Cys Ser Val Met Ile Gly Thr Cys Ala Val Leu
                          20                  25                  30
              Leu Gly Gly Asn Ile Ala Gly Glu Ser Val Val Tyr Ala Asp Glu Thr
                      35                  40                  45
<removed-apn>
              Leu Ile Thr His Thr Ala Glu Lys Pro Lys Glu Glu Lys Met Ile Val
                  50                  55                  60
              Glu Glu Lys Ala Asp Lys Ala Leu Glu Thr Lys Asn Ile Val Glu Arg
              65                  70                  75                  80
              Thr Glu Gln Ser Glu Pro Ser Ser Thr Glu Ala Ile Ala Ser Glu Lys
                              85                  90                  95
              Lys Glu Asp Glu Ala Val Thr Pro Lys Glu Glu Lys Val Ser Ala Lys
                          100                 105                 110
              Pro Glu Glu Lys Ala Pro Arg Ile Glu Ser Gln Ala Ser Asn Gln Glu
                      115                 120                 125
              Lys Pro Leu Lys Glu Asp Ala Lys Ala Val Thr Asn Glu Glu Val Asn
                  130                 135                 140
              Gln Met Ile Glu Asp Arg Lys Val Asp Phe Asn Gln Asn Trp Tyr Phe
              145                 150                 155                 160
              Lys Leu Asn Ala Asn Ser Lys Glu Ala Ile Lys Pro Asp Ala Asp Val
                              165                 170                 175
              Ser Thr Trp Lys Lys Leu Asp Leu Pro Tyr Asp Trp Ser Ile Phe Asn
                          180                 185                 190
              Asp Phe Asp His Glu Ser Pro Ala Gln Asn Glu Gly Gly Gln Leu Asn
                      195                 200                 205
              Gly Gly Glu Ala Trp Tyr Arg Lys Thr Phe Lys Leu Asp Glu Lys Asp
                                                  Page 40

                  210                 215                   220
<removed-date>
              Leu Lys Lys Asn Val Arg Leu Thr Phe Asp Gly Val Tyr Met Asp Ser
              225                 230                 235                 240
              Gln Val Tyr Val Asn Gly Gln Leu Val Gly His Tyr Pro Asn Gly Tyr
                              245                 250                 255
<removed-apn>
              Asn Gln Phe Ser Tyr Asp Ile Thr Lys Tyr Leu Gln Lys Asp Gly Arg
                          260                 265                 270
              Glu Asn Val Ile Ala Val His Ala Val Asn Lys Gln Pro Ser Ser Arg
                      275                 280                 285
              Trp Tyr Ser Gly Ser Gly Ile Tyr Arg Asp Val Thr Leu Gln Val Thr
                  290                 295                 300
              Asp Lys Val His Val Glu Lys Asn Gly Thr Thr Ile Leu Thr Pro Lys
              305                 310                 315                 320
              Leu Glu Glu Gln Gln His Gly Lys Val Glu Thr His Val Thr Ser Lys
                              325                 330                 335
              Ile Val Asn Thr Asp Asp Lys Asp His Glu Leu Val Ala Glu Tyr Gln
                          340                 345                 350
              Ile Val Glu Arg Gly Gly His Ala Val Thr Gly Leu Val Arg Thr Ala
                      355                 360                 365
              Ser Arg Thr Leu Lys Ala His Glu Ser Thr Ser Leu Asp Ala Ile Leu
                  370                 375                 380
              Glu Val Glu Arg Pro Lys Leu Trp Thr Val Leu Asn Asp Lys Pro Ala
              385                 390                 395                 400
              Leu Tyr Glu Leu Ile Thr Arg Val Tyr Arg Asp Gly Gln Leu Val Asp
                              405                 410                 415
              Ala Lys Lys Asp Leu Phe Gly Tyr Arg Tyr Tyr His Trp Thr Pro Asn
                          420                 425                 430
                                                  Page 41

<removed-date>
              Glu Gly Phe Ser Leu Asn Gly Glu Arg Ile Lys Phe His Gly Val Ser
                      435                 440                 445
              Leu His His Asp His Gly Ala Leu Gly Ala Glu Glu Asn Tyr Lys Ala
                  450                 455                 460
              Glu Tyr Arg Arg Leu Lys Gln Met Lys Glu Met Gly Val Asn Ser Ile
<removed-apn>
              465                 470                 475                 480
              Arg Thr Thr His Asn Pro Ala Ser Glu Gln Thr Leu Gln Ile Ala Ala
                              485                 490                 495
              Glu Leu Gly Leu Leu Val Gln Glu Glu Ala Phe Asp Thr Trp Tyr Gly
                          500                 505                 510
              Gly Lys Lys Pro Tyr Asp Tyr Gly Arg Phe Phe Glu Lys Asp Ala Thr
                      515                 520                 525
              His Pro Glu Ala Arg Lys Gly Glu Lys Trp Ser Asp Phe Asp Leu Arg
                  530                 535                 540
              Thr Met Val Glu Arg Gly Lys Asn Asn Pro Ala Ile Phe Met Trp Ser
              545                 550                 555                 560
              Ile Gly Asn Glu Ile Gly Glu Ala Asn Gly Asp Ala His Ser Leu Ala
                              565                 570                 575
              Thr Val Lys Arg Leu Val Lys Val Ile Lys Asp Val Asp Lys Thr Arg
                          580                 585                 590
              Tyr Val Thr Met Gly Ala Asp Lys Phe Arg Phe Gly Asn Gly Ser Gly
                      595                 600                 605
              Gly His Glu Lys Ile Ala Asp Glu Leu Asp Ala Val Gly Phe Asn Tyr
                  610                 615                 620
              Ser Glu Asp Asn Tyr Lys Ala Leu Arg Ala Lys His Pro Lys Trp Leu
              625                 630                 635                 640
                                                  Page 42

<removed-date>
              Ile Tyr Gly Ser Glu Thr Ser Ser Ala Thr Arg Thr Arg Gly Ser Tyr
                              645                 650                 655
              Tyr Arg Pro Glu Arg Glu Leu Lys His Ser Asn Gly Pro Glu Arg Asn
                          660                 665                 670
              Tyr Glu Gln Ser Asp Tyr Gly Asn Asp Arg Val Gly Trp Gly Lys Thr
                      675                 680                 685
<removed-apn>
              Ala Thr Ala Ser Trp Thr Phe Asp Arg Asp Asn Ala Gly Tyr Ala Gly
                  690                 695                 700
              Gln Phe Ile Trp Thr Gly Thr Asp Tyr Ile Gly Glu Pro Thr Pro Trp
              705                 710                 715                 720
              His Asn Gln Asn Gln Thr Pro Val Lys Ser Ser Tyr Phe Gly Ile Val
                              725                 730                 735
              Asp Thr Ala Gly Ile Pro Lys His Asp Phe Tyr Leu Tyr Gln Ser Gln
                          740                 745                 750
              Trp Val Ser Val Lys Lys Lys Pro Met Val His Leu Leu Pro His Trp
                      755                 760                 765
              Asn Trp Glu Asn Lys Glu Leu Ala Ser Lys Val Ala Asp Ser Glu Gly
                  770                 775                 780
              Lys Ile Pro Val Arg Ala Tyr Ser Asn Ala Ser Ser Val Glu Leu Phe
              785                 790                 795                 800
              Leu Asn Gly Lys Ser Leu Gly Leu Lys Thr Phe Asn Lys Lys Gln Thr
                              805                 810                 815
              Ser Asp Gly Arg Thr Tyr Gln Glu Gly Ala Asn Ala Asn Glu Leu Tyr
                          820                 825                 830
              Leu Glu Trp Lys Val Ala Tyr Gln Pro Gly Thr Leu Glu Ala Ile Ala
                      835                 840                 845
                                                  Page 43

              Arg Asp Glu Ser Gly Lys Glu Ile Ala Arg Asp Lys Ile Thr Thr Ala
<removed-date>
                  850                 855                 860
              Gly Lys Pro Ala Ala Val Arg Leu Ile Lys Glu Asp His Ala Ile Ala
              865                 870                 875                 880
              Ala Asp Gly Lys Asp Leu Thr Tyr Ile Tyr Tyr Glu Ile Val Asp Ser
                              885                 890                 895
<removed-apn>
              Gln Gly Asn Val Val Pro Thr Ala Asn Asn Leu Val Arg Phe Gln Leu
                          900                 905                 910
              His Gly Gln Gly Gln Leu Val Gly Val Asp Asn Gly Glu Gln Ala Ser
                      915                 920                 925
              Arg Glu Arg Tyr Lys Ala Gln Ala Asp Gly Ser Trp Ile Arg Lys Ala
                  930                 935                 940
              Phe Asn Gly Lys Gly Val Ala Ile Val Lys Ser Thr Glu Gln Ala Gly
              945                 950                 955                 960
              Lys Phe Thr Leu Thr Ala His Ser Asp Leu Leu Lys Ser Asn Gln Val
                              965                 970                 975
              Thr Val Phe Thr Gly Lys Lys Glu Gly Gln Glu Lys Thr Val Leu Gly
                          980                 985                 990
              Thr Glu Val Pro Lys Val Gln Thr Ile Ile Gly Glu Ala Pro Glu Met
                      995                 1000                1005
              Pro Thr Thr Val Pro Phe Val Tyr Ser Asp Gly Ser Arg Ala Glu
                  1010                1015                1020
              Arg Pro Val Thr Trp Ser Ser Val Asp Val Ser Lys Pro Gly Ile
                  1025                1030                1035
              Val Thr Val Lys Gly Met Ala Asp Gly Arg Glu Val Glu Ala Arg
                  1040                1045                1050
              Val Glu   Val Ile Ala Leu Lys   Ser Glu Leu Pro Val   Val Lys Arg
                                                    Page 44

                 1055                1060                 1065
<removed-date>
              Ile Ala Pro Asn Thr Asp Leu Asn Ser Val Asp Lys Ser Val Ser
                  1070                1075                1080
              Tyr Val Leu Ile Asp Gly Ser Val Glu Glu Tyr Glu Val Asp Lys
                  1085                1090                1095
<removed-apn>
              Trp Glu Ile Ala Glu Glu Asp Lys Ala Lys Leu Ala Ile Pro Gly
                  1100                1105                1110
              Ser Arg Ile Gln Ala Thr Gly Tyr Leu Glu Gly Gln Pro Ile His
                  1115                1120                1125
              Ala Thr Leu Val Val Glu Glu Gly Asn Pro Ala Ala Pro Ala Val
                  1130                1135                1140
              Pro Thr Val Thr Val Gly Gly Glu Ala Val Thr Gly Leu Thr Ser
                  1145                1150                1155
              Gln Lys Pro Met Gln Tyr Arg Thr Leu Ala Tyr Gly Ala Lys Leu
                  1160                1165                1170
              Pro Glu Val Thr Ala Ser Ala Lys Asn Ala Ala Val Thr Val Leu
                  1175                1180                1185
              Gln Ala Ser Ala Ala Asn Gly Met Arg Ala Ser Ile Phe Ile Gln
                  1190                1195                1200
              Pro Lys Asp Gly Gly Pro Leu Gln Thr Tyr Ala Ile Gln Phe Leu
                  1205                1210                1215
              Glu Glu Ala Pro Lys Ile Ala His Leu Ser Leu Gln Val Glu Lys
                  1220                1225                1230
              Ala Asp Ser Leu Lys Glu Asp Gln Thr Val Lys Leu Ser Val Arg
                  1235                1240                1245
              Ala His Tyr Gln Asp Gly Thr Gln Ala Val Leu Pro Ala Asp Lys
                  1250                1255                1260
                                                Page 45

<removed-date>
              Val Thr Phe Ser Thr Ser Gly Glu Gly Glu Val Ala Ile Arg Lys
                  1265                1270                1275
              Gly Met Leu Glu Leu His Lys Pro Gly Ala Val Thr Leu Asn Ala
                  1280                1285                1290
              Glu Tyr Glu Gly Ala Lys Asp Gln Val Glu Leu Thr Ile Gln Ala
<removed-apn>
                  1295                1300                1305
              Asn Thr Glu Lys Lys Ile Ala Gln Ser Ile Arg Pro Val Asn Val
                  1310                1315                1320
              Val Thr Asp Leu His Gln Glu Pro Ser Leu Pro Ala Thr Val Thr
                  1325                1330                1335
              Val Glu Tyr Asp Lys Gly Phe Pro Lys Thr His Lys Val Thr Trp
                  1340                1345                1350
              Gln Ala Ile Pro Lys Glu Lys Leu Asp Ser Tyr Gln Thr Phe Glu
                  1355                1360                1365
              Val Leu Gly Lys Val Glu Gly Ile Asp Leu Glu Ala Arg Ala Lys
                  1370                1375                1380
              Val Ser Val Glu Gly Ile Val Ser Val Glu Glu Val Ser Val Thr
                  1385                1390                1395
              Thr Pro Ile Ala Glu Ala Pro Gln Leu Pro Glu Ser Val Arg Thr
                  1400                1405                1410
              Tyr Asp Ser Asn Gly His Val Ser Ser Ala Lys Val Ala Trp Asp
                  1415                1420                1425
              Ala Ile Arg Pro Glu Gln Tyr Ala Lys Glu Gly Val Phe Thr Val
                  1430                1435                1440
              Asn Gly Arg Leu Glu Gly Thr Gln Leu Thr Thr Lys Leu His Val
                  1445                1450                1455
                                                Page 46

<removed-date>
              Arg Val Ser Ala Gln Thr Glu Gln Gly Ala Asn Ile Ser Asp Gln
                  1460                1465                1470
              Trp Thr Gly Ser Glu Leu Pro Leu Ala Phe Ala Ser Asp Ser Asn
                  1475                1480                1485
              Pro Ser Asp Pro Val Ser Asn Val Asn Asp Lys Leu Ile Ser Tyr
                  1490                1495                1500
<removed-apn>
              Asn Asn Gln Pro Ala Asn Arg Trp Thr Asn Trp Asn Arg Thr Asn
                  1505                1510                1515
              Pro Glu Ala Ser Val Gly Val Leu Phe Gly Asp Ser Gly Ile Leu
                  1520                1525                1530
              Ser Lys Arg Ser Val Asp Asn Leu Ser Val Gly Phe His Glu Asp
                  1535                1540                1545
              His Gly Val Gly Val Pro Lys Ser Tyr Val Ile Glu Tyr Tyr Val
                  1550                1555                1560
              Gly Lys Thr Val Pro Thr Ala Pro Lys Asn Pro Ser Phe Val Gly
                  1565                1570                1575
              Asn Glu Asp His Val Phe Asn Asp Ser Ala Asn Trp Lys Pro Val
                  1580                1585                1590
              Thr Asn Leu Lys Ala Pro Ala Gln Leu Lys Ala Gly Glu Met Asn
                  1595                1600                1605
              His Phe Ser Phe Asp Lys Val Glu Thr Tyr Ala Val Arg Ile Arg
                  1610                1615                1620
              Met Val Lys Ala Asp Asn Lys Arg Gly Thr Ser Ile Thr Glu Val
                  1625                1630                1635
              Gln Ile Phe Ala Lys Gln Val Ala Ala Ala Lys Gln Gly Gln Thr
                  1640                1645                1650
                                                Page 47

              Arg Ile Gln Val Asp Gly Lys Asp Leu Ala Asn Phe Asn Pro Asp
<removed-date>
                  1655                1660                1665
              Leu Thr Asp Tyr Tyr Leu Glu Ser Val Asp Gly Lys Val Pro Ala
                  1670                1675                1680
              Val Thr Ala Ser Val Ser Asn Asn Gly Leu Ala Thr Val Val Pro
                  1685                1690                1695
<removed-apn>
              Ser Val Arg Glu Gly Glu Pro Val Arg Val Ile Ala Lys Ala Glu
                  1700                1705                1710
              Asn Gly Asp Ile Leu Gly Glu Tyr Arg Leu His Phe Thr Lys Asp
                  1715                1720                1725
              Lys Ser Leu Leu Ser His Lys Pro Val Ala Ala Val Lys Gln Ala
                  1730                1735                1740
              Arg Leu Leu Gln Val Gly Gln Ala Leu Glu Leu Pro Thr Lys Val
                  1745                1750                1755
              Pro Val Tyr Phe Thr Gly Lys Asp Gly Tyr Glu Thr Lys Asp Leu
                  1760                1765                1770
              Thr Val Glu Trp Glu Glu Val Pro Ala Glu Asn Leu Thr Lys Ala
                  1775                1780                1785
              Gly Gln Phe Thr Val Arg Gly Arg Val Leu Gly Ser Asn Leu Val
                  1790                1795                1800
              Ala Glu Ile Thr Val Arg Val Thr Asp Lys Leu Gly Glu Thr Leu
                  1805                1810                1815
              Ser Asp Asn Pro Asn Tyr Asp Glu Asn Ser Asn Gln Ala Phe Ala
                  1820                1825                1830
              Ser Ala Thr Asn Asp Ile Asp Lys Asn Ser His Asp Arg Val Asp
                  1835                1840                1845
              Tyr Leu   Asn Asp Gly Asp His   Ser Glu Asn Arg Arg   Trp Thr Asn
                                                    Page 48

                 1850                1855                 1860
<removed-date>
              Trp Ser Pro Thr Pro Ser Ser Asn Pro Glu Val Ser Ala Gly Val
                  1865                1870                1875
              Ile Phe Arg Glu Asn Gly Lys Ile Val Glu Arg Thr Val Thr Gln
                  1880                1885                1890
<removed-apn>
              Gly Lys Val Gln Phe Phe Ala Asp Ser Gly Thr Asp Ala Pro Ser
                  1895                1900                1905
              Lys Leu Val Leu Glu Arg Tyr Val Gly Pro Glu Phe Glu Val Pro
                  1910                1915                1920
              Thr Tyr Tyr Ser Asn Tyr Gln Ala Tyr Asp Ala Asp His Pro Phe
                  1925                1930                1935
              Asn Asn Pro Glu Asn Trp Glu Ala Val Pro Tyr Arg Ala Asp Lys
                  1940                1945                1950
              Asp Ile Ala Ala Gly Asp Glu Ile Asn Val Thr Phe Lys Ala Ile
                  1955                1960                1965
              Lys Ala Lys Ala Met Arg Trp Arg Met Glu Arg Lys Ala Asp Lys
                  1970                1975                1980
              Ser Gly Val Ala Met Ile Glu Met Thr Phe Leu Ala Pro Ser Glu
                  1985                1990                1995
              Leu Pro Gln Glu Ser Thr Gln Ser Lys Ile Leu Val Asp Gly Lys
                  2000                2005                2010
              Glu Leu Ala Asp Phe Ala Glu Asn Arg Gln Asp Tyr Gln Ile Thr
                  2015                2020                2025
              Tyr Lys Gly Gln Arg Pro Lys Val Ser Val Glu Glu Asn Asn Gln
                  2030                2035                2040
              Val Ala Ser Thr Val Val Asp Ser Gly Glu Asp Ser Phe Pro Val
                  2045                2050                2055
                                                Page 49

<removed-date>
              Leu Val Arg Leu Val Ser Glu Ser Gly Lys Gln Val Lys Glu Tyr
                  2060                2065                2070
              Arg Ile His Leu Thr Lys Glu Lys Pro Val Ser Glu Lys Thr Val
                  2075                2080                2085
              Ala Ala Val Gln Glu Asp Leu Pro Lys Ile Glu Phe Val Glu Lys
<removed-apn>
                  2090                2095                2100
              Asp Leu Ala Tyr Lys Thr Val Glu Lys Lys Asp Ser Thr Leu Tyr
                  2105                2110                2115
              Leu Gly Glu Thr Arg Val Glu Gln Glu Gly Lys Val Gly Lys Glu
                  2120                2125                2130
              Arg Ile Phe Thr Ala Ile Asn Pro Asp Gly Ser Lys Glu Glu Lys
                  2135                2140                2145
              Leu Arg Glu Val Val Glu Val Pro Thr Asp Arg Ile Val Leu Val
                  2150                2155                2160
              Gly Thr Lys Pro Val Ala Gln Glu Ala Lys Lys Pro Gln Val Ser
                  2165                2170                2175
              Glu Lys Ala Asp Thr Lys Pro Ile Asp Ser Ser Glu Ala Ser Gln
                  2180                2185                2190
              Thr Asn Lys Ala Gln Leu Pro Ser Thr Gly Ser Ala Ala Ser Gln
                  2195                2200                2205
              Ala Ala Val Ala Ala Gly Leu Thr Leu Leu Gly Leu Ser Ala Gly
                  2210                2215                2220
              Leu Val Val Thr Lys Gly Lys Lys Glu Asp
                  2225                2230
              <210> 27
              <211> 188
              <212> PRT
                                                Page 50

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 27
              Met Lys Lys Trp Gln Thr Cys Val Leu Gly Ala Gly Ser Leu Leu Cys
              1               5                   10                  15
              Leu Thr Ala Cys Ser Gly Lys Ser Val Thr Ser Glu His Gln Thr Lys
                          20                  25                  30
<removed-apn>
              Asp Glu Met Lys Thr Glu Gln Thr Ala Ser Lys Thr Ser Ala Ala Lys
                      35                  40                  45
              Gly Lys Glu Val Ala Asp Phe Glu Leu Met Gly Val Asp Gly Lys Thr
                  50                  55                  60
              Tyr Arg Leu Ser Asp Tyr Lys Gly Lys Lys Val Tyr Leu Lys Phe Trp
              65                  70                  75                  80
              Ala Ser Trp Cys Ser Ile Cys Leu Ala Ser Leu Pro Asp Thr Asp Glu
                              85                  90                  95
              Ile Ala Lys Glu Ala Gly Asp Asp Tyr Val Val Leu Thr Val Val Ser
                          100                 105                 110
              Pro Gly His Lys Gly Glu Gln Ser Glu Ala Asp Phe Lys Asn Trp Tyr
                      115                 120                 125
              Lys Gly Leu Asp Tyr Lys Asn Leu Pro Val Leu Val Asp Pro Ser Gly
                  130                 135                 140
              Lys Leu Leu Glu Thr Tyr Gly Val Arg Ser Tyr Pro Thr Gln Ala Phe
              145                 150                 155                 160
              Ile Asp Lys Glu Gly Lys Leu Val Lys Thr His Pro Gly Phe Met Glu
                              165                 170                 175
              Lys Asp Ala Ile Leu Gln Thr Leu Lys Glu Leu Ala
                          180                 185
              <210> 28
              <211> 563
                                                  Page 51

              <212> PRT
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 28
              Met Lys Arg Ser Ser Leu Leu Val Arg Met Val Ile Ser Ile Phe Leu
              1               5                   10                  15
              Val Phe Leu Ile Leu Leu Ala Leu Val Gly Thr Phe Tyr Tyr Gln Ser
                          20                  25                  30
<removed-apn>
              Ser Ser Ser Ala Ile Glu Ala Thr Ile Glu Gly Asn Ser Gln Thr Thr
                      35                  40                  45
              Ile Ser Gln Thr Ser His Phe Ile Gln Ser Tyr Ile Lys Lys Leu Glu
                  50                  55                  60
              Thr Thr Ser Thr Gly Leu Thr Gln Gln Thr Asp Val Leu Ala Tyr Ala
              65                  70                  75                  80
              Glu Asn Pro Ser Gln Asp Lys Val Glu Gly Ile Arg Asp Leu Phe Leu
                              85                  90                  95
              Thr Ile Leu Lys Ser Asp Lys Asp Leu Lys Thr Val Val Leu Val Thr
                          100                 105                 110
              Lys Ser Gly Gln Val Ile Ser Thr Asp Asp Ser Val Gln Met Lys Thr
                      115                 120                 125
              Ser Ser Asp Met Met Ala Glu Asp Trp Tyr Gln Lys Ala Ile His Gln
                  130                 135                 140
              Gly Ala Met Pro Val Leu Thr Pro Ala Arg Lys Ser Asp Ser Gln Trp
              145                 150                 155                 160
              Val Ile Ser Val Thr Gln Glu Leu Val Asp Ala Lys Gly Ala Asn Leu
                              165                 170                 175
              Gly Val Leu Arg Leu Asp Ile Ser Tyr Glu Thr Leu Glu Ala Tyr Leu
                          180                 185                 190
              Asn Gln Leu Gln Leu Gly Gln Gln Gly Phe Ala Phe Ile Ile Asn Glu
                                                  Page 52

                      195                 200                 205
<removed-date>
              Asn His Glu Phe Val Tyr His Pro Gln His Thr Val Tyr Ser Ser Ser
                  210                 215                 220
              Ser Lys Met Glu Ala Met Lys Pro Tyr Ile Asp Thr Gly Gln Gly Tyr
              225                 230                 235                 240
<removed-apn>
              Thr Pro Gly His Lys Ser Tyr Val Ser Gln Glu Lys Ile Ala Gly Thr
                              245                 250                 255
              Asp Trp Thr Val Leu Gly Val Ser Ser Leu Glu Lys Leu Asp Gln Val
                          260                 265                 270
              Arg Ser Gln Leu Leu Trp Thr Leu Leu Gly Ala Ser Val Thr Ser Leu
                      275                 280                 285
              Leu Val Cys Leu Cys Leu Val Trp Phe Ser Leu Lys Arg Trp Ile Ala
                  290                 295                 300
              Pro Leu Lys Asp Leu Arg Glu Thr Met Leu Glu Ile Ala Ser Gly Ala
              305                 310                 315                 320
              Gln Asn Leu Arg Ala Lys Glu Val Gly Ala Tyr Glu Leu Arg Glu Val
                              325                 330                 335
              Thr Arg Gln Phe Asn Ala Met Leu Asp Gln Ile Asp Gln Leu Met Val
                          340                 345                 350
              Ala Ile Arg Ser Gln Glu Glu Thr Thr Arg Gln Tyr Gln Leu Gln Ala
                      355                 360                 365
              Leu Ser Ser Gln Ile Asn Pro His Phe Leu Tyr Asn Thr Leu Asp Thr
                  370                 375                 380
              Ile Ile Trp Met Ala Glu Phe His Asp Ser Gln Arg Val Val Gln Val
              385                 390                 395                 400
              Thr Lys Ser Leu Ala Thr Tyr Phe Arg Leu Ala Leu Asn Gln Gly Lys
                              405                 410                 415
                                                  Page 53

<removed-date>
              Asp Leu Ile Cys Leu Ser Asp Glu Ile Asn His Val Arg Gln Tyr Leu
                          420                 425                 430
              Phe Ile Gln Lys Gln Arg Tyr Gly Asp Lys Leu Glu Tyr Glu Ile Asn
                      435                 440                 445
              Glu Asn Val Ala Phe Asp Asn Leu Val Leu Pro Lys Leu Val Leu Gln
<removed-apn>
                  450                 455                 460
              Pro Leu Val Glu Asn Ala Leu Tyr His Gly Ile Lys Glu Lys Glu Gly
              465                 470                 475                 480
              Gln Gly His Ile Lys Leu Ser Val Gln Lys Gln Asp Ser Gly Leu Val
                              485                 490                 495
              Ile Arg Ile Glu Asp Asp Gly Val Gly Phe Gln Asp Ala Gly Asp Ser
                          500                 505                 510
              Ser Gln Ser Gln Leu Lys Arg Gly Gly Val Gly Leu Gln Asn Val Asp
                      515                 520                 525
              Gln Arg Leu Lys Leu His Phe Gly Ala Asn Tyr His Met Lys Ile Asp
                  530                 535                 540
              Ser Arg Pro Gln Lys Gly Thr Lys Val Glu Ile Tyr Ile Asn Arg Ile
              545                 550                 555                 560
              Glu Thr Ser
              <210>   29
              <211>   1881
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 29
              Met Ala Pro Ser Val Val Asp Ala Ala Thr Tyr His Tyr Val Asn Lys
              1               5                   10                  15
              Glu Ile Ile Ser Gln Glu Ala Lys Asp Leu Ile Gln Thr Gly Lys Pro
                                                  Page 54

                          20                  25                  30
<removed-date>
              Asp Arg Asn Glu Val Val Tyr Gly Leu Val Tyr Gln Lys Asp Gln Leu
                      35                  40                  45
              Pro Gln Thr Gly Thr Glu Ala Ser Val Leu Thr Ala Phe Gly Leu Leu
                  50                  55                  60
<removed-apn>
              Thr Val Gly Ser Leu Leu Leu Ile Tyr Lys Arg Lys Lys Ile Ala Ser
              65                  70                  75                  80
              Val Phe Leu Val Gly Ala Met Gly Leu Val Val Leu Pro Ser Ala Gly
                              85                  90                  95
              Ala Val Asp Pro Val Ala Thr Leu Ala Leu Ala Ser Arg Glu Gly Val
                          100                 105                 110
              Val Glu Met Glu Gly Tyr Arg Tyr Val Gly Tyr Leu Ser Gly Asp Ile
                      115                 120                 125
              Leu Lys Thr Leu Gly Leu Asp Thr Val Leu Glu Glu Thr Ser Ala Lys
                  130                 135                 140
              Pro Gly Glu Val Thr Val Val Glu Val Glu Thr Pro Gln Ser Ile Thr
              145                 150                 155                 160
              Asn Gln Glu Gln Ala Arg Thr Glu Asn Gln Val Val Glu Thr Glu Glu
                              165                 170                 175
              Ala Pro Lys Glu Glu Ala Pro Lys Thr Glu Glu Ser Pro Lys Glu Glu
                          180                 185                 190
              Pro Lys Ser Glu Val Lys Pro Thr Asp Asp Thr Leu Pro Lys Val Glu
                      195                 200                 205
              Glu Gly Lys Glu Asp Ser Ala Glu Pro Ala Pro Val Glu Glu Val Gly
                  210                 215                 220
              Gly Glu Val Glu Ser Lys Pro Glu Glu Lys Val Ala Val Lys Pro Glu
              225                 230                 235                 240
                                                   Page 55

<removed-date>
              Ser Gln Pro Ser Asp Lys Pro Ala Glu Glu Ser Lys Val Glu Gln Ala
                              245                 250                 255
              Gly Glu Pro Val Ala Pro Arg Glu Asp Glu Lys Ala Pro Val Glu Pro
                          260                 265                 270
              Glu Lys Gln Pro Glu Ala Pro Glu Glu Glu Lys Ala Val Glu Glu Thr
<removed-apn>
                      275                 280                 285
              Pro Lys Gln Glu Glu Ser Thr Pro Asp Thr Lys Ala Glu Glu Thr Val
                  290                 295                 300
              Glu Pro Lys Glu Glu Thr Val Asn Gln Ser Ile Glu Gln Pro Lys Val
              305                 310                 315                 320
              Glu Thr Pro Ala Val Glu Lys Gln Thr Glu Pro Thr Glu Glu Pro Lys
                              325                 330                 335
              Val Glu Gln Ala Gly Glu Pro Val Ala Pro Arg Glu Asp Glu Gln Ala
                          340                 345                 350
              Pro Thr Ala Pro Val Glu Pro Glu Lys Gln Pro Glu Val Pro Glu Glu
                      355                 360                 365
              Glu Lys Ala Val Glu Glu Thr Pro Lys Pro Glu Asp Lys Ile Lys Gly
                  370                 375                 380
              Ile Gly Thr Lys Glu Pro Val Asp Lys Ser Glu Leu Asn Asn Gln Ile
              385                 390                 395                 400
              Asp Lys Ala Ser Ser Val Ser Pro Thr Asp Tyr Ser Thr Ala Ser Tyr
                              405                 410                 415
              Asn Ala Leu Gly Pro Val Leu Glu Thr Ala Lys Gly Val Tyr Ala Ser
                          420                 425                 430
              Glu Pro Val Lys Gln Pro Glu Val Asn Ser Glu Thr Asn Lys Leu Lys
                      435                 440                 445
                                                  Page 56

<removed-date>
              Thr Ala Ile Asp Ala Leu Asn Val Asp Lys Thr Glu Leu Asn Asn Thr
                  450                 455                 460
              Ile Ala Asp Ala Lys Thr Lys Val Lys Glu His Tyr Ser Asp Arg Ser
              465                 470                 475                 480
              Trp Gln Asn Leu Gln Thr Glu Val Thr Lys Ala Glu Lys Val Ala Ala
                              485                 490                 495
<removed-apn>
              Asn Thr Asp Ala Lys Gln Ser Glu Val Asn Glu Ala Val Glu Lys Leu
                          500                 505                 510
              Thr Ala Thr Ile Glu Lys Leu Val Glu Leu Ser Glu Lys Pro Ile Leu
                      515                 520                 525
              Thr Leu Thr Ser Thr Asp Lys Lys Ile Leu Glu Arg Glu Ala Val Ala
                  530                 535                 540
              Lys Tyr Thr Leu Glu Asn Gln Asn Lys Thr Lys Ile Lys Ser Ile Thr
              545                 550                 555                 560
              Ala Glu Leu Lys Lys Gly Glu Glu Val Ile Asn Thr Val Val Leu Thr
                              565                 570                 575
              Asp Asp Lys Val Thr Thr Glu Thr Ile Ser Ala Ala Phe Lys Asn Leu
                          580                 585                 590
              Glu Tyr Tyr Lys Glu Tyr Thr Leu Ser Thr Thr Met Ile Tyr Asp Arg
                      595                 600                 605
              Gly Asn Gly Glu Glu Thr Glu Thr Leu Glu Asn Gln Asn Ile Gln Leu
                  610                 615                 620
              Asp Leu Lys Lys Val Glu Leu Lys Asn Ile Lys Arg Thr Asp Leu Ile
              625                 630                 635                 640
              Lys Tyr Glu Asn Gly Lys Glu Thr Asn Glu Ser Leu Ile Thr Thr Ile
                              645                 650                 655
                                                  Page 57

              Pro Asp Asp Lys Ser Asn Tyr Tyr Leu Lys Ile Thr Ser Asn Asn Gln
<removed-date>
                          660                 665                 670
              Lys Thr Thr Leu Leu Ala Val Lys Asn Ile Glu Glu Thr Thr Val Asn
                      675                 680                 685
              Gly Thr Pro Val Tyr Lys Val Thr Ala Ile Ala Asp Asn Leu Val Ser
                  690                 695                 700
<removed-apn>
              Arg Thr Ala Asp Asn Lys Phe Glu Glu Glu Tyr Val His Tyr Ile Glu
              705                 710                 715                 720
              Lys Pro Lys Val His Glu Asp Asn Val Tyr Tyr Asn Phe Lys Glu Leu
                              725                 730                 735
              Val Glu Ala Ile Gln Asn Asp Pro Ser Lys Glu Tyr Arg Leu Gly Gln
                          740                 745                 750
              Ser Met Ser Ala Arg Asn Val Val Pro Asn Gly Lys Ser Tyr Ile Thr
                      755                 760                 765
              Lys Glu Phe Thr Gly Lys Leu Leu Ser Ser Glu Gly Lys Gln Phe Ala
                  770                 775                 780
              Ile Thr Glu Leu Glu His Pro Leu Phe Asn Val Ile Thr Asn Ala Thr
              785                 790                 795                 800
              Ile Asn Asn Val Asn Phe Glu Asn Val Glu Ile Glu Arg Ser Gly Gln
                              805                 810                 815
              Asp Asn Ile Ala Ser Leu Ala Asn Thr Met Lys Gly Ser Ser Val Ile
                          820                 825                 830
              Thr Asn Val Lys Ile Thr Gly Thr Leu Ser Gly Arg Asn Asn Val Ala
                      835                 840                 845
              Gly Phe Val Asn Asn Met Asn Asp Gly Thr Arg Ile Glu Asn Val Ala
                  850                 855                 860
              Phe Phe Gly Lys Leu His Ser Thr Ser Gly Asn Gly Ser His Thr Gly
                                                  Page 58

              865                 870                 875                 880
<removed-date>
              Gly Ile Ala Gly Thr Asn Tyr Arg Gly Ile Val Arg Lys Ala Tyr Val
                              885                 890                 895
              Asp Ala Thr Ile Thr Gly Asn Lys Thr Arg Ala Ser Leu Leu Val Pro
                          900                 905                 910
<removed-apn>
              Lys Val Asp Tyr Gly Leu Thr Leu Asp His Leu Ile Gly Thr Lys Ala
                      915                 920                 925
              Leu Leu Thr Glu Ser Val Val Lys Gly Lys Ile Asp Val Ser Asn Pro
                  930                 935                 940
              Val Glu Val Gly Ala Ile Ala Ser Lys Thr Trp Pro Val Gly Thr Val
              945                 950                 955                 960
              Ser Asn Ser Val Ser Tyr Ala Lys Ile Ile Arg Gly Glu Glu Leu Phe
                              965                 970                 975
              Gly Ser Asn Asp Val Asp Asp Ser Asp Tyr Ala Ser Ala His Ile Lys
                          980                 985                 990
              Asp Leu Tyr Ala Val Glu Gly Tyr Ser Ser Gly Asn Arg Ser Phe Arg
                      995                 1000                1005
              Lys Ser Lys Thr Phe Thr Lys Leu Thr Lys Glu Gln Ala Asp Ala
                  1010                1015                1020
              Lys Val Thr Thr Phe Asn Ile Thr Ala Asp Lys Leu Glu Ser Asp
                  1025                1030                1035
              Leu Ser Pro Leu Ala Lys Leu Asn Glu Glu Lys Ala Tyr Ser Ser
                  1040                1045                1050
              Ile Gln Asp Tyr Asn Ala Glu Tyr Asn Gln Ala Tyr Lys Asn Leu
                  1055                1060                1065
              Glu Lys Leu Ile Pro Phe Tyr Asn Lys Asp Tyr Ile Val Tyr Gln
                  1070                1075                1080
                                                  Page 59

<removed-date>
              Gly Asn Lys Leu Asn Lys Glu His His Leu Asn Thr Lys Glu Val
                  1085                1090                1095
              Leu Ser Val Thr Ala Met Asn Asn Asn Glu Phe Ile Thr Asn Leu
                  1100                1105                1110
              Asp Glu Ala Asn Lys Ile Ile Val His Tyr Ala Asp Gly Thr Lys
<removed-apn>
                  1115                1120                1125
              Asp Tyr Phe Asn Leu Ser Ser Ser Ser Glu Gly Leu Ser Asn Val
                  1130                1135                1140
              Lys Glu Tyr Thr Ile Thr Asp Leu Gly Ile Lys Tyr Thr Pro Asn
                  1145                1150                1155
              Ile Val Gln Lys Asp Asn Thr Thr Leu Val Asn Asp Ile Lys Ser
                  1160                1165                1170
              Ile Leu Glu Ser Val Glu Leu Gln Ser Gln Thr Met Tyr Gln His
                  1175                1180                1185
              Leu Asn Arg Leu Gly Asp Tyr Arg Val Asn Ala Ile Lys Asp Leu
                  1190                1195                1200
              Tyr Leu Glu Glu Ser Phe Thr Asp Val Lys Glu Asn Leu Thr Asn
                  1205                1210                1215
              Leu Ile Thr Lys Leu Val Gln Asn Glu Glu His Gln Leu Asn Asp
                  1220                1225                1230
              Ser Pro Ala Ala Arg Gln Met Ile Arg Asp Lys Val Glu Lys Asn
                  1235                1240                1245
              Lys Ala Ala Leu Leu Leu Gly Leu Thr Tyr Leu Asn Arg Tyr Tyr
                  1250                1255                1260
              Gly Val Lys Phe Gly Asp Val Asn Ile Lys Glu Leu Met Leu Phe
                  1265                1270                1275
                                                Page 60

<removed-date>
              Lys Pro Asp Phe Tyr Gly Glu Lys Val Ser Val Leu Asp Arg Leu
                  1280                1285                1290
              Ile Glu Ile Gly Ser Lys Glu Asn Asn Ile Lys Gly Ser Arg Thr
                  1295                1300                1305
              Phe Asp Ala Phe Gly Gln Val Leu Ala Lys Tyr Thr Lys Ser Gly
                  1310                1315                1320
<removed-apn>
              Asn Leu Asp Ala Phe Leu Asn Tyr Asn Arg Gln Leu Phe Thr Asn
                  1325                1330                1335
              Ile Asp Asn Met Asn Asp Trp Phe Ile Asp Ala Thr Glu Asp His
                  1340                1345                1350
              Val Tyr Ile Ala Glu Arg Ala Ser Glu Val Glu Glu Ile Lys Asn
                  1355                1360                1365
              Ser Lys His Arg Ala Phe Asp Asn Leu Lys Arg Ser His Leu Arg
                  1370                1375                1380
              Asn Thr Ile Leu Pro Leu Leu Asn Ile Asp Lys Ala His Leu Tyr
                  1385                1390                1395
              Leu Ile Ser Asn Tyr Asn Ala Ile Ala Phe Gly Ser Ala Glu Arg
                  1400                1405                1410
              Leu Gly Lys Lys Ser Leu Glu Asp Ile Lys Asp Ile Val Asn Lys
                  1415                1420                1425
              Ala Ala Asp Gly Tyr Arg Asn Tyr Tyr Asp Phe Trp Tyr Arg Leu
                  1430                1435                1440
              Ala Ser Asp Asn Val Lys Gln Arg Leu Leu Arg Asp Ala Val Ile
                  1445                1450                1455
              Pro Ile Trp Glu Gly Tyr Asn Ala Pro Gly Gly Trp Val Glu Lys
                  1460                1465                1470
                                                Page 61

              Tyr Gly Arg Tyr Asn Thr Asp Lys Val Tyr Thr Pro Leu Arg Glu
<removed-date>
                  1475                1480                1485
              Phe Phe Gly Pro Met Asp Lys Tyr Tyr Asn Tyr Asn Gly Thr Gly
                  1490                1495                1500
              Ala Tyr Ala Ala Ile Tyr Pro Asn Ser Asp Asp Ile Arg Thr Asp
                  1505                1510                1515
<removed-apn>
              Val Lys Tyr Val His Leu Glu Met Val Gly Glu Tyr Gly Ile Ser
                  1520                1525                1530
              Val Tyr Thr His Glu Thr Thr His Val Asn Asp Arg Ala Ile Tyr
                  1535                1540                1545
              Leu Gly Gly Phe Gly His Arg Glu Gly Thr Asp Ala Glu Ala Tyr
                  1550                1555                1560
              Ala Gln Gly Met Leu Gln Thr Pro Val Thr Gly Ser Gly Phe Asp
                  1565                1570                1575
              Glu Phe Gly Ser Leu Gly Ile Asn Met Val Phe Lys Arg Lys Asn
                  1580                1585                1590
              Asp Gly Asn Gln Trp Tyr Ile Thr Asp Pro Lys Thr Leu Lys Thr
                  1595                1600                1605
              Arg Glu Asp Ile Asn Arg Tyr Met Lys Gly Tyr Asn Asp Thr Leu
                  1610                1615                1620
              Thr Leu Leu Asp Glu Ile Glu Ala Glu Ser Val Ile Ser Gln Gln
                  1625                1630                1635
              Asn Lys Asp Leu Asn Ser Ala Trp Phe Lys Lys Ile Asp Arg Glu
                  1640                1645                1650
              Tyr Arg Asp Asn Asn Lys Leu Asn Gln Trp Asp Lys Ile Arg Asn
                  1655                1660                1665
              Leu Ser   Gln Glu Glu Lys Asn   Glu Leu Asn Ile Gln   Ser Val Asn
                                                    Page 62

                 1670                1675                 1680
<removed-date>
              Asp Leu Val Asp Gln Gln Leu Met Thr Asn Arg Asn Pro Gly Asn
                  1685                1690                1695
              Gly Ile Tyr Lys Pro Glu Ala Ile Ser Tyr Asn Asp Gln Ser Pro
                  1700                1705                1710
<removed-apn>
              Tyr Val Gly Val Arg Met Met Thr Gly Ile Tyr Gly Gly Asn Thr
                  1715                1720                1725
              Ser Lys Gly Ala Pro Gly Ala Val Ser Phe Lys His Asn Ala Phe
                  1730                1735                1740
              Arg Leu Trp Gly Tyr Tyr Gly Tyr Glu Asn Gly Phe Leu Gly Tyr
                  1745                1750                1755
              Ala Ser Asn Lys Tyr Lys Gln Gln Ser Lys Thr Asp Gly Glu Ser
                  1760                1765                1770
              Val Leu Ser Asp Glu Tyr Ile Ile Lys Lys Ile Ser Asn Asn Thr
                  1775                1780                1785
              Phe Asn Thr Ile Glu Glu Phe Lys Lys Ala Tyr Phe Lys Glu Val
                  1790                1795                1800
              Lys Asp Lys Ala Thr Lys Gly Leu Thr Thr Phe Glu Val Asn Gly
                  1805                1810                1815
              Ser Ser Val Ser Ser Tyr Asp Asp Leu Leu Thr Leu Phe Lys Glu
                  1820                1825                1830
              Ala Val Lys Lys Asp Ala Glu Thr Leu Lys Gln Glu Ala Asn Gly
                  1835                1840                1845
              Asn Lys Thr Val Ser Met Asn Asn Thr Val Lys Leu Lys Glu Ala
                  1850                1855                1860
              Val Tyr Lys Lys Leu Leu Gln Gln Thr Asn Ser Phe Lys Thr Ser
                  1865                1870                1875
                                                Page 63

<removed-date>
              Ile Phe Lys
                  1880
              <210>   30
              <211>   126
              <212>   PRT
              <213>   Streptococcus pneumoniae
<removed-apn>
              <400> 30
              Met Val Thr Trp Ile Leu Trp Ala Leu Ile Leu Ala Met Leu Ala Trp
              1               5                   10                  15
              Met Gly Phe Asn Tyr Leu Arg Ile Arg Arg Ala Ala Lys Ile Val Asp
                          20                  25                  30
              Asn Glu Glu Phe Glu Ala Leu Ile Arg Thr Gly Gln Leu Ile Asp Leu
                      35                  40                  45
              Arg Asp Pro Ala Glu Phe His Arg Lys His Ile Leu Gly Ala Arg Asn
                  50                  55                  60
              Ile Pro Ser Ser Gln Leu Lys Thr Ser Leu Ala Ala Leu Arg Lys Asp
              65                  70                  75                  80
              Lys Pro Val Leu Leu Tyr Glu Asn Gln Arg Ala Gln Arg Val Thr Asn
                              85                  90                  95
              Ala Ala Leu Tyr Leu Lys Lys Gln Gly Phe Ser Glu Ile Tyr Ile Leu
                          100                 105                 110
              Ser Tyr Gly Leu Asp Ser Trp Lys Gly Lys Val Lys Thr Ser
                      115                 120                 125
              <210>   31
              <211>   267
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 31
              Met Gln Glu Phe Thr Asn Pro Phe Pro Ile Gly Ser Ser Ser Leu Ile
              1               5                   10                  15
                                                  Page 64

<removed-date>
              His Cys Ile Thr Asn Glu Ile Ser Cys Glu Met Leu Ala Asn Gly Ile
                          20                  25                  30
              Leu Ala Leu Gly Cys Lys Pro Val Met Ala Asp Asp Ser Arg Glu Val
                      35                  40                  45
              Leu Asp Phe Thr Lys Gln Ser Gln Ala Leu Phe Ile Asn Leu Gly His
                  50                  55                  60
<removed-apn>
              Leu Ser Ala Glu Lys Glu Lys Ala Ile Arg Met Ala Ala Ser Tyr Ala
              65                  70                  75                  80
              Asn Gln Ser Ser Leu Pro Met Val Val Asp Ala Val Gly Val Thr Thr
                              85                  90                  95
              Ser Ser Ile Arg Lys Ser Leu Val Lys Asp Leu Leu Asp Tyr Arg Pro
                          100                 105                 110
              Thr Val Leu Lys Gly Asn Met Ser Glu Ile Arg Ser Leu Val Gly Leu
                      115                 120                 125
              Lys His His Gly Val Gly Val Asp Ala Ser Ala Lys Asp Gln Glu Thr
                  130                 135                 140
              Glu Asp Leu Leu Gln Val Leu Lys Asp Trp Cys Gln Thr Tyr Pro Gly
              145                 150                 155                 160
              Met Ser Phe Leu Val Thr Gly Pro Lys Asp Leu Val Val Ser Lys Asn
                              165                 170                 175
              Gln Val Ala Val Leu Gly Asn Gly Cys Thr Glu Leu Asp Trp Ile Thr
                          180                 185                 190
              Gly Thr Gly Asp Leu Val Gly Ala Leu Thr Ala Val Phe Leu Ser Gln
                      195                 200                 205
              Gly Lys Thr Gly Phe Glu Ala Ser Cys Leu Ala Val Ser Tyr Leu Asn
                  210                 215                 220
                                                  Page 65

              Ile Ala Ala Glu Lys Ile Val Val Gln Gly Met Gly Leu Glu Glu Phe
<removed-date>
              225                 230                 235                 240
              Arg Tyr Gln Val Leu Asn Gln Leu Ser Leu Leu Arg Arg Asp Glu Asn
                              245                 250                 255
              Trp Leu Asp Thr Ile Lys Gly Glu Val Tyr Glu
                          260                 265
<removed-apn>
              <210>   32
              <211>   281
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 32
              Met Thr Trp Lys Ile Ile Ala Asp Ser Gly Cys Asp Tyr Arg Gln Leu
              1               5                   10                  15
              Pro Thr Pro Ala Ile Asn Thr Thr Phe Val Ser Val Pro Leu Thr Ile
                          20                  25                  30
              Gln Val Ala Asp Gln Val Phe Val Asp Asp Ala Ser Leu Asp Ile Asp
                      35                  40                  45
              Gln Met Met Glu Thr Met Tyr Ala Thr Ala Glu Ala Ser Lys Ser Ala
                  50                  55                  60
              Cys Pro Ser Pro Asp Asp Tyr Leu Arg Ala Phe Glu Gly Ala Lys Asn
              65                  70                  75                  80
              Ile Phe Leu Val Thr Ile Thr Gly Thr Leu Ser Gly Ser His Asn Ser
                              85                  90                  95
              Ala Gln Leu Ala Lys Asn Ile Tyr Leu Glu Asp His Pro Asp Thr Lys
                          100                 105                 110
              Ile His Val Ile Asp Ser Leu Ser Ala Gly Gly Glu Val Asp Leu Leu
                      115                 120                 125
              Val Glu Lys Leu Asn Asp Leu Ile Asp Gln Gly Leu Ser Phe Glu Glu
                  130                 135                 140
                                                  Page 66

<removed-date>
              Val Val Glu Ala Ile Thr Ala Tyr Gln Glu Lys Thr Lys Leu Leu Phe
              145                 150                 155                 160
              Val Leu Ala Lys Val Asp Asn Leu Val Lys Asn Gly Arg Leu Ser Lys
                              165                 170                 175
              Leu Ile Gly Thr Val Val Gly Leu Leu Asn Ile Arg Met Val Gly Lys
                          180                 185                 190
<removed-apn>
              Ala Ser Glu Thr Gly Thr Leu Glu Leu Leu Gln Lys Ala Arg Gly Ser
                      195                 200                 205
              Lys Lys Ser Val Gln Ala Ala Tyr Asp Glu Leu Val Lys Ala Gly Tyr
                  210                 215                 220
              Ala Gly Gly Arg Ile Val Met Ala Gln Arg Asn Asn Glu Lys Cys Cys
              225                 230                 235                 240
              Gln Gln Leu Ser Glu Arg Ile Arg Glu Thr Phe Pro Gln Ala Asp Ile
                              245                 250                 255
              Lys Ile Leu Pro Thr Ser Gly Leu Cys Ser Phe Tyr Ala Glu Glu Gly
                          260                 265                 270
              Gly Leu Leu Met Gly Tyr Glu Ile Asp
                      275                 280
              <210>   33
              <211>   308
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 33
              Met Ile Ser Arg Phe Phe Arg His Leu Phe Glu Ala Leu Lys Ser Leu
              1               5                   10                  15
              Lys Arg Asn Gly Trp Met Thr Val Ala Ala Val Ser Ser Val Met Ile
                          20                  25                  30
              Thr Leu Thr Leu Val Ala Ile Phe Ala Ser Val Ile Phe Asn Thr Ala
                      35                  40                  45
                                                    Page 67

<removed-date>
              Lys Leu Ala Thr Asp Ile Glu Asn Asn Val Arg Val Val Val Tyr Ile
                  50                  55                  60
              Arg Lys Asp Val Glu Asp Asn Ser Gln Thr Ile Glu Lys Glu Gly Gln
              65                  70                  75                  80
              Thr Val Thr Asn Asn Asp Tyr His Lys Val Tyr Asp Ser Leu Lys Asn
<removed-apn>
                              85                  90                  95
              Met Ser Thr Val Lys Ser Val Thr Phe Ser Ser Lys Glu Glu Gln Tyr
                          100                 105                 110
              Glu Lys Leu Thr Glu Ile Met Gly Asp Asn Trp Lys Ile Phe Glu Gly
                      115                 120                 125
              Asp Ala Asn Pro Leu Tyr Asp Ala Tyr Ile Val Glu Ala Asn Thr Pro
                  130                 135                 140
              Asn Asp Val Lys Thr Ile Ala Glu Asp Ala Lys Lys Ile Glu Gly Val
              145                 150                 155                 160
              Ser Glu Val Gln Asp Gly Gly Ala Asn Thr Glu Arg Leu Phe Lys Leu
                              165                 170                 175
              Ala Ser Phe Ile Arg Val Trp Gly Leu Gly Ile Ala Ala Leu Leu Ile
                          180                 185                 190
              Phe Ile Ala Val Phe Leu Ile Ser Asn Thr Ile Arg Ile Thr Ile Ile
                      195                 200                 205
              Ser Arg Ser Arg Glu Ile Gln Ile Met Arg Leu Val Gly Ala Lys Asn
                  210                 215                 220
              Ser Tyr Ile Arg Gly Pro Phe Leu Leu Glu Gly Ala Phe Ile Gly Leu
              225                 230                 235                 240
              Leu Gly Ala Ile Ala Pro Ser Val Leu Val Phe Ile Val Tyr Gln Ile
                              245                 250                 255
                                                  Page 68

<removed-date>
              Val Tyr Gln Ser Val Asn Lys Ser Leu Val Gly Gln Asn Leu Ser Met
                          260                 265                 270
              Ile Ser Pro Asp Leu Phe Ser Pro Leu Met Ile Ala Leu Leu Phe Val
                      275                 280                 285
              Ile Gly Val Phe Ile Gly Ser Leu Gly Ser Gly Ile Ser Met Arg Arg
                  290                 295                 300
<removed-apn>
              Phe Leu Lys Ile
              305
              <210>   34
              <211>   399
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 34
              Met Lys Lys Lys Asn Gly Lys Ala Lys Lys Trp Gln Leu Tyr Ala Ala
              1               5                   10                  15
              Ile Gly Ala Ala Ser Val Val Val Leu Gly Ala Gly Gly Ile Leu Leu
                          20                  25                  30
              Phe Arg Gln Pro Ser Gln Thr Ala Leu Lys Asp Glu Pro Thr His Leu
                      35                  40                  45
              Val Val Ala Lys Glu Gly Ser Val Ala Ser Ser Val Leu Leu Ser Gly
                  50                  55                  60
              Thr Val Thr Ala Lys Asn Glu Gln Tyr Val Tyr Phe Asp Ala Ser Lys
              65                  70                  75                  80
              Gly Asp Leu Asp Glu Ile Leu Val Ser Val Gly Asp Lys Val Ser Glu
                              85                  90                  95
              Gly Gln Ala Leu Val Lys Tyr Ser Ser Ser Glu Ala Gln Ala Ala Tyr
                          100                 105                 110
              Asp Ser Ala Ser Arg Ala Val Ala Arg Ala Asp Arg His Ile Asn Glu
                      115                 120                 125
                                                  Page 69

<removed-date>
              Leu Asn Gln Ala Arg Asn Glu Ala Ala Ser Ala Pro Ala Pro Gln Leu
                  130                 135                 140
              Pro Ala Pro Val Gly Gly Glu Asp Ala Thr Val Gln Ser Pro Thr Pro
              145                 150                 155                 160
              Val Ala Gly Asn Ser Val Ala Ser Ile Asp Ala Gln Leu Gly Asp Ala
<removed-apn>
                              165                 170                 175
              Arg Asp Ala Arg Ala Asp Ala Ala Ala Gln Leu Ser Lys Ala Gln Ser
                          180                 185                 190
              Gln Leu Asp Ala Thr Thr Val Leu Ser Thr Leu Glu Gly Thr Val Val
                      195                 200                 205
              Glu Val Asn Ser Asn Val Ser Lys Ser Pro Thr Gly Ala Ser Gln Val
                  210                 215                 220
              Met Val His Ile Val Ser Asn Glu Asn Leu Gln Val Lys Gly Glu Leu
              225                 230                 235                 240
              Ser Glu Tyr Asn Leu Ala Asn Leu Ser Val Gly Gln Glu Val Ser Phe
                              245                 250                 255
              Thr Ser Lys Val Tyr Pro Asp Lys Lys Trp Thr Gly Lys Leu Ser Tyr
                          260                 265                 270
              Ile Ser Asp Tyr Pro Lys Asn Asn Gly Glu Ala Ala Ser Pro Ala Ala
                      275                 280                 285
              Gly Asn Asn Thr Gly Ser Lys Tyr Pro Tyr Thr Ile Asp Val Thr Gly
                  290                 295                 300
              Glu Val Gly Asp Leu Lys Gln Gly Phe Ser Val Asn Ile Glu Val Lys
              305                 310                 315                 320
              Ser Lys Thr Lys Ala Ile Leu Val Pro Val Ser Ser Leu Val Met Asp
                              325                 330                 335
                                                  Page 70

<removed-date>
              Asp Ser Lys Asn Tyr Val Trp Ile Val Asp Glu Gln Gln Lys Ala Lys
                          340                 345                 350
              Lys Val Glu Val Ser Leu Gly Asn Ala Asp Ala Glu Asn Gln Glu Ile
                      355                 360                 365
              Thr Ser Gly Leu Thr Asn Gly Ala Lys Val Ile Ser Asn Pro Thr Ser
                  370                 375                 380
<removed-apn>
              Ser Leu Glu Glu Gly Lys Glu Val Lys Ala Asp Glu Ala Thr Asn
              385                 390                 395
              <210>   35
              <211>   419
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 35
              Met Gln Asn Leu Lys Phe Ala Phe Ser Ser Ile Met Ala His Lys Met
              1               5                   10                  15
              Arg Ser Leu Leu Thr Met Ile Gly Ile Ile Ile Gly Val Ser Ser Val
                          20                  25                  30
              Val Val Ile Met Ala Leu Gly Asp Ser Leu Ser Arg Gln Val Asn Lys
                      35                  40                  45
              Asp Met Thr Lys Ser Gln Lys Asn Ile Ser Val Phe Phe Ser Pro Lys
                  50                  55                  60
              Lys Ser Lys Asp Gly Ser Phe Thr Gln Lys Gln Ser Ala Phe Thr Val
              65                  70                  75                  80
              Ser Gly Lys Glu Glu Glu Val Pro Val Glu Pro Pro Lys Pro Gln Glu
                              85                  90                  95
              Ser Trp Val Gln Glu Ala Ala Lys Leu Lys Gly Val Asp Ser Tyr Tyr
                          100                 105                 110
              Val Thr Asn Ser Thr Asn Ala Ile Leu Thr Tyr Gln Asp Lys Lys Val
                      115                 120                 125
                                                  Page 71

<removed-date>
              Glu Asn Ala Asn Leu Thr Gly Gly Asn Arg Thr Tyr Met Asp Ala Val
                  130                 135                 140
              Lys Asn Glu Ile Ile Ala Gly Arg Ser Leu Arg Glu Gln Asp Phe Lys
              145                 150                 155                 160
              Glu Phe Ala Ser Val Ile Leu Leu Asp Glu Glu Leu Ser Ile Ser Leu
<removed-apn>
                              165                 170                 175
              Phe Glu Ser Pro Gln Glu Ala Ile Asn Lys Val Val Glu Val Asn Gly
                          180                 185                 190
              Phe Ser Tyr Arg Val Ile Gly Val Tyr Thr Ser Pro Glu Ala Lys Arg
                      195                 200                 205
              Ser Lys Ile Tyr Gly Phe Gly Gly Leu Pro Ile Thr Thr Asn Ile Ser
                  210                 215                 220
              Leu Ala Ala Asn Phe Asn Val Asp Glu Ile Ala Asn Ile Val Phe Arg
              225                 230                 235                 240
              Val Asn Asp Thr Ser Leu Thr Pro Thr Leu Gly Pro Glu Leu Ala Arg
                              245                 250                 255
              Lys Met Thr Glu Leu Ala Gly Leu Gln Gln Gly Glu Tyr Gln Val Ala
                          260                 265                 270
              Asp Glu Ser Val Val Phe Ala Glu Ile Gln Gln Ser Phe Ser Phe Met
                      275                 280                 285
              Thr Thr Ile Ile Ser Ser Ile Ala Gly Ile Ser Leu Phe Val Gly Gly
                  290                 295                 300
              Thr Gly Val Met Asn Ile Met Leu Val Ser Val Thr Glu Arg Thr Arg
              305                 310                 315                 320
              Glu Ile Gly Leu Arg Lys Ala Leu Gly Ala Thr Arg Ala Asn Ile Leu
                              325                 330                 335
                                                  Page 72

<removed-date>
              Ile Gln Phe Leu Ile Glu Ser Met Ile Leu Thr Leu Leu Gly Gly Leu
                          340                 345                 350
              Ile Gly Leu Thr Ile Ala Ser Gly Leu Thr Ala Leu Ala Gly Leu Leu
                      355                 360                 365
              Leu Gln Gly Leu Ile Glu Gly Ile Glu Val Gly Val Ser Ile Pro Val
                  370                 375                 380
<removed-apn>
              Ala Leu Phe Ser Leu Ala Val Ser Ala Ser Val Gly Met Ile Phe Gly
              385                 390                 395                 400
              Val Leu Pro Ala Asn Lys Ala Ser Lys Leu Asp Pro Ile Glu Ala Leu
                              405                 410                 415
              Arg Tyr Glu
              <210>   36
              <211>   413
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 36
              Met Lys Lys Ile Phe Leu Thr Leu Leu Thr Val Ser Leu Leu Gly Gly
              1               5                   10                  15
              Ala Ser Thr Ala Val Ala Gln Asp Phe Thr Ile Ala Ala Lys His Ala
                          20                  25                  30
              Ile Ala Val Glu Ala Asn Thr Gly Lys Ile Leu Tyr Glu Lys Asp Ala
                      35                  40                  45
              Thr Gln Pro Val Glu Ile Ala Ser Ile Thr Lys Leu Ile Thr Val Tyr
                  50                  55                  60
              Leu Val Tyr Glu Ala Leu Glu Asn Gly Ser Ile Thr Leu Ser Thr Pro
              65                  70                  75                  80
              Val Asp Ile Ser Asp Tyr Pro Tyr Gln Leu Thr Thr Asn Ser Glu Ala
                              85                  90                  95
                                                  Page 73

<removed-date>
              Ser Asn Ile Pro Met Glu Ala Arg Asn Tyr Thr Val Glu Glu Leu Leu
                          100                 105                 110
              Glu Ala Thr Leu Val Ser Ser Ala Asn Ser Ala Ala Ile Ala Leu Ala
                      115                 120                 125
              Glu Lys Ile Ala Gly Ser Glu Lys Asp Phe Val Asp Met Met Arg Ala
<removed-apn>
                  130                 135                 140
              Lys Leu Leu Glu Trp Gly Ile Gln Asp Ala Thr Val Val Asn Thr Thr
              145                 150                 155                 160
              Gly Leu Asn Asn Glu Thr Leu Gly Asp Asn Ile Tyr Pro Gly Ser Lys
                              165                 170                 175
              Lys Asp Glu Glu Asn Lys Leu Ser Ala Tyr Asp Val Ala Ile Val Ala
                          180                 185                 190
              Arg Asn Leu Ile Lys Lys Tyr Pro Gln Val Leu Glu Ile Thr Lys Lys
                      195                 200                 205
              Pro Ser Ser Thr Phe Ala Gly Met Thr Ile Thr Ser Thr Asn Tyr Met
                  210                 215                 220
              Leu Glu Gly Met Pro Ala Tyr Arg Gly Gly Phe Asp Gly Leu Lys Thr
              225                 230                 235                 240
              Gly Thr Thr Asp Lys Ala Gly Glu Ser Phe Val Gly Thr Thr Val Glu
                              245                 250                 255
              Lys Gly Met Arg Val Ile Thr Val Val Leu Asn Ala Asp His Gln Asp
                          260                 265                 270
              Asn Asn Pro Tyr Ala Arg Phe Thr Ala Thr Ser Ser Leu Met Asp Tyr
                      275                 280                 285
              Ile Ser Ser Thr Phe Thr Leu Arg Lys Ile Val Gln Gln Gly Asp Ala
                  290                 295                 300
                                                  Page 74

<removed-date>
              Tyr Gln Asp Ser Lys Ala Pro Val Gln Asp Gly Lys Glu Asp Thr Val
              305                 310                 315                 320
              Thr Ala Val Ala Pro Glu Asp Ile Tyr Leu Ile Glu Arg Val Gly Asn
                              325                 330                 335
              Gln Ser Ser Gln Ser Val Gln Phe Thr Pro Asp Ser Lys Ala Ile Pro
                          340                 345                 350
<removed-apn>
              Ala Pro Leu Glu Ala Gly Thr Val Val Gly His Leu Thr Tyr Glu Asp
                      355                 360                 365
              Lys Asp Leu Ile Gly Gln Gly Tyr Ile Thr Thr Glu Arg Pro Ser Phe
                  370                 375                 380
              Glu Met Val Ala Asp Lys Lys Ile Glu Lys Ala Phe Phe Leu Lys Val
              385                 390                 395                 400
              Trp Trp Asn Gln Phe Val Arg Phe Val Asn Glu Lys Leu
                              405                 410
              <210>   37
              <211>   767
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 37
              Met Ala Asn Lys Asn Thr Ser Thr Thr Arg Arg Arg Pro Ser Lys Ala
              1               5                   10                  15
              Glu Leu Glu Arg Lys Glu Ala Ile Gln Arg Met Leu Ile Ser Leu Gly
                          20                  25                  30
              Ile Ala Ile Leu Leu Ile Phe Ala Ala Phe Lys Leu Gly Ala Ala Gly
                      35                  40                  45
              Ile Thr Leu Tyr Asn Leu Ile Arg Leu Leu Val Gly Ser Leu Ala Tyr
                  50                  55                  60
              Leu Ala Ile Phe Gly Leu Leu Ile Tyr Leu Phe Phe Phe Lys Trp Ile
              65                  70                  75                  80
                                                  Page 75

<removed-date>
              Arg Lys Gln Glu Gly Leu Leu Ser Gly Phe Phe Thr Ile Phe Ala Gly
                              85                  90                  95
              Leu Leu Leu Ile Phe Glu Ala Tyr Leu Val Trp Lys Tyr Gly Leu Asp
                          100                 105                 110
              Lys Ser Val Leu Lys Gly Thr Met Ala Gln Val Val Thr Asp Leu Thr
<removed-apn>
                      115                 120                 125
              Gly Phe Arg Thr Thr Ser Phe Ala Gly Gly Gly Leu Ile Gly Val Ala
                  130                 135                 140
              Leu Tyr Ile Pro Thr Ala Phe Leu Phe Ser Asn Ile Gly Thr Tyr Phe
              145                 150                 155                 160
              Ile Gly Ser Ile Leu Ile Leu Val Gly Ser Leu Leu Val Ser Pro Trp
                              165                 170                 175
              Ser Val Tyr Asp Ile Ala Glu Phe Phe Ser Arg Gly Phe Ala Lys Trp
                          180                 185                 190
              Trp Glu Gly His Glu Arg Arg Lys Glu Glu Arg Phe Val Lys Gln Glu
                      195                 200                 205
              Glu Lys Ala Arg Gln Lys Ala Glu Lys Glu Ala Arg Leu Glu Gln Glu
                  210                 215                 220
              Glu Thr Glu Lys Ala Leu Leu Asp Leu Pro Pro Val Asp Met Glu Thr
              225                 230                 235                 240
              Gly Glu Ile Leu Thr Glu Glu Ala Val Gln Asn Leu Pro Pro Ile Pro
                              245                 250                 255
              Glu Glu Lys Trp Val Glu Pro Glu Ile Ile Leu Pro Gln Ala Glu Leu
                          260                 265                 270
              Lys Phe Pro Glu Gln Glu Asp Asp Ser Asp Asp Glu Asp Val Gln Val
                      275                 280                 285
                                                  Page 76

<removed-date>
              Asp Phe Ser Ala Lys Glu Ala Leu Glu Tyr Lys Leu Pro Ser Leu Gln
                  290                 295                 300
              Leu Phe Ala Pro Asp Lys Pro Lys Asp Gln Ser Lys Glu Lys Lys Ile
              305                 310                 315                 320
              Val Arg Glu Asn Ile Lys Ile Leu Glu Ala Thr Phe Ala Ser Phe Gly
                              325                 330                 335
<removed-apn>
              Ile Lys Val Thr Val Glu Arg Ala Glu Ile Gly Pro Ser Val Thr Lys
                          340                 345                 350
              Tyr Glu Val Lys Pro Ala Val Gly Val Arg Val Asn Arg Ile Ser Asn
                      355                 360                 365
              Leu Ser Asp Asp Leu Ala Leu Ala Leu Ala Ala Lys Asp Val Arg Ile
                  370                 375                 380
              Glu Ala Pro Ile Pro Gly Lys Ser Leu Ile Gly Ile Glu Val Pro Asn
              385                 390                 395                 400
              Ser Asp Ile Ala Thr Val Ser Phe Arg Glu Leu Trp Glu Gln Ser Gln
                              405                 410                 415
              Thr Lys Ala Glu Asn Phe Leu Glu Ile Pro Leu Gly Lys Ala Val Asn
                          420                 425                 430
              Gly Thr Ala Arg Ala Phe Asp Leu Ser Lys Met Pro His Leu Leu Val
                      435                 440                 445
              Ala Gly Ser Thr Gly Ser Gly Lys Ser Val Ala Val Asn Gly Ile Ile
                  450                 455                 460
              Ala Ser Ile Leu Met Lys Ala Arg Pro Asp Gln Val Lys Phe Met Met
              465                 470                 475                 480
              Val Asp Pro Lys Met Val Glu Leu Ser Val Tyr Asn Asp Ile Pro His
                              485                 490                 495
                                                  Page 77

              Leu Leu Ile Pro Val Val Thr Asn Pro Arg Lys Ala Ser Lys Ala Leu
<removed-date>
                          500                 505                 510
              Gln Lys Val Val Asp Glu Met Glu Asn Arg Tyr Glu Leu Phe Ala Lys
                      515                 520                 525
              Val Gly Val Arg Asn Ile Ala Gly Phe Asn Ala Lys Val Glu Glu Phe
                  530                 535                 540
<removed-apn>
              Asn Ser Gln Ser Glu Tyr Lys Gln Ile Pro Leu Pro Phe Ile Val Val
              545                 550                 555                 560
              Ile Val Asp Glu Leu Ala Asp Leu Met Met Val Ala Ser Lys Glu Val
                              565                 570                 575
              Glu Asp Ala Ile Ile Arg Leu Gly Gln Lys Ala Arg Ala Ala Gly Ile
                          580                 585                 590
              His Met Ile Leu Ala Thr Gln Arg Pro Ser Val Asp Val Ile Ser Gly
                      595                 600                 605
              Leu Ile Lys Ala Asn Val Pro Ser Arg Val Ala Phe Ala Val Ser Ser
                  610                 615                 620
              Gly Thr Asp Ser Arg Thr Ile Leu Asp Glu Asn Gly Ala Glu Lys Leu
              625                 630                 635                 640
              Leu Gly Arg Gly Asp Met Leu Phe Lys Pro Ile Asp Glu Asn His Pro
                              645                 650                 655
              Val Arg Leu Gln Gly Ser Phe Ile Ser Asp Asp Asp Val Glu Arg Ile
                          660                 665                 670
              Val Asn Phe Ile Lys Thr Gln Ala Asp Ala Asp Tyr Asp Glu Ser Phe
                      675                 680                 685
              Asp Pro Gly Glu Val Ser Glu Asn Glu Gly Glu Phe Ser Asp Gly Asp
                  690                 695                 700
              Ala Gly Gly Asp Pro Leu Phe Glu Glu Ala Lys Ser Leu Val Ile Glu
                                                  Page 78

              705                   710               715                   720
<removed-date>
              Thr Gln Lys Ala Ser Ala Ser Met Ile Gln Arg Arg Leu Ser Val Gly
                              725                 730                 735
              Phe Asn Arg Ala Thr Arg Leu Met Glu Glu Leu Glu Ile Ala Gly Val
                          740                 745                 750
<removed-apn>
              Ile Gly Pro Ala Glu Gly Thr Lys Pro Arg Lys Val Leu Gln Gln
                      755                 760                 765
              <210>   38
              <211>   290
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 38
              Met Lys Lys Ser Arg Lys Leu Ala Thr Leu Gly Ile Cys Ser Ala Leu
              1               5                   10                  15
              Phe Leu Gly Leu Ala Ala Cys Gln Gln Gln His Ala Thr Ser Glu Gly
                          20                  25                  30
              Thr Asn Gln Arg Gln Ser Ser Ser Ala Lys Val Pro Trp Lys Ala Ser
                      35                  40                  45
              Tyr Thr Asn Leu Asn Asn Gln Val Ser Thr Glu Glu Val Lys Ser Leu
                  50                  55                  60
              Leu Ser Ala His Leu Asp Pro Asn Ser Val Asp Ala Phe Phe Asn Leu
              65                  70                  75                  80
              Val Asn Asp Tyr Asn Thr Ile Val Gly Ser Thr Gly Leu Ser Gly Asp
                              85                  90                  95
              Phe Thr Ser Phe Thr His Thr Glu Tyr Asp Val Glu Lys Ile Ser His
                          100                 105                 110
              Leu Trp Asn Gln Lys Lys Gly Asp Phe Val Gly Thr Asn Cys Arg Ile
                      115                 120                 125
                                                  Page 79

              Asn Ser Tyr Cys Leu Leu Lys Asn Ser Val Thr Ile Pro Lys Leu Glu
<removed-date>
                  130                 135                 140
              Lys Asn Asp Gln Leu Leu Phe Leu Asp Asn Asp Ala Ile Asp Lys Gly
              145                 150                 155                 160
              Lys Val Phe Asp Ser Gln Asp Lys Glu Glu Phe Asp Ile Leu Phe Ser
                              165                 170                 175
<removed-apn>
              Arg Val Pro Thr Glu Ser Thr Thr Asp Val Lys Val His Ala Glu Lys
                          180                 185                 190
              Met Glu Ala Phe Phe Ser Gln Phe Gln Phe Asn Glu Lys Ala Arg Met
                      195                 200                 205
              Leu Ser Val Val Leu His Asp Asn Leu Asp Gly Glu Tyr Leu Phe Val
                  210                 215                 220
              Gly His Val Gly Val Leu Val Pro Ala Asp Asp Gly Phe Leu Phe Val
              225                 230                 235                 240
              Glu Lys Leu Thr Phe Glu Glu Pro Tyr Gln Ala Ile Lys Phe Ala Ser
                              245                 250                 255
              Lys Glu Asp Cys Tyr Lys Tyr Leu Gly Thr Lys Tyr Ala Asp Tyr Thr
                          260                 265                 270
              Gly Glu Gly Leu Ala Lys Pro Phe Ile Met Asp Asn Asp Lys Trp Val
                      275                 280                 285
              Lys Leu
                  290
              <210>   39
              <211>   305
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 39
              Met Lys Lys Gln Asn Leu Phe Leu Val Leu Leu Ser Val Phe Leu Leu
              1               5                   10                  15
                                                  Page 80

<removed-date>
              Cys Leu Gly Ala Cys Gly Gln Lys Glu Ser Gln Thr Gly Lys Gly Met
                          20                  25                  30
              Lys Ile Val Thr Ser Phe Tyr Pro Ile Tyr Ala Met Val Lys Glu Val
                      35                  40                  45
              Ser Gly Asp Leu Asn Asp Val Arg Met Ile Gln Ser Ser Ser Gly Ile
                  50                  55                  60
<removed-apn>
              His Ser Phe Glu Pro Ser Ala Asn Asp Ile Ala Ala Ile Tyr Asp Ala
              65                  70                  75                  80
              Asp Val Phe Val Tyr His Ser His Thr Leu Glu Ser Trp Ala Gly Ser
                              85                  90                  95
              Leu Asp Pro Asn Leu Lys Lys Ser Lys Val Lys Val Leu Glu Ala Ser
                          100                 105                 110
              Glu Gly Met Thr Leu Glu Arg Val Pro Gly Leu Glu Asp Val Glu Ala
                      115                 120                 125
              Gly Asp Gly Val Asp Glu Lys Thr Leu Tyr Asp Pro His Thr Trp Leu
                  130                 135                 140
              Asp Pro Glu Lys Ala Gly Glu Glu Ala Gln Ile Ile Ala Asp Lys Leu
              145                 150                 155                 160
              Ser Glu Val Asp Ser Glu His Lys Glu Thr Tyr Gln Lys Asn Ala Gln
                              165                 170                 175
              Ala Phe Ile Lys Lys Ala Gln Glu Leu Thr Lys Lys Phe Gln Pro Lys
                          180                 185                 190
              Phe Glu Lys Ala Thr Gln Lys Thr Phe Val Thr Gln His Thr Ala Phe
                      195                 200                 205
              Ser Tyr Leu Ala Lys Arg Phe Gly Leu Asn Gln Leu Gly Ile Ala Gly
                  210                 215                 220
                                                  Page 81

              Ile Ser Pro Glu Gln Glu Pro Ser Pro Arg Gln Leu Thr Glu Ile Gln
<removed-date>
              225                 230                 235                 240
              Glu Phe Val Lys Thr Tyr Lys Val Lys Thr Ile Phe Thr Glu Ser Asn
                              245                 250                 255
              Ala Ser Ser Lys Val Ala Glu Thr Leu Val Lys Ser Thr Gly Val Gly
                          260                 265                 270
<removed-apn>
              Leu Lys Thr Leu Asn Pro Leu Glu Ser Asp Pro Gln Asn Asp Lys Thr
                      275                 280                 285
              Tyr Leu Glu Asn Leu Glu Glu Asn Met Ser Ile Leu Ala Glu Glu Leu
                  290                 295                 300
              Lys
              305
              <210>   40
              <211>   204
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 40
              Met Phe Lys Arg Ile Arg Arg Val Leu Val Leu Ala Val Phe Leu Phe
              1               5                   10                  15
              Ala Gly Tyr Lys Ala Tyr Arg Val His Gln Asp Val Lys Gln Val Met
                          20                  25                  30
              Thr Tyr Gln Pro Met Val Arg Glu Ile Leu Ser Glu Gln Asp Thr Pro
                      35                  40                  45
              Ala Asn Glu Glu Leu Val Leu Ala Met Ile Tyr Thr Glu Thr Lys Gly
                  50                  55                  60
              Lys Glu Gly Asp Val Met Gln Ser Ser Glu Ser Ala Ser Gly Ser Thr
              65                  70                  75                  80
              Asn Thr Ile Asn Asp Asn Ala Ser Ser Ile Arg Gln Gly Ile Gln Thr
                              85                  90                  95
                                                  Page 82

<removed-date>
              Leu Thr Gly Asn Leu Tyr Leu Ala Gln Lys Lys Gly Val Asp Ile Trp
                          100                 105                 110
              Thr Ala Val Gln Ala Tyr Asn Phe Gly Pro Ala Tyr Ile Asp Phe Ile
                      115                 120                 125
              Ala Gln Asn Gly Lys Glu Asn Thr Leu Ala Leu Ala Lys Gln Tyr Ser
                  130                 135                 140
<removed-apn>
              Arg Glu Thr Val Ala Pro Leu Leu Gly Asn Arg Thr Gly Lys Thr Tyr
              145                 150                 155                 160
              Ser Tyr Ile His Pro Ile Ser Ile Phe His Gly Ala Glu Leu Tyr Val
                              165                 170                 175
              Asn Gly Gly Asn Tyr Tyr Tyr Ser Arg Gln Val Arg Leu Asn Leu Tyr
                          180                 185                 190
              Ile Ile Lys Cys Phe Thr Leu Phe Ser Thr Ser Gly
                      195                 200
              <210>   41
              <211>   341
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 41
              Met Lys Asn Lys Phe Phe Leu Ile Ala Ile Leu Ala Met Cys Ile Val
              1               5                   10                  15
              Phe Ser Ala Cys Ser Ser Asn Ser Val Lys Asn Glu Glu Asn Thr Ser
                          20                  25                  30
              Lys Glu His Ala Pro Asp Lys Ile Val Leu Asp His Ala Phe Gly Gln
                      35                  40                  45
              Thr Ile Leu Asp Lys Lys Pro Glu Arg Val Ala Thr Ile Ala Trp Gly
                  50                  55                  60
              Asn His Asp Val Ala Leu Ala Leu Gly Ile Val Pro Val Gly Phe Ser
              65                  70                  75                  80
                                                  Page 83

<removed-date>
              Lys Ala Asn Tyr Gly Val Ser Ala Asp Lys Gly Val Leu Pro Trp Thr
                              85                  90                  95
              Glu Glu Lys Ile Lys Glu Leu Asn Gly Lys Ala Asn Leu Phe Asp Asp
                          100                 105                 110
              Leu Asp Gly Leu Asn Phe Glu Ala Ile Ser Asn Ser Lys Pro Asp Val
<removed-apn>
                      115                 120                 125
              Ile Leu Ala Gly Tyr Ser Gly Ile Thr Lys Glu Asp Tyr Asp Thr Leu
                  130                 135                 140
              Ser Lys Ile Ala Pro Val Ala Ala Tyr Lys Ser Lys Pro Trp Gln Thr
              145                 150                 155                 160
              Leu Trp Arg Asp Met Ile Lys Ile Asp Ser Lys Ala Leu Gly Met Glu
                              165                 170                 175
              Lys Glu Gly Asp Glu Leu Ile Lys Asn Thr Glu Ala Arg Ile Ser Lys
                          180                 185                 190
              Glu Leu Glu Lys His Pro Glu Ile Lys Gly Lys Ile Lys Gly Lys Lys
                      195                 200                 205
              Val Leu Phe Thr Met Ile Asn Ala Ala Asp Thr Ser Lys Phe Trp Ile
                  210                 215                 220
              Tyr Thr Ser Lys Asp Pro Arg Ala Asn Tyr Leu Thr Asp Leu Gly Leu
              225                 230                 235                 240
              Val Phe Pro Glu Ser Leu Lys Glu Phe Glu Ser Glu Asp Ser Phe Ala
                              245                 250                 255
              Lys Glu Ile Ser Ala Glu Glu Ala Asn Lys Ile Asn Asp Ala Asp Val
                          260                 265                 270
              Ile Ile Thr Tyr Gly Asp Asp Lys Thr Leu Glu Ala Leu Gln Lys Asp
                      275                 280                 285
                                                  Page 84

<removed-date>
              Pro Leu Leu Gly Lys Ile Asn Ala Ile Lys Asn Gly Ala Val Ala Val
                  290                 295                 300
              Ile Pro Asp Asn Thr Pro Leu Ala Ala Ser Cys Thr Pro Thr Pro Leu
              305                 310                 315                 320
              Ser Ile Asn Tyr Thr Ile Glu Glu Tyr Leu Asn Leu Leu Gly Asn Ala
                              325                 330                 335
<removed-apn>
              Cys Lys Asn Ala Lys
                          340
              <210>   42
              <211>   344
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 42
              Met Leu Lys Glu Ile Lys Arg Arg Asn Arg Met Lys Asn Lys Arg Leu
              1               5                   10                  15
              Ile Gly Ile Ile Ala Ala Leu Ala Val Leu Val Ala Gly Ser Leu Ile
                          20                  25                  30
              Tyr Ser Ser Met Asn Lys Ser Glu Ala Gln Asn Asn Lys Asp Glu Lys
                      35                  40                  45
              Lys Ile Thr Lys Ile Gly Val Leu Gln Phe Val Ser His Pro Ser Leu
                  50                  55                  60
              Asp Leu Ile Tyr Lys Gly Ile Gln Asp Gly Leu Ala Glu Glu Gly Tyr
              65                  70                  75                  80
              Lys Asp Asp Gln Val Lys Ile Asp Phe Met Asn Ser Glu Gly Asp Gln
                              85                  90                  95
              Ser Lys Val Ala Thr Met Ser Lys Gln Leu Val Ala Asn Gly Asn Asp
                          100                 105                 110
              Leu Val Val Gly Ile Ala Thr Pro Ala Ala Gln Gly Leu Ala Ser Ala
                      115                 120                 125
                                                  Page 85

<removed-date>
              Thr Lys Asp Leu Pro Val Ile Met Ala Ala Ile Thr Asp Pro Ile Gly
                  130                 135                 140
              Ala Asn Leu Val Lys Asp Leu Lys Lys Pro Gly Gly Asn Val Thr Gly
              145                 150                 155                 160
              Val Ser Asp His Asn Pro Ala Gln Gln Gln Val Glu Leu Ile Lys Ala
<removed-apn>
                              165                 170                 175
              Leu Thr Pro Asn Val Lys Thr Ile Gly Ala Leu Tyr Ser Ser Ser Glu
                          180                 185                 190
              Asp Asn Ser Lys Thr Gln Val Glu Glu Phe Lys Ala Tyr Ala Glu Lys
                      195                 200                 205
              Ala Gly Leu Thr Val Glu Thr Phe Ala Val Pro Ser Thr Asn Glu Ile
                  210                 215                 220
              Ala Ser Thr Val Thr Val Met Thr Ser Lys Val Asp Ala Ile Trp Val
              225                 230                 235                 240
              Pro Ile Asp Asn Thr Ile Ala Ser Gly Phe Pro Thr Val Val Ser Ser
                              245                 250                 255
              Asn Gln Ser Ser Lys Lys Pro Ile Tyr Pro Ser Ala Thr Ala Met Val
                          260                 265                 270
              Glu Val Gly Gly Leu Ala Ser Val Val Ile Asp Gln His Asp Leu Gly
                      275                 280                 285
              Val Ala Thr Gly Lys Met Ile Val Gln Val Leu Lys Gly Ala Lys Pro
                  290                 295                 300
              Ala Asp Thr Pro Val Asn Val Phe Ser Thr Gly Lys Ser Val Ile Asn
              305                 310                 315                 320
              Lys Lys Ile Ala Gln Glu Leu Gly Ile Thr Ile Pro Glu Ser Val Leu
                              325                 330                 335
                                                  Page 86

<removed-date>
              Lys Glu Ala Gly Gln Val Ile Glu
                          340
              <210>   43
              <211>   2004
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 43
<removed-apn>
              Met Glu Lys Tyr Phe Gly Glu Lys Gln Glu Arg Phe Ser Phe Arg Lys
              1               5                   10                  15
              Leu Ser Val Gly Leu Val Ser Ala Thr Ile Ser Ser Leu Phe Phe Met
                          20                  25                  30
              Ser Val Leu Ala Ser Ser Ser Val Asp Ala Gln Glu Thr Ala Gly Val
                      35                  40                  45
              His Tyr Lys Tyr Val Ala Asp Ser Glu Leu Ser Ser Glu Glu Lys Lys
                  50                  55                  60
              Gln Leu Val Tyr Asp Ile Pro Thr Tyr Val Glu Asn Asp Asp Glu Thr
              65                  70                  75                  80
              Tyr Tyr Leu Val Tyr Lys Leu Asn Ser Gln Asn Gln Leu Ala Glu Leu
                              85                  90                  95
              Pro Asn Thr Gly Ser Lys Asn Glu Arg Gln Ala Leu Val Ala Gly Ala
                          100                 105                 110
              Ser Leu Ala Ala Met Gly Ile Leu Ile Phe Ala Val Ser Lys Lys Lys
                      115                 120                 125
              Val Lys Asn Lys Thr Val Leu His Leu Val Leu Val Ala Gly Ile Gly
                  130                 135                 140
              Asn Gly Val Leu Val Ser Val His Ala Leu Glu Asn His Leu Leu Leu
              145                 150                 155                 160
              Asn Tyr Asn Thr Asp Tyr Glu Leu Thr Ser Gly Glu Lys Leu Pro Leu
                              165                 170                 175
                                                  Page 87

<removed-date>
              Pro Lys Glu Ile Ser Gly Tyr Thr Tyr Ile Gly Tyr Ile Lys Glu Gly
                          180                 185                 190
              Lys Thr Thr Ser Glu Ser Glu Val Ser Asn Gln Lys Ser Ser Val Ala
                      195                 200                 205
              Thr Pro Thr Lys Gln Gln Lys Val Asp Tyr Asn Val Thr Pro Asn Phe
<removed-apn>
                  210                 215                 220
              Val Asp His Pro Ser Thr Val Gln Ala Ile Gln Glu Gln Thr Pro Val
              225                 230                 235                 240
              Ser Ser Thr Lys Pro Thr Glu Val Gln Val Val Glu Lys Pro Phe Ser
                              245                 250                 255
              Thr Glu Leu Ile Asn Pro Arg Lys Glu Glu Lys Gln Ser Ser Asp Ser
                          260                 265                 270
              Gln Glu Gln Leu Ala Glu His Lys Asn Leu Glu Thr Lys Lys Glu Glu
                      275                 280                 285
              Lys Ile Ser Pro Lys Glu Lys Thr Gly Val Asn Thr Leu Asn Pro Gln
                  290                 295                 300
              Asp Glu Val Leu Ser Gly Gln Leu Asn Lys Pro Glu Leu Leu Tyr Arg
              305                 310                 315                 320
              Glu Glu Thr Met Glu Thr Lys Ile Asp Phe Gln Glu Glu Ile Gln Glu
                              325                 330                 335
              Asn Pro Asp Leu Ala Glu Gly Thr Val Arg Val Lys Gln Glu Gly Lys
                          340                 345                 350
              Leu Gly Lys Lys Val Glu Ile Val Arg Ile Phe Ser Val Asn Lys Glu
                      355                 360                 365
              Glu Val Ser Arg Glu Ile Val Ser Thr Ser Thr Thr Ala Pro Ser Pro
                  370                 375                 380
                                                  Page 88

<removed-date>
              Arg Ile Val Glu Lys Gly Thr Lys Lys Thr Gln Val Ile Lys Glu Gln
              385                 390                 395                 400
              Pro Glu Thr Gly Val Glu His Lys Asp Val Gln Ser Gly Ala Ile Val
                              405                 410                 415
              Glu Pro Ala Ile Gln Pro Glu Leu Pro Glu Ala Val Val Ser Asp Lys
                          420                 425                 430
<removed-apn>
              Gly Glu Pro Glu Val Gln Pro Thr Leu Pro Glu Ala Val Val Thr Asp
                      435                 440                 445
              Lys Gly Glu Thr Glu Val Gln Pro Glu Ser Pro Asp Thr Val Val Ser
                  450                 455                 460
              Asp Lys Gly Glu Pro Glu Gln Val Ala Pro Leu Pro Glu Tyr Lys Gly
              465                 470                 475                 480
              Asn Ile Glu Gln Val Lys Pro Glu Thr Pro Val Glu Lys Thr Lys Glu
                              485                 490                 495
              Gln Gly Pro Glu Lys Thr Glu Glu Val Pro Val Lys Pro Thr Glu Glu
                          500                 505                 510
              Thr Pro Val Asn Pro Asn Glu Gly Thr Thr Glu Gly Thr Ser Ile Gln
                      515                 520                 525
              Glu Ala Glu Asn Pro Val Gln Pro Ala Glu Glu Ser Thr Thr Asn Ser
                  530                 535                 540
              Glu Lys Val Ser Pro Asp Thr Ser Ser Lys Asn Thr Gly Glu Val Ser
              545                 550                 555                 560
              Ser Asn Pro Ser Asp Ser Thr Thr Ser Val Gly Glu Ser Asn Lys Pro
                              565                 570                 575
              Glu His Asn Asp Ser Lys Asn Glu Asn Ser Glu Lys Thr Val Glu Glu
                          580                 585                 590
                                                  Page 89

              Val Pro Val Asn Pro Asn Glu Gly Thr Val Glu Gly Thr Ser Asn Gln
<removed-date>
                      595                 600                 605
              Glu Thr Glu Lys Pro Val Gln Pro Ala Glu Glu Thr Gln Thr Asn Ser
                  610                 615                 620
              Gly Lys Ile Ala Asn Glu Asn Thr Gly Glu Val Ser Asn Lys Pro Ser
              625                 630                 635                 640
<removed-apn>
              Asp Ser Lys Pro Pro Val Glu Glu Ser Asn Gln Pro Glu Lys Asn Gly
                              645                 650                 655
              Thr Ala Thr Lys Pro Glu Asn Ser Gly Asn Thr Thr Ser Glu Asn Gly
                          660                 665                 670
              Gln Thr Glu Pro Glu Pro Ser Asn Gly Asn Ser Thr Glu Asp Val Ser
                      675                 680                 685
              Thr Glu Ser Asn Thr Ser Asn Ser Asn Gly Asn Glu Glu Ile Lys Gln
                  690                 695                 700
              Glu Asn Glu Leu Asp Pro Asp Lys Lys Val Glu Glu Pro Glu Lys Thr
              705                 710                 715                 720
              Leu Glu Leu Arg Asn Val Ser Asp Leu Glu Leu Tyr Ser Leu Ser Asn
                              725                 730                 735
              Gly Thr Tyr Lys Gln His Ile Ser Leu Glu Gln Val Pro Ser Asn Pro
                          740                 745                 750
              Asn Ser Tyr Phe Val Lys Val Lys Ser Ser Ser Phe Lys Asp Val Tyr
                      755                 760                 765
              Leu Pro Val Ala Ser Ile Ser Glu Glu Arg Lys Asn Asp Lys Ile Leu
                  770                 775                 780
              Tyr Lys Ile Thr Ala Lys Val Glu Lys Leu Gln Gln Glu Ile Glu Ser
              785                 790                 795                 800
              Arg Tyr Lys Asp Asn Phe Thr Phe Tyr Leu Ala Lys Lys Gly Thr Glu
                                                  Page 90

                              805                 810                 815
<removed-date>
              Glu Thr Thr Asn Phe Thr Ser Phe Ser Asn Leu Val Lys Ala Ile Asn
                          820                 825                 830
              Gln Asn Pro Ser Gly Thr Tyr His Leu Ala Ala Ser Leu Asn Ala Asn
                      835                 840                 845
<removed-apn>
              Glu Val Glu Leu Gly Pro Asp Glu Arg Ser Tyr Ile Lys Asp Thr Phe
                  850                 855                 860
              Thr Gly Arg Leu Ile Gly Glu Lys Asp Gly Lys Asn Tyr Ala Ile Tyr
              865                 870                 875                 880
              Asn Leu Lys Lys Pro Leu Phe Glu Asn Leu Ser Gly Ala Thr Val Glu
                              885                 890                 895
              Lys Leu Ser Leu Lys Asn Val Ala Ile Ser Gly Lys Asp Asp Ile Gly
                          900                 905                 910
              Ser Leu Ala Asn Glu Ala Gln Asn Asn Thr Lys Ile Lys Gln Val His
                      915                 920                 925
              Val Asp Gly Val Leu Ala Gly Glu Arg Gly Ile Gly Gly Leu Leu Ala
                  930                 935                 940
              Lys Ala Glu Gln Ser Ser Ile Thr Glu Ser Ser Phe Lys Gly Arg Ile
              945                 950                 955                 960
              Ile Asn Thr Tyr Glu Thr Thr Ala Ala Tyr Asn Ile Gly Gly Met Val
                              965                 970                 975
              Gly His Leu Thr Gly Asp Lys Ala Leu Leu Thr Lys Ser Lys Ala Thr
                          980                 985                 990
              Val Ala Ile Ser Ser Asn Thr Asn Thr Ser Asp Gln Thr Val Gly Gly
                      995                 1000                1005
              Leu Ala Gly Leu Val Asp Arg Asp Ala Gln Ile Gln Asp Ser Tyr
                  1010                1015                1020
                                                  Page 91

<removed-date>
              Ala Glu Gly Asp Ile Asn Asn Val Lys His Phe Gly Arg Val Ala
                  1025                1030                1035
              Gly Val Ala Gly Asn Leu Trp Asp Arg Thr Ser Gly Asp Val Arg
                  1040                1045                1050
              His Ala Gly Ser Leu Thr Asn Val Leu Ser Asp Val Asn Val Thr
<removed-apn>
                  1055                1060                1065
              Asn Gly Asn Ala Ile Thr Gly Tyr His Tyr Asn Glu Met Lys Val
                  1070                1075                1080
              Lys Asp Thr Phe Ser Ser Lys Ala Asn Arg Val Tyr Asn Val Thr
                  1085                1090                1095
              Leu Val Lys Asp Glu Val Val Ser Lys Glu Ser Phe Glu Glu Arg
                  1100                1105                1110
              Gly Thr Met Leu Asp Ala Ser Gln Ile Ala Ser Lys Lys Ala Glu
                  1115                1120                1125
              Ile Asn Pro Leu Ile Leu Pro Thr Val Glu Pro Leu Ser Thr Ser
                  1130                1135                1140
              Gly Lys Lys Asp Ser Asp Phe Ser Lys Val Ala Tyr Tyr Gln Ala
                  1145                1150                1155
              Lys Arg Asn Leu Thr Tyr Lys Asn Ile Glu Lys Leu Leu Pro Phe
                  1160                1165                1170
              Tyr Asn Lys Ala Thr Ile Val Lys Tyr Gly Asn Leu Val Asn Glu
                  1175                1180                1185
              Asn Ser Leu Leu Tyr Gln Lys Glu Leu Leu Ser Ala Val Met Met
                  1190                1195                1200
              Lys Asp Asn Gln Val Ile Thr Asp Ile Val Ser Asn Lys Gln Thr
                  1205                1210                1215
                                                Page 92

<removed-date>
              Ala Asn Lys Leu Leu Leu His Tyr Lys Asp Asp Leu Ser Glu Lys
                  1220                1225                1230
              Leu Asp Leu Lys Tyr Gln Asn Asp Phe Ala Lys Leu Ala Glu Tyr
                  1235                1240                1245
              Ser Leu Gly Asn Thr Gly Leu Leu Tyr Thr Pro Asn Gln Phe Leu
                  1250                1255                1260
<removed-apn>
              Tyr Asp Gln Thr Ser Ile Ile Lys Gln Val Leu Pro Asp Leu Gln
                  1265                1270                1275
              Lys Val Asp Tyr His Ser Glu Ala Ile Arg Lys Thr Leu Gly Ile
                  1280                1285                1290
              Ser Pro Asn Val Lys Gln Thr Glu Leu Tyr Leu Glu Asp Gln Phe
                  1295                1300                1305
              Ala Lys Thr Lys Gln Gln Leu Glu Asp Ser Leu Lys Lys Leu Leu
                  1310                1315                1320
              Ser Ala Asp Ala Gly Leu Ala Ser Ala Asn Pro Val Thr Glu Gly
                  1325                1330                1335
              Tyr Leu Val Asp Lys Ile Lys Arg Asn Lys Glu Ala Leu Leu Leu
                  1340                1345                1350
              Gly Leu Thr Tyr Leu Glu Arg Trp Tyr Asn Phe Ser Tyr Gly Gln
                  1355                1360                1365
              Val Asn Val Lys Asp Leu Val Leu Tyr His Leu Asp Phe Phe Gly
                  1370                1375                1380
              Lys Gly Asn Ala Ser Pro Leu Asp Thr Leu Ile Glu Leu Gly Lys
                  1385                1390                1395
              Ser Gly Phe Asn Asn Leu Leu Ala Lys Asn Asn Val Asp Thr Tyr
                  1400                1405                1410
                                                Page 93

              Gly Ile Ser Leu Ala Ser Gln His Gly Thr Thr Asp Leu Phe Ser
<removed-date>
                  1415                1420                1425
              Thr Leu Glu His Tyr Arg Lys Val Phe Leu Pro Asn Thr Ser Asn
                  1430                1435                1440
              Asn Asp Trp Phe Lys Ser Glu Thr Lys Ala Tyr Ile Val Glu Glu
                  1445                1450                1455
<removed-apn>
              Lys Ser Thr Ile Glu Glu Val Lys Thr Lys Gln Gly Leu Ala Gly
                  1460                1465                1470
              Thr Lys Tyr Ser Ile Gly Val Tyr Asp Arg Ile Thr Ser Ala Thr
                  1475                1480                1485
              Trp Lys Tyr Arg Asn Met Val Leu Pro Leu Leu Thr Leu Pro Glu
                  1490                1495                1500
              Arg Ser Val Phe Val Ile Ser Thr Met Ser Ser Leu Gly Phe Gly
                  1505                1510                1515
              Ala Tyr Asp Arg Tyr Arg Ser Ser Asp His Lys Ala Gly Lys Ala
                  1520                1525                1530
              Leu Asn Asp Phe Val Glu Glu Asn Ala Arg Glu Thr Ala Lys Arg
                  1535                1540                1545
              Gln Arg Asp His Tyr Asp Tyr Trp Tyr Arg Ile Leu Asp Asp Asn
                  1550                1555                1560
              Ala Arg Glu Lys Leu Tyr Arg Asn Ile Leu Leu Tyr Asp Ala Tyr
                  1565                1570                1575
              Lys Phe Gly Asp Asp Asn Thr Val Gly Lys Ala Thr Glu Val Ala
                  1580                1585                1590
              Asp Phe Asp Asn Pro Asn Pro Ala Met Gln His Phe Phe Gly Pro
                  1595                1600                1605
              Val Gly   Asn Lys Val Gly His   Asn Gln His Gly Ala   Tyr Ala Thr
                                                    Page 94

                 1610                1615                 1620
<removed-date>
              Gly Asp Ala Val Tyr Tyr Met Gly Tyr Arg Met Leu Asp Lys Asp
                  1625                1630                1635
              Gly Ala Ile Thr Tyr Thr His Glu Met Thr His Asp Ser Asp Gln
                  1640                1645                1650
<removed-apn>
              Asp Ile Tyr Leu Gly Gly Tyr Gly Arg Arg Ser Gly Leu Gly Pro
                  1655                1660                1665
              Glu Phe Phe Ala Lys Gly Leu Leu Gln Ala Pro Asp His Pro Asp
                  1670                1675                1680
              Asp Ala Thr Ile Thr Ile Asn Ser Ile Leu Lys His Ser Lys Ser
                  1685                1690                1695
              Asp Ser Thr Glu Ser Arg Arg Leu Gln Val Leu Asp Pro Thr Thr
                  1700                1705                1710
              Arg Phe Asn Asn Ala Asp Asp Leu Lys Gln Tyr Val His Asn Met
                  1715                1720                1725
              Phe Asp Val Val Tyr Met Leu Glu Tyr Leu Glu Gly Asn Ser Ile
                  1730                1735                1740
              Leu Lys Leu Asp Thr Asn Gln Lys Gln Gln Leu Leu Arg Lys Val
                  1745                1750                1755
              Thr Asn Glu Tyr His Pro Asp Pro Asp Gly Asn Lys Val Tyr Ala
                  1760                1765                1770
              Thr Asn Val Val Arg Asn Leu Thr Val Glu Glu Val Glu Arg Leu
                  1775                1780                1785
              Arg Ser Phe Asn Asp Leu Ile Asp Asn Asn Ile Leu Ser Ser Arg
                  1790                1795                1800
              Glu Tyr Ala Ser Gly Lys Tyr Glu Arg Asn Gly Tyr Phe Thr Ile
                  1805                1810                1815
                                                Page 95

<removed-date>
              Lys Leu Phe Ala Pro Ile Tyr Ala Ala Leu Ser Asn Asp Ile Gly
                  1820                1825                1830
              Thr Pro Gly Asp Leu Met Gly Arg Arg Ile Ala Tyr Glu Leu Leu
                  1835                1840                1845
              Ala Ala Lys Gly Phe Lys Asp Gly Met Val Pro Tyr Ile Ser Asn
<removed-apn>
                  1850                1855                1860
              Gln Tyr Glu Glu Glu Ala Lys Gln Lys Gly Lys Thr Ile Asn Leu
                  1865                1870                1875
              Tyr Gly Lys Thr Arg Gly Leu Val Thr Asp Asp Leu Val Leu Glu
                  1880                1885                1890
              Lys Val Phe Asn Asn Gln Tyr His Thr Trp Ser Glu Phe Lys Lys
                  1895                1900                1905
              Ala Met Tyr Gln Glu Arg Gln Asp Gln Phe Asp Arg Leu Asn Lys
                  1910                1915                1920
              Val Thr Phe Asn Asp Thr Thr Gln Pro Trp Gln Thr Phe Ala Lys
                  1925                1930                1935
              Lys Thr Thr Ser Ser Val Asp Glu Leu Gln Lys Leu Met Asp Val
                  1940                1945                1950
              Ala Val Arg Lys Asp Ala Glu His Asn Tyr Tyr His Trp Asn Asn
                  1955                1960                1965
              Tyr Asn Pro Asp Ile Asp Ser Glu Val His Lys Leu Lys Arg Ala
                  1970                1975                1980
              Ile Phe Lys Ala Tyr Leu Asp Gln Thr Asn Asp Phe Arg Ser Ser
                  1985                1990                1995
              Ile Phe Glu Asn Lys Lys
                  2000
                                                Page 96

<removed-date>
              <210>   44
              <211>   229
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 44
              Met Lys Ala Ile Ile Leu Ala Ala Gly Leu Gly Thr Arg Leu Arg Pro
              1               5                   10                  15
<removed-apn>
              Met Thr Glu Asn Thr Pro Lys Ala Leu Val Gln Val Asn Gln Lys Pro
                          20                  25                  30
              Leu Ile Glu Tyr Gln Ile Glu Phe Leu Lys Glu Lys Gly Ile Asn Asp
                      35                  40                  45
              Ile Ile Ile Ile Val Gly Tyr Leu Lys Glu Gln Phe Asp Tyr Leu Lys
                  50                  55                  60
              Glu Lys Tyr Gly Val Arg Leu Val Phe Asn Asp Lys Tyr Ala Asp Tyr
              65                  70                  75                  80
              Asn Asn Phe Tyr Ser Leu Tyr Leu Val Lys Glu Glu Leu Ala Asn Ser
                              85                  90                  95
              Tyr Val Ile Asp Ala Asp Asn Tyr Leu Phe Lys Asn Met Phe Arg Asn
                          100                 105                 110
              Asp Leu Thr Arg Ser Thr Tyr Phe Ser Val Tyr Arg Glu Asp Cys Thr
                      115                 120                 125
              Asn Glu Trp Phe Leu Val Tyr Gly Asp Asp Tyr Lys Val Gln Asp Ile
                  130                 135                 140
              Ile Val Asp Ser Lys Ala Gly Arg Ile Leu Ser Gly Val Ser Phe Trp
              145                 150                 155                 160
              Asp Ala Pro Thr Ala Glu Lys Ile Val Ser Phe Ile Asp Lys Ala Tyr
                              165                 170                 175
              Val Ser Gly Glu Phe Val Asp Leu Tyr Trp Asp Asn Met Val Lys Asp
                          180                 185                 190
                                                  Page 97

<removed-date>
              Asn Ile Lys Glu Leu Asp Val Tyr Val Glu Glu Leu Glu Gly Asn Ser
                      195                 200                 205
              Ile Tyr Glu Ile Asp Ser Val Gln Asp Tyr Arg Lys Leu Glu Glu Ile
                  210                 215                 220
              Leu Lys Asn Glu Asn
<removed-apn>
              225
              <210>   45
              <211>   284
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 45
              Met Lys Leu Asp Gly Tyr Thr Arg Leu Ala Ala Val Val Ala Asn Pro
              1               5                   10                  15
              Ile Lys His Ser Ile Ser Pro Phe Ile His Asn Arg Ala Phe Glu Ala
                          20                  25                  30
              Thr Ala Thr Asn Gly Ala Tyr Val Ala Trp Glu Ile Glu Ala Ser Asp
                      35                  40                  45
              Leu Val Glu Thr Val Ala Asn Ile Arg Arg Tyr Gln Met Phe Gly Ile
                  50                  55                  60
              Asn Leu Ser Met Pro Tyr Lys Glu Gln Val Ile Pro Tyr Leu Asp Lys
              65                  70                  75                  80
              Leu Ser Asp Glu Ala Arg Leu Ile Gly Ala Val Asn Thr Val Val Asn
                              85                  90                  95
              Glu Asn Gly Asn Leu Ile Gly Tyr Asn Thr Asp Gly Lys Gly Phe Phe
                          100                 105                 110
              Lys Cys Leu Pro Ser Phe Thr Ile Ser Gly Lys Lys Met Thr Leu Leu
                      115                 120                 125
              Gly Ala Gly Gly Ala Ala Lys Ser Ile Leu Ala Gln Ala Ile Leu Asp
                                                  Page 98

                  130                   135                 140
<removed-date>
              Gly Val Ser Gln Ile Ser Val Phe Val Arg Ser Val Ser Met Glu Lys
              145                 150                 155                 160
              Thr Arg Pro Tyr Leu Asp Lys Leu Gln Glu Gln Thr Gly Phe Lys Val
                              165                 170                 175
<removed-apn>
              Asp Leu Cys Ala Leu Glu Tyr Val Ser Glu Leu Gln Ala Arg Ile Ala
                          180                 185                 190
              Glu Ser Asp Leu Leu Val Asn Ala Thr Ser Val Gly Met Asp Gly Gln
                      195                 200                 205
              Ser Ser Pro Val Pro Glu Asn Ile Val Leu Pro Glu Thr Leu Leu Val
                  210                 215                 220
              Ala Asp Ile Ile Tyr Gln Pro Phe Glu Thr Pro Phe Leu Lys Trp Ala
              225                 230                 235                 240
              Arg Ser Gln Gly Asn Pro Ala Val Asn Gly Leu Gly Met Leu Leu Tyr
                              245                 250                 255
              Gln Ala Ala Glu Ala Phe Gln Leu Trp Thr Gly Lys Glu Met Pro Thr
                          260                 265                 270
              Glu Glu Ile Trp Gln Ser Leu Thr Glu Lys Tyr Gln
                      275                 280
              <210>   46
              <211>   356
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 46
              Met Lys Lys Ile Tyr Ser Phe Leu Ala Gly Ile Ala Ala Ile Ile Leu
              1               5                   10                  15
              Val Leu Trp Gly Ile Ala Thr His Leu Asp Ser Lys Ile Asn Ser Arg
                          20                  25                  30
                                                  Page 99

              Asp Ser Gln Lys Leu Val Ile Tyr Asn Trp Gly Asp Tyr Ile Asp Pro
<removed-date>
                      35                  40                  45
              Glu Leu Leu Thr Gln Phe Thr Glu Glu Thr Gly Ile Gln Val Gln Tyr
                  50                  55                  60
              Glu Thr Phe Asp Ser Asn Glu Ala Met Tyr Thr Lys Ile Lys Gln Gly
              65                  70                  75                  80
<removed-apn>
              Gly Thr Thr Tyr Asp Ile Ala Ile Pro Ser Glu Tyr Met Ile Asn Lys
                              85                  90                  95
              Met Lys Asp Glu Asp Leu Leu Val Pro Leu Asp Tyr Ser Lys Ile Glu
                          100                 105                 110
              Gly Ile Glu Asn Ile Gly Pro Glu Phe Leu Asn Gln Ser Phe Asp Pro
                      115                 120                 125
              Gly Asn Lys Phe Ser Ile Pro Tyr Phe Trp Gly Thr Leu Gly Ile Val
                  130                 135                 140
              Tyr Asn Glu Thr Met Val Asp Glu Ala Pro Glu His Trp Asp Asp Leu
              145                 150                 155                 160
              Trp Lys Pro Glu Tyr Lys Asn Ser Ile Met Leu Phe Asp Gly Ala Arg
                              165                 170                 175
              Glu Val Leu Gly Leu Gly Leu Asn Ser Leu Gly Tyr Ser Leu Asn Ser
                          180                 185                 190
              Lys Asp Leu Gln Gln Leu Glu Glu Thr Val Asp Lys Leu Tyr Lys Leu
                      195                 200                 205
              Thr Pro Asn Ile Lys Ala Ile Val Ala Asp Glu Met Lys Gly Tyr Met
                  210                 215                 220
              Ile Gln Asn Asn Val Ala Ile Gly Val Thr Phe Ser Gly Glu Ala Ser
              225                 230                 235                 240
              Gln Met Leu Glu Lys Asn Glu Asn Leu Arg Tyr Val Val Pro Thr Glu
                                                 Page 100

                                245               250                 255
<removed-date>
              Ala Ser Asn Leu Trp Phe Asp Asn Met Val Ile Pro Lys Thr Val Lys
                          260                 265                 270
              Asn Gln Asn Ser Ala Tyr Ala Phe Ile Asn Phe Met Leu Lys Pro Glu
                      275                 280                 285
<removed-apn>
              Asn Ala Leu Gln Asn Ala Glu Tyr Val Gly Tyr Ser Thr Pro Asn Leu
                  290                 295                 300
              Pro Ala Lys Glu Leu Leu Pro Glu Glu Thr Lys Glu Asp Lys Ala Phe
              305                 310                 315                 320
              Tyr Pro Asp Val Glu Thr Met Lys His Leu Glu Val Tyr Glu Lys Phe
                              325                 330                 335
              Asp His Lys Trp Thr Gly Lys Tyr Ser Asp Leu Phe Leu Gln Phe Lys
                          340                 345                 350
              Met Tyr Arg Lys
                      355
              <210>   47
              <211>   92
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 47
              Met Asn Lys Gln Tyr Ser Tyr Pro Leu Asp Leu Ser Trp Ser Thr Glu
              1               5                   10                  15
              Glu Leu Ala Ser Val Leu Ser Phe Phe Asn Asp Val Glu Ala Ala Tyr
                          20                  25                  30
              Glu Gly Lys Val Glu Ala Lys Lys Leu Leu Asp Ser Tyr Lys Gly Phe
                      35                  40                  45
              Lys Ala Val Val Pro Ser Lys Ser Glu Glu Lys Arg Leu Gly Arg Glu
                  50                  55                  60
                                                 Page 101

              Phe Glu Thr Val Ser Gly Tyr Ser Leu Tyr Arg Ala Val Gln Ala Ala
<removed-date>
              65                  70                  75                  80
              Lys Glu Lys Gly Glu Gly Lys Ile Ser Leu Gly Lys
                              85                  90
              <210>   48
              <211>   133
              <212>   PRT
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 48
              Met Ile Thr Leu Phe Leu Ser Pro Ser Cys Thr Ser Cys Arg Lys Ala
              1               5                   10                  15
              Lys Ala Trp Leu Glu Lys His Lys Val Pro Phe Val Glu His Asn Ile
                          20                  25                  30
              Met Thr Ser Pro Leu Thr Arg Lys Glu Leu Gln His Ile Leu Ser Leu
                      35                  40                  45
              Thr Glu Asn Gly Thr Asp Asp Ile Ile Ser Thr Arg Ser Lys Ile Phe
                  50                  55                  60
              Gln Lys Leu Asn Ile Asp Val Glu Ser Ile Ser Val Ser Glu Leu Leu
              65                  70                  75                  80
              His Leu Ile Glu Gln Tyr Pro Ser Leu Leu Arg Arg Pro Ile Ile Ile
                              85                  90                  95
              Asp Ala Lys Arg Met Gln Ile Gly Phe Asn Glu Asp Glu Ile Arg Ala
                          100                 105                 110
              Phe Leu Pro Arg Ser Tyr Arg Lys Gln Glu Leu Lys Glu Ala Arg Met
                      115                 120                 125
              Arg Ala Gly Ile Ser
                  130
              <210> 49
              <211> 183
              <212> PRT
                                                 Page 102

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 49
              Met Lys Ser Ile Gly Thr Gln Ile Leu Gln Thr Glu Arg Leu Ile Leu
              1               5                   10                  15
              Arg Arg Phe Val Glu Ser Asp Ala Glu Ala Met Phe Gln Asn Trp Ala
                          20                  25                  30
<removed-apn>
              Ser Ser Ala Glu Asn Leu Thr Tyr Val Thr Trp Asp Pro His Pro Asp
                      35                  40                  45
              Val Glu Ile Thr Arg Asn Ser Ile Cys Asn Trp Val Ala Ser Tyr Thr
                  50                  55                  60
              Asn Leu Asn Tyr Tyr Lys Trp Ala Ile Cys Leu Lys Glu Asn Pro Glu
              65                  70                  75                  80
              Gln Val Ile Gly Asp Ile Ser Ile Val Lys Ile Asp Glu Ala Asp Leu
                              85                  90                  95
              Ser Cys Glu Ile Gly Tyr Val Leu Gly Lys Ala Tyr Trp Gly Asn Gly
                          100                 105                 110
              Met Met Thr Glu Thr Leu Lys Ala Ile Leu Asp Phe Cys Phe Thr Gln
                      115                 120                 125
              Ala Gly Phe Gln Lys Val Arg Ala Arg Tyr Ala Ser Leu Asn Pro Ala
                  130                 135                 140
              Ser Gly Arg Val Met Glu Lys Ala Gly Met Ser Tyr Leu Gln Thr Ile
              145                 150                 155                 160
              Val Asn Gly Val Glu Arg Lys Gly Tyr Leu Ala Asp Leu Ile Tyr Tyr
                              165                 170                 175
              Gly Ile Ser Arg Glu Glu Cys
                          180
              <210> 50
              <211> 463
                                                 Page 103

              <212> PRT
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 50
              Met Asn Lys Ser Arg Leu Gly Arg Gly Arg His Gly Lys Thr Arg His
              1               5                   10                  15
              Val Leu Leu Ala Leu Ile Gly Ile Leu Ala Ile Ser Ile Cys Leu Leu
                          20                  25                  30
<removed-apn>
              Gly Gly Phe Ile Ala Phe Lys Ile Tyr Gln Gln Lys Ser Phe Glu Gln
                      35                  40                  45
              Lys Ile Glu Ser Leu Lys Lys Glu Lys Asp Asp Gln Leu Ser Glu Gly
                  50                  55                  60
              Asn Gln Lys Glu His Phe Arg Gln Gly Gln Ala Glu Val Ile Ala Tyr
              65                  70                  75                  80
              Tyr Pro Leu Gln Gly Glu Lys Val Ile Ser Ser Val Arg Glu Leu Ile
                              85                  90                  95
              Asn Gln Asp Val Lys Asp Lys Leu Glu Ser Lys Asp Asn Leu Val Phe
                          100                 105                 110
              Tyr Tyr Thr Glu Gln Glu Glu Ser Gly Leu Lys Gly Val Val Asn Arg
                      115                 120                 125
              Asn Val Thr Lys Gln Ile Tyr Asp Leu Val Ala Phe Lys Ile Glu Glu
                  130                 135                 140
              Thr Glu Lys Thr Ser Leu Gly Lys Val His Leu Thr Glu Asp Gly Gln
              145                 150                 155                 160
              Pro Phe Thr Leu Asp Gln Leu Phe Ser Asp Ala Ser Lys Ala Lys Glu
                              165                 170                 175
              Gln Leu Ile Lys Glu Leu Thr Ser Phe Ile Glu Asp Lys Lys Ile Glu
                          180                 185                 190
              Gln Asp Gln Ser Glu Gln Ile Val Lys Asn Phe Ser Asp Gln Asp Leu
                                                 Page 104

                      195                 200                 205
<removed-date>
              Ser Ala Trp Asn Phe Asp Tyr Lys Asp Ser Gln Ile Ile Leu Tyr Pro
                  210                 215                 220
              Ser Pro Val Val Glu Asn Leu Glu Glu Ile Ala Leu Pro Val Ser Ala
              225                 230                 235                 240
<removed-apn>
              Phe Phe Asp Val Ile Gln Ser Ser Tyr Leu Leu Glu Lys Asp Ala Ala
                              245                 250                 255
              Leu Tyr Gln Ser Tyr Phe Asp Lys Lys His Gln Lys Val Val Ala Leu
                          260                 265                 270
              Thr Phe Asp Asp Gly Pro Asn Pro Ala Thr Thr Pro Gln Val Leu Glu
                      275                 280                 285
              Thr Leu Ala Lys Tyr Asp Ile Lys Ala Thr Phe Phe Val Leu Gly Lys
                  290                 295                 300
              Asn Val Ser Gly Asn Glu Asp Leu Val Lys Arg Ile Lys Ser Glu Gly
              305                 310                 315                 320
              His Val Val Gly Asn His Ser Trp Ser His Pro Ile Leu Ser Gln Leu
                              325                 330                 335
              Ser Leu Asp Glu Ala Lys Lys Gln Ile Thr Asp Thr Glu Asp Val Leu
                          340                 345                 350
              Thr Lys Val Leu Gly Ser Ser Ser Lys Leu Met Arg Pro Pro Tyr Gly
                      355                 360                 365
              Ala Ile Thr Asp Asp Ile Arg Asn Ser Leu Asp Leu Ser Phe Ile Met
                  370                 375                 380
              Trp Asp Val Asp Ser Leu Asp Trp Lys Ser Lys Asn Glu Ala Ser Ile
              385                 390                 395                 400
              Leu Thr Glu Ile Gln Tyr Gln Val Ala Asn Gly Ser Ile Val Leu Met
                              405                 410                 415
                                                 Page 105

<removed-date>
              His Asp Ile His Ser Pro Thr Val Asn Ala Leu Pro Arg Val Ile Glu
                          420                 425                 430
              Tyr Leu Lys Asn Gln Gly Tyr Thr Phe Val Thr Ile Pro Glu Met Leu
                      435                 440                 445
              Asn Thr Arg Leu Lys Ala His Glu Leu Tyr Tyr Ser Arg Asp Glu
<removed-apn>
                  450                 455                 460
              <210>   51
              <211>   278
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 51
              Met Lys Lys Trp Met Leu Val Leu Val Ser Leu Met Thr Ala Leu Phe
              1               5                   10                  15
              Leu Val Ala Cys Gly Lys Asn Ser Ser Glu Thr Ser Gly Asp Asn Trp
                          20                  25                  30
              Ser Lys Tyr Gln Ser Asn Lys Ser Ile Thr Ile Gly Phe Asp Ser Thr
                      35                  40                  45
              Phe Val Pro Met Gly Phe Ala Gln Lys Asp Gly Ser Tyr Ala Gly Phe
                  50                  55                  60
              Asp Ile Asp Leu Ala Thr Ala Val Phe Glu Lys Tyr Gly Ile Thr Val
              65                  70                  75                  80
              Asn Trp Gln Pro Ile Asp Trp Asp Leu Lys Glu Ala Glu Leu Thr Lys
                              85                  90                  95
              Gly Thr Ile Asp Leu Ile Trp Asn Gly Tyr Ser Ala Thr Asp Glu Arg
                          100                 105                 110
              Arg Glu Lys Val Ala Phe Ser Asn Ser Tyr Met Lys Asn Glu Gln Val
                      115                 120                 125
              Leu Val Thr Lys Lys Ser Ser Gly Ile Thr Thr Ala Lys Asp Met Thr
                                                 Page 106

                  130                   135                 140
<removed-date>
              Gly Lys Thr Leu Gly Ala Gln Ala Gly Ser Ser Gly Tyr Ala Asp Phe
              145                 150                 155                 160
              Glu Ala Asn Pro Glu Ile Leu Lys Asn Ile Val Ala Asn Lys Glu Ala
                              165                 170                 175
<removed-apn>
              Asn Gln Tyr Gln Thr Phe Asn Glu Ala Leu Ile Asp Leu Lys Asn Asp
                          180                 185                 190
              Arg Ile Asp Gly Leu Leu Ile Asp Arg Val Tyr Ala Asn Tyr Tyr Leu
                      195                 200                 205
              Glu Ala Glu Gly Val Leu Asn Asp Tyr Asn Val Phe Thr Val Gly Leu
                  210                 215                 220
              Glu Thr Glu Ala Phe Ala Val Gly Ala Arg Lys Glu Asp Thr Asn Leu
              225                 230                 235                 240
              Val Lys Lys Ile Asn Glu Ala Phe Ser Ser Leu Tyr Lys Asp Gly Lys
                              245                 250                 255
              Phe Gln Glu Ile Ser Gln Lys Trp Phe Gly Glu Asp Val Ala Thr Lys
                          260                 265                 270
              Glu Val Lys Glu Gly Gln
                      275
              <210>   52
              <211>   143
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 52
              Met Thr Ile Leu Phe Val Val Ile Ser Gly Ser Phe Leu Tyr Met Val
              1               5                   10                  15
              Ser Leu Ser Met Lys Pro Tyr Gln Thr Ala Lys Ser Glu Gly Glu Lys
                          20                  25                  30
                                                 Page 107

              Leu Ala Gln Gln Tyr Ala Gly Leu Glu Gln Ala Asp Gln Val Asp Leu
<removed-date>
                      35                  40                  45
              Tyr Asn Gly Leu Glu Ser Tyr Tyr Ser Val Leu Gly Arg Asn Lys Gln
                  50                  55                  60
              Gln Glu Ala Leu Ala Val Leu Ile Gly Lys Asp Asp His Lys Ile Tyr
              65                  70                  75                  80
<removed-apn>
              Val Tyr Gln Leu Asn Gln Gly Val Ser Gln Glu Lys Ala Glu Thr Val
                              85                  90                  95
              Ser Lys Glu Lys Gly Ala Gly Glu Ile Asp Lys Ile Thr Phe Gly Arg
                          100                 105                 110
              Tyr Gln Asp Lys Pro Ile Trp Glu Val Lys Ser Gly Ser Asp Phe Tyr
                      115                 120                 125
              Leu Val Asp Phe Glu Thr Gly Ala Leu Val Asn Lys Glu Gly Leu
                  130                 135                 140
              <210>   53
              <211>   259
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 53
              Met Lys Lys Asn Ser Leu Tyr Ile Ile Ser Ser Leu Phe Phe Ala Cys
              1               5                   10                  15
              Val Leu Phe Val Tyr Ala Thr Ala Thr Asn Phe Gln Asn Ser Thr Ser
                          20                  25                  30
              Ala Arg Gln Val Lys Thr Glu Thr Tyr Thr Asn Thr Val Thr Asn Val
                      35                  40                  45
              Pro Ile Asp Ile Arg Tyr Asn Ser Asp Lys Tyr Phe Ile Ser Gly Phe
                  50                  55                  60
              Ala Ser Glu Val Ser Val Val Leu Thr Gly Ala Asn Arg Leu Ser Leu
              65                  70                  75                  80
                                                 Page 108

<removed-date>
              Ala Ser Glu Met Gln Glu Ser Thr Arg Lys Phe Lys Val Thr Ala Asp
                              85                  90                  95
              Leu Thr Asp Ala Gly Val Gly Thr Ile Glu Val Pro Leu Ser Ile Glu
                          100                 105                 110
              Asp Leu Pro Asn Gly Leu Thr Ala Val Ala Thr Pro Gln Lys Ile Thr
                      115                 120                 125
<removed-apn>
              Val Lys Ile Gly Lys Lys Ala Gln Lys Asp Lys Val Lys Ile Val Pro
                  130                 135                 140
              Glu Ile Asp Pro Ser Gln Ile Asp Ser Arg Val Gln Ile Glu Asn Val
              145                 150                 155                 160
              Met Val Ser Asp Lys Glu Val Ser Ile Thr Ser Asp Gln Glu Thr Leu
                              165                 170                 175
              Asp Arg Ile Asp Lys Ile Ile Ala Val Leu Pro Thr Ser Glu Arg Ile
                          180                 185                 190
              Thr Gly Asn Tyr Ser Gly Ser Val Pro Leu Gln Ala Ile Asp Arg Asn
                      195                 200                 205
              Gly Val Val Leu Pro Ala Val Ile Thr Pro Phe Asp Thr Ile Met Lys
                  210                 215                 220
              Val Thr Thr Lys Pro Val Ala Pro Ser Ser Ser Thr Ser Asn Ser Ser
              225                 230                 235                 240
              Thr Ser Ser Ser Ser Glu Thr Ser Ser Ser Thr Lys Ala Thr Ser Ser
                              245                 250                 255
              Lys Thr Asn
              <210>   54
              <211>   249
              <212>   PRT
              <213>   Streptococcus pneumoniae
                                                 Page 109

<removed-date>
              <400> 54
              Met Phe Tyr Thr Tyr Leu Arg Gly Leu Val Val Leu Leu Leu Trp Ser
              1               5                   10                  15
              Ile Asn Gly Asn Ala His Tyr His Asn Thr Asp Lys Ile Pro Asn Gln
                          20                  25                  30
              Asp Glu Asn Tyr Ile Leu Val Ala Pro His Arg Thr Trp Trp Asp Pro
<removed-apn>
                      35                  40                  45
              Val Tyr Met Ala Phe Ala Thr Lys Pro Lys Gln Phe Ile Phe Met Ala
                  50                  55                  60
              Lys Lys Glu Leu Phe Thr Asn Arg Ile Phe Gly Trp Trp Ile Arg Met
              65                  70                  75                  80
              Cys Gly Ala Phe Pro Ile Asp Arg Glu Asn Pro Ser Ala Ser Ala Ile
                              85                  90                  95
              Lys Tyr Pro Ile Asn Val Leu Lys Lys Ser Asp Arg Ser Leu Ile Met
                          100                 105                 110
              Phe Pro Ser Gly Ser Arg His Ser Asn Asp Val Lys Gly Gly Ala Ala
                      115                 120                 125
              Leu Ile Ala Lys Met Ala Lys Val Arg Ile Met Pro Val Thr Tyr Thr
                  130                 135                 140
              Gly Pro Met Thr Leu Lys Gly Leu Ile Ser Arg Glu Arg Val Asp Met
              145                 150                 155                 160
              Asn Phe Gly Asn Pro Ile Asp Ile Ser Asp Ile Lys Lys Met Asn Asp
                              165                 170                 175
              Glu Gly Ile Glu Thr Val Ala Asn Arg Ile Gln Thr Glu Phe Gln Arg
                          180                 185                 190
              Leu Asp Glu Glu Thr Lys Gln Trp His Asn Asp Lys Lys Pro Asn Pro
                      195                 200                 205
                                                 Page 110

<removed-date>
              Leu Trp Trp Phe Ile Arg Ile Pro Ala Leu Ile Leu Ala Ile Ile Leu
                  210                 215                 220
              Ala Ile Leu Thr Ile Ile Phe Ser Phe Ile Ala Ser Phe Ile Trp Asn
              225                 230                 235                 240
              Pro Asp Lys Lys Arg Glu Glu Leu Ala
                              245
<removed-apn>
              <210>   55
              <211>   924
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 55
              Met Pro Val Ser Arg Met Trp Cys Ser Thr Ser Ile Leu Arg Ile Leu
              1               5                   10                  15
              Thr Val Trp Ser Thr Ser Met Ile Lys Arg Lys Thr Tyr Trp Lys Asp
                          20                  25                  30
              Leu Val Gln Ser Phe Thr Gly Ser Lys Gly Arg Phe Leu Ser Ile Leu
                      35                  40                  45
              Ile Leu Met Met Leu Gly Ser Leu Ala Leu Val Gly Leu Lys Val Thr
                  50                  55                  60
              Ser Pro Asn Met Glu Ala Thr Ala Asn Ala Tyr Leu Thr Thr Ala Gln
              65                  70                  75                  80
              Thr Leu Asp Leu Ala Val Met Ser Asn Tyr Gly Leu Asp Gln Ala Asp
                              85                  90                  95
              Gln Glu Glu Leu Lys Gln Thr Glu Gly Ala Glu Val Glu Phe Gly Tyr
                          100                 105                 110
              Leu Thr Asp Val Thr Met Asp Asn Gly Gln Asp Ala Ile Arg Leu Tyr
                      115                 120                 125
              Ser Lys Pro Glu Arg Ile Ser Thr Phe Gln Leu Arg Lys Gly Arg Leu
                  130                 135                 140
                                                    Page 111

<removed-date>
              Pro Gln Ser Asp Lys Glu Ile Ala Leu Ala Thr His Leu Gln Gly Gln
              145                 150                 155                 160
              Tyr Ser Val Gly Gln Glu Ile Ser Phe Lys Glu Lys Glu Glu Gly His
                              165                 170                 175
              Ser Ser Leu Lys Asp His Thr Tyr Thr Ile Thr Gly Phe Val Asp Ser
<removed-apn>
                          180                 185                 190
              Ala Glu Ile Leu Ser Gln Arg Asp Met Gly Tyr Ala Gly Ser Gly Ser
                      195                 200                 205
              Gly Thr Leu Thr Ala Tyr Gly Val Ile Leu Pro Ser Gln Phe Asp Gln
                  210                 215                 220
              Lys Val Tyr Asn Ile Ala Arg Leu Lys Tyr Gln Asp Leu Ala Gly Leu
              225                 230                 235                 240
              Asn Ala Phe Ser Ser Ala Tyr Glu Glu Lys Ser Lys Gln His Gln Glu
                              245                 250                 255
              Glu Leu Glu Gln Ile Leu Ser Asp Asn Gly Lys Val Arg Leu Gln Leu
                          260                 265                 270
              Leu Lys Lys Glu Gly Gln Glu Ser Leu Asp Lys Gly Gln Glu Thr Leu
                      275                 280                 285
              Asp Lys Ala Gln Thr Asn Leu Gln Glu Gly Lys Arg Arg Leu Ala Ala
                  290                 295                 300
              Ala Gln Ala Arg Ile Gln Ala Gln Glu Ser Gln Leu Ala Leu Phe Pro
              305                 310                 315                 320
              Gln Val Gln Arg Glu Gln Ala Ser Ala Gln Leu Thr Gln Ala Lys Gln
                              325                 330                 335
              Glu Leu Gly Lys Glu Glu Asp Lys Leu Lys Gln Ala Glu Gln Asn Leu
                          340                 345                 350
                                                 Page 112

<removed-date>
              Ala Gln Glu Lys Glu Lys Leu Glu Lys His Gln Gln Val Leu Asp Asp
                      355                 360                 365
              Leu Ala Glu Pro Arg Tyr Gln Val Tyr Asn Arg Gln Thr Met Pro Gly
                  370                 375                 380
              Gly Gln Gly Tyr Leu Met Tyr Ser Asn Ala Ser Ser Ser Ile Arg Ala
              385                 390                 395                 400
<removed-apn>
              Val Gly Asn Ile Phe Pro Val Val Leu Tyr Ala Val Ala Ala Met Val
                              405                 410                 415
              Thr Phe Thr Thr Met Thr Arg Phe Val Asp Glu Glu Arg Thr His Ala
                          420                 425                 430
              Gly Ile Phe Lys Ala Leu Gly Tyr Arg Ser Lys Asp Ile Ile Ala Lys
                      435                 440                 445
              Phe Leu Leu Tyr Gly Leu Val Ala Gly Thr Val Gly Thr Ala Leu Gly
                  450                 455                 460
              Ser Ile Leu Gly His Tyr Leu Leu Ala Ser Val Ile Ser Ser Val Ile
              465                 470                 475                 480
              Thr Lys Gly Met Val Val Gly Glu Thr Gln Ile Gln Phe Tyr Trp Thr
                              485                 490                 495
              Tyr Ser Leu Leu Ala Phe Val Leu Ser Leu Leu Ala Ser Val Leu Pro
                          500                 505                 510
              Ala Tyr Leu Val Ala Trp Arg Glu Leu His Asp Glu Ala Ala Gln Leu
                      515                 520                 525
              Leu Leu Pro Lys Pro Pro Val Lys Gly Ala Lys Ile Leu Leu Glu Arg
                  530                 535                 540
              Ile Gly Phe Ile Trp Arg Arg Leu Ser Phe Thr His Lys Val Thr Ala
              545                 550                 555                 560
                                                 Page 113

              Arg Asn Ile Phe Arg Tyr Lys Gln Arg Met Leu Met Thr Ile Phe Gly
<removed-date>
                              565                 570                 575
              Val Ala Gly Ser Val Ala Leu Leu Phe Ala Gly Leu Gly Ile Gln Ser
                          580                 585                 590
              Ser Val Ala Gly Val Pro Ser Lys Gln Phe Gln Gln Ile Gln Gln Tyr
                      595                 600                 605
<removed-apn>
              Gln Met Leu Val Ser Glu Asn Pro Ser Ala Thr Asn Gln Asp Lys Val
                  610                 615                 620
              Glu Leu Ala Glu Val Leu Lys Gly Gln Glu Ile Leu Ala Tyr Gln Lys
              625                 630                 635                 640
              Ile Tyr Ser Lys Ala Leu Tyr Lys Asp Phe Lys Gly Lys Ala Gly Leu
                              645                 650                 655
              Gln Asn Ile Thr Leu Met Met Ile Glu Lys Glu Asp Leu Thr Pro Phe
                          660                 665                 670
              Ile His Leu Gln His His Gln Gln Glu Leu Thr Leu Lys Asp Gly Ile
                      675                 680                 685
              Val Ile Thr Ala Lys Leu Ala Gln Leu Ala Gly Val Lys Val Gly Gln
                  690                 695                 700
              Thr Leu Glu Ile Glu Gly Lys Glu Leu Lys Val Val Ala Ile Thr Glu
              705                 710                 715                 720
              Asn Tyr Val Gly His Phe Ile Tyr Met Ser Gln Ala Ser Tyr Glu Gln
                              725                 730                 735
              Leu Tyr Gly Gln Leu Pro Gln Ala Asn Thr Tyr Leu Val Ser Leu Arg
                          740                 745                 750
              Asp Thr Ser Ala Thr Ser Ile Glu Ser Gln Ala Gly Leu Leu Met Asn
                      755                 760                 765
              Gln Ser Ala Val Ser Ser Val Val Gln Asn Ala Ser Ala Ile Arg Leu
                                                 Page 114

                  770                   775                 780
<removed-date>
              Phe Asp Ser Ile Ala Ser Ser Leu Asn Gln Thr Met Thr Ile Leu Val
              785                 790                 795                 800
              Ile Val Ser Val Leu Leu Ala Ile Val Ile Leu Tyr Asn Leu Thr Asn
                              805                 810                 815
<removed-apn>
              Ile Asn Val Ala Glu Arg Ile Arg Glu Leu Ser Thr Ile Lys Val Leu
                          820                 825                 830
              Gly Phe His Asn Asn Glu Val Thr Leu Tyr Ile Tyr Arg Glu Thr Ile
                      835                 840                 845
              Val Leu Ser Leu Val Gly Ile Val Leu Gly Leu Ile Ala Gly Phe Tyr
                  850                 855                 860
              Leu His Gln Phe Leu Ile Gln Met Ile Ser Pro Ala Thr Ile Leu Phe
              865                 870                 875                 880
              Tyr Pro Gln Val Gly Trp Glu Val Tyr Val Ile Pro Val Ala Ala Val
                              885                 890                 895
              Ser Ile Ile Leu Thr Leu Leu Gly Phe Phe Val Asn Tyr Tyr Leu Arg
                          900                 905                 910
              Lys Val Asp Met Leu Glu Ala Leu Lys Ser Val Glu
                      915                 920
              <210>   56
              <211>   442
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 56
              Met Lys Phe Arg Lys Leu Ala Cys Thr Val Leu Ala Gly Ala Ala Val
              1               5                   10                  15
              Leu Gly Leu Ala Ala Cys Gly Asn Ser Gly Gly Ser Lys Asp Ala Ala
                          20                  25                  30
                                                 Page 115

              Lys Ser Gly Gly Asp Gly Ala Lys Thr Glu Ile Thr Trp Trp Ala Phe
<removed-date>
                      35                  40                  45
              Pro Val Phe Thr Gln Glu Lys Thr Gly Asp Gly Val Gly Thr Tyr Glu
                  50                  55                  60
              Lys Ser Ile Ile Glu Ala Phe Glu Lys Ala Asn Pro Asp Ile Lys Val
              65                  70                  75                  80
<removed-apn>
              Lys Leu Glu Thr Ile Asp Phe Lys Ser Gly Pro Glu Lys Ile Thr Thr
                              85                  90                  95
              Ala Ile Glu Ala Gly Thr Ala Pro Asp Val Leu Phe Asp Ala Pro Gly
                          100                 105                 110
              Arg Ile Ile Gln Tyr Gly Lys Asn Gly Lys Leu Ala Glu Leu Asn Asp
                      115                 120                 125
              Leu Phe Thr Asp Glu Phe Val Lys Asp Val Asn Asn Glu Asn Ile Val
                  130                 135                 140
              Gln Ala Ser Lys Ala Gly Asp Lys Ala Tyr Met Tyr Pro Ile Ser Ser
              145                 150                 155                 160
              Ala Pro Phe Tyr Met Ala Met Asn Lys Lys Met Leu Glu Asp Ala Gly
                              165                 170                 175
              Val Ala Asn Leu Val Lys Glu Gly Trp Thr Thr Asp Asp Phe Glu Lys
                          180                 185                 190
              Val Leu Lys Ala Leu Lys Asp Lys Gly Tyr Thr Pro Gly Ser Leu Phe
                      195                 200                 205
              Ser Ser Gly Gln Gly Gly Asp Gln Gly Thr Arg Ala Phe Ile Ser Asn
                  210                 215                 220
              Leu Tyr Ser Gly Ser Val Thr Asp Glu Lys Val Ser Lys Tyr Thr Thr
              225                 230                 235                 240
              Asp Asp Pro Lys Phe Val Lys Gly Leu Glu Lys Ala Thr Ser Trp Ile
                                                 Page 116

                              245                 250                 255
<removed-date>
              Lys Asp Asn Leu Ile Asn Asn Gly Ser Gln Phe Asp Gly Gly Ala Asp
                          260                 265                 270
              Ile Gln Asn Phe Ala Asn Gly Gln Thr Ser Tyr Thr Ile Leu Trp Ala
                      275                 280                 285
<removed-apn>
              Pro Ala Gln Asn Gly Ile Gln Ala Lys Leu Leu Glu Ala Ser Lys Val
                  290                 295                 300
              Glu Val Val Glu Val Pro Phe Pro Ser Asp Glu Gly Lys Pro Ala Leu
              305                 310                 315                 320
              Glu Tyr Leu Val Asn Gly Phe Ala Val Phe Asn Asn Lys Asp Asp Lys
                              325                 330                 335
              Lys Val Ala Ala Ser Lys Lys Phe Ile Gln Phe Ile Ala Asp Asp Lys
                          340                 345                 350
              Glu Trp Gly Pro Lys Asp Val Val Arg Thr Gly Ala Phe Pro Val Arg
                      355                 360                 365
              Thr Ser Phe Gly Lys Leu Tyr Glu Asp Lys Arg Met Glu Thr Ile Ser
                  370                 375                 380
              Gly Trp Thr Gln Tyr Tyr Ser Pro Tyr Tyr Asn Thr Ile Asp Gly Phe
              385                 390                 395                 400
              Ala Glu Met Arg Thr Leu Trp Phe Pro Met Leu Gln Ser Val Ser Asn
                              405                 410                 415
              Gly Asp Glu Lys Pro Ala Asp Ala Leu Lys Ala Phe Thr Glu Lys Ala
                          420                 425                 430
              Asn Glu Thr Ile Lys Lys Ala Met Lys Gln
                      435                 440
              <210> 57
              <211> 355
                                                 Page 117

              <212> PRT
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 57
              Met Lys Lys Met Lys Val Trp Ser Thr Val Leu Ala Thr Gly Val Ala
              1               5                   10                  15
              Leu Thr Thr Leu Ala Ala Cys Ser Gly Gly Ser Asn Ser Thr Thr Ala
                          20                  25                  30
<removed-apn>
              Ser Ser Ser Glu Glu Lys Ala Asp Lys Ser Gln Glu Leu Val Ile Tyr
                      35                  40                  45
              Ser Asn Ser Val Ser Asn Gly Arg Gly Asp Trp Leu Thr Ala Lys Ala
                  50                  55                  60
              Lys Glu Ala Gly Phe Asn Ile Lys Met Val Asp Ile Ala Gly Ala Gln
              65                  70                  75                  80
              Leu Ala Asp Arg Val Ile Ala Glu Lys Asn Asn Ala Val Ala Asp Met
                              85                  90                  95
              Val Phe Gly Ile Gly Ala Val Asp Ser Asn Lys Ile Arg Asp Gln Lys
                          100                 105                 110
              Leu Leu Val Gln Tyr Lys Pro Lys Trp Leu Asp Lys Ile Asp Gln Ser
                      115                 120                 125
              Leu Ser Asp Lys Asp Asn Tyr Tyr Asn Pro Val Ile Val Gln Pro Leu
                  130                 135                 140
              Val Leu Ile Gly Ala Pro Asp Val Lys Glu Met Pro Lys Asp Trp Thr
              145                 150                 155                 160
              Glu Leu Gly Ser Lys Tyr Lys Gly Lys Tyr Ser Ile Ser Gly Leu Gln
                              165                 170                 175
              Gly Gly Thr Gly Arg Ala Ile Leu Ala Ser Ile Leu Val Arg Tyr Leu
                          180                 185                 190
              Asp Asp Lys Gly Glu Leu Gly Val Ser Glu Lys Gly Trp Glu Val Ala
                                                 Page 118

                        195                 200               205
<removed-date>
              Lys Glu Tyr Leu Lys Asn Ala Tyr Thr Leu Gln Lys Gly Glu Ser Ser
                  210                 215                 220
              Ile Val Lys Met Leu Asp Lys Glu Asp Pro Ile Gln Tyr Gly Met Met
              225                 230                 235                 240
<removed-apn>
              Trp Gly Ser Gly Ala Leu Val Gly Gln Lys Glu Gln Asn Val Val Phe
                              245                 250                 255
              Lys Val Met Thr Pro Glu Ile Gly Val Pro Phe Val Thr Glu Gln Thr
                          260                 265                 270
              Met Val Leu Ser Thr Ser Lys Lys Gln Ala Leu Ala Lys Glu Phe Ile
                      275                 280                 285
              Asp Trp Phe Gly Gln Ser Glu Ile Gln Val Glu Tyr Ser Lys Asn Phe
                  290                 295                 300
              Gly Ser Ile Pro Ala Asn Lys Asp Ala Leu Lys Asp Leu Pro Glu Asp
              305                 310                 315                 320
              Thr Lys Lys Phe Val Asp Gln Val Lys Pro Gln Asn Ile Asp Trp Glu
                              325                 330                 335
              Ala Val Gly Lys His Leu Asp Glu Trp Val Glu Lys Ala Glu Leu Glu
                          340                 345                 350
              Tyr Val Gln
                      355
              <210>   58
              <211>   321
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 58
              Met Lys Thr Ser Leu Lys Leu Tyr Phe Thr Ala Leu Val Ala Ser Phe
              1               5                   10                  15
                                                  Page 119

              Leu Leu Leu Leu Gly Ala Cys Ser Thr Asn Ser Ser Thr Ser Gln Thr
<removed-date>
                          20                  25                  30
              Glu Thr Ser Ser Ser Ala Pro Thr Glu Val Thr Ile Lys Ser Ser Leu
                      35                  40                  45
              Asp Glu Val Lys Leu Ser Lys Val Pro Glu Lys Ile Val Thr Phe Asp
                  50                  55                  60
<removed-apn>
              Leu Gly Ala Ala Asp Thr Ile Arg Ala Leu Gly Phe Glu Lys Asn Ile
              65                  70                  75                  80
              Val Gly Met Pro Thr Lys Thr Val Pro Thr Tyr Leu Lys Asp Leu Val
                              85                  90                  95
              Gly Thr Val Lys Asn Val Gly Ser Met Lys Glu Pro Asp Leu Glu Ala
                          100                 105                 110
              Ile Ala Ala Leu Glu Pro Asp Leu Ile Ile Ala Ser Pro Arg Thr Gln
                      115                 120                 125
              Lys Phe Val Asp Lys Phe Lys Glu Ile Ala Pro Thr Val Leu Phe Gln
                  130                 135                 140
              Ala Ser Lys Asp Asp Tyr Trp Thr Ser Thr Lys Ala Asn Ile Glu Ser
              145                 150                 155                 160
              Leu Ala Ser Ala Phe Gly Glu Thr Gly Thr Gln Lys Ala Lys Glu Glu
                              165                 170                 175
              Leu Thr Lys Leu Asp Lys Ser Ile Gln Glu Val Ala Thr Lys Asn Glu
                          180                 185                 190
              Ser Ser Asp Lys Lys Ala Leu Ala Ile Leu Leu Asn Glu Gly Lys Met
                      195                 200                 205
              Ala Ala Phe Gly Ala Lys Ser Arg Phe Ser Phe Leu Tyr Gln Thr Leu
                  210                 215                 220
              Lys Phe Lys Pro Thr Asp Thr Lys Phe Glu Asp Ser Arg His Gly Gln
                                                 Page 120

              225                   230               235                 240
<removed-date>
              Glu Val Ser Phe Glu Ser Val Lys Glu Ile Asn Pro Asp Ile Leu Phe
                              245                 250                 255
              Val Ile Asn Arg Thr Leu Ala Ile Gly Gly Asp Asn Ser Ser Asn Asp
                          260                 265                 270
<removed-apn>
              Gly Val Leu Glu Asn Ala Leu Ile Ala Glu Thr Pro Ala Ala Lys Asn
                      275                 280                 285
              Gly Lys Ile Ile Gln Leu Thr Pro Asp Leu Trp Tyr Leu Ser Gly Gly
                  290                 295                 300
              Gly Leu Glu Ser Thr Lys Leu Met Ile Glu Asp Ile Gln Lys Ala Leu
              305                 310                 315                 320
              Lys
              <210>   59
              <211>   659
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 59
              Met Lys Lys Asn Arg Val Phe Ala Thr Ala Gly Leu Val Leu Leu Ala
              1               5                   10                  15
              Ala Gly Val Leu Ala Ala Cys Ser Ser Ser Lys Ser Ser Asp Ser Ser
                          20                  25                  30
              Ala Pro Lys Ala Tyr Gly Tyr Val Tyr Thr Ala Asp Pro Glu Thr Leu
                      35                  40                  45
              Asp Tyr Leu Ile Ser Ser Lys Asn Ser Thr Thr Val Val Thr Ser Asn
                  50                  55                  60
              Gly Ile Asp Gly Leu Phe Thr Asn Asp Asn Tyr Gly Asn Leu Ala Pro
              65                  70                  75                  80
                                                 Page 121

              Ala Val Ala Glu Asp Trp Glu Val Ser Lys Asp Gly Leu Thr Tyr Thr
<removed-date>
                              85                  90                  95
              Tyr Lys Ile Arg Lys Gly Val Lys Trp Phe Thr Ser Asp Gly Glu Glu
                          100                 105                 110
              Tyr Ala Glu Val Thr Ala Lys Asp Phe Val Asn Gly Leu Lys His Ala
                      115                 120                 125
<removed-apn>
              Ala Asp Lys Lys Ser Glu Ala Met Tyr Leu Ala Glu Asn Ser Val Lys
                  130                 135                 140
              Gly Leu Ala Asp Tyr Leu Ser Gly Thr Ser Thr Asp Phe Ser Thr Val
              145                 150                 155                 160
              Gly Val Lys Ala Val Asp Asp Tyr Thr Leu Gln Tyr Thr Leu Asn Gln
                              165                 170                 175
              Pro Glu Pro Phe Trp Asn Ser Lys Leu Thr Tyr Ser Ile Phe Trp Pro
                          180                 185                 190
              Leu Asn Glu Glu Phe Glu Thr Ser Lys Gly Ser Asp Phe Ala Lys Pro
                      195                 200                 205
              Thr Asp Pro Thr Ser Leu Leu Tyr Asn Gly Pro Phe Leu Leu Lys Gly
                  210                 215                 220
              Leu Thr Ala Lys Ser Ser Val Glu Phe Val Lys Asn Glu Gln Tyr Trp
              225                 230                 235                 240
              Asp Lys Glu Asn Val His Leu Asp Thr Ile Asn Leu Ala Tyr Tyr Asp
                              245                 250                 255
              Gly Ser Asp Gln Glu Ser Leu Glu Arg Asn Phe Thr Ser Gly Ala Tyr
                          260                 265                 270
              Ser Tyr Ala Arg Leu Tyr Pro Thr Ser Ser Asn Tyr Ser Lys Val Ala
                      275                 280                 285
              Glu Glu Tyr Lys Asp Asn Ile Tyr Tyr Thr Gln Ser Gly Ser Gly Ile
                                                 Page 122

                  290                 295                   300
<removed-date>
              Ala Gly Leu Gly Val Asn Ile Asp Arg Gln Ser Tyr Asn Tyr Thr Ser
              305                 310                 315                 320
              Lys Thr Thr Asp Ser Glu Lys Val Ala Thr Lys Lys Ala Leu Leu Asn
                              325                 330                 335
<removed-apn>
              Lys Asp Phe Arg Gln Ala Leu Asn Phe Ala Leu Asp Arg Ser Ala Tyr
                          340                 345                 350
              Ser Ala Gln Ile Asn Gly Lys Asp Gly Ala Ala Leu Ala Val Arg Asn
                      355                 360                 365
              Leu Phe Val Lys Pro Asp Phe Val Ser Ala Gly Glu Lys Thr Phe Gly
                  370                 375                 380
              Asp Leu Val Ala Ala Gln Leu Pro Ala Tyr Gly Asp Glu Trp Lys Gly
              385                 390                 395                 400
              Val Asn Leu Ala Asp Gly Gln Asp Gly Leu Phe Asn Ala Asp Lys Ala
                              405                 410                 415
              Lys Ala Glu Phe Ala Lys Ala Lys Lys Ala Leu Glu Ala Asp Gly Val
                          420                 425                 430
              Gln Phe Pro Ile His Leu Asp Val Pro Val Asp Gln Ala Ser Lys Asn
                      435                 440                 445
              Tyr Ile Ser Arg Ile Gln Ser Phe Lys Gln Ser Val Glu Thr Val Leu
                  450                 455                 460
              Gly Val Glu Asn Val Val Val Asp Ile Gln Gln Met Thr Ser Asp Glu
              465                 470                 475                 480
              Phe Leu Asn Ile Thr Tyr Tyr Ala Ala Asn Ala Ser Ser Glu Asp Trp
                              485                 490                 495
              Asp Val Ser Gly Gly Val Ser Trp Gly Pro Asp Tyr Gln Asp Pro Ser
                          500                 505                 510
                                                 Page 123

<removed-date>
              Thr Tyr Leu Asp Ile Leu Lys Thr Thr Ser Ser Glu Thr Thr Lys Thr
                      515                 520                 525
              Tyr Leu Gly Phe Asp Asn Pro Asn Ser Pro Ser Val Val Gln Val Gly
                  530                 535                 540
              Leu Lys Glu Tyr Asp Lys Leu Val Asp Glu Ala Ala Arg Glu Thr Ser
<removed-apn>
              545                 550                 555                 560
              Asp Leu Asn Val Arg Tyr Glu Lys Tyr Ala Ala Ala Gln Ala Trp Leu
                              565                 570                 575
              Thr Asp Ser Ser Leu Phe Ile Pro Ala Met Ala Ser Ser Gly Ala Ala
                          580                 585                 590
              Pro Val Leu Ser Arg Ile Val Pro Phe Thr Gly Ala Ser Ala Gln Thr
                      595                 600                 605
              Gly Ser Lys Gly Ser Asp Val Tyr Phe Lys Tyr Leu Lys Ser Gln Asp
                  610                 615                 620
              Lys Val Val Thr Lys Glu Glu Tyr Glu Lys Ala Arg Glu Lys Trp Leu
              625                 630                 635                 640
              Lys Glu Lys Ala Glu Ser Asn Glu Lys Ala Gln Lys Glu Leu Ala Ser
                              645                 650                 655
              His Val Lys
              <210>   60
              <211>   419
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 60
              Met Glu Trp Tyr Lys Lys Ile Gly Leu Leu Ala Thr Thr Gly Leu Ala
              1               5                   10                  15
              Leu Phe Gly Leu Gly Ala Cys Ser Asn Tyr Gly Lys Ser Ala Asp Gly
                                                 Page 124

                          20                  25                  30
<removed-date>
              Thr Val Thr Ile Glu Tyr Phe Asn Gln Lys Lys Glu Met Thr Lys Thr
                      35                  40                  45
              Leu Glu Glu Ile Thr Arg Asp Phe Glu Lys Glu Asn Pro Lys Ile Lys
                  50                  55                  60
<removed-apn>
              Val Lys Val Val Asn Val Pro Asn Ala Gly Glu Val Leu Lys Thr Arg
              65                  70                  75                  80
              Val Leu Ala Gly Asp Val Pro Asp Val Val Asn Ile Tyr Pro Gln Ser
                              85                  90                  95
              Ile Glu Leu Gln Glu Trp Ala Lys Ala Gly Val Phe Glu Asp Leu Ser
                          100                 105                 110
              Asn Lys Asp Tyr Leu Lys Arg Val Lys Asn Gly Tyr Ala Glu Lys Tyr
                      115                 120                 125
              Ala Val Asn Glu Lys Val Tyr Asn Val Pro Phe Thr Ala Asn Ala Tyr
                  130                 135                 140
              Gly Ile Tyr Tyr Asn Lys Asp Lys Phe Glu Glu Leu Gly Leu Lys Val
              145                 150                 155                 160
              Pro Glu Thr Trp Asp Glu Phe Glu Gln Leu Val Lys Asp Ile Val Ala
                              165                 170                 175
              Lys Gly Gln Thr Pro Phe Gly Ile Ala Gly Ala Asp Ala Trp Thr Leu
                          180                 185                 190
              Asn Gly Tyr Asn Gln Leu Ala Phe Ala Thr Ala Thr Gly Gly Gly Lys
                      195                 200                 205
              Glu Ala Asn Gln Tyr Leu Arg Tyr Ser Gln Pro Asn Ala Ile Lys Leu
                  210                 215                 220
              Ser Asp Pro Ile Met Lys Asp Asp Ile Lys Val Met Asp Ile Leu Arg
              225                 230                 235                 240
                                                   Page 125

<removed-date>
              Ile Asn Gly Ser Lys Gln Lys Asn Trp Glu Gly Ala Gly Tyr Thr Asp
                              245                 250                 255
              Val Ile Gly Ala Phe Ala Arg Gly Asp Val Leu Met Thr Pro Asn Gly
                          260                 265                 270
              Ser Trp Ala Ile Thr Ala Ile Asn Glu Gln Lys Pro Asn Phe Lys Ile
<removed-apn>
                      275                 280                 285
              Gly Thr Phe Met Ile Pro Gly Lys Glu Lys Gly Gln Ser Leu Thr Val
                  290                 295                 300
              Gly Ala Gly Asp Leu Ala Trp Ser Ile Ser Ala Thr Thr Lys His Pro
              305                 310                 315                 320
              Lys Glu Ala Asn Ala Phe Val Glu Tyr Met Thr Arg Pro Glu Val Met
                              325                 330                 335
              Gln Lys Tyr Tyr Asp Val Asp Gly Ser Pro Thr Ala Ile Glu Gly Val
                          340                 345                 350
              Lys Gln Ala Gly Glu Asp Ser Pro Leu Ala Gly Met Thr Glu Tyr Ala
                      355                 360                 365
              Phe Thr Asp Arg His Leu Val Trp Leu Gln Gln Tyr Trp Thr Ser Glu
                  370                 375                 380
              Ala Asp Phe His Thr Leu Thr Met Asn Tyr Val Leu Thr Gly Asp Lys
              385                 390                 395                 400
              Gln Gly Met Val Asn Asp Leu Asn Ala Phe Phe Asn Pro Met Lys Ala
                              405                 410                 415
              Asp Val Asp
              <210> 61
              <211> 338
              <212> PRT
                                                 Page 126

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 61
              Met Val Lys Lys Ile Ile Gly Met Val Leu Ala Leu Leu Ser Val Thr
              1               5                   10                  15
              Val Val Gly Val Gly Val Phe Ala Tyr Thr Ile Tyr Gln Gln Gly Thr
                          20                  25                  30
<removed-apn>
              Glu Thr Leu Ala Lys Thr Tyr Lys Lys Ile Gly Glu Glu Thr Lys Val
                      35                  40                  45
              Ile Glu Ala Thr Glu Pro Leu Thr Ile Leu Leu Met Gly Val Asp Thr
                  50                  55                  60
              Gly Asn Val Glu Arg Thr Glu Thr Trp Val Gly Arg Ser Asp Ser Met
              65                  70                  75                  80
              Ile Leu Met Thr Val Asn Pro Lys Thr Lys Lys Thr Thr Met Met Ser
                              85                  90                  95
              Leu Glu Arg Asp Ile Leu Thr Arg Ile Glu Ser Gly Asn Gly Gln Ala
                          100                 105                 110
              His Glu Ala Lys Leu Asn Ser Ala Tyr Ala Asp Gly Gly Ala Glu Leu
                      115                 120                 125
              Ala Ile Glu Thr Ile Gln Lys Met Met Asn Ile His Ile Asp Arg Tyr
                  130                 135                 140
              Val Met Val Asn Met Arg Gly Leu Gln Lys Leu Val Asp Ala Val Gly
              145                 150                 155                 160
              Gly Ile Thr Val Asn Asn Ile Leu Gly Phe Pro Ile Ser Ile Ser Asp
                              165                 170                 175
              Gln Glu Glu Phe Asn Thr Ile Ser Ile Gly Val Gly Glu Gln His Ile
                          180                 185                 190
              Gly Gly Glu Glu Ala Leu Val Tyr Ala Arg Met Arg Tyr Gln Asp Pro
                      195                 200                 205
                                                 Page 127

<removed-date>
              Glu Gly Asp Tyr Gly Arg Gln Lys Arg Gln Arg Glu Val Ile Gln Lys
                  210                 215                 220
              Val Met Glu Lys Ala Leu Ser Leu Asn Ser Ile Gly His Tyr Gln Glu
              225                 230                 235                 240
              Ile Leu Lys Ala Leu Ser Asp Asn Met Gln Thr Asn Ile Asp Leu Ser
<removed-apn>
                              245                 250                 255
              Ala Lys Ser Ile Pro Asn Leu Leu Gly Tyr Lys Asp Ser Phe Lys Thr
                          260                 265                 270
              Ile Glu Thr Gln Gln Leu Gln Gly Glu Gly Glu Ile Leu Gln Gly Val
                      275                 280                 285
              Ser Tyr Gln Ile Val Ser Arg Ala His Met Leu Glu Met Gln Asn Leu
                  290                 295                 300
              Leu Arg Arg Ser Leu Gly Gln Glu Glu Val Thr Gln Leu Glu Thr Asn
              305                 310                 315                 320
              Ala Val Leu Phe Glu Asp Leu Phe Gly Arg Ala Pro Val Gly Asp Glu
                              325                 330                 335
              Asp Asn
              <210>   62
              <211>   427
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 62
              Met Asp Lys Ile Val Val Gln Gly Gly Asp Asn Arg Leu Val Gly Ser
              1               5                   10                  15
              Val Thr Ile Glu Gly Ala Lys Asn Ala Val Leu Pro Leu Leu Ala Ala
                          20                  25                  30
              Thr Ile Leu Ala Ser Glu Gly Lys Thr Val Leu Gln Asn Val Pro Ile
                                                 Page 128

                      35                  40                  45
<removed-date>
              Leu Ser Asp Val Phe Ile Met Asn Gln Val Val Gly Gly Leu Asn Ala
                  50                  55                  60
              Lys Val Asp Phe Asp Glu Glu Ala His Leu Val Lys Val Asp Ala Thr
              65                  70                  75                  80
<removed-apn>
              Gly Asp Ile Thr Glu Glu Ala Pro Tyr Lys Tyr Val Ser Lys Met Arg
                              85                  90                  95
              Ala Ser Ile Val Val Leu Gly Pro Ile Leu Ala Arg Val Gly His Ala
                          100                 105                 110
              Lys Val Ser Met Pro Gly Gly Cys Thr Ile Gly Ser Arg Pro Ile Asp
                      115                 120                 125
              Leu His Leu Lys Gly Leu Glu Ala Met Gly Val Lys Ile Ser Gln Thr
                  130                 135                 140
              Ala Gly Tyr Ile Glu Ala Lys Ala Glu Arg Leu His Gly Ala His Ile
              145                 150                 155                 160
              Tyr Met Asp Phe Pro Ser Val Gly Ala Thr Gln Asn Leu Met Met Ala
                              165                 170                 175
              Ala Thr Leu Ala Asp Gly Val Thr Val Ile Glu Asn Ala Ala Arg Glu
                          180                 185                 190
              Pro Glu Ile Val Asp Leu Ala Ile Leu Leu Asn Glu Met Gly Ala Lys
                      195                 200                 205
              Val Lys Gly Ala Gly Thr Glu Thr Ile Thr Ile Thr Gly Val Glu Lys
                  210                 215                 220
              Leu His Gly Thr Thr His Asn Val Val Gln Asp Arg Ile Glu Ala Gly
              225                 230                 235                 240
              Thr Phe Met Val Ala Ala Ala Met Thr Gly Gly Asp Val Leu Ile Arg
                              245                 250                 255
                                                 Page 129

<removed-date>
              Asp Ala Val Trp Glu His Asn Arg Pro Leu Ile Ala Lys Leu Leu Glu
                          260                 265                 270
              Met Gly Val Glu Val Ile Glu Glu Asp Glu Gly Ile Arg Val Arg Ser
                      275                 280                 285
              Gln Leu Glu Asn Leu Lys Ala Val His Val Lys Thr Leu Pro His Pro
<removed-apn>
                  290                 295                 300
              Gly Phe Pro Thr Asp Met Gln Ala Gln Phe Thr Ala Leu Met Thr Val
              305                 310                 315                 320
              Ala Lys Gly Glu Ser Thr Met Val Glu Thr Val Phe Glu Asn Arg Phe
                              325                 330                 335
              Gln His Leu Glu Glu Met Arg Arg Met Gly Leu His Ser Glu Ile Ile
                          340                 345                 350
              Arg Asp Thr Ala Arg Ile Val Gly Gly Gln Pro Leu Gln Gly Ala Glu
                      355                 360                 365
              Val Leu Ser Thr Asp Leu Arg Ala Ser Ala Ala Leu Ile Leu Thr Gly
                  370                 375                 380
              Leu Val Ala Gln Gly Glu Thr Val Val Gly Lys Leu Val His Leu Asp
              385                 390                 395                 400
              Arg Gly Tyr Tyr Gly Phe His Glu Lys Leu Ala Gln Leu Gly Ala Lys
                              405                 410                 415
              Ile Gln Arg Ile Glu Ala Ser Asp Glu Asp Glu
                          420                 425
              <210>   63
              <211>   345
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 63
              Met Lys Lys Lys Ile Arg Trp Pro Leu Tyr Val Ile Ala Ala Leu Ile
                                                 Page 130

              1               5                   10                  15
<removed-date>
              Val Thr Phe Leu Ala Phe Val Val Pro Leu Pro Tyr Tyr Ile Glu Val
                          20                  25                  30
              Pro Gly Gly Ser Glu Asp Ile Arg Gln Val Leu Lys Val Asn Asp Thr
                      35                  40                  45
<removed-apn>
              Glu Asp Lys Glu Ala Gly Ala Tyr Gln Phe Val Thr Val Gly Val Gln
                  50                  55                  60
              His Ala Thr Leu Ala His Met Ile Tyr Ala Trp Leu Thr Pro Phe Thr
              65                  70                  75                  80
              Asp Ile Arg Ser Ala Gln Glu Thr Thr Gly Gly Ser Ser Asp Val Glu
                              85                  90                  95
              Phe Met Arg Ile Asn Gln Phe Tyr Met Gln Thr Ser Gln Asn Met Ala
                          100                 105                 110
              Lys Tyr Gln Gly Leu Lys Thr Ala Gly Lys Asp Ile Glu Leu Lys Tyr
                      115                 120                 125
              Phe Gly Val Tyr Val Leu Asn Val Thr Asp Asn Ser Thr Phe Lys Gly
                  130                 135                 140
              Ile Leu Asn Ile Ser Asp Thr Val Thr Ala Val Asn Asp Gln Thr Phe
              145                 150                 155                 160
              Asp Ser Ser Lys Asp Leu Ile Asp Tyr Val Ser Ser Gln Lys Leu Gly
                              165                 170                 175
              Asp Ser Val Lys Val Thr Tyr Glu Glu Asp Gly Gln Thr Lys Ser Ala
                          180                 185                 190
              Glu Gly Lys Ile Ile Thr Leu Glu Asn Gly Lys Asn Gly Ile Gly Ile
                      195                 200                 205
              Gly Leu Ile Asp Arg Thr Glu Val Ile Ser Asn Val Pro Ile Ser Phe
                  210                 215                 220
                                                 Page 131

<removed-date>
              Ser Thr Ala Gly Ile Gly Gly Pro Ser Ala Gly Leu Met Phe Ser Leu
              225                 230                 235                 240
              Ala Ile Tyr Thr Gln Ile Ala His Pro Asp Leu Arg Asn Gly Arg Ile
                              245                 250                 255
              Val Ala Gly Thr Gly Thr Ile Asp Arg Asp Gly Asn Val Gly Asp Ile
<removed-apn>
                          260                 265                 270
              Gly Gly Ile Asp Lys Lys Val Val Ala Ser Ala Arg Ala Gly Ala Ala
                      275                 280                 285
              Ile Phe Phe Ala Pro Asp Asn Pro Val Ser Glu Glu Glu Gln Lys Ala
                  290                 295                 300
              His Pro Asp Ala Lys Asn Asn Tyr Gln Thr Ala Leu Glu Ala Ala Lys
              305                 310                 315                 320
              Thr Ile Lys Thr Asp Met Lys Ile Val Pro Val Lys Thr Leu Gln Asp
                              325                 330                 335
              Ala Ile Asp Tyr Leu Lys Asn Asn Pro
                          340                 345
              <210>   64
              <211>   320
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 64
              Met Pro Lys Lys Ile Leu Val Leu His Thr Gly Gly Thr Ile Ser Met
              1               5                   10                  15
              Gln Ala Asp Ala Ser Gly Ala Val Val Thr Ser Ser Asp Asn Pro Met
                          20                  25                  30
              Asn His Val Ser Asn Pro Leu Glu Gly Ile Gln Val His Ala Leu Asp
                      35                  40                  45
              Phe Phe Asn Leu Pro Ser Pro His Ile Lys Pro Lys His Met Leu Val
                                                    Page 132

                  50                  55                    60
<removed-date>
              Leu Tyr Gln Lys Ile Lys Glu Glu Ala Asp Asn Tyr Asp Gly Val Val
              65                  70                  75                  80
              Ile Thr His Gly Thr Asp Thr Leu Glu Glu Thr Ala Tyr Phe Leu Asp
                              85                  90                  95
<removed-apn>
              Thr Met Glu Val Pro His Met Pro Ile Val Leu Thr Gly Ala Met Arg
                          100                 105                 110
              Ser Ser Asn Glu Leu Gly Ser Asp Gly Val Tyr Asn Tyr Leu Ser Ala
                      115                 120                 125
              Leu Arg Val Ala Ser Asp Asp Arg Ala Ala Asp Lys Gly Val Leu Val
                  130                 135                 140
              Val Met Asn Asp Glu Ile His Ala Ala Lys Tyr Val Thr Lys Thr His
              145                 150                 155                 160
              Thr Thr Asn Val Ser Thr Phe Gln Thr Pro Thr His Gly Pro Leu Gly
                              165                 170                 175
              Leu Ile Met Lys Gln Glu Ile Leu Tyr Phe Lys Thr Ala Glu Pro Arg
                          180                 185                 190
              Val Arg Phe Asp Leu Asp His Ile Gln Gly Leu Val Pro Ile Ile Ser
                      195                 200                 205
              Ala Tyr Ala Gly Met Thr Asp Glu Leu Ile Asp Met Leu Asp Leu Glu
                  210                 215                 220
              His Leu Asp Gly Leu Ile Ile Gln Ala Phe Gly Ala Gly Asn Ile Pro
              225                 230                 235                 240
              Lys Glu Thr Ala Gln Lys Leu Glu Ser Leu Leu Gln Lys Gly Ile Pro
                              245                 250                 255
              Val Ala Leu Val Ser Arg Cys Phe Asn Gly Ile Ala Glu Pro Val Tyr
                          260                 265                 270
                                                 Page 133

<removed-date>
              Ala Tyr Gln Gly Gly Gly Val Gln Leu Gln Lys Ala Gly Val Phe Phe
                      275                 280                 285
              Val Lys Glu Leu Asn Ala Gln Lys Ala Arg Leu Lys Leu Leu Ile Ala
                  290                 295                 300
              Leu Asn Ala Gly Leu Thr Gly Gln Ala Leu Lys Asp Tyr Met Glu Gly
<removed-apn>
              305                 310                 315                 320
              <210>   65
              <211>   153
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 65
              Met Val Gln Asn Ser Cys Trp Gln Ser Lys Ser His Lys Val Lys Ala
              1               5                   10                  15
              Phe Thr Leu Leu Glu Ser Leu Leu Ala Leu Ile Val Ile Ser Gly Gly
                          20                  25                  30
              Leu Leu Leu Phe Gln Ala Met Ser Gln Leu Leu Ile Ser Glu Val Arg
                      35                  40                  45
              Tyr Gln Gln Gln Ser Glu Gln Lys Glu Trp Leu Leu Phe Val Asp Gln
                  50                  55                  60
              Leu Glu Val Glu Leu Asp Arg Ser Gln Phe Glu Lys Val Glu Gly Asn
              65                  70                  75                  80
              Arg Leu Tyr Met Lys Gln Asp Gly Lys Asp Ile Ala Ile Gly Lys Ser
                              85                  90                  95
              Lys Ser Asp Asp Phe Arg Lys Thr Asn Ala Arg Gly Arg Gly Tyr Gln
                          100                 105                 110
              Pro Met Val Tyr Gly Leu Lys Ser Val Arg Ile Thr Glu Asp Asn Gln
                      115                 120                 125
              Leu Val Arg Phe His Phe Gln Phe Gln Lys Gly Leu Glu Arg Glu Phe
                                                 Page 134

                  130                   135                    140
<removed-date>
              Ile Tyr Arg Val Glu Lys Glu Lys Ser
              145                 150
              <210>   66
              <211>   134
              <212>   PRT
              <213>   Streptococcus pneumoniae
<removed-apn>
              <400> 66
              Met Ile Lys Ala Phe Thr Met Leu Glu Ser Leu Leu Val Leu Gly Leu
              1               5                   10                  15
              Val Ser Ile Leu Ala Leu Gly Leu Ser Gly Ser Val Gln Ser Thr Phe
                          20                  25                  30
              Ser Ala Val Glu Glu Gln Ile Phe Phe Met Glu Phe Glu Glu Leu Tyr
                      35                  40                  45
              Arg Glu Thr Gln Lys Arg Ser Val Ala Ser Gln Gln Lys Thr Ser Leu
                  50                  55                  60
              Asn Leu Asp Gly Gln Thr Leu Ser Asn Gly Ser Gln Lys Leu Pro Val
              65                  70                  75                  80
              Pro Lys Gly Ile Gln Ala Pro Ser Gly Gln Ser Ile Thr Phe Asp Arg
                              85                  90                  95
              Ala Gly Gly Asn Ser Ser Leu Ala Lys Val Glu Phe Gln Thr Ser Lys
                          100                 105                 110
              Gly Ala Ile Arg Tyr Gln Leu Tyr Leu Gly Asn Gly Lys Ile Lys Arg
                      115                 120                 125
              Ile Lys Glu Thr Lys Asn
                  130
              <210>   67
              <211>   443
              <212>   PRT
              <213>   Streptococcus pneumoniae
                                                    Page 135

<removed-date>
              <400> 67
              Met Lys Arg Tyr Leu Gln Phe Trp Leu Val Asn Leu Ser Val Ser Leu
              1               5                   10                  15
              Ile Leu Ile Ala Gly Met Ala Leu Thr Trp Ile Ser Lys Gly Ile Gly
                          20                  25                  30
              Leu Phe Leu Leu Ala Leu Ser Leu Gly Leu Gly Gly Tyr Trp Leu Phe
<removed-apn>
                      35                  40                  45
              Cys Leu Trp Lys Trp Glu Val Ala Phe Glu Thr Leu His Gln Pro Leu
                  50                  55                  60
              Leu Thr Ser Ser Glu Tyr Phe Leu Glu Lys Gly Gln Glu Asp Leu Lys
              65                  70                  75                  80
              Ser Leu Ala Gln Tyr Val Ser Gly Leu Lys Thr Lys Val Ser Gln Gln
                              85                  90                  95
              Asp Gln Gln Tyr Lys Asp Leu Ala Glu Thr Met Glu Val Leu Leu Ser
                          100                 105                 110
              His Leu Thr Met Gly Thr Phe Leu Val Ser Ala Gln Gly Gln Met Leu
                      115                 120                 125
              Leu Ser Ser Arg Ser Leu Pro His Tyr Phe Pro Asp Val Asp Gly Asp
                  130                 135                 140
              Ile Ser Ser Leu Asp Asp Leu Lys Arg Met Asp Ile Arg Asn Leu Val
              145                 150                 155                 160
              His Gln Ala Phe Asp Gln Lys Thr Arg Leu Lys Gln Glu Val Ser Gly
                              165                 170                 175
              Phe His Glu Gly Asp Leu Ile Leu Glu Val Thr Ala Val Pro Val Phe
                          180                 185                 190
              Ser Pro Thr Gln Ser Val Glu Ala Val Leu Val Leu Leu Tyr Asp Leu
                      195                 200                 205
                                                 Page 136

<removed-date>
              Thr Thr Ile Arg Thr Tyr Glu Lys Leu Asn Leu Ala Phe Val Ser Asn
                  210                 215                 220
              Ala Ser His Glu Leu Arg Thr Pro Val Thr Ser Ile Lys Gly Phe Ala
              225                 230                 235                 240
              Glu Thr Ile Lys Gly Met Ser Ala Glu Glu Glu Ala Leu Lys Asp Asp
                              245                 250                 255
<removed-apn>
              Phe Leu Asp Ile Ile Tyr Lys Glu Ser Leu Arg Leu Glu His Ile Val
                          260                 265                 270
              Glu His Leu Leu Thr Leu Ser Lys Ala Gln Gln Met Pro Ile Gln Trp
                      275                 280                 285
              Thr Thr Leu Ser Leu Ala Glu Phe Val Gln Asp Leu Thr Gln Ser Leu
                  290                 295                 300
              Gln Pro Gln Leu Lys Lys Lys Asp Leu Gln Leu Lys Val Gln Val Pro
              305                 310                 315                 320
              Asp Asp Val Thr Leu Val Ser Asp Ser Gln Leu Leu Ser Gln Ile Leu
                              325                 330                 335
              Leu Asn Leu Leu Ser Asn Ala Ile Arg Tyr Thr Glu Gln Gly Gly Lys
                          340                 345                 350
              Ile Glu Val Lys Thr Gln Lys Val Asn Glu Gly Ile Lys Ile Ser Val
                      355                 360                 365
              Ser Asp Thr Gly Ile Gly Ile Ser Gln Leu Glu Gln Asp Arg Ile Phe
                  370                 375                 380
              Glu Arg Phe Tyr Arg Val Asn Lys Gly Arg Ser Arg Gln Thr Gly Gly
              385                 390                 395                 400
              Thr Gly Leu Gly Leu Ala Ile Val Lys Glu Leu Ser Gln Leu Leu Gly
                              405                 410                 415
                                                 Page 137

              Gly Gln Val Thr Val Thr Ser Gln Leu Gly Arg Gly Ser Cys Phe Thr
<removed-date>
                          420                 425                 430
              Ile Phe Leu Pro Asn Gln Ser Phe Ala Gln Asp
                      435                 440
              <210>   68
              <211>   291
              <212>   PRT
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 68
              Met Lys Phe Lys Lys Met Leu Thr Leu Ala Ala Ile Gly Leu Ser Gly
              1               5                   10                  15
              Phe Gly Leu Val Ala Cys Gly Asn Gln Ser Ala Ala Ser Lys Gln Ser
                          20                  25                  30
              Ala Ser Gly Thr Ile Glu Val Ile Ser Arg Glu Asn Gly Ser Gly Thr
                      35                  40                  45
              Arg Gly Ala Phe Thr Glu Ile Thr Gly Ile Leu Lys Lys Asp Gly Asp
                  50                  55                  60
              Lys Lys Ile Asp Asn Thr Ala Lys Thr Ala Val Ile Gln Asn Ser Thr
              65                  70                  75                  80
              Glu Gly Val Leu Ser Ala Val Gln Gly Asn Ala Asn Ala Ile Gly Tyr
                              85                  90                  95
              Ile Ser Leu Gly Ser Leu Thr Lys Ser Val Lys Ala Leu Glu Ile Asp
                          100                 105                 110
              Gly Val Lys Ala Ser Arg Asp Thr Val Leu Asp Gly Glu Tyr Pro Leu
                      115                 120                 125
              Gln Arg Pro Phe Asn Ile Val Trp Ser Ser Asn Leu Ser Lys Leu Gly
                  130                 135                 140
              Gln Asp Phe Ile Ser Phe Ile His Ser Lys Gln Gly Gln Gln Val Val
              145                 150                 155                 160
                                                 Page 138

<removed-date>
              Thr Asp Asn Lys Phe Ile Glu Ala Lys Thr Glu Thr Thr Glu Tyr Thr
                              165                 170                 175
              Ser Gln His Leu Ser Gly Lys Leu Ser Val Val Gly Ser Thr Ser Val
                          180                 185                 190
              Ser Ser Leu Met Glu Lys Leu Ala Glu Ala Tyr Lys Lys Glu Asn Pro
                      195                 200                 205
<removed-apn>
              Glu Val Thr Ile Asp Ile Thr Ser Asn Gly Ser Ser Ala Gly Ile Thr
                  210                 215                 220
              Ala Val Lys Glu Lys Thr Ala Asp Ile Gly Met Val Ser Arg Glu Leu
              225                 230                 235                 240
              Thr Pro Glu Glu Gly Lys Ser Leu Thr His Asp Ala Ile Ala Leu Asp
                              245                 250                 255
              Gly Ile Ala Val Val Val Asn Asn Asp Asn Lys Ala Ser Gln Val Ser
                          260                 265                 270
              Met Ala Glu Leu Ala Asp Val Phe Ser Gly Lys Leu Thr Thr Trp Asp
                      275                 280                 285
              Lys Ile Lys
                  290
              <210>   69
              <211>   216
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 69
              Met Arg Asn Gln Phe Asp Leu Glu Leu His Glu Leu Glu Gln Ser Phe
              1               5                   10                  15
              Leu Gly Leu Gly Gln Leu Val Leu Glu Thr Ala Ser Lys Ala Leu Leu
                          20                  25                  30
              Ala Leu Ala Ser Lys Asp Lys Glu Met Ala Glu Leu Ile Ile Asn Lys
                      35                  40                  45
                                                 Page 139

<removed-date>
              Asp His Ala Ile Asn Gln Gly Gln Ser Ala Ile Glu Leu Thr Cys Ala
                  50                  55                  60
              Arg Leu Leu Ala Leu Gln Gln Pro Gln Val Ser Asp Leu Arg Phe Val
              65                  70                  75                  80
              Ile Ser Ile Met Ser Ser Cys Ser Asp Leu Glu Arg Met Gly Asp His
<removed-apn>
                              85                  90                  95
              Met Ala Gly Ile Ala Lys Ala Val Leu Gln Leu Lys Glu Asn Gln Leu
                          100                 105                 110
              Ala Pro Asp Glu Glu Gln Leu His Gln Met Gly Lys Leu Ser Leu Ser
                      115                 120                 125
              Met Leu Ala Asp Leu Leu Val Ala Phe Pro Leu His Gln Ala Ser Lys
                  130                 135                 140
              Ala Ile Ser Ile Ala Gln Lys Asp Glu Gln Ile Asp Gln Tyr Tyr Tyr
              145                 150                 155                 160
              Ala Leu Ser Lys Glu Ile Ile Gly Leu Met Lys Asp Gln Glu Thr Ser
                              165                 170                 175
              Ile Pro Asn Gly Thr Gln Tyr Leu Tyr Ile Ile Gly His Leu Glu Arg
                          180                 185                 190
              Phe Ala Asp Tyr Ile Ala Asn Ile Cys Glu Arg Leu Val Tyr Leu Glu
                      195                 200                 205
              Thr Gly Glu Leu Val Asp Leu Asn
                  210                 215
              <210>   70
              <211>   694
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 70
              Met Lys Pro Leu Leu Glu Thr Ile Asp Thr Arg Phe Gly Thr Thr Asn
                                                 Page 140

              1               5                   10                  15
<removed-date>
              Lys His Ala Phe Ser Arg Gly Asn Thr Leu Pro Tyr Thr Gly Val Pro
                          20                  25                  30
              Phe Gly Met Asn Tyr Phe Val Pro Gln Thr Ser Asp Gln Asp Gly Ser
                      35                  40                  45
<removed-apn>
              Trp Phe Phe Asp Pro His Leu Pro Ile Phe Gln Gly Ile Arg Leu Thr
                  50                  55                  60
              His Gln Pro Ser Pro Trp Ile Gly Asp Tyr Ser Trp Leu Leu Leu Thr
              65                  70                  75                  80
              Pro Val Thr Ser Gln Leu Gly Gly Asp Ser Leu Phe His Arg Gln Ser
                              85                  90                  95
              Ser Tyr Asp Ile Asp Lys Ala Cys Phe Gln Pro His Tyr Leu Lys Leu
                          100                 105                 110
              Phe Ser Leu Arg Tyr Gln Ile Glu Thr Gln Leu Thr Pro Thr Cys Tyr
                      115                 120                 125
              Gly Ala Ser Ile Arg Leu Asn Gln Lys Gln Gly Lys Ala Leu Ser Leu
                  130                 135                 140
              Tyr Leu His Ala Ala Asp Glu Leu Thr Val Glu Gln Val Asp Lys Arg
              145                 150                 155                 160
              Thr Leu Ala Leu Arg Gln Glu Gly Lys Thr Glu Thr Asn Lys Asn Ser
                              165                 170                 175
              Leu Thr Met Phe Thr Ala Leu Gln Met Asn Thr Asp Ile Leu Ala Ile
                          180                 185                 190
              Ser Gln Glu Ala Gly Asp Trp Arg Ile Asp Leu Ala Ser Ser Gln Thr
                      195                 200                 205
              Glu Met Gln Leu Ala Thr Ser Phe Ile Ser Pro Ser Gln Ala Leu Ile
                  210                 215                 220
                                                 Page 141

<removed-date>
              Asn Leu Pro Gln Glu Asp Phe Asp Ser Cys Lys Ser Ser Ala Gln Val
              225                 230                 235                 240
              Asp Trp Glu Asn Leu Leu His Arg Phe Asp Ile Ile Glu Thr Gly Glu
                              245                 250                 255
              Ala Asp Arg Thr Phe Phe Asp His Cys Leu Tyr Arg Leu Phe Leu Phe
<removed-apn>
                          260                 265                 270
              Pro Gln Thr Phe Tyr Glu Ile Asn Glu Ser Gly Gln Ala Ile His Met
                      275                 280                 285
              Asp Leu Ala Thr Gly Thr Val Lys Pro Gly Val Leu Phe Ser Asn Asn
                  290                 295                 300
              Gly Phe Trp Asp Thr Phe Arg Thr Thr Phe Pro Leu Phe Ala Leu Ile
              305                 310                 315                 320
              Ile Pro Glu His Tyr Gln Arg Phe Leu Glu Gly Phe Leu Asn Ser Tyr
                              325                 330                 335
              Arg Asp Thr Gly Phe Leu Pro Lys Trp Leu Ala Pro Asp Glu Arg Gly
                          340                 345                 350
              Met Met Pro Gly Thr Leu Leu Asp Gly Ile Ile Ala Asp Ser Ala Cys
                      355                 360                 365
              Lys Asp Met Thr Pro Asp Leu Glu Gly Glu Leu Phe Gln Ala Met Leu
                  370                 375                 380
              Glu Thr Ala Ser Lys Ala Asp Pro Leu Gly Ile Asn Gly Arg His Gly
              385                 390                 395                 400
              Leu Ala Gln Tyr Gln Glu Leu Gly Tyr Leu Ser Thr Asp His His Glu
                              405                 410                 415
              Ser Val Ser His Thr Leu Asp Tyr Ala Tyr Ser Asp Phe Cys Ile Ala
                          420                 425                 430
                                                 Page 142

<removed-date>
              Ser Cys Ala Lys Lys Leu Glu Asn Ile Glu Ile Ala Glu Thr Tyr Lys
                      435                 440                 445
              Ala Ala Ser Gln Asn Tyr Arg Gln Leu Phe Asp Ala Glu Thr Gly Tyr
                  450                 455                 460
              Met Arg Ala Arg Asp Asn Gln Gly Asn Phe His Pro Asp Phe Ser Pro
              465                 470                 475                 480
<removed-apn>
              Tyr Ser Trp Gly Arg Asp Tyr Ala Glu Cys Ser Ala Ile Gln Ala Thr
                              485                 490                 495
              Leu Gly Val Leu His Asp Ile Pro Gly Leu Ile Gln Leu Met Gly Gly
                          500                 505                 510
              Lys Glu Thr Phe Ser Asn Tyr Leu Leu Lys Ala Cys Gln Asp Ala Pro
                      515                 520                 525
              Leu Phe Glu Thr Thr Gly Tyr Gly Tyr Glu Ile His Glu Met Ser Glu
                  530                 535                 540
              Met Ala Thr Ala Pro Phe Gly Gln Ile Ala Ile Ser Asn Gln Pro Ser
              545                 550                 555                 560
              Phe His Ile Pro Tyr Leu Phe Arg Tyr Ser Asp Tyr Pro Asp Tyr Thr
                              565                 570                 575
              Ala Leu Leu Ile Lys Thr Leu Arg Gln Lys Ala Phe His Pro Ser Trp
                          580                 585                 590
              Glu Ala Tyr Pro Gly Asp Glu Asp Asn Gly Ser Leu Ser Ala Trp Tyr
                      595                 600                 605
              Ile Trp Ser Ala Leu Gly Phe Tyr Pro Thr Cys Pro Gly Lys Pro Ser
                  610                 615                 620
              Tyr Asp Leu Gly Ile Pro Leu Phe Asp His Leu Arg Val Tyr Leu Ala
              625                 630                 635                 640
                                                 Page 143

              Lys Glu Asp Lys Trp Leu Asp Ile His Thr Lys Gln Asn His Asn His
<removed-date>
                              645                 650                 655
              Phe Asn Phe Val Lys Glu Cys Arg Leu Asp Lys Thr Leu Val Ser Thr
                          660                 665                 670
              Ile Gln His Gln Asp Leu Leu Lys Ala Glu Gln Leu Thr Phe Thr Leu
                      675                 680                 685
<removed-apn>
              Ser Trp Leu Pro Ser His
                  690
              <210>   71
              <211>   315
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 71
              Met Ala Asn Arg Lys Ile Val Val Ala Leu Gly Gly Asn Ala Ile Leu
              1               5                   10                  15
              Ser Ser Asp Pro Ser Ala Lys Ala Gln Gln Glu Ala Leu Val Glu Thr
                          20                  25                  30
              Ala Lys His Leu Val Lys Leu Ile Lys Asn Gly Asp Asp Leu Ile Ile
                      35                  40                  45
              Thr His Gly Asn Gly Pro Gln Val Gly Asn Leu Leu Leu Gln His Leu
                  50                  55                  60
              Ala Ser Asp Ser Glu Lys Asn Pro Ala Phe Pro Leu Asp Ser Leu Val
              65                  70                  75                  80
              Ala Met Thr Glu Gly Ser Ile Gly Phe Trp Leu Lys Asn Ala Leu Gln
                              85                  90                  95
              Asn Ala Leu Leu Asp Glu Gly Ile Glu Lys Asn Val Ala Ser Val Val
                          100                 105                 110
              Thr Gln Val Val Val Asp Lys Asn Asp Pro Ala Phe Val Asn Leu Ser
                      115                 120                 125
                                                 Page 144

<removed-date>
              Lys Pro Ile Gly Pro Phe Tyr Ser Glu Glu Glu Ala Lys Ala Glu Ala
                  130                 135                 140
              Glu Lys Ser Gly Ala Thr Phe Lys Glu Asp Ala Gly Arg Gly Trp Arg
              145                 150                 155                 160
              Lys Val Val Ala Ser Pro Lys Pro Val Asp Ile Lys Glu Ile Glu Thr
                              165                 170                 175
<removed-apn>
              Ile Arg Thr Leu Leu Asn Asn Gly Gln Val Val Val Ala Ala Gly Gly
                          180                 185                 190
              Gly Gly Ile Pro Val Val Lys Glu Asn Asn Gly His Leu Thr Gly Val
                      195                 200                 205
              Glu Ala Val Ile Asp Lys Asp Phe Ala Ser Gln Arg Leu Ala Glu Leu
                  210                 215                 220
              Val Asp Ala Asp Leu Phe Ile Val Leu Thr Gly Val Asp Tyr Val Phe
              225                 230                 235                 240
              Val Asn Tyr Asn Lys Pro Asn Gln Glu Lys Leu Glu His Val Asn Val
                              245                 250                 255
              Ala Gln Leu Glu Glu Tyr Ile Lys Gln Asp Gln Phe Ala Pro Gly Ser
                          260                 265                 270
              Met Leu Pro Lys Val Glu Ala Ala Ile Ala Phe Val Asn Gly Arg Pro
                      275                 280                 285
              Glu Gly Lys Ala Val Ile Thr Ser Leu Glu Asn Leu Gly Ala Leu Ile
                  290                 295                 300
              Glu Ser Glu Ser Gly Thr Ile Ile Glu Lys Gly
              305                 310                 315
              <210>   72
              <211>   475
              <212>   PRT
              <213>   Streptococcus pneumoniae
                                                 Page 145

<removed-date>
              <400> 72
              Met Tyr Leu Gly Asp Leu Met Glu Lys Ala Glu Cys Gly Gln Phe Ser
              1               5                   10                  15
              Ile Leu Ser Phe Leu Leu Gln Glu Ser Gln Thr Thr Val Lys Ala Val
                          20                  25                  30
              Met Glu Glu Thr Gly Phe Ser Lys Ala Thr Leu Thr Lys Tyr Val Thr
<removed-apn>
                      35                  40                  45
              Leu Leu Asn Asp Lys Ala Leu Asp Ser Gly Leu Glu Leu Ala Ile His
                  50                  55                  60
              Ser Glu Asp Glu Asn Leu Arg Leu Ser Ile Gly Ala Ala Thr Lys Gly
              65                  70                  75                  80
              Arg Asp Ile Arg Ser Leu Phe Leu Glu Ser Ala Val Lys Tyr Gln Ile
                              85                  90                  95
              Leu Val Tyr Leu Leu Tyr His Gln Gln Phe Leu Ala His Gln Leu Ala
                          100                 105                 110
              Gln Glu Leu Val Ile Ser Glu Ala Thr Leu Gly Arg His Leu Ala Gly
                      115                 120                 125
              Leu Asn Gln Ile Leu Ser Glu Phe Asp Leu Ser Ile Gln Asn Gly Arg
                  130                 135                 140
              Trp Arg Gly Pro Glu His Gln Ile His Tyr Phe Tyr Phe Cys Leu Phe
              145                 150                 155                 160
              Arg Lys Val Trp Ser Ser Gln Glu Trp Glu Gly His Met Gln Lys Pro
                              165                 170                 175
              Glu Arg Lys Gln Glu Ile Ala Asn Leu Glu Glu Ile Cys Gly Ala Ser
                          180                 185                 190
              Leu Ser Ala Gly Gln Lys Leu Asp Leu Val Leu Trp Ala His Ile Ser
                      195                 200                 205
                                                 Page 146

<removed-date>
              Gln Gln Arg Leu Arg Val Asn Ala Cys Gln Phe Gln Val Ile Glu Glu
                  210                 215                 220
              Lys Met Arg Gly Tyr Phe Asp Asn Ile Phe Tyr Leu Arg Leu Leu Arg
              225                 230                 235                 240
              Lys Val Pro Ser Phe Phe Ala Gly Gln His Ile Pro Leu Gly Val Glu
                              245                 250                 255
<removed-apn>
              Asp Gly Glu Met Met Ile Phe Phe Ser Phe Leu Leu Ser His Arg Ile
                          260                 265                 270
              Leu Pro Leu His Thr Met Glu Tyr Ile Leu Gly Phe Gly Gly Gln Leu
                      275                 280                 285
              Ala Asp Leu Leu Thr Gln Leu Ile Gln Glu Met Lys Lys Glu Glu Leu
                  290                 295                 300
              Leu Gly Asp Tyr Thr Glu Asp His Val Thr Tyr Glu Leu Ser Gln Leu
              305                 310                 315                 320
              Cys Ala Gln Val Tyr Leu Tyr Lys Gly Tyr Ile Leu Gln Asp Arg Tyr
                              325                 330                 335
              Lys Tyr Gln Leu Glu Asn Arg His Pro Tyr Leu Leu Met Glu His Asp
                          340                 345                 350
              Phe Lys Glu Thr Ala Glu Glu Ile Phe His Ala Leu Pro Ala Phe Gln
                      355                 360                 365
              Gln Gly Thr Asp Leu Asp Lys Lys Ile Leu Trp Glu Trp Leu Gln Leu
                  370                 375                 380
              Ile Glu Tyr Met Ala Glu Asn Gly Gly Gln His Met Arg Ile Gly Leu
              385                 390                 395                 400
              Asp Leu Thr Ser Gly Phe Leu Val Phe Ser Arg Met Ala Ala Ile Leu
                              405                 410                 415
                                                 Page 147

              Lys Arg Tyr Leu Glu Tyr Asn Arg Phe Ile Thr Ile Glu Ala Tyr Asp
<removed-date>
                          420                 425                 430
              Pro Ser Arg His Tyr Asp Leu Leu Val Thr Asn Asn Pro Ile His Lys
                      435                 440                 445
              Lys Glu Gln Thr Pro Val Tyr Tyr Leu Lys Asn Asp Leu Asp Met Glu
                  450                 455                 460
<removed-apn>
              Asp Leu Val Ala Ile Arg Gln Leu Leu Phe Thr
              465                 470                 475
              <210>   73
              <211>   443
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 73
              Met Ile Lys Asn Pro Lys Leu Leu Thr Lys Ser Phe Leu Arg Ser Phe
              1               5                   10                  15
              Ala Ile Leu Gly Gly Val Gly Leu Val Ile His Ile Ala Ile Tyr Leu
                          20                  25                  30
              Thr Phe Pro Phe Tyr Tyr Ile Gln Leu Glu Gly Glu Lys Phe Asn Glu
                      35                  40                  45
              Ser Ala Arg Val Phe Thr Glu Tyr Leu Lys Thr Lys Thr Ser Asp Glu
                  50                  55                  60
              Ile Pro Ser Leu Leu Gln Ser Tyr Ser Lys Ser Leu Thr Ile Ser Ala
              65                  70                  75                  80
              His Leu Lys Arg Asp Ile Val Asp Lys Arg Leu Pro Leu Val His Asp
                              85                  90                  95
              Leu Asp Ile Lys Asp Gly Lys Leu Ser Asn Tyr Ile Val Met Leu Asp
                          100                 105                 110
              Met Ser Val Ser Thr Ala Asp Gly Lys Gln Val Thr Val Gln Phe Val
                      115                 120                 125
                                                 Page 148

<removed-date>
              His Gly Val Asp Val Tyr Lys Glu Ala Lys Asn Ile Leu Leu Leu Tyr
                  130                 135                 140
              Leu Pro Tyr Thr Phe Leu Val Thr Ile Ala Phe Ser Phe Val Phe Ser
              145                 150                 155                 160
              Tyr Phe Tyr Thr Lys Arg Leu Leu Asn Pro Leu Phe Tyr Ile Ser Glu
                              165                 170                 175
<removed-apn>
              Val Thr Ser Lys Met Gln Asp Leu Asp Asp Asn Ile Arg Phe Asp Glu
                          180                 185                 190
              Ser Arg Lys Asp Glu Val Gly Glu Val Gly Lys Gln Ile Asn Gly Met
                      195                 200                 205
              Tyr Glu His Leu Leu Lys Val Ile Tyr Glu Leu Glu Ser Arg Asn Glu
                  210                 215                 220
              Gln Ile Val Lys Leu Gln Asn Gln Lys Val Ser Phe Val Arg Gly Ala
              225                 230                 235                 240
              Ser His Glu Leu Lys Thr Pro Leu Ala Ser Leu Arg Ile Ile Leu Glu
                              245                 250                 255
              Asn Met Gln His Asn Ile Gly Asp Tyr Lys Asp His Pro Lys Tyr Ile
                          260                 265                 270
              Ala Lys Ser Ile Asn Lys Ile Asp Gln Met Ser His Leu Leu Glu Glu
                      275                 280                 285
              Val Leu Glu Ser Ser Lys Phe Gln Glu Trp Thr Glu Cys Arg Glu Thr
                  290                 295                 300
              Leu Thr Val Lys Pro Val Leu Val Asp Ile Leu Ser Arg Tyr Gln Glu
              305                 310                 315                 320
              Leu Ala His Ser Ile Gly Val Thr Ile Glu Asn Gln Leu Thr Asp Ala
                              325                 330                 335
                                                 Page 149

              Thr Arg Val Val Met Ser Leu Arg Ala Leu Asp Lys Val Leu Thr Asn
<removed-date>
                          340                 345                 350
              Leu Ile Ser Asn Ala Ile Lys Tyr Ser Asp Lys Asn Gly Arg Val Ile
                      355                 360                 365
              Ile Ser Glu Gln Asp Gly Tyr Leu Ser Ile Lys Asn Thr Cys Ala Pro
                  370                 375                 380
<removed-apn>
              Leu Ser Asp Gln Glu Leu Glu His Leu Phe Asp Ile Phe Tyr His Ser
              385                 390                 395                 400
              Gln Ile Val Thr Asp Lys Asp Glu Ser Ser Gly Leu Gly Leu Tyr Ile
                              405                 410                 415
              Val Asn Asn Ile Leu Glu Ser Tyr Gln Met Asp Tyr Ser Phe Leu Pro
                          420                 425                 430
              Tyr Glu His Gly Met Glu Phe Lys Ile Ser Leu
                      435                 440
              <210>   74
              <211>   335
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 74
              Met Lys Lys Thr Trp Lys Val Phe Leu Thr Leu Val Thr Ala Leu Val
              1               5                   10                  15
              Ala Val Val Leu Val Ala Cys Gly Gln Gly Thr Ala Ser Lys Asp Asn
                          20                  25                  30
              Lys Glu Ala Glu Leu Lys Lys Val Asp Phe Ile Leu Asp Trp Thr Pro
                      35                  40                  45
              Asn Thr Asn His Thr Gly Leu Tyr Val Ala Lys Glu Lys Gly Tyr Phe
                  50                  55                  60
              Lys Glu Ala Gly Val Asp Val Asp Leu Lys Leu Pro Pro Glu Glu Ser
              65                  70                  75                  80
                                                 Page 150

<removed-date>
              Ser Ser Asp Leu Val Ile Asn Gly Lys Ala Pro Phe Ala Val Tyr Phe
                              85                  90                  95
              Gln Asp Tyr Met Ala Lys Lys Leu Glu Lys Gly Ala Gly Ile Thr Ala
                          100                 105                 110
              Val Ala Ala Ile Val Glu His Asn Thr Ser Gly Ile Ile Ser Arg Lys
                      115                 120                 125
<removed-apn>
              Ser Asp Asn Val Ser Ser Pro Lys Asp Leu Val Gly Lys Lys Tyr Gly
                  130                 135                 140
              Thr Trp Asn Asp Pro Thr Glu Leu Ala Met Leu Lys Thr Leu Val Glu
              145                 150                 155                 160
              Ser Gln Gly Gly Asp Phe Glu Lys Val Glu Lys Val Pro Asn Asn Asp
                              165                 170                 175
              Ser Asn Ser Ile Thr Pro Ile Ala Asn Gly Val Phe Asp Thr Ala Trp
                          180                 185                 190
              Ile Tyr Tyr Gly Trp Asp Gly Ile Leu Ala Lys Ser Gln Gly Val Asp
                      195                 200                 205
              Ala Asn Phe Met Tyr Leu Lys Asp Tyr Val Lys Glu Phe Asp Tyr Tyr
                  210                 215                 220
              Ser Pro Val Ile Ile Ala Asn Asn Asp Tyr Leu Lys Asp Asn Lys Glu
              225                 230                 235                 240
              Glu Ala Arg Lys Val Ile Gln Ala Ile Lys Lys Gly Tyr Gln Tyr Ala
                              245                 250                 255
              Met Glu His Pro Glu Glu Ala Ala Asp Ile Leu Ile Lys Asn Ala Pro
                          260                 265                 270
              Glu Leu Lys Glu Lys Arg Asp Phe Val Ile Glu Ser Gln Lys Tyr Leu
                      275                 280                 285
                                                 Page 151

              Ser Lys Glu Tyr Ala Ser Asp Lys Glu Lys Trp Gly Gln Phe Asp Ala
<removed-date>
                  290                 295                 300
              Ala Arg Trp Asn Ala Phe Tyr Lys Trp Asp Lys Glu Asn Gly Ile Leu
              305                 310                 315                 320
              Lys Glu Asp Leu Thr Asp Lys Gly Phe Thr Asn Glu Phe Val Lys
                              325                 330                 335
<removed-apn>
              <210>   75
              <211>   220
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 75
              Met Lys Cys Leu Leu Cys Gly Gln Thr Met Lys Thr Val Leu Thr Phe
              1               5                   10                  15
              Ser Ser Leu Leu Leu Leu Arg Asn Asp Asp Ser Cys Leu Cys Ser Asp
                          20                  25                  30
              Cys Asp Ser Thr Phe Glu Arg Ile Gly Glu Glu Asn Cys Pro Asn Cys
                      35                  40                  45
              Met Lys Thr Glu Leu Ser Thr Lys Cys Gln Asp Cys Gln Leu Trp Cys
                  50                  55                  60
              Lys Glu Gly Val Glu Val Ser His Arg Ala Ile Phe Thr Tyr Asn Gln
              65                  70                  75                  80
              Ala Met Lys Asp Phe Phe Ser Arg Tyr Lys Phe Asp Gly Asp Phe Leu
                              85                  90                  95
              Leu Arg Lys Val Phe Ala Ser Phe Leu Ser Glu Glu Leu Lys Lys Tyr
                          100                 105                 110
              Lys Glu Tyr Gln Phe Val Val Ile Pro Leu Ser Pro Asp Arg Tyr Ala
                      115                 120                 125
              Asn Arg Gly Phe Asn Gln Val Glu Gly Leu Val Glu Ala Ala Gly Phe
                  130                 135                 140
                                                 Page 152

<removed-date>
              Glu Tyr Leu Asp Leu Leu Glu Lys Arg Glu Glu Arg Ala Ser Ser Ser
              145                 150                 155                 160
              Lys Asn Arg Ser Glu Arg Leu Gly Thr Glu Leu Pro Phe Phe Ile Lys
                              165                 170                 175
              Ser Gly Val Thr Ile Pro Lys Lys Ile Leu Leu Ile Asp Asp Ile Tyr
                          180                 185                 190
<removed-apn>
              Thr Thr Gly Ala Thr Ile Asn Arg Val Lys Lys Leu Leu Glu Glu Ala
                      195                 200                 205
              Gly Ala Lys Asp Val Lys Thr Phe Ser Leu Val Arg
                  210                 215                 220
              <210>   76
              <211>   272
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 76
              Met Asn Arg Phe Lys Lys Ser Lys Tyr Val Ile Ile Val Phe Val Thr
              1               5                   10                  15
              Val Leu Leu Val Ser Ala Leu Leu Ala Thr Thr Tyr Ser Ser Thr Ile
                          20                  25                  30
              Val Thr Lys Leu Gly Asp Gly Ile Ser Leu Val Asp Arg Val Val Gln
                      35                  40                  45
              Lys Pro Phe Gln Trp Phe Asp Ser Val Lys Ser Asp Leu Ala His Leu
                  50                  55                  60
              Thr Arg Thr Tyr Asn Glu Asn Glu Ser Leu Lys Lys Gln Leu Tyr Gln
              65                  70                  75                  80
              Leu Glu Val Lys Ser Asn Glu Val Glu Ser Leu Lys Thr Glu Asn Glu
                              85                  90                  95
              Gln Leu Arg Gln Leu Leu Asp Met Lys Ser Lys Leu Gln Ala Thr Lys
                          100                 105                 110
                                                 Page 153

<removed-date>
              Thr Leu Ala Ala Asp Val Ile Met Arg Ser Pro Val Ser Trp Lys Gln
                      115                 120                 125
              Glu Leu Thr Leu Asp Ala Gly Arg Ser Lys Gly Ala Ser Glu Asn Met
                  130                 135                 140
              Leu Ala Ile Ala Asn Gly Gly Leu Ile Gly Ser Val Ser Lys Val Glu
<removed-apn>
              145                 150                 155                 160
              Glu Asn Ser Thr Ile Val Asn Leu Leu Thr Asn Thr Glu Asn Ala Asp
                              165                 170                 175
              Lys Ile Ser Val Lys Ile Gln His Gly Ser Thr Thr Ile Tyr Gly Ile
                          180                 185                 190
              Ile Ile Gly Tyr Asp Lys Glu Asn Asp Val Leu Lys Ile Ser Gln Leu
                      195                 200                 205
              Asn Ser Asn Ser Asp Ile Ser Ala Gly Asp Lys Val Thr Thr Gly Gly
                  210                 215                 220
              Leu Gly Asn Phe Asn Val Ala Asp Ile Pro Val Gly Glu Val Val Ala
              225                 230                 235                 240
              Thr Thr His Ser Thr Asp Tyr Leu Thr Arg Glu Val Thr Val Lys Leu
                              245                 250                 255
              Ser Ala Asp Thr His Asn Val Asp Val Ile Glu Leu Val Gly Asn Ser
                          260                 265                 270
              <210>   77
              <211>   1269
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 77
              atgcgtaaat tcttaattat tttgttgcta ccaagttttt tgaccatttc aaaagtcgtt    60
              agcacagaaa aagaagtcgt ctatacttcg aaagaaattt attacctttc acaatctgac   120
              tttggtattt attttagaga aaaattaagt tctcccatgg tttatggaga ggttcctgtt   180
                                                 Page 154

<removed-date>
              tatgcgaatg aagatttagt agtggaatct gggaaattga ctcccaaaac aagttttcaa    240
              ataaccgagt ggcgcttaaa taaacaagga attccagtat ttaagctatc aaatcatcaa    300
              tttatagctg cggacaaacg atttttatat gatcaatcag aggtaactcc aacaataaaa    360
              aaagtatggt tagaatctga ctttaaactg tacaatagtc cttatgattt aaaagaagtg    420
              aaatcatcct tatcagctta ttcgcaagta tcaatcgaca agaccatgtt tgtagaagga    480
<removed-apn>
              agagaatttc tacatattga tcaggctgga tgggtagcta aagaatcaac ttctgaagaa    540
              gataatcgga tgagtaaagt tcaagaaatg ttatctgaaa aatatcagaa agattctttc    600
              tctatttatg ttaagcaact gactactgga aaagaagctg gtatcaatca agatgaaaag    660
              atgtatgcag ccagcgtttt gaaactctct tatctctatt atacgcaaga aaaaataaat    720
              gagggtcttt atcagttaga tacgactgta aaatacgtat ctgcagtcaa tgattttcca    780
              ggttcttata aaccagaggg aagtggtagt cttcctaaaa aagaagataa taaagaatat    840
              tctttaaagg atttaattac gaaagtatca aaagaatctg ataatgtagc tcataatcta    900
              ttgggatatt acatttcaaa ccaatctgat gccacattca aatccaagat gtctgccatt    960
              atgggagatg attgggatcc aaaagaaaaa ttgatttctt ctaagatggc cgggaagttt   1020
              atggaagcta tttataatca aaatggattt gtgctagagt ctttgactaa aacagatttt   1080
              gatagtcagc gaattgccaa aggtgtttct gttaaagtag ctcataaaat tggagatgcg   1140
              gatgaattta agcatgatac gggtgttgtc tatgcagatt ctccatttat tctttctatt   1200
              ttcactaaga attctgatta tgatacgatt tctaagatag ccaaggatgt ttatgaggtt   1260
              ctaaaatga                                                           1269
              <210>   78
              <211>   1350
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 78
              atgaaaccag aatttttaga aagtgcggag ttttataatc gtcgttacca taatttttcc     60
              agtagtgtga ttgtacccat ggcccttctg cttgtgtttt tacttggctt tgcaactgtt    120
              gcagagaagg agatgagttt gtccactaga gctactgtcg aacctagtcg tatccttgca    180
              aatatccagt caactagcaa caatcgtatt cttgtcaatc atttggaaga aaataagctg    240
                                                 Page 155

<removed-date>
              gttaagaagg gggatctttt ggttcaatac caagaagggg cagagggtgt ccaagcggag    300
              tcctatgcca gtcagttgga catgctaaag gatcaaaaaa agcaattgga gtatctgcaa    360
              aagagcctgc aagaagggga gaaccacttt ccagaggagg ataagtttgg ctaccaagcc    420
              acctttcgcg actacatcag tcaagcaggc agtcttaggg ctagtacatc gcaacaaaat    480
              gagaccatcg cgtcccagaa tgcagcagct agccaaaccc aagccgaaat cggcaacctc    540
<removed-apn>
              atcagtcaaa cagaggctaa aattcgcgat taccagacag ctaagtcagc tattgaaaca    600
              ggtgcttcct tggccggtca gaatctagcc tactctcttt accagtccta caagtctcag    660
              ggcgaggaaa atccccaaac taaggttcag gcagttgcac aggttgaagc acagatttct    720
              cagttagaat ctagtcttgc tacttaccgt gtccagtatg caggttcagg tacccagcaa    780
              gcctatgcgt cagggttaag cagtcaattg gaatccctta aatcccaaca cttggcaaag    840
              gttggtcagg aattgaccct tctagcccag aaaattttgg aggcagagtc aggtaagaag    900
              gtacagggaa atcttttaga caaggggaaa gttacggcga gtgaggatgg ggtgcttcat    960
              cttaatcctg agaccagtga ttctagcatg gttgcagaag gtgccctact agcccaactt   1020
              tatccatctt tggaaagaga agggaaagcc aaactcacag cttatctaag ttcaaaatat   1080
              gtagcaagaa tcaaggtcgg tgattctgtt cgctatacta cgactcatga tgccgggaat   1140
              caacttttcc tagattctac tattacaagt attgatgcga cagctactaa gactgagaaa   1200
              gggaatttct ttaaaatcga ggcggagact aatctaactt cggagcaggc tgaaaaactt   1260
              aggtacgggg tggaaggccg cttgcagatg attacgggca agaaaagtta cctacgttat   1320
              tatttggatc aatttttgaa caaagagtaa                                    1350
              <210>   79
              <211>   666
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 79
              atgtcagatc gtacgattgg aattttgggc ttgggaattt ttgggagcag tgtcctagct     60
              gccctagcca agcaggatat gaatattatc gctattgatg accacgcaga gcgcatcaat    120
              cagtttgagc cagttttggc gcgtggagtg attggtgaca tcacagatga agaattattg    180
              agatcagcag ggattgatac ctgcgatacc gttgtagtcg cgacaggtga aaatctggag    240
                                                 Page 156

<removed-date>
              tcgagtgtgc ttgcggttat gcactgtaag agtttggggg taccgactgt tattgctaag   300
              gtcaaaagtc agaccgctaa gaaagtgcta gaaaagattg gagctgactc ggttatctcg   360
              ccagagtatg aaatggggca gtctctagca cagaccattc ttttccataa tagtgttgat   420
              gtctttcagt tggataaaaa tgtgtctatc gtggagatga aaattcctca gtcttgggca   480
              ggtcaaagtc tgagtaaatt agacctccgt ggcaaataca atctgaatat tttgggtttc   540
<removed-apn>
              cgagagcagg aaaattcccc attggatgtt gaatttggac cagatgacct cttgaaagca   600
              gatacctata ttttggcagt catcaacaac cagtatttgg ataccctagt agcattgaat   660
              tcgtaa                                                              666
              <210>    80
              <211>    1053
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 80
              atgaaactaa aaagttatat tttggttgga tatattattt caaccctctt aaccattttg    60
              gttgtttttt gggctgttca aaaaatgctg attgcgaaag gcgagattta ctttttgctt   120
              gggatgacca tcgttgccag ccttgtcggt gctgggatta gtctctttct cctattgcca   180
              gtctttacgt cgttgggcaa actcaaggag catgccaagc gggtagcggc caaggatttt   240
              ccttcaaatt tggaggttca aggtcctgta gaatttcagc aattagggca aacttttaat   300
              gagatgtccc atgatttgca ggtaagcttt gattccttgg aagaaagcga acgagaaaag   360
              ggcttgatga ttgcccagtt gtcgcatgat attaagactc ctatcacttc gatccaagcg   420
              acggtagaag ggattttgga tgggattatc aaggagtcgg agcaagctca ttatctagca   480
              accattggac gccagacgga gaggctcaat aaactggttg aggagttgaa ttttttgacc   540
              ctaaacacag ctagaaatca ggtggaaact accagtaaag acagtatttt tctggacaag   600
              ctcttaattg agtgcatgag tgaatttcag tttttgattg agcaggagag aagagatgtc   660
              cacttgcagg taatcccaga gtctgcccgg attgagggag attatgctaa gctttctcgt   720
              atcttggtga atctggtcga taacgctttt aaatattctg ctccaggaac caagctggaa   780
              gtggtggcta agctggagaa ggaccagctt tcaatcagtg tgaccgatga agggcagggt   840
              attgccccag aggatttgga aaatattttc aaacgccttt atcgtgtcga aacttcgcgt   900
                                                  Page 157

<removed-date>
              aacatgaaga caggtggtca tggattagga cttgcgattg cgcgtgaatt ggcccatcaa    960
              ttgggtgggg aaatcacagt cagcagccag tacggtctag gaagtacctt taccctcgtt   1020
              ctcaacctct ctggtagtga aaataaagcc taa                                1053
              <210>   81
              <211>   1476
              <212>   DNA
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 81
              atgaaaaact ggaaaaaata tgcttttgca tctgctagtg tagtcgctct ggctgcaggt     60
              cttgctgctt gtggaaattt gacaggtaac agcaaaaaag ctgctgattc aggtgacaaa    120
              cctgttatca aaatgtacca aatcggtgac aaaccagaca acttggatga attgttagca    180
              aatgccaaca aaatcattga agaaaaagtt ggtgccaaat tggatatcca ataccttggc    240
              tggggtgact atggtaagaa aatgtcagtt atcacatcat ctggtgaaaa ctatgatatt    300
              gcctttgcag ataactatat tgtaaatgct caaaaaggtg cttacgctga cttgacagaa    360
              ttgtacaaaa aagaaggtaa agacctttac aaagcacttg acccagctta catcaagggt    420
              aatactgtaa atggtaagat ttacgctgtt ccagttgcag ccaacgttgc atcatctcaa    480
              aactttgcct tcaacggaac tctccttgct aaatatggta tcgatatttc aggtgttact    540
              tcttacgaaa ctcttgagcc agtcttgaaa caaatcaaag aaaaagctcc agacgtagta    600
              ccatttgcta ttggtaaagt tttcatccca tctgataatt ttgactaccc agtagcaaac    660
              ggtcttccat tcgttatcga ccttgaaggc gatactacta aagttgtaaa ccgttacgaa    720
              gtgcctcgtt tcaaagaaca cttgaagact cttcacaaat tctatgaagc tggctacatt    780
              ccaaaagacg tcgcaacaag cgatacttcc tttgaccttc aacaagatac ttggttcgtt    840
              cgtgaagaaa cagtaggacc agctgactac ggtaacagct tgctttcacg tgttgccaac    900
              aaagatatcc aaatcaaacc aattactaac ttcatcaaga aaaaccaaac aacacaagtt    960
              gctaactttg tcatctcaaa caactctaag aacaaagaaa aatcaatgga aatcttgaac   1020
              ctcttgaata cgaacccaga actcttgaac ggtcttgttt acggtccaga aggcaagaac   1080
              tgggaaaaaa ttgaaggtaa agaaaaccgt gttcgcgttc ttgatggcta caaaggaaac   1140
              actcacatgg gtggatggaa cactggtaac aactggatcc tttacatcaa cgaaaacgtt   1200
                                                 Page 158

<removed-date>
              acagaccaac aaatcgaaaa ttctaagaaa gaattggcag aagctaaaga atctccagcg   1260
              cttggattta tcttcaatac tgacaatgtg aaatctgaaa tctcagctat tgctaacaca   1320
              atgcaacaat ttgatacagc tatcaacact ggtactgtag acccagataa agcgattcca   1380
              gaattgatgg aaaaattgaa atctgaaggt gcctacgaaa aagtattgaa cgaaatgcaa   1440
              aaacaatacg atgaattctt gaaaaacaaa aaataa                             1476
<removed-apn>
              <210>   82
              <211>   912
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 82
              atgcgtaaat ggacaaaagg atttctcatc tttggtgtgg tgactaccgt tatcggcttt     60
              atcctgcttt ttgtaggtat ccaatctgac gggattaaga gcctactttc catgtccaaa    120
              gaacctgtct atgatagccg tacggaaaag ctaacctttg gcaaggaagt cgaaaaccta    180
              gaaattactc tccaccaaca cacgctcacc atcacagact ctttcgatga tcaaatccac    240
              atttcttacc atccatctct ttctgctcac catgatctta tcaccaatca gaacgataga    300
              actctgagtc tcactgataa gaaactgtct gaaactccgt ttctctcttc tggaattggt    360
              gggattcttc atatcgcaag tagctactct agtcgttttg aagaagttat tctccgacta    420
              ccaaaaggga gaactctaaa agggatcaac atctcagcca atcgcggaca aaccaccatc    480
              ataaatgcta gccttgaaaa tgcgaccctc aatacaaaca gctatatcct ccgaattgaa   540
              ggaagtcgta tcaaaaacag taaactcaca acgcccaata tcgttaatat ctttgataca    600
              gttcttacag atagtcagct agagtcaaca gagaatcact tccacgctga aaatatccaa    660
              gtccatggca aggttgaact gactgccaaa gattatctca gaatcatcct agaccagaaa    720
              gaaagccaac gaattaactg ggacatctca agcaactatg gttctatctt ccaattcaca    780
              agagaaaagc ctgaatcaag aggtacggaa ttaagcaacc cttacaaaac tgaaaaaacc    840
              gatgtcaagg atcaactcat tgcgagatct gatgataata ttgatctaat atccacacca    900
              agcagacgtt ga                                                        912
              <210> 83
              <211> 1065
                                                 Page 159

              <212> DNA
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 83
              gtgactcaaa atgttgaaag tcttctcgta tccattgtaa tcagtgcata caatgaagaa     60
              aaatatctgc ctggtctaat tgaagactta aaaaatcaaa cctatcctaa agaggatatt    120
              gaaattctat ttataaatgc tatgtccaca gatgggacca cagctatcat tcagcaattt    180
              ataaaggaag atacagagtt taactcaatt agattgtata acaatcctaa gaaaaatcaa    240
<removed-apn>
              gctagtggtt ttaacctggg agttaaacat tctgtagggg accttatttt aaaaattgat   300
              gctcattcaa aagttactga gacttttgta atgaacaatg tggctattat tcaacaaggt   360
              gaatttgtct gtggggggcc tagaccgacg attgtcgaag gaaaaggaaa atgggcagag    420
              accttgcatc ttgttgagga aaatatgttt ggcagtagca ttgccaatta tcgaaatagt    480
              tctgaggata gatatgtttc ttctattttt catggaatgt ataaacgaga ggttttccag    540
              aaggttggtt tagtaaatga gcaacttggc cgaactgaag ataatgatat tcattataga    600
              attcgagaat atggttataa aatccgctat agcccaagta ttctatctta tcagtatatt    660
              cgaccaacat tcaagaaaat gctgcatcaa aagtattcaa atggtttgtg gattggcttg   720
              acaagtcatg ttcagtttaa gtgtttatca ttatttcact atgttccttg tttatttgtt   780
              ttgagtcttg tgtttagtct agcattgtta ccgatcacat tcgtattcat aactttacta   840
              ttaggtgcct attttctact tttgtcatta ctcactttgc tgactttatt aaaacataaa    900
              aatggatttc taattgtgat gccctttatt ttattttcca ttcactttgc ttatggcctt    960
              gggacgattg taggtttaat tagaggattt aaatggaaga aggagtacaa gagaacaata   1020
              atttatttgg ataaaataag ccaaataaat caaaatatgc tataa                   1065
              <210>   84
              <211>   588
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 84
              atgaaatcaa taactaaaaa gattaaagca actcttgcag gagtagctgc cttgtttgca     60
              gtatttgctc catcatttgt atctgctcaa gaatcatcaa cttacactgt taaagaaggt   120
              gatacacttt cagaaatcgc tgaaactcac aacacaacag ttgaaaaatt ggcagaaaac   180
                                                 Page 160

              aaccacattg ataacattca tttgatttat gttgatcaag agttggttat cgatggccct   240
<removed-date>
              gtagcgcctg ttgcaacacc agcgccagct acttatgcgg caccagccgc tcaagatgaa   300
              actgtttcag ctccagtagc agaaactcca gtagtaagtg aaacagttgt ttcaactgta   360
              agcggatctg aagcagaagc caaagaatgg atcgctcaaa aagaatcagg tggtagctat   420
              acagctacaa atggacgtta tatcggacgt taccaattaa cagattcata cctgaacggt   480
              gactactcag ctgaaaacca agaacgtgta gcagatgcct acgttgcagg acgttacggt   540
<removed-apn>
              tcatggactg ctgctaaaaa cttctggctt aacaatggct ggtattaa                588
              <210>   85
              <211>   684
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 85
              atgaaagtat tagcttttga tacgtccagc aaggctcttt ctctggctat tttagaggat    60
              aagcaggttc ttgccgagac gacgattaat attaagaaaa atcacagtat tactcttatg   120
              cctgccatcg attttttgat ggcaagtttg gattggacac ccaaggattt ggaccgaatc   180
              gtggtagctg aagggccggg tagctataca ggcttgcgaa ttgcggtagc aactgctaag   240
              accttagctc acaccctgaa catcgagttg gttggtatgt cgagtctctt ggctctggtg   300
              ccccatcaac aagaaggttt gtttgtcccc ttgatggatg cgcgtcgcaa taatgtttat   360
              gcaggatttt atgaaaatgc caaacctgtc atggcagaag cgcacctatc ttttgaagag   420
              gtgctagaaa aagtcaaggg tactagtcag gtaacctttg tcggagaagt tggccccttt   480
              gttgagcaga ttcaaaaaca cttgccaagg actgattaca aagaaacatt gcccaatgca   540
              gctaatctag ctcttttggc ctgggacaag gaagcagact ccttgcatga ttttgtgccg   600
              aattacctca aacgagtcga ggctgaggaa aactggctca agaaccatac cgagtctggc   660
              gagtcttaca ttaaacgcct atga                                          684
              <210>   86
              <211>   855
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 86
              atgaaaatca aaaaatggct tggtctagca gcccttgcta cagtcgcagg tttggctctt    60
                                                 Page 161

<removed-date>
              gcagcttgcg gaaactcaga aaagaaagca gacaatgcaa caactatcaa aatcgcaact   120
              gttaaccgta gcggttctga agaaaaacgt tgggacaaaa tccaagaatt ggttaaaaaa   180
              gacggaatta ccttggaatt tacagagttc acagactact cacaaccaaa caaagcaact   240
              gctgatggcg aagtagattt gaacgctttc caacactata acttcttgaa caactggaac   300
              aaagaaaacg gaaaagacct tgtagcgatt gcagatactt acatctctcc aatccgcctt   360
<removed-apn>
              tactcaggtt tgaatggaag tgccaacaag tacactaaag tagaagacat cccagcaaac   420
              ggagaaatcg ctgtaccgaa tgacgctaca aacgaaagcc gtgcgcttta tttgcttcaa   480
              tcagctggct tgattaaatt ggatgtttct ggaactgctc ttgcaacagt tgccaacatc   540
              aaagaaaatc caaagaactt gaaaatcact gaattggacg ctagccaaac agctcgttca   600
              ttgtcatcag ttgacgctgc cgttgtaaac aataccttcg ttacagaagc aaaattggac   660
              tacaagaaat cacttttcaa agaacaagct gatgaaaact caaaacaatg gtacaacatc   720
              attgttgcaa aaaaagattg ggaaacatca cctaaggctg atgctatcaa gaaagtaatc   780
              gcagcttacc acacagatga cgtgaaaaaa gttatcgaag aatcatcaga tggtttggat   840
              caaccagttt ggtaa                                                    855
              <210>   87
              <211>   570
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 87
              atgaaaaaaa tagttcttgt tagtctagct ttcctttttg tcctggttgg ttgcggacag    60
              aaaaaagaaa ctggaccagc tacaaaaaca gaaaaagata cgcttcagtc ggcattgcca   120
              gttattgaaa atgctgagaa gaatacagtt gtaactaaga ctttggtctt gcccaagtca   180
              gatgatggta gccagcagac acaaacaatt acttacaaag acaagacttt tttgagtcta   240
              gctatccaac aaaaacgtcc agtctctgat gagttgaaga cttatattga ccaacatgga   300
              gtggaggaaa ctcaaaaagc tcttcttgaa gcggaggaga aggataagtc tatcattgaa   360
              gctcgtaaat tggcaggttt caaacttgaa acaaaactat tgagcgcaac ggaacttcaa   420
              acaacgacta gttttgattt tcaagttctg gatgtcaaga aggcttccca gttggaacat   480
              ctgaagaata ttggtttgga aaatcttttg aaaaatgaac caagcaaata tatttcagat   540
                                                 Page 162

<removed-date>
              agattggcaa atggcgcgac agaacaatag                                    570
              <210>   88
              <211>   459
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 88
              atgaaattaa aaagattcac actttctctt gcttctctag caagttttag tctcttagta    60
<removed-apn>
              gcttgttcac aaagagctca acaggttcaa cagcctgttg ctcagcagca ggtccaacaa   120
              cctgctcaac agaataccaa tactgcaaat gcaggaggta accaaaatca agcggctcca   180
              gtacaaaacc aacctgttgc tcaaccgacc gatattgatg ggacttatac tggtcaggat   240
              gacggagacc gtatcacttt agtggtaact ggaacgactg gtacatggac tgagctcgaa   300
              tctgacgggg atcagaaagt caaacaggtt acattggatt cagcaaatca acgcatgatt   360
              attggcgatg atgtcaaaat ttacactgta aacggtaatc aaatcgtcgt agatgatatg   420
              gatagagacc catcggacca aatcgtttta actaaataa                          459
              <210>   89
              <211>   309
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 89
              atggtgaaga ttggtttgtt ttgtgcagca ggtttttcta ctggtatgct tgtaaataat    60
              atgaaaattg cagcgcaatc tagtggagtt gaggcagaaa tagaggcgtt ttctcagtct   120
              aaattagcgg attatgcgcc aaatatagat gttgcactat tgggtccaca agttgcttat   180
              acattagata aatcaaaaga aatttgtgat aagtgtgatg ttccgatagc tgttattccg   240
              atgatggact atggtatgtt agatgggaaa aaagtattag atttggccct atctttgatt   300
              agtgggtaa                                                           309
              <210>   90
              <211>   435
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 90
              atgaaaattg tacttgtagg gcatggacat tttgctacag ggatttatag ttctttacaa    60
                                                 Page 163

<removed-date>
              ttgattgcag gtaatcaaga aaatgtggag gcgattgact ttgtggaagg aatgtcagca   120
              gatgaactca agcaaaaaat cttacttgca atttcaaatg aagaagaagt tttaatccta   180
              agtgatctct tgggaggatc gccattcaag gtttcttcta ccataatggg agaaaatcca   240
              gccaagacaa tgaatgttct ctcgggtttg aacttagcca tgttaatgga agcagtcttt   300
              gctagaatgg ctcatagctt tgatgaggtt gttaataaat cagtagtggc ggcccagggc   360
<removed-apn>
              ggagtcgtaa atggtaaaga attgttttca acggatgcag aggaagagga agaagatttc   420
              gaatcgggta tttaa                                                    435
              <210>   91
              <211>   1446
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 91
              atgagtagac gttttaaaaa atcacgttca cagaaagtga agcgaagtgt taatatagtt    60
              ttgctgacta tttatttatt gttagtttgt tttttattgt tcttaatctt taagtacaat   120
              atccttgctt ttagatatct taatctagtg gtaactgcgt tagtcctact agttgccttg   180
              gtagggctac tcttgattat ctataaaaaa gctgaaaagt ttactatttt tctgttggtg   240
              ttctctatcc ttgtcagctc tgtgtcgctc tttgcagtac agcagtttgt tggactgacc   300
              aatcgtttaa atgcgacttc taattactca gaatattcaa tcagtgtcgc tgttttagca   360
              gatagtgaga tcgaaaatgt tacgcaactg acgagtgtga cagcaccgac tgggactaat   420
              aatgaaaata ttcagaaatt actagctgat atcaagtcaa gtcagaatac cgatttgacg   480
              gtcaaccaga gttcgtctta cttggcagct tacaagagtt tgattgcagg ggagactaag   540
              gccattgtcc taaatagtgt ctttgaaaac atcatcgagt cagagtatcc agactacgca   600
              tcgaagataa aaaagattta tactaaggga ttcactaaaa aagtagaagc tcctaagacg   660
              tctaagagtc agtctttcaa tatctatgtt agtggaattg acacctatgg tcctattagt   720
              tcggtgtcgc gatcagatgt caacatcctg atgactgtca atcgagatac caagaaaatc   780
              ctcttgacca caacgccacg tgatgcctat gtaccaatcg cagatggtgg aaataatcaa   840
              aaagataaat tgactcatgc gggcatttat ggagttgatt cgtccattca caccttagaa   900
              aatctctatg gagtggatat caattactat gtgcgattga acttcacttc gtttttgaaa   960
                                                 Page 164

<removed-date>
              ttgattgatt tgttgggtgg aattgatgtt tataatgatc aagaatttac tgcccatacg   1020
              aatggaaagt attaccctgc aggcaatgtt catcttgatt cagaacaggc tctcggtttt   1080
              gttcgtgagc gctactccct agcagatggc gatcgtgacc gcgggcgcca tcaacaaaag   1140
              gtgattgtgg ctatccttca aaaattaacg tcaaccgaag tgctgaaaaa ttatagtacg   1200
              atcattaata gcttgcaaga ttctatccaa acaaatatgc cacttgagac catgataaat   1260
<removed-apn>
              ttggtcaatg ctcagttaga aagtggaggg aattataaag taaattctca agatttaaaa   1320
              gggacaggtc ggatggatct tccttcttat gcaatgccag acagtaacct ctatgtgatg   1380
              gaaatagatg atagtagttt agctgtagtt aaagcagcta tacaggatgt gatggagggt   1440
              agatga                                                              1446
              <210>    92
              <211>    615
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 92
              atgaattcat ttaaaaattt cttaaaagag tggggattgt tcctcctaat tctgtcatta     60
              ctagctttaa gtcgtatctt tttttggagc aatgttcgcg tagaaggaca ttccatggat    120
              ccgaccctag cggatggcga aattctcttc gttgtaaaac accttcctat tgaccgtttt    180
              gatatcgtgg tggcccatga ggaagatggc aataaggaca tcgtcaagcg cgtgattgga    240
              atgcctggcg acaccattcg ttacgaaaat gataaactct acatcaatga caaagaaacg    300
              gacgagcctt atctagcaga ctatatcaaa cgcttcaagg atgacaaact ccaaagcact    360
              tactcaggca agggctttga aggaaataaa ggaactttct ttagaagtat cgctcaaaaa    420
              gctcaagcct tcacagttga tgtcaactac aacaccaact ttagctttac tgttccagaa    480
              ggagaatacc ttctcctcgg agatgaccgc ttggtttcga gcgacagccg ccacgtaggt    540
              accttcaaag caaaagatat cacaggggaa gctaaattcc gcttatggcc aatcacccgt    600
              atcggaacat tttaa                                                     615
              <210>    93
              <211>    1566
              <212>    DNA
              <213>    Streptococcus pneumoniae
                                                  Page 165

<removed-date>
              <400> 93
              atgagaaaaa tatacttatc tattttcaca agtctcttgc tgatgctagg acttgtcaat     60
              gttgctcaag ccgatgaata tttacgcatc ggtatggaag cagcatatgc tccctttaac    120
              tggacccagg atgatgatag caacggagct gtcaaaatcg atgggaccaa tcagtatgcc    180
              aacggatacg atgttcaaat cgccaagaaa atcgctaagg acttaggtaa agaacctttg    240
              gttgttaaaa ccaagtggga aggtctagtc cctgccctta cttctggtaa gattgacatg    300
<removed-apn>
              attatcgcag gtatgagtcc aactgcagaa cgcaaacaag aaattgcctt ttcgagcagt    360
              tactatacta gcgaaccagt tttgcttgtc aaaaaagatt ctgcctacgc aagtgctaaa    420
              tctttggatg actttaacgg tgcaaaaatc acttctcaac aaggggtcta cctttataac    480
              ttgattgcac aaatcccagg tgctaaaaaa gaaacagcca tgggagactt cgctcaaatg    540
              cgacaagctc ttgaggctgg tgtcattgat gcttatgttt ctgaacgtcc agaagcactg    600
              actgctgaag ctgcgaactc taagttcaag atgattcaag tagaacctgg tttcaaaact    660
              ggggaagaag atacagctat cgctatcggg cttcgtaaaa atgacaatcg tattagccaa    720
              atcaatgcca gcattgaaac catttcaaaa gatgaccaag ttgccttgat ggatcgtatg    780
              atcaaggaac aacctgccga agctacaaca actgaagaga ctagcagtag tttctttagc    840
              caagttgcta aaattctttc tgaaaactgg caacaactct tgcgtggtgc tggtatcact    900
              cttttaatct ctatcgtcgg aaccatcata ggtctcatta ttggacttgc cattggtgtc    960
              ttccgtactg ctcctctctc tgaaaacaaa gtcatttacg gcctacaaaa actagtcggc   1020
              tgggttctca atgtctacat tgaaattttc cgtggtacgc caatgattgt tcaatcgatg   1080
              gttatctact atggaactgc ccaagctttc gggatcaacc ttgaccgtac actggctgct   1140
              atcttcatcg tttcaatcaa taccggtgcc tacatgactg aaatcgtccg tggtggtatc   1200
              ctagcagttg acaagggaca atttgaagct gcgactgctc ttggtatgac ccataaccag   1260
              accatgcgta agattgtcct acctcaggta gtccgtaaca tcctacctgc aactggtaat   1320
              gaatttgtca tcaatatcaa agatacatct gtattgaacg ttatctctgt tgtcgaactt   1380
              tatttctcag gaaataccgt ggcaacacaa acctatcaat acttccagac atttacaatc   1440
              atcgccgtga tttactttgt cctcaccttc accgtaacac gtatcctacg ctttatcgag   1500
              cgcagaatgg acatggatac ctacactaca ggtgctaacc aaatgcaaac ggaggatttg   1560
                                                 Page 166

<removed-date>
              aaataa                                                              1566
              <210>    94
              <211>    396
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 94
              atgtcaaaga aactcaatcg taaaaaacaa ttacgaaatg gcctccgtcg cgcaggtgcc     60
<removed-apn>
              ttttcaagta cggtgactaa ggttgtagat gagacaaaaa aagtcgtgaa gcgtgcagaa   120
              cagtcagcaa gcgcagctgg taaggctgtt tctaaaaaag ttgaacaagc agtagaagct   180
              accaaagagc aagctcaaaa agtagctaat tctgtagaag attttgcagc aaatttgggt   240
              ggacttccac ttgatcgtgc caagactttc tatgatgaag gaatcaagtc tgcttcagat   300
              ttcaaaaact ggactgaaaa agaactcctt gccttgaaag gaatcggccc agctaccatc   360
              aagaaattga aagaaaatgg catcaagttc aagtaa                              396
              <210>    95
              <211>    1002
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 95
              atgattaaaa catttctctc tgccctttcg gtcattctct tttctatccc tatcataact     60
              tattcttttt tcccatcttc taatcttaac atttggctat ctacccaacc tatcttggca   120
              cagatttatg ccttcccctt agctactgca actatggctg ctattttaag tttcttattt   180
              tttttcctat ctttttacaa gaaaaataaa caaatacggt tttactctgg cattttgctc   240
              ttactatcgc tcatattact attattcgga acagataaaa ccctttcttc tgcatcaaat   300
              aagactaaaa ccttaaaatt agtaacttgg aacgtcgcta atcaaataga agcacaacat    360
              attgagcgaa tttttagcca ttttgacgcc gatatggcta tattccctga actagctacc    420
              aatatcagag gtgagcaaga aaaccagaga atcaaactat tgtttcatca agttggactt   480
              tctatggcca actatgatat tttcacttct ccacctacca atagtggaat agctcctgtg   540
              actgtgattg tcaagaaaag ttatggtttc tatacagaag ctaaaacttt tcatacaaca   600
              cggttcggga caattgtatt acattcgaga aaacaaaata taccagatat cattgccttg   660
                                                  Page 167

              catactgcgc ctcctctgcc aggtttaatg gaaatctgga agcaagactt aaacatcatt    720
<removed-date>
              cataatcaat tggcttcaaa atatccaaag gctattattg caggtgattt taatgcaact    780
              atgcgtcatg gagcacttgc aaaaataagc tctcataggg acgcattaaa tgcactgcca    840
              ccttttgaaa gaggaacttg gaatagccaa agtccaaaac tttttaatgc aacaatagat    900
              catattttat tgcctaaaaa ccactactat gttaaagatt tagacattgt aagttttcaa    960
              aactctgatc atagatgtat ttttacagaa atcacatttt aa                      1002
<removed-apn>
              <210>   96
              <211>   618
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 96
              atggggtggt ggcgcgaaac cattgatatt gtaaaagaaa atgatccagc ggcccgcacc     60
              actttggagg ttttgctgac ttatccaggt gtcaaggcct tggcggccca ccgtctctcg    120
              cattttctct ggaagcacgg cttcaaacta ttagctcgta tgtacagtca gttttggcgc    180
              ttttggactc agattgagat tcatccagga gcccagattg attcaggtgt ttttattgac    240
              catggttctg gtctggtgat tggagagaca gcgattgttg aaaaaggcgt tcttctctat    300
              cacggagtga ctctcggggg aacagggaaa gactgtggca aacgccatcc gactgtacga    360
              aagggagccc tcatatcagc ccatgcccaa gttatcgggc ctgtggaaat tggtgaaaat    420
              gccaaggtcg gtgctgcagc agttgtcgta gcagatgtac ctagtgacgt gacggttgtc    480
              ggtattccgg ccaagattgt ccgtcttcat ggtaagaaag atgagcctgt cattcacgaa    540
              gtcgaagaaa aacgagagta ttatgtcaat aaactcgagc aggctaaaga tgccagtcac    600
              agatcgtctg gtttgtag                                                  618
              <210>   97
              <211>   1380
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 97
              atgttacaca acgcatttgc ctatgttaca aggaagtttt tcaaatcgat tgtcatcttc     60
              ctgattattc tcctcatggc gagcttgagt ttggtcggct tgtcaatcaa gggagctact    120
              gccaaggctt ctcaggagac ctttaaaaat atcaccaata gcttctccat gcaaatcaat    180
                                                 Page 168

<removed-date>
              cgtcgcgtca accaaggaac gcctcgtggt gctgggaata tcaagggtga agacatcaaa    240
              aaaatcaccg aaaacaaggc cattgagtct tatgtcaaac gtatcaacgc tatcggagat    300
              ttgactggat atgacctgat tgaaacgcca gaaaccaaga agaatctcac tgctgatcgt    360
              gccaagcgtt ttggaagtag cttgatgatt acaggtgtca atgactcctc taaagaagac    420
              aagtttgtct ctggttctta taaactagtc gaaggagagc acttaaccaa cgacgacaag    480
<removed-apn>
              gataaaatcc tcttgcacaa ggacttggca gccaaacacg gctggaaagt aggggacaag    540
              gttaaactgg actctaatat ctacgatgca gataatgaaa aaggagccaa ggaaacagtt    600
              gaagtgacaa tcaagggact ctttgatggt cataataagt cagcagtaac ctactcacaa    660
              gaactttacg aaaacacagc tattacagac attcacactg ctgcaaaact ttatggatac    720
              acagaagaca cagccattta tggggacgca accttctttg taacagcaga caagaacttg    780
              gatgatgtta tgaaagagtt gaatggcatc agtggtatca actggaagag ctacacactc    840
              gtcaagagct cctctaacta cccagctctt gagcaatcta tctctggtat gtacaagatg    900
              gccaacctcc tcttctgggg tagcttgagc ttctcagttc tcctccttgc cctcttgctc    960
              agcctttgga tcaacgcccg tcgcaaggaa gtgggaattc tcctctctat cggcctcaag   1020
              caggcaagta tcttgggtca attcatcacc gaatctatct tgattgctat ccctgctcta   1080
              gtttctgctt acttcctagc taattacact gcccgtgcaa ttggaaacac tgtccttgcc   1140
              aatgtgactt caggtgttgc caaacaggct agtaaggcgg ctcaagcctc taaccttggt   1200
              ggtggtgcag aagtagatgg ctttagcaag accttgtcga gcctagacat ttccattcag   1260
              acatcagact ttatcatcat ttttgtcctt gccttggttc tagtggttct cgttatggcg   1320
              cttgcttcaa gcaatctcct tagaaaacaa ccaaaagagc tcttgctgga tggtgaataa   1380
              <210>   98
              <211>   1329
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 98
              atgaaacgaa caggtttatt tgcaaagata tttatctata ccttctcgat atttagtgtt     60
              ctggttatct gccttcattt agctatttat tttctttttc cttcgactta tctgagtcat    120
              cgtcaggaaa ccattggtca aaaggcaaca gccattgccc agtccctaga agggaaagat    180
                                                 Page 169

<removed-date>
              aggcagagta tcgagcaagt gttagacttg tattcccaga ctagtgatat caaggggacc    240
              gtcaaaggtg agatgaccga ggacaagtta gaagtcaagg acagtcttcc tctggacaca    300
              gaccgccaga caacctctct ctttattgag gagcgcgagg tgaaaacgca agacggtggt    360
              actatgattc tccagtttct agcttccatg gatttacaaa aggaagcgga gcaaatcagt    420
              ctccagtttc ttccctatac cttgctggcc tcctttctga tttccctttt ggtggcctac    480
<removed-apn>
              atctacgctc ggactattgt tgcaccgatt ttggaaatca agcgggtgac ccgtcggatg    540
              atggacctgg attcccaagt gcgattgcgc gtggattcta aggatgagat aggtaatctc    600
              aaggaacaaa tcaatagcct ctaccagcat ctcttgactg ttattgcgga cttgcatgaa    660
              aagaatgaag ccattctcca gctggagaag atgaaggtcg aattcctacg aggagcttct    720
              catgaattga aaacaccgct ggctagtttg aaaatcctaa tcgaaaatat gagagagaat    780
              atcggtcgtt ataaggatag agaccagtat ctgggagttg ccttggggat tgtggatgaa    840
              ctcaatcacc atgttctgca gatactttcc ctctcttctg tgcaggaatt gcgagatgat    900
              agggaaacaa ttgacctcct ccagatgacg caaaatctgg tcaaagatta tgccttgcta    960
              gccaaggaaa gagagctcca gatagacaat agtttgaccc atcagcaggc ttatctaaac   1020
              ccatcagtta tgaagttgat tctttctaat ctcatcagca atgccattaa gcactctgtt   1080
              ccaggtggct tagttcgaat tggagaaaga gaaggagaac tttttatcga aaatagctgt   1140
              agctcagagg aacaagaaaa actagcccag tctttttctg acaatgccag tcgcaaggtc   1200
              aaggggtctg gtatggggct ctttgtggtt aagagtctat tagaacatga aaaattagct   1260
              tatcgtttcg agatggagga gaatagttta accttcttta tagattttcc aaaagtcgtc   1320
              caagactag                                                           1329
              <210>   99
              <211>   723
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 99
              ttgctagaaa ggtggagaga catgcgctgg ctttttcgtt tgataggggc tttcttttct     60
              tttgtgtggc gtttgttttg gcgtctggtt tggatagttg tgctcttatg tgtgcttgct    120
              ttcggacttc tctggtatct gaacggagat tttcaaggag cgctaaagca agcagaacgg    180
                                                 Page 170

<removed-date>
              tcagtaaaaa ttggtcaaca aagtattgac caatgggaga aaacagggca actgcctaag   240
              ttaagccaga cagatagtca ccagcattct gaaggaaggt gggcacaggc ctctgctcgt   300
              atttacctgg atccgcagat ggattcacgc tttcaagagg cttatttaga agcaatccag   360
              aactggaatc aaactggtgc ttttaacttt gaactcgtga ctgagtctag taaggcggat   420
              attacggcta cggagatgaa cgacggaggc actcctgtgg caggagaggc ggaaagtcaa   480
<removed-apn>
              actaatctct taacagggca attcttgtcc gtaacggtgc ggttgaatca ttattatttg   540
              tccaatccat actatggcta ctcctatgaa cgccttgtcc atacggcaga acatgagtta   600
              ggtcatgcga ttggcttgga ccatacagat gagaagtctg tcatgcaacc agcaggttcc   660
              ttttatggta tccaggaaga ggatgttgca aacctccgaa aaatatatga gactagtgag   720
              tag                                                                 723
              <210>   100
              <211>   801
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 100
              atgaaaaaat ttagcctatt actagctatc ctaccatttt tggttgcctg tgagaatcaa    60
              gctacaccca aagagactag cgctcaaaag acaatcgtcc ttgctacagc tggcgacgtg   120
              ccaccatttg actacgaaga caagggcaat ctgacaggct ttgatatcga agttttaaag   180
              gcagtagatg aaaaactcag cgactacgag attcaattcc aaagaaccgc ctgggagagc   240
              atcttcccag gacttgattc tggtcactat caggctgcgg ccaataactt gagttacaca   300
              aaagagcgtg ctgaaaaata cctttactcg cttccaattt ccaacaatcc cctcgtcctt   360
              gtcagcaaca agaaaaatcc tttgacttct cttgaccaga tcgctggtaa aacaacacaa   420
              gaggataccg gaacttctaa cgctcaattc atcaataact ggaatcagaa acacactgat   480
              aatcccgcta caattaattt ttctggtgag gatattggta aacgaatcct agaccttgct   540
              aacggagagt ttgatttcct agtttttgac aaggtatccg ttcaaaagat tatcaaggac   600
              cgtggtttag acctctcagt cgttgattta ccttctgcag atagccccag caattatatc   660
              attttctcaa gcgaccaaaa agagtttaaa gagcaatttg ataaagcgct caaagaactc   720
              tatcaagacg gaacccttga aaaactcagc aatacctatc taggtggttc ttacctccca   780
                                                 Page 171

<removed-date>
              gatcaatctc agttacaata a                                             801
              <210>   101
              <211>   717
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 101
              atgaagaaaa gatacctagt cttgacagct ttgctagcct tgagtctagc agcttgttca    60
<removed-apn>
              caagaaaaaa caaaaaatga agatggagaa actaagacag aacagacagc caaagctgat   120
              ggaacagtcg gtagtaagtc tcaaggagct gcccagaaga aagcagaagt ggtcaataaa   180
              ggtgattact acagcattca agggaaatac gatgaaatca tcgtagccaa caaacactat   240
              ccattgtcta aagactataa tccaggggaa aatccaacag ccaaggcaga gttggtcaaa   300
              ctcatcaaag cgatgcaaga ggcaggtttc cctattagtg atcattacag tggttttaga   360
              agttatgaaa ctcagaccaa gctctatcaa gattatgtca accaagatgg aaaggcagca   420
              gctgaccgtt actctgcccg tcctggctat agcgaacacc agacaggctt ggcctttgat   480
              gtgattggga ctgatggtga tttggtgaca gaagaaaaag cagcccaatg gctcttggat   540
              catgcagctg attatggctt tgttgtccgt tatctcaaag gcaaggaaaa ggaaacaggc   600
              tatatggctg aagaatggca cctgcgttat gtaggaaaag aagctaaaga aattgctgca   660
              agtggtctca gtttggaaga atactatggc tttgaaggcg gagactacgt cgattaa      717
              <210>   102
              <211>   6702
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 102
              atggggaaag gccattggaa tcggaaaaga gtttatagca ttcgtaagtt tgctgtggga    60
              gcttgctcag taatgattgg gacttgtgca gttttattag gaggaaatat agctggagaa   120
              tctgtagttt atgcggatga aacacttatt actcatactg ctgagaaacc taaagaggaa   180
              aaaatgatag tagaagaaaa ggctgataaa gctttggaaa ctaaaaatat agttgaaagg   240
              acagaacaaa gtgaacctag ttcaactgag gctattgcat ctgagaagaa agaagatgaa   300
              gccgtaactc caaaagagga aaaagtgtct gctaaaccgg aagaaaaagc tccaaggata   360
                                                 Page 172

              gaatcacaag cttcaaatca agaaaaaccg ctcaaggaag atgctaaagc tgtaacaaat    420
<removed-date>
              gaagaagtga atcaaatgat tgaagacagg aaagtggatt ttaatcaaaa ttggtacttt    480
              aaactcaatg caaattctaa ggaagccatt aaacctgatg cagacgtatc tacgtggaaa    540
              aaattagatt taccgtatga ctggagtatc tttaacgatt tcgatcatga atctcctgca    600
              caaaatgaag gtggacagct caacggtggg gaagcttggt atcgcaagac tttcaaacta    660
              gatgaaaaag acctcaagaa aaatgttcgc cttacttttg atggcgtcta catggattct    720
<removed-apn>
              caagtttatg tcaatggtca gttagtgggg cattatccaa atggttataa ccagttctca    780
              tatgatatca ccaaatacct tcaaaaagat ggtcgtgaga atgtgattgc tgtccatgca    840
              gtcaacaaac agccaagtag ccgttggtat tcaggaagtg gtatctatcg tgatgtgact    900
              ttacaagtga cagataaggt gcatgttgag aaaaatggga caactatttt aacaccaaaa    960
              cttgaagaac aacaacatgg caaggttgaa actcatgtga ccagcaaaat cgtcaatacg   1020
              gacgacaaag accatgaact tgtagccgaa tatcaaatcg ttgaacgagg tggtcatgct   1080
              gtaacaggct tagttcgtac agcgagtcgt accttaaaag cacatgaatc aacaagccta   1140
              gatgcgattt tagaagttga aagaccaaaa ctctggactg ttttaaatga caaacctgcc   1200
              ttgtacgaat tgattacgcg tgtttaccgt gacggtcaat tggttgatgc taagaaggat   1260
              ttgtttggtt accgttacta tcactggact ccaaatgaag gtttctcttt gaatggtgaa   1320
              cgtattaaat tccatggagt atccttgcac cacgaccatg gggcgcttgg agcagaagaa   1380
              aactataaag cagaatatcg ccgtctcaaa caaatgaagg agatgggagt taactccatc   1440
              cgtacaaccc acaaccctgc tagtgagcaa accttgcaaa tcgcagcaga actaggttta   1500
              ctcgttcagg aagaggcctt tgatacgtgg tatggtggca agaaacctta tgactatgga   1560
              cgtttctttg aaaaagatgc cactcaccca gaagctcgaa aaggtgaaaa atggtctgat   1620
              tttgacctac gtaccatggt cgaaagaggc aaaaacaacc ctgctatctt catgtggtca   1680
              attggtaatg aaataggtga agctaatggt gatgcccact ctttagcaac tgttaaacgt   1740
              ttggttaagg ttatcaagga tgttgataag actcgctatg ttaccatggg agcagataaa   1800
              ttccgtttcg gtaatggtag cggagggcat gagaaaattg ctgatgaact cgatgctgtt   1860
              ggatttaact attctgaaga taattacaaa gcccttagag ctaagcatcc aaaatggttg   1920
              atttatggat cagaaacatc ttcagctacc cgtacacgtg gaagttacta tcgccctgaa   1980
                                                 Page 173

<removed-date>
              cgtgaattga aacatagcaa tggacctgag cgtaattatg aacagtcaga ttatggaaat   2040
              gatcgtgtgg gttgggggaa aacagcaacc gcttcatgga cttttgaccg tgacaacgct   2100
              ggctatgctg gacagtttat ctggacaggt acggactata ttggtgaacc tacaccatgg   2160
              cacaaccaaa atcaaactcc tgttaagagc tcttactttg gtatcgtaga tacagccggc   2220
              attccaaaac atgacttcta tctctaccaa agccaatggg tttctgttaa gaagaaaccg   2280
<removed-apn>
              atggtacacc ttcttcctca ctggaactgg gaaaacaaag aattagcatc caaagtagct   2340
              gactcagaag gtaagattcc agttcgtgct tattcgaatg cttctagtgt agaattgttc   2400
              ttgaatggaa aatctcttgg tcttaagact ttcaataaaa aacaaaccag cgatgggcgg   2460
              acttaccaag aaggtgcaaa tgctaatgaa ctttatcttg aatggaaagt tgcctatcaa   2520
              ccaggtacct tggaagcaat tgctcgtgat gaatctggca aggaaattgc tcgagataag   2580
              attacgactg ctggtaagcc agcggcagtt cgtcttatta aggaagacca tgcgattgca   2640
              gcagatggaa aagacttgac ttacatctac tatgaaattg ttgacagcca ggggaatgtg   2700
              gttccaactg ctaataatct ggttcgcttc caattgcatg gccaaggtca actggtcggt   2760
              gtagataacg gagaacaagc cagccgtgaa cgctataagg cgcaagcaga tggttcttgg   2820
              attcgtaaag catttaatgg taaaggtgtt gccattgtca aatcaactga acaagcaggg   2880
              aaattcaccc tgactgccca ctctgatctc ttgaaatcga accaagtcac tgtctttact   2940
              ggtaagaaag aaggacaaga gaagactgtt ttggggacag aagtgccaaa agtacagacc   3000
              attattggag aggcacctga aatgcctacc actgttccgt ttgtatacag tgatggtagc   3060
              cgtgcagaac gtcctgtaac ctggtcttca gtagatgtga gcaagcctgg tattgtaacg   3120
              gtgaaaggta tggctgacgg acgagaagta gaagctcgtg tagaagtgat tgctcttaaa   3180
              tcagagctac cagttgtgaa acgtattgct ccaaatactg acttgaattc tgtagacaaa   3240
              tctgtttcct atgttttgat tgatggaagt gttgaagagt atgaagtgga caagtgggag   3300
              attgccgaag aagataaagc taagttagca attccaggtt ctcgtattca agcgaccggt   3360
              tatttagaag gtcaaccaat tcatgcaacc cttgtggtag aagaaggcaa tcctgcggca   3420
              cctgcagtac caactgtaac ggttggtggt gaggcagtaa caggtcttac tagtcaaaaa   3480
              ccaatgcaat accgcactct tgcttatgga gctaagttgc cagaagtcac agcaagtgct   3540
                                                 Page 174

              aaaaatgcag ctgttacagt tcttcaagca agcgcagcaa acggcatgcg tgcgagcatc   3600
<removed-date>
              tttattcagc ctaaagatgg tggccctctt caaacctatg caattcaatt ccttgaagaa   3660
              gcgccaaaaa ttgctcactt gagcttgcaa gtggaaaaag ctgacagtct caaagaagac   3720
              caaactgtca aattgtcggt tcgagctcac tatcaagatg gaacgcaagc tgtattacca   3780
              gctgataaag taaccttctc tacaagtggt gaaggggaag tcgcaattcg taaaggaatg   3840
              cttgagttgc ataagccagg agcagtcact ctgaacgctg aatatgaggg agctaaagac   3900
<removed-apn>
              caagttgaac tcactatcca agccaatact gagaagaaga ttgcgcaatc catccgtcct   3960
              gtaaatgtag tgacagattt gcatcaggaa ccaagtcttc cagcaacagt aacagttgag   4020
              tatgacaaag gtttccctaa aactcataaa gtcacttggc aagctattcc gaaagaaaaa   4080
              ctagactcct atcaaacatt tgaagtacta ggtaaagttg aaggaattga ccttgaagcg   4140
              cgtgcaaaag tctctgtaga aggtatcgtt tcagttgaag aagtcagtgt gacaactcca   4200
              atcgcagaag caccacaatt accagaaagt gttcggacat atgattcaaa tggtcacgtt   4260
              tcatcagcta aggttgcatg ggatgcgatt cgtccagagc aatacgctaa ggaaggtgtc   4320
              tttacagtta atggtcgctt agaaggtacg caattaacaa ctaaacttca tgttcgcgta   4380
              tctgctcaaa ctgagcaagg tgcaaacatt tctgaccaat ggaccggttc agaattgcca   4440
              cttgcctttg cttcagactc aaatccaagc gacccagttt caaatgttaa tgacaagctc   4500
              atttcctaca ataaccaacc agccaatcgt tggacaaact ggaatcgtac taatccagaa   4560
              gcttcagtcg gtgttctgtt tggagattca ggtatcttga gcaaacgctc cgttgataat   4620
              ctaagtgtcg gattccatga agaccatgga gttggtgtac cgaagtctta tgtgattgag   4680
              tattatgttg gtaagactgt cccaacagct cctaaaaacc ctagttttgt tggtaatgag   4740
              gaccatgtct ttaatgattc tgccaactgg aaaccagtta ctaatctaaa agcccctgct   4800
              caactcaagg ctggagaaat gaaccacttt agctttgata aagttgaaac ctatgctgtt   4860
              cgtattcgca tggttaaagc agataacaag cgtggaacgt ctatcacaga ggtacaaatc   4920
              tttgcgaaac aagttgcggc agccaagcaa ggacaaacaa gaatccaagt tgacggcaaa   4980
              gacttagcaa acttcaaccc tgatttgaca gactactacc ttgagtctgt agatggaaaa   5040
              gttccggcag tcacagcaag tgttagcaac aatggtctcg ctaccgtcgt tccaagcgtt   5100
              cgtgaaggtg agccagttcg tgtcatcgcg aaagctgaaa atggcgacat cttaggagaa   5160
                                                 Page 175

<removed-date>
              taccgtctgc acttcactaa ggataagagc ttactttctc ataaaccagt tgctgcggtt   5220
              aaacaagctc gcttgctaca agtaggtcaa gcacttgaat tgccgactaa ggttccagtt   5280
              tacttcacag gtaaagacgg ctacgaaaca aaagacctga cagttgaatg ggaagaagtt   5340
              ccagcggaaa atctgacaaa agcaggtcaa tttactgttc gaggccgtgt ccttggtagt   5400
              aaccttgttg ctgagatcac tgtacgagtg acagacaaac ttggtgagac tctttcagat   5460
<removed-apn>
              aaccctaact atgatgaaaa cagtaaccag gcctttgctt cagcaaccaa tgatattgac   5520
              aaaaactctc atgaccgcgt tgactatctc aatgacggag atcattcaga aaatcgtcgt   5580
              tggacaaact ggtcaccaac accatcttct aatccagaag tatcagcggg tgtgattttc   5640
              cgtgaaaatg gtaagattgt agaacggact gttacacaag gaaaagttca gttctttgca   5700
              gatagtggta cggatgcacc atctaaactc gttttagaac gctatgtcgg tccagagttt   5760
              gaagtgccaa cctactattc aaactaccaa gcctacgacg cagaccatcc attcaacaat   5820
              ccagaaaatt gggaagctgt tccttatcgt gcggataaag acattgcagc tggtgatgaa   5880
              atcaacgtaa catttaaagc tatcaaagcc aaagctatga gatggcgtat ggagcgtaaa   5940
              gcagataaga gcggtgttgc gatgattgag atgaccttcc ttgcaccaag tgaattgcct   6000
              caagaaagca ctcaatcaaa gattcttgta gatggaaaag aacttgctga tttcgctgaa   6060
              aatcgtcaag actatcaaat tacctataaa ggtcaacggc caaaagtctc agttgaagaa   6120
              aacaatcaag tagcttcaac tgtggtagat agtggagaag atagctttcc agtacttgtt   6180
              cgcctcgttt cagaaagtgg aaaacaagtc aaggaatacc gtatccactt gactaaggaa   6240
              aaaccagttt ctgagaagac agttgctgct gtacaagaag atcttccaaa aatcgaattt   6300
              gttgaaaaag atttggcata caagacagtt gagaaaaaag attcaacact gtatctaggt   6360
              gaaactcgtg tagaacaaga aggaaaagtt ggaaaagaac gtatctttac agcgattaat   6420
              cctgatggaa gtaaggaaga aaaactccgt gaagtggtag aagttccgac agaccgcatc   6480
              gtcttggttg gaaccaaacc agtagctcaa gaagctaaaa aaccacaagt gtcagaaaaa   6540
              gcagatacaa aaccaattga ttcaagtgaa gctagtcaaa ctaataaagc ccagttacca   6600
              agtacaggta gtgcggcaag ccaagcagca gtagcagcag gtttaactct tctaggtttg   6660
              agtgcaggat tagtagttac taaaggtaaa aaagaagact ag                      6702
                                                 Page 176

<removed-date>
              <210>   103
              <211>   567
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 103
              atgaaaaaat ggcaaacatg tgttcttgga gcaggttcgc tcctttgttt gacggcttgt    60
              tcaggcaagt ccgtgactag tgaacaccaa acgaaagatg aaatgaagac ggagcagaca   120
<removed-apn>
              gctagtaaaa caagcgcagc taaagggaaa gaggtggctg attttgaatt gatgggagta   180
              gatggcaaga cctaccgttt atctgattac aagggcaaga aagtctatct caaattctgg   240
              gcttcttggt gttccatctg tctggctagt cttccagata cggatgagat tgctaaagaa   300
              gctggtgatg actatgtggt cttgacagta gtgtcaccag gacataaggg agagcaatct   360
              gaagcggact ttaagaattg gtataaggga ttggattata aaaatctccc agtcctagtt   420
              gacccatcag gcaaactttt ggaaacttat ggtgtccgtt cttacccaac ccaagccttt   480
              atagacaaag aaggcaagct ggtcaaaaca catccaggat tcatggaaaa agatgcaatt   540
              ttgcaaactt tgaaggaatt agcctag                                       567
              <210>   104
              <211>   1692
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 104
              atgaagcgtt cttctctttt agttagaatg gttatttcca tctttctggt ctttctcatt    60
              ctcctagctc tggttggaac tttctactat caatcaagtt cttcagccat tgaggccacc   120
              attgagggca acagccaaac gaccatcagc cagactagcc actttattca gtcttatatc   180
              aaaaaactag aaaccacctc gactggtttg acccagcaga cggatgttct ggcctatgct   240
              gagaatccca gtcaagacaa ggtcgaggga atccgagatt tgtttttgac catcttgaag   300
              tcagataagg acttgaaaac tgttgtgctg gtgaccaaat ctggtcaggt catttctaca   360
              gatgacagtg tgcagatgaa aacttcctct gatatgatgg ctgaggattg gtaccaaaag   420
              gccattcatc agggagctat gcctgttttg actccagctc gtaaatcaga tagtcagtgg   480
              gtcatttctg tcactcaaga acttgttgat gcaaagggag ccaatcttgg tgtgcttcgt   540
              ttggatattt cttatgaaac tctggaagcc tatctcaatc aactccagtt ggggcagcag   600
                                                 Page 177

<removed-date>
              ggctttgcct tcattatcaa tgaaaaccat gaatttgtct accatcctca acacacagtt    660
              tatagttcgt ctagcaaaat ggaggctatg aaaccctaca tcgatacagg tcagggttat    720
              actcctggtc acaaatccta cgtcagtcaa gagaagattg caggaactga ttggacggtg    780
              cttggcgtgt catcattgga aaagttagac caggttcgga gtcagctctt gtggaccttg    840
              cttggggcca gtgtcacatc tcttcttgtc tgtctctgct tagtgtggtt cagtcttaaa    900
<removed-apn>
              cgctggattg ctcctttgaa ggatttgaga gaaaccatgt tggaaattgc ttctggtgct    960
              caaaatcttc gtgccaagga agttggtgcc tatgaactga gagaagtaac tcgccaattt   1020
              aatgctatgt tggatcagat tgatcagttg atggtagcta ttcgtagcca ggaagaaacg   1080
              acccgtcagt accaacttca agccctttcg agccagatta atccacattt cctctataac   1140
              actttggaca ccatcatctg gatggctgaa tttcatgata gtcagcgagt ggtgcaggtg   1200
              accaagtcct tggcaaccta tttccgcttg gcgctcaatc aaggcaagga cttgatttgt   1260
              ctctctgacg aaatcaatca tgtccgccag tatctcttta tccagaaaca acgctatgga   1320
              gataagctgg aatacgaaat taatgaaaat gttgcctttg ataatttagt cttacccaag   1380
              ctggtcctac aaccccttgt agaaaatgct ctttaccatg gcattaagga aaaggaaggt   1440
              cagggccata ttaaactttc tgtccagaaa caggattcgg gattggtcat ccgtattgag   1500
              gatgatggcg ttggcttcca agatgctggt gatagtagtc aaagtcaact caaacgtggg   1560
              ggagttggtc ttcaaaatgt cgatcaacgg ctcaaacttc attttggagc caattaccat   1620
              atgaagattg attctagacc ccaaaaaggg acgaaagttg aaatatatat aaatagaata   1680
              gaaactagct aa                                                       1692
              <210>   105
              <211>   5646
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 105
              atggctcctt ctgtagtgga cgcagccacc tatcactatg taaataaaga gattatttca     60
              caagaagcta aagatttaat tcagacagga aagcctgaca ggaatgaagt tgtatatggt    120
              ttggtgtatc aaaaagatca gttgcctcaa acagggacag aagcatctgt tttgacagct    180
              tttggtttgc tgactgttgg gagcttgctt ttaatctaca agagaaagaa aattgctagc    240
                                                 Page 178

<removed-date>
              gtctttctag ttggagctat gggattggta gttcttccta gtgcaggggc tgtagaccca    300
              gttgcgaccc tagcgctggc tagtcgagag ggtgttgttg aaatggaggg ctatcgctat    360
              gttggttatc tatcaggtga catcctcaaa acgcttggct tggacactgt tttagaagaa    420
              acctcagcaa aacctggaga ggtgactgtg gtcgaagttg agactcctca atcaataaca    480
              aatcaggagc aagctaggac agaaaaccaa gtagtagaga cagaggaagc tccaaaagaa    540
<removed-apn>
              gaagcaccta aaacagaaga aagtccaaag gaagaaccaa aatcggaggt aaaacctact    600
              gacgacaccc ttcctaaagt agaagagggg aaagaagatt cagcagaacc agctccagtt    660
              gaagaagtag gtggagaagt tgagtcaaaa ccagaggaaa aagtagcagt taagccagaa    720
              agtcaaccat cagacaaacc agctgaggaa tcaaaagttg aacaagcagg tgaaccagtc    780
              gcgccaagag aagacgaaaa ggcaccagtc gagccagaaa agcaaccaga agctcctgaa    840
              gaagagaagg ctgtagagga aacaccgaaa caagaagagt caactccaga taccaaggct    900
              gaagaaactg tagaaccaaa agaggagact gttaatcaat ctattgaaca accaaaagtt    960
              gaaacgcctg ctgtagaaaa acaaacagaa ccaacagagg aaccaaaagt tgaacaagca   1020
              ggtgaaccag tcgcgccaag agaagacgaa caggcaccaa cggcaccagt tgagccagaa   1080
              aagcaaccag aagttcctga agaagagaag gctgtagagg aaacaccgaa accagaagat   1140
              aaaataaagg gtattggtac taaagaacca gttgataaaa gtgagttaaa taatcaaatt   1200
              gataaagcta gttcagtttc tcctactgat tattctacag caagttacaa tgctcttgga   1260
              cctgttttag aaactgcaaa aggtgtctat gcttcagagc ctgtaaaaca gcctgaggta   1320
              aatagcgaga caaataaact taaaacggct attgacgctc taaacgttga taaaactgaa   1380
              ttaaacaata cgattgcaga tgcaaaaaca aaggtaaaag aacattacag tgatagaagt   1440
              tggcaaaacc tccaaactga agttacaaag gctgaaaaag ttgcagctaa tacagatgct   1500
              aaacaaagtg aagttaacga agctgttgaa aaattaactg caactattga aaaattggtt   1560
              gaattatctg aaaagccaat attaacattg actagtaccg ataagaaaat attggaacgt   1620
              gaagctgttg ctaagtatac tctagaaaat caaaacaaaa caaaaatcaa atcaatcaca   1680
              gctgaattga aaaaaggaga agaagttatt aatactgtag tccttacaga tgacaaggta   1740
              acaacagaaa ctataagcgc tgcatttaag aacctagagt actacaaaga atacacccta   1800
                                                 Page 179

              tctacaacta tgatttacga cagaggtaac ggtgaagaaa ctgaaactct agaaaatcaa   1860
<removed-date>
              aatattcaat tagatcttaa aaaagttgag cttaaaaata ttaaacgtac agatttaatc   1920
              aaatacgaaa atggaaaaga aactaatgaa tcactgataa caactattcc tgatgataag   1980
              agcaattatt atttaaaaat aacttcaaat aatcagaaaa ctacattact agctgttaaa   2040
              aatatagaag aaactacggt taacggaaca cctgtatata aagttacagc aatcgcagac   2100
              aatttagtct ctagaactgc tgataataaa tttgaagaag aatacgttca ctatattgaa   2160
<removed-apn>
              aaacctaaag tccacgaaga taatgtatat tataatttca aagaattagt ggaagctatt   2220
              caaaacgatc cttcaaaaga atatcgtctg ggacaatcaa tgagcgctag aaatgttgtt   2280
              cctaatggaa aatcatatat cactaaagaa ttcacaggaa aacttttaag ttctgaagga   2340
              aaacaatttg ctattactga attggaacat ccattattta atgtgataac aaacgcaacg   2400
              ataaataatg tgaattttga aaatgtagag atagaacgtt ctggtcaaga taatattgca   2460
              tcattagcca atactatgaa aggttcttca gttattacaa atgtcaaaat tacaggcaca   2520
              ctttcaggtc gtaataatgt tgctggattt gtaaataata tgaatgatgg aactcgtatt   2580
              gaaaatgttg ctttctttgg caaactacac tctacaagtg gaaatggctc tcatacaggg   2640
              ggaattgcag gtacaaacta tagaggaatt gttagaaaag catatgttga tgctactatt   2700
              acaggaaaca aaacacgcgc cagcttgtta gttcctaaag tagattatgg attaactcta   2760
              gaccatctta ttggtacaaa agctctccta actgagtcgg ttgtaaaagg taaaatagat   2820
              gtttcaaatc cagtagaagt tggagcaata gcaagtaaga cttggcctgt aggtacggta   2880
              agtaattctg tcagctatgc taagattatc cgtggagagg agttattcgg ctctaacgac   2940
              gttgatgatt ctgattatgc tagtgctcat ataaaagatt tatatgcggt agagggatat   3000
              tcgtcaggta atagatcatt taggaaatct aaaacattta ctaaattaac taaagaacaa   3060
              gctgatgcta aagttactac tttcaatatt actgctgata aattagaaag tgatctatct   3120
              cctcttgcaa aacttaatga agaaaaagcc tattctagta ttcaagatta taacgctgaa   3180
              tataaccaag cctataaaaa tcttgaaaaa ttaataccat tctacaataa agattatatt   3240
              gtatatcaag gtaataaatt aaataaagaa caccatctaa atactaaaga agttctttct   3300
              gttaccgcga tgaacaacaa tgagtttatc acaaacctag atgaagctaa taaaattatt   3360
              gttcactatg cggacggtac aaaagattac tttaacttgt cttctagcag tgaaggttta   3420
                                                 Page 180

<removed-date>
              agtaatgtaa aagaatatac tataactgac ttaggaatta aatatacacc taatatcgtt   3480
              caaaaagata acactactct tgttaatgat ataaaatcta ttttagaatc agtagagctt   3540
              cagtctcaaa cgatgtatca gcatctaaat cgattaggtg actatagagt taatgcaatc   3600
              aaagatttat atttagaaga aagcttcaca gatgttaaag aaaacttaac aaacctaatc   3660
              acaaaattag ttcaaaacga agaacatcaa ctaaatgatt ctccagctgc tcgtcaaatg   3720
<removed-apn>
              attcgtgata aagtcgagaa aaacaaagca gctttattac taggtttaac ttacctaaat   3780
              cgttactatg gagttaaatt tggtgatgtt aatattaaag aattaatgct attcaaacca   3840
              gatttctatg gtgaaaaagt tagcgtatta gacagattaa ttgaaatcgg ttctaaagag   3900
              aacaacatta aaggttcacg tacattcgac gcattcggtc aagtattggc taaatatact   3960
              aaatcaggta atttagatgc atttttaaat tataatagac aattgttcac aaatatagac   4020
              aatatgaacg attggtttat tgatgctaca gaagaccatg tctacatcgc agaacgcgct   4080
              tctgaggtcg aagaaattaa aaattctaaa catcgtgcat tcgataattt aaaacgaagt   4140
              caccttagaa atactatact cccactactg aatattgata aagcacatct ttatttaatt   4200
              tcaaattata atgcaattgc ctttggtagt gcagagcgat taggtaaaaa atcattagaa   4260
              gatattaaag atatcgttaa caaagctgca gatggttata gaaactatta tgatttctgg   4320
              tatcgtctag cgtctgataa cgttaaacaa cgactactaa gagatgctgt tattcctatt   4380
              tgggaaggtt ataacgctcc tggtggatgg gttgaaaaat atggccgcta taataccgac   4440
              aaagtatata ctcctcttag agaattcttt ggtcctatgg ataagtatta taattataat   4500
              ggaacaggag cttatgctgc tatatatcct aactctgatg atattagaac tgatgtaaaa   4560
              tatgttcatt tagaaatggt tggtgaatac ggtatttcag tttacacaca tgaaacaaca   4620
              cacgtcaacg accgtgcgat ttacttaggt ggctttggac accgtgaagg tactgatgct   4680
              gaagcatatg ctcagggtat gctacaaact cctgttactg gtagtggatt tgatgagttt   4740
              ggttctttag gtattaatat ggtatttaaa cgcaaaaatg atgggaatca gtggtatatt   4800
              acagatccaa aaactctaaa aacacgagaa gatattaata gatatatgaa gggttataat   4860
              gacactttaa ctcttcttga tgaaattgag gctgaatctg tgatttctca acaaaataaa   4920
              gatttaaata gtgcatggtt caaaaaaata gatagagaat accgtgataa caataaatta   4980
                                                 Page 181

              aatcaatggg ataaaattcg aaatctaagt caagaagaga aaaatgaatt aaatattcaa   5040
<removed-date>
              tctgttaatg atttagttga tcaacaatta atgactaatc gcaatccagg taatggtatc   5100
              tataaacccg aagcaattag ctataacgat caatcacctt atgtaggtgt tagaatgatg   5160
              accggtatct acggaggtaa tactagtaaa ggtgctcctg gagctgtttc attcaaacat   5220
              aatgctttta gattatgggg ttactacgga tacgaaaatg ggttcttagg ttatgcttca   5280
              aataaatata aacaacaatc taaaacagat ggtgagtctg ttctaagtga tgaatatatt   5340
<removed-apn>
              atcaagaaaa tatctaacaa tacatttaat actattgaag aatttaaaaa agcttacttc   5400
              aaagaagtta aagataaagc aacgaaagga ttaacaacat tcgaagtaaa tggttcttcc   5460
              gtttcatcat acgatgattt actgacattg tttaaagaag ctgttaaaaa agatgccgaa   5520
              actcttaaac aagaagcaaa cggtaataaa acagtatcta tgaataatac agttaaatta   5580
              aaagaagctg tttataagaa acttcttcaa caaacaaata gctttaaaac ttcaatcttt   5640
              aaataa                                                              5646
              <210>    106
              <211>    381
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 106
              atggttactt ggattttgtg ggcacttata ctagcaatgt tggcgtggat gggctttaac     60
              tatcttcgta ttcgccgtgc ggctaaaatt gtggacaatg aggagtttga agccttgatt    120
              cgtacgggtc aattgattga tttgcgcgac ccagcagaat tccacagaaa acatatcctt    180
              ggtgcacgca atattccttc aagtcagttg aaaactagtc ttgcagccct tcgtaaagat    240
              aaacctgtcc ttctctacga aaaccaacgt gcgcaacgag ttacaaatgc agctctttac    300
              ttgaaaaaac aaggtttttc tgagatttat atcctttctt atggcttgga ttcttggaaa    360
              gggaaagtga agactagcta a                                              381
              <210>    107
              <211>    804
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 107
              atgcaggaat ttacaaatcc ctttcctata ggctctagtt ccctcattca ctgcattacc     60
                                                  Page 182

<removed-date>
              aatgagattt cttgtgagat gctggcaaat gggattttgg ctctgggatg caaacctgtc   120
              atggcagatg attcccgtga agttcttgat tttactaagc aaagtcaggc tctcttcatc   180
              aatttggggc atttgtcagc tgagaaggaa aaagcaatcc gcatggcagc ttcgtatgca   240
              aaccaatctt ctctcccgat ggtagtagat gcggttggcg taacgacttc atccattcgt   300
              aagagcttag ttaaagacct tttagactat agacctacgg tccttaaagg aaacatgtca   360
<removed-apn>
              gaaattcgaa gtcttgttgg attaaagcac cacggcgttg gggtcgatgc gagtgctaaa   420
              gatcaagaaa cggaggattt gcttcaagtc ttgaaagact ggtgtcagac ctatcctggt   480
              atgtctttct tagtcacagg tcccaaggac ctcgtcgttt cgaaaaatca ggtcgctgta   540
              ctgggaaatg gctgtactga attagactgg ataacaggga caggagactt ggttggagcc   600
              ttaacagctg tttttctcag ccaaggaaag actggttttg aagcttcttg cttagcagtc   660
              tcttatctca atatcgctgc tgagaaaata gttgttcaag gaatgggatt ggaagaattt   720
              cgttaccaag tactcaatca gctttcgctc ctaagaagag atgaaaattg gctagatacc   780
              atcaaaggag aggtttatga atag                                          804
              <210>   108
              <211>   846
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 108
              atgacttgga agattattgc tgactctggt tgtgattatc gtcaactgcc aacaccagct    60
              attaacacaa cctttgtaag tgtcccctta accattcaag tagctgatca ggtctttgtt   120
              gatgacgcca gtctcgatat tgaccaaatg atggaaacca tgtatgcaac tgcagaagct   180
              tcaaaatcgg cttgtccaag cccagatgac tatttgcgag catttgaagg tgccaaaaac   240
              attttcctag taaccatcac aggtaccctt tctggcagtc acaatagtgc tcaactagca   300
              aagaatattt atctggaaga ccatcctgac actaagattc atgtgattga tagtttatct   360
              gctggtggtg aagttgacct actcgtagaa aaattgaatg acttgattga ccagggcttg   420
              tcttttgaag aagtggttga agctatcacc gcctatcaag aaaaaactaa gttgctcttt   480
              gtcctagcca aagtcgataa cttggtgaag aacggccgtt tgagcaagct tatcggtacg   540
              gtcgttggcc ttctcaacat tcgtatggtc ggaaaagcta gtgaaactgg gactctcgaa   600
                                                 Page 183

<removed-date>
              ttgctacaaa aagcaagggg atcaaagaaa tcagttcaag ctgcctatga tgagttagta   660
              aaagctggat atgctggtgg ccgtattgtc atggcccaac gcaataacga aaaatgttgt   720
              caacagctct cagagcgaat ccgtgaaacc ttcccacaag cggatattaa aattctacca   780
              acctctggtc tctgcagttt ctatgcagaa gagggcggtt tgctgatggg ctatgaaatt   840
              gattaa                                                              846
<removed-apn>
              <210>    109
              <211>    927
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 109
              atgattagta gattttttcg ccatttattt gaagccttaa aaagtttgaa acgaaatggt    60
              tggatgacag tagctgctgt cagttcagtc atgattactt tgaccttggt ggcaatattt   120
              gcatctgtta ttttcaatac agcgaaacta gctacagata ttgaaaataa tgtccgtgta   180
              gtagtttata tccgaaagga tgtggaagat aatagtcaga caattgaaaa agaaggtcaa   240
              actgttacaa ataatgacta ccacaaggta tatgattctt tgaagaacat gtctacggtt   300
              aaaagtgtta ccttttcaag taaagaagaa caatatgaaa aattaaccga gataatggga   360
              gataactgga aaatctttga aggagatgcc aatcctctct atgatgccta tattgtagag   420
              gcaaacactc caaatgatgt aaaaactata gccgaagatg ctaaaaaaat tgaaggtgtc   480
              tctgaggttc aagatggcgg tgccaataca gaaagactct tcaagttagc ttcatttatc   540
              cgtgtttggg gactagggat tgctgctttg ttaattttta tcgcagtttt cttgatttca   600
              aataccattc gtattaccat tatttcccgc agtcgcgaaa ttcaaatcat gcgcttggtc   660
              ggagctaaaa acagttatat ccgtggaccg ttcttgttag aaggagcctt tatcggttta   720
              ttgggagcta tcgcaccatc tgttttggtc tttattgttt atcaaattgt ttaccaatct   780
              gtcaacaaat cgttggtagg gcaaaatcta tccatgatta gtccagattt atttagtccg   840
              ttgatgattg ccctactatt tgtgattggg gttttcattg gttcattggg atcaggaata   900
              tccatgcgcc gattcttgaa gatttag                                       927
              <210> 110
              <211> 1200
                                                  Page 184

              <212> DNA
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 110
              atgaagaaaa agaatggtaa agctaaaaag tggcaactgt atgcagcaat cggtgctgcg     60
              agtgtagttg tattgggtgc tggggggatt ttactcttta gacaaccttc tcagactgct    120
              ctaaaagatg agcctactca tcttgttgtt gccaaggaag gaagcgtggc ctcctctgtt    180
              ttattgtcag ggacagtaac agcaaaaaat gaacaatatg tttattttga tgctagtaag    240
<removed-apn>
              ggtgatttag atgaaatcct tgtttctgtg ggcgataagg tcagcgaagg gcaggcttta    300
              gtcaagtaca gtagttcaga agcgcaggcg gcctatgatt cagctagtcg agcagtagct    360
              agggcagatc gtcatatcaa tgaactcaat caagcacgaa atgaagccgc ttcagctccg    420
              gctccacagt taccagcgcc agtaggagga gaagatgcaa cggtgcaaag cccaactcca    480
              gtggctggaa attctgttgc ttctattgac gctcaattgg gtgatgcccg tgatgcgcgt    540
              gcagatgctg cggcgcaatt aagcaaggct caaagtcaat tggatgcaac aactgttctc    600
              agtaccctag agggaactgt ggtcgaagtc aatagcaatg tttctaaatc tccaacaggg    660
              gcgagtcaag ttatggttca tattgtcagc aatgaaaatt tacaagtcaa gggagaattg    720
              tctgagtaca atctagccaa cctttctgta ggtcaagaag taagctttac ttctaaagtg    780
              tatcctgata aaaaatggac tgggaaatta agctatattt ctgactatcc taaaaacaat   840
              ggtgaagcag ctagtccagc agccgggaat aatacaggtt ctaaataccc ttatactatt    900
              gatgtgacag gcgaggttgg tgatttgaaa caaggttttt ctgtcaacat tgaggttaaa    960
              agcaaaacta aggctattct tgttcctgtt agcagtctag taatggatga tagtaaaaat   1020
              tatgtctgga ttgtggatga acaacaaaag gctaaaaaag ttgaggtttc attgggaaat   1080
              gctgacgcag aaaatcaaga aatcacttct ggtttaacga acggtgctaa ggtcatcagt   1140
              aatccaacat cttccttgga agaaggaaaa gaggtgaagg ctgatgaagc aactaattag   1200
              <210>   111
              <211>   1260
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 111
              atgcagaatc tgaaatttgc cttttcatct atcatggctc acaagatgcg ttctttgctt     60
                                                 Page 185

              actatgattg ggattattat cggtgtttca tcagttgttg tgattatggc tttgggtgat    120
<removed-date>
              tccctatctc gtcaagtcaa taaagatatg actaaatctc agaaaaatat tagcgtcttt    180
              ttctctccta aaaaaagtaa agacgggtct tttactcaga aacaatcagc ttttacggtt    240
              tctggaaagg aagaggaagt tcctgttgaa ccgccaaaac cgcaagaatc ctgggtccaa    300
              gaggcagcta aactgaaggg agtggatagt tactatgtaa ccaattcaac gaatgccatc    360
              ttgacctatc aagataaaaa ggttgagaat gctaatttga caggtggaaa cagaacttac   420
<removed-apn>
              atggacgctg ttaagaatga aattattgca ggtcgtagtc tgagagagca agatttcaaa   480
              gagtttgcaa gtgtcatttt gctagatgag gaattgtcca ttagtttatt tgaatctcct    540
              caagaggcta ttaacaaggt tgtagaagtc aatggattta gttaccgggt cattggggtt    600
              tatactagtc cggaggctaa aagatcaaaa atatatgggt ttggtggctt gcctattact    660
              accaatatct cccttgctgc gaattttaat gtagatgaaa tagctaatat tgtctttcga    720
              gtgaatgata ccagtttaac cccaactctg ggtccagaac tggcacgaaa aatgacagag    780
              cttgcaggct tacaacaggg agaataccag gtggcagatg agtccgttgt atttgcagaa    840
              attcaacaat cgtttagttt tatgacgacg attattagtt ccatcgcagg gatttctctc   900
              tttgttggag gaactggtgt catgaacatc atgctggttt cggtgacaga gcgcactcgt   960
              gagattggtc ttcgtaaggc tttgggtgca acacgtgcca atattttaat tcagtttttg   1020
              attgaatcca tgattttgac cttgttaggt ggcttaattg gcttgacaat tgcaagtggt   1080
              ttaactgcct tagcaggttt gttactgcaa ggtttaatag aaggtataga agttggagta   1140
              tcaatcccag tcgccctatt tagtcttgca gtttcggcta gtgttggtat gatttttgga   1200
              gtcttgccag ccaacaaggc atcgaaactt gatccaattg aagcccttcg ttatgaatga   1260
              <210>   112
              <211>   1242
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 112
              atgaaaaaaa tatttttaac tttgttaact gtctctcttt tagggggtgc ttctactgct     60
              gttgctcaag attttaccat tgccgctaaa catgcgattg ctgttgaggc aaatactggt   120
              aaaattctct atgagaagga tgcaacgcaa cctgtcgaaa ttgcttccat aacaaaattg    180
                                                 Page 186

              attactgttt atctggtcta tgaagctttg gaaaacggaa gtattaccct ctccactcct    240
<removed-date>
              gtagatattt ctgattatcc ttatcaattg acgacaaatt ctgaagccag taatattcct    300
              atggaggccc gtaattatac tgtcgaagag ttgcttgaag caactctggt atctagtgcc    360
              aacagcgccg ctattgccct agctgagaaa attgctggct cagaaaaaga tttcgtcgat    420
              atgatgcggg caaaactctt ggaatgggga attcaggatg ccactgttgt caatacgaca    480
              ggtcttaaca atgaaactct aggggataac atttacccag gttctaaaaa agatgaggaa    540
<removed-apn>
              aataagctta gtgcttatga tgtcgctatc gttgctcgca acctcatcaa aaaataccca    600
              caagtcttag aaatcaccaa aaaaccttct tctacttttg ctgggatgac aatcacttca    660
              accaactaca tgttagaagg tatgcctgct taccgtggtg gttttgatgg gctaaaaaca    720
              ggaacaacag ataaggctgg agagtctttt gttggtacta ctgtcgaaaa aggcatgaga    780
              gtcatcacag ttgttttaaa tgcagatcat caagacaata atccttacgc tcgatttaca    840
              gctacatctt ccctaatgga ttatatttct tctacattta cacttcgcaa aatcgttcaa    900
              caaggcgatg cctatcaaga tagcaaagcc cctgtacaag atggaaaaga agatacagta    960
              actgcagtgg ctccagagga tatctatcta atcgaacgtg ttgggaatca atcttcccaa   1020
              tctgttcaat tcacacctga ttccaaagca atcccagcac cacttgaagc tggaacagtg   1080
              gttggccatt tgacttatga agacaaggac ttgattggtc aaggttacat caccacagag   1140
              cgccctagtt tcgaaatggt agcagacaag aaaattgaaa aagccttctt cttaaaagtt   1200
              tggtggaatc agtttgtccg ctttgttaac gagaaattat aa                      1242
              <210>   113
              <211>   2304
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 113
              atggcaaaca agaatacaag tacaacaaga cggagaccgt ctaaagcaga actggaaaga     60
              aaagaagcga ttcaacgaat gttgatttcg ttaggaattg cgattttatt gattttcgca    120
              gccttcaaat taggggctgc aggtataacc ctttataatt taattcgctt gctagtgggt    180
              agcctagctt atctggcgat attcggccta ttaatctatc tcttcttttt caagtggata    240
              cgaaaacagg aaggactctt atctggcttt ttcaccatat ttgctggctt actcttgatt    300
                                                 Page 187

              tttgaggcct acttggtttg gaaatatggt ttggacaagt ccgttctaaa agggaccatg    360
<removed-date>
              gctcaggttg tgacagatct gactggtttt cgaacgacta gctttgctgg agggggcttg    420
              atcggggtcg ctctttatat tccaacagcc tttctctttt caaatatcgg aacttacttt    480
              attggttcta tcttgatttt agtgggttct ctcctagtca gcccttggtc tgtttacgat    540
              attgctgaat ttttcagtag aggctttgcc aaatggtggg aagggcacga gcgtcgaaaa    600
              gaggaacgct ttgtcaaaca agaagaaaaa gctcgccaaa aggctgagaa agaggctaga    660
<removed-apn>
              ttagaacaag aagagactga aaaagcctta ctcgatttgc ctcctgttga tatggaaacg    720
              ggtgaaattc tgacagagga agctgttcaa aatcttccac ctattccaga agaaaagtgg    780
              gtggaaccag aaatcatcct gcctcaagct gaacttaaat tccctgaaca ggaagatgac    840
              tcagatgacg aagatgttca ggtcgatttt tcagccaaag aagcccttga atacaaactt    900
              ccaagcttac aactctttgc accagataaa ccaaaagatc agtctaaaga gaagaaaatt    960
              gtcagagaaa atatcaaaat cttagaagca acctttgcta gctttggtat taaggtaaca   1020
              gttgaacggg ccgaaattgg gccatcagtg accaagtatg aagtcaagcc ggctgttggt   1080
              gtaagggtca accgcatttc caatctatca gatgacctcg ctctagcctt ggctgccaaa   1140
              gatgtccgga ttgaagcacc aatccctggg aaatccctaa tcggaattga agtgcccaac   1200
              tccgatattg ccactgtatc tttccgagaa ctatgggaac aatcgcaaac gaaagcagaa   1260
              aatttcttgg aaattccttt agggaaggct gttaatggaa ccgcaagagc ttttgacctt   1320
              tctaaaatgc cccacttgct agttgcaggt tcaacgggtt cagggaagtc agtagcagtt   1380
              aacggcatta ttgctagcat tctcatgaag gcgagaccag atcaagttaa atttatgatg   1440
              gtcgatccca agatggttga gttatctgtt tacaatgata ttccccacct cttgattcca   1500
              gtcgtgacca atccacgcaa agccagcaag gctctgcaaa aggttgtgga tgaaatggaa   1560
              aaccgttatg aactctttgc caaggtggga gttcggaata ttgcaggttt taatgccaag   1620
              gtagaagagt tcaattccca gtctgagtac aagcaaattc cgctaccatt cattgtcgtg   1680
              attgtggatg agttggctga cctcatgatg gtggccagca aggaagtgga agatgctatc   1740
              atccgtcttg ggcagaaggc gcgtgctgca ggtatccaca tgattcttgc aactcagcgt   1800
              ccatctgttg atgtcatctc tggtttgatt aaggccaatg ttccatctcg tgtagcattt   1860
              gcggtttcat caggaacaga ctcccgtacg attttggatg aaaatggagc agaaaaactt   1920
                                                 Page 188

<removed-date>
              cttggtcgag gagacatgct ctttaaaccg attgatgaaa atcatccagt tcgtctccaa   1980
              ggctccttta tctcggatga cgatgttgag cgcattgtga acttcatcaa gactcaggca   2040
              gatgcagact acgatgagag ttttgatcca ggtgaggttt ctgaaaatga aggagaattt   2100
              tcggatggag atgctggtgg tgatccgctt tttgaagaag ctaagtcttt ggttatcgaa   2160
              acacagaaag ccagtgcgtc tatgattcag cgtcgtttat cagttggatt taaccgtgcg   2220
<removed-apn>
              acccgtctca tggaagaact ggagatagca ggtgtcatcg gtccagctga aggtaccaaa   2280
              cctcgaaaag tgttacaaca ataa                                          2304
              <210>   114
              <211>   873
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 114
              atgaagaaat caagaaaatt agccacatta ggaatctgtt cagccttgtt tttaggcttg     60
              gctgcttgtc aacaacaaca tgctacttct gaggggacga atcaaaggca aagcagttca    120
              gcgaaagttc catggaaagc ttcatacacc aacctaaaca accaggtaag tacagaagag    180
              gtcaaatctc tcttatcagc tcacttggat ccaaatagtg ttgatgcatt ttttaatctc    240
              gttaatgact ataataccat tgtcggctca actggcttat caggagattt cacttccttt    300
              actcacaccg aatacgatgt tgagaaaatc agtcatctct ggaatcaaaa gaagggcgat    360
              tttgttggga ccaactgccg tatcaatagt tattgtcttt tgaaaaattc agtcaccatt    420
              ccaaagcttg aaaagaatga ccagttgctt ttcctagata atgatgcgat tgataaagga    480
              aaggtctttg attcacaaga taaggaagag tttgatattc tattttcgag agttccaact    540
              gagtcaacta cagatgtcaa ggttcacgct gaaaagatgg aagcattctt ctcacaattt    600
              caattcaatg aaaaagctcg aatgctgtct gtagtcttgc acgacaattt ggatggcgag    660
              tatctgtttg taggccacgt tggggtctta gtacctgctg atgacggttt cttatttgta    720
              gagaaattga ctttcgaaga gccctaccaa gcgattaaat ttgctagtaa ggaagattgc    780
              tacaagtatt tgggcaccaa gtatgcggat tatacaggcg agggactggc taagcctttt    840
              atcatggata atgataagtg ggttaaactt taa                                 873
                                                 Page 189

              <210>   115
<removed-date>
              <211>   918
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 115
              atgaagaaac aaaatttatt tttagtcctg ttaagtgtct ttcttttgtg cttgggggct    60
              tgtggtcaaa aggaaagtca gacaggaaag gggatgaaaa ttgtgaccag tttttatcct   120
              atctacgcta tggttaagga agtatctggt gacttgaatg atgttcggat gattcagtca   180
<removed-apn>
              agtagtggta ttcactcctt tgaaccttcg gcaaatgata tcgcagccat ctatgatgca   240
              gatgtctttg tttaccattc tcatacactc gaatcttggg caggaagtct ggatccaaat   300
              ctaaaaaaat ccaaagtgaa ggtcttagag gcttctgagg gaatgacctt ggaacgtgtc   360
              cctggactag aggatgtgga agcaggggat ggagttgatg aaaaaacgct ctatgaccct   420
              cacacatggc tagatcctga aaaagctgga gaagaagccc aaattatcgc tgataaactt   480
              tcagaggtgg atagtgagca taaagagact tatcaaaaaa atgcgcaagc ctttatcaaa   540
              aaagctcagg aattgactaa gaaattccaa ccaaaatttg aaaaagcgac tcagaaaaca   600
              tttgtaacac aacatacagc cttttcttat ctagcgaaga gatttgggct taatcaactt   660
              ggtattgcag gtatctctcc tgaacaagaa ccaagtccac gacaactaac agaaattcag   720
              gaatttgtta agacctataa ggttaaaacg atttttacag aaagtaacgc ttcttcaaaa   780
              gtagctgaaa ctcttgtcaa atcaacaggt gtgggtctta aaactctgaa tcctttagag   840
              tcagacccac aaaatgacaa gacctattta gaaaatcttg aagaaaatat gagtattcta   900
              gcagaagaat taaagtga                                                 918
              <210>   116
              <211>   615
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 116
              atgtttaaac gaattcgaag agtgcttgta ctagcagtct tcctttttgc tggctataaa    60
              gcttaccgcg ttcatcaaga tgtcaaacaa gtcatgacct atcaacccat ggtgcgagaa   120
              atattgagtg aacaagacac cccagcaaac gaagagcttg tgcttgctat gatttatact   180
              gaaacaaaag gaaaagaagg cgatgttatg cagtctagtg agtctgcaag tggttccacc   240
                                                 Page 190

              aacaccatca atgataatgc ctctagcatt cggcaaggca ttcaaactct gacaggcaat   300
<removed-date>
              ctctatctgg cgcagaagaa gggggtagat atctggacag ctgttcaagc ctataatttt   360
              ggacctgcct atatcgattt tatcgcccaa aatggcaagg aaaataccct ggctctagcc   420
              aaacagtact ctcgtgagac tgttgccccc ttgcttggta ataggactgg aaagacttat   480
              agttatattc accccatttc catttttcac ggtgctgaac tctatgtaaa tggaggaaac   540
              tattattatt ctagacaggt acgacttaac ctttacatca tcaaatgttt cactctcttt   600
<removed-apn>
              tcaacatctg gctag                                                    615
              <210>   117
              <211>   1026
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 117
              atgaaaaaca aattttttct aatagctatt ttagctatgt gtatagtttt tagcgcttgt    60
              tcttctaatt ctgttaaaaa tgaagaaaat acttctaaag agcatgcgcc tgataaaata   120
              gttttagatc atgctttcgg tcaaactata ttagataaaa aacctgaaag agttgcaact   180
              attgcttggg gaaatcatga tgtagcatta gctttaggaa tagttcctgt tggattttca   240
              aaagcaaatt acggtgtaag tgctgataaa ggagttttac catggacaga agaaaaaatc   300
              aaagaactaa atggtaaagc taacctattt gacgatttgg atggacttaa ctttgaagca   360
              atatcaaatt ctaaaccaga tgttatctta gcaggttatt ctggtataac taaagaagat   420
              tatgacactc tatcaaaaat tgctcctgta gcagcataca aatctaaacc ttggcaaact   480
              ttatggagag atatgattaa aattgattca aaagccttag gtatggaaaa agaaggtgat   540
              gagttaatca aaaatactga agctcgtata tccaaagaat tagaaaaaca tccagaaatc   600
              aaaggaaaaa tcaaaggaaa aaaagtatta tttactatga ttaatgctgc agatacatca   660
              aaattctgga tttatactag caaagatcca agagcaaatt atttaacaga tttaggtcta   720
              gttttccctg aatcattaaa agaatttgag agtgaagata gttttgcaaa ggaaatttct   780
              gcagaagaag caaataagat aaatgatgct gatgtaatca taacttatgg tgatgataaa   840
              actcttgaag ctttacaaaa agatcctctt ttaggtaaaa taaatgcaat taaaaatggt   900
              gccgttgctg taattccaga taatacaccg ttagcagcct catgcactcc aacaccactt   960
                                                 Page 191

              tcaataaact atactattga agaataccta aatcttttag gaaatgcatg caaaaatgcg   1020
<removed-date>
              aaataa                                                              1026
              <210>    118
              <211>    1035
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 118
<removed-apn>
              atgttaaagg aaataaaaag gagaaacaga atgaaaaata aacgtttaat tggaattatt     60
              gctgcattag cagtcttagt agcaggaagc ttgatttatt cttcaatgaa taaatcagaa    120
              gctcagaata ataaggatga gaagaaaata accaagattg gtgtgcttca atttgtgagc    180
              catccatccc ttgatttgat ttataaaggg atccaagatg gacttgcaga agaaggatat    240
              aaagatgatc aagttaaaat tgattttatg aactcagaag gtgaccaaag taaggttgcg   300
              acaatgagta aacaattggt tgcaaatggg aatgaccttg tggttggtat cgcaacacca    360
              gcagcccaag ggttggctag tgcaacaaaa gacctaccgg ttatcatggc cgctattaca    420
              gacccaattg gtgctaactt ggttaaagat ttgaaaaaac caggtggcaa cgttacaggg    480
              gtatctgacc acaatccagc tcaacaacaa gttgaactca tcaaggctct gacaccgaat    540
              gtgaaaacaa tcggagctct ttactcaagt agcgaagaca attcaaaaac acaggtcgaa    600
              gaatttaagg cttatgctga aaaagcaggt ctgacagtgg aaacatttgc agttccttca   660
              acaaatgaaa ttgcctcaac tgtcactgtt atgactagca aggtagatgc tatttgggtt   720
              ccaattgata acaccattgc atcaggattt ccaacggttg tctctagcaa tcaaagttct    780
              aagaaaccaa tttatcccag tgcgacagct atggtagaag taggtggttt ggcatcagtt    840
              gtaattgacc aacatgacct tggtgtggca acaggtaaaa tgattgtgca agtcttgaaa    900
              ggtgcaaaac cagccgatac cccagtcaat gtcttttcaa ctggtaagtc agtcatcaat    960
              aaaaaaatag cacaagaact aggtattact attcctgagt ctgttctcaa agaagcagga   1020
              caagtcatcg aataa                                                    1035
              <210>    119
              <211>    6015
              <212>    DNA
              <213>    Streptococcus pneumoniae
                                                  Page 192

              <400> 119
<removed-date>
              atggaaaagt attttggtga aaaacaagag cgtttttcat ttagaaaatt atcagtagga     60
              cttgtatctg caacgatttc aagtttattt tttatgtctg tattagctag ttcatctgtg    120
              gatgctcaag aaactgcggg agttcactat aaatatgtgg cagattcaga gctatcatca    180
              gaagaaaaga agcagcttgt ctatgatatt ccgacatacg tggagaatga tgatgaaact    240
              tattatcttg tttataagtt aaattctcaa aatcaactgg cggaattgcc aaatactgga    300
<removed-apn>
              agcaagaatg agaggcaagc cctagttgct ggtgctagct tagctgctat gggaatttta    360
              atttttgctg tttccaagaa aaaggttaag aataaaacgg tattacattt agtattggtt    420
              gcagggatag gaaatggtgt cttagtttca gtccatgctt tagaaaatca tcttttgcta    480
              aattacaata cggactatga attgacctct ggagaaaaat tacctcttcc taaagagatt    540
              tcaggttaca cttatattgg atatatcaaa gagggaaaaa cgacttctga gtctgaagta    600
              agtaatcaaa agagttcagt tgccactcct acaaaacaac aaaaggtgga ttataatgtt    660
              acaccgaatt ttgtagacca tccatcaaca gtacaagcta ttcaggaaca aacacctgtt    720
              tcttcaacta agccgacaga agttcaagta gttgaaaaac ctttctctac tgaattaatc    780
              aatccaagaa aagaagagaa acaatcttca gattctcaag aacaattagc cgaacataag    840
              aatctagaaa cgaagaaaga ggagaagatt tctccaaaag aaaagactgg ggtaaataca    900
              ttaaatccac aggatgaagt tttatcaggt caattgaaca aacctgaact cttatatcgt    960
              gaggaaacta tggagacaaa aatagatttt caagaagaaa ttcaagaaaa tcctgattta   1020
              gctgaaggaa ctgtaagagt aaaacaagaa ggtaaattag gtaagaaagt tgaaatcgtc   1080
              agaatattct ctgtaaacaa ggaagaagtt tcgcgagaaa ttgtttcaac ttcaacgact   1140
              gcgcctagtc caagaatagt cgaaaaaggt actaaaaaaa ctcaagttat aaaggaacaa   1200
              cctgagactg gtgtagaaca taaggacgta cagtctggag ctattgttga acccgcaatt   1260
              cagcctgagt tgcccgaagc tgtagtaagt gacaaaggcg aaccagaagt tcaacctaca   1320
              ttacccgaag cagttgtgac cgacaaaggt gagactgagg ttcaaccaga gtcgccagat   1380
              actgtggtaa gtgataaagg tgaaccagag caggtagcac cgcttccaga atataagggt   1440
              aatattgagc aagtaaaacc tgaaactccg gttgagaaga ccaaagaaca aggtccagaa   1500
              aaaactgaag aagttccagt aaaaccaaca gaagaaacac cagtaaatcc aaatgaaggt   1560
                                                 Page 193

              actacagaag gaacctcaat tcaagaagca gaaaatccag ttcaacctgc agaagaatca   1620
<removed-date>
              acaacgaatt cagagaaagt atcaccagat acatctagca aaaatactgg ggaagtgtcc   1680
              agtaatccta gtgattcgac aacctcagtt ggagaatcaa ataaaccaga acataatgac   1740
              tctaaaaatg aaaattcaga aaaaactgta gaagaagttc cagtaaatcc aaatgaaggc   1800
              acagtagaag gtacctcaaa tcaagaaaca gaaaaaccag ttcaacctgc agaagaaaca   1860
              caaacaaact ctgggaaaat agctaacgaa aatactggag aagtatccaa taaacctagt   1920
<removed-apn>
              gattcaaaac caccagttga agaatcaaat caaccagaaa aaaacggaac tgcaacaaaa   1980
              ccagaaaatt caggtaatac aacatcagag aatggacaaa cagaaccaga accatcaaac   2040
              ggaaattcaa ctgaggatgt ttcaaccgaa tcaaacacat ccaattcaaa tggaaacgaa   2100
              gaaattaaac aagaaaatga actagaccct gataaaaagg tagaagaacc agagaaaaca   2160
              cttgaattaa gaaatgtttc cgacctagag ttatacagtt tgtcaaatgg tacttataaa   2220
              caacacattt cgttagagca agttccaagc aatccaaata gctactttgt taaagtgaaa   2280
              tcttcttcat tcaaagatgt atacctacca gtagcatcaa tatcagagga aagaaaaaat   2340
              gataaaatcc tttataaaat cacagcaaaa gtagagaagc ttcagcagga gatagaaagc   2400
              agatataaag ataattttac cttctatcta gctaagaagg gaacagaaga aacaacaaac   2460
              tttacttcct ttagtaatct ggtcaaagct ataaaccaaa atccctctgg aacctatcat   2520
              ttagcggcca gcctgaatgc taacgaagtg gagcttggtc ctgatgaaag atcctatatc   2580
              aaggacacct ttactggtcg tttaatcggt gaaaaagatg gcaagaatta tgctatctat   2640
              aatttgaaaa aacctctgtt tgaaaacttg agtggtgcta cagtagaaaa actgagtcta   2700
              aaaaatgttg ctatttcagg gaaagatgat atcggttcac tggcaaatga agctcagaat   2760
              aacacaaaaa ttaagcaagt tcacgtcgat ggtgttctgg ctggtgaacg tggtatcggt   2820
              ggtttgctgg ctaaggctga gcaatcaagc atcacagaga gcagtttcaa gggaagaatt   2880
              atcaacactt atgaaacgac tgctgcctac aatatcggtg gtatggtcgg tcatttgaca   2940
              ggtgacaagg ctttacttac taagtcaaaa gcgacagtag ccatttcatc taacacaaat   3000
              acttcagatc agactgtggg tggacttgca ggcctagtag accgagatgc acagatccaa   3060
              gatagctatg ctgaaggtga tatcaacaat gtcaagcact ttggtagagt cgctggagtg   3120
              gcaggcaatt tgtgggatcg aacttctggt gatgttaggc atgctggaag tttgaccaat   3180
                                                 Page 194

<removed-date>
              gttctcagcg atgttaatgt aaccaacgga aatgccatca ctggttacca ctataacgaa   3240
              atgaaggtaa aggacacatt cagcagcaag gccaacagag tctacaatgt caccttggtc   3300
              aaggatgagg tcgtcagcaa ggaatccttt gaagaaagag gaacaatgct agatgcttct   3360
              caaattgcaa gcaaaaaagc agaaatcaat cctctcattt taccaacagt ggagccactt   3420
              tcaacaagtg gcaaaaaaga cagtgatttt tctaaggtgg cctattatca agctaagcgc   3480
<removed-apn>
              aacttgactt ataaaaacat tgaaaaattg ctacctttct acaacaaggc aaccatcgtc   3540
              aaatacggaa acctggtcaa tgagaacagt cttttatatc aaaaagaact cttgtcagca   3600
              gtcatgatga aggacaacca agtcatcaca gacattgttt ctaacaaaca gactgcaaac   3660
              aaactcttgc ttcactacaa ggatgattta tctgagaagc tggatctcaa ataccagaat   3720
              gatttcgcca aattagcaga atatagtctg ggcaatactg gacttctcta tacgccaaac   3780
              caattcctgt atgaccaaac ctctatcatc aagcaagtct tacctgactt acaaaaggtt   3840
              gactatcatt cagaagccat cagaaagacg ctgggtattt ctccaaacgt caagcaaact   3900
              gagctctatc tagaagacca gttcgccaaa acaaaacaac aactggaaga cagtttgaaa   3960
              aaactcttgt cagcggatgc tggactggct agtgctaacc ccgtcactga aggttatctt   4020
              gtagataaaa tcaaacgcaa caaggaagcc ttgctacttg gcttgaccta tctggaacgg   4080
              tggtataact ttagctatgg tcaggtgaat gtcaaagacc tagttctgta ccatttggac   4140
              ttctttggta aggggaatgc ttcaccatta gatactctga ttgagttggg taaatctggc   4200
              tttaacaatc ttctagctaa gaataatgtc gatacttatg gtatcagtct tgccagtcaa   4260
              catggaacga cagatttgtt tagcacgctg gaacattacc gaaaagtctt tttaccaaat   4320
              acaagcaata atgactggtt taaatcagag actaaggctt acattgtcga agaaaaatcc   4380
              actatcgaag aggtgaaaac gaagcaaggg ttagctggca ccaagtattc tatcggtgtt   4440
              tatgatcgta tcacgagtgc cacatggaaa taccgcaata tggtcttgcc tctcctgacc   4500
              ttgccagaga gatccgtatt tgtcatctcg accatgtcta gtctaggatt tggagcttat   4560
              gatcgctacc gcagtagtga ccataaagcg ggcaaggctc tcaatgattt tgttgaagaa   4620
              aatgcgcgtg aaacagccaa acgtcagcga gatcactacg attattggta tcgtatttta   4680
              gacgacaatg cacgtgaaaa actttataga aatattttgc tttacgatgc ttataaattt   4740
                                                 Page 195

              ggcgatgata ataccgtagg gaaagctaca gaagtggcag attttgataa tccaaatcct   4800
<removed-date>
              gcaatgcaac atttctttgg acctgttgga aataaagttg ggcataatca acacggtgct   4860
              tatgctacag gtgatgcagt ttattatatg ggttatcgaa tgttggataa ggatggagct   4920
              attacttata cgcatgagat gacacatgac tcagatcagg acatttatct tggaggatat   4980
              ggtcgaagaa gtggcttggg accagagttc tttgctaaag gattattaca agcaccagac   5040
              catccagatg atgcgaccat taccatcaac tccatcttga aacattcaaa atctgatagt   5100
<removed-apn>
              acagaaagtc gacgattaca agtacttgat ccaactacaa gatttaataa tgcagatgat   5160
              ttgaagcaat atgtccacaa catgtttgac gttgtttata tgttggaata tctcgaagga   5220
              aattcaattc ttaaattgga tacgaatcaa aaacaacaac ttcttagaaa agttacaaat   5280
              gagtaccatc ctgatcctga tggaaataag gtctatgcaa caaatgttgt cagaaatcta   5340
              acagtagaag aagttgaaag actacgttca ttcaatgatt tgattgataa taatattctt   5400
              tcgtctaggg aatatgcctc aggtaaatac gaaagaaatg gctacttcac tattaagtta   5460
              tttgcaccga tttatgctgc attaagtaat gatataggaa caccaggtga cctgatggga   5520
              cgtcgtatag cctatgaact actagctgct aaaggcttta aagatggtat ggtaccatat   5580
              atctcaaacc aatacgaaga agaagccaaa caaaagggca agacaatcaa tctctacggt   5640
              aaaacaagag gtttggttac agatgacttg gttttggaaa aggtatttaa taaccaatat   5700
              catacttgga gtgagtttaa gaaagctatg tatcaagaac gacaagatca gtttgataga   5760
              ttgaacaaag ttacttttaa tgatacaaca cagccttggc aaacatttgc caagaaaact   5820
              acaagcagtg tagatgaatt acagaaatta atggacgttg ctgttcgtaa ggatgcagaa   5880
              cacaattact accattggaa taactacaat ccagacatag atagtgaagt ccacaagctc   5940
              aagagagcaa tctttaaagc ctatcttgac caaacaaatg attttagaag ttcaattttt   6000
              gagaataaaa aatag                                                    6015
              <210>   120
              <211>   690
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 120
              gtgaaagcca ttatcttagc agcgggattg ggaactcgct tgcgtcctat gactgaaaat     60
                                                 Page 196

              acccctaaag ccttggttca ggttaatcaa aaacctttga ttgagtacca aattgagttt   120
<removed-date>
              ctcaaagaaa aaggaatcaa tgacatcatc atcattgttg gttatcttaa agaacaattc   180
              gattacttga aagagaaata cggtgttcgt ctcgttttca atgataaata cgctgactac   240
              aataactttt actctctcta tcttgtaaaa gaagaattgg ccaacagcta tgttattgat   300
              gctgacaatt atctctttaa aaatatgttc cgcaatgatt tgacacgttc gacttatttt   360
              agtgtttatc gtgaagattg taccaacgaa tggttcttgg tttatggaga tgactacaag   420
<removed-apn>
              gttcaagaca ttattgttga tagcaaggca ggtcgcatcc ttagtggtgt atccttctgg   480
              gatgctccaa ctgcagaaaa gattgtcagc tttatcgaca aggcttatgt aagtggtgaa   540
              tttgttgatc tctattggga caatatggtt aaggataata tcaaagagct agatgtctat   600
              gttgaagaat tagaaggcaa tagcatttat gagatcgata gtgtccaaga ctatcgtaaa   660
              ttagaagaaa ttcttaaaaa cgaaaattaa                                    690
              <210>   121
              <211>   855
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 121
              atgaagcttg atggctatac acgtttagct gcagttgttg ccaatcctat taagcattct    60
              atttctccct tcatccacaa tagagccttt gaggcgacag ctaccaacgg tgcttatgtg   120
              gcttgggaga ttgaagcgag tgacttggta gaaacagtgg ccaatattcg tcgctaccag   180
              atgtttggca tcaatctgtc catgccctat aaggagcagg tgattcctta tttggataag   240
              ctgagcgatg aagcgcgctt gattggtgcg gttaatacgg ttgtcaatga gaatggcaat   300
              ttaattggat ataatacaga tggcaaggga ttttttaagt gcttgccttc ttttacaatt   360
              tcaggtaaaa agatgaccct gctgggtgca ggtggtgcgg ctaaatcaat cttggcacag   420
              gctattttgg atggcgtcag tcagatttcg gtctttgttc gttccgtttc tatggaaaaa   480
              acaagacctt acctagacaa gttacaggag cagacaggtt ttaaagtgga tttgtgtgct   540
              ttagaatatg tttctgaact gcaagcaagg attgccgagt cggatttgct agttaatgcc   600
              accagtgtgg gcatggatgg ccaatcctct cctgttcctg aaaacatagt cttaccagaa   660
              actcttttag ttgcagatat catataccaa ccctttgaaa caccgttttt gaaatgggct   720
                                                 Page 197

              agaagtcagg gcaatccagc agtcaatggt ctgggaatgt tactctatca agctgcagaa    780
<removed-date>
              gcttttcaac tgtggacagg caaggaaatg ccgacagaag agatttggca gtctttaaca    840
              gaaaaatacc aataa                                                     855
              <210>   122
              <211>   1071
              <212>   DNA
              <213>   Streptococcus pneumoniae
<removed-apn>
              <400> 122
              atgaaaaaaa tctattcatt tttagcagga attgcagcga ttatccttgt cttgtgggga     60
              attgcgactc atttagatag taaaatcaat agtcgagata gtcaaaaatt ggttatctat    120
              aactggggag actatatcga tcctgaactc ttgactcagt ttacagaaga aacaggaatt    180
              caagttcagt acgagacttt tgactccaac gaagccatgt acactaagat aaagcagggt    240
              ggaacgacct acgatattgc cattccaagt gaatacatga ttaacaagat gaaggacgaa    300
              gacctcttgg ttccgcttga ttattcaaaa attgaaggaa tcgaaaatat cggaccagag    360
              tttctcaacc agtcctttga cccaggtaat aaattctcca tcccttactt ctggggaacc    420
              ttaggaattg tctacaacga aaccatggta gatgaagcgc ctgagcattg ggatgacctt    480
              tggaagccgg agtataagaa ttctatcatg ctctttgatg gggcgcgtga ggtgctggga    540
              ctaggactca attccctcgg ctacagcctc aactccaagg atctgcagca gttggaagag    600
              acagtggata agctctacaa actgactcca aatatcaagg ctatcgttgc ggacgagatg    660
              aagggctata tgattcagaa taatgttgca atcggcgtga ccttctctgg tgaagccagc    720
              caaatgttag aaaaaaatga aaatctacgt tatgtggtac cgacagaggc cagcaatctt    780
              tggtttgaca atatggtcat tcccaaaaca gttaaaaacc aaaactcagc ctatgccttt    840
              atcaacttta tgttgaaacc tgaaaatgct ctccaaaatg cggagtatgt cggctattca    900
              acaccaaacc taccagcgaa ggaattgctc ccagaggaaa caaaggaaga taaggccttc    960
              tatcccgatg ttgaaaccat gaaacaccta gaagtttatg agaaatttga ccataaatgg   1020
              acagggaaat atagcgacct cttcctacag tttaaaatgt atcggaagta g            1071
              <210> 123
              <211> 279
              <212> DNA
                                                 Page 198

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 123
              atgaacaaac agtatagtta cccactagat ttgtcgtgga gcactgaaga acttgcttca    60
              gtgctttctt tttttaatga tgttgaagct gcctatgaag gcaaagtaga ggctaaaaag   120
              ttactggact cctataaggg attcaaagcg gtcgtgccaa gcaagagcga agagaaacgt   180
              ttgggacgag aatttgaaac ggttagtggc tattcacttt accgagcagt tcaggctgcc   240
<removed-apn>
              aaagaaaaag gggaaggaaa gatttctctt ggaaagtaa                          279
              <210>   124
              <211>   402
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 124
              atgattacac tatttctatc accgagctgt acatcatgtc gtaaggctaa ggcctggtta    60
              gaaaaacata aggttccctt tgtggaacac aatattatga ccagtccttt aacaagaaaa   120
              gaattgcaac acatcctttc cttgaccgaa aatggtactg atgacatcat ttcaactcgt   180
              tcaaaaattt ttcaaaaatt gaatattgat gtagagagta tttcggtatc ggaattgctt   240
              catttgattg agcagtatcc tagtcttttg cgtcgtccaa ttattattga tgccaagcgt   300
              atgcaaatcg gttttaatga agatgagatt cgtgcttttc tccctcgtag ttatcgtaag   360
              caagaactaa aagaagcaag aatgagagct ggtattagtt aa                      402
              <210>   125
              <211>   552
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 125
              atgaaatcta tcggtacgca aatattacag acagaacgtt tgattttaag aagatttgtg    60
              gagagtgatg cagaagccat gtttcaaaat tgggcttcat ccgctgagaa tctgacctat   120
              gttacctggg atccccatcc tgatgtcgaa atcactcgaa actcgatttg caattgggtt   180
              gcttcctata ctaatctcaa ctattataaa tgggccattt gtctaaaaga aaacccagag   240
              caagtaatag gagatatcag cattgttaag atagacgagg ctgatttaag ctgtgaaatt   300
              ggctatgtgt taggcaaggc ttactgggga aatggtatga tgacagagac tttgaaagct   360
                                                 Page 199

              atcttggact tttgttttac tcaagcaggt tttcaaaagg tcagagcacg ttatgccagt    420
<removed-date>
              ctcaacccag cttcaggtcg tgtcatggaa aaggctggaa tgtcctatct acaaaccatt    480
              gttaatggtg tagagagaaa aggctatctt gcggatctta tttattatgg tataagtagg    540
              gaagaatgtt ga                                                        552
              <210>   126
              <211>   1392
<removed-apn>
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 126
              atgaataaaa gtagactagg acgtggcaga cacgggaaaa cgagacatgt attattggct     60
              ttgattggta ttttagcaat ttctatttgc ctattaggcg gatttattgc ttttaagatc    120
              taccagcaaa aaagttttga gcaaaagatt gaatcgctca aaaaagagaa agatgatcaa    180
              ttgagtgagg gaaatcagaa ggagcatttt cgtcaggggc aagccgaagt gattgcctat    240
              tatcctctcc aaggggagaa agtgatttcc tctgttaggg agctgataaa tcaagatgtt    300
              aaggacaagc tagaaagtaa ggacaatctt gttttctact atacagagca agaagagtca    360
              ggtttaaagg gagtcgttaa tcgtaatgtg accaaacaaa tctatgattt agttgctttt    420
              aagattgaag agactgaaaa gaccagtcta ggaaaggttc acttaacaga agatgggcaa    480
              ccttttacac ttgaccaact gttttcagat gctagtaagg ctaaggaaca gctgataaaa    540
              gagttgacct ccttcataga ggataaaaaa atagagcaag accagagtga gcagattgta    600
              aaaaacttct ctgaccaaga cttgtctgca tggaattttg attacaagga tagtcagatt    660
              atcctttatc caagtcctgt ggttgaaaat ttagaagaga tagccttgcc agtatctgct    720
              ttctttgatg ttatccaatc ttcgtactta ctcgaaaaag atgcggcctt gtaccaatct    780
              tactttgata agaaacatca aaaagttgtc gctctaacct ttgatgatgg tccaaatcca    840
              gcaacgaccc cgcaggtatt agagacccta gctaaatatg atattaaagc gactttcttt    900
              gtgcttggga aaaatgtttc tgggaatgag gacttggtga agaggataaa atctgaaggt    960
              catgttgttg gaaaccatag ctggagccat ccgattctct cgcaactctc tcttgatgaa   1020
              gctaaaaagc agattactga tactgaggat gtgctaacta aagtgctggg ttctagttct   1080
              aaactcatgc gtccacctta tggtgctatt acagatgata ttcgcaatag cttggatttg   1140
                                                 Page 200

              agctttatca tgtgggatgt ggatagtctg gactggaaga gtaaaaatga agcatctatt   1200
<removed-date>
              ttgacagaaa ttcagtatca agtagctaat ggctctatcg ttttgatgca tgatattcac   1260
              agtccgacag tcaatgcctt gccaagggtc attgagtatt tgaaaaatca aggttatacc   1320
              tttgtgacca taccagagat gctcaatact cgcctaaaag ctcatgagct gtactatagt   1380
              cgtgatgaat aa                                                       1392
<removed-apn>
              <210>   127
              <211>   837
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 127
              atgaaaaaat ggatgcttgt attagtcagt ctgatgactg ctttgttctt agtagcttgt     60
              gggaaaaatt ctagcgaaac tagtggagat aattggtcaa agtaccagtc taacaagtct   120
              attactattg gatttgatag tacttttgtt ccaatgggat ttgctcagaa agatggttct    180
              tatgcaggat ttgatattga tttagctaca gctgtttttg aaaaatacgg aatcacggta    240
              aattggcaac cgattgattg ggatttgaaa gaagctgaat tgacaaaagg aacgattgat    300
              ctgatttgga atggctattc cgctacagac gaacgccgtg aaaaggtggc tttcagtaac    360
              tcatatatga agaatgagca ggtattggtt acgaagaaat catctggtat cacgactgca    420
              aaggatatga ctggaaagac attaggagct caagctggtt catctggtta tgcggacttt    480
              gaagcaaatc cagaaatttt gaagaatatt gtcgctaata aggaagcgaa tcaataccaa   540
              acctttaatg aagccttgat tgatttgaaa aacgatcgaa ttgatggtct attgattgac    600
              cgtgtctatg caaactatta tttagaagca gaaggtgttt taaacgatta taatgtcttt    660
              acagttggac tagaaacaga agcttttgcg gttggagccc gtaaggaaga tacaaacttg    720
              gttaagaaga taaatgaagc tttttctagt ctttacaagg acggcaagtt ccaagaaatc    780
              agccaaaaat ggtttggaga agatgtagca accaaagaag taaaagaagg acagtaa       837
              <210>   128
              <211>   432
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 128
              atgacgattt tgtttgtggt tatcagtggt tcctttctgt atatggtttc tcttagcatg     60
                                                 Page 201

<removed-date>
              aaaccctatc aaacagctaa aagtgaagga gaaaaattag ctcagcagta tgcaggatta   120
              gagcaggctg atcaggttga tttatacaat ggcttggaat cttattacag cgttcttggt   180
              cgtaacaaac agcaagaagc gcttgctgtc ctgattggta aagatgacca taagatttac   240
              gtttatcagc taaatcaggg tgtttcacaa gaaaaagcag aaacggtttc taaggaaaag   300
              ggagctggcg agattgacaa gataaccttt ggccgttatc aagataagcc aatctgggaa   360
<removed-apn>
              gttaagtcag gatctgattt ttatctagta gattttgaaa caggagcatt ggtcaacaag   420
              gagggcctat ga                                                       432
              <210>   129
              <211>   780
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 129
              atgaaaaaaa atagtttata tatcatatcc tcactctttt ttgcttgtgt cttatttgtc    60
              tatgctacgg cgacgaattt tcaaaacagt accagtgcta ggcaggtaaa aacggaaacc   120
              tatactaata cagtaacaaa tgtccctatt gacatacgct ataatagtga taagtatttt   180
              attagcggtt ttgcttcaga agtatcagtg gtcttgactg gtgcaaatcg cctatcgcta   240
              gctagtgaaa tgcaagaaag tacacgtaaa ttcaaggtta ctgctgacct aacagatgcc   300
              ggtgttggaa cgattgaagt tcctttgagc attgaagatt tacccaatgg gctgaccgct   360
              gtggcgactc cgcaaaaaat tacagtcaag attggtaaga aggctcagaa ggataaggta   420
              aagattgtac cagagattga ccctagtcaa attgatagtc gggtacaaat tgaaaatgtc   480
              atggtgtcag ataaagaagt gtctattacg agtgaccaag agacattgga tagaattgat   540
              aagattatcg ctgttttgcc aactagcgaa cgtataacag gtaattacag tggttcagta   600
              cctttgcagg caatcgaccg caatggtgtt gtcttaccgg cagttatcac tccgtttgat   660
              acaataatga aggtgactac aaaaccagta gcaccaagtt caagcacatc aaattcaagt   720
              acaagcagtt catcggagac atcttcgtca acgaaagcaa ctagttcaaa aacgaattaa   780
              <210>   130
              <211>   750
              <212>   DNA
              <213>   Streptococcus pneumoniae
                                                 Page 202

<removed-date>
              <400> 130
              atgttttata cttatttgcg tggattagtt gtattgctct tatggtccat caatggcaat    60
              gctcactatc ataatactga taaaattcct aatcaagatg aaaattatat tttagttgcg   120
              cctcaccgta cctggtggga tcctgtttat atggcctttg cgaccaagcc aaaacagttc   180
              atctttatgg caaaaaaaga actctttacc aaccgtatct ttggttggtg gattcgtatg   240
              tgtggcgcct ttcccatcga ccgtgaaaat cccagcgcct cagccatcaa atatcctatc   300
<removed-apn>
              aacgttctca aaaaaagtga ccgctctctc atcatgtttc caagtggtag ccgccactca   360
              aacgatgtca aggggggcgc agcactgatt gccaaaatgg ccaaggtccg tatcatgccg   420
              gttacctaca ccggtcccat gactttgaag ggcttgatta gccgtgaacg tgtcgatatg   480
              aactttggaa atccaatcga tatctcagat atcaagaaaa tgaatgatga aggcattgaa   540
              acagtcgcca atcgtattca aacagaattc caacgtctgg acgaagaaac gaaacaatgg   600
              cacaatgata aaaaaccaaa tccactctgg tggtttatcc gcatccctgc cctcatcctt   660
              gctattatcc tcgctatcct aaccatcatc tttagcttta tcgcaagctt catctggaac   720
              ccagataaga aaagagaaga acttgcatag                                    750
              <210>   131
              <211>   2775
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 131
              atgccagtgt caaggatgtg gtgctcaacc agcatcctca ggatattgac agtttggagt    60
              actagcatga tcaagcgaaa aacttattgg aaggacttag ttcagtcctt cacaggctcc   120
              aaggggcgtt ttttatccat cttgatcctg atgatgttgg gatctctagc cttagtaggc   180
              ctcaaagtaa ccagtcccaa catggaggcg acagctaatg cttatttaac aactgctcaa   240
              accttggatt tggcagtcat gtctaactat ggcttggatc aagcagacca agaagaacta   300
              aaacagacgg agggcgcaga ggtcgagttt ggctatttga cagatgtgac tatggataat   360
              gggcaggatg ccattcggct gtactccaaa ccagagcgaa tttcaacctt tcagctaaga   420
              aagggacgac ttcctcagtc agacaaggaa atcgctttgg ccactcattt gcaaggccaa   480
              tacagcgtgg gacaggagat tagttttaaa gaaaaagaag agggtcattc ctctttaaaa   540
                                                 Page 203

              gaccatactt ataccattac tggttttgtg gattcggctg aaatcctctc ccagcgagat    600
<removed-date>
              atgggctacg caggaagtgg aagtgggact ctgacagcct atggggtgat tttacctagt    660
              caatttgatc agaaagtcta caatatagct cgtttgaaat atcaagattt agcgggttta    720
              aatgcctttt catcagctta tgaagaaaaa tccaagcaac atcaagaaga gcttgaacaa    780
              attttatcag ataatggcaa ggtacgtctg caacttttga aaaaagaagg acaagagtct    840
              ctagacaagg ggcaagagac ccttgacaag gctcagacta atttgcagga aggcaagcgt    900
<removed-apn>
              cgtttagcag ctgctcaagc tcgtatacag gctcaagaaa gtcaactagc cttgtttcct    960
              caagttcaga gagagcaggc tagtgctcaa cttacccaag ccaagcagga attgggcaag   1020
              gaagaggaca aactaaagca agctgaacaa aatctagccc aagaaaagga aaaattagaa   1080
              aaacatcagc aagtcttgga tgatttggcg gagccaaggt atcaggttta taatcgtcag   1140
              accatgccag gtggtcaggg ctatcttatg tatagcaatg cttcatccag tattcgagca   1200
              gtgggcaata tctttcctgt ggtactttat gccgtagcag ccatggtgac ctttacgacc   1260
              atgactcgct ttgtagacga agagcgaact catgcaggga tttttaaggc cttgggttat   1320
              cgtagtaagg atattatcgc caagtttctc ctttatggac tagtagctgg gactgtcgga   1380
              acggctctag gtagtatact tggtcattat ttgctagcca gtgtaatttc aagtgtcatt   1440
              acaaaaggca tggtggtggg agaaactcag attcagttct attggaccta tagcttacta   1500
              gcttttgtct tgagcttgtt ggcgagtgtg ttaccagcct atctggtggc ttggagggaa   1560
              cttcatgacg aagcagccca gcttctactt cctaaacctc ctgtcaaagg agctaaaatc   1620
              ttattggagc gtatcggttt tatctggcgt cgtctcagtt ttactcataa ggtaacagcc   1680
              cgcaacatct ttcgttataa gcagagaatg ttgatgacaa tctttggtgt ggcaggttct   1740
              gtagctctgc tctttgcagg tttgggaatc caatcttctg tagcaggagt tccgtctaaa   1800
              cagtttcaac aaatccaaca gtatcagatg cttgtctctg aaaatcctag tgcgaccaat   1860
              caggacaagg tagagctagc agaagtgttg aaagggcagg agatactagc ctaccagaaa   1920
              atctattcta aagcgctata caaggatttc aaaggcaaag ctggtcttca aaacattact   1980
              cttatgatga tagagaagga agatttgact ccctttatcc atcttcaaca tcatcagcag   2040
              gagctgacat taaaagatgg catcgttatt acagctaaac tcgcccagct ggcaggtgtc   2100
              aaggttgggc agactttaga aattgaaggt aaggaactaa aggtcgttgc tattactgag   2160
                                                 Page 204

<removed-date>
              aactacgttg gtcactttat ttatatgagt caggctagct atgagcaact ttacggacag   2220
              ctaccccaag ccaacactta tctggtctca ttaagggata ccagtgcaac tagtatcgaa   2280
              agtcaggcgg gcttgcttat gaatcaatct gcggtgtcca gcgttgtcca aaatgcttca   2340
              gccattcgac tcttcgactc tatcgctagc tcactcaatc agaccatgac catcttggtc   2400
              atcgtatcgg ttctattagc tattgtcatc ctttacaatc tgaccaatat caacgtagct   2460
<removed-apn>
              gagagaatcc gtgaactctc cactatcaag gttcttggtt ttcataataa tgaagtcacc   2520
              ctctacattt accgtgagac gattgtgctg tcccttgtgg gaatcgtact tggtctgata   2580
              gctggtttct atttacacca atttttgatt caaatgattt cgcctgcgac tattctcttt   2640
              tatccgcagg taggctggga agtctatgta atcccagtgg cagcagtaag catcattttg   2700
              accttgcttg gtttcttcgt caattattat ctgagaaagg ttgatatgtt agaagccctg   2760
              aaatctgtag agtaa                                                    2775
              <210>   132
              <211>   1329
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 132
              atgaaattta gaaaattagc ttgtacagta cttgcgggtg ctgcggttct tggtcttgct     60
              gcttgtggca attctggcgg aagtaaagat gctgccaaat caggtggtga cggtgccaaa    120
              acagaaatca cttggtgggc attcccagta tttacccaag aaaaaactgg tgacggtgtt    180
              ggaacttatg aaaaatcaat catcgaagcg tttgaaaaag caaacccaga tataaaagtg    240
              aaattggaaa ccatcgactt caagtcaggt cctgaaaaaa tcacaacagc catcgaagca    300
              ggaacagctc cagacgtact ctttgatgca ccaggacgta tcatccaata cggtaaaaac    360
              ggtaaattgg ctgagttgaa tgacctcttc acagatgaat ttgttaaaga tgtcaacaat    420
              gaaaacatcg tacaagcaag taaagctgga gacaaggctt atatgtatcc gattagttct    480
              gccccattct acatggcaat gaacaagaaa atgttagaag atgctggagt agcaaacctt    540
              gtaaaagaag gttggacaac tgatgatttt gaaaaagtat tgaaagcact taaagacaag    600
              ggttacacac caggttcatt gttcagttct ggtcaagggg gagaccaagg aacacgtgcc    660
              tttatctcta acctttatag cggttctgta acagatgaaa aagttagcaa atatacaact    720
                                                 Page 205

<removed-date>
              gatgatccta aattcgtcaa aggtcttgaa aaagcaacta gctggattaa agacaatttg    780
              atcaataatg gttcacaatt tgacggtggg gcagatatcc aaaactttgc caacggtcaa    840
              acatcttaca caatcctttg ggcaccagct caaaatggta tccaagctaa acttttagaa    900
              gcaagtaagg tagaagtggt agaagtacca ttcccatcag acgaaggtaa gccagctctt    960
              gagtaccttg taaacgggtt tgcagtattc aacaataaag acgacaagaa agtcgctgca   1020
<removed-apn>
              tctaagaaat tcatccagtt tatcgcagat gacaaggagt ggggacctaa agacgtagtt   1080
              cgtacaggtg ctttcccagt ccgtacttca tttggaaaac tttatgaaga caaacgcatg   1140
              gaaacaatca gcggctggac tcaatactac tcaccatact acaacactat tgatggattt   1200
              gctgaaatga gaacactttg gttcccaatg ttgcaatctg tatcaaatgg tgacgaaaaa   1260
              ccagcagatg ctttgaaagc cttcactgaa aaagcgaacg aaacaatcaa aaaagctatg   1320
              aaacaatag                                                           1329
              <210>   133
              <211>   1068
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 133
              atgaaaaaaa tgaaagtttg gtctactgta cttgcaacgg gagttgctct tactacactt     60
              gctgcttgct ctggaggttc aaattctacg actgcttctt catctgaaga aaaagctgat    120
              aaaagtcaag aattagttat ctattcgaac tcagtctcaa atggtcgtgg tgattggtta    180
              actgctaaag caaaagaagc tggttttaat ataaaaatgg ttgatatcgc tggcgctcaa    240
              ttagcagacc gtgttattgc tgagaagaat aatgcagttg cagatatggt atttggaatt    300
              ggtgctgttg attcaaataa aattagagat caaaaattac tagtacagta caagcctaaa    360
              tggttagata aaattgatca atctttatca gataaagata attattataa tcctgtgatt    420
              gttcaaccat tagttttaat tggggcgcct gatgtaaaag aaatgcctaa agattggact    480
              gaattaggta gtaagtataa aggtaaatat tcaatttctg gtcttcaagg aggtacagga    540
              cgggcaattc tagcaagtat cttagttcga taccttgatg ataaaggtga attaggtgtt    600
              tccgaaaaag gttgggaagt agcaaaagaa tatttgaaaa atgcatacac tcttcaaaag    660
              ggagaaagtt caattgttaa gatgttagac aaagaagatc caatacaata tggaatgatg    720
                                                 Page 206

<removed-date>
              tggggttctg gtgcattagt tggacaaaaa gaacaaaatg ttgttttcaa agttatgact    780
              cctgagattg gtgtaccatt tgtaactgaa caaactatgg ttttaagcac tagtaaaaaa    840
              caagcgttag ctaaagaatt tattgattgg tttggtcaat cagaaattca agtagaatat    900
              agtaagaact ttggatctat tcctgcaaat aaagatgccc tcaaagatct acctgaagat    960
              acgaagaaat ttgttgatca agtgaaacca caaaatattg actgggaagc tgttggaaag   1020
<removed-apn>
              catttggatg aatgggtaga aaaagctgaa ttagaatacg tacaataa                1068
              <210>    134
              <211>    966
              <212>    DNA
              <213>    Streptococcus pneumoniae
              <400> 134
              atgaaaacat cccttaaact ttatttcact gccctagtgg ccagcttctt gctcctactt     60
              ggtgcatgta gtacaaactc aagcactagt cagacagaga ccagtagctc tgctccaaca    120
              gaggtaacca ttaaaagttc actggacgag gtcaaacttt ccaaagttcc tgaaaagatt    180
              gtgacctttg acctcggcgc tgcggatact attcgcgctt taggatttga aaaaaatatc    240
              gtcggaatgc ctacaaaaac tgttccgact tatctaaaag acctagtggg aactgtcaaa    300
              aatgttggtt ctatgaaaga acctgattta gaagctatcg ccgcccttga gcctgatttg    360
              attatcgctt cgccacgtac acaaaaattc gtagacaaat tcaaagaaat cgccccaacc    420
              gttctcttcc aagcaagcaa ggacgactac tggacttcta ccaaggctaa tatcgaatcc    480
              ttagcaagtg ccttcggcga aactggtaca cagaaagcca aggaagaatt gaccaagcta    540
              gacaagagca tccaagaagt cgctactaaa aatgaaagct ctgacaaaaa agcccttgcg    600
              atcctcctta atgaaggaaa aatggcagcc tttggtgcca aatctcgttt ctctttcttg    660
              taccaaacct tgaaattcaa accaactgat acaaaatttg aagactcacg ccacggacaa    720
              gaagtcagct ttgaaagtgt caaagaaatc aaccctgaca tcctctttgt catcaaccgt    780
              acccttgcca tcggtgggga caactctagc aacgacggtg tcctagaaaa tgcccttatc    840
              gctgaaacac ctgctgctaa aaatggtaag attatccaac taacaccaga cctctggtat    900
              ctaagcggag gcggacttga atcaacaaaa ctcatgattg aagacataca aaaagctttg    960
              aaataa                                                               966
                                                  Page 207

<removed-date>
              <210>   135
              <211>   1980
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 135
              atgaaaaaaa atcgtgtatt tgctacagca ggtcttgttt tattagcagc aggtgtactt     60
              gcagcatgca gttcttcaaa atcatctgat tcatcagccc ctaaagctta tggctatgtt    120
<removed-apn>
              tatacagcag acccagaaac cttggactac ctgatttcaa gtaaaaatag tacaacagta    180
              gtgacttcaa atgggattga tggtttattc actaacgata attacggtaa tcttgctcct    240
              gcagttgcag aggattggga agtctctaag gatggtttga cctacactta taagattcgt    300
              aaaggggtta aatggtttac ctctgatgga gaagaatatg cagaggtgac ggctaaagat    360
              ttcgtgaacg gtttaaaaca cgcagcagat aaaaaatcag aagctatgta tttagctgaa    420
              aattcggtta aaggcttggc agattatcta tcaggaactt caacagattt ttcaacagtt    480
              ggtgtcaagg cggttgatga ttatacgtta caatacactt tgaaccagcc tgaaccgttc    540
              tggaactcta agttgaccta ttctattttc tggcctctga atgaagaatt cgaaacatca    600
              aaaggaagcg attttgctaa accaacagat ccgacatcct tgctttataa tggtccattc    660
              ttgttgaaag ggttgactgc aaaatcttct gtagagtttg taaaaaatga gcaatattgg    720
              gataaagaaa atgtccacct agatactatc aatctagctt actatgatgg atcagatcag    780
              gagtcgctag agcgtaactt cactagtgga gcttatagtt atgcccgtct ttaccctacc    840
              agctccaact attctaaggt tgcagaagaa tacaaggaca atatctatta cacacaatca    900
              ggctctggga ttgctggtct gggtgtgaat attgatcgcc aaagttacaa ctatacttct    960
              aaaactacag attcagagaa agtagctact aagaaggcat tgcttaacaa agatttccgt   1020
              caagccttga attttgctct tgatcgctca gcttactcag ctcaaatcaa tggtaaagat   1080
              ggagcagctt tagcagttcg taatttattt gtaaaaccag actttgtttc agctggtgag   1140
              aagacctttg gtgatttagt cgctgctcaa cttcctgctt atggtgatga gtggaaaggt   1200
              gtgaatttag ctgatgggca ggatggttta ttcaatgctg acaaggccaa ggcagagttt   1260
              gcgaaagcta agaaagcttt agaagcagac ggcgttcagt ttcctattca tctggacgtt   1320
              ccagtagacc aagcatcaaa aaactacata tctcgtattc agtcctttaa acaatctgta   1380
                                                 Page 208

<removed-date>
              gaaacagttc ttggtgttga aaatgtcgtt gttgatattc aacaaatgac aagtgatgaa   1440
              ttccttaata ttacttacta tgctgccaat gcttcatctg aggattggga tgtatcagga   1500
              ggagtttcat gggggccaga ctatcaagac ccatctactt acctggatat tttaaaaaca   1560
              actagcagtg aaactacaaa aacatattta ggatttgata atccaaatag cccttcagta   1620
              gttcaagttg gtttgaaaga atacgataaa ttagttgatg aagctgccag agagacaagc   1680
<removed-apn>
              gacttgaatg tccgttatga aaaatatgca gcggctcaag catggttgac agatagttca   1740
              ctctttattc ctgctatggc ttcttctggt gcagcaccag tgctttcacg aattgttcca   1800
              tttactggag cttctgcgca aacaggctct aaggggtcag atgtttactt caaatatttg   1860
              aaatcacaag ataaagtggt gactaaggaa gagtatgaaa aagctcgtga aaaatggttg   1920
              aaagaaaaag ctgaatcaaa tgagaaagct caaaaagaat tggcaagtca tgtgaagtaa   1980
              <210>   136
              <211>   1260
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 136
              atggaatggt ataaaaaaat cggacttctt gcaactacag gtttagcttt gtttgggctc     60
              ggcgcttgct ccaactatgg taaatctgcg gatggcacag tgaccatcga gtatttcaac    120
              cagaaaaaag aaatgaccaa aaccttggaa gaaatcactc gtgattttga gaaggaaaac    180
              cctaagatca aggtcaaagt cgtcaatgta ccaaatgctg gtgaagtatt gaagacacgc    240
              gttctcgcag gagatgtgcc tgatgtggtc aatatttacc cacagtccat cgaactgcaa    300
              gaatgggcaa aagcaggtgt ttttgaagat ttgagcaaca aagactacct gaaacgcgtg    360
              aaaaatggct acgctgaaaa atatgctgta aacgaaaaag tttacaacgt tccttttaca    420
              gctaatgctt atggaattta ctacaacaaa gataaattcg aagaactggg cttgaaggtt    480
              cctgaaacct gggatgaatt tgaacagtta gtcaaagata tcgttgctaa aggacaaaca    540
              ccatttggaa ttgcaggtgc agatgcttgg acactcaatg gttacaatca attagccttt    600
              gcgacagcaa caggtggagg aaaagaagca aatcaatacc ttcgttattc tcaaccaaat    660
              gccattaaat tgtcggatcc gattatgaaa gatgatatca aggtcatgga catccttcgc    720
              atcaatggat ctaagcaaaa gaactgggaa ggtgctggct ataccgatgt tatcggagcc    780
                                                 Page 209

<removed-date>
              ttcgcacgtg gggatgtcct catgacacca aatgggtctt gggcgatcac agcgattaat    840
              gaacaaaaac cgaactttaa gattgggacc ttcatgattc caggaaaaga aaaaggacaa    900
              agcttaaccg ttggtgcggg agacttggca tggtctatct cagccaccac caaacatcca    960
              aaagaagcca atgcctttgt ggaatatatg acccgtccag aagtcatgca aaaatactac   1020
              gatgtggacg gatctccaac agcgatcgaa ggggtcaaac aagcaggaga agattcaccg   1080
<removed-apn>
              cttgctggta tgaccgaata tgcctttacg gatcgtcact tggtctggtt gcaacaatac   1140
              tggaccagtg aagcagactt ccataccttg accatgaact atgtcttgac cggtgataaa   1200
              caaggcatgg tcaatgattt gaatgccttc tttaacccga tgaaagcgga tgtggattag   1260
              <210>   137
              <211>   1017
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 137
              atggttaaaa aaattattgg aatggtgcta gctttacttt ctgtaactgt agtaggagta     60
              ggtgtttttg cttatactat ttatcaacaa gggacagaaa ccttagctaa aacctataaa    120
              aaaatcggtg aagaaaccaa ggttattgaa gcgactgaac ctctaaccat tctgttaatg    180
              ggagtggaca ccggaaatgt tgaacgaact gaaacttggg tcggtagaag tgatagcatg    240
              atcttgatga cagtgaatcc taaaacgaaa aaaacaacaa tgatgagttt agagcgggat    300
              attctgacgc gcattgaatc agggaatggt caggctcatg aagcgaaact gaactcagca    360
              tatgcagatg gtggagcaga gcttgctata gaaaccattc aaaaaatgat gaatatccat    420
              attgatcgct atgtgatggt caatatgaga ggattgcaaa aactagtgga tgcagtagga    480
              ggtattacag tcaataatat cctaggtttc ccaatttcta tcagtgacca agaagaattt    540
              aatactattt ctatcggtgt tggggagcaa catattgggg gagaagaagc cctagtctat    600
              gcacgaatgc gttaccaaga tcctgagggg gattatggtc gtcaaaaacg tcaacgtgaa    660
              gttattcaaa aagtcatgga aaaagctctc agtttaaata gcattggtca ttatcaagag    720
              attctaaaag ctttgagtga caatatgcag accaatattg atttgtctgc aaaaagtatc    780
              cctaacttgc taggctataa agattcattt aaaaccattg aaactcagca gttgcagggt    840
              gaaggagaga tacttcaagg tgtttcttac cagattgttt cgagagcaca tatgttggaa    900
                                                 Page 210

<removed-date>
              atgcaaaatc tactccgacg ttctttggga caagaagaag ttactcagct tgaaaccaat    960
              gcggttttat ttgaagattt atttggcaga gcacctgttg gtgatgaaga taattaa      1017
              <210>   138
              <211>   1284
              <212>   DNA
              <213>   Streptococcus pneumoniae
<removed-apn>
              <400> 138
              atggataaaa ttgtggttca aggtggcgat aatcgtctgg taggaagcgt gacgatcgag     60
              ggagcaaaaa atgcagtctt acccttgttg gcagcgacta ttctagcaag tgaaggaaag    120
              accgtcttgc agaatgttcc gattttgtcg gatgtcttta ttatgaatca ggtagttggt    180
              ggtttgaatg ccaaggttga ctttgatgag gaagctcatc ttgtcaaggt ggatgctact    240
              ggcgacatca ctgaggaagc cccttacaag tatgtcagca agatgcgcgc ctccatcgtt    300
              gtattagggc caatccttgc ccgtgtgggt catgccaagg tatccatgcc aggtggttgt    360
              acgattggta gccgtcctat tgatcttcat ttgaaaggtc tggaagctat gggggttaag    420
              attagtcaga cagctggtta catcgaagcc aaggcagaac gcttgcatgg tgctcatatc    480
              tatatggact ttccaagtgt tggtgcaacg cagaacttga tgatggcagc gactctggct    540
              gatggggtga cagtgattga gaatgctgcg cgtgagcctg agattgttga cttagccatt    600
              ctccttaatg aaatgggagc caaggtcaaa ggtgctggta cagagactat aaccattact    660
              ggtgttgaga aacttcatgg tacgactcac aatgtagtcc aagaccgtat cgaagcagga    720
              acctttatgg tagctgctgc catgactggt ggtgatgtct tgattcgaga cgctgtctgg    780
              gagcacaacc gtcccttgat tgccaagtta cttgaaatgg gtgttgaagt aattgaagaa    840
              gacgaaggaa ttcgtgttcg ttctcaacta gaaaatctaa aagctgttca tgtgaaaacc    900
              ttgccccacc caggatttcc aacagatatg caggctcaat ttacagcctt gatgacagtt    960
              gcaaaaggcg aatcaaccat ggtggagaca gttttcgaaa atcgtttcca acacctagaa   1020
              gagatgcgcc gcatgggctt gcattctgag attatccgtg atacagctcg tattgttggt   1080
              ggacagcctt tgcagggagc agaagttctt tcaactgacc ttcgtgccag tgcggccttg   1140
              attttgacag gtttggtagc acagggagaa actgtggtcg gtaaattggt tcacttggat   1200
              agaggttact acggtttcca tgagaagttg gcgcagctag gtgctaagat tcagcggatt   1260
                                                 Page 211

<removed-date>
              gaggcaagtg atgaagatga ataa                                          1284
              <210>   139
              <211>   1038
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 139
              atgaaaaaaa agattagatg gcccttatac gtcattgcgg ccttgattgt gactttcttg     60
<removed-apn>
              gcatttgtag tgcccttgcc ttattatata gaggttccag gtggttcgga agatattcgc    120
              caagtcctta aagtaaatga cacagaagat aaggaagctg gtgcctatca attcgttacg    180
              gttggtgttc aacatgccac tttagctcat atgatttatg cttggttgac accttttaca    240
              gatattcgta gtgctcagga gactacaggt ggttcttccg atgttgaatt tatgcgaatc    300
              aatcaattct acatgcaaac atcgcaaaat atggccaagt atcaaggact aaaaacagct    360
              ggtaaggata tcgaactcaa gtactttgga gtttatgttt tgaatgtgac ggataattca    420
              acctttaaag ggattctcaa tatctctgat acagtcacag cagtcaatga tcagaccttt    480
              gatagttcca aagacttgat tgattacgtc agttctcaaa aattagggga ttccgtcaag    540
              gtcacctatg aagaggatgg gcaaaccaag tctgcagaag gaaaaatcat caccttggaa    600
              aatggcaaaa atggaattgg aatcggcttg attgaccgta cagaggtaat cagcaatgtc    660
              ccaattagct tttcaacagc tggtattggc ggtccaagtg ctggtctcat gtttagtcta   720
              gctatctata ctcaaatagc tcacccagat cttcgtaatg gtcgtattgt tgccggtaca   780
              ggtaccattg accgcgatgg taatgtggga gacattggag gtattgataa gaaggttgta    840
              gcttcggcta gggcaggtgc tgctattttc tttgctcctg ataaccctgt tagcgaagaa    900
              gaacaaaagg cgcatccgga cgcgaaaaac aactaccaaa cagccctaga agcggctaaa    960
              acaatcaaga cggatatgaa aatcgtgccc gttaaaaccc tacaagatgc gattgattac   1020
              ttgaaaaaca atccctaa                                                 1038
              <210>   140
              <211>   963
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 140
                                                 Page 212

              atgcctaaga aaatccttgt tttacatacg ggtggaacta tttccatgca ggccgatgct    60
<removed-date>
              tctggcgctg ttgtgacgag ttcagataat cccatgaacc atgtgtccaa cccacttgaa   120
              ggaatccaag tccacgcctt ggactttttt aaccttccaa gtccccatat caaacccaaa   180
              catatgctgg tcctctacca gaaaattaaa gaggaagcag ataactacga tggagtggtg   240
              atcacacacg gaaccgatac tttagaggaa acagcctatt tccttgatac catggaagtt   300
              ccccatatgc ctatcgttct aacaggagcc atgcgtagct ccaatgagct cggtagtgat   360
<removed-apn>
              ggtgtttata attacctaag tgctttacga gtggccagcg atgacagggc tgctgacaaa   420
              ggagttttgg tcgttatgaa cgatgaaatc cacgctgcca agtatgtcac caaaacacat   480
              acgactaatg tcagcacctt ccagactcca acacatggcc cccttggtct catcatgaaa   540
              caggaaatcc tctacttcaa aacagctgaa cctcgtgttc gctttgacct tgatcacata   600
              caaggtttag tccctatcat ctcggcttat gctggtatga cagatgagct gattgatatg   660
              ctggatttag aacacttgga cggtttgatt atccaagcct tcggagctgg taatattccc   720
              aaagaaacgg ctcaaaaatt agaaagcctt ctgcaaaaag gaattccagt cgctctggta   780
              tcacgatgct ttaacggtat tgccgagcct gtttatgcat accagggtgg gggcgtacag   840
              ttgcaaaaag caggcgtttt ctttgttaaa gaactcaacg cccaaaaagc tcgcttgaaa   900
              ctcctcatcg ccctcaatgc cggactaaca ggacaggctt tgaaagacta tatggaaggc   960
              taa                                                                 963
              <210>   141
              <211>   462
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 141
              atggttcaga acagttgttg gcaatcaaag agccataagg tcaaggcttt taccttgtta    60
              gaatccctgc ttgccctcat tgtcatcagt gggggattac tcctttttca agctatgagt   120
              cagctcctca tttcagaagt tcgctaccag caacaaagcg agcaaaagga gtggctcttg   180
              tttgtggacc aacttgaggt agaattagac cgttcgcagt tcgaaaaagt agaaggcaat   240
              cgcctataca tgaagcaaga tggcaaggac atcgccatcg gtaagtcaaa gtcagatgat   300
              ttccgtaaaa cgaatgctcg tggtcgaggt tatcagccta tggtttatgg actcaaatct   360
                                                 Page 213

              gtacggatta cagaggacaa tcaactggtt cgctttcatt tccagttcca aaaaggctta   420
<removed-date>
              gaaagggagt tcatctatcg tgtggaaaaa gaaaaaagtt aa                      462
              <210>   142
              <211>   405
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 142
<removed-apn>
              atgattaagg cctttaccat gctggaaagt ctcttggttt tgggacttgt gagtatcctt    60
              gccttgggct tgtccggctc tgtccagtcc actttttcag cggtagagga acagattttc   120
              tttatggagt ttgaagaact ctatcgggaa acccaaaaac gcagtgtagc cagtcagcaa   180
              aagactagtc tgaacttaga tgggcagacg cttagcaatg gcagtcaaaa gttgccagtc   240
              cctaaaggaa ttcaggcccc atcaggccaa agtattacat ttgaccgagc tgggggcaat   300
              tcgtccctgg ctaaggttga atttcagacc agtaaaggag cgattcgcta tcaattatat   360
              ctaggaaatg gaaaaattaa acgcattaag gaaacaaaaa attag                   405
              <210>   143
              <211>   1332
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 143
              atgaaacgct accttcaatt ttggctagtc aatctaagtg ttagcctcat tctgattgca    60
              gggatggcat taacttggat cagtaaaggc atcggtctct ttcttctagc cctttctttg   120
              ggactaggtg gctactggct cttttgcctt tggaaatggg aagttgcttt tgagaccttg   180
              caccaacctc tcttgaccag tagtgaatac tttttagaaa aagggcaaga agacttaaag   240
              tctttggctc agtatgtgtc tggcctaaaa accaaagtct cccaacagga tcagcaatac   300
              aaggatctag ccgaaacaat ggaggttctt ctgtcgcacc taaccatggg gacgttttta   360
              gtttccgctc aaggtcagat gttattatcc agtcgctctc tgcctcatta ttttcccgat   420
              gtggacggcg acataagttc acttgatgac ctcaaacgga tggatattcg gaatttagtt   480
              caccaagcct ttgatcaaaa aacaaggtta aaacaagaag taagtgggtt tcatgagggt   540
              gacttgattt tagaagtgac agcagttccc gtttttagcc ccacccaatc tgtggaagct   600
              gtgctcgtct tgctatatga tttaacaacg attagaactt atgaaaagtt aaatttagcc   660
                                                 Page 214

<removed-date>
              tttgtctcaa atgcctccca tgaattgagg acaccagtta cttcgattaa gggctttgct    720
              gaaaccatta aggggatgtc agctgaagaa gaagcgctca aggatgactt tctagacatt    780
              atttacaaag aaagtttgcg tcttgagcat attgttgagc atcttcttac cttatctaag    840
              gctcaacaaa tgcctataca atggacgacc ctttctttgg cagaatttgt acaggatttg    900
              actcaaagct tgcaacctca gctcaagaag aaggatttac agctaaaggt gcaggtgcca    960
<removed-apn>
              gatgatgtca ccctcgtatc agatagtcaa ttactttccc aaatcttact caatctttta   1020
              tccaatgcca tccgttacac tgaacaaggg ggaaaaattg aggtcaagac ccaaaaggtg   1080
              aacgaaggca ttaagatttc tgtatcagat acagggattg gtattagtca attagagcag   1140
              gatcgtattt ttgaacgttt ttaccgagtt aataaaggtc gaagcagaca aactggtggc   1200
              actggtcttg gccttgccat tgtcaaagaa ctcagtcaat tattaggtgg ccaagtcacg   1260
              gtgacgagtc agcttggcag aggcagttgc ttcacgattt ttcttcctaa ccaatctttc   1320
              gcacaggact aa                                                       1332
              <210>   144
              <211>   876
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 144
              atgaaattca aaaaaatgct tactcttgca gccattggct tatcaggatt tgggcttgtt     60
              gcctgtggca atcagtcagc tgcttccaaa cagtcagctt caggaacgat tgaggtgatt    120
              tcacgagaaa atggctctgg gacacggggt gccttcacag aaatcacagg gattctcaaa    180
              aaagacggtg ataaaaaaat tgacaacact gccaaaacag ctgtgattca aaatagtaca    240
              gaaggtgttc tctcagcagt tcaagggaat gctaatgcta tcggctacat ctccttggga    300
              tctttaacga aatctgtcaa ggctttagag attgatggtg tcaaggctag tcgagacaca    360
              gttttagatg gtgaataccc tcttcaacgt cccttcaaca ttgtttggtc ttctaatctt    420
              tccaagctag gtcaagattt tatcagcttt atccactcca aacaaggtca acaagtggtc    480
              acagataata aatttattga agctaaaacc gaaaccacgg aatatacaag ccaacactta    540
              tcaggcaagt tgtctgttgt aggttccact tcagtatctt ctttaatgga aaaattagca    600
              gaagcttata aaaaagaaaa tccagaagtt acgattgata ttacctctaa tgggtcttca    660
                                                 Page 215

<removed-date>
              gcaggtatta ccgctgttaa ggagaaaacc gctgatattg gtatggtttc tagggaatta   720
              actcctgaag aaggtaagag tctcacccat gatgctattg ctttagacgg tattgctgtt   780
              gtggtcaata atgacaataa ggcaagccaa gtcagtatgg ctgaacttgc agacgttttt   840
              agtggcaaat taaccacctg ggacaagatt aaataa                             876
              <210>   145
<removed-apn>
              <211>   651
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 145
              atgagaaatc aatttgactt agaattgcat gaattagaac aatccttttt aggactaggg    60
              caacttgtcc ttgaaacagc ttcaaaagcc ttactggcct tagcctccaa agacaaggag   120
              atggcagagc taattatcaa taaggatcat gctatcaacc aaggtcaaag cgctatcgaa   180
              ttgacctgtg cccgtttgtt ggccttgcag cagccacaag tgtctgacct tcgatttgtg   240
              attagcatca tgtcttcttg ttcagacctt gaacgtatgg gagaccatat ggcaggcatt   300
              gccaaagctg ttttgcaact aaaagaaaat caactagccc ctgacgaaga acagttacac   360
              caaatgggta aattatccct cagcatgcta gccgatttat tggttgcctt tcctttgcac   420
              caagcctcaa aagctattag tattgctcaa aaagatgaac agattgacca atattattat   480
              gccttatcaa aggaaatcat tggacttatg aaagaccaag aaacctcaat tcccaatgga   540
              actcaatacc tttatatcat agggcatctg gaacgcttcg ctgattacat tgctaacatt   600
              tgtgaacgcc tagtctacct agaaacagga gaactagtgg atttgaatta a            651
              <210>   146
              <211>   2085
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 146
              atgaaaccac tacttgaaac catcgatacc cgctttggaa ctaccaacaa gcatgccttt    60
              tctcggggaa ataccctgcc atacacaggc gtgccttttg ggatgaatta ctttgtgccc   120
              cagaccagtg accaggatgg atcttggttt tttgatccac atctgcctat ctttcagggg   180
              attcgattaa ctcaccagcc cagtccttgg attggggact actcttggct ccttctgaca   240
                                                 Page 216

              cctgtcacca gtcaactggg gggagacagc ctctttcacc gccagtcttc ttatgatata    300
<removed-date>
              gataaagctt gcttccagcc tcactatttg aagctctttt ctctgcgtta tcagattgaa    360
              acccagctca caccgacttg ctatggtgct tctattcgtt tgaatcaaaa gcaaggcaaa    420
              gccctctccc tctatcttca cgcagcagat gaactgacag tagagcaagt agataagcgg    480
              actcttgccc tgcgacaaga aggtaaaact gaaactaaca aaaattcgct aacgatgttc    540
              actgccctgc aaatgaacac ggatattctt gctatcagcc aagaagctgg agactggcga    600
<removed-apn>
              attgacttag caagtagtca aaccgagatg caactagcca cttctttcat ctctccttct    660
              caagctctaa tcaatctacc tcaagaagat tttgatagct gtaaatcaag tgcccaagtg    720
              gattgggaaa atctcctcca tcgttttgac attatagaga caggagaggc tgaccgaacc    780
              ttctttgacc actgcctcta cagactcttc ctcttcccac agacttttta tgagattaat    840
              gaatcagggc aagccatcca catggatctg gctactggta ctgtcaagcc tggtgtcctc    900
              tttagcaaca atggtttctg ggataccttc cgcaccacct tccccctctt tgcccttatc    960
              ataccggagc actatcaacg ctttttagaa ggtttcctca atagctaccg cgatactggt   1020
              ttccttccaa aatggctggc tccagatgaa cggggtatga tgccaggtac acttttagac   1080
              ggtattatcg cagatagcgc ctgcaaggac atgacccccg acctagaagg agaactcttc   1140
              caagccatgc tcgaaacagc cagcaaagcc gaccctctcg gcatcaatgg ccgccacgga   1200
              ctagcccaat accaagaact aggttacctc tctaccgacc accacgaaag tgttagccat   1260
              actctagact atgcctatag tgacttttgt atcgccagct gtgccaaaaa actagagaac   1320
              atagaaatcg ctgaaaccta caaggctgct tcacaaaatt accgccagct atttgacgct   1380
              gagacaggtt acatgcgagc acgagacaat caaggaaact ttcaccctga cttctctcct   1440
              tatagttggg ggcgagacta cgctgaatgc tctgccattc aagctacttt aggcgttctc   1500
              cacgacatcc ctggcttaat ccaactgatg ggtggaaaag aaacctttag caactatctt   1560
              ttgaaagcct gtcaagatgc tcccctcttt gaaacaacag gctatggtta cgaaattcac   1620
              gaaatgagcg agatggctac tgctcctttt ggacaaatag ccatttccaa ccagcctagt   1680
              ttccacattc cttatctctt ccgttacagc gattaccctg actacactgc ccttcttatc   1740
              aagacgctcc gtcagaaagc ttttcaccca agttgggaag cctatcctgg agatgaagac   1800
              aatggtagtc tctctgcttg gtacatctgg tcagctctcg gattttatcc aacctgtcca   1860
                                                 Page 217

<removed-date>
              ggaaaaccaa gctatgacct cggaatccct ctctttgacc atctacgagt ctacctcgct   1920
              aaagaagata aatggctgga tatccatact aaacaaaacc acaaccattt taactttgtc   1980
              aaagaatgcc gactggacaa aacactcgta tcaactattc aacaccaaga cctcttaaaa   2040
              gctgaacaac taactttcac cctcagctgg ttaccaagtc actaa                   2085
              <210>   147
<removed-apn>
              <211>   948
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 147
              atggcaaatc gtaaaattgt agtagctttg ggaggaaatg cgattctttc ttctgaccca     60
              tcagcaaagg ctcaacaaga agctttagtt gaaacagcta agcatcttgt aaaattgatt   120
              aaaaatggag atgatctgat tatcactcac ggtaatggac ctcaagttgg gaatctcttg    180
              ctccaacatt tggcatcaga ctctgaaaag aaccctgcct tcccactcga ctcacttgtc    240
              gctatgacag aaggtagcat cggtttctgg ttgaaaaatg ctttgcaaaa tgctctcttg    300
              gatgaaggca tcgaaaaaaa tgttgcctct gttgtaacgc aagttgtcgt agataaaaat    360
              gatccagctt ttgttaactt gagtaaacca atcggtcctt tctattcaga agaagaagca    420
              aaagcagaag ccgaaaaaag cggagcgact ttcaaggaag atgctggccg tggctggcgt    480
              aaggtcgttg cctcaccaaa acctgttgac atcaaagaaa ttgaaaccat ccgtactctt   540
              ttaaataatg gtcaagtcgt cgtagctgca ggtggtggcg gtattcccgt cgtcaaagaa   600
              aacaatggac atttgactgg tgtcgaagcg gttattgata aagacttcgc ttcccaacgt    660
              ttggcagaat tggttgatgc agacctcttc atcgttttga caggtgtaga ttatgtattt    720
              gttaactaca acaagccaaa ccaggaaaaa ttggaacatg tgaatgttgc ccagctggaa    780
              gaatatatca aacaagatca gtttgcacca ggtagcatgc ttccaaaagt agaagcagct    840
              atcgcttttg tcaatggtcg tccagaagga aaagcagtta ttacttccct tgaaaatcta    900
              ggcgccttga ttgaatctga aagcggaaca attattgaaa aaggataa                948
              <210>   148
              <211>   1428
              <212>   DNA
              <213>   Streptococcus pneumoniae
                                                 Page 218

<removed-date>
              <400> 148
              atgtatttag gagatttgat ggagaaagcc gagtgtggtc aattttcaat actttccttt     60
              ctattacaag agtctcagac gaccgtcaag gctgtaatgg aagaaacagg attttcaaaa    120
              gcaaccctaa ccaaatatgt caccctgctc aatgacaagg ctttggatag tggcttagag    180
              ctggctattc actcagaaga tgaaaatctg cgtctgtcta tcggtgcagc taccaagggg    240
              agagatattc ggagcttgtt tttggagagt gctgttaaat accagatttt ggtttatctt    300
<removed-apn>
              ctctaccacc aacagttttt agcccatcag ctggctcaag aattggtgat tagcgaggct    360
              acgcttggtc gtcacttggc tggtttaaat cagattttgt cagaatttga tttatccatc    420
              caaaatggcc gttggcgagg tccagagcat cagattcact atttctattt ctgtcttttc    480
              cgaaaggtct ggtcgagtca ggaatgggaa ggtcacatgc agaaaccaga gagaaaacag    540
              gagattgcca atttagagga aatctgcggt gcaagtttgt ctgcggggca gaaattggac    600
              ttggttctct gggctcacat cagtcaacaa cgtcttcggg tcaatgcttg tcagtttcaa    660
              gtcatagaag agaaaatgcg agggtatttt gacaatatct tttatcttcg tttgctgaga    720
              aaggttccgt ccttttttgc tgggcaacat attccactag gagttgagga tggtgagatg    780
              atgatattct tctcttttct cctatctcat cgcattcttc ctcttcatac tatggagtat    840
              attcttggtt ttggagggca gttggcagat ttactgacgc aattgattca agaaatgaag    900
              aaggaggaac tattggggga ttatacagag gaccatgtca cctatgaact cagtcagctt    960
              tgtgctcaag tctatctcta taagggctat attttacagg atcgctacaa gtaccagtta   1020
              gagaatcgtc atccatattt actgatggaa catgatttta aagagacagc agaggagatt   1080
              tttcatgctc tacctgcttt tcaacagggg acagatttag ataagaagat tctctgggaa   1140
              tggctccagt taatcgaata tatggctgaa aacggtggcc agcatatgcg gattggtctg   1200
              gatttgacat ctggttttct tgtcttttca aggatggcag ccattttgaa acggtatttg   1260
              gaatacaatc gttttattac cattgaagct tatgacccta gtcggcatta tgatttgctg   1320
              gttaccaata acccgattca taagaaggaa cagacaccag tctattattt aaaaaatgac   1380
              ttggatatgg aggatttggt agcgattcgc cagttattat tcacttaa                1428
              <210> 149
              <211> 1332
                                                 Page 219

              <212> DNA
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 149
              atgataaaaa atcctaaatt attaaccaag tcttttttaa gaagttttgc aattctaggt     60
              ggtgttggtc tagtcattca tatagctatt tatttgacct ttccttttta ttatattcaa    120
              ctggaggggg aaaagtttaa tgagagcgca agagtgttta cggagtattt aaagactaag    180
              acatctgatg aaattccaag cttactccag tcttattcaa agtccttgac catatctgct    240
<removed-apn>
              caccttaaaa gagatattgt agataagcgg ctccctcttg tgcatgactt ggatattaaa    300
              gatggaaagc tatcaaatta tatcgtgatg ttagatatgt ctgttagtac agcagatggt    360
              aaacaggtaa ccgtgcaatt tgttcacggg gtggatgtct acaaagaagc aaagaatatt    420
              ttgcttttgt atctcccata tacatttttg gttacaattg ctttttcctt tgttttttct    480
              tatttttata ctaaacgctt gctcaatcct cttttttaca tttcagaagt gactagtaaa    540
              atgcaagatt tggatgacaa tattcgtttt gatgaaagta ggaaagatga agttggtgaa    600
              gttggaaaac agattaatgg tatgtatgag cacttgttga aggttattta tgagttggaa    660
              agtcgtaatg agcaaattgt aaaattgcaa aatcaaaagg tttcctttgt ccgcggagca    720
              tcacatgagt tgaaaacccc tttagccagt cttagaatta tcctagagaa tatgcagcat    780
              aatattggag attacaaaga tcatccaaaa tatattgcaa agagtataaa taagattgac    840
              cagatgagcc acttattaga agaagtactg gagtcttcta aattccaaga gtggacagag    900
              tgtcgtgaga ccttgactgt taagccagtt ttagtagata ttttatcacg ttatcaagaa    960
              ttagctcatt caataggtgt tacaattgaa aatcaattga cagatgctac cagggtcgtc   1020
              atgagtctta gggcattgga taaggttttg acaaacctga ttagtaatgc aattaaatat   1080
              tcagataaaa atgggcgtgt aatcatatcc gagcaagatg gctatctctc tatcaaaaat   1140
              acatgtgcgc ctctaagtga ccaagaacta gaacatttat ttgatatatt ctatcattct   1200
              caaatcgtga cagataagga tgaaagttcc ggtttgggtc tttacattgt gaataatatt   1260
              ttagaaagct atcaaatgga ttatagtttt ctcccttatg aacacggtat ggaatttaag   1320
              attagcttgt ag                                                       1332
              <210> 150
              <211> 1008
                                                 Page 220

              <212> DNA
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 150
              atgaagaaaa catggaaagt gtttttaacg cttgtaacag ctcttgtagc tgttgtgctt     60
              gtggcctgtg gtcaaggaac tgcttctaaa gacaacaaag aggcagaact taagaaggtt    120
              gactttatcc tagactggac accaaatacc aaccacacag ggctttatgt tgccaaggaa    180
              aaaggttatt tcaaagaagc tggagtggat gttgatttga aattgccacc agaagaaagt   240
<removed-apn>
              tcttctgact tggttatcaa cggaaaggca ccatttgcag tgtatttcca agactacatg   300
              gctaagaaat tggaaaaagg agcaggaatc actgccgttg cagctattgt tgaacacaat   360
              acatcaggaa tcatctctcg taaatctgat aatgtaagca gtccaaaaga cttggttggt    420
              aagaaatatg ggacatggaa tgacccaact gaacttgcta tgttgaaaac cttggtagaa    480
              tctcaaggtg gagactttga gaaggttgaa aaagtaccaa ataacgactc aaactcaatc    540
              acaccgattg ccaatggcgt ctttgatact gcttggattt actacggttg ggatggtatc    600
              cttgctaaat ctcaaggtgt agatgctaac ttcatgtact tgaaagacta tgtcaaggag   660
              tttgactact attcaccagt tatcatcgca aacaacgact atctgaaaga taacaaagaa   720
              gaagctcgca aagtcatcca agccatcaaa aaaggctacc aatatgccat ggaacatcca   780
              gaagaagctg cagatattct catcaagaat gcacctgaac tcaaggaaaa acgtgacttt   840
              gtcatcgaat ctcaaaaata cttgtcaaaa gaatacgcaa gcgacaagga aaaatggggt    900
              caatttgacg cagctcgctg gaatgctttc tacaaatggg ataaagaaaa tggtatcctt    960
              aaagaagact tgacagacaa aggcttcacc aacgaatttg tgaaataa                1008
              <210>   151
              <211>   663
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 151
              atgaagtgct tgttatgtgg gcagactatg aagactgttt taacttttag tagtctctta     60
              cttctgagga atgatgactc ttgtctttgt tcagactgtg attctacttt tgaaagaatt   120
              ggggaagaga actgtccaaa ttgtatgaaa acagagttgt caacaaagtg tcaagattgt   180
              caactttggt gtaaagaggg agttgaagtc agtcatagag cgatttttac ttacaatcaa   240
                                                 Page 221

              gctatgaagg attttttcag tcggtataag tttgatggag acttcctgtt aagaaaagtt   300
<removed-date>
              ttcgcttcat ttttaagtga ggagttgaaa aagtacaaag agtatcaatt tgttgtaatt   360
              cccctaagtc ctgatagata tgctaataga ggatttaatc aggttgaggg cttggtagag   420
              gcagcaggct ttgagtatct ggatttatta gagaaaagag aagagagagc cagttcttct   480
              aaaaatcgtt cagagcgctt ggggacagaa cttcctttct ttattaaaag tggagtcact   540
              attcctaaaa aaatcctact tatagatgat atctatacta caggagcaac tataaatcgt   600
<removed-apn>
              gttaagaaac tgttggaaga agctggtgct aaggatgtaa aaacattttc ccttgtaaga   660
              tga                                                                 663
              <210>   152
              <211>   819
              <212>   DNA
              <213>   Streptococcus pneumoniae
              <400> 152
              atgaaccgtt ttaaaaaatc aaaatatgtc attattgttt ttgtcactgt tctgcttgtg    60
              tcagctctct tagcgacgac ttattcaagt acaattgtga caaaattagg agatggaatc   120
              tcattggttg atagagttgt acaaaaacct tttcagtggt ttgattctgt caaatcagat   180
              ttggctcatt tgacacgaac atataatgaa aatgaaagtt tgaagaaaca gctttaccaa   240
              ttagaagtta aatcaaatga ggtggaaagt ttaaagacag aaaatgaaca actgcgccaa   300
              ttgcttgata tgaagtctaa attgcaagcc acaaagactt tagcagcaga tgttattatg   360
              cgttctccgg tatcttggaa gcaggagttg accttagatg caggtagatc aaaaggtgct   420
              tctgagaaca tgttagctat tgcaaatggt ggcttgattg ggagtgtttc aaaagtagag   480
              gagaactcta ctatagtcaa ccttctgaca aatacggaaa atgctgataa gatttctgtt   540
              aaaattcaac atggctctac tacaatttat ggaattatta ttggctatga caaggaaaat   600
              gacgttctta aaattagcca attaaatagt aatagcgata ttagtgcggg agataaggtg   660
              actactggtg gattaggaaa ctttaacgtt gctgatattc ctgttggtga agtggttgcc   720
              acaacgcata gtacagacta tttgacacga gaagtaactg ttaaattgag tgcagatact   780
              cataatgtag atgtgataga attagtgggg aattcataa                          819
              <210> 153
                                                 Page 222

              <211> 400
<removed-date>
              <212> PRT
              <213> Streptococcus pneumoniae
              <400> 153
              Glu Lys Glu Val Val Tyr Thr Ser Lys Glu Ile Tyr Tyr Leu Ser Gln
              1               5                   10                  15
              Ser Asp Phe Gly Ile Tyr Phe Arg Glu Lys Leu Ser Ser Pro Met Val
                          20                  25                  30
<removed-apn>
              Tyr Gly Glu Val Pro Val Tyr Ala Asn Glu Asp Leu Val Val Glu Ser
                      35                  40                  45
              Gly Lys Leu Thr Pro Lys Thr Ser Phe Gln Ile Thr Glu Trp Arg Leu
                  50                  55                  60
              Asn Lys Gln Gly Ile Pro Val Phe Lys Leu Ser Asn His Gln Phe Ile
              65                  70                  75                  80
              Ala Ala Asp Lys Arg Phe Leu Tyr Asp Gln Ser Glu Val Thr Pro Thr
                              85                  90                  95
              Ile Lys Lys Val Trp Leu Glu Ser Asp Phe Lys Leu Tyr Asn Ser Pro
                          100                 105                 110
              Tyr Asp Leu Lys Glu Val Lys Ser Ser Leu Ser Ala Tyr Ser Gln Val
                      115                 120                 125
              Ser Ile Asp Lys Thr Met Phe Val Glu Gly Arg Glu Phe Leu His Ile
                  130                 135                 140
              Asp Gln Ala Gly Trp Val Ala Lys Glu Ser Thr Ser Glu Glu Asp Asn
              145                 150                 155                 160
              Arg Met Ser Lys Val Gln Glu Met Leu Ser Glu Lys Tyr Gln Lys Asp
                              165                 170                 175
              Ser Phe Ser Ile Tyr Val Lys Gln Leu Thr Thr Gly Lys Glu Ala Gly
                          180                 185                 190
                                                 Page 223

              Ile Asn Gln Asp Glu Lys Met Tyr Ala Ala Ser Val Leu Lys Leu Ser
<removed-date>
                      195                 200                 205
              Tyr Leu Tyr Tyr Thr Gln Glu Lys Ile Asn Glu Gly Leu Tyr Gln Leu
                  210                 215                 220
              Asp Thr Thr Val Lys Tyr Val Ser Ala Val Asn Asp Phe Pro Gly Ser
              225                 230                 235                 240
<removed-apn>
              Tyr Lys Pro Glu Gly Ser Gly Ser Leu Pro Lys Lys Glu Asp Asn Lys
                              245                 250                 255
              Glu Tyr Ser Leu Lys Asp Leu Ile Thr Lys Val Ser Lys Glu Ser Asp
                          260                 265                 270
              Asn Val Ala His Asn Leu Leu Gly Tyr Tyr Ile Ser Asn Gln Ser Asp
                      275                 280                 285
              Ala Thr Phe Lys Ser Lys Met Ser Ala Ile Met Gly Asp Asp Trp Asp
                  290                 295                 300
              Pro Lys Glu Lys Leu Ile Ser Ser Lys Met Ala Gly Lys Phe Met Glu
              305                 310                 315                 320
              Ala Ile Tyr Asn Gln Asn Gly Phe Val Leu Glu Ser Leu Thr Lys Thr
                              325                 330                 335
              Asp Phe Asp Ser Gln Arg Ile Ala Lys Gly Val Ser Val Lys Val Ala
                          340                 345                 350
              His Lys Ile Gly Asp Ala Asp Glu Phe Lys His Asp Thr Gly Val Val
                      355                 360                 365
              Tyr Ala Asp Ser Pro Phe Ile Leu Ser Ile Phe Thr Lys Asn Ser Asp
                  370                 375                 380
              Tyr Asp Thr Ile Ser Lys Ile Ala Lys Asp Val Tyr Glu Val Leu Lys
              385                 390                 395                 400
              <210> 154
                                                 Page 224

              <211> 408
<removed-date>
              <212> PRT
              <213> Streptococcus pneumoniae
              <400> 154
              Glu Lys Glu Met Ser Leu Ser Thr Arg Ala Thr Val Glu Pro Ser Arg
              1               5                   10                  15
              Ile Leu Ala Asn Ile Gln Ser Thr Ser Asn Asn Arg Ile Leu Val Asn
                          20                  25                  30
<removed-apn>
              His Leu Glu Glu Asn Lys Leu Val Lys Lys Gly Asp Leu Leu Val Gln
                      35                  40                  45
              Tyr Gln Glu Gly Ala Glu Gly Val Gln Ala Glu Ser Tyr Ala Ser Gln
                  50                  55                  60
              Leu Asp Met Leu Lys Asp Gln Lys Lys Gln Leu Glu Tyr Leu Gln Lys
              65                  70                  75                  80
              Ser Leu Gln Glu Gly Glu Asn His Phe Pro Glu Glu Asp Lys Phe Gly
                              85                  90                  95
              Tyr Gln Ala Thr Phe Arg Asp Tyr Ile Ser Gln Ala Gly Ser Leu Arg
                          100                 105                 110
              Ala Ser Thr Ser Gln Gln Asn Glu Thr Ile Ala Ser Gln Asn Ala Ala
                      115                 120                 125
              Ala Ser Gln Thr Gln Ala Glu Ile Gly Asn Leu Ile Ser Gln Thr Glu
                  130                 135                 140
              Ala Lys Ile Arg Asp Tyr Gln Thr Ala Lys Ser Ala Ile Glu Thr Gly
              145                 150                 155                 160
              Ala Ser Leu Ala Gly Gln Asn Leu Ala Tyr Ser Leu Tyr Gln Ser Tyr
                              165                 170                 175
              Lys Ser Gln Gly Glu Glu Asn Pro Gln Thr Lys Val Gln Ala Val Ala
                          180                 185                 190
                                                 Page 225

              Gln Val Glu Ala Gln Ile Ser Gln Leu Glu Ser Ser Leu Ala Thr Tyr
<removed-date>
                      195                 200                 205
              Arg Val Gln Tyr Ala Gly Ser Gly Thr Gln Gln Ala Tyr Ala Ser Gly
                  210                 215                 220
              Leu Ser Ser Gln Leu Glu Ser Leu Lys Ser Gln His Leu Ala Lys Val
              225                 230                 235                 240
<removed-apn>
              Gly Gln Glu Leu Thr Leu Leu Ala Gln Lys Ile Leu Glu Ala Glu Ser
                              245                 250                 255
              Gly Lys Lys Val Gln Gly Asn Leu Leu Asp Lys Gly Lys Val Thr Ala
                          260                 265                 270
              Ser Glu Asp Gly Val Leu His Leu Asn Pro Glu Thr Ser Asp Ser Ser
                      275                 280                 285
              Met Val Ala Glu Gly Ala Leu Leu Ala Gln Leu Tyr Pro Ser Leu Glu
                  290                 295                 300
              Arg Glu Gly Lys Ala Lys Leu Thr Ala Tyr Leu Ser Ser Lys Tyr Val
              305                 310                 315                 320
              Ala Arg Ile Lys Val Gly Asp Ser Val Arg Tyr Thr Thr Thr His Asp
                              325                 330                 335
              Ala Gly Asn Gln Leu Phe Leu Asp Ser Thr Ile Thr Ser Ile Asp Ala
                          340                 345                 350
              Thr Ala Thr Lys Thr Glu Lys Gly Asn Phe Phe Lys Ile Glu Ala Glu
                      355                 360                 365
              Thr Asn Leu Thr Ser Glu Gln Ala Glu Lys Leu Arg Tyr Gly Val Glu
                  370                 375                 380
              Gly Arg Leu Gln Met Ile Thr Gly Lys Lys Ser Tyr Leu Arg Tyr Tyr
              385                 390                 395                 400
              Leu Asp Gln Phe Leu Asn Lys Glu
                                                 Page 226

                                405
<removed-date>
              <210>   155
              <211>   198
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 155
              Lys Gln Asp Met Asn Ile Ile Ala Ile Asp Asp His Ala Glu Arg Ile
              1               5                   10                  15
<removed-apn>
              Asn Gln Phe Glu Pro Val Leu Ala Arg Gly Val Ile Gly Asp Ile Thr
                          20                  25                  30
              Asp Glu Glu Leu Leu Arg Ser Ala Gly Ile Asp Thr Cys Asp Thr Val
                      35                  40                  45
              Val Val Ala Thr Gly Glu Asn Leu Glu Ser Ser Val Leu Ala Val Met
                  50                  55                  60
              His Cys Lys Ser Leu Gly Val Pro Thr Val Ile Ala Lys Val Lys Ser
              65                  70                  75                  80
              Gln Thr Ala Lys Lys Val Leu Glu Lys Ile Gly Ala Asp Ser Val Ile
                              85                  90                  95
              Ser Pro Glu Tyr Glu Met Gly Gln Ser Leu Ala Gln Thr Ile Leu Phe
                          100                 105                 110
              His Asn Ser Val Asp Val Phe Gln Leu Asp Lys Asn Val Ser Ile Val
                      115                 120                 125
              Glu Met Lys Ile Pro Gln Ser Trp Ala Gly Gln Ser Leu Ser Lys Leu
                  130                 135                 140
              Asp Leu Arg Gly Lys Tyr Asn Leu Asn Ile Leu Gly Phe Arg Glu Gln
              145                 150                 155                 160
              Glu Asn Ser Pro Leu Asp Val Glu Phe Gly Pro Asp Asp Leu Leu Lys
                              165                 170                 175
                                                 Page 227

              Ala Asp Thr Tyr Ile Leu Ala Val Ile Asn Asn Gln Tyr Leu Asp Thr
<removed-date>
                          180                 185                 190
              Leu Val Ala Leu Asn Ser
                      195
              <210>   156
              <211>   241
              <212>   PRT
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 156
              Phe Asp Ser Leu Glu Glu Ser Glu Arg Glu Lys Gly Leu Met Ile Ala
              1               5                   10                  15
              Gln Leu Ser His Asp Ile Lys Thr Pro Ile Thr Ser Ile Gln Ala Thr
                          20                  25                  30
              Val Glu Gly Ile Leu Asp Gly Ile Ile Lys Glu Ser Glu Gln Ala His
                      35                  40                  45
              Tyr Leu Ala Thr Ile Gly Arg Gln Thr Glu Arg Leu Asn Lys Leu Val
                  50                  55                  60
              Glu Glu Leu Asn Phe Leu Thr Leu Asn Thr Ala Arg Asn Gln Val Glu
              65                  70                  75                  80
              Thr Thr Ser Lys Asp Ser Ile Phe Leu Asp Lys Leu Leu Ile Glu Cys
                              85                  90                  95
              Met Ser Glu Phe Gln Phe Leu Ile Glu Gln Glu Arg Arg Asp Val His
                          100                 105                 110
              Leu Gln Val Ile Pro Glu Ser Ala Arg Ile Glu Gly Asp Tyr Ala Lys
                      115                 120                 125
              Leu Ser Arg Ile Leu Val Asn Leu Val Asp Asn Ala Phe Lys Tyr Ser
                  130                 135                 140
              Ala Pro Gly Thr Lys Leu Glu Val Val Ala Lys Leu Glu Lys Asp Gln
              145                 150                 155                 160
                                                 Page 228

<removed-date>
              Leu Ser Ile Ser Val Thr Asp Glu Gly Gln Gly Ile Ala Pro Glu Asp
                              165                 170                 175
              Leu Glu Asn Ile Phe Lys Arg Leu Tyr Arg Val Glu Thr Ser Arg Asn
                          180                 185                 190
              Met Lys Thr Gly Gly His Gly Leu Gly Leu Ala Ile Ala Arg Glu Leu
                      195                 200                 205
<removed-apn>
              Ala His Gln Leu Gly Gly Glu Ile Thr Val Ser Ser Gln Tyr Gly Leu
                  210                 215                 220
              Gly Ser Thr Phe Thr Leu Val Leu Asn Leu Ser Gly Ser Glu Asn Lys
              225                 230                 235                 240
              Ala
              <210>   157
              <211>   462
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 157
              Asn Ser Lys Lys Ala Ala Asp Ser Gly Asp Lys Pro Val Ile Lys Met
              1               5                   10                  15
              Tyr Gln Ile Gly Asp Lys Pro Asp Asn Leu Asp Glu Leu Leu Ala Asn
                          20                  25                  30
              Ala Asn Lys Ile Ile Glu Glu Lys Val Gly Ala Lys Leu Asp Ile Gln
                      35                  40                  45
              Tyr Leu Gly Trp Gly Asp Tyr Gly Lys Lys Met Ser Val Ile Thr Ser
                  50                  55                  60
              Ser Gly Glu Asn Tyr Asp Ile Ala Phe Ala Asp Asn Tyr Ile Val Asn
              65                  70                  75                  80
              Ala Gln Lys Gly Ala Tyr Ala Asp Leu Thr Glu Leu Tyr Lys Lys Glu
                              85                  90                  95
                                                 Page 229

<removed-date>
              Gly Lys Asp Leu Tyr Lys Ala Leu Asp Pro Ala Tyr Ile Lys Gly Asn
                          100                 105                 110
              Thr Val Asn Gly Lys Ile Tyr Ala Val Pro Val Ala Ala Asn Val Ala
                      115                 120                 125
              Ser Ser Gln Asn Phe Ala Phe Asn Gly Thr Leu Leu Ala Lys Tyr Gly
<removed-apn>
                  130                 135                 140
              Ile Asp Ile Ser Gly Val Thr Ser Tyr Glu Thr Leu Glu Pro Val Leu
              145                 150                 155                 160
              Lys Gln Ile Lys Glu Lys Ala Pro Asp Val Val Pro Phe Ala Ile Gly
                              165                 170                 175
              Lys Val Phe Ile Pro Ser Asp Asn Phe Asp Tyr Pro Val Ala Asn Gly
                          180                 185                 190
              Leu Pro Phe Val Ile Asp Leu Glu Gly Asp Thr Thr Lys Val Val Asn
                      195                 200                 205
              Arg Tyr Glu Val Pro Arg Phe Lys Glu His Leu Lys Thr Leu His Lys
                  210                 215                 220
              Phe Tyr Glu Ala Gly Tyr Ile Pro Lys Asp Val Ala Thr Ser Asp Thr
              225                 230                 235                 240
              Ser Phe Asp Leu Gln Gln Asp Thr Trp Phe Val Arg Glu Glu Thr Val
                              245                 250                 255
              Gly Pro Ala Asp Tyr Gly Asn Ser Leu Leu Ser Arg Val Ala Asn Lys
                          260                 265                 270
              Asp Ile Gln Ile Lys Pro Ile Thr Asn Phe Ile Lys Lys Asn Gln Thr
                      275                 280                 285
              Thr Gln Val Ala Asn Phe Val Ile Ser Asn Asn Ser Lys Asn Lys Glu
                  290                 295                 300
                                                 Page 230

<removed-date>
              Lys Ser Met Glu Ile Leu Asn Leu Leu Asn Thr Asn Pro Glu Leu Leu
              305                 310                 315                 320
              Asn Gly Leu Val Tyr Gly Pro Glu Gly Lys Asn Trp Glu Lys Ile Glu
                              325                 330                 335
              Gly Lys Glu Asn Arg Val Arg Val Leu Asp Gly Tyr Lys Gly Asn Thr
                          340                 345                 350
<removed-apn>
              His Met Gly Gly Trp Asn Thr Gly Asn Asn Trp Ile Leu Tyr Ile Asn
                      355                 360                 365
              Glu Asn Val Thr Asp Gln Gln Ile Glu Asn Ser Lys Lys Glu Leu Ala
                  370                 375                 380
              Glu Ala Lys Glu Ser Pro Ala Leu Gly Phe Ile Phe Asn Thr Asp Asn
              385                 390                 395                 400
              Val Lys Ser Glu Ile Ser Ala Ile Ala Asn Thr Met Gln Gln Phe Asp
                              405                 410                 415
              Thr Ala Ile Asn Thr Gly Thr Val Asp Pro Asp Lys Ala Ile Pro Glu
                          420                 425                 430
              Leu Met Glu Lys Leu Lys Ser Glu Gly Ala Tyr Glu Lys Val Leu Asn
                      435                 440                 445
              Glu Met Gln Lys Gln Tyr Asp Glu Phe Leu Lys Asn Lys Lys
                  450                 455                 460
              <210>   158
              <211>   274
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 158
              Asp Gly Ile Lys Ser Leu Leu Ser Met Ser Lys Glu Pro Val Tyr Asp
              1               5                   10                  15
              Ser Arg Thr Glu Lys Leu Thr Phe Gly Lys Glu Val Glu Asn Leu Glu
                          20                  25                  30
                                                 Page 231

<removed-date>
              Ile Thr Leu His Gln His Thr Leu Thr Ile Thr Asp Ser Phe Asp Asp
                      35                  40                  45
              Gln Ile His Ile Ser Tyr His Pro Ser Leu Ser Ala His His Asp Leu
                  50                  55                  60
              Ile Thr Asn Gln Asn Asp Arg Thr Leu Ser Leu Thr Asp Lys Lys Leu
<removed-apn>
              65                  70                  75                  80
              Ser Glu Thr Pro Phe Leu Ser Ser Gly Ile Gly Gly Ile Leu His Ile
                              85                  90                  95
              Ala Ser Ser Tyr Ser Ser Arg Phe Glu Glu Val Ile Leu Arg Leu Pro
                          100                 105                 110
              Lys Gly Arg Thr Leu Lys Gly Ile Asn Ile Ser Ala Asn Arg Gly Gln
                      115                 120                 125
              Thr Thr Ile Ile Asn Ala Ser Leu Glu Asn Ala Thr Leu Asn Thr Asn
                  130                 135                 140
              Ser Tyr Ile Leu Arg Ile Glu Gly Ser Arg Ile Lys Asn Ser Lys Leu
              145                 150                 155                 160
              Thr Thr Pro Asn Ile Val Asn Ile Phe Asp Thr Val Leu Thr Asp Ser
                              165                 170                 175
              Gln Leu Glu Ser Thr Glu Asn His Phe His Ala Glu Asn Ile Gln Val
                          180                 185                 190
              His Gly Lys Val Glu Leu Thr Ala Lys Asp Tyr Leu Arg Ile Ile Leu
                      195                 200                 205
              Asp Gln Lys Glu Ser Gln Arg Ile Asn Trp Asp Ile Ser Ser Asn Tyr
                  210                 215                 220
              Gly Ser Ile Phe Gln Phe Thr Arg Glu Lys Pro Glu Ser Arg Gly Thr
              225                 230                 235                 240
                                                 Page 232

<removed-date>
              Glu Leu Ser Asn Pro Tyr Lys Thr Glu Lys Thr Asp Val Lys Asp Gln
                              245                 250                 255
              Leu Ile Ala Arg Ser Asp Asp Asn Ile Asp Leu Ile Ser Thr Pro Ser
                          260                 265                 270
              Arg Arg
<removed-apn>
              <210>   159
              <211>   195
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 159
              Val Arg Ile Gly Lys Ile Val Ser Ser Ile Phe Asp Asp Thr Pro Thr
              1               5                   10                  15
              Glu Val Glu Phe Gln Leu Phe Asn Ser Phe Ala Lys Thr Tyr Arg Gly
                          20                  25                  30
              His Gly Thr Asp Leu Ala Leu Val Ala Gly Ile Leu Gly Met Asp Thr
                      35                  40                  45
              Asp Asp Pro Glu Ile Pro Asn Ser Leu Glu Ile Ala His Lys Arg Gly
                  50                  55                  60
              Ile Lys Ile Val Trp Thr Ile Gln Lys Asp Ser Asn Ala Pro His Pro
              65                  70                  75                  80
              Asn Thr Thr Lys Ile Thr Val Lys Asn Ala His Lys Thr Ile Ser Val
                              85                  90                  95
              Thr Gly Ile Ser Ile Gly Gly Gly Asn Ile Gln Val Thr Glu Leu Asn
                          100                 105                 110
              Gly Phe Ala Val Ser Leu Asn Met Asn Thr Pro Thr Ile Ile Ile Val
                      115                 120                 125
              His Gln Asp Ile Pro Gly Met Ile Ala Leu Val Thr Glu Ala Leu Ser
                  130                 135                 140
                                                 Page 233

<removed-date>
              Arg Tyr Gly Ile Asn Ile Ala Gln Met Asn Val Thr Arg Glu Lys Ala
              145                 150                 155                 160
              Gly Glu Lys Ala Ile Met Ile Ile Glu Val Asp Ser Arg Asn Cys Asp
                              165                 170                 175
              Glu Ala Ile Glu Glu Ile Arg Lys Ile Pro His Leu His Asn Val Asn
<removed-apn>
                          180                 185                 190
              Phe Phe Lys
                      195
              <210>   160
              <211>   166
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 160
              Gln Glu Ser Ser Thr Tyr Thr Val Lys Glu Gly Asp Thr Leu Ser Glu
              1               5                   10                  15
              Ile Ala Glu Thr His Asn Thr Thr Val Glu Lys Leu Ala Glu Asn Asn
                          20                  25                  30
              His Ile Asp Asn Ile His Leu Ile Tyr Val Asp Gln Glu Leu Val Ile
                      35                  40                  45
              Asp Gly Pro Val Ala Pro Val Ala Thr Pro Ala Pro Ala Thr Tyr Ala
                  50                  55                  60
              Ala Pro Ala Ala Gln Asp Glu Thr Val Ser Ala Pro Val Ala Glu Thr
              65                  70                  75                  80
              Pro Val Val Ser Glu Thr Val Val Ser Thr Val Ser Gly Ser Glu Ala
                              85                  90                  95
              Glu Ala Lys Glu Trp Ile Ala Gln Lys Glu Ser Gly Gly Ser Tyr Thr
                          100                 105                 110
              Ala Thr Asn Gly Arg Tyr Ile Gly Arg Tyr Gln Leu Thr Asp Ser Tyr
                                                 Page 234

                       115                  120               125
<removed-date>
              Leu Asn Gly Asp Tyr Ser Ala Glu Asn Gln Glu Arg Val Ala Asp Ala
                  130                 135                 140
              Tyr Val Ala Gly Arg Tyr Gly Ser Trp Thr Ala Ala Lys Asn Phe Trp
              145                 150                 155                 160
<removed-apn>
              Leu Asn Asn Gly Trp Tyr
                              165
              <210>   161
              <211>   202
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 161
              Glu Thr Thr Ile Asn Ile Lys Lys Asn His Ser Ile Thr Leu Met Pro
              1               5                   10                  15
              Ala Ile Asp Phe Leu Met Ala Ser Leu Asp Trp Thr Pro Lys Asp Leu
                          20                  25                  30
              Asp Arg Ile Val Val Ala Glu Gly Pro Gly Ser Tyr Thr Gly Leu Arg
                      35                  40                  45
              Ile Ala Val Ala Thr Ala Lys Thr Leu Ala His Thr Leu Asn Ile Glu
                  50                  55                  60
              Leu Val Gly Met Ser Ser Leu Leu Ala Leu Val Pro His Gln Gln Glu
              65                  70                  75                  80
              Gly Leu Phe Val Pro Leu Met Asp Ala Arg Arg Asn Asn Val Tyr Ala
                              85                  90                  95
              Gly Phe Tyr Glu Asn Ala Lys Pro Val Met Ala Glu Ala His Leu Ser
                          100                 105                 110
              Phe Glu Glu Val Leu Glu Lys Val Lys Gly Thr Ser Gln Val Thr Phe
                      115                 120                 125
                                                  Page 235

              Val Gly Glu Val Gly Pro Phe Val Glu Gln Ile Gln Lys His Leu Pro
<removed-date>
                  130                 135                 140
              Arg Thr Asp Tyr Lys Glu Thr Leu Pro Asn Ala Ala Asn Leu Ala Leu
              145                 150                 155                 160
              Leu Ala Trp Asp Lys Glu Ala Asp Ser Leu His Asp Phe Val Pro Asn
                              165                 170                 175
<removed-apn>
              Tyr Leu Lys Arg Val Glu Ala Glu Glu Asn Trp Leu Lys Asn His Thr
                          180                 185                 190
              Glu Ser Gly Glu Ser Tyr Ile Lys Arg Leu
                      195                 200
              <210>   162
              <211>   260
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 162
              Asn Ser Glu Lys Lys Ala Asp Asn Ala Thr Thr Ile Lys Ile Ala Thr
              1               5                   10                  15
              Val Asn Arg Ser Gly Ser Glu Glu Lys Arg Trp Asp Lys Ile Gln Glu
                          20                  25                  30
              Leu Val Lys Lys Asp Gly Ile Thr Leu Glu Phe Thr Glu Phe Thr Asp
                      35                  40                  45
              Tyr Ser Gln Pro Asn Lys Ala Thr Ala Asp Gly Glu Val Asp Leu Asn
                  50                  55                  60
              Ala Phe Gln His Tyr Asn Phe Leu Asn Asn Trp Asn Lys Glu Asn Gly
              65                  70                  75                  80
              Lys Asp Leu Val Ala Ile Ala Asp Thr Tyr Ile Ser Pro Ile Arg Leu
                              85                  90                  95
              Tyr Ser Gly Leu Asn Gly Ser Ala Asn Lys Tyr Thr Lys Val Glu Asp
                          100                 105                 110
                                                 Page 236

<removed-date>
              Ile Pro Ala Asn Gly Glu Ile Ala Val Pro Asn Asp Ala Thr Asn Glu
                      115                 120                 125
              Ser Arg Ala Leu Tyr Leu Leu Gln Ser Ala Gly Leu Ile Lys Leu Asp
                  130                 135                 140
              Val Ser Gly Thr Ala Leu Ala Thr Val Ala Asn Ile Lys Glu Asn Pro
              145                 150                 155                 160
<removed-apn>
              Lys Asn Leu Lys Ile Thr Glu Leu Asp Ala Ser Gln Thr Ala Arg Ser
                              165                 170                 175
              Leu Ser Ser Val Asp Ala Ala Val Val Asn Asn Thr Phe Val Thr Glu
                          180                 185                 190
              Ala Lys Leu Asp Tyr Lys Lys Ser Leu Phe Lys Glu Gln Ala Asp Glu
                      195                 200                 205
              Asn Ser Lys Gln Trp Tyr Asn Ile Ile Val Ala Lys Lys Asp Trp Glu
                  210                 215                 220
              Thr Ser Pro Lys Ala Asp Ala Ile Lys Lys Val Ile Ala Ala Tyr His
              225                 230                 235                 240
              Thr Asp Asp Val Lys Lys Val Ile Glu Glu Ser Ser Asp Gly Leu Asp
                              245                 250                 255
              Gln Pro Val Trp
                          260
              <210>   163
              <211>   164
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 163
              Pro Ala Thr Lys Thr Glu Lys Asp Thr Leu Gln Ser Ala Leu Pro Val
              1               5                   10                  15
              Ile Glu Asn Ala Glu Lys Asn Thr Val Val Thr Lys Thr Leu Val Leu
                          20                  25                  30
                                                 Page 237

<removed-date>
              Pro Lys Ser Asp Asp Gly Ser Gln Gln Thr Gln Thr Ile Thr Tyr Lys
                      35                  40                  45
              Asp Lys Thr Phe Leu Ser Leu Ala Ile Gln Gln Lys Arg Pro Val Ser
                  50                  55                  60
              Asp Glu Leu Lys Thr Tyr Ile Asp Gln His Gly Val Glu Glu Thr Gln
<removed-apn>
              65                  70                  75                  80
              Lys Ala Leu Leu Glu Ala Glu Glu Lys Asp Lys Ser Ile Ile Glu Ala
                              85                  90                  95
              Arg Lys Leu Ala Gly Phe Lys Leu Glu Thr Lys Leu Leu Ser Ala Thr
                          100                 105                 110
              Glu Leu Gln Thr Thr Thr Ser Phe Asp Phe Gln Val Leu Asp Val Lys
                      115                 120                 125
              Lys Ala Ser Gln Leu Glu His Leu Lys Asn Ile Gly Leu Glu Asn Leu
                  130                 135                 140
              Leu Lys Asn Glu Pro Ser Lys Tyr Ile Ser Asp Arg Leu Ala Asn Gly
              145                 150                 155                 160
              Ala Thr Glu Gln
              <210>   164
              <211>   108
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 164
              Asn Thr Asn Thr Ala Asn Ala Gly Gly Asn Gln Asn Gln Ala Ala Pro
              1               5                   10                  15
              Val Gln Asn Gln Pro Val Ala Gln Pro Thr Asp Ile Asp Gly Thr Tyr
                          20                  25                  30
              Thr Gly Gln Asp Asp Gly Asp Arg Ile Thr Leu Val Val Thr Gly Thr
                                                 Page 238

                        35                  40                  45
<removed-date>
              Thr Gly Thr Trp Thr Glu Leu Glu Ser Asp Gly Asp Gln Lys Val Lys
                  50                  55                  60
              Gln Val Thr Leu Asp Ser Ala Asn Gln Arg Met Ile Ile Gly Asp Asp
              65                  70                  75                  80
<removed-apn>
              Val Lys Ile Tyr Thr Val Asn Gly Asn Gln Ile Val Val Asp Asp Met
                              85                  90                  95
              Asp Arg Asp Pro Ser Asp Gln Ile Val Leu Thr Lys
                          100                 105
              <210>   165
              <211>   77
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 165
              Gln Ser Ser Gly Val Glu Ala Glu Ile Glu Ala Phe Ser Gln Ser Lys
              1               5                   10                  15
              Leu Ala Asp Tyr Ala Pro Asn Ile Asp Val Ala Leu Leu Gly Pro Gln
                          20                  25                  30
              Val Ala Tyr Thr Leu Asp Lys Ser Lys Glu Ile Cys Asp Lys Cys Asp
                      35                  40                  45
              Val Pro Ile Ala Val Ile Pro Met Met Asp Tyr Gly Met Leu Asp Gly
                  50                  55                  60
              Lys Lys Val Leu Asp Leu Ala Leu Ser Leu Ile Ser Gly
              65                  70                  75
              <210>   166
              <211>   384
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 166
              Gly Leu Thr Asn Arg Leu Asn Ala Thr Ser Asn Tyr Ser Glu Tyr Ser
              1               5                   10                  15
                                                 Page 239

<removed-date>
              Ile Ser Val Ala Val Leu Ala Asp Ser Glu Ile Glu Asn Val Thr Gln
                          20                  25                  30
              Leu Thr Ser Val Thr Ala Pro Thr Gly Thr Asn Asn Glu Asn Ile Gln
                      35                  40                  45
              Lys Leu Leu Ala Asp Ile Lys Ser Ser Gln Asn Thr Asp Leu Thr Val
<removed-apn>
                  50                  55                  60
              Asn Gln Ser Ser Ser Tyr Leu Ala Ala Tyr Lys Ser Leu Ile Ala Gly
              65                  70                  75                  80
              Glu Thr Lys Ala Ile Val Leu Asn Ser Val Phe Glu Asn Ile Ile Glu
                              85                  90                  95
              Ser Glu Tyr Pro Asp Tyr Ala Ser Lys Ile Lys Lys Ile Tyr Thr Lys
                          100                 105                 110
              Gly Phe Thr Lys Lys Val Glu Ala Pro Lys Thr Ser Lys Ser Gln Ser
                      115                 120                 125
              Phe Asn Ile Tyr Val Ser Gly Ile Asp Thr Tyr Gly Pro Ile Ser Ser
                  130                 135                 140
              Val Ser Arg Ser Asp Val Asn Ile Leu Met Thr Val Asn Arg Asp Thr
              145                 150                 155                 160
              Lys Lys Ile Leu Leu Thr Thr Thr Pro Arg Asp Ala Tyr Val Pro Ile
                              165                 170                 175
              Ala Asp Gly Gly Asn Asn Gln Lys Asp Lys Leu Thr His Ala Gly Ile
                          180                 185                 190
              Tyr Gly Val Asp Ser Ser Ile His Thr Leu Glu Asn Leu Tyr Gly Val
                      195                 200                 205
              Asp Ile Asn Tyr Tyr Val Arg Leu Asn Phe Thr Ser Phe Leu Lys Leu
                  210                 215                 220
                                                 Page 240

<removed-date>
              Ile Asp Leu Leu Gly Gly Ile Asp Val Tyr Asn Asp Gln Glu Phe Thr
              225                 230                 235                 240
              Ala His Thr Asn Gly Lys Tyr Tyr Pro Ala Gly Asn Val His Leu Asp
                              245                 250                 255
              Ser Glu Gln Ala Leu Gly Phe Val Arg Glu Arg Tyr Ser Leu Ala Asp
                          260                 265                 270
<removed-apn>
              Gly Asp Arg Asp Arg Gly Arg His Gln Gln Lys Val Ile Val Ala Ile
                      275                 280                 285
              Leu Gln Lys Leu Thr Ser Thr Glu Val Leu Lys Asn Tyr Ser Thr Ile
                  290                 295                 300
              Ile Asn Ser Leu Gln Asp Ser Ile Gln Thr Asn Met Pro Leu Glu Thr
              305                 310                 315                 320
              Met Ile Asn Leu Val Asn Ala Gln Leu Glu Ser Gly Gly Asn Tyr Lys
                              325                 330                 335
              Val Asn Ser Gln Asp Leu Lys Gly Thr Gly Arg Met Asp Leu Pro Ser
                          340                 345                 350
              Tyr Ala Met Pro Asp Ser Asn Leu Tyr Val Met Glu Ile Asp Asp Ser
                      355                 360                 365
              Ser Leu Ala Val Val Lys Ala Ala Ile Gln Asp Val Met Glu Gly Arg
                  370                 375                 380
              <210>   167
              <211>   176
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 167
              Trp Ser Asn Val Arg Val Glu Gly His Ser Met Asp Pro Thr Leu Ala
              1               5                   10                  15
              Asp Gly Glu Ile Leu Phe Val Val Lys His Leu Pro Ile Asp Arg Phe
                          20                  25                  30
                                                 Page 241

<removed-date>
              Asp Ile Val Val Ala His Glu Glu Asp Gly Asn Lys Asp Ile Val Lys
                      35                  40                  45
              Arg Val Ile Gly Met Pro Gly Asp Thr Ile Arg Tyr Glu Asn Asp Lys
                  50                  55                  60
              Leu Tyr Ile Asn Asp Lys Glu Thr Asp Glu Pro Tyr Leu Ala Asp Tyr
<removed-apn>
              65                  70                  75                  80
              Ile Lys Arg Phe Lys Asp Asp Lys Leu Gln Ser Thr Tyr Ser Gly Lys
                              85                  90                  95
              Gly Phe Glu Gly Asn Lys Gly Thr Phe Phe Arg Ser Ile Ala Gln Lys
                          100                 105                 110
              Ala Gln Ala Phe Thr Val Asp Val Asn Tyr Asn Thr Asn Phe Ser Phe
                      115                 120                 125
              Thr Val Pro Glu Gly Glu Tyr Leu Leu Leu Gly Asp Asp Arg Leu Val
                  130                 135                 140
              Ser Ser Asp Ser Arg His Val Gly Thr Phe Lys Ala Lys Asp Ile Thr
              145                 150                 155                 160
              Gly Glu Ala Lys Phe Arg Leu Trp Pro Ile Thr Arg Ile Gly Thr Phe
                              165                 170                 175
              <210>   168
              <211>   274
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 168
              Asp Glu Tyr Leu Arg Ile Gly Met Glu Ala Ala Tyr Ala Pro Phe Asn
              1               5                   10                  15
              Trp Thr Gln Asp Asp Asp Ser Asn Gly Ala Val Lys Ile Asp Gly Thr
                          20                  25                  30
              Asn Gln Tyr Ala Asn Gly Tyr Asp Val Gln Ile Ala Lys Lys Ile Ala
                                                 Page 242

                      35                  40                  45
<removed-date>
              Lys Asp Leu Gly Lys Glu Pro Leu Val Val Lys Thr Lys Trp Glu Gly
                  50                  55                  60
              Leu Val Pro Ala Leu Thr Ser Gly Lys Ile Asp Met Ile Ile Ala Gly
              65                  70                  75                  80
<removed-apn>
              Met Ser Pro Thr Ala Glu Arg Lys Gln Glu Ile Ala Phe Ser Ser Ser
                              85                  90                  95
              Tyr Tyr Thr Ser Glu Pro Val Leu Leu Val Lys Lys Asp Ser Ala Tyr
                          100                 105                 110
              Ala Ser Ala Lys Ser Leu Asp Asp Phe Asn Gly Ala Lys Ile Thr Ser
                      115                 120                 125
              Gln Gln Gly Val Tyr Leu Tyr Asn Leu Ile Ala Gln Ile Pro Gly Ala
                  130                 135                 140
              Lys Lys Glu Thr Ala Met Gly Asp Phe Ala Gln Met Arg Gln Ala Leu
              145                 150                 155                 160
              Glu Ala Gly Val Ile Asp Ala Tyr Val Ser Glu Arg Pro Glu Ala Leu
                              165                 170                 175
              Thr Ala Glu Ala Ala Asn Ser Lys Phe Lys Met Ile Gln Val Glu Pro
                          180                 185                 190
              Gly Phe Lys Thr Gly Glu Glu Asp Thr Ala Ile Ala Ile Gly Leu Arg
                      195                 200                 205
              Lys Asn Asp Asn Arg Ile Ser Gln Ile Asn Ala Ser Ile Glu Thr Ile
                  210                 215                 220
              Ser Lys Asp Asp Gln Val Ala Leu Met Asp Arg Met Ile Lys Glu Gln
              225                 230                 235                 240
              Pro Ala Glu Ala Thr Thr Thr Glu Glu Thr Ser Ser Ser Phe Phe Ser
                              245                 250                 255
                                                 Page 243

<removed-date>
              Gln Val Ala Lys Ile Leu Ser Glu Asn Trp Gln Gln Leu Leu Arg Gly
                          260                 265                 270
              Ala Gly
              <210>   169
<removed-apn>
              <211>   111
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 169
              Phe Ser Ser Thr Val Thr Lys Val Val Asp Glu Thr Lys Lys Val Val
              1               5                   10                  15
              Lys Arg Ala Glu Gln Ser Ala Ser Ala Ala Gly Lys Ala Val Ser Lys
                          20                  25                  30
              Lys Val Glu Gln Ala Val Glu Ala Thr Lys Glu Gln Ala Gln Lys Val
                      35                  40                  45
              Ala Asn Ser Val Glu Asp Phe Ala Ala Asn Leu Gly Gly Leu Pro Leu
                  50                  55                  60
              Asp Arg Ala Lys Thr Phe Tyr Asp Glu Gly Ile Lys Ser Ala Ser Asp
              65                  70                  75                  80
              Phe Lys Asn Trp Thr Glu Lys Glu Leu Leu Ala Leu Lys Gly Ile Gly
                              85                  90                  95
              Pro Ala Thr Ile Lys Lys Leu Lys Glu Asn Gly Ile Lys Phe Lys
                          100                 105                 110
              <210>   170
              <211>   242
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 170
              Asp Lys Thr Leu Ser Ser Ala Ser Asn Lys Thr Lys Thr Leu Lys Leu
              1               5                   10                  15
                                                 Page 244

<removed-date>
              Val Thr Trp Asn Val Ala Asn Gln Ile Glu Ala Gln His Ile Glu Arg
                          20                  25                  30
              Ile Phe Ser His Phe Asp Ala Asp Met Ala Ile Phe Pro Glu Leu Ala
                      35                  40                  45
              Thr Asn Ile Arg Gly Glu Gln Glu Asn Gln Arg Ile Lys Leu Leu Phe
                  50                  55                  60
<removed-apn>
              His Gln Val Gly Leu Ser Met Ala Asn Tyr Asp Ile Phe Thr Ser Pro
              65                  70                  75                  80
              Pro Thr Asn Ser Gly Ile Ala Pro Val Thr Val Ile Val Lys Lys Ser
                              85                  90                  95
              Tyr Gly Phe Tyr Thr Glu Ala Lys Thr Phe His Thr Thr Arg Phe Gly
                          100                 105                 110
              Thr Ile Val Leu His Ser Arg Lys Gln Asn Ile Pro Asp Ile Ile Ala
                      115                 120                 125
              Leu His Thr Ala Pro Pro Leu Pro Gly Leu Met Glu Ile Trp Lys Gln
                  130                 135                 140
              Asp Leu Asn Ile Ile His Asn Gln Leu Ala Ser Lys Tyr Pro Lys Ala
              145                 150                 155                 160
              Ile Ile Ala Gly Asp Phe Asn Ala Thr Met Arg His Gly Ala Leu Ala
                              165                 170                 175
              Lys Ile Ser Ser His Arg Asp Ala Leu Asn Ala Leu Pro Pro Phe Glu
                          180                 185                 190
              Arg Gly Thr Trp Asn Ser Gln Ser Pro Lys Leu Phe Asn Ala Thr Ile
                      195                 200                 205
              Asp His Ile Leu Leu Pro Lys Asn His Tyr Tyr Val Lys Asp Leu Asp
                  210                 215                 220
                                                 Page 245

              Ile Val Ser Phe Gln Asn Ser Asp His Arg Cys Ile Phe Thr Glu Ile
<removed-date>
              225                 230                 235                 240
              Thr Phe
              <210>   171
              <211>   170
              <212>   PRT
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 171
              Ala His Arg Leu Ser His Phe Leu Trp Lys His Gly Phe Lys Leu Leu
              1               5                   10                  15
              Ala Arg Met Tyr Ser Gln Phe Trp Arg Phe Trp Thr Gln Ile Glu Ile
                          20                  25                  30
              His Pro Gly Ala Gln Ile Asp Ser Gly Val Phe Ile Asp His Gly Ser
                      35                  40                  45
              Gly Leu Val Ile Gly Glu Thr Ala Ile Val Glu Lys Gly Val Leu Leu
                  50                  55                  60
              Tyr His Gly Val Thr Leu Gly Gly Thr Gly Lys Asp Cys Gly Lys Arg
              65                  70                  75                  80
              His Pro Thr Val Arg Lys Gly Ala Leu Ile Ser Ala His Ala Gln Val
                              85                  90                  95
              Ile Gly Pro Val Glu Ile Gly Glu Asn Ala Lys Val Gly Ala Ala Ala
                          100                 105                 110
              Val Val Val Ala Asp Val Pro Ser Asp Val Thr Val Val Gly Ile Pro
                      115                 120                 125
              Ala Lys Ile Val Arg Leu His Gly Lys Lys Asp Glu Pro Val Ile His
                  130                 135                 140
              Glu Val Glu Glu Lys Arg Glu Tyr Tyr Val Asn Lys Leu Glu Gln Ala
              145                 150                 155                 160
                                                 Page 246

<removed-date>
              Lys Asp Ala Ser His Arg Ser Ser Gly Leu
                              165                 170
              <210>   172
              <211>   262
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 172
<removed-apn>
              Ile Lys Gly Ala Thr Ala Lys Ala Ser Gln Glu Thr Phe Lys Asn Ile
              1               5                   10                  15
              Thr Asn Ser Phe Ser Met Gln Ile Asn Arg Arg Val Asn Gln Gly Thr
                          20                  25                  30
              Pro Arg Gly Ala Gly Asn Ile Lys Gly Glu Asp Ile Lys Lys Ile Thr
                      35                  40                  45
              Glu Asn Lys Ala Ile Glu Ser Tyr Val Lys Arg Ile Asn Ala Ile Gly
                  50                  55                  60
              Asp Leu Thr Gly Tyr Asp Leu Ile Glu Thr Pro Glu Thr Lys Lys Asn
              65                  70                  75                  80
              Leu Thr Ala Asp Arg Ala Lys Arg Phe Gly Ser Ser Leu Met Ile Thr
                              85                  90                  95
              Gly Val Asn Asp Ser Ser Lys Glu Asp Lys Phe Val Ser Gly Ser Tyr
                          100                 105                 110
              Lys Leu Val Glu Gly Glu His Leu Thr Asn Asp Asp Lys Asp Lys Ile
                      115                 120                 125
              Leu Leu His Lys Asp Leu Ala Ala Lys His Gly Trp Lys Val Gly Asp
                  130                 135                 140
              Lys Val Lys Leu Asp Ser Asn Ile Tyr Asp Ala Asp Asn Glu Lys Gly
              145                 150                 155                 160
              Ala Lys Glu Thr Val Glu Val Thr Ile Lys Gly Leu Phe Asp Gly His
                              165                 170                 175
                                                 Page 247

<removed-date>
              Asn Lys Ser Ala Val Thr Tyr Ser Gln Glu Leu Tyr Glu Asn Thr Ala
                          180                 185                 190
              Ile Thr Asp Ile His Thr Ala Ala Lys Leu Tyr Gly Tyr Thr Glu Asp
                      195                 200                 205
              Thr Ala Ile Tyr Gly Asp Ala Thr Phe Phe Val Thr Ala Asp Lys Asn
<removed-apn>
                  210                 215                 220
              Leu Asp Asp Val Met Lys Glu Leu Asn Gly Ile Ser Gly Ile Asn Trp
              225                 230                 235                 240
              Lys Ser Tyr Thr Leu Val Lys Ser Ser Ser Asn Tyr Pro Ala Leu Glu
                              245                 250                 255
              Gln Ser Ile Ser Gly Met
                          260
              <210>   173
              <211>   220
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 173
              Glu Ala Ile Leu Gln Leu Glu Lys Met Lys Val Glu Phe Leu Arg Gly
              1               5                   10                  15
              Ala Ser His Glu Leu Lys Thr Pro Leu Ala Ser Leu Lys Ile Leu Ile
                          20                  25                  30
              Glu Asn Met Arg Glu Asn Ile Gly Arg Tyr Lys Asp Arg Asp Gln Tyr
                      35                  40                  45
              Leu Gly Val Ala Leu Gly Ile Val Asp Glu Leu Asn His His Val Leu
                  50                  55                  60
              Gln Ile Leu Ser Leu Ser Ser Val Gln Glu Leu Arg Asp Asp Arg Glu
              65                  70                  75                  80
              Thr Ile Asp Leu Leu Gln Met Thr Gln Asn Leu Val Lys Asp Tyr Ala
                                                 Page 248

                                85                90                  95
<removed-date>
              Leu Leu Ala Lys Glu Arg Glu Leu Gln Ile Asp Asn Ser Leu Thr His
                          100                 105                 110
              Gln Gln Ala Tyr Leu Asn Pro Ser Val Met Lys Leu Ile Leu Ser Asn
                      115                 120                 125
<removed-apn>
              Leu Ile Ser Asn Ala Ile Lys His Ser Val Pro Gly Gly Leu Val Arg
                  130                 135                 140
              Ile Gly Glu Arg Glu Gly Glu Leu Phe Ile Glu Asn Ser Cys Ser Ser
              145                 150                 155                 160
              Glu Glu Gln Glu Lys Leu Ala Gln Ser Phe Ser Asp Asn Ala Ser Arg
                              165                 170                 175
              Lys Val Lys Gly Ser Gly Met Gly Leu Phe Val Val Lys Ser Leu Leu
                          180                 185                 190
              Glu His Glu Lys Leu Ala Tyr Arg Phe Glu Met Glu Glu Asn Ser Leu
                      195                 200                 205
              Thr Phe Phe Ile Asp Phe Pro Lys Val Val Gln Asp
                  210                 215                 220
              <210>   174
              <211>   193
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 174
              Asn Gly Asp Phe Gln Gly Ala Leu Lys Gln Ala Glu Arg Ser Val Lys
              1               5                   10                  15
              Ile Gly Gln Gln Ser Ile Asp Gln Trp Glu Lys Thr Gly Gln Leu Pro
                          20                  25                  30
              Lys Leu Ser Gln Thr Asp Ser His Gln His Ser Glu Gly Arg Trp Ala
                      35                  40                  45
                                                 Page 249

              Gln Ala Ser Ala Arg Ile Tyr Leu Asp Pro Gln Met Asp Ser Arg Phe
<removed-date>
                  50                  55                  60
              Gln Glu Ala Tyr Leu Glu Ala Ile Gln Asn Trp Asn Gln Thr Gly Ala
              65                  70                  75                  80
              Phe Asn Phe Glu Leu Val Thr Glu Ser Ser Lys Ala Asp Ile Thr Ala
                              85                  90                  95
<removed-apn>
              Thr Glu Met Asn Asp Gly Gly Thr Pro Val Ala Gly Glu Ala Glu Ser
                          100                 105                 110
              Gln Thr Asn Leu Leu Thr Gly Gln Phe Leu Ser Val Thr Val Arg Leu
                      115                 120                 125
              Asn His Tyr Tyr Leu Ser Asn Pro Tyr Tyr Gly Tyr Ser Tyr Glu Arg
                  130                 135                 140
              Leu Val His Thr Ala Glu His Glu Leu Gly His Ala Ile Gly Leu Asp
              145                 150                 155                 160
              His Thr Asp Glu Lys Ser Val Met Gln Pro Ala Gly Ser Phe Tyr Gly
                              165                 170                 175
              Ile Gln Glu Glu Asp Val Ala Asn Leu Arg Lys Ile Tyr Glu Thr Ser
                          180                 185                 190
              Glu
              <210>   175
              <211>   240
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 175
              Ser Ala Gln Lys Thr Ile Val Leu Ala Thr Ala Gly Asp Val Pro Pro
              1               5                   10                  15
              Phe Asp Tyr Glu Asp Lys Gly Asn Leu Thr Gly Phe Asp Ile Glu Val
                          20                  25                  30
                                                 Page 250

<removed-date>
              Leu Lys Ala Val Asp Glu Lys Leu Ser Asp Tyr Glu Ile Gln Phe Gln
                      35                  40                  45
              Arg Thr Ala Trp Glu Ser Ile Phe Pro Gly Leu Asp Ser Gly His Tyr
                  50                  55                  60
              Gln Ala Ala Ala Asn Asn Leu Ser Tyr Thr Lys Glu Arg Ala Glu Lys
              65                  70                  75                  80
<removed-apn>
              Tyr Leu Tyr Ser Leu Pro Ile Ser Asn Asn Pro Leu Val Leu Val Ser
                              85                  90                  95
              Asn Lys Lys Asn Pro Leu Thr Ser Leu Asp Gln Ile Ala Gly Lys Thr
                          100                 105                 110
              Thr Gln Glu Asp Thr Gly Thr Ser Asn Ala Gln Phe Ile Asn Asn Trp
                      115                 120                 125
              Asn Gln Lys His Thr Asp Asn Pro Ala Thr Ile Asn Phe Ser Gly Glu
                  130                 135                 140
              Asp Ile Gly Lys Arg Ile Leu Asp Leu Ala Asn Gly Glu Phe Asp Phe
              145                 150                 155                 160
              Leu Val Phe Asp Lys Val Ser Val Gln Lys Ile Ile Lys Asp Arg Gly
                              165                 170                 175
              Leu Asp Leu Ser Val Val Asp Leu Pro Ser Ala Asp Ser Pro Ser Asn
                          180                 185                 190
              Tyr Ile Ile Phe Ser Ser Asp Gln Lys Glu Phe Lys Glu Gln Phe Asp
                      195                 200                 205
              Lys Ala Leu Lys Glu Leu Tyr Gln Asp Gly Thr Leu Glu Lys Leu Ser
                  210                 215                 220
              Asn Thr Tyr Leu Gly Gly Ser Tyr Leu Pro Asp Gln Ser Gln Leu Gln
              225                 230                 235                 240
                                                 Page 251

              <210>   176
<removed-date>
              <211>   218
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 176
              Gln Glu Lys Thr Lys Asn Glu Asp Gly Glu Thr Lys Thr Glu Gln Thr
              1               5                   10                  15
              Ala Lys Ala Asp Gly Thr Val Gly Ser Lys Ser Gln Gly Ala Ala Gln
<removed-apn>
                          20                  25                  30
              Lys Lys Ala Glu Val Val Asn Lys Gly Asp Tyr Tyr Ser Ile Gln Gly
                      35                  40                  45
              Lys Tyr Asp Glu Ile Ile Val Ala Asn Lys His Tyr Pro Leu Ser Lys
                  50                  55                  60
              Asp Tyr Asn Pro Gly Glu Asn Pro Thr Ala Lys Ala Glu Leu Val Lys
              65                  70                  75                  80
              Leu Ile Lys Ala Met Gln Glu Ala Gly Phe Pro Ile Ser Asp His Tyr
                              85                  90                  95
              Ser Gly Phe Arg Ser Tyr Glu Thr Gln Thr Lys Leu Tyr Gln Asp Tyr
                          100                 105                 110
              Val Asn Gln Asp Gly Lys Ala Ala Ala Asp Arg Tyr Ser Ala Arg Pro
                      115                 120                 125
              Gly Tyr Ser Glu His Gln Thr Gly Leu Ala Phe Asp Val Ile Gly Thr
                  130                 135                 140
              Asp Gly Asp Leu Val Thr Glu Glu Lys Ala Ala Gln Trp Leu Leu Asp
              145                 150                 155                 160
              His Ala Ala Asp Tyr Gly Phe Val Val Arg Tyr Leu Lys Gly Lys Glu
                              165                 170                 175
              Lys Glu Thr Gly Tyr Met Ala Glu Glu Trp His Leu Arg Tyr Val Gly
                          180                 185                 190
                                                 Page 252

<removed-date>
              Lys Glu Ala Lys Glu Ile Ala Ala Ser Gly Leu Ser Leu Glu Glu Tyr
                      195                 200                 205
              Tyr Gly Phe Glu Gly Gly Asp Tyr Val Asp
                  210                 215
              <210>   177
              <211>   817
<removed-apn>
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 177
              Glu Ser Val Val Tyr Ala Asp Glu Thr Leu Ile Thr His Thr Ala Glu
              1               5                   10                  15
              Lys Pro Lys Glu Glu Lys Met Ile Val Glu Glu Lys Ala Asp Lys Ala
                          20                  25                  30
              Leu Glu Thr Lys Asn Ile Val Glu Arg Thr Glu Gln Ser Glu Pro Ser
                      35                  40                  45
              Ser Thr Glu Ala Ile Ala Ser Glu Lys Lys Glu Asp Glu Ala Val Thr
                  50                  55                  60
              Pro Lys Glu Glu Lys Val Ser Ala Lys Pro Glu Glu Lys Ala Pro Arg
              65                  70                  75                  80
              Ile Glu Ser Gln Ala Ser Asn Gln Glu Lys Pro Leu Lys Glu Asp Ala
                              85                  90                  95
              Lys Ala Val Thr Asn Glu Glu Val Asn Gln Met Ile Glu Asp Arg Lys
                          100                 105                 110
              Val Asp Phe Asn Gln Asn Trp Tyr Phe Lys Leu Asn Ala Asn Ser Lys
                      115                 120                 125
              Glu Ala Ile Lys Pro Asp Ala Asp Val Ser Thr Trp Lys Lys Leu Asp
                  130                 135                 140
              Leu Pro Tyr Asp Trp Ser Ile Phe Asn Asp Phe Asp His Glu Ser Pro
              145                 150                 155                 160
                                                 Page 253

<removed-date>
              Ala Gln Asn Glu Gly Gly Gln Leu Asn Gly Gly Glu Ala Trp Tyr Arg
                              165                 170                 175
              Lys Thr Phe Lys Leu Asp Glu Lys Asp Leu Lys Lys Asn Val Arg Leu
                          180                 185                 190
              Thr Phe Asp Gly Val Tyr Met Asp Ser Gln Val Tyr Val Asn Gly Gln
<removed-apn>
                      195                 200                 205
              Leu Val Gly His Tyr Pro Asn Gly Tyr Asn Gln Phe Ser Tyr Asp Ile
                  210                 215                 220
              Thr Lys Tyr Leu Gln Lys Asp Gly Arg Glu Asn Val Ile Ala Val His
              225                 230                 235                 240
              Ala Val Asn Lys Gln Pro Ser Ser Arg Trp Tyr Ser Gly Ser Gly Ile
                              245                 250                 255
              Tyr Arg Asp Val Thr Leu Gln Val Thr Asp Lys Val His Val Glu Lys
                          260                 265                 270
              Asn Gly Thr Thr Ile Leu Thr Pro Lys Leu Glu Glu Gln Gln His Gly
                      275                 280                 285
              Lys Val Glu Thr His Val Thr Ser Lys Ile Val Asn Thr Asp Asp Lys
                  290                 295                 300
              Asp His Glu Leu Val Ala Glu Tyr Gln Ile Val Glu Arg Gly Gly His
              305                 310                 315                 320
              Ala Val Thr Gly Leu Val Arg Thr Ala Ser Arg Thr Leu Lys Ala His
                              325                 330                 335
              Glu Ser Thr Ser Leu Asp Ala Ile Leu Glu Val Glu Arg Pro Lys Leu
                          340                 345                 350
              Trp Thr Val Leu Asn Asp Lys Pro Ala Leu Tyr Glu Leu Ile Thr Arg
                      355                 360                 365
                                                 Page 254

<removed-date>
              Val Tyr Arg Asp Gly Gln Leu Val Asp Ala Lys Lys Asp Leu Phe Gly
                  370                 375                 380
              Tyr Arg Tyr Tyr His Trp Thr Pro Asn Glu Gly Phe Ser Leu Asn Gly
              385                 390                 395                 400
              Glu Arg Ile Lys Phe His Gly Val Ser Leu His His Asp His Gly Ala
                              405                 410                 415
<removed-apn>
              Leu Gly Ala Glu Glu Asn Tyr Lys Ala Glu Tyr Arg Arg Leu Lys Gln
                          420                 425                 430
              Met Lys Glu Met Gly Val Asn Ser Ile Arg Thr Thr His Asn Pro Ala
                      435                 440                 445
              Ser Glu Gln Thr Leu Gln Ile Ala Ala Glu Leu Gly Leu Leu Val Gln
                  450                 455                 460
              Glu Glu Ala Phe Asp Thr Trp Tyr Gly Gly Lys Lys Pro Tyr Asp Tyr
              465                 470                 475                 480
              Gly Arg Phe Phe Glu Lys Asp Ala Thr His Pro Glu Ala Arg Lys Gly
                              485                 490                 495
              Glu Lys Trp Ser Asp Phe Asp Leu Arg Thr Met Val Glu Arg Gly Lys
                          500                 505                 510
              Asn Asn Pro Ala Ile Phe Met Trp Ser Ile Gly Asn Glu Ile Gly Glu
                      515                 520                 525
              Ala Asn Gly Asp Ala His Ser Leu Ala Thr Val Lys Arg Leu Val Lys
                  530                 535                 540
              Val Ile Lys Asp Val Asp Lys Thr Arg Tyr Val Thr Met Gly Ala Asp
              545                 550                 555                 560
              Lys Phe Arg Phe Gly Asn Gly Ser Gly Gly His Glu Lys Ile Ala Asp
                              565                 570                 575
                                                 Page 255

              Glu Leu Asp Ala Val Gly Phe Asn Tyr Ser Glu Asp Asn Tyr Lys Ala
<removed-date>
                          580                 585                 590
              Leu Arg Ala Lys His Pro Lys Trp Leu Ile Tyr Gly Ser Glu Thr Ser
                      595                 600                 605
              Ser Ala Thr Arg Thr Arg Gly Ser Tyr Tyr Arg Pro Glu Arg Glu Leu
                  610                 615                 620
<removed-apn>
              Lys His Ser Asn Gly Pro Glu Arg Asn Tyr Glu Gln Ser Asp Tyr Gly
              625                 630                 635                 640
              Asn Asp Arg Val Gly Trp Gly Lys Thr Ala Thr Ala Ser Trp Thr Phe
                              645                 650                 655
              Asp Arg Asp Asn Ala Gly Tyr Ala Gly Gln Phe Ile Trp Thr Gly Thr
                          660                 665                 670
              Asp Tyr Ile Gly Glu Pro Thr Pro Trp His Asn Gln Asn Gln Thr Pro
                      675                 680                 685
              Val Lys Ser Ser Tyr Phe Gly Ile Val Asp Thr Ala Gly Ile Pro Lys
                  690                 695                 700
              His Asp Phe Tyr Leu Tyr Gln Ser Gln Trp Val Ser Val Lys Lys Lys
              705                 710                 715                 720
              Pro Met Val His Leu Leu Pro His Trp Asn Trp Glu Asn Lys Glu Leu
                              725                 730                 735
              Ala Ser Lys Val Ala Asp Ser Glu Gly Lys Ile Pro Val Arg Ala Tyr
                          740                 745                 750
              Ser Asn Ala Ser Ser Val Glu Leu Phe Leu Asn Gly Lys Ser Leu Gly
                      755                 760                 765
              Leu Lys Thr Phe Asn Lys Lys Gln Thr Ser Asp Gly Arg Thr Tyr Gln
                  770                 775                 780
              Glu Gly Ala Asn Ala Asn Glu Leu Tyr Leu Glu Trp Lys Val Ala Tyr
                                                 Page 256

              785                   790               795                 800
<removed-date>
              Gln Pro Gly Thr Leu Glu Ala Ile Ala Arg Asp Glu Ser Gly Lys Glu
                              805                 810                 815
              Ile
<removed-apn>
              <210>   178
              <211>   900
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 178
              Ala Arg Asp Lys Ile Thr Thr Ala Gly Lys Pro Ala Ala Val Arg Leu
              1               5                   10                  15
              Ile Lys Glu Asp His Ala Ile Ala Ala Asp Gly Lys Asp Leu Thr Tyr
                          20                  25                  30
              Ile Tyr Tyr Glu Ile Val Asp Ser Gln Gly Asn Val Val Pro Thr Ala
                      35                  40                  45
              Asn Asn Leu Val Arg Phe Gln Leu His Gly Gln Gly Gln Leu Val Gly
                  50                  55                  60
              Val Asp Asn Gly Glu Gln Ala Ser Arg Glu Arg Tyr Lys Ala Gln Ala
              65                  70                  75                  80
              Asp Gly Ser Trp Ile Arg Lys Ala Phe Asn Gly Lys Gly Val Ala Ile
                              85                  90                  95
              Val Lys Ser Thr Glu Gln Ala Gly Lys Phe Thr Leu Thr Ala His Ser
                          100                 105                 110
              Asp Leu Leu Lys Ser Asn Gln Val Thr Val Phe Thr Gly Lys Lys Glu
                      115                 120                 125
              Gly Gln Glu Lys Thr Val Leu Gly Thr Glu Val Pro Lys Val Gln Thr
                  130                 135                 140
                                                 Page 257

              Ile Ile Gly Glu Ala Pro Glu Met Pro Thr Thr Val Pro Phe Val Tyr
<removed-date>
              145                 150                 155                 160
              Ser Asp Gly Ser Arg Ala Glu Arg Pro Val Thr Trp Ser Ser Val Asp
                              165                 170                 175
              Val Ser Lys Pro Gly Ile Val Thr Val Lys Gly Met Ala Asp Gly Arg
                          180                 185                 190
<removed-apn>
              Glu Val Glu Ala Arg Val Glu Val Ile Ala Leu Lys Ser Glu Leu Pro
                      195                 200                 205
              Val Val Lys Arg Ile Ala Pro Asn Thr Asp Leu Asn Ser Val Asp Lys
                  210                 215                 220
              Ser Val Ser Tyr Val Leu Ile Asp Gly Ser Val Glu Glu Tyr Glu Val
              225                 230                 235                 240
              Asp Lys Trp Glu Ile Ala Glu Glu Asp Lys Ala Lys Leu Ala Ile Pro
                              245                 250                 255
              Gly Ser Arg Ile Gln Ala Thr Gly Tyr Leu Glu Gly Gln Pro Ile His
                          260                 265                 270
              Ala Thr Leu Val Val Glu Glu Gly Asn Pro Ala Ala Pro Ala Val Pro
                      275                 280                 285
              Thr Val Thr Val Gly Gly Glu Ala Val Thr Gly Leu Thr Ser Gln Lys
                  290                 295                 300
              Pro Met Gln Tyr Arg Thr Leu Ala Tyr Gly Ala Lys Leu Pro Glu Val
              305                 310                 315                 320
              Thr Ala Ser Ala Lys Asn Ala Ala Val Thr Val Leu Gln Ala Ser Ala
                              325                 330                 335
              Ala Asn Gly Met Arg Ala Ser Ile Phe Ile Gln Pro Lys Asp Gly Gly
                          340                 345                 350
              Pro Leu Gln Thr Tyr Ala Ile Gln Phe Leu Glu Glu Ala Pro Lys Ile
                                                 Page 258

                      355                 360                 365
<removed-date>
              Ala His Leu Ser Leu Gln Val Glu Lys Ala Asp Ser Leu Lys Glu Asp
                  370                 375                 380
              Gln Thr Val Lys Leu Ser Val Arg Ala His Tyr Gln Asp Gly Thr Gln
              385                 390                 395                 400
<removed-apn>
              Ala Val Leu Pro Ala Asp Lys Val Thr Phe Ser Thr Ser Gly Glu Gly
                              405                 410                 415
              Glu Val Ala Ile Arg Lys Gly Met Leu Glu Leu His Lys Pro Gly Ala
                          420                 425                 430
              Val Thr Leu Asn Ala Glu Tyr Glu Gly Ala Lys Asp Gln Val Glu Leu
                      435                 440                 445
              Thr Ile Gln Ala Asn Thr Glu Lys Lys Ile Ala Gln Ser Ile Arg Pro
                  450                 455                 460
              Val Asn Val Val Thr Asp Leu His Gln Glu Pro Ser Leu Pro Ala Thr
              465                 470                 475                 480
              Val Thr Val Glu Tyr Asp Lys Gly Phe Pro Lys Thr His Lys Val Thr
                              485                 490                 495
              Trp Gln Ala Ile Pro Lys Glu Lys Leu Asp Ser Tyr Gln Thr Phe Glu
                          500                 505                 510
              Val Leu Gly Lys Val Glu Gly Ile Asp Leu Glu Ala Arg Ala Lys Val
                      515                 520                 525
              Ser Val Glu Gly Ile Val Ser Val Glu Glu Val Ser Val Thr Thr Pro
                  530                 535                 540
              Ile Ala Glu Ala Pro Gln Leu Pro Glu Ser Val Arg Thr Tyr Asp Ser
              545                 550                 555                 560
              Asn Gly His Val Ser Ser Ala Lys Val Ala Trp Asp Ala Ile Arg Pro
                              565                 570                 575
                                                 Page 259

<removed-date>
              Glu Gln Tyr Ala Lys Glu Gly Val Phe Thr Val Asn Gly Arg Leu Glu
                          580                 585                 590
              Gly Thr Gln Leu Thr Thr Lys Leu His Val Arg Val Ser Ala Gln Thr
                      595                 600                 605
              Glu Gln Gly Ala Asn Ile Ser Asp Gln Trp Thr Gly Ser Glu Leu Pro
<removed-apn>
                  610                 615                 620
              Leu Ala Phe Ala Ser Asp Ser Asn Pro Ser Asp Pro Val Ser Asn Val
              625                 630                 635                 640
              Asn Asp Lys Leu Ile Ser Tyr Asn Asn Gln Pro Ala Asn Arg Trp Thr
                              645                 650                 655
              Asn Trp Asn Arg Thr Asn Pro Glu Ala Ser Val Gly Val Leu Phe Gly
                          660                 665                 670
              Asp Ser Gly Ile Leu Ser Lys Arg Ser Val Asp Asn Leu Ser Val Gly
                      675                 680                 685
              Phe His Glu Asp His Gly Val Gly Val Pro Lys Ser Tyr Val Ile Glu
                  690                 695                 700
              Tyr Tyr Val Gly Lys Thr Val Pro Thr Ala Pro Lys Asn Pro Ser Phe
              705                 710                 715                 720
              Val Gly Asn Glu Asp His Val Phe Asn Asp Ser Ala Asn Trp Lys Pro
                              725                 730                 735
              Val Thr Asn Leu Lys Ala Pro Ala Gln Leu Lys Ala Gly Glu Met Asn
                          740                 745                 750
              His Phe Ser Phe Asp Lys Val Glu Thr Tyr Ala Val Arg Ile Arg Met
                      755                 760                 765
              Val Lys Ala Asp Asn Lys Arg Gly Thr Ser Ile Thr Glu Val Gln Ile
                  770                 775                 780
                                                 Page 260

<removed-date>
              Phe Ala Lys Gln Val Ala Ala Ala Lys Gln Gly Gln Thr Arg Ile Gln
              785                 790                 795                 800
              Val Asp Gly Lys Asp Leu Ala Asn Phe Asn Pro Asp Leu Thr Asp Tyr
                              805                 810                 815
              Tyr Leu Glu Ser Val Asp Gly Lys Val Pro Ala Val Thr Ala Ser Val
                          820                 825                 830
<removed-apn>
              Ser Asn Asn Gly Leu Ala Thr Val Val Pro Ser Val Arg Glu Gly Glu
                      835                 840                 845
              Pro Val Arg Val Ile Ala Lys Ala Glu Asn Gly Asp Ile Leu Gly Glu
                  850                 855                 860
              Tyr Arg Leu His Phe Thr Lys Asp Lys Ser Leu Leu Ser His Lys Pro
              865                 870                 875                 880
              Val Ala Ala Val Lys Gln Ala Arg Leu Leu Gln Val Gly Gln Ala Leu
                              885                 890                 895
              Glu Leu Pro Thr
                          900
              <210>   179
              <211>   477
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 179
              Lys Val Pro Val Tyr Phe Thr Gly Lys Asp Gly Tyr Glu Thr Lys Asp
              1               5                   10                  15
              Leu Thr Val Glu Trp Glu Glu Val Pro Ala Glu Asn Leu Thr Lys Ala
                          20                  25                  30
              Gly Gln Phe Thr Val Arg Gly Arg Val Leu Gly Ser Asn Leu Val Ala
                      35                  40                  45
              Glu Ile Thr Val Arg Val Thr Asp Lys Leu Gly Glu Thr Leu Ser Asp
                  50                  55                  60
                                                 Page 261

<removed-date>
              Asn Pro Asn Tyr Asp Glu Asn Ser Asn Gln Ala Phe Ala Ser Ala Thr
              65                  70                  75                  80
              Asn Asp Ile Asp Lys Asn Ser His Asp Arg Val Asp Tyr Leu Asn Asp
                              85                  90                  95
              Gly Asp His Ser Glu Asn Arg Arg Trp Thr Asn Trp Ser Pro Thr Pro
<removed-apn>
                          100                 105                 110
              Ser Ser Asn Pro Glu Val Ser Ala Gly Val Ile Phe Arg Glu Asn Gly
                      115                 120                 125
              Lys Ile Val Glu Arg Thr Val Thr Gln Gly Lys Val Gln Phe Phe Ala
                  130                 135                 140
              Asp Ser Gly Thr Asp Ala Pro Ser Lys Leu Val Leu Glu Arg Tyr Val
              145                 150                 155                 160
              Gly Pro Glu Phe Glu Val Pro Thr Tyr Tyr Ser Asn Tyr Gln Ala Tyr
                              165                 170                 175
              Asp Ala Asp His Pro Phe Asn Asn Pro Glu Asn Trp Glu Ala Val Pro
                          180                 185                 190
              Tyr Arg Ala Asp Lys Asp Ile Ala Ala Gly Asp Glu Ile Asn Val Thr
                      195                 200                 205
              Phe Lys Ala Ile Lys Ala Lys Ala Met Arg Trp Arg Met Glu Arg Lys
                  210                 215                 220
              Ala Asp Lys Ser Gly Val Ala Met Ile Glu Met Thr Phe Leu Ala Pro
              225                 230                 235                 240
              Ser Glu Leu Pro Gln Glu Ser Thr Gln Ser Lys Ile Leu Val Asp Gly
                              245                 250                 255
              Lys Glu Leu Ala Asp Phe Ala Glu Asn Arg Gln Asp Tyr Gln Ile Thr
                          260                 265                 270
                                                 Page 262

<removed-date>
              Tyr Lys Gly Gln Arg Pro Lys Val Ser Val Glu Glu Asn Asn Gln Val
                      275                 280                 285
              Ala Ser Thr Val Val Asp Ser Gly Glu Asp Ser Phe Pro Val Leu Val
                  290                 295                 300
              Arg Leu Val Ser Glu Ser Gly Lys Gln Val Lys Glu Tyr Arg Ile His
              305                 310                 315                 320
<removed-apn>
              Leu Thr Lys Glu Lys Pro Val Ser Glu Lys Thr Val Ala Ala Val Gln
                              325                 330                 335
              Glu Asp Leu Pro Lys Ile Glu Phe Val Glu Lys Asp Leu Ala Tyr Lys
                          340                 345                 350
              Thr Val Glu Lys Lys Asp Ser Thr Leu Tyr Leu Gly Glu Thr Arg Val
                      355                 360                 365
              Glu Gln Glu Gly Lys Val Gly Lys Glu Arg Ile Phe Thr Ala Ile Asn
                  370                 375                 380
              Pro Asp Gly Ser Lys Glu Glu Lys Leu Arg Glu Val Val Glu Val Pro
              385                 390                 395                 400
              Thr Asp Arg Ile Val Leu Val Gly Thr Lys Pro Val Ala Gln Glu Ala
                              405                 410                 415
              Lys Lys Pro Gln Val Ser Glu Lys Ala Asp Thr Lys Pro Ile Asp Ser
                          420                 425                 430
              Ser Glu Ala Ser Gln Thr Asn Lys Ala Gln Leu Pro Ser Thr Gly Ser
                      435                 440                 445
              Ala Ala Ser Gln Ala Ala Val Ala Ala Gly Leu Thr Leu Leu Gly Leu
                  450                 455                 460
              Ser Ala Gly Leu Val Val Thr Lys Gly Lys Lys Glu Asp
              465                 470                 475
                                                 Page 263

              <210>   180
<removed-date>
              <211>   161
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 180
              Glu His Gln Thr Lys Asp Glu Met Lys Thr Glu Gln Thr Ala Ser Lys
              1               5                   10                  15
              Thr Ser Ala Ala Lys Gly Lys Glu Val Ala Asp Phe Glu Leu Met Gly
<removed-apn>
                          20                  25                  30
              Val Asp Gly Lys Thr Tyr Arg Leu Ser Asp Tyr Lys Gly Lys Lys Val
                      35                  40                  45
              Tyr Leu Lys Phe Trp Ala Ser Trp Cys Ser Ile Cys Leu Ala Ser Leu
                  50                  55                  60
              Pro Asp Thr Asp Glu Ile Ala Lys Glu Ala Gly Asp Asp Tyr Val Val
              65                  70                  75                  80
              Leu Thr Val Val Ser Pro Gly His Lys Gly Glu Gln Ser Glu Ala Asp
                              85                  90                  95
              Phe Lys Asn Trp Tyr Lys Gly Leu Asp Tyr Lys Asn Leu Pro Val Leu
                          100                 105                 110
              Val Asp Pro Ser Gly Lys Leu Leu Glu Thr Tyr Gly Val Arg Ser Tyr
                      115                 120                 125
              Pro Thr Gln Ala Phe Ile Asp Lys Glu Gly Lys Leu Val Lys Thr His
                  130                 135                 140
              Pro Gly Phe Met Glu Lys Asp Ala Ile Leu Gln Thr Leu Lys Glu Leu
              145                 150                 155                 160
              Ala
              <210> 181
              <211> 248
              <212> PRT
                                                 Page 264

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 181
              Tyr Tyr Gln Ser Ser Ser Ser Ala Ile Glu Ala Thr Ile Glu Gly Asn
              1               5                   10                  15
              Ser Gln Thr Thr Ile Ser Gln Thr Ser His Phe Ile Gln Ser Tyr Ile
                          20                  25                  30
<removed-apn>
              Lys Lys Leu Glu Thr Thr Ser Thr Gly Leu Thr Gln Gln Thr Asp Val
                      35                  40                  45
              Leu Ala Tyr Ala Glu Asn Pro Ser Gln Asp Lys Val Glu Gly Ile Arg
                  50                  55                  60
              Asp Leu Phe Leu Thr Ile Leu Lys Ser Asp Lys Asp Leu Lys Thr Val
              65                  70                  75                  80
              Val Leu Val Thr Lys Ser Gly Gln Val Ile Ser Thr Asp Asp Ser Val
                              85                  90                  95
              Gln Met Lys Thr Ser Ser Asp Met Met Ala Glu Asp Trp Tyr Gln Lys
                          100                 105                 110
              Ala Ile His Gln Gly Ala Met Pro Val Leu Thr Pro Ala Arg Lys Ser
                      115                 120                 125
              Asp Ser Gln Trp Val Ile Ser Val Thr Gln Glu Leu Val Asp Ala Lys
                  130                 135                 140
              Gly Ala Asn Leu Gly Val Leu Arg Leu Asp Ile Ser Tyr Glu Thr Leu
              145                 150                 155                 160
              Glu Ala Tyr Leu Asn Gln Leu Gln Leu Gly Gln Gln Gly Phe Ala Phe
                              165                 170                 175
              Ile Ile Asn Glu Asn His Glu Phe Val Tyr His Pro Gln His Thr Val
                          180                 185                 190
              Tyr Ser Ser Ser Ser Lys Met Glu Ala Met Lys Pro Tyr Ile Asp Thr
                      195                 200                 205
                                                 Page 265

<removed-date>
              Gly Gln Gly Tyr Thr Pro Gly His Lys Ser Tyr Val Ser Gln Glu Lys
                  210                 215                 220
              Ile Ala Gly Thr Asp Trp Thr Val Leu Gly Val Ser Ser Leu Glu Lys
              225                 230                 235                 240
              Leu Asp Gln Val Arg Ser Gln Leu
<removed-apn>
                              245
              <210>   182
              <211>   264
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 182
              Lys Arg Trp Ile Ala Pro Leu Lys Asp Leu Arg Glu Thr Met Leu Glu
              1               5                   10                  15
              Ile Ala Ser Gly Ala Gln Asn Leu Arg Ala Lys Glu Val Gly Ala Tyr
                          20                  25                  30
              Glu Leu Arg Glu Val Thr Arg Gln Phe Asn Ala Met Leu Asp Gln Ile
                      35                  40                  45
              Asp Gln Leu Met Val Ala Ile Arg Ser Gln Glu Glu Thr Thr Arg Gln
                  50                  55                  60
              Tyr Gln Leu Gln Ala Leu Ser Ser Gln Ile Asn Pro His Phe Leu Tyr
              65                  70                  75                  80
              Asn Thr Leu Asp Thr Ile Ile Trp Met Ala Glu Phe His Asp Ser Gln
                              85                  90                  95
              Arg Val Val Gln Val Thr Lys Ser Leu Ala Thr Tyr Phe Arg Leu Ala
                          100                 105                 110
              Leu Asn Gln Gly Lys Asp Leu Ile Cys Leu Ser Asp Glu Ile Asn His
                      115                 120                 125
              Val Arg Gln Tyr Leu Phe Ile Gln Lys Gln Arg Tyr Gly Asp Lys Leu
                                                 Page 266

                  130                   135                 140
<removed-date>
              Glu Tyr Glu Ile Asn Glu Asn Val Ala Phe Asp Asn Leu Val Leu Pro
              145                 150                 155                 160
              Lys Leu Val Leu Gln Pro Leu Val Glu Asn Ala Leu Tyr His Gly Ile
                              165                 170                 175
<removed-apn>
              Lys Glu Lys Glu Gly Gln Gly His Ile Lys Leu Ser Val Gln Lys Gln
                          180                 185                 190
              Asp Ser Gly Leu Val Ile Arg Ile Glu Asp Asp Gly Val Gly Phe Gln
                      195                 200                 205
              Asp Ala Gly Asp Ser Ser Gln Ser Gln Leu Lys Arg Gly Gly Val Gly
                  210                 215                 220
              Leu Gln Asn Val Asp Gln Arg Leu Lys Leu His Phe Gly Ala Asn Tyr
              225                 230                 235                 240
              His Met Lys Ile Asp Ser Arg Pro Gln Lys Gly Thr Lys Val Glu Ile
                              245                 250                 255
              Tyr Ile Asn Arg Ile Glu Thr Ser
                          260
              <210>   183
              <211>   608
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 183
              Thr Leu Ala Leu Ala Ser Arg Glu Gly Val Val Glu Met Glu Gly Tyr
              1               5                   10                  15
              Arg Tyr Val Gly Tyr Leu Ser Gly Asp Ile Leu Lys Thr Leu Gly Leu
                          20                  25                  30
              Asp Thr Val Leu Glu Glu Thr Ser Ala Lys Pro Gly Glu Val Thr Val
                      35                  40                  45
                                                 Page 267

              Val Glu Val Glu Thr Pro Gln Ser Ile Thr Asn Gln Glu Gln Ala Arg
<removed-date>
                  50                  55                  60
              Thr Glu Asn Gln Val Val Glu Thr Glu Glu Ala Pro Lys Glu Glu Ala
              65                  70                  75                  80
              Pro Lys Thr Glu Glu Ser Pro Lys Glu Glu Pro Lys Ser Glu Val Lys
                              85                  90                  95
<removed-apn>
              Pro Thr Asp Asp Thr Leu Pro Lys Val Glu Glu Gly Lys Glu Asp Ser
                          100                 105                 110
              Ala Glu Pro Ala Pro Val Glu Glu Val Gly Gly Glu Val Glu Ser Lys
                      115                 120                 125
              Pro Glu Glu Lys Val Ala Val Lys Pro Glu Ser Gln Pro Ser Asp Lys
                  130                 135                 140
              Pro Ala Glu Glu Ser Lys Val Glu Gln Ala Gly Glu Pro Val Ala Pro
              145                 150                 155                 160
              Arg Glu Asp Glu Lys Ala Pro Val Glu Pro Glu Lys Gln Pro Glu Ala
                              165                 170                 175
              Pro Glu Glu Glu Lys Ala Val Glu Glu Thr Pro Lys Gln Glu Glu Ser
                          180                 185                 190
              Thr Pro Asp Thr Lys Ala Glu Glu Thr Val Glu Pro Lys Glu Glu Thr
                      195                 200                 205
              Val Asn Gln Ser Ile Glu Gln Pro Lys Val Glu Thr Pro Ala Val Glu
                  210                 215                 220
              Lys Gln Thr Glu Pro Thr Glu Glu Pro Lys Val Glu Gln Ala Gly Glu
              225                 230                 235                 240
              Pro Val Ala Pro Arg Glu Asp Glu Gln Ala Pro Thr Ala Pro Val Glu
                              245                 250                 255
              Pro Glu Lys Gln Pro Glu Val Pro Glu Glu Glu Lys Ala Val Glu Glu
                                                 Page 268

                          260                 265                 270
<removed-date>
              Thr Pro Lys Pro Glu Asp Lys Ile Lys Gly Ile Gly Thr Lys Glu Pro
                      275                 280                 285
              Val Asp Lys Ser Glu Leu Asn Asn Gln Ile Asp Lys Ala Ser Ser Val
                  290                 295                 300
<removed-apn>
              Ser Pro Thr Asp Tyr Ser Thr Ala Ser Tyr Asn Ala Leu Gly Pro Val
              305                 310                 315                 320
              Leu Glu Thr Ala Lys Gly Val Tyr Ala Ser Glu Pro Val Lys Gln Pro
                              325                 330                 335
              Glu Val Asn Ser Glu Thr Asn Lys Leu Lys Thr Ala Ile Asp Ala Leu
                          340                 345                 350
              Asn Val Asp Lys Thr Glu Leu Asn Asn Thr Ile Ala Asp Ala Lys Thr
                      355                 360                 365
              Lys Val Lys Glu His Tyr Ser Asp Arg Ser Trp Gln Asn Leu Gln Thr
                  370                 375                 380
              Glu Val Thr Lys Ala Glu Lys Val Ala Ala Asn Thr Asp Ala Lys Gln
              385                 390                 395                 400
              Ser Glu Val Asn Glu Ala Val Glu Lys Leu Thr Ala Thr Ile Glu Lys
                              405                 410                 415
              Leu Val Glu Leu Ser Glu Lys Pro Ile Leu Thr Leu Thr Ser Thr Asp
                          420                 425                 430
              Lys Lys Ile Leu Glu Arg Glu Ala Val Ala Lys Tyr Thr Leu Glu Asn
                      435                 440                 445
              Gln Asn Lys Thr Lys Ile Lys Ser Ile Thr Ala Glu Leu Lys Lys Gly
                  450                 455                 460
              Glu Glu Val Ile Asn Thr Val Val Leu Thr Asp Asp Lys Val Thr Thr
              465                 470                 475                 480
                                                    Page 269

<removed-date>
              Glu Thr Ile Ser Ala Ala Phe Lys Asn Leu Glu Tyr Tyr Lys Glu Tyr
                              485                 490                 495
              Thr Leu Ser Thr Thr Met Ile Tyr Asp Arg Gly Asn Gly Glu Glu Thr
                          500                 505                 510
              Glu Thr Leu Glu Asn Gln Asn Ile Gln Leu Asp Leu Lys Lys Val Glu
<removed-apn>
                      515                 520                 525
              Leu Lys Asn Ile Lys Arg Thr Asp Leu Ile Lys Tyr Glu Asn Gly Lys
                  530                 535                 540
              Glu Thr Asn Glu Ser Leu Ile Thr Thr Ile Pro Asp Asp Lys Ser Asn
              545                 550                 555                 560
              Tyr Tyr Leu Lys Ile Thr Ser Asn Asn Gln Lys Thr Thr Leu Leu Ala
                              565                 570                 575
              Val Lys Asn Ile Glu Glu Thr Thr Val Asn Gly Thr Pro Val Tyr Lys
                          580                 585                 590
              Val Thr Ala Ile Ala Asp Asn Leu Val Ser Arg Thr Ala Asp Asn Lys
                      595                 600                 605
              <210>   184
              <211>   570
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 184
              Phe Glu Glu Glu Tyr Val His Tyr Ile Glu Lys Pro Lys Val His Glu
              1               5                   10                  15
              Asp Asn Val Tyr Tyr Asn Phe Lys Glu Leu Val Glu Ala Ile Gln Asn
                          20                  25                  30
              Asp Pro Ser Lys Glu Tyr Arg Leu Gly Gln Ser Met Ser Ala Arg Asn
                      35                  40                  45
              Val Val Pro Asn Gly Lys Ser Tyr Ile Thr Lys Glu Phe Thr Gly Lys
                                                 Page 270

                  50                  55                    60
<removed-date>
              Leu Leu Ser Ser Glu Gly Lys Gln Phe Ala Ile Thr Glu Leu Glu His
              65                  70                  75                  80
              Pro Leu Phe Asn Val Ile Thr Asn Ala Thr Ile Asn Asn Val Asn Phe
                              85                  90                  95
<removed-apn>
              Glu Asn Val Glu Ile Glu Arg Ser Gly Gln Asp Asn Ile Ala Ser Leu
                          100                 105                 110
              Ala Asn Thr Met Lys Gly Ser Ser Val Ile Thr Asn Val Lys Ile Thr
                      115                 120                 125
              Gly Thr Leu Ser Gly Arg Asn Asn Val Ala Gly Phe Val Asn Asn Met
                  130                 135                 140
              Asn Asp Gly Thr Arg Ile Glu Asn Val Ala Phe Phe Gly Lys Leu His
              145                 150                 155                 160
              Ser Thr Ser Gly Asn Gly Ser His Thr Gly Gly Ile Ala Gly Thr Asn
                              165                 170                 175
              Tyr Arg Gly Ile Val Arg Lys Ala Tyr Val Asp Ala Thr Ile Thr Gly
                          180                 185                 190
              Asn Lys Thr Arg Ala Ser Leu Leu Val Pro Lys Val Asp Tyr Gly Leu
                      195                 200                 205
              Thr Leu Asp His Leu Ile Gly Thr Lys Ala Leu Leu Thr Glu Ser Val
                  210                 215                 220
              Val Lys Gly Lys Ile Asp Val Ser Asn Pro Val Glu Val Gly Ala Ile
              225                 230                 235                 240
              Ala Ser Lys Thr Trp Pro Val Gly Thr Val Ser Asn Ser Val Ser Tyr
                              245                 250                 255
              Ala Lys Ile Ile Arg Gly Glu Glu Leu Phe Gly Ser Asn Asp Val Asp
                          260                 265                 270
                                                 Page 271

<removed-date>
              Asp Ser Asp Tyr Ala Ser Ala His Ile Lys Asp Leu Tyr Ala Val Glu
                      275                 280                 285
              Gly Tyr Ser Ser Gly Asn Arg Ser Phe Arg Lys Ser Lys Thr Phe Thr
                  290                 295                 300
              Lys Leu Thr Lys Glu Gln Ala Asp Ala Lys Val Thr Thr Phe Asn Ile
<removed-apn>
              305                 310                 315                 320
              Thr Ala Asp Lys Leu Glu Ser Asp Leu Ser Pro Leu Ala Lys Leu Asn
                              325                 330                 335
              Glu Glu Lys Ala Tyr Ser Ser Ile Gln Asp Tyr Asn Ala Glu Tyr Asn
                          340                 345                 350
              Gln Ala Tyr Lys Asn Leu Glu Lys Leu Ile Pro Phe Tyr Asn Lys Asp
                      355                 360                 365
              Tyr Ile Val Tyr Gln Gly Asn Lys Leu Asn Lys Glu His His Leu Asn
                  370                 375                 380
              Thr Lys Glu Val Leu Ser Val Thr Ala Met Asn Asn Asn Glu Phe Ile
              385                 390                 395                 400
              Thr Asn Leu Asp Glu Ala Asn Lys Ile Ile Val His Tyr Ala Asp Gly
                              405                 410                 415
              Thr Lys Asp Tyr Phe Asn Leu Ser Ser Ser Ser Glu Gly Leu Ser Asn
                          420                 425                 430
              Val Lys Glu Tyr Thr Ile Thr Asp Leu Gly Ile Lys Tyr Thr Pro Asn
                      435                 440                 445
              Ile Val Gln Lys Asp Asn Thr Thr Leu Val Asn Asp Ile Lys Ser Ile
                  450                 455                 460
              Leu Glu Ser Val Glu Leu Gln Ser Gln Thr Met Tyr Gln His Leu Asn
              465                 470                 475                 480
                                                 Page 272

<removed-date>
              Arg Leu Gly Asp Tyr Arg Val Asn Ala Ile Lys Asp Leu Tyr Leu Glu
                              485                 490                 495
              Glu Ser Phe Thr Asp Val Lys Glu Asn Leu Thr Asn Leu Ile Thr Lys
                          500                 505                 510
              Leu Val Gln Asn Glu Glu His Gln Leu Asn Asp Ser Pro Ala Ala Arg
                      515                 520                 525
<removed-apn>
              Gln Met Ile Arg Asp Lys Val Glu Lys Asn Lys Ala Ala Leu Leu Leu
                  530                 535                 540
              Gly Leu Thr Tyr Leu Asn Arg Tyr Tyr Gly Val Lys Phe Gly Asp Val
              545                 550                 555                 560
              Asn Ile Lys Glu Leu Met Leu Phe Lys Pro
                              565                 570
              <210>   185
              <211>   601
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 185
              Asp Phe Tyr Gly Glu Lys Val Ser Val Leu Asp Arg Leu Ile Glu Ile
              1               5                   10                  15
              Gly Ser Lys Glu Asn Asn Ile Lys Gly Ser Arg Thr Phe Asp Ala Phe
                          20                  25                  30
              Gly Gln Val Leu Ala Lys Tyr Thr Lys Ser Gly Asn Leu Asp Ala Phe
                      35                  40                  45
              Leu Asn Tyr Asn Arg Gln Leu Phe Thr Asn Ile Asp Asn Met Asn Asp
                  50                  55                  60
              Trp Phe Ile Asp Ala Thr Glu Asp His Val Tyr Ile Ala Glu Arg Ala
              65                  70                  75                  80
              Ser Glu Val Glu Glu Ile Lys Asn Ser Lys His Arg Ala Phe Asp Asn
                              85                  90                  95
                                                 Page 273

<removed-date>
              Leu Lys Arg Ser His Leu Arg Asn Thr Ile Leu Pro Leu Leu Asn Ile
                          100                 105                 110
              Asp Lys Ala His Leu Tyr Leu Ile Ser Asn Tyr Asn Ala Ile Ala Phe
                      115                 120                 125
              Gly Ser Ala Glu Arg Leu Gly Lys Lys Ser Leu Glu Asp Ile Lys Asp
<removed-apn>
                  130                 135                 140
              Ile Val Asn Lys Ala Ala Asp Gly Tyr Arg Asn Tyr Tyr Asp Phe Trp
              145                 150                 155                 160
              Tyr Arg Leu Ala Ser Asp Asn Val Lys Gln Arg Leu Leu Arg Asp Ala
                              165                 170                 175
              Val Ile Pro Ile Trp Glu Gly Tyr Asn Ala Pro Gly Gly Trp Val Glu
                          180                 185                 190
              Lys Tyr Gly Arg Tyr Asn Thr Asp Lys Val Tyr Thr Pro Leu Arg Glu
                      195                 200                 205
              Phe Phe Gly Pro Met Asp Lys Tyr Tyr Asn Tyr Asn Gly Thr Gly Ala
                  210                 215                 220
              Tyr Ala Ala Ile Tyr Pro Asn Ser Asp Asp Ile Arg Thr Asp Val Lys
              225                 230                 235                 240
              Tyr Val His Leu Glu Met Val Gly Glu Tyr Gly Ile Ser Val Tyr Thr
                              245                 250                 255
              His Glu Thr Thr His Val Asn Asp Arg Ala Ile Tyr Leu Gly Gly Phe
                          260                 265                 270
              Gly His Arg Glu Gly Thr Asp Ala Glu Ala Tyr Ala Gln Gly Met Leu
                      275                 280                 285
              Gln Thr Pro Val Thr Gly Ser Gly Phe Asp Glu Phe Gly Ser Leu Gly
                  290                 295                 300
                                                 Page 274

<removed-date>
              Ile Asn Met Val Phe Lys Arg Lys Asn Asp Gly Asn Gln Trp Tyr Ile
              305                 310                 315                 320
              Thr Asp Pro Lys Thr Leu Lys Thr Arg Glu Asp Ile Asn Arg Tyr Met
                              325                 330                 335
              Lys Gly Tyr Asn Asp Thr Leu Thr Leu Leu Asp Glu Ile Glu Ala Glu
                          340                 345                 350
<removed-apn>
              Ser Val Ile Ser Gln Gln Asn Lys Asp Leu Asn Ser Ala Trp Phe Lys
                      355                 360                 365
              Lys Ile Asp Arg Glu Tyr Arg Asp Asn Asn Lys Leu Asn Gln Trp Asp
                  370                 375                 380
              Lys Ile Arg Asn Leu Ser Gln Glu Glu Lys Asn Glu Leu Asn Ile Gln
              385                 390                 395                 400
              Ser Val Asn Asp Leu Val Asp Gln Gln Leu Met Thr Asn Arg Asn Pro
                              405                 410                 415
              Gly Asn Gly Ile Tyr Lys Pro Glu Ala Ile Ser Tyr Asn Asp Gln Ser
                          420                 425                 430
              Pro Tyr Val Gly Val Arg Met Met Thr Gly Ile Tyr Gly Gly Asn Thr
                      435                 440                 445
              Ser Lys Gly Ala Pro Gly Ala Val Ser Phe Lys His Asn Ala Phe Arg
                  450                 455                 460
              Leu Trp Gly Tyr Tyr Gly Tyr Glu Asn Gly Phe Leu Gly Tyr Ala Ser
              465                 470                 475                 480
              Asn Lys Tyr Lys Gln Gln Ser Lys Thr Asp Gly Glu Ser Val Leu Ser
                              485                 490                 495
              Asp Glu Tyr Ile Ile Lys Lys Ile Ser Asn Asn Thr Phe Asn Thr Ile
                          500                 505                 510
                                                 Page 275

              Glu Glu Phe Lys Lys Ala Tyr Phe Lys Glu Val Lys Asp Lys Ala Thr
<removed-date>
                      515                 520                 525
              Lys Gly Leu Thr Thr Phe Glu Val Asn Gly Ser Ser Val Ser Ser Tyr
                  530                 535                 540
              Asp Asp Leu Leu Thr Leu Phe Lys Glu Ala Val Lys Lys Asp Ala Glu
              545                 550                 555                 560
<removed-apn>
              Thr Leu Lys Gln Glu Ala Asn Gly Asn Lys Thr Val Ser Met Asn Asn
                              565                 570                 575
              Thr Val Lys Leu Lys Glu Ala Val Tyr Lys Lys Leu Leu Gln Gln Thr
                          580                 585                 590
              Asn Ser Phe Lys Thr Ser Ile Phe Lys
                      595                 600
              <210>   186
              <211>   104
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 186
              Arg Ile Arg Arg Ala Ala Lys Ile Val Asp Asn Glu Glu Phe Glu Ala
              1               5                   10                  15
              Leu Ile Arg Thr Gly Gln Leu Ile Asp Leu Arg Asp Pro Ala Glu Phe
                          20                  25                  30
              His Arg Lys His Ile Leu Gly Ala Arg Asn Ile Pro Ser Ser Gln Leu
                      35                  40                  45
              Lys Thr Ser Leu Ala Ala Leu Arg Lys Asp Lys Pro Val Leu Leu Tyr
                  50                  55                  60
              Glu Asn Gln Arg Ala Gln Arg Val Thr Asn Ala Ala Leu Tyr Leu Lys
              65                  70                  75                  80
              Lys Gln Gly Phe Ser Glu Ile Tyr Ile Leu Ser Tyr Gly Leu Asp Ser
                              85                  90                  95
                                                    Page 276

<removed-date>
              Trp Lys Gly Lys Val Lys Thr Ser
                          100
              <210>   187
              <211>   225
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 187
<removed-apn>
              Asp Asp Ser Arg Glu Val Leu Asp Phe Thr Lys Gln Ser Gln Ala Leu
              1               5                   10                  15
              Phe Ile Asn Leu Gly His Leu Ser Ala Glu Lys Glu Lys Ala Ile Arg
                          20                  25                  30
              Met Ala Ala Ser Tyr Ala Asn Gln Ser Ser Leu Pro Met Val Val Asp
                      35                  40                  45
              Ala Val Gly Val Thr Thr Ser Ser Ile Arg Lys Ser Leu Val Lys Asp
                  50                  55                  60
              Leu Leu Asp Tyr Arg Pro Thr Val Leu Lys Gly Asn Met Ser Glu Ile
              65                  70                  75                  80
              Arg Ser Leu Val Gly Leu Lys His His Gly Val Gly Val Asp Ala Ser
                              85                  90                  95
              Ala Lys Asp Gln Glu Thr Glu Asp Leu Leu Gln Val Leu Lys Asp Trp
                          100                 105                 110
              Cys Gln Thr Tyr Pro Gly Met Ser Phe Leu Val Thr Gly Pro Lys Asp
                      115                 120                 125
              Leu Val Val Ser Lys Asn Gln Val Ala Val Leu Gly Asn Gly Cys Thr
                  130                 135                 140
              Glu Leu Asp Trp Ile Thr Gly Thr Gly Asp Leu Val Gly Ala Leu Thr
              145                 150                 155                 160
              Ala Val Phe Leu Ser Gln Gly Lys Thr Gly Phe Glu Ala Ser Cys Leu
                              165                 170                 175
                                                 Page 277

<removed-date>
              Ala Val Ser Tyr Leu Asn Ile Ala Ala Glu Lys Ile Val Val Gln Gly
                          180                 185                 190
              Met Gly Leu Glu Glu Phe Arg Tyr Gln Val Leu Asn Gln Leu Ser Leu
                      195                 200                 205
              Leu Arg Arg Asp Glu Asn Trp Leu Asp Thr Ile Lys Gly Glu Val Tyr
<removed-apn>
                  210                 215                 220
              Glu
              225
              <210>   188
              <211>   247
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 188
              Ala Asp Gln Val Phe Val Asp Asp Ala Ser Leu Asp Ile Asp Gln Met
              1               5                   10                  15
              Met Glu Thr Met Tyr Ala Thr Ala Glu Ala Ser Lys Ser Ala Cys Pro
                          20                  25                  30
              Ser Pro Asp Asp Tyr Leu Arg Ala Phe Glu Gly Ala Lys Asn Ile Phe
                      35                  40                  45
              Leu Val Thr Ile Thr Gly Thr Leu Ser Gly Ser His Asn Ser Ala Gln
                  50                  55                  60
              Leu Ala Lys Asn Ile Tyr Leu Glu Asp His Pro Asp Thr Lys Ile His
              65                  70                  75                  80
              Val Ile Asp Ser Leu Ser Ala Gly Gly Glu Val Asp Leu Leu Val Glu
                              85                  90                  95
              Lys Leu Asn Asp Leu Ile Asp Gln Gly Leu Ser Phe Glu Glu Val Val
                          100                 105                 110
              Glu Ala Ile Thr Ala Tyr Gln Glu Lys Thr Lys Leu Leu Phe Val Leu
                                                 Page 278

                        115                 120               125
<removed-date>
              Ala Lys Val Asp Asn Leu Val Lys Asn Gly Arg Leu Ser Lys Leu Ile
                  130                 135                 140
              Gly Thr Val Val Gly Leu Leu Asn Ile Arg Met Val Gly Lys Ala Ser
              145                 150                 155                 160
<removed-apn>
              Glu Thr Gly Thr Leu Glu Leu Leu Gln Lys Ala Arg Gly Ser Lys Lys
                              165                 170                 175
              Ser Val Gln Ala Ala Tyr Asp Glu Leu Val Lys Ala Gly Tyr Ala Gly
                          180                 185                 190
              Gly Arg Ile Val Met Ala Gln Arg Asn Asn Glu Lys Cys Cys Gln Gln
                      195                 200                 205
              Leu Ser Glu Arg Ile Arg Glu Thr Phe Pro Gln Ala Asp Ile Lys Ile
                  210                 215                 220
              Leu Pro Thr Ser Gly Leu Cys Ser Phe Tyr Ala Glu Glu Gly Gly Leu
              225                 230                 235                 240
              Leu Met Gly Tyr Glu Ile Asp
                              245
              <210>   189
              <211>   136
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 189
              Ile Phe Asn Thr Ala Lys Leu Ala Thr Asp Ile Glu Asn Asn Val Arg
              1               5                   10                  15
              Val Val Val Tyr Ile Arg Lys Asp Val Glu Asp Asn Ser Gln Thr Ile
                          20                  25                  30
              Glu Lys Glu Gly Gln Thr Val Thr Asn Asn Asp Tyr His Lys Val Tyr
                      35                  40                  45
                                                  Page 279

              Asp Ser Leu Lys Asn Met Ser Thr Val Lys Ser Val Thr Phe Ser Ser
<removed-date>
                  50                  55                  60
              Lys Glu Glu Gln Tyr Glu Lys Leu Thr Glu Ile Met Gly Asp Asn Trp
              65                  70                  75                  80
              Lys Ile Phe Glu Gly Asp Ala Asn Pro Leu Tyr Asp Ala Tyr Ile Val
                              85                  90                  95
<removed-apn>
              Glu Ala Asn Thr Pro Asn Asp Val Lys Thr Ile Ala Glu Asp Ala Lys
                          100                 105                 110
              Lys Ile Glu Gly Val Ser Glu Val Gln Asp Gly Gly Ala Asn Thr Glu
                      115                 120                 125
              Arg Leu Phe Lys Leu Ala Ser Phe
                  130                 135
              <210>   190
              <211>   367
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 190
              Phe Arg Gln Pro Ser Gln Thr Ala Leu Lys Asp Glu Pro Thr His Leu
              1               5                   10                  15
              Val Val Ala Lys Glu Gly Ser Val Ala Ser Ser Val Leu Leu Ser Gly
                          20                  25                  30
              Thr Val Thr Ala Lys Asn Glu Gln Tyr Val Tyr Phe Asp Ala Ser Lys
                      35                  40                  45
              Gly Asp Leu Asp Glu Ile Leu Val Ser Val Gly Asp Lys Val Ser Glu
                  50                  55                  60
              Gly Gln Ala Leu Val Lys Tyr Ser Ser Ser Glu Ala Gln Ala Ala Tyr
              65                  70                  75                  80
              Asp Ser Ala Ser Arg Ala Val Ala Arg Ala Asp Arg His Ile Asn Glu
                              85                  90                  95
                                                 Page 280

<removed-date>
              Leu Asn Gln Ala Arg Asn Glu Ala Ala Ser Ala Pro Ala Pro Gln Leu
                          100                 105                 110
              Pro Ala Pro Val Gly Gly Glu Asp Ala Thr Val Gln Ser Pro Thr Pro
                      115                 120                 125
              Val Ala Gly Asn Ser Val Ala Ser Ile Asp Ala Gln Leu Gly Asp Ala
                  130                 135                 140
<removed-apn>
              Arg Asp Ala Arg Ala Asp Ala Ala Ala Gln Leu Ser Lys Ala Gln Ser
              145                 150                 155                 160
              Gln Leu Asp Ala Thr Thr Val Leu Ser Thr Leu Glu Gly Thr Val Val
                              165                 170                 175
              Glu Val Asn Ser Asn Val Ser Lys Ser Pro Thr Gly Ala Ser Gln Val
                          180                 185                 190
              Met Val His Ile Val Ser Asn Glu Asn Leu Gln Val Lys Gly Glu Leu
                      195                 200                 205
              Ser Glu Tyr Asn Leu Ala Asn Leu Ser Val Gly Gln Glu Val Ser Phe
                  210                 215                 220
              Thr Ser Lys Val Tyr Pro Asp Lys Lys Trp Thr Gly Lys Leu Ser Tyr
              225                 230                 235                 240
              Ile Ser Asp Tyr Pro Lys Asn Asn Gly Glu Ala Ala Ser Pro Ala Ala
                              245                 250                 255
              Gly Asn Asn Thr Gly Ser Lys Tyr Pro Tyr Thr Ile Asp Val Thr Gly
                          260                 265                 270
              Glu Val Gly Asp Leu Lys Gln Gly Phe Ser Val Asn Ile Glu Val Lys
                      275                 280                 285
              Ser Lys Thr Lys Ala Ile Leu Val Pro Val Ser Ser Leu Val Met Asp
                  290                 295                 300
                                                 Page 281

              Asp Ser Lys Asn Tyr Val Trp Ile Val Asp Glu Gln Gln Lys Ala Lys
<removed-date>
              305                 310                 315                 320
              Lys Val Glu Val Ser Leu Gly Asn Ala Asp Ala Glu Asn Gln Glu Ile
                              325                 330                 335
              Thr Ser Gly Leu Thr Asn Gly Ala Lys Val Ile Ser Asn Pro Thr Ser
                          340                 345                 350
<removed-apn>
              Ser Leu Glu Glu Gly Lys Glu Val Lys Ala Asp Glu Ala Thr Asn
                      355                 360                 365
              <210>   191
              <211>   248
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 191
              Ser Arg Gln Val Asn Lys Asp Met Thr Lys Ser Gln Lys Asn Ile Ser
              1               5                   10                  15
              Val Phe Phe Ser Pro Lys Lys Ser Lys Asp Gly Ser Phe Thr Gln Lys
                          20                  25                  30
              Gln Ser Ala Phe Thr Val Ser Gly Lys Glu Glu Glu Val Pro Val Glu
                      35                  40                  45
              Pro Pro Lys Pro Gln Glu Ser Trp Val Gln Glu Ala Ala Lys Leu Lys
                  50                  55                  60
              Gly Val Asp Ser Tyr Tyr Val Thr Asn Ser Thr Asn Ala Ile Leu Thr
              65                  70                  75                  80
              Tyr Gln Asp Lys Lys Val Glu Asn Ala Asn Leu Thr Gly Gly Asn Arg
                              85                  90                  95
              Thr Tyr Met Asp Ala Val Lys Asn Glu Ile Ile Ala Gly Arg Ser Leu
                          100                 105                 110
              Arg Glu Gln Asp Phe Lys Glu Phe Ala Ser Val Ile Leu Leu Asp Glu
                      115                 120                 125
                                                 Page 282

<removed-date>
              Glu Leu Ser Ile Ser Leu Phe Glu Ser Pro Gln Glu Ala Ile Asn Lys
                  130                 135                 140
              Val Val Glu Val Asn Gly Phe Ser Tyr Arg Val Ile Gly Val Tyr Thr
              145                 150                 155                 160
              Ser Pro Glu Ala Lys Arg Ser Lys Ile Tyr Gly Phe Gly Gly Leu Pro
                              165                 170                 175
<removed-apn>
              Ile Thr Thr Asn Ile Ser Leu Ala Ala Asn Phe Asn Val Asp Glu Ile
                          180                 185                 190
              Ala Asn Ile Val Phe Arg Val Asn Asp Thr Ser Leu Thr Pro Thr Leu
                      195                 200                 205
              Gly Pro Glu Leu Ala Arg Lys Met Thr Glu Leu Ala Gly Leu Gln Gln
                  210                 215                 220
              Gly Glu Tyr Gln Val Ala Asp Glu Ser Val Val Phe Ala Glu Ile Gln
              225                 230                 235                 240
              Gln Ser Phe Ser Phe Met Thr Thr
                              245
              <210>   192
              <211>   384
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 192
              Lys His Ala Ile Ala Val Glu Ala Asn Thr Gly Lys Ile Leu Tyr Glu
              1               5                   10                  15
              Lys Asp Ala Thr Gln Pro Val Glu Ile Ala Ser Ile Thr Lys Leu Ile
                          20                  25                  30
              Thr Val Tyr Leu Val Tyr Glu Ala Leu Glu Asn Gly Ser Ile Thr Leu
                      35                  40                  45
              Ser Thr Pro Val Asp Ile Ser Asp Tyr Pro Tyr Gln Leu Thr Thr Asn
                  50                  55                  60
                                                 Page 283

<removed-date>
              Ser Glu Ala Ser Asn Ile Pro Met Glu Ala Arg Asn Tyr Thr Val Glu
              65                  70                  75                  80
              Glu Leu Leu Glu Ala Thr Leu Val Ser Ser Ala Asn Ser Ala Ala Ile
                              85                  90                  95
              Ala Leu Ala Glu Lys Ile Ala Gly Ser Glu Lys Asp Phe Val Asp Met
<removed-apn>
                          100                 105                 110
              Met Arg Ala Lys Leu Leu Glu Trp Gly Ile Gln Asp Ala Thr Val Val
                      115                 120                 125
              Asn Thr Thr Gly Leu Asn Asn Glu Thr Leu Gly Asp Asn Ile Tyr Pro
                  130                 135                 140
              Gly Ser Lys Lys Asp Glu Glu Asn Lys Leu Ser Ala Tyr Asp Val Ala
              145                 150                 155                 160
              Ile Val Ala Arg Asn Leu Ile Lys Lys Tyr Pro Gln Val Leu Glu Ile
                              165                 170                 175
              Thr Lys Lys Pro Ser Ser Thr Phe Ala Gly Met Thr Ile Thr Ser Thr
                          180                 185                 190
              Asn Tyr Met Leu Glu Gly Met Pro Ala Tyr Arg Gly Gly Phe Asp Gly
                      195                 200                 205
              Leu Lys Thr Gly Thr Thr Asp Lys Ala Gly Glu Ser Phe Val Gly Thr
                  210                 215                 220
              Thr Val Glu Lys Gly Met Arg Val Ile Thr Val Val Leu Asn Ala Asp
              225                 230                 235                 240
              His Gln Asp Asn Asn Pro Tyr Ala Arg Phe Thr Ala Thr Ser Ser Leu
                              245                 250                 255
              Met Asp Tyr Ile Ser Ser Thr Phe Thr Leu Arg Lys Ile Val Gln Gln
                          260                 265                 270
                                                 Page 284

<removed-date>
              Gly Asp Ala Tyr Gln Asp Ser Lys Ala Pro Val Gln Asp Gly Lys Glu
                      275                 280                 285
              Asp Thr Val Thr Ala Val Ala Pro Glu Asp Ile Tyr Leu Ile Glu Arg
                  290                 295                 300
              Val Gly Asn Gln Ser Ser Gln Ser Val Gln Phe Thr Pro Asp Ser Lys
              305                 310                 315                 320
<removed-apn>
              Ala Ile Pro Ala Pro Leu Glu Ala Gly Thr Val Val Gly His Leu Thr
                              325                 330                 335
              Tyr Glu Asp Lys Asp Leu Ile Gly Gln Gly Tyr Ile Thr Thr Glu Arg
                          340                 345                 350
              Pro Ser Phe Glu Met Val Ala Asp Lys Lys Ile Glu Lys Ala Phe Phe
                      355                 360                 365
              Leu Lys Val Trp Trp Asn Gln Phe Val Arg Phe Val Asn Glu Lys Leu
                  370                 375                 380
              <210>   193
              <211>   523
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 193
              Thr Glu Glu Ala Val Gln Asn Leu Pro Pro Ile Pro Glu Glu Lys Trp
              1               5                   10                  15
              Val Glu Pro Glu Ile Ile Leu Pro Gln Ala Glu Leu Lys Phe Pro Glu
                          20                  25                  30
              Gln Glu Asp Asp Ser Asp Asp Glu Asp Val Gln Val Asp Phe Ser Ala
                      35                  40                  45
              Lys Glu Ala Leu Glu Tyr Lys Leu Pro Ser Leu Gln Leu Phe Ala Pro
                  50                  55                  60
              Asp Lys Pro Lys Asp Gln Ser Lys Glu Lys Lys Ile Val Arg Glu Asn
              65                  70                  75                  80
                                                 Page 285

<removed-date>
              Ile Lys Ile Leu Glu Ala Thr Phe Ala Ser Phe Gly Ile Lys Val Thr
                              85                  90                  95
              Val Glu Arg Ala Glu Ile Gly Pro Ser Val Thr Lys Tyr Glu Val Lys
                          100                 105                 110
              Pro Ala Val Gly Val Arg Val Asn Arg Ile Ser Asn Leu Ser Asp Asp
<removed-apn>
                      115                 120                 125
              Leu Ala Leu Ala Leu Ala Ala Lys Asp Val Arg Ile Glu Ala Pro Ile
                  130                 135                 140
              Pro Gly Lys Ser Leu Ile Gly Ile Glu Val Pro Asn Ser Asp Ile Ala
              145                 150                 155                 160
              Thr Val Ser Phe Arg Glu Leu Trp Glu Gln Ser Gln Thr Lys Ala Glu
                              165                 170                 175
              Asn Phe Leu Glu Ile Pro Leu Gly Lys Ala Val Asn Gly Thr Ala Arg
                          180                 185                 190
              Ala Phe Asp Leu Ser Lys Met Pro His Leu Leu Val Ala Gly Ser Thr
                      195                 200                 205
              Gly Ser Gly Lys Ser Val Ala Val Asn Gly Ile Ile Ala Ser Ile Leu
                  210                 215                 220
              Met Lys Ala Arg Pro Asp Gln Val Lys Phe Met Met Val Asp Pro Lys
              225                 230                 235                 240
              Met Val Glu Leu Ser Val Tyr Asn Asp Ile Pro His Leu Leu Ile Pro
                              245                 250                 255
              Val Val Thr Asn Pro Arg Lys Ala Ser Lys Ala Leu Gln Lys Val Val
                          260                 265                 270
              Asp Glu Met Glu Asn Arg Tyr Glu Leu Phe Ala Lys Val Gly Val Arg
                      275                 280                 285
                                                 Page 286

<removed-date>
              Asn Ile Ala Gly Phe Asn Ala Lys Val Glu Glu Phe Asn Ser Gln Ser
                  290                 295                 300
              Glu Tyr Lys Gln Ile Pro Leu Pro Phe Ile Val Val Ile Val Asp Glu
              305                 310                 315                 320
              Leu Ala Asp Leu Met Met Val Ala Ser Lys Glu Val Glu Asp Ala Ile
                              325                 330                 335
<removed-apn>
              Ile Arg Leu Gly Gln Lys Ala Arg Ala Ala Gly Ile His Met Ile Leu
                          340                 345                 350
              Ala Thr Gln Arg Pro Ser Val Asp Val Ile Ser Gly Leu Ile Lys Ala
                      355                 360                 365
              Asn Val Pro Ser Arg Val Ala Phe Ala Val Ser Ser Gly Thr Asp Ser
                  370                 375                 380
              Arg Thr Ile Leu Asp Glu Asn Gly Ala Glu Lys Leu Leu Gly Arg Gly
              385                 390                 395                 400
              Asp Met Leu Phe Lys Pro Ile Asp Glu Asn His Pro Val Arg Leu Gln
                              405                 410                 415
              Gly Ser Phe Ile Ser Asp Asp Asp Val Glu Arg Ile Val Asn Phe Ile
                          420                 425                 430
              Lys Thr Gln Ala Asp Ala Asp Tyr Asp Glu Ser Phe Asp Pro Gly Glu
                      435                 440                 445
              Val Ser Glu Asn Glu Gly Glu Phe Ser Asp Gly Asp Ala Gly Gly Asp
                  450                 455                 460
              Pro Leu Phe Glu Glu Ala Lys Ser Leu Val Ile Glu Thr Gln Lys Ala
              465                 470                 475                 480
              Ser Ala Ser Met Ile Gln Arg Arg Leu Ser Val Gly Phe Asn Arg Ala
                              485                 490                 495
                                                 Page 287

              Thr Arg Leu Met Glu Glu Leu Glu Ile Ala Gly Val Ile Gly Pro Ala
<removed-date>
                          500                 505                 510
              Glu Gly Thr Lys Pro Arg Lys Val Leu Gln Gln
                      515                 520
              <210>   194
              <211>   260
              <212>   PRT
<removed-apn>
              <213>   Streptococcus pneumoniae
              <400> 194
              Glu Gly Thr Asn Gln Arg Gln Ser Ser Ser Ala Lys Val Pro Trp Lys
              1               5                   10                  15
              Ala Ser Tyr Thr Asn Leu Asn Asn Gln Val Ser Thr Glu Glu Val Lys
                          20                  25                  30
              Ser Leu Leu Ser Ala His Leu Asp Pro Asn Ser Val Asp Ala Phe Phe
                      35                  40                  45
              Asn Leu Val Asn Asp Tyr Asn Thr Ile Val Gly Ser Thr Gly Leu Ser
                  50                  55                  60
              Gly Asp Phe Thr Ser Phe Thr His Thr Glu Tyr Asp Val Glu Lys Ile
              65                  70                  75                  80
              Ser His Leu Trp Asn Gln Lys Lys Gly Asp Phe Val Gly Thr Asn Cys
                              85                  90                  95
              Arg Ile Asn Ser Tyr Cys Leu Leu Lys Asn Ser Val Thr Ile Pro Lys
                          100                 105                 110
              Leu Glu Lys Asn Asp Gln Leu Leu Phe Leu Asp Asn Asp Ala Ile Asp
                      115                 120                 125
              Lys Gly Lys Val Phe Asp Ser Gln Asp Lys Glu Glu Phe Asp Ile Leu
                  130                 135                 140
              Phe Ser Arg Val Pro Thr Glu Ser Thr Thr Asp Val Lys Val His Ala
              145                 150                 155                 160
                                                 Page 288

<removed-date>
              Glu Lys Met Glu Ala Phe Phe Ser Gln Phe Gln Phe Asn Glu Lys Ala
                              165                 170                 175
              Arg Met Leu Ser Val Val Leu His Asp Asn Leu Asp Gly Glu Tyr Leu
                          180                 185                 190
              Phe Val Gly His Val Gly Val Leu Val Pro Ala Asp Asp Gly Phe Leu
                      195                 200                 205
<removed-apn>
              Phe Val Glu Lys Leu Thr Phe Glu Glu Pro Tyr Gln Ala Ile Lys Phe
                  210                 215                 220
              Ala Ser Lys Glu Asp Cys Tyr Lys Tyr Leu Gly Thr Lys Tyr Ala Asp
              225                 230                 235                 240
              Tyr Thr Gly Glu Gly Leu Ala Lys Pro Phe Ile Met Asp Asn Asp Lys
                              245                 250                 255
              Trp Val Lys Leu
                          260
              <210>   195
              <211>   284
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 195
              Gly Gln Lys Glu Ser Gln Thr Gly Lys Gly Met Lys Ile Val Thr Ser
              1               5                   10                  15
              Phe Tyr Pro Ile Tyr Ala Met Val Lys Glu Val Ser Gly Asp Leu Asn
                          20                  25                  30
              Asp Val Arg Met Ile Gln Ser Ser Ser Gly Ile His Ser Phe Glu Pro
                      35                  40                  45
              Ser Ala Asn Asp Ile Ala Ala Ile Tyr Asp Ala Asp Val Phe Val Tyr
                  50                  55                  60
              His Ser His Thr Leu Glu Ser Trp Ala Gly Ser Leu Asp Pro Asn Leu
              65                  70                  75                  80
                                                 Page 289

<removed-date>
              Lys Lys Ser Lys Val Lys Val Leu Glu Ala Ser Glu Gly Met Thr Leu
                              85                  90                  95
              Glu Arg Val Pro Gly Leu Glu Asp Val Glu Ala Gly Asp Gly Val Asp
                          100                 105                 110
              Glu Lys Thr Leu Tyr Asp Pro His Thr Trp Leu Asp Pro Glu Lys Ala
<removed-apn>
                      115                 120                 125
              Gly Glu Glu Ala Gln Ile Ile Ala Asp Lys Leu Ser Glu Val Asp Ser
                  130                 135                 140
              Glu His Lys Glu Thr Tyr Gln Lys Asn Ala Gln Ala Phe Ile Lys Lys
              145                 150                 155                 160
              Ala Gln Glu Leu Thr Lys Lys Phe Gln Pro Lys Phe Glu Lys Ala Thr
                              165                 170                 175
              Gln Lys Thr Phe Val Thr Gln His Thr Ala Phe Ser Tyr Leu Ala Lys
                          180                 185                 190
              Arg Phe Gly Leu Asn Gln Leu Gly Ile Ala Gly Ile Ser Pro Glu Gln
                      195                 200                 205
              Glu Pro Ser Pro Arg Gln Leu Thr Glu Ile Gln Glu Phe Val Lys Thr
                  210                 215                 220
              Tyr Lys Val Lys Thr Ile Phe Thr Glu Ser Asn Ala Ser Ser Lys Val
              225                 230                 235                 240
              Ala Glu Thr Leu Val Lys Ser Thr Gly Val Gly Leu Lys Thr Leu Asn
                              245                 250                 255
              Pro Leu Glu Ser Asp Pro Gln Asn Asp Lys Thr Tyr Leu Glu Asn Leu
                          260                 265                 270
              Glu Glu Asn Met Ser Ile Leu Ala Glu Glu Leu Lys
                      275                 280
                                                 Page 290

<removed-date>
              <210>   196
              <211>   181
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 196
              Val His Gln Asp Val Lys Gln Val Met Thr Tyr Gln Pro Met Val Arg
              1               5                   10                  15
<removed-apn>
              Glu Ile Leu Ser Glu Gln Asp Thr Pro Ala Asn Glu Glu Leu Val Leu
                          20                  25                  30
              Ala Met Ile Tyr Thr Glu Thr Lys Gly Lys Glu Gly Asp Val Met Gln
                      35                  40                  45
              Ser Ser Glu Ser Ala Ser Gly Ser Thr Asn Thr Ile Asn Asp Asn Ala
                  50                  55                  60
              Ser Ser Ile Arg Gln Gly Ile Gln Thr Leu Thr Gly Asn Leu Tyr Leu
              65                  70                  75                  80
              Ala Gln Lys Lys Gly Val Asp Ile Trp Thr Ala Val Gln Ala Tyr Asn
                              85                  90                  95
              Phe Gly Pro Ala Tyr Ile Asp Phe Ile Ala Gln Asn Gly Lys Glu Asn
                          100                 105                 110
              Thr Leu Ala Leu Ala Lys Gln Tyr Ser Arg Glu Thr Val Ala Pro Leu
                      115                 120                 125
              Leu Gly Asn Arg Thr Gly Lys Thr Tyr Ser Tyr Ile His Pro Ile Ser
                  130                 135                 140
              Ile Phe His Gly Ala Glu Leu Tyr Val Asn Gly Gly Asn Tyr Tyr Tyr
              145                 150                 155                 160
              Ser Arg Gln Val Arg Leu Asn Leu Tyr Ile Ile Lys Cys Phe Thr Leu
                              165                 170                 175
              Phe Ser Thr Ser Gly
                          180
                                                 Page 291

<removed-date>
              <210>   197
              <211>   320
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 197
              Ser Asn Ser Val Lys Asn Glu Glu Asn Thr Ser Lys Glu His Ala Pro
              1               5                   10                  15
<removed-apn>
              Asp Lys Ile Val Leu Asp His Ala Phe Gly Gln Thr Ile Leu Asp Lys
                          20                  25                  30
              Lys Pro Glu Arg Val Ala Thr Ile Ala Trp Gly Asn His Asp Val Ala
                      35                  40                  45
              Leu Ala Leu Gly Ile Val Pro Val Gly Phe Ser Lys Ala Asn Tyr Gly
                  50                  55                  60
              Val Ser Ala Asp Lys Gly Val Leu Pro Trp Thr Glu Glu Lys Ile Lys
              65                  70                  75                  80
              Glu Leu Asn Gly Lys Ala Asn Leu Phe Asp Asp Leu Asp Gly Leu Asn
                              85                  90                  95
              Phe Glu Ala Ile Ser Asn Ser Lys Pro Asp Val Ile Leu Ala Gly Tyr
                          100                 105                 110
              Ser Gly Ile Thr Lys Glu Asp Tyr Asp Thr Leu Ser Lys Ile Ala Pro
                      115                 120                 125
              Val Ala Ala Tyr Lys Ser Lys Pro Trp Gln Thr Leu Trp Arg Asp Met
                  130                 135                 140
              Ile Lys Ile Asp Ser Lys Ala Leu Gly Met Glu Lys Glu Gly Asp Glu
              145                 150                 155                 160
              Leu Ile Lys Asn Thr Glu Ala Arg Ile Ser Lys Glu Leu Glu Lys His
                              165                 170                 175
              Pro Glu Ile Lys Gly Lys Ile Lys Gly Lys Lys Val Leu Phe Thr Met
                                                 Page 292

                            180                  185              190
<removed-date>
              Ile Asn Ala Ala Asp Thr Ser Lys Phe Trp Ile Tyr Thr Ser Lys Asp
                      195                 200                 205
              Pro Arg Ala Asn Tyr Leu Thr Asp Leu Gly Leu Val Phe Pro Glu Ser
                  210                 215                 220
<removed-apn>
              Leu Lys Glu Phe Glu Ser Glu Asp Ser Phe Ala Lys Glu Ile Ser Ala
              225                 230                 235                 240
              Glu Glu Ala Asn Lys Ile Asn Asp Ala Asp Val Ile Ile Thr Tyr Gly
                              245                 250                 255
              Asp Asp Lys Thr Leu Glu Ala Leu Gln Lys Asp Pro Leu Leu Gly Lys
                          260                 265                 270
              Ile Asn Ala Ile Lys Asn Gly Ala Val Ala Val Ile Pro Asp Asn Thr
                      275                 280                 285
              Pro Leu Ala Ala Ser Cys Thr Pro Thr Pro Leu Ser Ile Asn Tyr Thr
                  290                 295                 300
              Ile Glu Glu Tyr Leu Asn Leu Leu Gly Asn Ala Cys Lys Asn Ala Lys
              305                 310                 315                 320
              <210>   198
              <211>   311
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 198
              Ser Ser Met Asn Lys Ser Glu Ala Gln Asn Asn Lys Asp Glu Lys Lys
              1               5                   10                  15
              Ile Thr Lys Ile Gly Val Leu Gln Phe Val Ser His Pro Ser Leu Asp
                          20                  25                  30
              Leu Ile Tyr Lys Gly Ile Gln Asp Gly Leu Ala Glu Glu Gly Tyr Lys
                      35                  40                  45
                                                       Page 293

              Asp Asp Gln Val Lys Ile Asp Phe Met Asn Ser Glu Gly Asp Gln Ser
<removed-date>
                  50                  55                  60
              Lys Val Ala Thr Met Ser Lys Gln Leu Val Ala Asn Gly Asn Asp Leu
              65                  70                  75                  80
              Val Val Gly Ile Ala Thr Pro Ala Ala Gln Gly Leu Ala Ser Ala Thr
                              85                  90                  95
<removed-apn>
              Lys Asp Leu Pro Val Ile Met Ala Ala Ile Thr Asp Pro Ile Gly Ala
                          100                 105                 110
              Asn Leu Val Lys Asp Leu Lys Lys Pro Gly Gly Asn Val Thr Gly Val
                      115                 120                 125
              Ser Asp His Asn Pro Ala Gln Gln Gln Val Glu Leu Ile Lys Ala Leu
                  130                 135                 140
              Thr Pro Asn Val Lys Thr Ile Gly Ala Leu Tyr Ser Ser Ser Glu Asp
              145                 150                 155                 160
              Asn Ser Lys Thr Gln Val Glu Glu Phe Lys Ala Tyr Ala Glu Lys Ala
                              165                 170                 175
              Gly Leu Thr Val Glu Thr Phe Ala Val Pro Ser Thr Asn Glu Ile Ala
                          180                 185                 190
              Ser Thr Val Thr Val Met Thr Ser Lys Val Asp Ala Ile Trp Val Pro
                      195                 200                 205
              Ile Asp Asn Thr Ile Ala Ser Gly Phe Pro Thr Val Val Ser Ser Asn
                  210                 215                 220
              Gln Ser Ser Lys Lys Pro Ile Tyr Pro Ser Ala Thr Ala Met Val Glu
              225                 230                 235                 240
              Val Gly Gly Leu Ala Ser Val Val Ile Asp Gln His Asp Leu Gly Val
                              245                 250                 255
              Ala Thr Gly Lys Met Ile Val Gln Val Leu Lys Gly Ala Lys Pro Ala
                                                 Page 294

                            260                  265              270
<removed-date>
              Asp Thr Pro Val Asn Val Phe Ser Thr Gly Lys Ser Val Ile Asn Lys
                      275                 280                 285
              Lys Ile Ala Gln Glu Leu Gly Ile Thr Ile Pro Glu Ser Val Leu Lys
                  290                 295                 300
<removed-apn>
              Glu Ala Gly Gln Val Ile Glu
              305                 310
              <210>   199
              <211>   539
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 199
              Glu Asn His Leu Leu Leu Asn Tyr Asn Thr Asp Tyr Glu Leu Thr Ser
              1               5                   10                  15
              Gly Glu Lys Leu Pro Leu Pro Lys Glu Ile Ser Gly Tyr Thr Tyr Ile
                          20                  25                  30
              Gly Tyr Ile Lys Glu Gly Lys Thr Thr Ser Glu Ser Glu Val Ser Asn
                      35                  40                  45
              Gln Lys Ser Ser Val Ala Thr Pro Thr Lys Gln Gln Lys Val Asp Tyr
                  50                  55                  60
              Asn Val Thr Pro Asn Phe Val Asp His Pro Ser Thr Val Gln Ala Ile
              65                  70                  75                  80
              Gln Glu Gln Thr Pro Val Ser Ser Thr Lys Pro Thr Glu Val Gln Val
                              85                  90                  95
              Val Glu Lys Pro Phe Ser Thr Glu Leu Ile Asn Pro Arg Lys Glu Glu
                          100                 105                 110
              Lys Gln Ser Ser Asp Ser Gln Glu Gln Leu Ala Glu His Lys Asn Leu
                      115                 120                 125
                                                       Page 295

              Glu Thr Lys Lys Glu Glu Lys Ile Ser Pro Lys Glu Lys Thr Gly Val
<removed-date>
                  130                 135                 140
              Asn Thr Leu Asn Pro Gln Asp Glu Val Leu Ser Gly Gln Leu Asn Lys
              145                 150                 155                 160
              Pro Glu Leu Leu Tyr Arg Glu Glu Thr Met Glu Thr Lys Ile Asp Phe
                              165                 170                 175
<removed-apn>
              Gln Glu Glu Ile Gln Glu Asn Pro Asp Leu Ala Glu Gly Thr Val Arg
                          180                 185                 190
              Val Lys Gln Glu Gly Lys Leu Gly Lys Lys Val Glu Ile Val Arg Ile
                      195                 200                 205
              Phe Ser Val Asn Lys Glu Glu Val Ser Arg Glu Ile Val Ser Thr Ser
                  210                 215                 220
              Thr Thr Ala Pro Ser Pro Arg Ile Val Glu Lys Gly Thr Lys Lys Thr
              225                 230                 235                 240
              Gln Val Ile Lys Glu Gln Pro Glu Thr Gly Val Glu His Lys Asp Val
                              245                 250                 255
              Gln Ser Gly Ala Ile Val Glu Pro Ala Ile Gln Pro Glu Leu Pro Glu
                          260                 265                 270
              Ala Val Val Ser Asp Lys Gly Glu Pro Glu Val Gln Pro Thr Leu Pro
                      275                 280                 285
              Glu Ala Val Val Thr Asp Lys Gly Glu Thr Glu Val Gln Pro Glu Ser
                  290                 295                 300
              Pro Asp Thr Val Val Ser Asp Lys Gly Glu Pro Glu Gln Val Ala Pro
              305                 310                 315                 320
              Leu Pro Glu Tyr Lys Gly Asn Ile Glu Gln Val Lys Pro Glu Thr Pro
                              325                 330                 335
              Val Glu Lys Thr Lys Glu Gln Gly Pro Glu Lys Thr Glu Glu Val Pro
                                                 Page 296

                          340                 345                 350
<removed-date>
              Val Lys Pro Thr Glu Glu Thr Pro Val Asn Pro Asn Glu Gly Thr Thr
                      355                 360                 365
              Glu Gly Thr Ser Ile Gln Glu Ala Glu Asn Pro Val Gln Pro Ala Glu
                  370                 375                 380
<removed-apn>
              Glu Ser Thr Thr Asn Ser Glu Lys Val Ser Pro Asp Thr Ser Ser Lys
              385                 390                 395                 400
              Asn Thr Gly Glu Val Ser Ser Asn Pro Ser Asp Ser Thr Thr Ser Val
                              405                 410                 415
              Gly Glu Ser Asn Lys Pro Glu His Asn Asp Ser Lys Asn Glu Asn Ser
                          420                 425                 430
              Glu Lys Thr Val Glu Glu Val Pro Val Asn Pro Asn Glu Gly Thr Val
                      435                 440                 445
              Glu Gly Thr Ser Asn Gln Glu Thr Glu Lys Pro Val Gln Pro Ala Glu
                  450                 455                 460
              Glu Thr Gln Thr Asn Ser Gly Lys Ile Ala Asn Glu Asn Thr Gly Glu
              465                 470                 475                 480
              Val Ser Asn Lys Pro Ser Asp Ser Lys Pro Pro Val Glu Glu Ser Asn
                              485                 490                 495
              Gln Pro Glu Lys Asn Gly Thr Ala Thr Lys Pro Glu Asn Ser Gly Asn
                          500                 505                 510
              Thr Thr Ser Glu Asn Gly Gln Thr Glu Pro Glu Pro Ser Asn Gly Asn
                      515                 520                 525
              Ser Thr Glu Asp Val Ser Thr Glu Ser Asn Thr
                  530                 535
              <210> 200
              <211> 690
                                                    Page 297

              <212> PRT
<removed-date>
              <213> Streptococcus pneumoniae
              <400> 200
              Ser Asn Ser Asn Gly Asn Glu Glu Ile Lys Gln Glu Asn Glu Leu Asp
              1               5                   10                  15
              Pro Asp Lys Lys Val Glu Glu Pro Glu Lys Thr Leu Glu Leu Arg Asn
                          20                  25                  30
<removed-apn>
              Val Ser Asp Leu Glu Leu Tyr Ser Leu Ser Asn Gly Thr Tyr Lys Gln
                      35                  40                  45
              His Ile Ser Leu Glu Gln Val Pro Ser Asn Pro Asn Ser Tyr Phe Val
                  50                  55                  60
              Lys Val Lys Ser Ser Ser Phe Lys Asp Val Tyr Leu Pro Val Ala Ser
              65                  70                  75                  80
              Ile Ser Glu Glu Arg Lys Asn Asp Lys Ile Leu Tyr Lys Ile Thr Ala
                              85                  90                  95
              Lys Val Glu Lys Leu Gln Gln Glu Ile Glu Ser Arg Tyr Lys Asp Asn
                          100                 105                 110
              Phe Thr Phe Tyr Leu Ala Lys Lys Gly Thr Glu Glu Thr Thr Asn Phe
                      115                 120                 125
              Thr Ser Phe Ser Asn Leu Val Lys Ala Ile Asn Gln Asn Pro Ser Gly
                  130                 135                 140
              Thr Tyr His Leu Ala Ala Ser Leu Asn Ala Asn Glu Val Glu Leu Gly
              145                 150                 155                 160
              Pro Asp Glu Arg Ser Tyr Ile Lys Asp Thr Phe Thr Gly Arg Leu Ile
                              165                 170                 175
              Gly Glu Lys Asp Gly Lys Asn Tyr Ala Ile Tyr Asn Leu Lys Lys Pro
                          180                 185                 190
              Leu Phe Glu Asn Leu Ser Gly Ala Thr Val Glu Lys Leu Ser Leu Lys
                                                 Page 298

                      195                 200                 205
<removed-date>
              Asn Val Ala Ile Ser Gly Lys Asp Asp Ile Gly Ser Leu Ala Asn Glu
                  210                 215                 220
              Ala Gln Asn Asn Thr Lys Ile Lys Gln Val His Val Asp Gly Val Leu
              225                 230                 235                 240
<removed-apn>
              Ala Gly Glu Arg Gly Ile Gly Gly Leu Leu Ala Lys Ala Glu Gln Ser
                              245                 250                 255
              Ser Ile Thr Glu Ser Ser Phe Lys Gly Arg Ile Ile Asn Thr Tyr Glu
                          260                 265                 270
              Thr Thr Ala Ala Tyr Asn Ile Gly Gly Met Val Gly His Leu Thr Gly
                      275                 280                 285
              Asp Lys Ala Leu Leu Thr Lys Ser Lys Ala Thr Val Ala Ile Ser Ser
                  290                 295                 300
              Asn Thr Asn Thr Ser Asp Gln Thr Val Gly Gly Leu Ala Gly Leu Val
              305                 310                 315                 320
              Asp Arg Asp Ala Gln Ile Gln Asp Ser Tyr Ala Glu Gly Asp Ile Asn
                              325                 330                 335
              Asn Val Lys His Phe Gly Arg Val Ala Gly Val Ala Gly Asn Leu Trp
                          340                 345                 350
              Asp Arg Thr Ser Gly Asp Val Arg His Ala Gly Ser Leu Thr Asn Val
                      355                 360                 365
              Leu Ser Asp Val Asn Val Thr Asn Gly Asn Ala Ile Thr Gly Tyr His
                  370                 375                 380
              Tyr Asn Glu Met Lys Val Lys Asp Thr Phe Ser Ser Lys Ala Asn Arg
              385                 390                 395                 400
              Val Tyr Asn Val Thr Leu Val Lys Asp Glu Val Val Ser Lys Glu Ser
                              405                 410                 415
                                                 Page 299

<removed-date>
              Phe Glu Glu Arg Gly Thr Met Leu Asp Ala Ser Gln Ile Ala Ser Lys
                          420                 425                 430
              Lys Ala Glu Ile Asn Pro Leu Ile Leu Pro Thr Val Glu Pro Leu Ser
                      435                 440                 445
              Thr Ser Gly Lys Lys Asp Ser Asp Phe Ser Lys Val Ala Tyr Tyr Gln
<removed-apn>
                  450                 455                 460
              Ala Lys Arg Asn Leu Thr Tyr Lys Asn Ile Glu Lys Leu Leu Pro Phe
              465                 470                 475                 480
              Tyr Asn Lys Ala Thr Ile Val Lys Tyr Gly Asn Leu Val Asn Glu Asn
                              485                 490                 495
              Ser Leu Leu Tyr Gln Lys Glu Leu Leu Ser Ala Val Met Met Lys Asp
                          500                 505                 510
              Asn Gln Val Ile Thr Asp Ile Val Ser Asn Lys Gln Thr Ala Asn Lys
                      515                 520                 525
              Leu Leu Leu His Tyr Lys Asp Asp Leu Ser Glu Lys Leu Asp Leu Lys
                  530                 535                 540
              Tyr Gln Asn Asp Phe Ala Lys Leu Ala Glu Tyr Ser Leu Gly Asn Thr
              545                 550                 555                 560
              Gly Leu Leu Tyr Thr Pro Asn Gln Phe Leu Tyr Asp Gln Thr Ser Ile
                              565                 570                 575
              Ile Lys Gln Val Leu Pro Asp Leu Gln Lys Val Asp Tyr His Ser Glu
                          580                 585                 590
              Ala Ile Arg Lys Thr Leu Gly Ile Ser Pro Asn Val Lys Gln Thr Glu
                      595                 600                 605
              Leu Tyr Leu Glu Asp Gln Phe Ala Lys Thr Lys Gln Gln Leu Glu Asp
                  610                 615                 620
                                                 Page 300

<removed-date>
              Ser Leu Lys Lys Leu Leu Ser Ala Asp Ala Gly Leu Ala Ser Ala Asn
              625                 630                 635                 640
              Pro Val Thr Glu Gly Tyr Leu Val Asp Lys Ile Lys Arg Asn Lys Glu
                              645                 650                 655
              Ala Leu Leu Leu Gly Leu Thr Tyr Leu Glu Arg Trp Tyr Asn Phe Ser
                          660                 665                 670
<removed-apn>
              Tyr Gly Gln Val Asn Val Lys Asp Leu Val Leu Tyr His Leu Asp Phe
                      675                 680                 685
              Phe Gly
                  690
              <210>   201
              <211>   621
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 201
              Lys Gly Asn Ala Ser Pro Leu Asp Thr Leu Ile Glu Leu Gly Lys Ser
              1               5                   10                  15
              Gly Phe Asn Asn Leu Leu Ala Lys Asn Asn Val Asp Thr Tyr Gly Ile
                          20                  25                  30
              Ser Leu Ala Ser Gln His Gly Thr Thr Asp Leu Phe Ser Thr Leu Glu
                      35                  40                  45
              His Tyr Arg Lys Val Phe Leu Pro Asn Thr Ser Asn Asn Asp Trp Phe
                  50                  55                  60
              Lys Ser Glu Thr Lys Ala Tyr Ile Val Glu Glu Lys Ser Thr Ile Glu
              65                  70                  75                  80
              Glu Val Lys Thr Lys Gln Gly Leu Ala Gly Thr Lys Tyr Ser Ile Gly
                              85                  90                  95
              Val Tyr Asp Arg Ile Thr Ser Ala Thr Trp Lys Tyr Arg Asn Met Val
                          100                 105                 110
                                                 Page 301

<removed-date>
              Leu Pro Leu Leu Thr Leu Pro Glu Arg Ser Val Phe Val Ile Ser Thr
                      115                 120                 125
              Met Ser Ser Leu Gly Phe Gly Ala Tyr Asp Arg Tyr Arg Ser Ser Asp
                  130                 135                 140
              His Lys Ala Gly Lys Ala Leu Asn Asp Phe Val Glu Glu Asn Ala Arg
<removed-apn>
              145                 150                 155                 160
              Glu Thr Ala Lys Arg Gln Arg Asp His Tyr Asp Tyr Trp Tyr Arg Ile
                              165                 170                 175
              Leu Asp Asp Asn Ala Arg Glu Lys Leu Tyr Arg Asn Ile Leu Leu Tyr
                          180                 185                 190
              Asp Ala Tyr Lys Phe Gly Asp Asp Asn Thr Val Gly Lys Ala Thr Glu
                      195                 200                 205
              Val Ala Asp Phe Asp Asn Pro Asn Pro Ala Met Gln His Phe Phe Gly
                  210                 215                 220
              Pro Val Gly Asn Lys Val Gly His Asn Gln His Gly Ala Tyr Ala Thr
              225                 230                 235                 240
              Gly Asp Ala Val Tyr Tyr Met Gly Tyr Arg Met Leu Asp Lys Asp Gly
                              245                 250                 255
              Ala Ile Thr Tyr Thr His Glu Met Thr His Asp Ser Asp Gln Asp Ile
                          260                 265                 270
              Tyr Leu Gly Gly Tyr Gly Arg Arg Ser Gly Leu Gly Pro Glu Phe Phe
                      275                 280                 285
              Ala Lys Gly Leu Leu Gln Ala Pro Asp His Pro Asp Asp Ala Thr Ile
                  290                 295                 300
              Thr Ile Asn Ser Ile Leu Lys His Ser Lys Ser Asp Ser Thr Glu Ser
              305                 310                 315                 320
                                                 Page 302

<removed-date>
              Arg Arg Leu Gln Val Leu Asp Pro Thr Thr Arg Phe Asn Asn Ala Asp
                              325                 330                 335
              Asp Leu Lys Gln Tyr Val His Asn Met Phe Asp Val Val Tyr Met Leu
                          340                 345                 350
              Glu Tyr Leu Glu Gly Asn Ser Ile Leu Lys Leu Asp Thr Asn Gln Lys
                      355                 360                 365
<removed-apn>
              Gln Gln Leu Leu Arg Lys Val Thr Asn Glu Tyr His Pro Asp Pro Asp
                  370                 375                 380
              Gly Asn Lys Val Tyr Ala Thr Asn Val Val Arg Asn Leu Thr Val Glu
              385                 390                 395                 400
              Glu Val Glu Arg Leu Arg Ser Phe Asn Asp Leu Ile Asp Asn Asn Ile
                              405                 410                 415
              Leu Ser Ser Arg Glu Tyr Ala Ser Gly Lys Tyr Glu Arg Asn Gly Tyr
                          420                 425                 430
              Phe Thr Ile Lys Leu Phe Ala Pro Ile Tyr Ala Ala Leu Ser Asn Asp
                      435                 440                 445
              Ile Gly Thr Pro Gly Asp Leu Met Gly Arg Arg Ile Ala Tyr Glu Leu
                  450                 455                 460
              Leu Ala Ala Lys Gly Phe Lys Asp Gly Met Val Pro Tyr Ile Ser Asn
              465                 470                 475                 480
              Gln Tyr Glu Glu Glu Ala Lys Gln Lys Gly Lys Thr Ile Asn Leu Tyr
                              485                 490                 495
              Gly Lys Thr Arg Gly Leu Val Thr Asp Asp Leu Val Leu Glu Lys Val
                          500                 505                 510
              Phe Asn Asn Gln Tyr His Thr Trp Ser Glu Phe Lys Lys Ala Met Tyr
                      515                 520                 525
                                                 Page 303

              Gln Glu Arg Gln Asp Gln Phe Asp Arg Leu Asn Lys Val Thr Phe Asn
<removed-date>
                  530                 535                 540
              Asp Thr Thr Gln Pro Trp Gln Thr Phe Ala Lys Lys Thr Thr Ser Ser
              545                 550                 555                 560
              Val Asp Glu Leu Gln Lys Leu Met Asp Val Ala Val Arg Lys Asp Ala
                              565                 570                 575
<removed-apn>
              Glu His Asn Tyr Tyr His Trp Asn Asn Tyr Asn Pro Asp Ile Asp Ser
                          580                 585                 590
              Glu Val His Lys Leu Lys Arg Ala Ile Phe Lys Ala Tyr Leu Asp Gln
                      595                 600                 605
              Thr Asn Asp Phe Arg Ser Ser Ile Phe Glu Asn Lys Lys
                  610                 615                 620
              <210>   202
              <211>   205
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 202
              Leu Val Gln Val Asn Gln Lys Pro Leu Ile Glu Tyr Gln Ile Glu Phe
              1               5                   10                  15
              Leu Lys Glu Lys Gly Ile Asn Asp Ile Ile Ile Ile Val Gly Tyr Leu
                          20                  25                  30
              Lys Glu Gln Phe Asp Tyr Leu Lys Glu Lys Tyr Gly Val Arg Leu Val
                      35                  40                  45
              Phe Asn Asp Lys Tyr Ala Asp Tyr Asn Asn Phe Tyr Ser Leu Tyr Leu
                  50                  55                  60
              Val Lys Glu Glu Leu Ala Asn Ser Tyr Val Ile Asp Ala Asp Asn Tyr
              65                  70                  75                  80
              Leu Phe Lys Asn Met Phe Arg Asn Asp Leu Thr Arg Ser Thr Tyr Phe
                              85                  90                  95
                                                 Page 304

<removed-date>
              Ser Val Tyr Arg Glu Asp Cys Thr Asn Glu Trp Phe Leu Val Tyr Gly
                          100                 105                 110
              Asp Asp Tyr Lys Val Gln Asp Ile Ile Val Asp Ser Lys Ala Gly Arg
                      115                 120                 125
              Ile Leu Ser Gly Val Ser Phe Trp Asp Ala Pro Thr Ala Glu Lys Ile
                  130                 135                 140
<removed-apn>
              Val Ser Phe Ile Asp Lys Ala Tyr Val Ser Gly Glu Phe Val Asp Leu
              145                 150                 155                 160
              Tyr Trp Asp Asn Met Val Lys Asp Asn Ile Lys Glu Leu Asp Val Tyr
                              165                 170                 175
              Val Glu Glu Leu Glu Gly Asn Ser Ile Tyr Glu Ile Asp Ser Val Gln
                          180                 185                 190
              Asp Tyr Arg Lys Leu Glu Glu Ile Leu Lys Asn Glu Asn
                      195                 200                 205
              <210>   203
              <211>   253
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 203
              Ala Thr Ala Thr Asn Gly Ala Tyr Val Ala Trp Glu Ile Glu Ala Ser
              1               5                   10                  15
              Asp Leu Val Glu Thr Val Ala Asn Ile Arg Arg Tyr Gln Met Phe Gly
                          20                  25                  30
              Ile Asn Leu Ser Met Pro Tyr Lys Glu Gln Val Ile Pro Tyr Leu Asp
                      35                  40                  45
              Lys Leu Ser Asp Glu Ala Arg Leu Ile Gly Ala Val Asn Thr Val Val
                  50                  55                  60
              Asn Glu Asn Gly Asn Leu Ile Gly Tyr Asn Thr Asp Gly Lys Gly Phe
              65                  70                  75                  80
                                                 Page 305

<removed-date>
              Phe Lys Cys Leu Pro Ser Phe Thr Ile Ser Gly Lys Lys Met Thr Leu
                              85                  90                  95
              Leu Gly Ala Gly Gly Ala Ala Lys Ser Ile Leu Ala Gln Ala Ile Leu
                          100                 105                 110
              Asp Gly Val Ser Gln Ile Ser Val Phe Val Arg Ser Val Ser Met Glu
<removed-apn>
                      115                 120                 125
              Lys Thr Arg Pro Tyr Leu Asp Lys Leu Gln Glu Gln Thr Gly Phe Lys
                  130                 135                 140
              Val Asp Leu Cys Ala Leu Glu Tyr Val Ser Glu Leu Gln Ala Arg Ile
              145                 150                 155                 160
              Ala Glu Ser Asp Leu Leu Val Asn Ala Thr Ser Val Gly Met Asp Gly
                              165                 170                 175
              Gln Ser Ser Pro Val Pro Glu Asn Ile Val Leu Pro Glu Thr Leu Leu
                          180                 185                 190
              Val Ala Asp Ile Ile Tyr Gln Pro Phe Glu Thr Pro Phe Leu Lys Trp
                      195                 200                 205
              Ala Arg Ser Gln Gly Asn Pro Ala Val Asn Gly Leu Gly Met Leu Leu
                  210                 215                 220
              Tyr Gln Ala Ala Glu Ala Phe Gln Leu Trp Thr Gly Lys Glu Met Pro
              225                 230                 235                 240
              Thr Glu Glu Ile Trp Gln Ser Leu Thr Glu Lys Tyr Gln
                              245                 250
              <210>   204
              <211>   324
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 204
              Asp Ser Gln Lys Leu Val Ile Tyr Asn Trp Gly Asp Tyr Ile Asp Pro
                                                 Page 306

              1               5                   10                  15
<removed-date>
              Glu Leu Leu Thr Gln Phe Thr Glu Glu Thr Gly Ile Gln Val Gln Tyr
                          20                  25                  30
              Glu Thr Phe Asp Ser Asn Glu Ala Met Tyr Thr Lys Ile Lys Gln Gly
                      35                  40                  45
<removed-apn>
              Gly Thr Thr Tyr Asp Ile Ala Ile Pro Ser Glu Tyr Met Ile Asn Lys
                  50                  55                  60
              Met Lys Asp Glu Asp Leu Leu Val Pro Leu Asp Tyr Ser Lys Ile Glu
              65                  70                  75                  80
              Gly Ile Glu Asn Ile Gly Pro Glu Phe Leu Asn Gln Ser Phe Asp Pro
                              85                  90                  95
              Gly Asn Lys Phe Ser Ile Pro Tyr Phe Trp Gly Thr Leu Gly Ile Val
                          100                 105                 110
              Tyr Asn Glu Thr Met Val Asp Glu Ala Pro Glu His Trp Asp Asp Leu
                      115                 120                 125
              Trp Lys Pro Glu Tyr Lys Asn Ser Ile Met Leu Phe Asp Gly Ala Arg
                  130                 135                 140
              Glu Val Leu Gly Leu Gly Leu Asn Ser Leu Gly Tyr Ser Leu Asn Ser
              145                 150                 155                 160
              Lys Asp Leu Gln Gln Leu Glu Glu Thr Val Asp Lys Leu Tyr Lys Leu
                              165                 170                 175
              Thr Pro Asn Ile Lys Ala Ile Val Ala Asp Glu Met Lys Gly Tyr Met
                          180                 185                 190
              Ile Gln Asn Asn Val Ala Ile Gly Val Thr Phe Ser Gly Glu Ala Ser
                      195                 200                 205
              Gln Met Leu Glu Lys Asn Glu Asn Leu Arg Tyr Val Val Pro Thr Glu
                  210                 215                 220
                                                 Page 307

<removed-date>
              Ala Ser Asn Leu Trp Phe Asp Asn Met Val Ile Pro Lys Thr Val Lys
              225                 230                 235                 240
              Asn Gln Asn Ser Ala Tyr Ala Phe Ile Asn Phe Met Leu Lys Pro Glu
                              245                 250                 255
              Asn Ala Leu Gln Asn Ala Glu Tyr Val Gly Tyr Ser Thr Pro Asn Leu
<removed-apn>
                          260                 265                 270
              Pro Ala Lys Glu Leu Leu Pro Glu Glu Thr Lys Glu Asp Lys Ala Phe
                      275                 280                 285
              Tyr Pro Asp Val Glu Thr Met Lys His Leu Glu Val Tyr Glu Lys Phe
                  290                 295                 300
              Asp His Lys Trp Thr Gly Lys Tyr Ser Asp Leu Phe Leu Gln Phe Lys
              305                 310                 315                 320
              Met Tyr Arg Lys
              <210>   205
              <211>   62
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 205
              Ala Tyr Glu Gly Lys Val Glu Ala Lys Lys Leu Leu Asp Ser Tyr Lys
              1               5                   10                  15
              Gly Phe Lys Ala Val Val Pro Ser Lys Ser Glu Glu Lys Arg Leu Gly
                          20                  25                  30
              Arg Glu Phe Glu Thr Val Ser Gly Tyr Ser Leu Tyr Arg Ala Val Gln
                      35                  40                  45
              Ala Ala Lys Glu Lys Gly Glu Gly Lys Ile Ser Leu Gly Lys
                  50                  55                  60
              <210> 206
                                                 Page 308

              <211> 115
<removed-date>
              <212> PRT
              <213> Streptococcus pneumoniae
              <400> 206
              Trp Leu Glu Lys His Lys Val Pro Phe Val Glu His Asn Ile Met Thr
              1               5                   10                  15
              Ser Pro Leu Thr Arg Lys Glu Leu Gln His Ile Leu Ser Leu Thr Glu
                          20                  25                  30
<removed-apn>
              Asn Gly Thr Asp Asp Ile Ile Ser Thr Arg Ser Lys Ile Phe Gln Lys
                      35                  40                  45
              Leu Asn Ile Asp Val Glu Ser Ile Ser Val Ser Glu Leu Leu His Leu
                  50                  55                  60
              Ile Glu Gln Tyr Pro Ser Leu Leu Arg Arg Pro Ile Ile Ile Asp Ala
              65                  70                  75                  80
              Lys Arg Met Gln Ile Gly Phe Asn Glu Asp Glu Ile Arg Ala Phe Leu
                              85                  90                  95
              Pro Arg Ser Tyr Arg Lys Gln Glu Leu Lys Glu Ala Arg Met Arg Ala
                          100                 105                 110
              Gly Ile Ser
                      115
              <210>   207
              <211>   157
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 207
              Met Phe Gln Asn Trp Ala Ser Ser Ala Glu Asn Leu Thr Tyr Val Thr
              1               5                   10                  15
              Trp Asp Pro His Pro Asp Val Glu Ile Thr Arg Asn Ser Ile Cys Asn
                          20                  25                  30
              Trp Val Ala Ser Tyr Thr Asn Leu Asn Tyr Tyr Lys Trp Ala Ile Cys
                      35                  40                  45
                                                 Page 309

<removed-date>
              Leu Lys Glu Asn Pro Glu Gln Val Ile Gly Asp Ile Ser Ile Val Lys
                  50                  55                  60
              Ile Asp Glu Ala Asp Leu Ser Cys Glu Ile Gly Tyr Val Leu Gly Lys
              65                  70                  75                  80
              Ala Tyr Trp Gly Asn Gly Met Met Thr Glu Thr Leu Lys Ala Ile Leu
<removed-apn>
                              85                  90                  95
              Asp Phe Cys Phe Thr Gln Ala Gly Phe Gln Lys Val Arg Ala Arg Tyr
                          100                 105                 110
              Ala Ser Leu Asn Pro Ala Ser Gly Arg Val Met Glu Lys Ala Gly Met
                      115                 120                 125
              Ser Tyr Leu Gln Thr Ile Val Asn Gly Val Glu Arg Lys Gly Tyr Leu
                  130                 135                 140
              Ala Asp Leu Ile Tyr Tyr Gly Ile Ser Arg Glu Glu Cys
              145                 150                 155
              <210>   208
              <211>   425
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 208
              Lys Ile Tyr Gln Gln Lys Ser Phe Glu Gln Lys Ile Glu Ser Leu Lys
              1               5                   10                  15
              Lys Glu Lys Asp Asp Gln Leu Ser Glu Gly Asn Gln Lys Glu His Phe
                          20                  25                  30
              Arg Gln Gly Gln Ala Glu Val Ile Ala Tyr Tyr Pro Leu Gln Gly Glu
                      35                  40                  45
              Lys Val Ile Ser Ser Val Arg Glu Leu Ile Asn Gln Asp Val Lys Asp
                  50                  55                  60
              Lys Leu Glu Ser Lys Asp Asn Leu Val Phe Tyr Tyr Thr Glu Gln Glu
                                                 Page 310

              65                  70                  75                  80
<removed-date>
              Glu Ser Gly Leu Lys Gly Val Val Asn Arg Asn Val Thr Lys Gln Ile
                              85                  90                  95
              Tyr Asp Leu Val Ala Phe Lys Ile Glu Glu Thr Glu Lys Thr Ser Leu
                          100                 105                 110
<removed-apn>
              Gly Lys Val His Leu Thr Glu Asp Gly Gln Pro Phe Thr Leu Asp Gln
                      115                 120                 125
              Leu Phe Ser Asp Ala Ser Lys Ala Lys Glu Gln Leu Ile Lys Glu Leu
                  130                 135                 140
              Thr Ser Phe Ile Glu Asp Lys Lys Ile Glu Gln Asp Gln Ser Glu Gln
              145                 150                 155                 160
              Ile Val Lys Asn Phe Ser Asp Gln Asp Leu Ser Ala Trp Asn Phe Asp
                              165                 170                 175
              Tyr Lys Asp Ser Gln Ile Ile Leu Tyr Pro Ser Pro Val Val Glu Asn
                          180                 185                 190
              Leu Glu Glu Ile Ala Leu Pro Val Ser Ala Phe Phe Asp Val Ile Gln
                      195                 200                 205
              Ser Ser Tyr Leu Leu Glu Lys Asp Ala Ala Leu Tyr Gln Ser Tyr Phe
                  210                 215                 220
              Asp Lys Lys His Gln Lys Val Val Ala Leu Thr Phe Asp Asp Gly Pro
              225                 230                 235                 240
              Asn Pro Ala Thr Thr Pro Gln Val Leu Glu Thr Leu Ala Lys Tyr Asp
                              245                 250                 255
              Ile Lys Ala Thr Phe Phe Val Leu Gly Lys Asn Val Ser Gly Asn Glu
                          260                 265                 270
              Asp Leu Val Lys Arg Ile Lys Ser Glu Gly His Val Val Gly Asn His
                      275                 280                 285
                                                 Page 311

<removed-date>
              Ser Trp Ser His Pro Ile Leu Ser Gln Leu Ser Leu Asp Glu Ala Lys
                  290                 295                 300
              Lys Gln Ile Thr Asp Thr Glu Asp Val Leu Thr Lys Val Leu Gly Ser
              305                 310                 315                 320
              Ser Ser Lys Leu Met Arg Pro Pro Tyr Gly Ala Ile Thr Asp Asp Ile
<removed-apn>
                              325                 330                 335
              Arg Asn Ser Leu Asp Leu Ser Phe Ile Met Trp Asp Val Asp Ser Leu
                          340                 345                 350
              Asp Trp Lys Ser Lys Asn Glu Ala Ser Ile Leu Thr Glu Ile Gln Tyr
                      355                 360                 365
              Gln Val Ala Asn Gly Ser Ile Val Leu Met His Asp Ile His Ser Pro
                  370                 375                 380
              Thr Val Asn Ala Leu Pro Arg Val Ile Glu Tyr Leu Lys Asn Gln Gly
              385                 390                 395                 400
              Tyr Thr Phe Val Thr Ile Pro Glu Met Leu Asn Thr Arg Leu Lys Ala
                              405                 410                 415
              His Glu Leu Tyr Tyr Ser Arg Asp Glu
                          420                 425
              <210>   209
              <211>   252
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 209
              Thr Ser Gly Asp Asn Trp Ser Lys Tyr Gln Ser Asn Lys Ser Ile Thr
              1               5                   10                  15
              Ile Gly Phe Asp Ser Thr Phe Val Pro Met Gly Phe Ala Gln Lys Asp
                          20                  25                  30
              Gly Ser Tyr Ala Gly Phe Asp Ile Asp Leu Ala Thr Ala Val Phe Glu
                                                    Page 312

                      35                  40                    45
<removed-date>
              Lys Tyr Gly Ile Thr Val Asn Trp Gln Pro Ile Asp Trp Asp Leu Lys
                  50                  55                  60
              Glu Ala Glu Leu Thr Lys Gly Thr Ile Asp Leu Ile Trp Asn Gly Tyr
              65                  70                  75                  80
<removed-apn>
              Ser Ala Thr Asp Glu Arg Arg Glu Lys Val Ala Phe Ser Asn Ser Tyr
                              85                  90                  95
              Met Lys Asn Glu Gln Val Leu Val Thr Lys Lys Ser Ser Gly Ile Thr
                          100                 105                 110
              Thr Ala Lys Asp Met Thr Gly Lys Thr Leu Gly Ala Gln Ala Gly Ser
                      115                 120                 125
              Ser Gly Tyr Ala Asp Phe Glu Ala Asn Pro Glu Ile Leu Lys Asn Ile
                  130                 135                 140
              Val Ala Asn Lys Glu Ala Asn Gln Tyr Gln Thr Phe Asn Glu Ala Leu
              145                 150                 155                 160
              Ile Asp Leu Lys Asn Asp Arg Ile Asp Gly Leu Leu Ile Asp Arg Val
                              165                 170                 175
              Tyr Ala Asn Tyr Tyr Leu Glu Ala Glu Gly Val Leu Asn Asp Tyr Asn
                          180                 185                 190
              Val Phe Thr Val Gly Leu Glu Thr Glu Ala Phe Ala Val Gly Ala Arg
                      195                 200                 205
              Lys Glu Asp Thr Asn Leu Val Lys Lys Ile Asn Glu Ala Phe Ser Ser
                  210                 215                 220
              Leu Tyr Lys Asp Gly Lys Phe Gln Glu Ile Ser Gln Lys Trp Phe Gly
              225                 230                 235                 240
              Glu Asp Val Ala Thr Lys Glu Val Lys Glu Gly Gln
                              245                 250
                                                 Page 313

<removed-date>
              <210>   210
              <211>   115
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 210
              Glu Gly Glu Lys Leu Ala Gln Gln Tyr Ala Gly Leu Glu Gln Ala Asp
              1               5                   10                  15
<removed-apn>
              Gln Val Asp Leu Tyr Asn Gly Leu Glu Ser Tyr Tyr Ser Val Leu Gly
                          20                  25                  30
              Arg Asn Lys Gln Gln Glu Ala Leu Ala Val Leu Ile Gly Lys Asp Asp
                      35                  40                  45
              His Lys Ile Tyr Val Tyr Gln Leu Asn Gln Gly Val Ser Gln Glu Lys
                  50                  55                  60
              Ala Glu Thr Val Ser Lys Glu Lys Gly Ala Gly Glu Ile Asp Lys Ile
              65                  70                  75                  80
              Thr Phe Gly Arg Tyr Gln Asp Lys Pro Ile Trp Glu Val Lys Ser Gly
                              85                  90                  95
              Ser Asp Phe Tyr Leu Val Asp Phe Glu Thr Gly Ala Leu Val Asn Lys
                          100                 105                 110
              Glu Gly Leu
                      115
              <210>   211
              <211>   232
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 211
              Gln Asn Ser Thr Ser Ala Arg Gln Val Lys Thr Glu Thr Tyr Thr Asn
              1               5                   10                  15
              Thr Val Thr Asn Val Pro Ile Asp Ile Arg Tyr Asn Ser Asp Lys Tyr
                          20                  25                  30
                                                 Page 314

<removed-date>
              Phe Ile Ser Gly Phe Ala Ser Glu Val Ser Val Val Leu Thr Gly Ala
                      35                  40                  45
              Asn Arg Leu Ser Leu Ala Ser Glu Met Gln Glu Ser Thr Arg Lys Phe
                  50                  55                  60
              Lys Val Thr Ala Asp Leu Thr Asp Ala Gly Val Gly Thr Ile Glu Val
              65                  70                  75                  80
<removed-apn>
              Pro Leu Ser Ile Glu Asp Leu Pro Asn Gly Leu Thr Ala Val Ala Thr
                              85                  90                  95
              Pro Gln Lys Ile Thr Val Lys Ile Gly Lys Lys Ala Gln Lys Asp Lys
                          100                 105                 110
              Val Lys Ile Val Pro Glu Ile Asp Pro Ser Gln Ile Asp Ser Arg Val
                      115                 120                 125
              Gln Ile Glu Asn Val Met Val Ser Asp Lys Glu Val Ser Ile Thr Ser
                  130                 135                 140
              Asp Gln Glu Thr Leu Asp Arg Ile Asp Lys Ile Ile Ala Val Leu Pro
              145                 150                 155                 160
              Thr Ser Glu Arg Ile Thr Gly Asn Tyr Ser Gly Ser Val Pro Leu Gln
                              165                 170                 175
              Ala Ile Asp Arg Asn Gly Val Val Leu Pro Ala Val Ile Thr Pro Phe
                          180                 185                 190
              Asp Thr Ile Met Lys Val Thr Thr Lys Pro Val Ala Pro Ser Ser Ser
                      195                 200                 205
              Thr Ser Asn Ser Ser Thr Ser Ser Ser Ser Glu Thr Ser Ser Ser Thr
                  210                 215                 220
              Lys Ala Thr Ser Ser Lys Thr Asn
              225                 230
                                                 Page 315

              <210>   212
<removed-date>
              <211>   217
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 212
              Met Phe Tyr Thr Tyr Leu Arg Gly Leu Val Val Leu Leu Leu Trp Ser
              1               5                   10                  15
              Ile Asn Gly Asn Ala His Tyr His Asn Thr Asp Lys Ile Pro Asn Gln
<removed-apn>
                          20                  25                  30
              Asp Glu Asn Tyr Ile Leu Val Ala Pro His Arg Thr Trp Trp Asp Pro
                      35                  40                  45
              Val Tyr Met Ala Phe Ala Thr Lys Pro Lys Gln Phe Ile Phe Met Ala
                  50                  55                  60
              Lys Lys Glu Leu Phe Thr Asn Arg Ile Phe Gly Trp Trp Ile Arg Met
              65                  70                  75                  80
              Cys Gly Ala Phe Pro Ile Asp Arg Glu Asn Pro Ser Ala Ser Ala Ile
                              85                  90                  95
              Lys Tyr Pro Ile Asn Val Leu Lys Lys Ser Asp Arg Ser Leu Ile Met
                          100                 105                 110
              Phe Pro Ser Gly Ser Arg His Ser Asn Asp Val Lys Gly Gly Ala Ala
                      115                 120                 125
              Leu Ile Ala Lys Met Ala Lys Val Arg Ile Met Pro Val Thr Tyr Thr
                  130                 135                 140
              Gly Pro Met Thr Leu Lys Gly Leu Ile Ser Arg Glu Arg Val Asp Met
              145                 150                 155                 160
              Asn Phe Gly Asn Pro Ile Asp Ile Ser Asp Ile Lys Lys Met Asn Asp
                              165                 170                 175
              Glu Gly Ile Glu Thr Val Ala Asn Arg Ile Gln Thr Glu Phe Gln Arg
                          180                 185                 190
                                                 Page 316

<removed-date>
              Leu Asp Glu Glu Thr Lys Gln Trp His Asn Asp Lys Lys Pro Asn Pro
                      195                 200                 205
              Leu Trp Trp Phe Ile Arg Ile Pro Ala
                  210                 215
              <210>   213
              <211>   336
<removed-apn>
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 213
              Lys Val Thr Ser Pro Asn Met Glu Ala Thr Ala Asn Ala Tyr Leu Thr
              1               5                   10                  15
              Thr Ala Gln Thr Leu Asp Leu Ala Val Met Ser Asn Tyr Gly Leu Asp
                          20                  25                  30
              Gln Ala Asp Gln Glu Glu Leu Lys Gln Thr Glu Gly Ala Glu Val Glu
                      35                  40                  45
              Phe Gly Tyr Leu Thr Asp Val Thr Met Asp Asn Gly Gln Asp Ala Ile
                  50                  55                  60
              Arg Leu Tyr Ser Lys Pro Glu Arg Ile Ser Thr Phe Gln Leu Arg Lys
              65                  70                  75                  80
              Gly Arg Leu Pro Gln Ser Asp Lys Glu Ile Ala Leu Ala Thr His Leu
                              85                  90                  95
              Gln Gly Gln Tyr Ser Val Gly Gln Glu Ile Ser Phe Lys Glu Lys Glu
                          100                 105                 110
              Glu Gly His Ser Ser Leu Lys Asp His Thr Tyr Thr Ile Thr Gly Phe
                      115                 120                 125
              Val Asp Ser Ala Glu Ile Leu Ser Gln Arg Asp Met Gly Tyr Ala Gly
                  130                 135                 140
              Ser Gly Ser Gly Thr Leu Thr Ala Tyr Gly Val Ile Leu Pro Ser Gln
              145                 150                 155                 160
                                                    Page 317

<removed-date>
              Phe Asp Gln Lys Val Tyr Asn Ile Ala Arg Leu Lys Tyr Gln Asp Leu
                              165                 170                 175
              Ala Gly Leu Asn Ala Phe Ser Ser Ala Tyr Glu Glu Lys Ser Lys Gln
                          180                 185                 190
              His Gln Glu Glu Leu Glu Gln Ile Leu Ser Asp Asn Gly Lys Val Arg
<removed-apn>
                      195                 200                 205
              Leu Gln Leu Leu Lys Lys Glu Gly Gln Glu Ser Leu Asp Lys Gly Gln
                  210                 215                 220
              Glu Thr Leu Asp Lys Ala Gln Thr Asn Leu Gln Glu Gly Lys Arg Arg
              225                 230                 235                 240
              Leu Ala Ala Ala Gln Ala Arg Ile Gln Ala Gln Glu Ser Gln Leu Ala
                              245                 250                 255
              Leu Phe Pro Gln Val Gln Arg Glu Gln Ala Ser Ala Gln Leu Thr Gln
                          260                 265                 270
              Ala Lys Gln Glu Leu Gly Lys Glu Glu Asp Lys Leu Lys Gln Ala Glu
                      275                 280                 285
              Gln Asn Leu Ala Gln Glu Lys Glu Lys Leu Glu Lys His Gln Gln Val
                  290                 295                 300
              Leu Asp Asp Leu Ala Glu Pro Arg Tyr Gln Val Tyr Asn Arg Gln Thr
              305                 310                 315                 320
              Met Pro Gly Gly Gln Gly Tyr Leu Met Tyr Ser Asn Ala Ser Ser Ser
                              325                 330                 335
              <210>   214
              <211>   378
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 214
              Lys Ser Ile Ile Glu Ala Phe Glu Lys Ala Asn Pro Asp Ile Lys Val
                                                 Page 318

              1               5                   10                  15
<removed-date>
              Lys Leu Glu Thr Ile Asp Phe Lys Ser Gly Pro Glu Lys Ile Thr Thr
                          20                  25                  30
              Ala Ile Glu Ala Gly Thr Ala Pro Asp Val Leu Phe Asp Ala Pro Gly
                      35                  40                  45
<removed-apn>
              Arg Ile Ile Gln Tyr Gly Lys Asn Gly Lys Leu Ala Glu Leu Asn Asp
                  50                  55                  60
              Leu Phe Thr Asp Glu Phe Val Lys Asp Val Asn Asn Glu Asn Ile Val
              65                  70                  75                  80
              Gln Ala Ser Lys Ala Gly Asp Lys Ala Tyr Met Tyr Pro Ile Ser Ser
                              85                  90                  95
              Ala Pro Phe Tyr Met Ala Met Asn Lys Lys Met Leu Glu Asp Ala Gly
                          100                 105                 110
              Val Ala Asn Leu Val Lys Glu Gly Trp Thr Thr Asp Asp Phe Glu Lys
                      115                 120                 125
              Val Leu Lys Ala Leu Lys Asp Lys Gly Tyr Thr Pro Gly Ser Leu Phe
                  130                 135                 140
              Ser Ser Gly Gln Gly Gly Asp Gln Gly Thr Arg Ala Phe Ile Ser Asn
              145                 150                 155                 160
              Leu Tyr Ser Gly Ser Val Thr Asp Glu Lys Val Ser Lys Tyr Thr Thr
                              165                 170                 175
              Asp Asp Pro Lys Phe Val Lys Gly Leu Glu Lys Ala Thr Ser Trp Ile
                          180                 185                 190
              Lys Asp Asn Leu Ile Asn Asn Gly Ser Gln Phe Asp Gly Gly Ala Asp
                      195                 200                 205
              Ile Gln Asn Phe Ala Asn Gly Gln Thr Ser Tyr Thr Ile Leu Trp Ala
                  210                 215                 220
                                                 Page 319

<removed-date>
              Pro Ala Gln Asn Gly Ile Gln Ala Lys Leu Leu Glu Ala Ser Lys Val
              225                 230                 235                 240
              Glu Val Val Glu Val Pro Phe Pro Ser Asp Glu Gly Lys Pro Ala Leu
                              245                 250                 255
              Glu Tyr Leu Val Asn Gly Phe Ala Val Phe Asn Asn Lys Asp Asp Lys
<removed-apn>
                          260                 265                 270
              Lys Val Ala Ala Ser Lys Lys Phe Ile Gln Phe Ile Ala Asp Asp Lys
                      275                 280                 285
              Glu Trp Gly Pro Lys Asp Val Val Arg Thr Gly Ala Phe Pro Val Arg
                  290                 295                 300
              Thr Ser Phe Gly Lys Leu Tyr Glu Asp Lys Arg Met Glu Thr Ile Ser
              305                 310                 315                 320
              Gly Trp Thr Gln Tyr Tyr Ser Pro Tyr Tyr Asn Thr Ile Asp Gly Phe
                              325                 330                 335
              Ala Glu Met Arg Thr Leu Trp Phe Pro Met Leu Gln Ser Val Ser Asn
                          340                 345                 350
              Gly Asp Glu Lys Pro Ala Asp Ala Leu Lys Ala Phe Thr Glu Lys Ala
                      355                 360                 365
              Asn Glu Thr Ile Lys Lys Ala Met Lys Gln
                  370                 375
              <210>   215
              <211>   320
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 215
              Glu Glu Lys Ala Asp Lys Ser Gln Glu Leu Val Ile Tyr Ser Asn Ser
              1               5                   10                  15
              Val Ser Asn Gly Arg Gly Asp Trp Leu Thr Ala Lys Ala Lys Glu Ala
                                                 Page 320

                          20                  25                  30
<removed-date>
              Gly Phe Asn Ile Lys Met Val Asp Ile Ala Gly Ala Gln Leu Ala Asp
                      35                  40                  45
              Arg Val Ile Ala Glu Lys Asn Asn Ala Val Ala Asp Met Val Phe Gly
                  50                  55                  60
<removed-apn>
              Ile Gly Ala Val Asp Ser Asn Lys Ile Arg Asp Gln Lys Leu Leu Val
              65                  70                  75                  80
              Gln Tyr Lys Pro Lys Trp Leu Asp Lys Ile Asp Gln Ser Leu Ser Asp
                              85                  90                  95
              Lys Asp Asn Tyr Tyr Asn Pro Val Ile Val Gln Pro Leu Val Leu Ile
                          100                 105                 110
              Gly Ala Pro Asp Val Lys Glu Met Pro Lys Asp Trp Thr Glu Leu Gly
                      115                 120                 125
              Ser Lys Tyr Lys Gly Lys Tyr Ser Ile Ser Gly Leu Gln Gly Gly Thr
                  130                 135                 140
              Gly Arg Ala Ile Leu Ala Ser Ile Leu Val Arg Tyr Leu Asp Asp Lys
              145                 150                 155                 160
              Gly Glu Leu Gly Val Ser Glu Lys Gly Trp Glu Val Ala Lys Glu Tyr
                              165                 170                 175
              Leu Lys Asn Ala Tyr Thr Leu Gln Lys Gly Glu Ser Ser Ile Val Lys
                          180                 185                 190
              Met Leu Asp Lys Glu Asp Pro Ile Gln Tyr Gly Met Met Trp Gly Ser
                      195                 200                 205
              Gly Ala Leu Val Gly Gln Lys Glu Gln Asn Val Val Phe Lys Val Met
                  210                 215                 220
              Thr Pro Glu Ile Gly Val Pro Phe Val Thr Glu Gln Thr Met Val Leu
              225                 230                 235                 240
                                                   Page 321

<removed-date>
              Ser Thr Ser Lys Lys Gln Ala Leu Ala Lys Glu Phe Ile Asp Trp Phe
                              245                 250                 255
              Gly Gln Ser Glu Ile Gln Val Glu Tyr Ser Lys Asn Phe Gly Ser Ile
                          260                 265                 270
              Pro Ala Asn Lys Asp Ala Leu Lys Asp Leu Pro Glu Asp Thr Lys Lys
<removed-apn>
                      275                 280                 285
              Phe Val Asp Gln Val Lys Pro Gln Asn Ile Asp Trp Glu Ala Val Gly
                  290                 295                 300
              Lys His Leu Asp Glu Trp Val Glu Lys Ala Glu Leu Glu Tyr Val Gln
              305                 310                 315                 320
              <210>   216
              <211>   282
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 216
              Thr Glu Val Thr Ile Lys Ser Ser Leu Asp Glu Val Lys Leu Ser Lys
              1               5                   10                  15
              Val Pro Glu Lys Ile Val Thr Phe Asp Leu Gly Ala Ala Asp Thr Ile
                          20                  25                  30
              Arg Ala Leu Gly Phe Glu Lys Asn Ile Val Gly Met Pro Thr Lys Thr
                      35                  40                  45
              Val Pro Thr Tyr Leu Lys Asp Leu Val Gly Thr Val Lys Asn Val Gly
                  50                  55                  60
              Ser Met Lys Glu Pro Asp Leu Glu Ala Ile Ala Ala Leu Glu Pro Asp
              65                  70                  75                  80
              Leu Ile Ile Ala Ser Pro Arg Thr Gln Lys Phe Val Asp Lys Phe Lys
                              85                  90                  95
              Glu Ile Ala Pro Thr Val Leu Phe Gln Ala Ser Lys Asp Asp Tyr Trp
                                                 Page 322

                            100                  105              110
<removed-date>
              Thr Ser Thr Lys Ala Asn Ile Glu Ser Leu Ala Ser Ala Phe Gly Glu
                      115                 120                 125
              Thr Gly Thr Gln Lys Ala Lys Glu Glu Leu Thr Lys Leu Asp Lys Ser
                  130                 135                 140
<removed-apn>
              Ile Gln Glu Val Ala Thr Lys Asn Glu Ser Ser Asp Lys Lys Ala Leu
              145                 150                 155                 160
              Ala Ile Leu Leu Asn Glu Gly Lys Met Ala Ala Phe Gly Ala Lys Ser
                              165                 170                 175
              Arg Phe Ser Phe Leu Tyr Gln Thr Leu Lys Phe Lys Pro Thr Asp Thr
                          180                 185                 190
              Lys Phe Glu Asp Ser Arg His Gly Gln Glu Val Ser Phe Glu Ser Val
                      195                 200                 205
              Lys Glu Ile Asn Pro Asp Ile Leu Phe Val Ile Asn Arg Thr Leu Ala
                  210                 215                 220
              Ile Gly Gly Asp Asn Ser Ser Asn Asp Gly Val Leu Glu Asn Ala Leu
              225                 230                 235                 240
              Ile Ala Glu Thr Pro Ala Ala Lys Asn Gly Lys Ile Ile Gln Leu Thr
                              245                 250                 255
              Pro Asp Leu Trp Tyr Leu Ser Gly Gly Gly Leu Glu Ser Thr Lys Leu
                          260                 265                 270
              Met Ile Glu Asp Ile Gln Lys Ala Leu Lys
                      275                 280
              <210>   217
              <211>   619
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 217
                                                       Page 323

              Tyr Thr Ala Asp Pro Glu Thr Leu Asp Tyr Leu Ile Ser Ser Lys Asn
<removed-date>
              1               5                   10                  15
              Ser Thr Thr Val Val Thr Ser Asn Gly Ile Asp Gly Leu Phe Thr Asn
                          20                  25                  30
              Asp Asn Tyr Gly Asn Leu Ala Pro Ala Val Ala Glu Asp Trp Glu Val
                      35                  40                  45
<removed-apn>
              Ser Lys Asp Gly Leu Thr Tyr Thr Tyr Lys Ile Arg Lys Gly Val Lys
                  50                  55                  60
              Trp Phe Thr Ser Asp Gly Glu Glu Tyr Ala Glu Val Thr Ala Lys Asp
              65                  70                  75                  80
              Phe Val Asn Gly Leu Lys His Ala Ala Asp Lys Lys Ser Glu Ala Met
                              85                  90                  95
              Tyr Leu Ala Glu Asn Ser Val Lys Gly Leu Ala Asp Tyr Leu Ser Gly
                          100                 105                 110
              Thr Ser Thr Asp Phe Ser Thr Val Gly Val Lys Ala Val Asp Asp Tyr
                      115                 120                 125
              Thr Leu Gln Tyr Thr Leu Asn Gln Pro Glu Pro Phe Trp Asn Ser Lys
                  130                 135                 140
              Leu Thr Tyr Ser Ile Phe Trp Pro Leu Asn Glu Glu Phe Glu Thr Ser
              145                 150                 155                 160
              Lys Gly Ser Asp Phe Ala Lys Pro Thr Asp Pro Thr Ser Leu Leu Tyr
                              165                 170                 175
              Asn Gly Pro Phe Leu Leu Lys Gly Leu Thr Ala Lys Ser Ser Val Glu
                          180                 185                 190
              Phe Val Lys Asn Glu Gln Tyr Trp Asp Lys Glu Asn Val His Leu Asp
                      195                 200                 205
              Thr Ile Asn Leu Ala Tyr Tyr Asp Gly Ser Asp Gln Glu Ser Leu Glu
                                                 Page 324

                  210                 215                   220
<removed-date>
              Arg Asn Phe Thr Ser Gly Ala Tyr Ser Tyr Ala Arg Leu Tyr Pro Thr
              225                 230                 235                 240
              Ser Ser Asn Tyr Ser Lys Val Ala Glu Glu Tyr Lys Asp Asn Ile Tyr
                              245                 250                 255
<removed-apn>
              Tyr Thr Gln Ser Gly Ser Gly Ile Ala Gly Leu Gly Val Asn Ile Asp
                          260                 265                 270
              Arg Gln Ser Tyr Asn Tyr Thr Ser Lys Thr Thr Asp Ser Glu Lys Val
                      275                 280                 285
              Ala Thr Lys Lys Ala Leu Leu Asn Lys Asp Phe Arg Gln Ala Leu Asn
                  290                 295                 300
              Phe Ala Leu Asp Arg Ser Ala Tyr Ser Ala Gln Ile Asn Gly Lys Asp
              305                 310                 315                 320
              Gly Ala Ala Leu Ala Val Arg Asn Leu Phe Val Lys Pro Asp Phe Val
                              325                 330                 335
              Ser Ala Gly Glu Lys Thr Phe Gly Asp Leu Val Ala Ala Gln Leu Pro
                          340                 345                 350
              Ala Tyr Gly Asp Glu Trp Lys Gly Val Asn Leu Ala Asp Gly Gln Asp
                      355                 360                 365
              Gly Leu Phe Asn Ala Asp Lys Ala Lys Ala Glu Phe Ala Lys Ala Lys
                  370                 375                 380
              Lys Ala Leu Glu Ala Asp Gly Val Gln Phe Pro Ile His Leu Asp Val
              385                 390                 395                 400
              Pro Val Asp Gln Ala Ser Lys Asn Tyr Ile Ser Arg Ile Gln Ser Phe
                              405                 410                 415
              Lys Gln Ser Val Glu Thr Val Leu Gly Val Glu Asn Val Val Val Asp
                          420                 425                 430
                                                 Page 325

<removed-date>
              Ile Gln Gln Met Thr Ser Asp Glu Phe Leu Asn Ile Thr Tyr Tyr Ala
                      435                 440                 445
              Ala Asn Ala Ser Ser Glu Asp Trp Asp Val Ser Gly Gly Val Ser Trp
                  450                 455                 460
              Gly Pro Asp Tyr Gln Asp Pro Ser Thr Tyr Leu Asp Ile Leu Lys Thr
<removed-apn>
              465                 470                 475                 480
              Thr Ser Ser Glu Thr Thr Lys Thr Tyr Leu Gly Phe Asp Asn Pro Asn
                              485                 490                 495
              Ser Pro Ser Val Val Gln Val Gly Leu Lys Glu Tyr Asp Lys Leu Val
                          500                 505                 510
              Asp Glu Ala Ala Arg Glu Thr Ser Asp Leu Asn Val Arg Tyr Glu Lys
                      515                 520                 525
              Tyr Ala Ala Ala Gln Ala Trp Leu Thr Asp Ser Ser Leu Phe Ile Pro
                  530                 535                 540
              Ala Met Ala Ser Ser Gly Ala Ala Pro Val Leu Ser Arg Ile Val Pro
              545                 550                 555                 560
              Phe Thr Gly Ala Ser Ala Gln Thr Gly Ser Lys Gly Ser Asp Val Tyr
                              565                 570                 575
              Phe Lys Tyr Leu Lys Ser Gln Asp Lys Val Val Thr Lys Glu Glu Tyr
                          580                 585                 590
              Glu Lys Ala Arg Glu Lys Trp Leu Lys Glu Lys Ala Glu Ser Asn Glu
                      595                 600                 605
              Lys Ala Gln Lys Glu Leu Ala Ser His Val Lys
                  610                 615
              <210> 218
              <211> 390
              <212> PRT
                                                 Page 326

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 218
              Ala Asp Gly Thr Val Thr Ile Glu Tyr Phe Asn Gln Lys Lys Glu Met
              1               5                   10                  15
              Thr Lys Thr Leu Glu Glu Ile Thr Arg Asp Phe Glu Lys Glu Asn Pro
                          20                  25                  30
<removed-apn>
              Lys Ile Lys Val Lys Val Val Asn Val Pro Asn Ala Gly Glu Val Leu
                      35                  40                  45
              Lys Thr Arg Val Leu Ala Gly Asp Val Pro Asp Val Val Asn Ile Tyr
                  50                  55                  60
              Pro Gln Ser Ile Glu Leu Gln Glu Trp Ala Lys Ala Gly Val Phe Glu
              65                  70                  75                  80
              Asp Leu Ser Asn Lys Asp Tyr Leu Lys Arg Val Lys Asn Gly Tyr Ala
                              85                  90                  95
              Glu Lys Tyr Ala Val Asn Glu Lys Val Tyr Asn Val Pro Phe Thr Ala
                          100                 105                 110
              Asn Ala Tyr Gly Ile Tyr Tyr Asn Lys Asp Lys Phe Glu Glu Leu Gly
                      115                 120                 125
              Leu Lys Val Pro Glu Thr Trp Asp Glu Phe Glu Gln Leu Val Lys Asp
                  130                 135                 140
              Ile Val Ala Lys Gly Gln Thr Pro Phe Gly Ile Ala Gly Ala Asp Ala
              145                 150                 155                 160
              Trp Thr Leu Asn Gly Tyr Asn Gln Leu Ala Phe Ala Thr Ala Thr Gly
                              165                 170                 175
              Gly Gly Lys Glu Ala Asn Gln Tyr Leu Arg Tyr Ser Gln Pro Asn Ala
                          180                 185                 190
              Ile Lys Leu Ser Asp Pro Ile Met Lys Asp Asp Ile Lys Val Met Asp
                      195                 200                 205
                                                 Page 327

<removed-date>
              Ile Leu Arg Ile Asn Gly Ser Lys Gln Lys Asn Trp Glu Gly Ala Gly
                  210                 215                 220
              Tyr Thr Asp Val Ile Gly Ala Phe Ala Arg Gly Asp Val Leu Met Thr
              225                 230                 235                 240
              Pro Asn Gly Ser Trp Ala Ile Thr Ala Ile Asn Glu Gln Lys Pro Asn
<removed-apn>
                              245                 250                 255
              Phe Lys Ile Gly Thr Phe Met Ile Pro Gly Lys Glu Lys Gly Gln Ser
                          260                 265                 270
              Leu Thr Val Gly Ala Gly Asp Leu Ala Trp Ser Ile Ser Ala Thr Thr
                      275                 280                 285
              Lys His Pro Lys Glu Ala Asn Ala Phe Val Glu Tyr Met Thr Arg Pro
                  290                 295                 300
              Glu Val Met Gln Lys Tyr Tyr Asp Val Asp Gly Ser Pro Thr Ala Ile
              305                 310                 315                 320
              Glu Gly Val Lys Gln Ala Gly Glu Asp Ser Pro Leu Ala Gly Met Thr
                              325                 330                 335
              Glu Tyr Ala Phe Thr Asp Arg His Leu Val Trp Leu Gln Gln Tyr Trp
                          340                 345                 350
              Thr Ser Glu Ala Asp Phe His Thr Leu Thr Met Asn Tyr Val Leu Thr
                      355                 360                 365
              Gly Asp Lys Gln Gly Met Val Asn Asp Leu Asn Ala Phe Phe Asn Pro
                  370                 375                 380
              Met Lys Ala Asp Val Asp
              385                 390
              <210> 219
              <211> 302
              <212> PRT
                                                 Page 328

              <213> Streptococcus pneumoniae
<removed-date>
              <400> 219
              Lys Thr Tyr Lys Lys Ile Gly Glu Glu Thr Lys Val Ile Glu Ala Thr
              1               5                   10                  15
              Glu Pro Leu Thr Ile Leu Leu Met Gly Val Asp Thr Gly Asn Val Glu
                          20                  25                  30
<removed-apn>
              Arg Thr Glu Thr Trp Val Gly Arg Ser Asp Ser Met Ile Leu Met Thr
                      35                  40                  45
              Val Asn Pro Lys Thr Lys Lys Thr Thr Met Met Ser Leu Glu Arg Asp
                  50                  55                  60
              Ile Leu Thr Arg Ile Glu Ser Gly Asn Gly Gln Ala His Glu Ala Lys
              65                  70                  75                  80
              Leu Asn Ser Ala Tyr Ala Asp Gly Gly Ala Glu Leu Ala Ile Glu Thr
                              85                  90                  95
              Ile Gln Lys Met Met Asn Ile His Ile Asp Arg Tyr Val Met Val Asn
                          100                 105                 110
              Met Arg Gly Leu Gln Lys Leu Val Asp Ala Val Gly Gly Ile Thr Val
                      115                 120                 125
              Asn Asn Ile Leu Gly Phe Pro Ile Ser Ile Ser Asp Gln Glu Glu Phe
                  130                 135                 140
              Asn Thr Ile Ser Ile Gly Val Gly Glu Gln His Ile Gly Gly Glu Glu
              145                 150                 155                 160
              Ala Leu Val Tyr Ala Arg Met Arg Tyr Gln Asp Pro Glu Gly Asp Tyr
                              165                 170                 175
              Gly Arg Gln Lys Arg Gln Arg Glu Val Ile Gln Lys Val Met Glu Lys
                          180                 185                 190
              Ala Leu Ser Leu Asn Ser Ile Gly His Tyr Gln Glu Ile Leu Lys Ala
                      195                 200                 205
                                                 Page 329

<removed-date>
              Leu Ser Asp Asn Met Gln Thr Asn Ile Asp Leu Ser Ala Lys Ser Ile
                  210                 215                 220
              Pro Asn Leu Leu Gly Tyr Lys Asp Ser Phe Lys Thr Ile Glu Thr Gln
              225                 230                 235                 240
              Gln Leu Gln Gly Glu Gly Glu Ile Leu Gln Gly Val Ser Tyr Gln Ile
<removed-apn>
                              245                 250                 255
              Val Ser Arg Ala His Met Leu Glu Met Gln Asn Leu Leu Arg Arg Ser
                          260                 265                 270
              Leu Gly Gln Glu Glu Val Thr Gln Leu Glu Thr Asn Ala Val Leu Phe
                      275                 280                 285
              Glu Asp Leu Phe Gly Arg Ala Pro Val Gly Asp Glu Asp Asn
                  290                 295                 300
              <210>   220
              <211>   403
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 220
              Ala Val Leu Pro Leu Leu Ala Ala Thr Ile Leu Ala Ser Glu Gly Lys
              1               5                   10                  15
              Thr Val Leu Gln Asn Val Pro Ile Leu Ser Asp Val Phe Ile Met Asn
                          20                  25                  30
              Gln Val Val Gly Gly Leu Asn Ala Lys Val Asp Phe Asp Glu Glu Ala
                      35                  40                  45
              His Leu Val Lys Val Asp Ala Thr Gly Asp Ile Thr Glu Glu Ala Pro
                  50                  55                  60
              Tyr Lys Tyr Val Ser Lys Met Arg Ala Ser Ile Val Val Leu Gly Pro
              65                  70                  75                  80
              Ile Leu Ala Arg Val Gly His Ala Lys Val Ser Met Pro Gly Gly Cys
                                                 Page 330

                              85                  90                  95
<removed-date>
              Thr Ile Gly Ser Arg Pro Ile Asp Leu His Leu Lys Gly Leu Glu Ala
                          100                 105                 110
              Met Gly Val Lys Ile Ser Gln Thr Ala Gly Tyr Ile Glu Ala Lys Ala
                      115                 120                 125
<removed-apn>
              Glu Arg Leu His Gly Ala His Ile Tyr Met Asp Phe Pro Ser Val Gly
                  130                 135                 140
              Ala Thr Gln Asn Leu Met Met Ala Ala Thr Leu Ala Asp Gly Val Thr
              145                 150                 155                 160
              Val Ile Glu Asn Ala Ala Arg Glu Pro Glu Ile Val Asp Leu Ala Ile
                              165                 170                 175
              Leu Leu Asn Glu Met Gly Ala Lys Val Lys Gly Ala Gly Thr Glu Thr
                          180                 185                 190
              Ile Thr Ile Thr Gly Val Glu Lys Leu His Gly Thr Thr His Asn Val
                      195                 200                 205
              Val Gln Asp Arg Ile Glu Ala Gly Thr Phe Met Val Ala Ala Ala Met
                  210                 215                 220
              Thr Gly Gly Asp Val Leu Ile Arg Asp Ala Val Trp Glu His Asn Arg
              225                 230                 235                 240
              Pro Leu Ile Ala Lys Leu Leu Glu Met Gly Val Glu Val Ile Glu Glu
                              245                 250                 255
              Asp Glu Gly Ile Arg Val Arg Ser Gln Leu Glu Asn Leu Lys Ala Val
                          260                 265                 270
              His Val Lys Thr Leu Pro His Pro Gly Phe Pro Thr Asp Met Gln Ala
                      275                 280                 285
              Gln Phe Thr Ala Leu Met Thr Val Ala Lys Gly Glu Ser Thr Met Val
                  290                 295                 300
                                                 Page 331

<removed-date>
              Glu Thr Val Phe Glu Asn Arg Phe Gln His Leu Glu Glu Met Arg Arg
              305                 310                 315                 320
              Met Gly Leu His Ser Glu Ile Ile Arg Asp Thr Ala Arg Ile Val Gly
                              325                 330                 335
              Gly Gln Pro Leu Gln Gly Ala Glu Val Leu Ser Thr Asp Leu Arg Ala
<removed-apn>
                          340                 345                 350
              Ser Ala Ala Leu Ile Leu Thr Gly Leu Val Ala Gln Gly Glu Thr Val
                      355                 360                 365
              Val Gly Lys Leu Val His Leu Asp Arg Gly Tyr Tyr Gly Phe His Glu
                  370                 375                 380
              Lys Leu Ala Gln Leu Gly Ala Lys Ile Gln Arg Ile Glu Ala Ser Asp
              385                 390                 395                 400
              Glu Asp Glu
              <210>   221
              <211>   316
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 221
              Ile Glu Val Pro Gly Gly Ser Glu Asp Ile Arg Gln Val Leu Lys Val
              1               5                   10                  15
              Asn Asp Thr Glu Asp Lys Glu Ala Gly Ala Tyr Gln Phe Val Thr Val
                          20                  25                  30
              Gly Val Gln His Ala Thr Leu Ala His Met Ile Tyr Ala Trp Leu Thr
                      35                  40                  45
              Pro Phe Thr Asp Ile Arg Ser Ala Gln Glu Thr Thr Gly Gly Ser Ser
                  50                  55                  60
              Asp Val Glu Phe Met Arg Ile Asn Gln Phe Tyr Met Gln Thr Ser Gln
                                                 Page 332

              65                  70                  75                  80
<removed-date>
              Asn Met Ala Lys Tyr Gln Gly Leu Lys Thr Ala Gly Lys Asp Ile Glu
                              85                  90                  95
              Leu Lys Tyr Phe Gly Val Tyr Val Leu Asn Val Thr Asp Asn Ser Thr
                          100                 105                 110
<removed-apn>
              Phe Lys Gly Ile Leu Asn Ile Ser Asp Thr Val Thr Ala Val Asn Asp
                      115                 120                 125
              Gln Thr Phe Asp Ser Ser Lys Asp Leu Ile Asp Tyr Val Ser Ser Gln
                  130                 135                 140
              Lys Leu Gly Asp Ser Val Lys Val Thr Tyr Glu Glu Asp Gly Gln Thr
              145                 150                 155                 160
              Lys Ser Ala Glu Gly Lys Ile Ile Thr Leu Glu Asn Gly Lys Asn Gly
                              165                 170                 175
              Ile Gly Ile Gly Leu Ile Asp Arg Thr Glu Val Ile Ser Asn Val Pro
                          180                 185                 190
              Ile Ser Phe Ser Thr Ala Gly Ile Gly Gly Pro Ser Ala Gly Leu Met
                      195                 200                 205
              Phe Ser Leu Ala Ile Tyr Thr Gln Ile Ala His Pro Asp Leu Arg Asn
                  210                 215                 220
              Gly Arg Ile Val Ala Gly Thr Gly Thr Ile Asp Arg Asp Gly Asn Val
              225                 230                 235                 240
              Gly Asp Ile Gly Gly Ile Asp Lys Lys Val Val Ala Ser Ala Arg Ala
                              245                 250                 255
              Gly Ala Ala Ile Phe Phe Ala Pro Asp Asn Pro Val Ser Glu Glu Glu
                          260                 265                 270
              Gln Lys Ala His Pro Asp Ala Lys Asn Asn Tyr Gln Thr Ala Leu Glu
                      275                 280                 285
                                                 Page 333

<removed-date>
              Ala Ala Lys Thr Ile Lys Thr Asp Met Lys Ile Val Pro Val Lys Thr
                  290                 295                 300
              Leu Gln Asp Ala Ile Asp Tyr Leu Lys Asn Asn Pro
              305                 310                 315
              <210>   222
<removed-apn>
              <211>   277
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 222
              Gly Ile Val Phe Gln Val Ile Asn Leu Pro Ser Pro His Ile Lys Pro
              1               5                   10                  15
              Lys His Met Leu Val Leu Tyr Gln Lys Ile Lys Glu Glu Ala Asp Asn
                          20                  25                  30
              Tyr Asp Gly Val Val Ile Thr His Gly Thr Asp Thr Leu Glu Glu Thr
                      35                  40                  45
              Ala Tyr Phe Leu Asp Thr Met Glu Val Pro His Met Pro Ile Val Leu
                  50                  55                  60
              Thr Gly Ala Met Arg Ser Ser Asn Glu Leu Gly Ser Asp Gly Val Tyr
              65                  70                  75                  80
              Asn Tyr Leu Ser Ala Leu Arg Val Ala Ser Asp Asp Arg Ala Ala Asp
                              85                  90                  95
              Lys Gly Val Leu Val Val Met Asn Asp Glu Ile His Ala Ala Lys Tyr
                          100                 105                 110
              Val Thr Lys Thr His Thr Thr Asn Val Ser Thr Phe Gln Thr Pro Thr
                      115                 120                 125
              His Gly Pro Leu Gly Leu Ile Met Lys Gln Glu Ile Leu Tyr Phe Lys
                  130                 135                 140
              Thr Ala Glu Pro Arg Val Arg Phe Asp Leu Asp His Ile Gln Gly Leu
                                                 Page 334

              145                   150               155                 160
<removed-date>
              Val Pro Ile Ile Ser Ala Tyr Ala Gly Met Thr Asp Glu Leu Ile Asp
                              165                 170                 175
              Met Leu Asp Leu Glu His Leu Asp Gly Leu Ile Ile Gln Ala Phe Gly
                          180                 185                 190
<removed-apn>
              Ala Gly Asn Ile Pro Lys Glu Thr Ala Gln Lys Leu Glu Ser Leu Leu
                      195                 200                 205
              Gln Lys Gly Ile Pro Val Ala Leu Val Ser Arg Cys Phe Asn Gly Ile
                  210                 215                 220
              Ala Glu Pro Val Tyr Ala Tyr Gln Gly Gly Gly Val Gln Leu Gln Lys
              225                 230                 235                 240
              Ala Gly Val Phe Phe Val Lys Glu Leu Asn Ala Gln Lys Ala Arg Leu
                              245                 250                 255
              Lys Leu Leu Ile Ala Leu Asn Ala Gly Leu Thr Gly Gln Ala Leu Lys
                          260                 265                 270
              Asp Tyr Met Glu Gly
                      275
              <210>   223
              <211>   114
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 223
              Ser Gln Leu Leu Ile Ser Glu Val Arg Tyr Gln Gln Gln Ser Glu Gln
              1               5                   10                  15
              Lys Glu Trp Leu Leu Phe Val Asp Gln Leu Glu Val Glu Leu Asp Arg
                          20                  25                  30
              Ser Gln Phe Glu Lys Val Glu Gly Asn Arg Leu Tyr Met Lys Gln Asp
                      35                  40                  45
                                                 Page 335

              Gly Lys Asp Ile Ala Ile Gly Lys Ser Lys Ser Asp Asp Phe Arg Lys
<removed-date>
                  50                  55                  60
              Thr Asn Ala Arg Gly Arg Gly Tyr Gln Pro Met Val Tyr Gly Leu Lys
              65                  70                  75                  80
              Ser Val Arg Ile Thr Glu Asp Asn Gln Leu Val Arg Phe His Phe Gln
                              85                  90                  95
<removed-apn>
              Phe Gln Lys Gly Leu Glu Arg Glu Phe Ile Tyr Arg Val Glu Lys Glu
                          100                 105                 110
              Lys Ser
              <210>   224
              <211>   100
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 224
              Val Glu Glu Gln Ile Phe Phe Met Glu Phe Glu Glu Leu Tyr Arg Glu
              1               5                   10                  15
              Thr Gln Lys Arg Ser Val Ala Ser Gln Gln Lys Thr Ser Leu Asn Leu
                          20                  25                  30
              Asp Gly Gln Thr Leu Ser Asn Gly Ser Gln Lys Leu Pro Val Pro Lys
                      35                  40                  45
              Gly Ile Gln Ala Pro Ser Gly Gln Ser Ile Thr Phe Asp Arg Ala Gly
                  50                  55                  60
              Gly Asn Ser Ser Leu Ala Lys Val Glu Phe Gln Thr Ser Lys Gly Ala
              65                  70                  75                  80
              Ile Arg Tyr Gln Leu Tyr Leu Gly Asn Gly Lys Ile Lys Arg Ile Lys
                              85                  90                  95
              Glu Thr Lys Asn
                          100
                                                 Page 336

<removed-date>
              <210>   225
              <211>   252
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 225
              Phe Ser Pro Thr Gln Ser Val Glu Ala Val Leu Val Leu Leu Tyr Asp
              1               5                   10                  15
<removed-apn>
              Leu Thr Thr Ile Arg Thr Tyr Glu Lys Leu Asn Leu Ala Phe Val Ser
                          20                  25                  30
              Asn Ala Ser His Glu Leu Arg Thr Pro Val Thr Ser Ile Lys Gly Phe
                      35                  40                  45
              Ala Glu Thr Ile Lys Gly Met Ser Ala Glu Glu Glu Ala Leu Lys Asp
                  50                  55                  60
              Asp Phe Leu Asp Ile Ile Tyr Lys Glu Ser Leu Arg Leu Glu His Ile
              65                  70                  75                  80
              Val Glu His Leu Leu Thr Leu Ser Lys Ala Gln Gln Met Pro Ile Gln
                              85                  90                  95
              Trp Thr Thr Leu Ser Leu Ala Glu Phe Val Gln Asp Leu Thr Gln Ser
                          100                 105                 110
              Leu Gln Pro Gln Leu Lys Lys Lys Asp Leu Gln Leu Lys Val Gln Val
                      115                 120                 125
              Pro Asp Asp Val Thr Leu Val Ser Asp Ser Gln Leu Leu Ser Gln Ile
                  130                 135                 140
              Leu Leu Asn Leu Leu Ser Asn Ala Ile Arg Tyr Thr Glu Gln Gly Gly
              145                 150                 155                 160
              Lys Ile Glu Val Lys Thr Gln Lys Val Asn Glu Gly Ile Lys Ile Ser
                              165                 170                 175
              Val Ser Asp Thr Gly Ile Gly Ile Ser Gln Leu Glu Gln Asp Arg Ile
                          180                 185                 190
                                                 Page 337

<removed-date>
              Phe Glu Arg Phe Tyr Arg Val Asn Lys Gly Arg Ser Arg Gln Thr Gly
                      195                 200                 205
              Gly Thr Gly Leu Gly Leu Ala Ile Val Lys Glu Leu Ser Gln Leu Leu
                  210                 215                 220
              Gly Gly Gln Val Thr Val Thr Ser Gln Leu Gly Arg Gly Ser Cys Phe
<removed-apn>
              225                 230                 235                 240
              Thr Ile Phe Leu Pro Asn Gln Ser Phe Ala Gln Asp
                              245                 250
              <210>   226
              <211>   262
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 226
              Lys Gln Ser Ala Ser Gly Thr Ile Glu Val Ile Ser Arg Glu Asn Gly
              1               5                   10                  15
              Ser Gly Thr Arg Gly Ala Phe Thr Glu Ile Thr Gly Ile Leu Lys Lys
                          20                  25                  30
              Asp Gly Asp Lys Lys Ile Asp Asn Thr Ala Lys Thr Ala Val Ile Gln
                      35                  40                  45
              Asn Ser Thr Glu Gly Val Leu Ser Ala Val Gln Gly Asn Ala Asn Ala
                  50                  55                  60
              Ile Gly Tyr Ile Ser Leu Gly Ser Leu Thr Lys Ser Val Lys Ala Leu
              65                  70                  75                  80
              Glu Ile Asp Gly Val Lys Ala Ser Arg Asp Thr Val Leu Asp Gly Glu
                              85                  90                  95
              Tyr Pro Leu Gln Arg Pro Phe Asn Ile Val Trp Ser Ser Asn Leu Ser
                          100                 105                 110
              Lys Leu Gly Gln Asp Phe Ile Ser Phe Ile His Ser Lys Gln Gly Gln
                                                 Page 338

                        115                 120               125
<removed-date>
              Gln Val Val Thr Asp Asn Lys Phe Ile Glu Ala Lys Thr Glu Thr Thr
                  130                 135                 140
              Glu Tyr Thr Ser Gln His Leu Ser Gly Lys Leu Ser Val Val Gly Ser
              145                 150                 155                 160
<removed-apn>
              Thr Ser Val Ser Ser Leu Met Glu Lys Leu Ala Glu Ala Tyr Lys Lys
                              165                 170                 175
              Glu Asn Pro Glu Val Thr Ile Asp Ile Thr Ser Asn Gly Ser Ser Ala
                          180                 185                 190
              Gly Ile Thr Ala Val Lys Glu Lys Thr Ala Asp Ile Gly Met Val Ser
                      195                 200                 205
              Arg Glu Leu Thr Pro Glu Glu Gly Lys Ser Leu Thr His Asp Ala Ile
                  210                 215                 220
              Ala Leu Asp Gly Ile Ala Val Val Val Asn Asn Asp Asn Lys Ala Ser
              225                 230                 235                 240
              Gln Val Ser Met Ala Glu Leu Ala Asp Val Phe Ser Gly Lys Leu Thr
                              245                 250                 255
              Thr Trp Asp Lys Ile Lys
                          260
              <210>   227
              <211>   187
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 227
              Ala Leu Leu Ala Leu Ala Ser Lys Asp Lys Glu Met Ala Glu Leu Ile
              1               5                   10                  15
              Ile Asn Lys Asp His Ala Ile Asn Gln Gly Gln Ser Ala Ile Glu Leu
                          20                  25                  30
                                                  Page 339

              Thr Cys Ala Arg Leu Leu Ala Leu Gln Gln Pro Gln Val Ser Asp Leu
<removed-date>
                      35                  40                  45
              Arg Phe Val Ile Ser Ile Met Ser Ser Cys Ser Asp Leu Glu Arg Met
                  50                  55                  60
              Gly Asp His Met Ala Gly Ile Ala Lys Ala Val Leu Gln Leu Lys Glu
              65                  70                  75                  80
<removed-apn>
              Asn Gln Leu Ala Pro Asp Glu Glu Gln Leu His Gln Met Gly Lys Leu
                              85                  90                  95
              Ser Leu Ser Met Leu Ala Asp Leu Leu Val Ala Phe Pro Leu His Gln
                          100                 105                 110
              Ala Ser Lys Ala Ile Ser Ile Ala Gln Lys Asp Glu Gln Ile Asp Gln
                      115                 120                 125
              Tyr Tyr Tyr Ala Leu Ser Lys Glu Ile Ile Gly Leu Met Lys Asp Gln
                  130                 135                 140
              Glu Thr Ser Ile Pro Asn Gly Thr Gln Tyr Leu Tyr Ile Ile Gly His
              145                 150                 155                 160
              Leu Glu Arg Phe Ala Asp Tyr Ile Ala Asn Ile Cys Glu Arg Leu Val
                              165                 170                 175
              Tyr Leu Glu Thr Gly Glu Leu Val Asp Leu Asn
                          180                 185
              <210>   228
              <211>   291
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 228
              Gln Gln Glu Ala Leu Val Glu Thr Ala Lys His Leu Val Lys Leu Ile
              1               5                   10                  15
              Lys Asn Gly Asp Asp Leu Ile Ile Thr His Gly Asn Gly Pro Gln Val
                          20                  25                  30
                                                 Page 340

<removed-date>
              Gly Asn Leu Leu Leu Gln His Leu Ala Ser Asp Ser Glu Lys Asn Pro
                      35                  40                  45
              Ala Phe Pro Leu Asp Ser Leu Val Ala Met Thr Glu Gly Ser Ile Gly
                  50                  55                  60
              Phe Trp Leu Lys Asn Ala Leu Gln Asn Ala Leu Leu Asp Glu Gly Ile
              65                  70                  75                  80
<removed-apn>
              Glu Lys Asn Val Ala Ser Val Val Thr Gln Val Val Val Asp Lys Asn
                              85                  90                  95
              Asp Pro Ala Phe Val Asn Leu Ser Lys Pro Ile Gly Pro Phe Tyr Ser
                          100                 105                 110
              Glu Glu Glu Ala Lys Ala Glu Ala Glu Lys Ser Gly Ala Thr Phe Lys
                      115                 120                 125
              Glu Asp Ala Gly Arg Gly Trp Arg Lys Val Val Ala Ser Pro Lys Pro
                  130                 135                 140
              Val Asp Ile Lys Glu Ile Glu Thr Ile Arg Thr Leu Leu Asn Asn Gly
              145                 150                 155                 160
              Gln Val Val Val Ala Ala Gly Gly Gly Gly Ile Pro Val Val Lys Glu
                              165                 170                 175
              Asn Asn Gly His Leu Thr Gly Val Glu Ala Val Ile Asp Lys Asp Phe
                          180                 185                 190
              Ala Ser Gln Arg Leu Ala Glu Leu Val Asp Ala Asp Leu Phe Ile Val
                      195                 200                 205
              Leu Thr Gly Val Asp Tyr Val Phe Val Asn Tyr Asn Lys Pro Asn Gln
                  210                 215                 220
              Glu Lys Leu Glu His Val Asn Val Ala Gln Leu Glu Glu Tyr Ile Lys
              225                 230                 235                 240
                                                 Page 341

              Gln Asp Gln Phe Ala Pro Gly Ser Met Leu Pro Lys Val Glu Ala Ala
<removed-date>
                              245                 250                 255
              Ile Ala Phe Val Asn Gly Arg Pro Glu Gly Lys Ala Val Ile Thr Ser
                          260                 265                 270
              Leu Glu Asn Leu Gly Ala Leu Ile Glu Ser Glu Ser Gly Thr Ile Ile
                      275                 280                 285
<removed-apn>
              Glu Lys Gly
                  290
              <210>   229
              <211>   444
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 229
              Val Met Glu Glu Thr Gly Phe Ser Lys Ala Thr Leu Thr Lys Tyr Val
              1               5                   10                  15
              Thr Leu Leu Asn Asp Lys Ala Leu Asp Ser Gly Leu Glu Leu Ala Ile
                          20                  25                  30
              His Ser Glu Asp Glu Asn Leu Arg Leu Ser Ile Gly Ala Ala Thr Lys
                      35                  40                  45
              Gly Arg Asp Ile Arg Ser Leu Phe Leu Glu Ser Ala Val Lys Tyr Gln
                  50                  55                  60
              Ile Leu Val Tyr Leu Leu Tyr His Gln Gln Phe Leu Ala His Gln Leu
              65                  70                  75                  80
              Ala Gln Glu Leu Val Ile Ser Glu Ala Thr Leu Gly Arg His Leu Ala
                              85                  90                  95
              Gly Leu Asn Gln Ile Leu Ser Glu Phe Asp Leu Ser Ile Gln Asn Gly
                          100                 105                 110
              Arg Trp Arg Gly Pro Glu His Gln Ile His Tyr Phe Tyr Phe Cys Leu
                      115                 120                 125
                                                 Page 342

<removed-date>
              Phe Arg Lys Val Trp Ser Ser Gln Glu Trp Glu Gly His Met Gln Lys
                  130                 135                 140
              Pro Glu Arg Lys Gln Glu Ile Ala Asn Leu Glu Glu Ile Cys Gly Ala
              145                 150                 155                 160
              Ser Leu Ser Ala Gly Gln Lys Leu Asp Leu Val Leu Trp Ala His Ile
                              165                 170                 175
<removed-apn>
              Ser Gln Gln Arg Leu Arg Val Asn Ala Cys Gln Phe Gln Val Ile Glu
                          180                 185                 190
              Glu Lys Met Arg Gly Tyr Phe Asp Asn Ile Phe Tyr Leu Arg Leu Leu
                      195                 200                 205
              Arg Lys Val Pro Ser Phe Phe Ala Gly Gln His Ile Pro Leu Gly Val
                  210                 215                 220
              Glu Asp Gly Glu Met Met Ile Phe Phe Ser Phe Leu Leu Ser His Arg
              225                 230                 235                 240
              Ile Leu Pro Leu His Thr Met Glu Tyr Ile Leu Gly Phe Gly Gly Gln
                              245                 250                 255
              Leu Ala Asp Leu Leu Thr Gln Leu Ile Gln Glu Met Lys Lys Glu Glu
                          260                 265                 270
              Leu Leu Gly Asp Tyr Thr Glu Asp His Val Thr Tyr Glu Leu Ser Gln
                      275                 280                 285
              Leu Cys Ala Gln Val Tyr Leu Tyr Lys Gly Tyr Ile Leu Gln Asp Arg
                  290                 295                 300
              Tyr Lys Tyr Gln Leu Glu Asn Arg His Pro Tyr Leu Leu Met Glu His
              305                 310                 315                 320
              Asp Phe Lys Glu Thr Ala Glu Glu Ile Phe His Ala Leu Pro Ala Phe
                              325                 330                 335
                                                 Page 343

              Gln Gln Gly Thr Asp Leu Asp Lys Lys Ile Leu Trp Glu Trp Leu Gln
<removed-date>
                          340                 345                 350
              Leu Ile Glu Tyr Met Ala Glu Asn Gly Gly Gln His Met Arg Ile Gly
                      355                 360                 365
              Leu Asp Leu Thr Ser Gly Phe Leu Val Phe Ser Arg Met Ala Ala Ile
                  370                 375                 380
<removed-apn>
              Leu Lys Arg Tyr Leu Glu Tyr Asn Arg Phe Ile Thr Ile Glu Ala Tyr
              385                 390                 395                 400
              Asp Pro Ser Arg His Tyr Asp Leu Leu Val Thr Asn Asn Pro Ile His
                              405                 410                 415
              Lys Lys Glu Gln Thr Pro Val Tyr Tyr Leu Lys Asn Asp Leu Asp Met
                          420                 425                 430
              Glu Asp Leu Val Ala Ile Arg Gln Leu Leu Phe Thr
                      435                 440
              <210>   230
              <211>   220
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 230
              Glu Gln Ile Val Lys Leu Gln Asn Gln Lys Val Ser Phe Val Arg Gly
              1               5                   10                  15
              Ala Ser His Glu Leu Lys Thr Pro Leu Ala Ser Leu Arg Ile Ile Leu
                          20                  25                  30
              Glu Asn Met Gln His Asn Ile Gly Asp Tyr Lys Asp His Pro Lys Tyr
                      35                  40                  45
              Ile Ala Lys Ser Ile Asn Lys Ile Asp Gln Met Ser His Leu Leu Glu
                  50                  55                  60
              Glu Val Leu Glu Ser Ser Lys Phe Gln Glu Trp Thr Glu Cys Arg Glu
              65                  70                  75                  80
                                                 Page 344

<removed-date>
              Thr Leu Thr Val Lys Pro Val Leu Val Asp Ile Leu Ser Arg Tyr Gln
                              85                  90                  95
              Glu Leu Ala His Ser Ile Gly Val Thr Ile Glu Asn Gln Leu Thr Asp
                          100                 105                 110
              Ala Thr Arg Val Val Met Ser Leu Arg Ala Leu Asp Lys Val Leu Thr
                      115                 120                 125
<removed-apn>
              Asn Leu Ile Ser Asn Ala Ile Lys Tyr Ser Asp Lys Asn Gly Arg Val
                  130                 135                 140
              Ile Ile Ser Glu Gln Asp Gly Tyr Leu Ser Ile Lys Asn Thr Cys Ala
              145                 150                 155                 160
              Pro Leu Ser Asp Gln Glu Leu Glu His Leu Phe Asp Ile Phe Tyr His
                              165                 170                 175
              Ser Gln Ile Val Thr Asp Lys Asp Glu Ser Ser Gly Leu Gly Leu Tyr
                          180                 185                 190
              Ile Val Asn Asn Ile Leu Glu Ser Tyr Gln Met Asp Tyr Ser Phe Leu
                      195                 200                 205
              Pro Tyr Glu His Gly Met Glu Phe Lys Ile Ser Leu
                  210                 215                 220
              <210>   231
              <211>   306
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 231
              Lys Asp Asn Lys Glu Ala Glu Leu Lys Lys Val Asp Phe Ile Leu Asp
              1               5                   10                  15
              Trp Thr Pro Asn Thr Asn His Thr Gly Leu Tyr Val Ala Lys Glu Lys
                          20                  25                  30
              Gly Tyr Phe Lys Glu Ala Gly Val Asp Val Asp Leu Lys Leu Pro Pro
                      35                  40                  45
                                                 Page 345

<removed-date>
              Glu Glu Ser Ser Ser Asp Leu Val Ile Asn Gly Lys Ala Pro Phe Ala
                  50                  55                  60
              Val Tyr Phe Gln Asp Tyr Met Ala Lys Lys Leu Glu Lys Gly Ala Gly
              65                  70                  75                  80
              Ile Thr Ala Val Ala Ala Ile Val Glu His Asn Thr Ser Gly Ile Ile
<removed-apn>
                              85                  90                  95
              Ser Arg Lys Ser Asp Asn Val Ser Ser Pro Lys Asp Leu Val Gly Lys
                          100                 105                 110
              Lys Tyr Gly Thr Trp Asn Asp Pro Thr Glu Leu Ala Met Leu Lys Thr
                      115                 120                 125
              Leu Val Glu Ser Gln Gly Gly Asp Phe Glu Lys Val Glu Lys Val Pro
                  130                 135                 140
              Asn Asn Asp Ser Asn Ser Ile Thr Pro Ile Ala Asn Gly Val Phe Asp
              145                 150                 155                 160
              Thr Ala Trp Ile Tyr Tyr Gly Trp Asp Gly Ile Leu Ala Lys Ser Gln
                              165                 170                 175
              Gly Val Asp Ala Asn Phe Met Tyr Leu Lys Asp Tyr Val Lys Glu Phe
                          180                 185                 190
              Asp Tyr Tyr Ser Pro Val Ile Ile Ala Asn Asn Asp Tyr Leu Lys Asp
                      195                 200                 205
              Asn Lys Glu Glu Ala Arg Lys Val Ile Gln Ala Ile Lys Lys Gly Tyr
                  210                 215                 220
              Gln Tyr Ala Met Glu His Pro Glu Glu Ala Ala Asp Ile Leu Ile Lys
              225                 230                 235                 240
              Asn Ala Pro Glu Leu Lys Glu Lys Arg Asp Phe Val Ile Glu Ser Gln
                              245                 250                 255
                                                 Page 346

<removed-date>
              Lys Tyr Leu Ser Lys Glu Tyr Ala Ser Asp Lys Glu Lys Trp Gly Gln
                          260                 265                 270
              Phe Asp Ala Ala Arg Trp Asn Ala Phe Tyr Lys Trp Asp Lys Glu Asn
                      275                 280                 285
              Gly Ile Leu Lys Glu Asp Leu Thr Asp Lys Gly Phe Thr Asn Glu Phe
                  290                 295                 300
<removed-apn>
              Val Lys
              305
              <210>   232
              <211>   191
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 232
              Cys Ser Asp Cys Asp Ser Thr Phe Glu Arg Ile Gly Glu Glu Asn Cys
              1               5                   10                  15
              Pro Asn Cys Met Lys Thr Glu Leu Ser Thr Lys Cys Gln Asp Cys Gln
                          20                  25                  30
              Leu Trp Cys Lys Glu Gly Val Glu Val Ser His Arg Ala Ile Phe Thr
                      35                  40                  45
              Tyr Asn Gln Ala Met Lys Asp Phe Phe Ser Arg Tyr Lys Phe Asp Gly
                  50                  55                  60
              Asp Phe Leu Leu Arg Lys Val Phe Ala Ser Phe Leu Ser Glu Glu Leu
              65                  70                  75                  80
              Lys Lys Tyr Lys Glu Tyr Gln Phe Val Val Ile Pro Leu Ser Pro Asp
                              85                  90                  95
              Arg Tyr Ala Asn Arg Gly Phe Asn Gln Val Glu Gly Leu Val Glu Ala
                          100                 105                 110
              Ala Gly Phe Glu Tyr Leu Asp Leu Leu Glu Lys Arg Glu Glu Arg Ala
                      115                 120                 125
                                                 Page 347

<removed-date>
              Ser Ser Ser Lys Asn Arg Ser Glu Arg Leu Gly Thr Glu Leu Pro Phe
                  130                 135                 140
              Phe Ile Lys Ser Gly Val Thr Ile Pro Lys Lys Ile Leu Leu Ile Asp
              145                 150                 155                 160
              Asp Ile Tyr Thr Thr Gly Ala Thr Ile Asn Arg Val Lys Lys Leu Leu
<removed-apn>
                              165                 170                 175
              Glu Glu Ala Gly Ala Lys Asp Val Lys Thr Phe Ser Leu Val Arg
                          180                 185                 190
              <210>   233
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 233
              cgggatccga attcgagctc cgaaaaagaa gtcgtctata c                     41
              <210>   234
              <211>   167
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 234
              Ser Lys Leu Gln Ala Thr Lys Thr Leu Ala Ala Asp Val Ile Met Arg
              1               5                   10                  15
              Ser Pro Val Ser Trp Lys Gln Glu Leu Thr Leu Asp Ala Gly Arg Ser
                          20                  25                  30
              Lys Gly Ala Ser Glu Asn Met Leu Ala Ile Ala Asn Gly Gly Leu Ile
                      35                  40                  45
              Gly Ser Val Ser Lys Val Glu Glu Asn Ser Thr Ile Val Asn Leu Leu
                  50                  55                  60
                                                 Page 348

              Thr Asn Thr Glu Asn Ala Asp Lys Ile Ser Val Lys Ile Gln His Gly
<removed-date>
              65                  70                  75                  80
              Ser Thr Thr Ile Tyr Gly Ile Ile Ile Gly Tyr Asp Lys Glu Asn Asp
                              85                  90                  95
              Val Leu Lys Ile Ser Gln Leu Asn Ser Asn Ser Asp Ile Ser Ala Gly
                          100                 105                 110
<removed-apn>
              Asp Lys Val Thr Thr Gly Gly Leu Gly Asn Phe Asn Val Ala Asp Ile
                      115                 120                 125
              Pro Val Gly Glu Val Val Ala Thr Thr His Ser Thr Asp Tyr Leu Thr
                  130                 135                 140
              Arg Glu Val Thr Val Lys Leu Ser Ala Asp Thr His Asn Val Asp Val
              145                 150                 155                 160
              Ile Glu Leu Val Gly Asn Ser
                              165
              <210>   235
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 235
              ctcgagtgcg gccgcaagct tttttagaac ctcataaaca tc                    42
              <210>   236
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 236
              cgggatccga attcgagctc cgagaaggag atgagtttgt c                     41
                                                 Page 349

<removed-date>
              <210>   237
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 237
<removed-apn>
              ctcgagtgcg gccgcaagct tctctttgtt caaaaattga tc                    42
              <210>   238
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 238
              cgggatccga attcgagctc caagcaggat atgaatatta tc                    42
              <210>   239
              <211>   27
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 239
              Glu Lys Ser Ala Asp Gln Gln Ala Glu Glu Asp Tyr Ala Arg Arg Ser
              1               5                   10                  15
              Glu Glu Glu Tyr Asn Arg Leu Thr Gln Gln Gln
                          20                  25
              <210>   240
              <211>   8
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 240
              Asp Leu Lys Lys Ala Val Asn Glu
              1               5
              <210> 241
              <211> 11
                                                 Page 350

              <212> PRT
<removed-date>
              <213> Streptococcus pneumoniae
              <220>
              <221> MOD_RES
              <222> (1)..(1)
              <223> Lys or Gly
              <220>
              <221> MOD_RES
<removed-apn>
              <222> (5)..(5)
              <223> Lys or Gly
              <400> 241
              Xaa Thr Gly Trp Xaa Gln Glu Asn Gly Met Trp
              1               5                   10
              <210>   242
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 242
              ctcgagtgcg gccgcaagct tggctttatt ttcactacca g         41
              <210>   243
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 243
              cgggatccga attcgagctc caacagcaaa aaagctgctg           40
              <210>   244
              <211>   45
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 351

<removed-date>
              <400> 244
              ctcgagtgcg gccgcaagct tttttttgtt tttcaagaat tcatc     45
              <210>   245
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
<removed-apn>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 245
              cgggatccga attcgagctc cgacgggatt aagagcctac           40
              <210>   246
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 246
              ctcgagtgcg gccgcaagct tacgtctgct tggtgtggat           40
              <210>   247
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 247
              cgggatccga attcgagctc cgttcgtatt gggaagattg           40
              <210>   248
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 352

              <400> 248
<removed-date>
              ctcgagtgcg gccgcaagct ttttaaagaa attgacattg tg        42
              <210>   249
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
<removed-apn>
                    primer
              <400> 249
              cgggatccga attcgagctc ccaagaatca tcaacttaca c         41
              <210>   250
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 250
              ctcgagtgcg gccgcaagct tataccagcc attgttaagc c         41
              <210>   251
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 251
              cgggatccga attcgagctc cgagacgacg attaatatta ag        42
              <210>   252
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 252
                                                 Page 353

              ctcgagtgcg gccgcaagct ttaggcgttt aatgtaagac tc        42
<removed-date>
              <210>   253
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 253
              cgggatccga attcgagctc caactcagaa aagaaagcag ac        42
              <210>   254
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 254
              ctcgagtgcg gccgcaagct tccaaactgg ttgatccaaa c         41
              <210>   255
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 255
              cgggatccga attcgagctc cccagctaca aaaacagaaa aag       43
              <210>   256
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 256
              ctcgagtgcg gccgcaagct tttgttctgt cgcgccattt gc        42
                                                 Page 354

<removed-date>
              <210>   257
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 257
              cgggatccga attcgagctc caataccaat actgcaaatg c         41
              <210>   258
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 258
              ctcgagtgcg gccgcaagct ttttagttaa aacgatttgg tc        42
              <210>   259
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 259
              cgggatccga attcgagctc ccaatctagt ggagttgagg           40
              <210>   260
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 260
              ctcgagtgcg gccgcaagct tcccactaat caaagatagg           40
                                                 Page 355

<removed-date>
              <210>   261
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 261
<removed-apn>
              cgggatccga attcgagctc catgaaaatt gtacttgtag           40
              <210>   262
              <211>   5
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 262
              Pro Ala Pro Ala Pro
              1               5
              <210>   263
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 263
              ctcgagtgcg gccgcaagct taatacccga ttcgaaatct tc        42
              <210>   264
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 264
              cgggatccga attcgagctc cggactgacc aatcgtttaa atg       43
              <210> 265
              <211> 40
              <212> DNA
                                                 Page 356

              <213> Artificial Sequence
<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 265
              ctcgagtgcg gccgcaagct ttctaccctc catcacatcc           40
              <210>   266
<removed-apn>
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 266
              cgggatccga attcgagctc ctggagcaat gttcgcgtag           40
              <210>   267
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 267
              ctcgagtgcg gccgcaagct taaatgttcc gatacgggtg           40
              <210>   268
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 268
              cgggatccga attcgagctc cgatgaatat ttacgcatcg           40
              <210>   269
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 357

<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 269
              ctcgagtgcg gccgcaagct taccagcacc acgcaagag            39
              <210>   270
              <211>   42
<removed-apn>
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 270
              cgggatccga attcgagctc cttttcaagt acggtgacta ag        42
              <210>   271
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 271
              ctcgagtgcg gccgcaagct tcttgaactt gatgccattt tc        42
              <210>   272
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 272
              cgggatccga attcgagctc cgataaaacc ctttcttctg c         41
              <210>   273
              <211>   44
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 358

              <220>
<removed-date>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 273
              ctcgagtgcg gccgcaagct taaatgtgat ttctgtaaaa atac      44
              <210>   274
              <211>   39
              <212>   DNA
<removed-apn>
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 274
              cgggatccga attcgagctc cgcccaccgt ctctcgcat            39
              <210>   275
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 275
              ctcgagtgcg gccgcaagct tcaaaccaga cgatctgtga c         41
              <210>   276
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 276
              cgggatccga attcgagctc catcaaggga gctactgcca ag        42
              <210>   277
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
                                                 Page 359

              <223> Description of Artificial Sequence: Synthetic
<removed-date>
                    primer
              <400> 277
              ctcgagtgcg gccgcaagct tcataccaga gatagattgc tc        42
              <210>   278
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 278
              cgggatccga attcgagctc cgaagccatt ctccagctgg           40
              <210>   279
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 279
              ctcgagtgcg gccgcaagct tgtcttggac gacttttgg            39
              <210>   280
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 280
              cgggatccga attcgagctc caacggagat tttcaaggag c         41
              <210>   281
              <211>   44
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                                                 Page 360

                      primer
<removed-date>
              <400> 281
              ctcgagtgcg gccgcaagct tctcactagt ctcatatatt tttc      44
              <210>   282
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 282
              cgggatccga attcgagctc cagcgctcaa aagacaatcg           40
              <210>   283
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 283
              ctcgagtgcg gccgcaagct tttgtaactg agattgatct g         41
              <210>   284
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 284
              cgggatccga attcgagctc ccaagaaaaa acaaaaaatg aag       43
              <210>   285
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 361

<removed-date>
              <400> 285
              ctcgagtgcg gccgcaagct tatcgacgta gtctccgcc            39
              <210>   286
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
<removed-apn>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 286
              cgggatccga attcgagctc cgaatctgta gtttatgcgg           40
              <210>   287
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 287
              ctcgagtgcg gccgcaagct ttgctaattc tttgttttcc           40
              <210>   288
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 288
              cgggatccga attcgagctc ctccaaagta gctgactcag           40
              <210>   289
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 362

              <400> 289
<removed-date>
              ctcgagtgcg gccgcaagct tagactcaag gtagtagtct g         41
              <210>   290
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
<removed-apn>
                    primer
              <400> 290
              cgggatccga attcgagctc cgtagatgga aaagttccg            39
              <210>   291
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 291
              ctcgagtgcg gccgcaagct tgtcttcttt tttaccttta g         41
              <210>   292
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 292
              cgggatccga attcgagctc cgaacaccaa acgaaagatg           40
              <210>   293
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 293
                                                 Page 363

              ctcgagtgcg gccgcaagct tggctaattc cttcaaagtt tg        42
<removed-date>
              <210>   294
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 294
              cgggatccga attcgagctc ctactatcaa tcaagttctt c         41
              <210>   295
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 295
              ctcgagtgcg gccgcaagct tgagctgact ccgaacctgg tc        42
              <210>   296
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 296
              cgggatccga attcgagctc caaacgctgg attgctcct            39
              <210>   297
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 297
              ctcgagtgcg gccgcaagct tgctagtttc tattctattt at        42
                                                 Page 364

<removed-date>
              <210>   298
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 298
              cgggatccga attcgagctc caccctagcg ctggctagtc g         41
              <210>   299
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 299
              ctcgagtgcg gccgcaagct tctcaacttt tttaagatct a         41
              <210>   300
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 300
              cgggatccga attcgagctc ccttaaaaat attaaacgta c         41
              <210>   301
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 301
              ctcgagtgcg gccgcaagct tgattgcatt aactctatag tc        42
                                                 Page 365

<removed-date>
              <210>   302
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 302
<removed-apn>
              cgggatccga attcgagctc caaagattta tatttagaag           40
              <210>   303
              <211>   44
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 303
              ctcgagtgcg gccgcaagct ttttaaagat tgaagtttta aagc      44
              <210>   304
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 304
              cgggatccga attcgagctc ccgtattcgc cgtgcggcta           40
              <210>   305
              <211>   38
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 305
              ctcgagtgcg gccgcaagct tgctagtctt cactttcc             38
                                                 Page 366

              <210>   306
<removed-date>
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 306
              cgggatccga attcgagctc cgatgattcc cgtgaagttc           40
<removed-apn>
              <210>   307
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 307
              ctcgagtgcg gccgcaagct tttcataaac ctctcctttg           40
              <210>   308
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 308
              cgggatccga attcgagctc cgctgatcag gtctttgttg           40
              <210>   309
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 309
              ctcgagtgcg gccgcaagct tatcaatttc atagcccatc ag        42
              <210> 310
                                                 Page 367

              <211> 40
<removed-date>
              <212> DNA
              <213> Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 310
              cgggatccga attcgagctc cattttcaat acagcgaaac           40
<removed-apn>
              <210>   311
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 311
              ctcgagtgcg gccgcaagct taaatgaagc taacttgaag ag        42
              <210>   312
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 312
              cgggatccga attcgagctc ctttagacaa ccttctcaga c         41
              <210>   313
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 313
              ctcgagtgcg gccgcaagct tattagttgc ttcatcagcc           40
              <210> 314
              <211> 40
                                                 Page 368

              <212> DNA
<removed-date>
              <213> Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 314
              cgggatccga attcgagctc ctctcgtcaa gtcaataaag           40
<removed-apn>
              <210>   315
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 315
              ctcgagtgcg gccgcaagct tcgtcgtcat aaaactaaac g         41
              <210>   316
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 316
              cgggatccga attcgagctc caaacatgcg attgctgttg           40
              <210>   317
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 317
              ctcgagtgcg gccgcaagct ttaatttctc gttaacaaag cg        42
              <210> 318
              <211> 43
              <212> DNA
                                                 Page 369

              <213> Artificial Sequence
<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 318
              cgggatccga attcgagctc cacagaggaa gctgttcaaa atc       43
              <210>   319
<removed-apn>
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 319
              ctcgagtgcg gccgcaagct tttgttgtaa cacttttcga gg        42
              <210>   320
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 320
              cgggatccga attcgagctc cgaggggacg aatcaaaggc           40
              <210>   321
              <211>   45
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 321
              ctcgagtgcg gccgcaagct taagtttaac ccacttatca ttatc     45
              <210>   322
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 370

<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 322
              cgggatccga attcgagctc cggtcaaaag gaaagtcaga c         41
              <210>   323
              <211>   44
<removed-apn>
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 323
              ctcgagtgcg gccgcaagct tctttaattc ttctgctaga atac      44
              <210>   324
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 324
              cgggatccga attcgagctc cgttcatcaa gatgtcaaac           40
              <210>   325
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 325
              ctcgagtgcg gccgcaagct tgccagatgt tgaaaagaga g         41
              <210>   326
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 371

              <220>
<removed-date>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 326
              cgggatccga attcgagctc ctctaattct gttaaaaatg aag       43
              <210>   327
              <211>   44
              <212>   DNA
<removed-apn>
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 327
              ctcgagtgcg gccgcaagct ttttcgcatt tttgcatgca tttc      44
              <210>   328
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 328
              cgggatccga attcgagctc ctcttcaatg aataaatcag           40
              <210>   329
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 329
              ctcgagtgcg gccgcaagct tttcgatgac ttgtcctgct tc        42
              <210>   330
              <211>   45
              <212>   DNA
              <213>   Artificial Sequence
              <220>
                                                 Page 372

              <223> Description of Artificial Sequence: Synthetic
<removed-date>
                    primer
              <400> 330
              cgggatccga attcgagctc cgaaaatcat cttttgctaa attac     45
              <210>   331
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 331
              ctcgagtgcg gccgcaagct ttgtgtttga ttcggttgaa ac        42
              <210>   332
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 332
              cgggatccga attcgagctc ctccaattca aatggaaacg           40
              <210>   333
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 333
              ctcgagtgcg gccgcaagct taccaaagaa gtccaaatgg           40
              <210>   334
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                                                 Page 373

                      primer
<removed-date>
              <400> 334
              cgggatccga attcgagctc caaggggaat gcttcaccat tag       43
              <210>   335
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 335
              ctcgagtgcg gccgcaagct tttttttatt ctcaaaaatt g         41
              <210>   336
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 336
              cgggatccga attcgagctc cttggttcag gttaatcaaa aac       43
              <210>   337
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 337
              ctcgagtgcg gccgcaagct tattttcgtt tttaagaatt tc        42
              <210>   338
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 374

<removed-date>
              <400> 338
              cgggatccga attcgagctc cgcgacagct accaacggtg           40
              <210>   339
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
<removed-apn>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 339
              ctcgagtgcg gccgcaagct tttggtattt ttctgttaaa g         41
              <210>   340
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 340
              cgggatccga attcgagctc cgatagtcaa aaattggtta tc        42
              <210>   341
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 341
              ctcgagtgcg gccgcaagct tcttccgata cattttaaac tg        42
              <210>   342
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 375

              <400> 342
<removed-date>
              cgggatccga attcgagctc cgcctatgaa ggcaaagtag           40
              <210>   343
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
<removed-apn>
                    primer
              <400> 343
              ctcgagtgcg gccgcaagct tctttccaag agaaatcttt c         41
              <210>   344
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 344
              cgggatccga attcgagctc ctggttagaa aaacataagg           40
              <210>   345
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 345
              ctcgagtgcg gccgcaagct tctaatacca gctctcattc           40
              <210>   346
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 346
                                                 Page 376

              cgggatccga attcgagctc catgtttcaa aattgggctt c         41
<removed-date>
              <210>   347
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 347
              ctcgagtgcg gccgcaagct tacattcttc cctacttata cc        42
              <210>   348
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 348
              cgggatccga attcgagctc caagatctac cagcaaaaaa g         41
              <210>   349
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 349
              ctcgagtgcg gccgcaagct tttcatcacg actatagtac agc       43
              <210>   350
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 350
              cgggatccga attcgagctc cactagtgga gataattggt c         41
                                                 Page 377

<removed-date>
              <210>   351
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 351
              ctcgagtgcg gccgcaagct tctgtccttc ttttacttct ttg       43
              <210>   352
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 352
              cgggatccga attcgagctc cgaaggagaa aaattagctc           40
              <210>   353
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 353
              ctcgagtgcg gccgcaagct ttaggccctc cttgttgacc           40
              <210>   354
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 354
              cgggatccga attcgagctc ccaaaacagt accagtgcta g         41
                                                 Page 378

<removed-date>
              <210>   355
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 355
<removed-apn>
              ctcgagtgcg gccgcaagct tattcgtttt tgaactagtt gc        42
              <210>   356
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 356
              cgggatccga attcgagctc catgttttat acttatttgc gtg       43
              <210>   357
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 357
              ctcgagtgcg gccgcaagct tggcagggat gcggataaac c         41
              <210>   358
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 358
              cgggatccga attcgagctc caaagtaacc agtcccaaca tgg       43
                                                 Page 379

              <210>   359
<removed-date>
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 359
              ctcgagtgcg gccgcaagct tactggatga agcattgcta tac       43
<removed-apn>
              <210>   360
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 360
              cgggatccga attcgagctc caaatcaatc atcgaagcgt ttg       43
              <210>   361
              <211>   44
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 361
              ctcgagtgcg gccgcaagct tttgtttcat agcttttttg attg      44
              <210>   362
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 362
              cgggatccga attcgagctc catgcctaat tataaatttg ttg       43
              <210> 363
                                                 Page 380

              <211> 40
<removed-date>
              <212> DNA
              <213> Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 363
              ctcgagtgcg gccgcaagct tttttctacc ctccttttcc           40
<removed-apn>
              <210>   364
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 364
              cgggatccga attcgagctc cgaagaaaaa gctgataaaa gtc       43
              <210>   365
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 365
              ctcgagtgcg gccgcaagct tgctgaatta gaatacgtac aa        42
              <210>   366
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 366
              cgggatccga attcgagctc cacagaggta accattaaaa g         41
              <210> 367
              <211> 42
                                                 Page 381

              <212> DNA
<removed-date>
              <213> Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 367
              ctcgagtgcg gccgcaagct ttttcaaagc tttttgtatg tc        42
<removed-apn>
              <210>   368
              <211>   39
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 368
              cgggatccga attcgagctc cgcggatggc acagtgacc            39
              <210>   369
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 369
              ctcgagtgcg gccgcaagct tatccacatc cgctttcatc           40
              <210>   370
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 370
              cgggatccga attcgagctc caaaacctat aaaaaaatcg gtg       43
              <210> 371
              <211> 42
              <212> DNA
                                                 Page 382

              <213> Artificial Sequence
<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 371
              ctcgagtgcg gccgcaagct tattatcttc atcaccaaca gg        42
              <210>   372
<removed-apn>
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 372
              cgggatccga attcgagctc cgcagtctta cccttgttgg c         41
              <210>   373
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 373
              ctcgagtgcg gccgcaagct tttcatcttc atcacttgcc           40
              <210>   374
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 374
              cgggatccga attcgagctc catagaggtt ccaggtggtt cg        42
              <210>   375
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 383

<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 375
              ctcgagtgcg gccgcaagct tgggattgtt tttcaagtaa tc        42
              <210>   376
              <211>   42
<removed-apn>
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 376
              cgggatccga attcgagctc cgggattgtt tttcaagtaa tc        42
              <210>   377
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 377
              ctcgagtgcg gccgcaagct tgccttccat atagtctttc           40
              <210>   378
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 378
              cgggatccga attcgagctc cagtcagctc ctcatttcag           40
              <210>   379
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 384

              <220>
<removed-date>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 379
              ctcgagtgcg gccgcaagct tacttttttc tttttccaca c         41
              <210>   380
              <211>   40
              <212>   DNA
<removed-apn>
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 380
              cgggatccga attcgagctc cgtagaggaa cagattttct           40
              <210>   381
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 381
              ctcgagtgcg gccgcaagct tattttttgt ttccttaatg cg        42
              <210>   382
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 382
              cgggatccga attcgagctc ctttagcccc acccaatctg tg        42
              <210>   383
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
                                                 Page 385

              <223> Description of Artificial Sequence: Synthetic
<removed-date>
                    primer
              <400> 383
              ctcgagtgcg gccgcaagct tgtcctgtgc gaaagattgg           40
              <210>   384
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 384
              cgggatccga attcgagctc caaacagtca gcttcaggaa c         41
              <210>   385
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 385
              ctcgagtgcg gccgcaagct ttttaatctt gtcccaggtg g         41
              <210>   386
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 386
              cgggatccga attcgagctc cgccttactg gccttagcct cc        42
              <210>   387
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                                                 Page 386

                      primer
<removed-date>
              <400> 387
              ctcgagtgcg gccgcaagct tattcaaatc cactagttct c         41
              <210>   388
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
<removed-apn>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 388
              cgggatccga attcgagctc catgaaacca ctacttgaaa cc        42
              <210>   389
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 389
              ctcgagtgcg gccgcaagct tgtgacttgg taaccagctg           40
              <210>   390
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 390
              cgggatccga attcgagctc ccaacaagaa gctttagttg           40
              <210>   391
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 387

<removed-date>
              <400> 391
              ctcgagtgcg gccgcaagct ttcctttttc aataattgtt cc        42
              <210>   392
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
<removed-apn>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 392
              cgggatccga attcgagctc cgtaatggaa gaaacaggat           40
              <210>   393
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 393
              ctcgagtgcg gccgcaagct tagtgaataa taactggcga atc       43
              <210>   394
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 394
              cgggatccga attcgagctc cgagcaaatt gtaaaattgc           40
              <210>   395
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
                                                 Page 388

              <400> 395
<removed-date>
              ctcgagtgcg gccgcaagct tcaagctaat cttaaattcc           40
              <210>   396
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
<removed-apn>
                    primer
              <400> 396
              cgggatccga attcgagctc caaagacaac aaagaggcag aac       43
              <210>   397
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 397
              ctcgagtgcg gccgcaagct ttttcacaaa ttcgttggtg aag       43
              <210>   398
              <211>   41
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 398
              cgggatccga attcgagctc ctgttcagac tgtgattcta c         41
              <210>   399
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 399
                                                 Page 389

              ctcgagtgcg gccgcaagct ttcttacaag ggaaaatgtt           40
<removed-date>
              <210>   400
              <211>   42
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
<removed-apn>
              <400> 400
              cgggatccga attcgagctc ctctaaattg caagccacaa ag        42
              <210>   401
              <211>   43
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 401
              ctcgagtgcg gccgcaagct ttgaattccc cactaattct atc       43
              <210>   402
              <211>   6
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 402
              Pro Lys Glu Pro Glu Gln
              1               5
              <210>   403
              <211>   4
              <212>   PRT
              <213>   Streptococcus pneumoniae
              <400> 403
              Pro Glu Lys Pro
              1
              <210>   404
              <211>   40
              <212>   DNA
              <213>   Artificial Sequence
                                                 Page 390

<removed-date>
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 404
              ctcgagtgcg gccgcaagct tcgaattcaa tgctactagg           40
              <210>   405
              <211>   41
<removed-apn>
              <212>   DNA
              <213>   Artificial Sequence
              <220>
              <223> Description of Artificial Sequence: Synthetic
                    primer
              <400> 405
              cgggatccga attcgagctc ctttgattcc ttggaagaaa g         41
                                                 Page 391

